



US008759059B2

(12) **United States Patent**
Gokarn et al.

(10) **Patent No.:** **US 8,759,059 B2**
(45) **Date of Patent:** ***Jun. 24, 2014**

(54) **3-HYDROXYPROPIONIC ACID AND OTHER ORGANIC COMPOUNDS**

(71) Applicant: **Cargill, Incorporated**, Minneapolis, MN (US)

(72) Inventors: **Ravi R. Gokarn**, Omaha, NE (US); **Olga V. Selifonova**, Plymouth, MN (US); **Holly Jean Jensen**, Chanhassen, MN (US); **Steven John Gort**, Apple Valley, MN (US); **Thorsten Selmer**, Bonn (DE); **Wolfgang Buckel**, Marburg (DE)

(73) Assignee: **Cargill, Incorporated**, Wayzata, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/925,997**

(22) Filed: **Jun. 25, 2013**

(65) **Prior Publication Data**

US 2013/0323807 A1 Dec. 5, 2013

Related U.S. Application Data

(60) Continuation of application No. 13/467,165, filed on May 9, 2012, now Pat. No. 8,501,455, which is a division of application No. 13/294,820, filed on Nov. 11, 2011, now Pat. No. 8,198,066, which is a division of application No. 12/127,700, filed on May 27, 2008, now Pat. No. 8,076,120, which is a division of application No. 11/539,856, filed on Oct. 9, 2006, now Pat. No. 7,393,676, which is a division of application No. 10/432,443, filed as application No. PCT/US01/43607 on Nov. 20, 2001, now Pat. No. 7,186,541.

(60) Provisional application No. 60/252,123, filed on Nov. 20, 2000, provisional application No. 60/285,478, filed on Apr. 20, 2001, provisional application No. 60/306,727, filed on Jul. 20, 2001, provisional application No. 60/317,845, filed on Sep. 7, 2001.

(51) **Int. Cl.**
C12N 9/02 (2006.01)
C12N 1/20 (2006.01)

(52) **U.S. Cl.**
USPC **435/189**; 435/252.3; 435/320.1;
536/23.2

(58) **Field of Classification Search**
USPC 435/252.3, 189; 536/23.2
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,323,010	B1	11/2001	Skraly et al.
6,329,183	B1	12/2001	Skraly et al.
6,852,517	B1	2/2005	Suthers et al.
7,638,316	B2	12/2009	Gokarn et al.
7,700,319	B2	4/2010	Liao et al.
7,785,837	B2	8/2010	Liao et al.
8,076,120	B2	12/2011	Gokarn et al.
8,124,388	B2	2/2012	Liao et al.
8,198,066	B2	6/2012	Gokarn et al.
8,501,455	B2 *	8/2013	Gokarn et al. 435/252.3
2013/0323772	A1	12/2013	Gokarn et al.

FOREIGN PATENT DOCUMENTS

EP	0 494 707	A1	7/1992
GB	2 142 340	A	1/1985
JP	53-18794		2/1978
JP	54-112877		9/1979
JP	58-158189		9/1983
JP	2002-053524		2/2002
WO	WO 00/08198	A1	2/2000
WO	WO 01/16346	A1	3/2001

OTHER PUBLICATIONS

Accession No. 053163 (May 30, 2000).
Accession No. P11569 (Oct. 1, 1989).
Accession No. D70893 (May 28, 1999).
Accession No. CAB77206 (Feb. 12, 2002).
Database UniProt, "enoyl-CoA hydratase echA12," XP002343849 retrieved from EBI Database Accession No. ECH12_MYCTU, May 2000.
GenBank Accession No. AC008805 "Homo sapiens chromosome 19 clone CTD-2085J24, complete sequence" Aug. 3, 1999.
Baldwin et al., "Lactate Metabolism by *Peptostreptococcus elsdenii*: Evidence for Lactyl Coenzyme A Dehydrase," *Biochim. Biophys. Acta* 97:202-213 (1965).
Krause and Russell, "An rRNA Approach for Assessing the Role of Obligate Amino Acid-Fermenting Bacteria in Ruminant Amino Acid Deamination," *Appl. Env. Microbiol.* 62:815-821, 1996.
Notification (with English-language translation) from Japanese Patent Office, mailed Nov. 2, 2010, for Japanese Patent Application No. 2003-580264, filed Mar. 25, 2003, 2 pp.
Tung and Wood, "Purification, New Assay, and Properties of Coenzyme A Transferase from *Peptostreptococcus elsdenii*," *J. Bacteriol.* 124:1462-1474 (1975).
Döhr et al., "Engineering of a Functional Human NADH-Dependent Cytochrome P450 System," *PNAS* 98:81-86, 2001.
Eppink et al., "Switch of Coenzyme Specificity of p-Hydroxybenzoate Hydroxylase," *J. Mol. Biol.* 292:87-96, 1999.
Hall and Tomsett, "Structure—Function Analysis of NADPH: Nitrate Reductase from *Aspergillus nidulans*: Analysis of Altered Pyridine Nucleotide Specificity in vivo," *Microbiol.* 146:1399-1406, 2000.
Sequence alignment between Applicants' SEQ ID No. 140 and Fukui sequence 1—Fukui et al. (JP2008212114-A, PD Sep. 18, 2008).

* cited by examiner

Primary Examiner — Tekchand Saidha

(74) Attorney, Agent, or Firm — Cargill, Incorporated

(57) **ABSTRACT**

Methods and materials related to producing 3-HP as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP and other organic compounds are disclosed.

22 Claims, 105 Drawing Sheets

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

ATGAGAAAAGTAGAAATCATTACAGCTGAACAAGCAGCTCAGCTCGTAAAAGACAACGAC
ACGATTACGTCTATCGGCTTTGTTCAGCAGCGCCATCCGGAAGCACTGACCAAAGCTTTG
GAAAAACGGTTCTTGGACACGAACACCCCGCAGAACTTGACCTACATCTATGCAGGCTCT
CAGGGCAAACGCGATGGCCGTGCCGCTGAACATCTGGCACACACAGGCCTTTTGAAACGC
GCCATCATCGGTCACTGGCAGACTGTACCGGCTATCGGTAACTGGCTGTCGAAAACAAG
ATTGAAGCTTACAACCTTCTCGCAGGGCACGTTGGTCCACTGGTTCGCGCCTTGGCAGGT
CATAAGCTCGGCGTCTTACCGACATCGGTCTGGAAACTTTCTCGATCCCCGTCAGCTC
GGCGGCAAGCTCAATGACGTAACCAAAGAAGACCTCGTCAAACCTGATCGAAGTCGATGGT
CATGAACAGCTTTTCTACCCGACCTTCCCGGTCAACGTAGCTTTCTCCGCGGTACGTAT
GCTGATGAATCCGGCAATATCACCATGGACGAAGAAATCGGGCCTTTCGAAAGCACTTCC
GTAGCCAGGCCGTTCAACAATGTGGCGGTAAAGTCGTCCAGGTCAAAGACGTCGTC
GCTCACGGCAGCCTCGACCCGCGCATGGTCAAGATCCCTGGCATCTATGTCGACTACGTC
GTCTAGCAGCTCCGGAAGACCATCAGCAGACGTATGACTGCGAATACGATCCGTCCCTC
AGCGGTGAACATCGTGCTCCTGAAGGCGCTACCGATGCAGCTCTCCCATGAGCGCTAAG
AAAATCATCGGCCCGCGCGCTTTGGAATTGACTGAAAACGCTGTCGTCAACCTCGGC
GTCGGTGCTCCGGAATACGTTGCTTCTGTTGCCGGTGAAGAAGGTATCGCCGATACCAT
ACCCTGACCCGTCGAAGGTGGCGCCATCGGTGGCGTACCGCAGGGCGGTGCCCGCTTCGGT
TCGTCCCGCAATGCCGATGCCATCATCGACCACCTATCAGTTCGACTTCTACGATGGC
GGCGGTCTGGACATCGCTTACCTCGGCCTGGCCAGTGCGATGGCTCGGGCAACATCAAC
GTCAGCAAGTTCGGTACTAACGTTGCCGGCTGCGGCGGTTTCCCAACATTTCCAGCAG
ACACCGAATGTTTACTTCTGCGGCACCTTCACGGCTGGCGGCTTGAATAATCGCTGTCGAA
GACGGCAAAGTCAAGATCCTCCAGGAAGGCAAAGCCAAGAAGTTCATCAAAGCTGTCGAC
CAGATCACTTTCAACGGTTCCTATGCAGCCCGCAACGGCAAACACGTTCTCTACATCACA
GAACGCTGCGTATTTGAACTGACCAAAGAAGGCTTGAACCTCATCGAAGTCGCACCGGGC
ATCGATATTGAAAAAGATATCCTCGCTCACATGGACTTCAAGCCGATCATTGATAATCCG
AAACTCATGGATGCCCGCTCTTCCAGGACGGTCCCATGGGACTGAAAAAATAA (SEQ
ID NO:1)

Figure 7

MRKVEIITAEQAAQLVKDNDTITSIGFVSSAHPEALTKALEKRFLDTNTPQNLTYYIYAGS
QGKRDGRAAEHLAHTGLLKRAIIGHWQTVPAIGKLAVENKIEAYNFSQGTLVHWFRLAG
HKLGVFTDIGLETFLDPRQLGGKLNVDTKEDLVKLIÉVDGHEQLFYPTFPVNVAFLRGTY
ADESGNITMDEEIGPFESTSVAQAVHNCGGKV VVQKDVVAHGS L D P R M V K I P G I Y V D Y V
VVAAPEDHQQT Y D C E Y D P S L S G E H R A P E G A T D A A L P M S A K K I I G R R G A L E L T E N A V V N L G
VGAPEYVASVAGEEG I A D T I T L T V E G G A I G G V P Q G G A R F G S S R N A D A I I D H T Y Q F D F Y D G
GGLDIAYLGLAQCDGSGNINVS K F G T N V A G C G G F P N I S Q Q T P N V Y F C G T F T A G G L K I A V E
DGKVKILQEGKAKKFIKAVDQITFNGSYAARNGKHVLYITERCVFELTKEGLKLIÉVAPG
IDIEKDILAHMDFKPIIDNPKLMDARLFQDGPMLKK (SEQ ID NO:2)

```
SEQ ID NO:1      1 atgagaaaagttagaatcattacagctgaacaagcagctc--agctcgta
SEQ ID NO:3      1 -----gtgccggtcctgtcggcacaggaagcgggtga--attatatt
SEQ ID NO:4      1 atgccgattctctcaaaaatatggcggtccagcagctggaatcttgag
SEQ ID NO:5      1 -----atgaa-----tgca

SEQ ID NO:1      49 aaagacaacgacacgattacgtctatcggtttgtcagcagcgccatcc
SEQ ID NO:3      40 cccgacgaagcaacactttgtgttaggcgtg---gcggcggtattct
SEQ ID NO:4      51 aaaactccgagaaatgctcatcaatgaggctaattctcaatga-catcc
SEQ ID NO:5      10 aaaga-----atta----atcg-----

SEQ ID NO:1      99 ggaagcactgaccaagctttggaanaacggttcctg-----
SEQ ID NO:3      87 ggaag-----ccaccacgtt--aattactgctcttgctgataaatataa
SEQ ID NO:4      100 tcgatgaaagcaaaagtcttt-----aactctgc-----
SEQ ID NO:5      23 -----

SEQ ID NO:1      136 ---gacacgaacaccccgacagaacttgacctacatctatgcag-gctctc
SEQ ID NO:3      129 acagactcaaacacacacgt--aatttatcgattattagtccaa-cagggc
SEQ ID NO:4      129 -----cgaagaagccgtgaaggatattccgat-aatgcaaagctttt
SEQ ID NO:5      23 -----ctcgccgaatt-----

SEQ ID NO:1      182 agggcaaacgcgatggccgtgccgctgaacatctggcacacacaggcctt
SEQ ID NO:3      176 ttggcgatcgccgcgacgctggtattagtctctggcgcaagaaggctctg
SEQ ID NO:4      171 a-----gttggc--ggcttcggactatgcgg-aatcccagaaaaat
SEQ ID NO:5      34 -----gcgatgg-----

SEQ ID NO:1      232 ttgaacgcgccatcatcggtcactggcagactgtaccggc-tatcggtta
SEQ ID NO:3      226 gtgaaatgggcattatgtgtcactgg-ggacaatcgccgctatttctg
SEQ ID NO:4      208 ctcatccaagctatca-caaaaactgggtcaa-----aaaggctc
SEQ ID NO:5      41 -----aattacatgatgga---ga-tattgtta

SEQ ID NO:1      281 aactggctgtcgaaaacaagattgaagcttacaacttctcgaggggcag
SEQ ID NO:3      275 aactcgagaaacaaaataaattattgcttataactaccacaaggtgta
SEQ ID NO:4      245 ttacatgtgtatcaacaatgcgggagttgataatt-----ggggac-
SEQ ID NO:5      65 atctcggc-----attg--gtttac-----caacacagg

SEQ ID NO:1      331 ttggtccactggttccgcgcttgccaggtcataagctcggcgtcttcac
SEQ ID NO:3      325 cttacacaaaccttacgcgcgcccgcagccaccagcctggtattattag
SEQ ID NO:4      287 ttggcttgctccttc--aaactcgacaaatc--aagaaaatgatctcatc
SEQ ID NO:5      92 ttgt----taattattacctgataatgtcaata-----ttac

SEQ ID NO:1      381 cgacatcggctct---ggaaa---ctttcctcgatccccgtcagctcggc
SEQ ID NO:3      375 tgatatgtggcat---cgga---catttgcgatccacgccagcaaggc
SEQ ID NO:4      333 gtacgtcgggtgaaaacggaga---atttgcgcga---caatatcttagc
SEQ ID NO:5      126 --actcaatca---gaaaatggcttcttggtttaactgca-----

SEQ ID NO:1      424 ggcaagctcaatgacgtaacca-----aagaagacctcgtcaaaactgat
SEQ ID NO:3      418 ggcaaaactgaatgaagtacta-----aagaagacctgattaaactggt
SEQ ID NO:4      376 ggagagctcgagttggaattcacaccacaaggaacactcgccgaacgaat
SEQ ID NO:5      163 -----tttgac---cca-----gaaaatgctaattcaaaact---

SEQ ID NO:1      468 cgaagtcgatggtca---tgaacagcttttctacccgacc-----
SEQ ID NO:3      462 cgagtttgataacaa---agaatatctctattacaaagcg-----
SEQ ID NO:4      426 tcgtgcagctggtgcgggtgttccgcattctacac-accaacaggatac
SEQ ID NO:5      191 --tagtaaatgctgg---tggtcagcctt-----
```

Figure 8A

```
SEQ ID NO:1 505 --ttccgg--tcaacgtagctttcctccgggtacgtatgctga---tg
SEQ ID NO:3 499 --attgccc--cagatattgccttcattccgctaccacctgcga---ca
SEQ ID NO:4 475 ggtaccagattcaagaaggagggtgctccga-ttaagtacagtaaaactg
SEQ ID NO:5 215 -----gtggaa-----ttaa---aa

SEQ ID NO:1 548 aatccggcaatatac-accatggacg-----aagaatcgggcctttc
SEQ ID NO:3 542 gtgaaggctacgcc-acttttgaag-----atgagggtgatgtatctc
SEQ ID NO:4 524 aaaaaggaaagattgaagttgcaagtaagcgaagaacacgcacaattc
SEQ ID NO:5 227 aaggcggctcta-----ctttt

SEQ ID NO:1 589 ga---aagcacttccgta---gccaggccgttcac--aactgtggcgggt
SEQ ID NO:3 583 ga-----cgcatgtgttattgccaggcgggtgcac--aatacggcggt
SEQ ID NO:4 574 aatggaattaattatgtaatggaaggcctatttggggagattttgcatt
SEQ ID NO:5 244 ga---tagtgctt-----t--ttctttcgcttt

SEQ ID NO:1 631 aaagtctgctccaggtcaaaagcgtgctgc-----tcacggcagcctc
SEQ ID NO:3 625 attgtgatgatgcagggtgcagaaatggttaa-----gaaagccacgctg
SEQ ID NO:4 624 gatcaaggcgtggagagcagatac-tcttgaaatattcaattcagacat
SEQ ID NO:5 267 aa-----ttc

SEQ ID NO:1 676 gaccgcgcgatggtcaagatccctg-----gcatctatgtcgactac
SEQ ID NO:3 670 catcctaaatctgtccgtattccgg-----g---ttatctgtgtggat
SEQ ID NO:4 673 gctgctggaatttcaataatccaatgtgcaaacgcctctaaatgcac--c
SEQ ID NO:5 272 gtggcggtcattgtt---gatgcctg-----tgtgctaggtggact--

SEQ ID NO:1 718 gtgctgtagcagctccggaagaccatcagcag--acgtatgactgcgaa
SEQ ID NO:3 709 attgtgtgtgtgcagccg---gatcaaacccaa---ctgtatggcgggtgca
SEQ ID NO:4 721 atcgtcgaagtag---aggaaatcgtcgaaacgggagtaattgctccaaa
SEQ ID NO:5 309 -----

SEQ ID NO:1 766 t-----acgatccgtccctcagcgggtgaacatcgtgctcctg-aaggc
SEQ ID NO:3 754 c-----cggttaaccgctttatttctggtgacttcacccttg-atgac
SEQ ID NO:4 768 cgatgtgcacattccatcaatctattgtcatcgtctagttttgggaaaga
SEQ ID NO:5 309 -----tg-aagtt

SEQ ID NO:1 808 gctac-----cgatgcagc-----tctcccatgagcgctaaga
SEQ ID NO:3 796 agtac-----caaacttag-----cctgcccctaacc-caacgt
SEQ ID NO:4 818 actacaaaaaaccatcgaacggccaatgttcgcacagaaggaccaata
SEQ ID NO:5 316 gatca-----agaagcaaa-----tctcgc-----

SEQ ID NO:1 842 aaatcatcggc-cgcccggcgcttttgaattgactgaaaacgctgtcgt
SEQ ID NO:3 829 aaattagttgcgcggcgccattattcgaaatgcgtaaaggcgggtggg
SEQ ID NO:4 868 aaacctctac-atcggc--tgctggaaatcgagagaaatcattg-cag
SEQ ID NO:5 336 -----taactgga-----

SEQ ID NO:1 891 caacctcggcgtcgggtgctcc-----ggaat--acgttgcttctgttggc
SEQ ID NO:3 879 gaatgtcggcgtcgggtattgc-----tgacg--gcattggcctggtgcgc
SEQ ID NO:4 914 cactgtcagctttggagttcacagatggaatgtacgccaatttgggtatc
SEQ ID NO:5 344 -----tggtgcc

SEQ ID NO:1 934 gg--tgaagaaggatatccga-----tacca-----ttaccctgac
SEQ ID NO:3 922 cg--agaagaaggttgtgctga-----tgact-----ttattctgac
SEQ ID NO:4 964 gggattccgactttggcgccaaattatataccaaatggatttactgttca
SEQ ID NO:5 351 tg--gcaaatggta-----

SEQ ID NO:1 969 cgtcgaagggtg-----gcgccatcgggtggcgt-accgcaggcgggtgcc
SEQ ID NO:3 957 ggtagaaacag-----gtccgattggcggaattacttcacaggggatcg
SEQ ID NO:4 1014 ttgcaaaagtgaatggtattattggagtgagg-accata-----tcca
SEQ ID NO:5 364 -----
```

Figure 8B

```
SEQ ID NO:1 1012 cgttcggttcgtcccgca-atgccgatgccatca----tcgaccacacc
SEQ ID NO:3 1001 c-ctttggcgcgaacgtga-ataccgtgccattc----tggatatgacg
SEQ ID NO:4 1057 agaaaaag----gaacagaaagacgcccgtctcattaatgctggaagagc
SEQ ID NO:5 364 -----ccagga-atg-----

SEQ ID NO:1 1057 tatcagttcgacttctacgatggcggc-----ggtctggacatcg
SEQ ID NO:3 1045 tcccagtttgatttttatcacggtggc-----ggtctggatgttt
SEQ ID NO:4 1103 ---caattactcttct-caaaggagcttcaattgttggttctgatgaatc
SEQ ID NO:5 373 -----ggcggg-----gcaatggacttag

SEQ ID NO:1 1097 cttacctcgccctgg-----cccagtcgatg-----gctcgggcaac
SEQ ID NO:3 1085 gttatttgagttttg-----ctgaagtcgacc-----agcacggtaac
SEQ ID NO:4 1149 attcgcaatgattcgtggttctcatatggatattactgtgctcggcgac
SEQ ID NO:5 392 -----tg-----actggtgcaa-

SEQ ID NO:1 1135 atcaacgtcagca-agttcgggtactaacgttgcgggctgcggcggtttcc
SEQ ID NO:3 1123 gtcggcgtgcata-aattcaatggtaaaatcatgggcaccggtggattta
SEQ ID NO:4 1199 ttca--gtgctcacagtttg---agatttagcgaatggatgattccg
SEQ ID NO:5 404 -----

SEQ ID NO:1 1184 ccaacatt--tcccagcagacaccgaatgtttacttctgcccacct-tc
SEQ ID NO:3 1172 ttgatatcagtgccacttcgaagaaatcatt--ttctgcccacat-ta
SEQ ID NO:4 1243 ggaataatt-----ggtga-aaggaatggcggtgcaatggatctgtc
SEQ ID NO:5 404 -----aaaaagtattatt-----ggca-----

SEQ ID NO:1 1231 acggctggcggcttgaanaatcgctgtcgaagacggcaagtcgaagtcct
SEQ ID NO:3 1219 actgcgggcagtttaaaacagaaatattaccgacggcaaatataatctgt
SEQ ID NO:4 1285 tctgtcccgg-----agcccgtgt-gatcgttgtaatggagcatgtat
SEQ ID NO:5 422 -----tggaacattg-----tgccaagtcaggttctt

SEQ ID NO:1 1281 ccaggaaggcaagccaagaagttcatcaagctgtcgaccagatcactt
SEQ ID NO:3 1269 ccaggaaggacgggtgaagaaatatttccgggaactacgggaatattactt
SEQ ID NO:4 1328 cgaagaacggagagccaaaatt-----ctagagcactg
SEQ ID NO:5 449 caaaaattctaaag---aaatgtacattaccgct-----cacagcaagt

SEQ ID NO:1 1331 tcaacgg-----ttcctatgcagc---ccgcaacggcaaacagttctct
SEQ ID NO:3 1319 tcagcggaaaaatcgctctcgagc---gagggctgg-----atgttcgtt
SEQ ID NO:4 1362 cgaac-----ttcctctga--c---cggcaagg--agtaatttcccg
SEQ ID NO:5 490 aaaaaag-----ttgccatggtggttaccgaattggca-----gtattta

SEQ ID NO:1 1373 a--catcacagaacgctgcgtatttgaactgacca--aagaa-ggcttga
SEQ ID NO:3 1361 a--tatcactgagcgcgcagatttcaagctgaaag--aagac-ggcctgc
SEQ ID NO:4 1398 aatcattactgatatggcagttttcgacgtggacacaaagacggattga
SEQ ID NO:5 530 a--cttcattgaaggcagattagtctta-----a--aagaa--catgc

SEQ ID NO:1 1418 aactcatcgaagtcgcaccgggcatcgatattgaaaagatatcctcgct
SEQ ID NO:3 1406 atttaatcgaatcgccctggcgctcgatttacaagaaagatatctcgac
SEQ ID NO:4 1448 cattgatcgaagt--caggaaggatc-ttactgtagatgatat-----
SEQ ID NO:5 567 tctcat-----gtggatttagaaaca--attaaagcc

SEQ ID NO:1 1468 cacatggacttcaagccgat--cattgata--atccga--aactcatgg
SEQ ID NO:3 1456 aaaaatggatttcaccccagt--gatttcgcagaaactca--aactgatgg
SEQ ID NO:4 1488 --caagaaactca--ccg-----cttgcaa--attcga--aatttccga
SEQ ID NO:5 598 aaaacag-----aagccgatttcattgtt-----gccgatgatttcaaag

SEQ ID NO:1 1511 atgcccgctcttccaggacgggtcccatggga-----ctgaaaaaa---
SEQ ID NO:3 1502 acgaaagattatttatcgatgcggcgatgggttttgcctgcctgaagcg
SEQ ID NO:4 1524 aaatctgaagccaatgggacaggctcctctta-----atcaaggataa-
SEQ ID NO:5 638 aaatgcaaatcagccag-----aaagga-----cttgaattatga
```

Figure 8C

SEQ ID NO:1	1552	-----taa
SEQ ID NO:3	1552	gctcattaa
SEQ ID NO:4	1567	-----
SEQ ID NO:5	673	-----

Figure 8D


```
SEQ ID NO:2      1 -----mrkveiit-----aeqaaqlv
SEQ ID NO:6      1 -----mpvis-----aqeavnyi
SEQ ID NO:7      1 mpilskiwaapaagilrktprnahqmrlismtssmkakvfnsaeavkdi
SEQ ID NO:8      1 -----mnakeli-----arriamel

SEQ ID NO:2      17 kdndtitsigfvssahpealt--kalekrfldntpqnltyiyagsqgkr
SEQ ID NO:6      14 pdeatlcvlg-agggileattlitaladkykqtqtpnlsisptglgdr
SEQ ID NO:7      51 pdnakllvggfglcgipenli--qai-----tktgqkgltcvsnnagv-
SEQ ID NO:8      16 hdgd-ivnlg-----

SEQ ID NO:2      65 dgraaehlahtgllkraighwqtvpaignklavenkieaynfsqgtlvhw
SEQ ID NO:6      63 adrgisplaqeglvkwalcghwgqsprielaenkiiaynypqgvltqt
SEQ ID NO:7      92 dnwglglllqtrqikkmissyvgengefarylsgeleleftpqgtlaer
SEQ ID NO:8      25 -----

SEQ ID NO:2      115 fralaghklgvftdigletfldprqlggklnvdkedivkliev-----
SEQ ID NO:6      113 lraaaahqpgiisdigigtfdvprqggklnvdkedliklvf-----
SEQ ID NO:7      142 iraagagvpafytpgygtql---qeggapikysktekgk-ievaskake
SEQ ID NO:8      25 -----igl-----

SEQ ID NO:2      159 ----dheqlfyptfpvnvafirgtvadesgnitmdeeigpffestavaqa
SEQ ID NO:6      157 ----dnkeylyykaiapdiafiratcdsegyatfedevmyldalviaqa
SEQ ID NO:7      188 trqfnginyvmeeaiwgdfalikawradtlgnlqfrhaagnfnnpckas
SEQ ID NO:8      28 -----ptqvv-----yldnvnitlqsengflglt-----

SEQ ID NO:2      205 vhnccgkvvvqvkdvvahgslpawkipgiyvdyvvaapedhqqtlydc
SEQ ID NO:6      203 vhnnggivmmqvqmkvkatlhpksvripgyld-ivvdpdqtqlygga
SEQ ID NO:7      238 --kc---tiveveelvepgvlapndvhipsiychrlylg-----knykk
SEQ ID NO:8      55 -----

SEQ ID NO:2      255 eydpslsgehrapegatdaalpsakkiigrrgalelttenavvnlgvg--
SEQ ID NO:6      252 pvnrfisgdfdl-ddstklslplnqrklvarralfemrkgaavnvgvg--
SEQ ID NO:7      277 pierpmfahegpikpstaas--gksreiaaraaleftdgmyanlgigip
SEQ ID NO:8      55 -fdp-----enansnl-vn--

SEQ ID NO:2      303 --apeyvasvageegiadtitltveggaig--gvpqggarfsgsrnad--
SEQ ID NO:6      299 --iadgiglvareegcaddfilitvetgpig--gitsqgiafganvnr--
SEQ ID NO:7      325 tlapnyipn-----gftvhlqsengliigvpyprkgtedadlinagke
SEQ ID NO:8      67 --a-----ggqpc--gikkggstf-----

SEQ ID NO:2      347 -----aiidhtyqdfdyggldiaylglaqcdqsgni-nvskfgtn
SEQ ID NO:6      343 -----aildmtsqdfdyhgglvdcylsfaevdqhgnv-gvhkfnkg
SEQ ID NO:7      368 pitllkgasivgsdesfamirgshmditvlgalcqsgfdlanwmipgkl
SEQ ID NO:8      82 -----dsafsfalirgghvdacvlgglevdqeanelanwmvpgkm

SEQ ID NO:2      388 vagcggfpnisqqtprnvycgtftagglkiav-----edgkvkilqegk
SEQ ID NO:6      384 imgtggfidisatskkiifcgtltaglktei-----tdgklnivqegr
SEQ ID NO:7      418 vkmgggamdl-----vsapgarvivvmehvskngepkilehce
SEQ ID NO:8      121 vpgmggamdlvtgakkvii-----gmehca-----ksgsskilk---

SEQ ID NO:2      432 akkfikavdqitfngsyaarnghvl--yitercvfel-tkeglklieva
SEQ ID NO:6      428 vkkfirelpeitfsgkialergldvr--yiteravftl-kedglhlieia
SEQ ID NO:7      456 -----lptgkgvisriitdmavfdvdtknlgltlievr
SEQ ID NO:8      155 -----kctlplt-----askkvam--vvtelavfnf-iegrlrvkeha
```

Figure 9A

```
SEQ ID NO:2      479 pgidiekdi--lahmdfkpiidnp-klmdarlfqdgpmglkk-----
SEQ ID NO:6      475 pgvdlqkdi--ldkmdftpvispelkmdlerlfidaamgfvlpeaah
SEQ ID NO:7      489 kdltvd-dikkltackfe-isenl-kpmgqaplnqg-----
SEQ ID NO:8      190 phvdle-ti--kakteadfivad-----dfkemqisqkglel-----
```

Figure 9B

Figure 10

GTGAAACTGTGTATACTCTCGGAATCGACGTTGGTTCTTCTTCTTCCAAGGCAGTCATC
CTGGAAGATGGCAAGAAGATCGTCGCCCATGCCGTCGTTGAAATCGGCACCGGTTGACC
GGTCCGGAACGCGTCTTGGACGAAGTCTTCAAAGATACCAACTTAAAAATTGAAGACATG
GCGAACATCATCGCCACAGGCTATGGCCGTTTCAATGTCGACTGCGCCAAAGGCGAAGTC
AGCGAAATCACGTGCCATGCCAAAGGGGCCCTCTTTGAATGCCCGGTACGACGACCATC
CTCGATATCGGCCGTCAGGACGTCAAGTCCATCAAATTGAATGGCCAGGGCCTGGTCATG
CAGTTTGCCATGAACGACAAATGCGCCGCTGGTACGGGCCGTTTCTCGACGTCATGTCG
AAGGTACTGGAATCCCATGTCTGAAATGGGGGACTGGTACTTCAAATCGAAGCATCCC
GCTGCCGTCAGCAGTACCTGCACGGTTTTTGCTGAATCGGAAGTCATTTCCCTTCTTTCC
AAGAATGTCCGAAAGAAGATATCGTAGCCGGTGCCATCAGTCCATCGCCGCCAAAGCC
TGCGCTCTCGTGCGCCGCTCGGTGTCGGTGAAGACCTGACCATGACCGGCGGTGGCTCC
CGCGATCCCGGCGTCGTGATGCCGTATCGAAAGAATTAGGTATTCCTGTCAGAGTCGCT
CTGCATCCCCAAGCGGTGGGTGCTCTCGGAGCTGCTTTGATTGCTTATGATAAAATCAAG
AAATAA (SEQ ID NO:9)

Figure 11

VKTVYTLGIDVGSSSSKAVILEDGKKIVAHAVVEIGTGSTGPervLDEVFKDTNLKIEDM
ANIATGYGRFNVDCAKGEVSEITCHAKGALFECPGTTTILDIGGQDVKSIKLNQGLVM
QFAMNDKCAAGTGRFLDVMSKVLEIPMSEMGDWYFKSKHPAAVSSTCTVFAESEVISLLS
KNVPKEDIVAGVHQSIAAKACALVRRVGVEDLMTGGGSRDPGVVDAVSKELGIPVRVA
LHPQAVGALGAALIAYDKIKK (SEQ ID NO:10)

SEQ ID NO:9 1 gtgaaaactgtgtatactctcggaaatcgacgttggttcttcttcttccaa
SEQ ID NO:11 1 ---atgagtatctataccttgggaatcgatgttggtatctactgcatccaa
SEQ ID NO:12 1 gtggcagtggtcatattcgattggcattgattccggctcaaccgccaccaa
SEQ ID NO:13 1 -----atgattttagggatagatgttggtatctacaacaacgaa

SEQ ID NO:9 51 ggcagtcacacctggaagatggcaagaagatcgctcgc-ccatgccgtcgtt
SEQ ID NO:11 48 gtgcattatcctgaaagatggaaaagaatcgctggc-gaaatccctggta
SEQ ID NO:12 51 agggatcttactggcagacggcgtgatta---cgcgccgtttcctcgtt
SEQ ID NO:13 39 gatggttctaattggaagatagc---aagataatttg-gtataagatagag

SEQ ID NO:9 100 gaaatcggcaccggttcgaccggtccggaaacgcgtcctggacgaagtctt
SEQ ID NO:11 97 gccgtggggaccggaaacttcgggtcccgacgggtctatttcggaagtccct
SEQ ID NO:12 97 ccaa---ccccctttcgcccg-gaacagcaattact---gaagcctg
SEQ ID NO:13 85 gatattgg-agttgtta-----ttgaggaagatattttatataaaatggt

SEQ ID NO:9 150 caaagatacc-aacttaaaaattgaagacatggcgaacatcatcgc-cac
SEQ ID NO:11 147 ggaaaatgcc-cacatgaaaaaagaagacatggcctttaccctggc-tac
SEQ ID NO:12 138 ggaa-actct-gcgcgaagggttagagacaacggcgtttctgacgctcac
SEQ ID NO:13 129 taaggagattgaacaaaaatatccaatagat----aaaatcgttgc-aac

SEQ ID NO:9 198 aggcctatggcgtttcaatgtcg-----actgcgcaaaaggcgaag
SEQ ID NO:11 195 cggctacggacg---caat-tcgtctggaaggcattgccgacaagcaga--
SEQ ID NO:12 186 cggctacggcgccgcaactggtgg-----atttgccgataaacagat
SEQ ID NO:13 174 tggatattggaaggcataaggtta-----gttttgagataaagatag

SEQ ID NO:9 239 tcagcgaatacagctgccatgccaaaggggcc---ctctttgaatgcccc
SEQ ID NO:11 239 tgagcgaactgagctgccatgccatggcgcc---agctttatctggccc
SEQ ID NO:12 227 taacggaaaatctctgtcacgggctggcgca---cggtttcttgccca
SEQ ID NO:13 215 ttccagaagtta-ttgcatgggaaaaggagctaactatttctttaacga

SEQ ID NO:9 286 ggtacgacga--ccatcctcgatatcgccgggtcaggacgtcaa-gtccat
SEQ ID NO:11 286 --aacgtccataccgtcatcgatatcgccgggcaggatgtgaa-ggtcat
SEQ ID NO:12 274 gcaacgcgcg--cggtaatcgacatcggtggtcaggacagcaagtgatt
SEQ ID NO:13 264 ggcagatgga----gttatagacattggaggcgaagatacaaaa-ggtcct

SEQ ID NO:9 333 caaattga--atggccaggcctggtcatgcagtttgcc-atgaacgaca
SEQ ID NO:11 333 ccatgtgg--aaaacgggaccatgacca---atttcag-atgaatgata
SEQ ID NO:12 322 cagcttgatgatgacggttaacctg---tgcgatttcctgatgaatgaca
SEQ ID NO:13 309 aaagattg--ataaaaacggaaaagtgttgattttatc-ctatcagata

SEQ ID NO:9 380 aatgcgcgctggtacggcggtttcctcgacgtcatgtcgaaggtactg
SEQ ID NO:11 377 aatgcgctgccgggactggccgtttcctggatgttatggccaatatcctg
SEQ ID NO:12 368 aatgcgcgcgggcaccggcggtttcctggaggtgatctcgcgacgctt
SEQ ID NO:13 356 aatgtgcgctggaactggaattcttaga-----aaaggcatta

SEQ ID NO:9 430 gaaatccccatgtct-ga--aatgggggactgtgactt-caaatcgaagc
SEQ ID NO:11 427 gaagtgaaggtttcc-ga--cctggctgagctgggagc-caaatccacca
SEQ ID NO:12 418 ggca--ccagcgtcgagc--aactcgacagcattaccg-aaaat---gtc
SEQ ID NO:13 397 gatattttaaaatt-gataaaatgagataaataaatacaaatcagata

SEQ ID NO:9 476 atccccgt-gccgtcagcgtacgtgcacggttttctgctgaatcggaagt
SEQ ID NO:11 473 aacgggtg-gctatcagctccacctgtactgtttgctgaaaagtgaagt
SEQ ID NO:12 460 acgcccgcagccatcacgagtatgtgcacagtgtttgctgaatcagaagc
SEQ ID NO:13 446 atatcgct-aaaatatcttcaatgtgtgctgtctttgctgaaagtgaagt

Figure 12A

```
SEQ ID NO: 9      525 catttccttctttccaagaatgtcccgaagaa--gatatcgtagccgg
SEQ ID NO: 11     522 catcagccagctgtccaa--aggaaccgacaagatcgacatcattgccgg
SEQ ID NO: 12     510 gatcagcctgcgctcagcggcgctcgccagaa--gcgattctcgagg
SEQ ID NO: 13     495 aataagcttactatcaaaaaagttccaaaggaa--ggcattttaatggg

SEQ ID NO: 9      573 tgtccatcagtcacgcgcgcaagcctgcgctctcgtgc-gccgcgtc
SEQ ID NO: 11     570 gatccatcggttctgtagccagccgggtcattggtcttgcca-atcggtg
SEQ ID NO: 12     558 agtgattaacgcgat-ggcgcggaggagtgc-caatttcatt-tgctcgtc
SEQ ID NO: 13     543 cgtctatgagagtat-----aataaatagggttatcccaatgaccaata

SEQ ID NO: 9      622 ggtgtcgg--tgaagacctgaccatgaccggcggtggctcccgcgat--c
SEQ ID NO: 11     619 gggattgt--gaaagacgtggtcatgaccggcggtgtagccagaaac--t
SEQ ID NO: 12     605 tctc-ctg--tgaagcgccgattctgtttactggtggcgttagtcattgc
SEQ ID NO: 13     587 ggcttaaaattcaaacatagtggttagtgaggaggttgctaaaaat--a

SEQ ID NO: 9      668 ccggcgtcgtcgatgccgtatcgaagaat-----taggtattcctgtc
SEQ ID NO: 11     665 atggcgtgagaggagccct-----ggaag-----aaggccttggcgtg
SEQ ID NO: 12     652 cagaagt-----tgcccggatgctggaatctcacctgcgaatgccggtg
SEQ ID NO: 13     635 aggttttggttgagatgtttgagaaaaat-----tgaataaaaaacta

SEQ ID NO: 9      712 agagtcgctctgcaccccaagcggtg-----ggtgctctcgagctgc
SEQ ID NO: 11     703 gaaatcaagacgtctcccctggctcagtacaacgggtgacctgggtgcccgc
SEQ ID NO: 12     697 aatacccatcctgatgcgcaatttgct-----ggcgcaattggcgcggc
SEQ ID NO: 13     679 ctaattccaaaagaaccacagattgtt-----tgctgtgttgagctat

SEQ ID NO: 9      756 tttgattgctta----tgataaaatcaagaaa-taa
SEQ ID NO: 11     753 tctgtatgcgta-----t-aaaaagcagccaaataa
SEQ ID NO: 12     741 ggtaattggtcaacgagtgaggacacgcgatga---
SEQ ID NO: 13     723 attggtt-----taa-----
```

Figure 12B

Figure 13

```
SEQ ID NO:10      1 vktvytlgidvgssskaviledgkkivahavveigtgstgpervldevf
SEQ ID NO:14      1 ms-iytlgidvgstaskciilkdgkeivakslvavgtgtsgparsisevl
SEQ ID NO:15      1 mavaysigidsgstatkgilladg-vitrflvpt---pfrpataiteaw
SEQ ID NO:16      1 ----milgidvgstttkmvlmeds-kiiwykiedigv--viedillkmv

SEQ ID NO:10      51 kdtnlkiedmanilatgygrfnvd-cakgevseitchakgalfecpgttt
SEQ ID NO:14      50 enahmkkedmaftlatgygrnslegiadqmselschamgasfiwpnvht
SEQ ID NO:15      47 etlreglettpfltltygygrqlvd-fadkqvteischglgarflapatra
SEQ ID NO:16      44 keieqkyp-idkivatgygrhkvs-fadkivpevialgkqanyffneadg

SEQ ID NO:10      100 ildigggdvksiklnggglvmqfamndkcaagtgrfldvmskvleipmse
SEQ ID NO:14      100 vidigggdvkvihev-ngtmtnfqmndkcaagtgrfldvmanilevkvsd
SEQ ID NO:15      96  vidigggdskviqlddgnlcdflmndkcaagtgrflevisrtltgtsveq
SEQ ID NO:16      92  vidigggdtkvlikidkngkvvdfiledkcaagtgkflekaldilkidkne

SEQ ID NO:10      150 mgdwyfkskhpavsstctvfaesevisllsknvpkedivagvhqsiaak
SEQ ID NO:14      149 laelgakstkrvaisstctvfaesevisqlskgtkdidiagihrsvasr
SEQ ID NO:15      146 l-dsitenvtphaitsmctvfaeseaislrsgavapeailagvinamarr
SEQ ID NO:16      142 ink--yksdniakissmcavfaeseiisllskvpkegilmgvyesiinr

SEQ ID NO:10      200 acalvrrrvvgedltmtgggsrdpgvvdavskelgipvrvalhpqavgal
SEQ ID NO:14      199 viglanrvgivkdvmvggvaqnygvrgaleeglgveiktsplaqyngal
SEQ ID NO:15      195 sanfiarlsceapilftggvshcqhfarmleshlrmpvntphdaqfagai
SEQ ID NO:16      190 vipmtnrilki-qnivfsggvaknkvlvemfekklinkllipkepqlvccv

SEQ ID NO:10      250 gaaliaydkikk--
SEQ ID NO:14      249 gaalyaykkaak--
SEQ ID NO:15      245 gaavig-qrvrtrr
SEQ ID NO:16      239 gailv-----
```

Figure 14

ATGAGTGAAGAAAAACAGTAGATATTGAAAGCATGAGCTCCAAGGAAGCCCTTGGTTAC
TTCTTGCCGAAAGTCGATGAAGACGCACGTAAAGCGAAAAAGAAGGCCGCTCGTTTGC
TGGTCCGCTTCTGTGCTCCTCCGGAATTCTGCACGGCTATGGACATCGCCATCGTCTAT
CCGGAAACTCACGCAGCTGGTATCGGTGCCCGTCACGGTGCTCCGGCCATGCTCGAAGTT
GCTGAAAACAAAGTTACAACCAGGACATCTGTTCCCTACTGCCGCGTCAACATGGGCTAC
ATGGAACTCCTCAAACAGCAGGCTCTGACAGGCGAAACGCCGGAAGTCTCAAAAACTCC
CCGGCTTCTCCGATTCCCCTTCCGGATGTTGTCTCACTTGCAACAACATCTGCAATACC
TTGCTCAAATGGTATGAAAACCTTGGCTAAAGAATTGAACGTACCTCTCATCAACATCGAC
GTACCGTTCAACCATGAATTCCCTGTTACGAAACACGCTAAACAGTACATCGTCGGCGAA
TTCAAACATGCTATCAAACAGCTCGAAGACCTTTGCGGCCGTCCTTCGACTATGACAAA
TTCTTCGAAGTACAGAAACAGACACAGCGCTCCATCGCTGCCTGGAACAAAATCGCTACG
TACTTCCAGTACAAACCGTCGCCGCTCAACGGCTTCGACCTCTTCAACTACATGGGCCTC
GCCGTTGCTGCCGCTCCTTGAACACTCTCGGAAATCACGTTCAACAAATTCCTCAAAGAA
TTGGACGAAAAAGTAGCTAATAAGAAATGGGCTTTCGGTGAAAACGAAAAATCCCGTGTT
ACTTGGGAAGGTATCGCTGTCTGGATCGCTCTCGGCCACACCTTCAAAGAACTCAAAGGT
CAGGGCGCTCTCATGACTGGTTCCGCTTATCCTGGCATGTGGGACGTTTCTACGAACCG
GGCGACCTCGAATCCATGGCAGAAGCTTATCCCGTACATACATCAACTGCTGCCTCGAA
CAGCGCGGTGCTGTTCTGAAAAAGTTGTCCGCGATGGCAATGCGACGGCTTGATCATG
CACCAGAACCCTCCTGCAAGAACATGAGCCTCCTCAACAACGAAGGCGGCCAGCGCATC
CAGAAGAACCTCGGCGTACCGTACGTCTCTCGACGGCGACCAAGCCGATGCTCGTAAC
TTCTCGGAAGCACAGTTCGATACCCGCTAGAAGCTTTGGCAGAAATGATGGCAGACAAA
AAAGCCAATGAAGGAGGAAACCACTAA (SEQ ID NO:17)

Figure 15

MSEKTVDIESMSKEALGYFLPKVDEDARKAKKEGRLVCWSASVAPPEFCTAMDIAIVY
PETHAAGIGARHGAPAMLEVAENKGYNQDICSYCRVNMGYMELLKQALTGETPEVLKNS
PASPIPLPDVVLTCCNICNTLLKWYENLAKELNVPLINIDVPFNHEFPVTKHAKQYIVGE
FKHAIKQLEDLCGRPFDDYDKFFEVQKQTSIAAWNKIATYFQYKPSPLNGFDLFNYMGL
AVAAARSLNYSEITFNKFLKELDEKVANKKWAFFGENEKSRTWEGIAVWIALGHTFKELKG
QGALMTGSAYPGMWDVSYEPGDLESMAEAYSRTYINCCLEQRGAVLEKVVRDGGKCDGLIM
HQNRSCKNMSLLNNEGGQRIQKNLGVPYVIFDGDQTDARNFSEAQFDTRVEALAEMMADK
KANEGGNH (SEQ ID NO:18)

```
SEQ ID NO:17      1 atgagtgaagaaaaaacagtagatatgaaagcatgagctccaaggaagc
SEQ ID NO:19      1 atg-----ccaaagacagta-----agccctggcggttcagg---
SEQ ID NO:20      1 ----atgatgaattaaag--gcaattgaaaagtga--tgcaa-----
SEQ ID NO:21      1 -----atgtcacttgtcaccga-----tcta-----ccccgc

SEQ ID NO:17      51 cctt---ggttacttcttgcgaaa--gtcgatgaagacgca-----c
SEQ ID NO:19      32 -cat---tgagagatgtagtgtgaaaaggtttacagagaactg-----c
SEQ ID NO:20      37 -----aaatt-----cgcca--gtagaaagaacagc-----t
SEQ ID NO:21      27 cattttcgatcagttct--ctgaag--ctcgccagacaggctttctcacc

SEQ ID NO:17      89 gta-aagcgaaaa-aagaaggccgcctcgttt-gctggtccgcttctgtc
SEQ ID NO:19      71 ggg-aaccgaaag--aaagaggagaaaaagtag-gctggtcctcttc--ca
SEQ ID NO:20      63 atataagcaaaaaagaaggttagaaaaagttt---ttggaatgttctgtg
SEQ ID NO:21      73 gtc-atggatctc-aaggag--cgcggcattccgctggt-----tggc

SEQ ID NO:17      136 gctcctccggaattctgcacggctatggacatcgccatcgtc--tatccg
SEQ ID NO:19      116 agttcccctgcgaactggctgaatcttttcggctgcatgttgggtatccg
SEQ ID NO:20      110 cct-----atgttcca-----atagaaat---aat--tt--tagcag
SEQ ID NO:21      112 act-----tactgcacctttatg---ccgcaagag-----atccc

SEQ ID NO:17      184 gaaactca--cgcagctggtatcggtgcc---cgtcacggtg-----
SEQ ID NO:19      166 gaaaacca--ggctgctggtatcgctgccaaccgtgacggcgaagtgatg
SEQ ID NO:20      140 caaatgcaatcccagttggtttgtgtgga--ggtaaaaat-----
SEQ ID NO:21      144 ga-----t--ggcagc-----cggtgcg---ggt---gtg-----

SEQ ID NO:17      221 -----ctccggccatgc
SEQ ID NO:19      214 tgcagggtgcagaaagatatcggttatgacaacgatatctcgcggtatgc
SEQ ID NO:20      178 -----gacacaa
SEQ ID NO:21      166 -----gttcgctctgt

SEQ ID NO:17      233 tcgaagt-t-----gctg-----aaaa--
SEQ ID NO:19      264 ccgtatt-tccctggcttatgctgccgggttcgggggtccaacacaaatg
SEQ ID NO:20      185 tcccaat-a-----gcag-----a-----
SEQ ID NO:21      178 tccacctct-----gatg-----aaac--

SEQ ID NO:17      249 --caaaggttacaaccaggacatctgttcctactgccggtcaacatg--
SEQ ID NO:19      313 gacaaagatggcaactatgtcatcaacccccacagcggcgaacagatgaa
SEQ ID NO:20      198 ---ggaggat-ttgccaagaaacctatgcc-----cattaata---
SEQ ID NO:21      195 --ca---ttgaagaagcggagaaagat----ctgccgcg--caacct--

SEQ ID NO:17      295 -----ggctacatggaactc--ctcaaacagcag-----
SEQ ID NO:19      363 agatgccaatggcaaaaaggtattcgacgcagatggcgaacccgtaatcg
SEQ ID NO:20      232 -----aaatc--atccta---tg-----
SEQ ID NO:21      231 -----ctgcccg---ctg--attaaa-agca-----

SEQ ID NO:17      322 -----
SEQ ID NO:19      413 atcccaagaccctgaaaccccttgcaccaccgacaacatctatgaaatc
SEQ ID NO:20      245 -----
SEQ ID NO:21      251 -----

SEQ ID NO:17      322 ---gctctgac---aggcgaaa-----cgccggaa-gtcctcaa
SEQ ID NO:19      463 gctgctctgccggaagggaagaaagacccgccgcggaatgccctgca
SEQ ID NO:20      245 ---gttttaa-----gaa-ggca--aa
SEQ ID NO:21      251 ---gctacggc---ttcggcaa-----aaccg-----at
```

Figure 16A

SEQ ID NO:17 354 aaactccccggttctccgattccccctccggatgttgctcctcacttgca
SEQ ID NO:19 513 caaatatcgtcagatgaccatgcccatgccgacttcgtgctgtgctgca
SEQ ID NO:20 261 aacctgccc--ttactttgaagcatct---gatatagttat-tggagaa
SEQ ID NO:21 274 aaatgccctacttct-----acttttcggatctggtggtc---ggtg

SEQ ID NO:17 404 acaacatctgca-----ataccttgctcaaatggtatgaaaacttg-
SEQ ID NO:19 563 acaacatctgca-----actgcatgaccaaatggtatgaagacattg-
SEQ ID NO:20 304 actacctgtgaaggaaagaagaagatgtttgagtgtatggagagattggt
SEQ ID NO:21 314 aaaccacctgcg-----acggcaaaaagaaatgtatgaatacatg-

SEQ ID NO:17 446 -ctaaagaattgaac---gtacctctca---tcaacatcgacgtac--c
SEQ ID NO:19 605 -cccgtcggcacaac---attcctttga---tcatgatcgacgttc--c
SEQ ID NO:20 354 gccaatgcataataat---gcacctcccacacatgaaagatgaagatt--c
SEQ ID NO:21 356 -c---ggagtttaagcctgttcatgtga---tgca-attgcccaacagc

SEQ ID NO:17 486 gttca--accatgaattc---cctg--tta-cgaa----ac--acgctaa
SEQ ID NO:19 645 ttaca--ac---gaattcgaccatg--tcaacgaa----gccaacgtgaa
SEQ ID NO:20 399 tttga--a-----aatct---ggat--taa-agaagttgaa--aagctaa
SEQ ID NO:21 397 gtttaaggacgatgcctcg---cgtgcgtta-tgga----a-----

SEQ ID NO:17 522 acagtacatcgctg----gcgaattcaaacatgctatca----aacagc
SEQ ID NO:19 684 a---tacatccggt-----cccagctggatacggccatcc----gtcaaa
SEQ ID NO:20 434 --aagaattggttgagaaagagactggaataaaaataacagaggaaaagt
SEQ ID NO:21 429 --agccgagatgct-----gcgcttgcaa-----a-----aaacgg

SEQ ID NO:17 563 tcgaagacctttgcgccgtcccttcgactatgacaaattcttcgaagta
SEQ ID NO:19 722 tggaagaaatcacccggcaagaagttcgatgaagacaaattc-----gaa
SEQ ID NO:20 482 taaaaga-----gacagttgat--aaagta
SEQ ID NO:21 458 tagaagaacgttttgggcacgagattagcgaagatgctctgcgcgatgcc

SEQ ID NO:17 613 cagaacacagacacagcgctc-catcg--ctgcc-----tggaacaaaat
SEQ ID NO:19 766 cag-tgctgccagaacgc-c-aaccgtactgccaaagcatggctgaaggt
SEQ ID NO:20 505 aataaagttagggag-----t-----tggtttataaa
SEQ ID NO:21 508 attgcgctgaaaaaccggaacgtcg--cgcac-----tgg---ctaata

SEQ ID NO:17 654 cgctacgtacttc--c--agtacaaaccgtcgccgctcaacggcttcgac
SEQ ID NO:19 813 ttgcgactacctg--c--agtacaaaccggctccgttcaacgggttcgac
SEQ ID NO:20 532 ctctatgaattga--ggaagaataaaccagctccaattaagggtttagat
SEQ ID NO:21 547 ttttatcatcttgggc--agttaaatcctccggcgcttagcggcagcgac

SEQ ID NO:17 700 ctcttcaactacatgggcctcgccg--ttgctgccgctccttgaactact
SEQ ID NO:19 859 ctggtcaaccatatggctgacgtgg--ttaccgcccgtggccgtgtggaag
SEQ ID NO:20 580 gttttaaaattattccagtttgctattttatggatattgatgacacaat
SEQ ID NO:21 595 attctga---aagtggtttacggcg--caaccttcgggttcgataaagagg

SEQ ID NO:17 749 cggaatcacgttcaacaaattcctcaaagaattggacgaaaaagtagc-
SEQ ID NO:19 908 ctgctgaagctttcgaactgctggccaaggaaactggaacagcatgt---
SEQ ID NO:20 630 agggatt----ttagaggatttaattgaggagtttagaggagagaggt---
SEQ ID NO:21 641 cg-----ttgatcaatgaactggatgcaatgaccgcc

SEQ ID NO:17 798 -----taataagaaatgggctttcggtgaa-----aacgaaaaatcccc
SEQ ID NO:19 954 -----gaaggaaggcaccaccacggctcccttcaaagaacagcatcg
SEQ ID NO:20 673 -----aaaaaaggagaaggttatgaaggaa-----agagaa-----
SEQ ID NO:21 673 cgcggtcgtcagcagtggaagaag--gcc-----agcgactggacccg

SEQ ID NO:17 837 tgttacttgggaaggta-tcgtgtctggatcgctctcggccacacc---
SEQ ID NO:19 996 tatcatgttcgaaggga-tcccctgctgg--ccgaaactgccgaacc---
SEQ ID NO:20 704 -----ttttaataac-tggctgtc-caatgggttgctggaacaataag
SEQ ID NO:21 715 cgt--ccgcgcattttaatcacccggctg---cccgatggcggcgc----

Figure 16B

```
SEQ ID NO:17 883 ----t--tcaaagaactca--aaggtcagggcgctctcatgactgggtcc
SEQ ID NO:19 1040 ----tgttcaaaccgctga--aagccaacggcctgaacatcacggcggt
SEQ ID NO:20 745 attgt--tgaattattgaggaagt--ggaggagtagttggttgtaa
SEQ ID NO:21 756 -----agcaga--aaaagtgtgcgcgattgaagagaatg

SEQ ID NO:17 925 gcttat---cctggcatgtgggacgtttcctacgaacc-----ggg-
SEQ ID NO:19 1084 gtatatgctcctgctttcgggttcgtgtacaacaacct-----gga-
SEQ ID NO:20 790 g--aaa---gctgcactggaacaagattctttgaaaactttgttgaggg-
SEQ ID NO:21 791 gc---g---gctgggttgtcggttatgaaaactgcacc-----gggg

SEQ ID NO:17 963 -----cga---cctcg-aatccatggcagaa---gcttattcccgtac
SEQ ID NO:19 1125 -----cga---attgg---tcaaagcctact---gcaaagccccgaac
SEQ ID NO:20 834 -----ctatagcgtag-aggacattgcaaaa---agata----cttta
SEQ ID NO:21 827 cgaaagcga---ccgagcaatgcgtggcagaaacgggcgagtgtctacgac

SEQ ID NO:17 999 atac-----atcaactgctgcct-----cgaacagcgcggtgct
SEQ ID NO:19 1159 -tcc-----gtca-----gcat-----cgaacaggggtgttgc
SEQ ID NO:20 869 aaat-----cccatgtgctttagatttaaaacgatgagagagttgaa
SEQ ID NO:21 874 gcgctggcgataaatactctggc-----gattggctgctcct

SEQ ID NO:17 1033 gttcttgaaaaagttgtccgcgatggcaaatgcgacggc-ttgatcatgc
SEQ ID NO:19 1186 tggcgtgaaggcctgatccgcgacaacaaggttgacggc-gtactggttc
SEQ ID NO:20 913 aatataaagagatttggttaagagttggacgtcgatggagttgtttat--
SEQ ID NO:21 911 gtgtttcgcgaacgatcagcgctgaaaatgc-tcagc-cagatggtgg

SEQ ID NO:17 1082 accagaacc-gttcctgcaagaacatgagcctcctcaacaacgaaggcg-
SEQ ID NO:19 1235 actacaacc-ggtcctgcaaaccttgagcggtacatgcctgaaatgc-
SEQ ID NO:20 961 ----tacac-tttgcagtattgccat----acatttaacatagagggagc
SEQ ID NO:21 959 aggaatatcaggtcgatggcgtagttga----tgtgattttgcaggcgt

SEQ ID NO:17 1130 ---gccagcgcatc-cagaagaacctc--ggcgtaccgtacgtcatcttc
SEQ ID NO:19 1283 ---agcgtcgtttc-accaaagacatg--ggtatccccactgctggattc
SEQ ID NO:20 1002 taaggtagaggagg-cattaaaaggaggggcattccaattataagaatt
SEQ ID NO:21 1004 ---gccatacctacgcggtggaatcgc--tggcgattaaacgtcatgtgc

SEQ ID NO:17 1174 gacggcgaccagaccgatgctcgtaacttctcggaagca-----
SEQ ID NO:19 1327 gacggtgaccaggctgacccgagaaactcaacgcggct-----
SEQ ID NO:20 1051 gaaactgactattctga-----aagtgatag--agag-----
SEQ ID NO:21 1049 gccagc-agcacaacattccttatatcgctattgaaacagactactccac

SEQ ID NO:17 1213 -----cagttcgatacccgcgtagaagctttggcagaaatga
SEQ ID NO:19 1366 -----cagtatgagaccgtgttcagggcttggcgaagcca
SEQ ID NO:20 1081 -----cagttaaaaacaaggttgaggcatttattgagatga
SEQ ID NO:21 1098 ctcggatgtcgggcagctcagtaccgtgtcgcggcctttattgagatgc

SEQ ID NO:17 1250 tggcagacaaaaaagccaatgaaggaggaaccactaa
SEQ ID NO:19 1403 tggaag-caaatgatgaaaagaagg-ggaaataa----
SEQ ID NO:20 1118 t-----ttaa-----
SEQ ID NO:21 1148 tgtaa-----
```

Figure 16C

Figure 17

```
SEQ ID NO:18 1 --mseektvdiessskealgyflpkvdedarkakkegrlvcwsasvapp
SEQ ID NO:22 1 ----mpktvs----pgvqalrdvvekvyrelrepkergekvgskskfp
SEQ ID NO:23 1 --mmkika--ieklmqkfa-----srkeqlykqkeegrkvfgm-----
SEQ ID NO:24 1 mslvtdlpaifdqfsearqtg-fltvmdlkergiplvg-----

SEQ ID NO:18 49 efctamdiaivypethaag---igarhgapamleavenkgynqdicyscr
SEQ ID NO:22 43 elaesfrlhvgypenqaag---iaanrdgevmcqaadigyndicgyar
SEQ ID NO:23 35 -fcayvpieiila-anaip---vglcgqkndtipiae-edlprnlcplik
SEQ ID NO:24 38 tyctfmpqei----pmaagavvslcstsdetieeae-kdlprnlcplik

SEQ ID NO:18 96 vnmgy-----
SEQ ID NO:22 90 islayaagfrgankmdkdgnyvinphsgkqmkdangkkvfdadgkpvldp
SEQ ID NO:23 79 ssygf-----
SEQ ID NO:24 83 ssygf-----

SEQ ID NO:18 102 ellkqgaltgetpev-----lknspaspiplpdivltcnn
SEQ ID NO:22 140 ktlkpfattdniyeiaalpegeektrrqnalhkyrgmtmpmpdfvlcnn
SEQ ID NO:23 84 -----kkaktcpyfeasdiviget
SEQ ID NO:24 88 -----gktdkcpyf-----y-----fsdlvvg-et

SEQ ID NO:18 137 icntllkwyenlakelnvplnidvpfnhefpvtkhakqyivgefkhak
SEQ ID NO:22 190 icnmtkwyediarrhniplimidvpnyefdhvneanvkysqldtair
SEQ ID NO:23 103 tceggkkmfelm--erlvpmhimhlphmkd----edsllkiwikeveklke
SEQ ID NO:24 107 tcdgkkkmyeymaefkpvhvmqlpnsvkdd-----asralwkaemrlqk

SEQ ID NO:18 187 qliedlgrpfdydkffe---vqkqtqrsiaawnkiatyfykpsplngfd
SEQ ID NO:22 240 qmeeitgkkfdekdfeq---ccqnanrtakawlkvcfylqykpapfngfd
SEQ ID NO:23 147 lveketgnkiteeklke---tvdkvnkvrelfyklyelrknkpapikgid
SEQ ID NO:24 152 tveerfgheisedalrdaialknrerralanfyhlg---qlnppalsgsd

SEQ ID NO:18 234 ---lfnymglavaarsllyseitfnkflkeldekvan--kkwafge--n-
SEQ ID NO:22 287 ---lfnhmadvvtargrveaaefellakeleghvke--gtttapf--k-
SEQ ID NO:23 194 vlklfqfaylldiddtigile---dlieeleerv---kk---ge--gy
SEQ ID NO:24 199 ---ilk---vvygatfrfdk---ealineldamtarvrqqweegqrlid-

SEQ ID NO:18 276 eksrvtwegiavwialghtfkelkgqgalmtg---say---pgmwdvay
SEQ ID NO:22 329 eqhrimfegipcpwklpnlfkplkanglnitg---vvy---apafgfv
SEQ ID NO:23 231 egkrilitgcpmvagnnkiveiieevgvgvvg---eesctgtrffenfv
SEQ ID NO:24 238 prprilitgcpiggaaekvvraieengwvvygencga---kateqcva

SEQ ID NO:18 319 epgd1-esmaeaysrtyinccl--eqrgavlekvvrdgkcdglimhqnrs
SEQ ID NO:22 372 --nnl-delvkayckapnsvsi--eqgvawreglirdnkvdgvlvhnrs
SEQ ID NO:23 277 egysv-ediakryfkipcacrfkndervenikrlvkeldvdgvyvtylqy
SEQ ID NO:24 285 etgdvydaladkylaigcscvspndqrlkmlsqmveeyqvvdgvvdlq

SEQ ID NO:18 366 cknmsllnnegg--qriqknlgvpyvifdgdqtdarnfseaqfdtrveal
SEQ ID NO:22 417 ckpwsgympemq--rrftkdmgiptagfdgdqadprnfnaaqyetrvggl
SEQ ID NO:23 326 cht---fniegakveealkeegipiirietdyses---dreqlktrleaf
SEQ ID NO:24 335 chtyaveslaik--rhvzqghnipyiai---etdystsdvgqistrvaaf

SEQ ID NO:18 414 aemmadkkaneggnh
SEQ ID NO:22 465 veameandekkgk--
SEQ ID NO:23 370 iemi-----
SEQ ID NO:24 380 ieml-----
```

Figure 18

ATGAGTCAGATCGACGAACTTATCAGCAAATTACAGGAAGTATCCAACCATCCCCAGAAG
ACGGTTTTGAATTATAAAAAACAGGGTAAAGGCCTCGTAGGCATGATGCCCTACTACGCT
CCGGAAGAAATCGTATATGCTGCAGGCTACCTCCCGGTAGGCATGTCGGTTCCCAGAAC
CCGCAGATCTCCGCAGCTCGTACGTACCTTCCTCCGTTGCTTGCCTTGCCTTGCATGCAGGCT
GACATGGAACTCCAGCTCAACGGCACCTATGACTGCCTCGACGCTGTTATCTTCTCCGTT
CCTTGCGCACTCTCCGCTGCATGAGCCAGAAATGGCACGGCAAAGCTCCGGTCATCGTTC
TTCACACAGCCGCAGAACCGTAAGATCCGCCCGGCTGTCGATTTCTCAAAGCTGAATAC
GAACATGTCCGTACGGAATTGGGACGTATCCTCAACGTAAAAATCTCCGACCTGGCTATC
CAGGAAGCTATCAAAGTATATAACGAAAACCGTCAGGTTATGCGTGAATTCTGCGACGTA
GCTGCTCAGTACCCGCAGATCTTCACTCCGATAAAACGTATGACGTCATCAAAGCCCGC
TGGTTCATGGACAAAGCTGAACACACCGCTTTGGTCCGCGAACTCATCGACGCTGTCAAG
AAAGAACCGGTACAGCCGTGGAATGGCAAAAAGTCATCCTCTCCGGTATCATGGCAGAA
CCGGATGAATTCTCGATATCTTCAGCGAATTCAACATCGCTGTGCTGCTGACGACCTC
GCTCAGGAATCCCGCCAGTTCCTGACAGCTACCGTCCGGCATCGATCCCTCGAACAG
CTCGCTCAGCAGTGGCAGGACTTCGATGGCTGCCCGCTCGCTTTGAACGAAGACAAACCG
CGTGGCCAGATGCTCATCGACATGACTAAGAAATACAATGCTGACGCCGTCGTCATCTGC
ATGATGCGTTTCTGCGATCCTGAAGAATTCGACTATCCGATTTACAAACCGGAATTTGAA
GCTGCTGGCGTTGTTACACGGTCCTCGACCTCGACATCGAATCTCCGTCCCTCGAACAG
CTCCGCACCCGTATCCAGGCTTTCTCGGAAATCCTCTAA (SEQ ID NO:25)

Figure 19

MSQIDELISKLQEVSNHPQKTVLNYKKQGKGLVGMPYYAPEEIVYAAGYLPVGMFGSQN
PQISAARTYLPPFACSLMQADMELQLNGTYDCLDAVIFSVPCDTLRCMSQKWHGKAPVIV
FTQPQNRKIRPAVDFLKAEYEHVTELGRILNVKISDLAIQEAIKVYNENRQVMREFCDV
AAQYPQIFTPIKRHDVIKARWFMDKAEHTALVRELIDAVKKEPVQFWNGKKVILSGIMAE
PDEFLDIFSEFNIAVVADDLAQESRQFRDVPFSGIDPLEQLAQWQDFDGCPLALNEDKP
RGQMLIDMTKKYNADAVVICMMRFCDPEEFDYPIYKPEFEAAGVRYTVLDDLIESPSLEQ
LRTRIQAFFSEIL (SEQ ID NO:26)

```
SEQ ID NO:25      1 atgagtcagatcgacgaacttatcagcaaattacaggaagtatccaacca
SEQ ID NO:27      1 atggct---atcagtgcaacttattgaagagttccaaaaagtat-ctgcca
SEQ ID NO:28      1 -----atgatgaaattaaaggcaattgaaaagttgatgcaaaaat
SEQ ID NO:29      1 atgtcacttgtcaccgatctacccgccattttcgatcagttctctgaagc

SEQ ID NO:25      51 tccccagaag-----ac-----gggttttg---aattataaaaaa
SEQ ID NO:27      47 gccc--gaag-----ac-----catgctggccaaatataaagcc
SEQ ID NO:28      41 tcgccagtag-----aaaagaacagctatat---aagcaaaaagaa
SEQ ID NO:29      51 tcgccagacaggctttctcac-----cgtcatg---gatctcaaggag

SEQ ID NO:25      82 cagggtaaaggcctcgtaggca--tgatgccctactacgctccggaagaa
SEQ ID NO:27      79 cagggcaaaaagccatcggt--gcctgccgtactatgttccggaagaa
SEQ ID NO:28      79 gaaggtagaaaagtttttgaa--tgttctgtgcctatgttccaatagaa
SEQ ID NO:29      91 cgcggcattccgctgggttgccacttactgcacctttatgc--cgcaagag

SEQ ID NO:25      130 atcgtatatgtgcaggctacctcccggtaggcatgt---tcggttccca
SEQ ID NO:27      127 ctggtctatgtgcaggcatggttcccatgggtgtat---ggggctgcaa
SEQ ID NO:28      127 ataatttttagcagcaaatgcaatcccgagttgggttgt---gtggaggtaa
SEQ ID NO:29      139 atcccgatggcagccgg-----tgcggttggtgttctgctctgttccac

SEQ ID NO:25      177 -----gaacccgcag-atctccgcagctcgtacgtaccttctccggtt
SEQ ID NO:27      174 -----tggcaaacagggaagtcggttccaaaggaa-tactgtgcttcctt
SEQ ID NO:28      174 -----aaatgacaca-atcccaatagcagaggaggatttgccaagaaa
SEQ ID NO:29      183 ctctgatgaaacc-----attgaagaagcggagaaagatctgccgcgcaa

SEQ ID NO:25      219 cgcttgctccttgatgcaggctgacatggaactccagctcaacggca---
SEQ ID NO:27      216 ctactgcaccattgcccagcagtcctctggaatgctgtggacggga---
SEQ ID NO:28      216 cctatgcccattataaaaatcatcctatggttttaag----aaggca---
SEQ ID NO:29      228 cctctgcccgtga-----ttaaagcagctacggct--tcggcaaaa

SEQ ID NO:25      266 cctatgactgcctcgacgctgttatcttctcc----gttctc-tgcg---
SEQ ID NO:27      263 ccctggatgggttggaaggatcatca-ctcc----ggtagtgtgtg---
SEQ ID NO:28      259 --aaaacctgcccttactttg-aagcatctgatagttatt-ggag---
SEQ ID NO:29      269 ccgataaatgccctac----ttctacttttc---ggatct-ggtggtc

SEQ ID NO:25      308 ----acactctccgctgcatgagccagaaat-----gg-----c-
SEQ ID NO:27      305 ----ataccctgcgtcccatgagccagaacttcaaagtgg-----cc
SEQ ID NO:28      302 ----aaact-----acctgtgaa-----gg-----a-
SEQ ID NO:29      310 ggtgaaaccacctgcgacggcaaaaagaaaa-----tgtatgaatac-

SEQ ID NO:25      338 ----acggcaagct----ccggtcatcg-tcttcacacagccgcagaa
SEQ ID NO:27      343 atgaaagacaagatg----ccggttattt-tcctggctcatcccagggtc
SEQ ID NO:28      319 ----aagaagaagat---gtttgagttgatggagagattggtgccaatg
SEQ ID NO:29      352 ----atggcggagttaagcctgttcatg-tgatgcaattgccaacagc

SEQ ID NO:25      379 cgtaaga-tccgcccggc-----tgtcgatttccctcaaag-ct
SEQ ID NO:27      388 cgtcagaatgccgccggc-----aagc-agttcacctatg-at
SEQ ID NO:28      361 catataa-tgcacctcccacacatgaaagatgaagattctttgaaaatct
SEQ ID NO:29      397 gttaagg-acgatgcctc-----gcgtgcgttatggaaag-cc

SEQ ID NO:25      415 gaat--acgaacatgtc---cgt-----acgg--aattgg----gacg
SEQ ID NO:27      424 gcct--acagcgaagt-----ga-----aaggccatctgg----aaga
SEQ ID NO:28      410 ggattaaagaagttgaaaagcta-----aaag--aattggttgagaaa
SEQ ID NO:29      433 ga-----gatgctgcg---cttgcaaaaacgg--tagaag----aacg
```

Figure 20A

SEQ ID NO:25 447 tctcctcaacgtaaaa--atctccgacctggctatccaggaagctatcaa
SEQ ID NO:27 456 aatctgcggccatgaa--atcaccaatgatgccatcctggatgccatcaa
SEQ ID NO:28 451 gagactggaaataaaataacagaggaaaagttaaaagagacagttagtaa
SEQ ID NO:29 468 ttttgggcacg--ag--attagcgaagatgctctgcgcgatgccattgc

SEQ ID NO:25 495 agtatataacgaaaaccgtcagggttatgcgtgaattct-----gcg
SEQ ID NO:27 504 agtgtaacaacaagagccgtgctgccgcgcggaattct-----gca
SEQ ID NO:28 501 agtaataaaagtta--gggagttgtttataaaactct-----atg
SEQ ID NO:29 513 gctgaaaaaccgcgaacgtcgcgcactggctaatttttatcatcttgggc

SEQ ID NO:25 536 acgtagctgctcag----taccgcgagatcttcaactccgataaa--acg
SEQ ID NO:27 545 aactggc--caacg----aacatcctgatctgatcccggcttccgtacg
SEQ ID NO:28 539 a-attgaggaagaa-----taaac-cag-----ctccaattaa--ggg
SEQ ID NO:29 563 agttaaatcctccggcgcttagcggcag--cgacattctgaaagt--ggt

SEQ ID NO:25 579 tcatgacgtcatc-----aaag----cccgttg-----ttca
SEQ ID NO:27 588 ggccaccgtactg-----cgtg----ccgcttac-----ttca
SEQ ID NO:28 573 tttagatgtttta-----aaattattccagtttgctatttat
SEQ ID NO:29 609 ttacggcgcaaccttccggttcgataaag--aggcgttg-----atca

SEQ ID NO:25 608 tggacaaagctgaacacaccgctttgggtccgcgaactcatcgacgtgtc
SEQ ID NO:27 617 tgctgaaggatgaatacacccgaaaaagctggaagaactgaacaagg-----
SEQ ID NO:28 611 tggatattgatgacacaatagggttttagaggatttaattgaggagttta
SEQ ID NO:29 650 atgaactggatgcaatgaccgc-----ccgcg--ttcgtcagcagtgagg

SEQ ID NO:25 658 aagaa-----ag--aaccggtacagccgtggaat----ggcaaaaaa
SEQ ID NO:27 662 aactg-----gc--agctgctcctgccggcgaagttcgacggccacaaa
SEQ ID NO:28 661 gaggagagagtttaa--aaaaggagaagggttatgaa-----ggaagaga
SEQ ID NO:29 692 aagaa-----ggccagcgactggaccgcgctccg-----cgcatttta

SEQ ID NO:25 694 gtcacctctcctcgggt-----atcatggcagaaccggatgaattcct---
SEQ ID NO:27 703 gtggttgtttccggc-----atcatctacaacacgcccggcatcct---
SEQ ID NO:28 703 attttaataactggctgtccaatgggtgtgctggaacaataagattgt---
SEQ ID NO:29 730 atcacccgctgcccg-----attggcggcgacgcagaaaaagtggtgcg

SEQ ID NO:25 735 cgatatcttcagcgaatt-caacatcgctgtcgtcgtgacgacctc-gc
SEQ ID NO:27 744 gaaagccatggatgacaa-caaactggccattgctgctgatgactgc-gc
SEQ ID NO:28 750 tgaaattattgaggaagt-tggaggagtagttgttggtgaagaaagctgc
SEQ ID NO:29 774 cgcgat-tgaagagaatggcggctgggttgctcggttatgaaaactgc-ac

SEQ ID NO:25 783 tcagga-atcccgccagttccgtacagacgtaccgtccggcatcgatccc
SEQ ID NO:27 792 ttatga-aagccgcagctttgccgtggatgctccggaagatctgga---c
SEQ ID NO:28 799 actgga-a-----caagattccttgaaaactttgttgagg--gctatagc
SEQ ID NO:29 822 cggggcgaaagcgaccgagcaatgc-gtggcagaaacggg---cgatgtc

SEQ ID NO:25 832 ctcgaaacagctcgtcag-----cagtg--caggacttcgat-g
SEQ ID NO:27 838 aacggactgcatgctgtggtgtacagttctccaaacagaagaacgat-g
SEQ ID NO:28 841 gtagaggacattgcaaa-----aaga-tacttt-a
SEQ ID NO:29 868 tacgacgcgctggcggat-----aatat-----ctgg---cgattg

SEQ ID NO:25 869 ---gctgcccgtcgtcttgaa---cgaagacaaaccgcg-tggccag
SEQ ID NO:27 887 ttctgctgtacgatcc---tgaatttgccaagaataaccggttctgaacac
SEQ ID NO:28 869 ---aaatcccatgtgcttgta-----gatttaaaacgat-gagagag
SEQ ID NO:29 902 ---gctgctc-ctgtgttcgc---cga--acgatcagcg-cctgaaa

SEQ ID NO:25 910 atgctcatcgaca-----tgactaagaaatacaatgctgacgccgtcgtc
SEQ ID NO:27 934 gttggca---atc-----tggtaaaagaaagcggcgagagactgac
SEQ ID NO:28 908 ttgaaaatataaagagattggttaaagagttggacgtcgatggagttgtt
SEQ ID NO:29 940 atgctcagccaga-----tggtggaggaatatcaggtcgatggcgtagtt

Figure 20B

```
SEQ ID NO:25 955 atctgcatgatgcggtttctgcgatcctgaagaattcgactatc---cgat
SEQ ID NO:27 976 gtgttcatgatgcagttctgcgatccggaagaatggaatatc---ctga
SEQ ID NO:28 958 tattacactttgcagtattgccatacatttaacatagagggag---ctaa
SEQ ID NO:29 985 gatgtgattttgcaggcgtgccatacctacgcggtggaatcgctgqcgat

SEQ ID NO:25 1002 ttacaaccggaatttgaagctgctgg----cgttcggttacacggtcctc
SEQ ID NO:27 1023 tctgaagaaggctctggtatgccacca----cattcctcatgtgaagatt
SEQ ID NO:28 1005 ggtagaggaggcattaaaaggaggagg----cattc-----caattata
SEQ ID NO:29 1035 t----aaacgtcatgtgcgccagcagcacacattccttatatcgctatt

SEQ ID NO:25 1048 gacctcgacatcgaatctccgtccctcgaa-----cagctccgcacccg
SEQ ID NO:27 1069 ggtgtggaccagatgacccgggactttggt-----caggcccagaccgc
SEQ ID NO:28 1045 agaattgaaactgactattctgaaagtgatagagagcagttaaaaacaag
SEQ ID NO:29 1081 gaaacagactactccacctcggtatgtcggg-----cagctcagtaccgc

SEQ ID NO:25 1092 tatccaggctttctcggaatcctctaa
SEQ ID NO:27 1113 tctggaagctttcgcagaaagcctgtaa
SEQ ID NO:28 1095 gttggaggcatttattgagatgatttaa
SEQ ID NO:29 1125 tgtcgcggcctttattgagatgctgtaa
```

Figure 20C

Figure 21

```
SEQ ID NO:26      1 msqideliisklqevsnhpqk---tvlnykkqgkglvgmppyapeeiavya
SEQ ID NO:30      1 -maisalieefqkvsaspt---mlakykaqgkkaigclpyyvpeelvyva
SEQ ID NO:31      1 mmkl-kaiekimqkfaskrke---qlykqkeegrkvfgmfcaypieila
SEQ ID NO:32      1 mslvtdlpaifdqfsearqtgfltvmdlkerkiplvgttyctfmpqeipma

SEQ ID NO:26      48 agylpvgmfgsqnpqisaartylppfacslmqadmelqlngt---ydc--
SEQ ID NO:30      47 agmvpmgvwcngkqgevrskeycasfyctiaqqslemldgt---ldg--
SEQ ID NO:31      47 anaipvglcggkndtipiaeedlprnlcpplikssygfkkaktcpyfea--
SEQ ID NO:32      51 agavvvs1cstsdetieeakdlprnlcplikss---yfgkt---dkcpry

SEQ ID NO:26      93 ---ldavifsvpcdtlrcmsqkwh----gkapviftqpqnrkirpavdf
SEQ ID NO:30      92 ---ldgiitpvlcdtlrpsmqnfkvamdkmpviflahpqvrqnaagkqf
SEQ ID NO:31      95 ---sdivigetttceggkkmfelme----rlvpmhimhlp-hmkdedslki
SEQ ID NO:32      96 fyfsdlvvgettcdgkkmeyema----efkpvhvmlpnsvkddasral

SEQ ID NO:26      136 lkaeyehvrtelgrilnvkisdlaiqaikvynenrqvmrefcdvaaqyp
SEQ ID NO:30      139 tydaysevkghleeicgheitndaildaikvynksraarrefcklanehp
SEQ ID NO:31      137 wikeveklkelveketgnkiteekketvdkvkvrelfyklyelrknpk
SEQ ID NO:32      142 wkaemlr1qktveerfgheisedalrdaialknrerralanfyhlqqlnp

SEQ ID NO:26      186 qiftpikrhdivk----arwf---mdkahtalvrelidavkk--epvqp
SEQ ID NO:30      189 dlipasvratv1r----aayf---mlkdeytekleelnkelaa--apagk
SEQ ID NO:31      187 ---apikgldvk----lfqfaylldiddttigiledlieeleervkkgeg
SEQ ID NO:32      192 ---palsgsdilkvvygatfr---fdk---ealinel-damta--rvrqq

SEQ ID NO:26      227 wn-gkk-----vilsg--imaepdefldifsefniavvaddlaqesrqf
SEQ ID NO:30      230 fd-ghk-----vvvsg--iiyntpgilkamddnklaiaaddcayesrsf
SEQ ID NO:31      230 ye-gkr-----ilitgcpmvagnnkiveiieevggvvvgeesctgtrff
SEQ ID NO:32      230 weegqrl1dprprilitgcpiggaekvvraieenggwwvgyenctgakat

SEQ ID NO:26      268 rtdvpsgidp-leqlaqqwqdfdgcp1ained---kprgqmlidmtkkyn
SEQ ID NO:30      271 avdapedldnglhalavqfskqkndv1lydpfakntrsehvgnlvkesg
SEQ ID NO:31      273 enfv-egys--vediakryfkip-cacr1knd---e-rvenikrlvkeld
SEQ ID NO:32      280 eqcvaetg1dv-ydaladkylai-gcscvspnd---q-rlkmlsqmveeyq

SEQ ID NO:26      314 adavvicmmrfcdpeefdy1pykpef-eaagvrytvldldiespsleqlr
SEQ ID NO:30      321 aeg1l1vfmmqfcdpeemeypd1kkal-dahhiphvkigvdqmrtdfggaq
SEQ ID NO:31      315 vdgvvyytlqyctfniegakveeal-keegipi1rietdysesdreq1k
SEQ ID NO:32      324 vdgvv1vilqachtyaves1aikrhvrqghnipy1aietdystsdv1gqls

SEQ ID NO:26      363 triqafseil
SEQ ID NO:30      370 taleafaesl
SEQ ID NO:31      364 trleafiemi
SEQ ID NO:32      374 trvaafiemi
```

1 CGACGGCCCG GGCTGGTATC ATTCTAGTCA GTAATTCACC TTTGGAAAAT TTTCACAAAG
61 GCAGTACGAC AGAAGCGTGC ATACATTCCA TTTAGCAGGA GGAAGTTACG GTAATGAGAA
121 AAGTAGAAAT CATTACAGCT GAACAAGCAG CTCAGCTCGT AAAAGACAAC GACACGATTA
181 CGTCTATCGG CTTTGTGAGC AGCGCCCATC CGGAAGCACT GACCAAAGCT TTGGAAAAAC
241 GGTTCCTGGA CACGAACACC CCGCAGAACT TGACCTACAT CTATGCAGGC TCTCAGGGCA
301 AACGCGATGG CCGTGCCGCT GAACATCTGG CACACACAGG CCTTTTGAAG CGCGCCATCA
361 TCGGTCACTG GCAGACTGTA CCGGCTATCG GTAAACTGGC TGTCGAAAAC AAGATTGAAG
421 CTTACAACCT CTGCGAGGGC ACGTTGGTCC ACTGGTTCGG CGCCTTGGCA GGTCATAAGC
481 TCGGCGTCTT CACCGACATC GGTCTGGAAA CTTTCCTCGA TCCCCTGTCAG CTCGGCGGCA
541 AGCTCAATGA CGTAACCAAA GAAGACCTCG TCAAACTGAT CGAAGTCGAT GGTTCATGAA
601 AGCTTTTCTA CCGGACCTTC CCGGTCAACG TAGCTTTCCT CCGCGGTAAG TATGCTGATG
661 AATCCGGCAA TATCACCATG GACGAAGAAA TCGGGCCTTT CGAAAGCACT TCCGTAGCCC
721 AGGCCGTTC AACTGTGGC GGTAAGTCG TCGTCCAGGT CAAAGACGTC GTCGCTCACG
781 GCAGCCTCGA CCGCGCATG GTCAAGATCC CTGGCATCTA TGTCGACTAC GTCGTGCTAG
841 CAGCTCCGGA AGACCATCAG CAGACGTATG ACTGCGAATA CGATCCGTCC CTCAGCGGTG
901 AACATCGTGC TCCTGAAGGC GCTACCGATG CAGCTCTCCC CATGAGCGCT AAGAAAATCA
961 TCGGCGCCCG CGGCGCTTTG GAATTGACTG AAAACGCTGT CGTCAACCTC GCGTCCGGTG
1021 CTCGCGAATA CGTTGCTTCT GTTGCCGGTG AAGAAGGTAT CGCCGATACC ATTACCTTGA
1081 CCGTCGAAGG TGGCGCCATC GGTGGCGTAC CGCAGGGCGG TGCCCGCTTC GGTTCGTCCC
1141 GCAATGCCGA TGCCATCATC GACCACACCT ATCAGTTCGA CTTCTACGAT GCGCGCGGTC
1201 TGACATCGCG TTACCTCGGC CTGGCCAGT GCGATGGCTC GGGCAACATC AACGTGAGCA
1261 AGTTCGGTAC TAACGTTGCC GGCTGCGGCG GTTCCCCAA CATTTCCAG CAGACACCGA
1321 ATGTTTACTT CTGCGGCACC TTCACGGCTG GCGGCTTGAA AATCGCTGTC GAAGACGGCA
1381 AAGTCAAGAT CCTCCAGGAA GGCAAGGCCA AGAAGTTCAT CAAAGCTGTC GACCAGATCA
1441 CTTTCAACGG TTCTATGCA GCCCGCAACG GCAACACAGT TCTCTACATC ACAGAACGCT
1501 GCGTATTGA ACTGACCAAA GAAGGCTTGA AACTCATCGA AGTCGCACCG GGCATCGATA
1561 TTGAAAAGA TATCCTCGCT CACATGGACT TCAAGCCGAT CATTGATAAT CCGAAACTCA
1621 TGGATGCCCG CCTCTTCCAG GACGGTCCCA TGGGACTGAA AAAATAAATC TCTGCTGTA
1681 AGGAGACTTT ACTATGAAAC CAATGAGACT ACATCAOGTA GGCATTGTCC TGCCGACCTT
1741 AGAAAAAGCC CATGAATTCA TGCAGAATAA TGGACTTGAA ATCGACTATG CCGGCTATGT
1801 CGATCGTTAC CAGGCTGATC TCATTTTAC TAAGTTTGGT GAATTTGCCA GCCCGATTGA
1861 AATGATTATC CCGCACTCCG GTGTGCTTAC CCAATTCAAT GGTGGCCCGG CCGGCATTGC
1921 CCACATCGCC TTGGAAGTGG ACGATGTGCA AGCTGTCCGC CAGGAAATGG AAGCAGATTG
1981 TCCGGGATGC ATGTTAGAAA AGAAAGCTGT CCAGGGTACG GACGACATTA TCGTCAACTT
2041 CCGCCGCCCG ACAACCAACC AGGGTATCCT CGTTGAATAT GTTCAGACGA CAGCACCTAT
2101 CACCGGCCCG GCGGAAAATC CTTTCGTAA GAATCTCGCG CCGGAAAAG GGAAGCTCAA
2161 CGAAACATGG CATCCATGC GCCTGCAOCA TATCGGCATC GTCTTGCCGA CCTTGAAAA
2221 GGCCCATGAA TTCAATCAAGA CCAATGGTCT GGAAGTGGAT TATTCGGGT TCGTCGACGC
2281 CTACCATGCG GATCTCATTT TCACTAAAAA AGGTGAAAAA AGTACGCCCTA TCGAATTCAT
2341 TATTCCCGGT GAAGGGGTCC TCAAAGATT CAATCATGGC AGGGGAGGTA TCGCTCATAT
2401 CGCCTTTGAA GTGGATGATG TCGAAAAGGT ACGTCAGATT ATGGAAGCC AGAAGCCTGG
2461 TTGCATGCTC GAAAGAAAAA CCGTCCGGGG AACGGACGAT ATCATCGTCA ACTTCCGCGC
2521 TCCAGCACAG GACGCCGCA TCCTCGTCA ATATGTCCAG ACCGTAGCTC CCATCAATCG
2581 CAGCAATCCC AACCCTTTTA ATGATTGATT TTTTATAAAG AAAGGTGAAA ACTGTGTATA
2641 CTCTCGGAAT CGACGTTGGT TCTTCTTCTT CCAAGGCAGT CATCTGGAA GATGGCAAGA
2701 AGATCGTCGC CCATGCCGTC GTTGAAATCG GCACCGGTTG GACCGGTCCG GAACGCGTCC
2761 TGGACGAAGT CTTCAAAGAT ACCAACTTAA AAATTGAAGA CATGGCGAAC ATCATCGCCA
2821 CAGGCTATGG CCGTTTCAAT GTCGACTGCG CCAAAGGCGA AGTCAGCGAA ATCAGTGGC
2881 ATGCCAAAGG GGCCCTCTTT GAATGCCCGG GTACGACGAC CATCCTCGAT ATCGGCGGTC
2941 AGGACGTCAA GTCCATCAAA TTGAATGGCC AGGGCCTGGT CATGCAGTTT GCCATGAACG
3001 ACAATGCGC CGCTGGTACG GGCCGTTTCC TCGACGTAT GTGGAAGGTA CTGGAATCC
3061 CCATGTCTGA AATGGGGGAC TGGTACTTCA AATCGAAGCA TCCCCTGCC GTGACGATG
3121 CCTGCACGGT TTTTGTGAA TCGGAAGTCA TTTCCCTTCT TTCCAAGAAT GTCCGGAAG
3181 AAGATATCGT AGCCGGTGTG CATCAGTCCA TCGCCGCCAA AGCCTGCGCT CTCGTGCGCC
3241 GCGTCGGTGT CCGTGAAGAC CTGACCATGA CCGGCGGTGG CTCCGCGAT CCGGCGGTGG
3301 TCGATGCCGT ATCGAAAGAA TTAGGTATTC CTGTGAGAGT CGCTCTGCAT CCCCAGGGG
3361 TGGGTGCTCT CGGAGCTGCT TTGATTGCTT ATGATAAAAT CAAGAAATAA GTCAAAGGAG

Figure 22A

3421 AGAACAAAAT CATGAGTGAA GAAAAAACAG TAGATATTGA AAGCATGAGC TCCAAGGAAG
3481 CCCTTGGTTA CTTCTTGCCG AAAGTCGATG AAGACGCACG TAAAGCGAAA AAAGAAGGCC
3541 GCCTCGTTTG CTGGTCCGCT TCTGTCGCTC CTCCGGAATT CTGCACGGCT ATGGACATCG
3601 CCATCGTCTA TCCGGAAACT CACGCAGCTG GTATCGGTGC CCGTCACGGT GCTCCGGCCA
3661 TGCTCGAAGT TGCTGAAAAC AAAGGTTACA ACCAGGACAT CTGTTCTTAC TGCCGCGTCA
3721 ACATGGGCTA CATGGAATCT CTCAAACAGC AGGCTCTGAC AGGCGAAACG CCGGAAGTCC
3781 TCAAAAACCTC CCCGGCTTCT CCGATTCCCC TTCGGATGT TGTCTCTACT TGCAACAACA
3841 TCTGCAATAC CTTGCTCAAA TGGTATGAAA ACTTGGCTAA AGAATTGAAC GTACCTCTCA
3901 TCAACATCGA CGTACCGTTC AACCATGAAT TCCCTGTTAC GAAACACGCT AAACAGTACA
3961 TCGTCGGCGA ATTCAAACAT GCTATCAAAC AGCTCGAAGA CCTTTGCGGC CGTCCCTTCG
4021 ACTATGACAA ATTCTTCGAA GTACAGAAAC AGACACAGCG CTCCATCGCT GCCTGGAACA
4081 AAATCGCTAC GTACTTCGAG TACAAACCGT CGCCGCTCAA CGGCTTCGAC CTCTTCAACT
4141 ACATGGGCCT CGCCGTTGCT GCCCGCTCCT TGAAGTACTC GGAATCAGG TTCAACAAAT
4201 TCCTCAAAGA ATTGGACGAA AAAGTAGCTA ATAAGAAATG GGCTTTCGGT GAAACGAAA
4261 AATCCCGTGT TACTTGGGAA GGTATCGCTG TCTGGATOGC TCTCGGCCAC ACCTTCAAAG
4321 AACTCAAAGG TCAGGGCGCT CTCATGACTG GTTCCGCTTA TCCTGGCATG TGGGACGTTT
4381 CCTACGAACC GGGCGACCTC GAATCCATGG CAGAAGCTTA TTCCCGTACA TACATCAACT
4441 GCTGCCTCGA ACAGCGCGGT GCTGTCTTG AAAAAGTTGT CCGCGATGGC AAATGCGAOC
4501 GCTTGATCAT GCACCAGAAC CGTTCCTGCA AGAATCATGAG CCTCCTCAAC AACGAAGGCG
4561 GCCAGCGCAT CCAGAAGAAC CTCGGCGTAC CGTACGTCAT CTTGACGGCG GACCAGACOG
4621 ATGCTCGTAA CTTCTCGGAA GCACAGTTCG ATACCCGCGT AGAAGCTTTG GCAGAAATGA
4681 TGGCAGACAA AAAAGCCAAT GAAGGAGGAA ACCACTAATG AGTCAGATCG ACGAACTTAT
4741 CAGCAAAATTA CAGGAAGTAT CCAACCATCC CCAGAAGACG GTTTTGAATT ATAAAAACA
4801 GGGTAAAGGC CTCGTAGGCA TGATGCCCTA CTACGCTCCG GAAGAAATCG TATATGCTGC
4861 AGGCTACCTC CCGGTAGGCA TGTTCCGTTT CCAGAACCCG CAGATCTCCG CAGCTCGTAC
4921 GTACCTTCCT CCGTTTCGTT GCTCCTTGAT GCAGGCTGAC ATGGAATCC AGCTCAACGG
4981 CACCTATGAC TGCTTCGACG CTGTTATCTT CTCGTTTCCT TCGGACACTC TCCGCTGCAT
5041 GAGCCAGAAA TGGCAGCGCA AAGCTCCGGT CATCGTCTTC ACACAGCCGC AGAACCGTAA
5101 GATCCGCCCC GCTGTCGATT TCCTCAAAGC TGAATACGAA CATGTCCGTA CCGAATTGGG
5161 ACGTATCCTC AACGTAAAAA TCTCCGACCT GGCTATCCAG GAAGCTATCA AAGTATATAA
5221 CGAAAAACCGT CAGGTTATGC GTGAATTCTG CGACGTAGCT GCTCAGTACC CGCAGATCTT
5281 CACTCCGATA AAACGTCATG ACGTCATCAA AGCCCGCTGG TTCTATGGACA AAGCTGAACA
5341 CACCGCTTTG GTCCGCGAAC TCATCGACGC TGTCAAGAAA GAACCGGTAC AGCCGTGGAA
5401 TGGCAAAAAA GTCATCTCTT CCGGTATCAT GGCAGAACCG GATGAATTCC TCGATATCTT
5461 CAGCGAATTG AACATCGCTG TCGTCGCTGA CGACCTCGCT CAGGAATCCC GCCAGTTCCG
5521 TACAGACGTA CCGTCCGCGA TCGATCCCTT CGAACAGCTC GCTCAGCAGT GGCAGGACTT
5581 CGATGGCTGC CCGCTCGCTT TGAACGAAGA CAAACCGCGT GGCCAGATGC TCATCGACAT
5641 GACTAAGAAA TACAATGCTG ACGCCGTCGT CATCTGCATG ATGCGTTTCT GCGATCCTGA
5701 AGAATTCGAC TATCCGATT ACRAACCGGA ATTTGAAGCT GCTGGCGTTC GTTACACGGT
5761 CCTCGACCTC GACATCGAAT CTCGCTCCCT CGAACAGCTC CGCACCCGTA TCCAGGCTTT
5821 CTCGGAAATC CTCTAAGAAAT CGCCTGAATC ATCAAACATC TGGGCGGGAC TCCGAAAGGT
5881 GCCTGTCTACA TGATACATTG CCTGTTTCA GGCAGACAGA TTTGACGCTT GCGGCCCCCA
5941 TTGTACGGGC TGCAAGCTGT CAATGATGCT TTAAGACGG CTCTGCGGTT TTTAAATAAA
6001 AACATAAAAC CATATATAAT CTATTAGGAG GAACTCAAT CATGGAATTC AAACCTTTCTG
6061 AATTACAGCA AGATATCGCA AATCTCGCAA AAGATTTTCG AGAAAAAAA TTAGCTCCCA
6121 CTGTCAAAGA GCGTGACGAA AAAGAAGTTT TCGATCGTGC TATCCTTGAC GAAGTGGGTA
6181 CTCTCGGCCT TCTCGGTATT CCCTGGGAAG AAGAAAACGG CGGCGTAGGC GCTGACTTCC
6241 TCAGCCTCGC AGTTGCTTGC GAAGAAGTAG CTAAGTTAC CAGCCCGGGC CGTGC (SEQ
ID NO: 33)

Figure 22B

Figure 23

ATGAAACCAATGAGACTACATCACGTAGGCATTGTCCTGCCGACCTTAGAAAAAGCCCAT
GAATTCATGCAGAATAATGGACTTGAAATCGACTATGCCGGCTATGTCGATGCTTACCAG
GCTGATCTCATTTTCACTAAGTTTGGTGAATTTGCCAGCCGATTGAAATGATTATCCCG
CACTCCGGTGTGCTTACCCAATTCAATGGTGGCCGCGCGGCATTGCCACATCGCCTTC
GAAGTGGACGATGTCGAAGCTGTCCGCCAGGAAATGGAAGCAGATTGTCCGGGATGCATG
TTAGAAAAGAAAGCTGTCCAGGGTACGGACGACATTATCGTCAACTTCCGCCGCCGACA
ACCAACCAGGGTATCCTCGTTGAATATGTTTCAGACGACAGCACCTATCACCGGCCGCGGC
GAAATCCTTTCGTTAAGAATCTCGGCCCGGAAAAAGGGAAGCTCAACGAAACATGGCAT
CCCATGCGCCTGCACCATATCGGCATCGTCTTGCCGACCTTGAAAAGGCCCATGAATTC
ATCAAGACCAATGGTCTGGAAGTGGATTATTCGGTTTCGTGACGCCTACCATGCGGAT
CTCATTTTCACTAAAAAGGTGAAAACAGTACGCCTATCGAATTCATTATCCCCGTGAA
GGGGTCTCAAAGATTTCAATCATGGCAGGGGAGGTATCGCTCATATCGCCTTTGAAGTG
GATGATGTCGAAAAGGTACGTGAGATTATGGAAGCCAGAAGCCTGGTTGCATGCTCGAA
AAGAAAGCCGTCCGGGGAACGGACGATATCATCGTCAACTTCCGCCGTCCAGCACGGAC
GCCGGCATCCTCGTCGAATATGTCCAGACCGTAGCTCCCATCAATCGCAGCAATCCCAAC
CCTTTTAATGATTGA (SEQ ID NO:34)

Figure 24

MKPMRLHHVGIVLPTLEKAHEFMQNNGLEIDYAGYVDAYQADLIFTKFGEFASPIEMIIP
HSGVLTQFNGGRGGIAHIAFEVDDVEAVRQEMEADCPGCMLEKKAVQGTDDIIVNFRPPT
TNQGILVEYVQTAPITGRGENPFVKNLGPEKGKLNETHWHPMRLHHIGIVLPTLEKAHEF
IKTNGLEVDYSGFVDAYHADLIFTKKGENSTPIEFIIIPREGVLKDFNHGRGGIAHIAFEV
DDVEKVRQIMESQKPGCMLEKKAVRGTDIIVNFRPSTDAGILVEYVQTVAPINRSNP
PFND (SEQ ID NO:35)

Figure 25

ATGGAATTCAACTTTCTGAATTACAGCAAGATATCGCAAATCTCGCAAAAGATTTGCA
GAAAAAAAAATTAGCTCCCACTGTCAAAGAGCGTGACGAAAAAGAAGTTTTCGATCGTGCT
ATCCTTGACGAAGTGGGTACTCTCGGCCTTCTCGGTATTCCTGGGAAGAAGAAAACGGC
GGCGTAGGCGCTGACTTCCTCAGCCTCGCAGTTGCTTGCGAAGAAGTAGCTAAAGTTACC
AGCCCGGGCCGTCG (SEQ ID NO: 36)

Figure 26

MEFKLSELQQDIANLAKDFAEKKLAPT VKERDEKEVFDRAILDEVGTLGLLGIPWEEENG
GVGADFLSLAVACEEVAKVTSPGR (SEQ ID NO:37)

1 GTGAGCACAC ACTTGATAGC TGATGCCGTC AATGATCAGT TGTTCTGTCTA TAGCAGGCTG
61 AAAGGACATG GGTTTGGTCA CAGTCTGAGC AGTTGCAGGC AGTCAAACAC GTTCGTAAC
121 ACGCTGTAGA TGATATAAGC AGTATACCAT CTGTCTACGC TCTCGTTGAT CAGGTTGAAT
181 GCTTTGAGGA AGGTGAGGCG AATAGCCATG CCTCTGTGTT CCAGAACATG GCATGGGGAT
241 GGATCGACGG TACCCTGTGC GATGCATGCT ATGCGTGGCA TTCATATCAT CAACCAGAAT
301 TTGATCTTGA ACTACACAGC AATTCTGCGC GTTATGCAAG TGTCTTCGGT CAGATGGTGA
361 ACAATTCTCA ATTTGTTGAGG TCTTGACGAA TTGCGTTATA CACTGTAGGC TATAGTATGC
421 ACCCCTTGTT ATCTATATCA CAACCGGTCT ATTAGCATTT GCGTCAAGGA GGATGGTCGA
481 TGATCGACAC TCGGCCCTT GCCCACCAC GGGCGCCCG CTCTAATCCG ATTCGGGATC
541 GAGTTGATTG GGAAGCTCAG CGCGCTGCTG CGCTGGCAGA TCCCGGTGCC TTTTCATGGCG
601 CGATTGCCCG GACAGTTATC CACTGGTACG ACCCACAACA CCATTGCTGG ATTCGCTTCA
661 ACAGTCTAG TCAGCGTTGG GAAGGGCTGG ATGCCGCTAC CGGTGCCCTT GTAACGGTAG
721 ACTATCCCGC CGATTATCAG CCCTGGCAAC AGGCGTTTGA TGATAGTGAA GCGCCGTTTT
781 ACGCGTGGTT TAGTGGTGGG TTGACAAATG CCTGCTTTAA TGAAGTAGAC CGGCATGTCA
841 TGATGGGCTA TGGCGACGAG GTGGCCTACT ACTTTGAAGG TGACCGCTGG GATAACTCGC
901 TCAACAATGG TCGTGGTGGT CCGGTTGTCC AGGAGACAAT CACGCGGCGG CGCCTGTTGG
961 TGGAGGTGGT GAAGGCTGCG CAGGTGTTGC GTGATCTGGG CCTGAAGAAG GGTGATCGGA
1021 TTGCTCTGAA TATGCCGAAT ATTATGCCGC AGATTATTA TACGGAAGCG GCAAAACGAC
1081 TGGGTATTCT GTACACGCCG GTCTTCGGTG GCTTCTCGGA CAAGACTCTT TCCGACCGTA
1141 TTACAAATGC CGGTGCACGA GTGGTGATTA CCTCTGATGG TCGGTACCGC AACGCGCAGG
1201 TGGTGCCTTA CAAAGAAGCG TATACCGATC AGGCGCTCGA TAAGTATATT CCGGTGAGA
1261 CGGCGCAGGC GATTGTTGCG CAGACCTGG CCACCTTGCC CTGACTGAG TCGCAGCGCC
1321 AGACGATCAT CACCGAAGT GAGGCCGCAC TGGCCGGTGA GATTACGGTT GAGCGCTCGG
1381 ACGTGATGCG TGGGGTGGT TCTGCCCTCG CAAAGCTCCG CGATCTTGAT GCAAGCGTGC
1441 AGGCAAAGGT GCGTACAGTA CTGGCGCAGG CGCTGGTCTGA GTCCGCGCGG CCGGTTGAAG
1501 CTGTGGTGGT TGTGCGTCAT ACCGGTCAGG AGATTTGTG GAACGAGGGG CGAGATCGCT
1561 GGAGTCACGA CTTGCTGGAT GCTGCGCTGG CGAAGATTCT GGCCAATGCG CGTGCTCCCG
1621 GCTTTGATGT GCACAGTGA AATGATCTGC TCAATCTCCC CGATGACCAG CTTATCCGTT
1681 CGCTCTACGC CAGTATTCCC TGTGAACCGG TTGATGCTGA ATATCCGATG TTTATCATTT
1741 ACACATCGGG TAGCACCGGT AAGCCCAAGG GTGTGATCCA CGTTCACGGC GGTATGTCTG
1801 CCGGTGTGGT GCACACCTTG CCGGTGAGTT TTGACGCCGA GCCGGGTGAT ACGATATATG
1861 TGATCGCCGA TCCGGGCTGG ATCACCAGTC AGAGCTATAT GCTCAGAGCC ACAATGGCCG
1921 GTCGGCTGAC CCGGGTGATT GCCGAGGGAT CACCGCTCTT CCCTCAGCC GGGCGTTATG
1981 CCAGCATCAT CGAGCGCTAT GGGGTGCAGA TCTTTAAGGC GGGTGTGACC TTCTCAAGA
2041 CAGTGATGTC CAATCCGCA AATGTTGAAG ATGTGCGACT CTATGATATG CACTCGCTGC
2101 GGGTTGCAAC CTTCTGCCCC GAGCCGGTCA GTCCGGCGGT GCAGCAGTTT GGTATGCAGA
2161 TCATGACCCC GCAGTATATC AATTCGTACT GGGCGACCGA GCACGGTGA ATTGTCTGGA
2221 CGCATTTCTA CGGTAATCAG GACTTCCCGC TTGCTCCCGA TGCCCATACC TATCCCTTGC
2281 CCTGGGTGAT GGGTGATGTC TGGGTGGCCG AAATGATGA GAGCGGGACG ACGCGCTATC
2341 GGGTCGCTGA TTTCGATGAG AAGGGCGAGA TTGTGATTAC CGCCCGGTAT CCCTACCTGA
2401 CCCGCACACT CTGGGGTGAT GTGCCCGGTT TCGAGGCGTA CCTGCGCGGT GAGATTCCGC
2461 TCGGGGCTG GAAGGGTGAT GCCGAGCGTT TCGTCAAGAC CTACTGGCGA CGTGGGCCAA
2521 ACGGTGAATG GGGCTATATC CAGGGTGATT TTGCCATCAA GTACCCCGAT GGTAGCTTCA
2581 CGCTCCACGG ACGCCCTGAC GATGTGATCA ATGTGTCGGG CCACCGTATG GGCACCGAGG
2641 AGATTGAGGG TGCCATTTTG CGTGACCGCC AGATCACGCC CGACTCGCCC GTCGGTAATT
2701 GTATTGTGGT CGGTGCGCCG CACCGTGAGA AGGGTCTGAC CCGGGTTGCC TTCAATCAAC
2761 CTGCGCCTGG CCGTCACTG ACCGGCGCCG ACCGGCGCCG TCTCGATGAG CTGGTGGTA
2821 CCGAGAAGGG GCGGGTCAGT GTCCAGAGG ATTACATCGA GGTCAAGTCC TTTCCCGAAA
2881 CCCGCAGCGG GAAGTATATG CGCGCTTTT TGCGCAATAT GATGCTCGAT GAACCACTGG
2941 GTGATACGAC GACGTTGCGC AATCCTGAAG TGCTCGAAGA GATTGAGCC AAGATCGCTG
3001 AGTGGAAACG CCGTCAGCGT ATGGCCGAAG AGCAGCAGAT CATCGAACGC TATCGCTACT
3061 TCCGGATCGA GTATCACCCA CCAACGGCCA GTGCGGGTAA ACTCGCGGTA GTGACGGTGA
3121 CAAATCCGCC GGTGAACGCA CTGAATGAGC GTGCGCTCGA TGAGTTGAAC ACAATTGTTG
3181 ACCACCTGGC CCGTCGTCAG GATGTTGCCG CAATTGTCTT CACCGACAG GCGGCCAGGA
3241 GTTTTGTGCG CGGCGCTGAT ATTCGCCAGT TGCTCGAAGA GATTCAATAC GTTGAAGAGG
3301 CAATGGCCCT GCCGAATAAC GCCCATCTTG CTTTCCGCAA GATTGAGCG ATGAATAAGC
3361 CGTGATCGC GGCATCAAC GGTGTGGCGC TCGGTGGTGG TCTGGAATTC GCCATGGCCT

Figure 27A

3421 GCCATTACCG GGTGCGCAT GTCTATGCCG AATTCGGTCA GCCAGAGATT AATCTGCGCT
3481 TGCTACCTGG TTATGGTGGC ACGCAGCGCT TGCCGCGCCT GTTGTTACAAG CGCAACAACG
3541 GCACCGGTCT GCTCCGAGCG CTGGAGATGA TTCTGGGTGG GCGTAGCGTA CCGGCTGATG
3601 AGGCGCTGAA GCTGGGTCTG ATCGATGCCA TTGCTACCGG CGATCAGGAC TCACTGTCGC
3661 TGGCATGCCG GTTAGCCCGT GCCGCAATCG GCGCCGATGG TCAGTTGATC GAGTCGGCTG
3721 CGGTGACCCA GGCTTTCCGC CATCGCCACG AGCAGCTTGA CGAGTGGCGC AAACCAGACC
3781 CGCGCTTTGC CGATGACGAA CTGCGCTCGA TTATCGCCCA TCCACGTATC GAGCGGATTA
3841 TCCGGCAGGC CCATACCGTT GGGCGCGATG CGGCAGTGCA TCGGGCACTG GATGCAATCC
3901 GCTATGGCAT TATCCACGGC TTCGAGGCCG GTCTGGAGCA CGAGGCGAAG CTCCTTGCCG
3961 AGGCAGTGGT TGACCCGAAC GGTGGCAAGC GTGGTATTCT CGAGTTCTCT GACCCGCCAGA
4021 GTGCGCCGTT GCCAACCCGC CGACCATTGA TTACACCTGA ACAGGAGCAA CTCCTGCGCG
4081 ATCAGAAAGA ACTGTTGCCG GTTGGTTCAC CCTTCTTCCC CGGTGTTGAC CGGATTCCGA
4141 AGTGGCAGTA CGCGCAGGCG GTTATTCTGT ATCCGGACAC CGGTGCGGCG GCTCAOCCG
4201 ATCCCATCGT GGCTGAAAAG CAGATTATTG TGCCGGTGGG ACGCCCCCGC GCCAATCAGG
4261 CGCTGATCTA TGTCTGGGCC TCGGAGGTGA ACTTCAACGA TATCTGGGCG ATTACCGGTA
4321 TTCCGGTGTC ACGGTTTGAT GAGCACGACC GCGACTGGCA CGTTACCGGT TCAGGTGGCA
4381 TCGGCCTGAT CGTTGCGCTG GGTGAAGAGG CCGGACGCGA AGGCCGCGTG AAGGTGGGTG
4441 ATCTGGTGGC GATCTACTCC GGGCAGTOGG ATCTGCTCTC ACCGCTGATG GGCCTTGATC
4501 CGATGGCCCG CGATTTCGTC ATCCAGGGGA ACGACACGCC AGATGGATCG CATCAGCAAT
4561 TTATGCTGGC CCAGGCCCGC CAGTGTCTGC CCATCCCAAC CGATATGTCT ATCGAGGCAG
4621 CCGGCAGCTA CATCTCAAT CTCGGTACGA TCTATCGCGC CCTCTTTACG ACGTTGCAAA
4681 TCAAGGCCGG ACGCACCATC TTTATCGAGG GTGCGGCGAC CGGTACCGGT CTGGACGCAG
4741 CCGGCTCGGC GGCCCGGAAT GGTCTGCGCG TAATTGGAAT GGTCAGTTCC TCGTCACGTG
4801 CGTCTACGCT GCTGGCTGCG GGTGCCCCAG GTGCGATTAA CCGTAAAGAC CCGGAGGTTG
4861 CCGATTGTTT CACGCGCGTG CCGGAAGATC CATCAGCCTG GGCAGCCTGG GAAGCCGCGC
4921 GTCAGCCGTT GCTGGCGATG TTCCGGGCGC AGAACGACGG GCGACTGGCC GATTATGTGG
4981 TCTCGCACGC GGGCGAGACG GCCTTCCCGC GCAGTTTCCA GCTTCTCGGC GAGCCACGCG
5041 ATGGTCACAT TCCGACGCTC ACATTCTACG GTGCCACCAG TGGCTACCAC TTCACCTTCC
5101 TGGGTAAGCC AGGGTCAGCT TCGCCGACCG AGATGCTGCG GCGGGCCAAT CTCGCGCCCG
5161 GTGAGCGCGT GTTGATCTAC TACGGGGTTG GGAGCGATGA CCTGGTAGAT ACCGGCGGTC
5221 TGGAGGCTAT CGAGGCGGCG CGGCAAAATG GAGCGCGGAT CGTCGTCGTT ACCGTACGCG
5281 ATCGCAACG CGAGTTTGTC CTCTCGTTGG GCTTCGGGGC TGCCCTACGT GGTGTCGTCA
5341 GCCTGGCGGA ACTCAAACGG CGCTTCGGCG ATGAGTTTGA GTGGCCGCGC ACGATGCCCG
5401 CGTTGCCGAA CGCCCGCCAG GACCCGACGG GTCTGAAAGA GGCTGTCCGC CGCTTCAACG
5461 ATCTGTCTT CAAGCCGCTA GGAAGCGCGG TCGGTGTCTT CTTCGGAGT GCCGACATC
5521 CGCGTGGCTA CCCCAGTCTG ATCATCGAGC GGGCTGCCCA CGATGCACTG GCGGTGAGCG
5581 CGATGCTGAT CAAGCCCTTC ACCGGACGGA TTGTCTACTT CGAGGACATT GGTGGGCGGC
5641 GTTACTCCTT CTTGCGACCG CAAATCTGGG TGCGCCAGCG CCGCATCTAC ATGCCGACGG
5701 CACAGATCTT TGGTACGCAC CTCTCAAATG CGTATGAAAT TCTGCGTCTG AATGATGAGA
5761 TCAGCGCCGG TCTGCTGACG ATTACCGAGC CGGCAGTGGT GCGGTGGGAT GAACTACCCG
5821 AAGCACATCA GCGATGTGG GAAATCGCC ACACGGCGGC CACTTATGTG GTGAATCATG
5881 CCTTACCACG TCTCGGCCTA AAGAACAGGG ACGAGCTGTA CGAGGCGTGG ACGGCCGCGC
5941 AGCGGTAGCG CGGATGGGTA TTGAACAGGT AACGGACGGA AGATCGAACC TTCCGTCCGT
6001 TATCTTTTGG CCGTCGAAGC GTGCTGAGCC GATTATCGTT GCCGTGGTTG TCCCGATGGG
6061 CAGACGCGCT CGAACCAGAT GATACCACCG ACGGCTATCG TCACCAAACC GCGGAAGACC
6121 AGGTAAGCCT CTGAAGGACG C (SEQ ID NO:38)

Figure 27B

Figure 28

1 MIDTAPLAPP RAPRSNPIRD RVDWEAQRAA ALADPGAFHG AIARTVIHWY DPQHHCWIRF
61 NESSQRWEGL DAATGAPVTV DYPADYQPWQ QAFDDSEAPF YRWFSGGLTN ACFNEVDRHV
121 MMGYGDEVAY YFEGDRWDNS LNNGRGGPVV QETITRRRL RDLGLKKGDR
181 IALNMPNIMP QIYYTEAAKR LGILYTPVFG GFSDKTSLDR IHNAGARVVI TSDGAYRNAQ
241 VVPYKEAYTD QALDKYIPVE TAQAIVAQTL ATLPLTESQR QTIITEVEAA LAGEITVERS
301 DVMRGVGSAL AKLRDLASV QAKVRTVLAQ ALVESPPRVE AVVVVRHTGQ EILWNEGRDR
361 WSHDLLDAAL AKILANARAA GFDVHSENDL LNLPPDQLIR ALYASIPCEP VDAEYPMFII
421 YTSGSTGKPK GVIHVHGGYV AGVVHTLRVS FDAEPGDTIY VIADPGWITG QSYMLTATMA
481 GRLTGVIAGS SPLFPSAGRY ASIIERYGVQ IFKAGVTFLK TVMSNPQNVE DVRLYDMHSL
541 RVATFCAEPV SPAVQQFGMQ IMTPQYINSY WATEHGGIVW THFYGNQDFP LRPDAHTYPL
601 FWMGMDVWVA ETDESGETRY RVADFDEKGE IVITAPYPYL TRTLWGDVPG FEAYLRGEIP
661 LRAWKGDAR FVKTYWRRGP NGEWGYIQGD FAIKYPDGSF TLHGRPDDVI NVSGHRMGTE
721 EIEGAILRDR QITPDSVPVN CIVVGAPHRE KGLTPVAFIQ PAPGRHLTGA DRRRLDELVR
781 TEKGAVSVPE DYIEVSAPPE TRSGKYMRRF LRNMMLDEPL GDTTTLRNPE VLEEIAAKIA
841 EWKRRQRMAE EQQIIERYRY FRIEYHPPTA SAGKLAVTV TNPPVNALNE RALDELNTIV
901 DHLARRQDVA AIVFTGQGAR SFVAGADIRQ LLEEIHTVEE AMALPNNALH AFRKIERMKN
961 PCIAAINGVA LGGGLEFAMA CHYRVADVYA EFGQPEINLR LLPGYGGTQR LPRLLYKRNN
1021 GTGLLRALAM ILGGRSVPAD EALKLGLIDA IATGDQDSLS LACALARAII GADGQLIESA
1081 AVTQAFRRHR EQLDEWRKPD PRFADDELRS IIAHPRIERI IRQAHTVGRD AAVHRAIDAI
1141 RYGIHGFEEA GLEHEAKLFA EAVVDPNGGK RGIREFLDRQ SAPLPTRRPL ITPEQEQLLR
1201 DQKELLPVGS PFFPGVDRIIP KWQYQAQVIR DPDTGAAAHG DPVIAEKQII VPVERPRANQ
1261 ALIYVVLASEV NFNDIWAITG IPVSRFDEHD RDWHVTGSGG IGLIVALGEE ARREGRLKVG
1321 DLVAIYSGQS DLLSPLMGLD PMAADFVIQG NDTPDGSHQQ FMLAQAPQCL PIPTDMSIEA
1381 AGSYIINLGT IYRALFTTLQ IKAGRTIFIE GAATGTGLDA ARSAARNGLR VIGMVSSSSR
1441 ASTLLAAGAH GAINRKDFEV ADCFTRVPED PSAAWAEAA GQPLLAMFRA QNDGRLADYV
1501 VSHAGETAFF RSFQLLGEPR DGHIPTLTFY GATSGYHFTF LGKPGSASPT EMLRRANLRA
1561 GEAVLIYYGV GSDDLVDVGG LEAIEAARQM GARIVVTVS DAQREVLVSL GFCAALRGVV
1621 SLAELKRRFG DEFEPWRTMP PLPNARQDPQ GLKEAVRRFN DLVFKPLGSA VGVFLRSADN
1681 PRGYPDLLIE RAAHDALAVS AMLIKPFTGR IVYFEDIGGR RYSFFAPQIW VRQRIYMP
1741 AQIFGTHLSN AYEILRLNDE ISAGLLTITE PAVVPWDEL P EAHQAMWENR HTAATYVVNH
1801 ALPRLGLKNR DELYEAWTAG ER (SEQ ID NO:39)

Figure 29

ATGAGTGAAGAGTCTCTGGTTCTCAGCACAATTGAAGGCCCCATCGCCATCCTCACCCCTC
AATCGCCCCCAGGCCCTCAATGCGCTCAGTCCGGCCTTGATTGATGACCTCATTTCGCCAT
TTAGAAGCCTGCGATGCCGATGACACAATCCGCGTGATCATTATCACCGGCGCCGGACGG
GCATTTGCTGCCGGCGCTGATATCAAAGCGATGGCCAATGCCACGCCTATTGATATGCTC
ACCAGTGGCATGATTGCGCGCTGGGCACGCATCGCCGCGGTGCGCAAACCGGTGATTGCT
GCCGTGAATGGGTATGCGCTCGGTGGTGGTTGTGAATTGGCAATGATGTGCGACATCATC
ATCGCCAGTGAACACGCGCAGTTCGGACAACCGGAAATCAATCTGGGCATCATTCCCGGT
GCTGGTGGCACCCAACGGCTGACCCGCGCCCTTGGCCCGTATCGCGCAATGGAATTGATC
CTGACCGGCGCGACCATCAGTGCTCAGGAAGCTCTCGCCCACGGCCTGGTGTGCCGGGTC
TGCCCGCCTGAAAGCCTGCTCGATGAAGCCCGTCGGATCGCGCAAACCATTGCCACCAAA
TCACCACTGGCTGTACAGTTGGCGAAAGAGGCAGTCCGTATGGCCGCCGAAACCACTGTG
CGCGAGGGGTTGGCTATCGAGCTGCGTAACTTCTATCTGCTGTTTGCCAGTGCTGACCAA
AAAGAGGGGATGCAGGCATTTATCGAGAAACGCGCTCCCAACTTCAGTGGTCGTTGA
(SEQ ID NO: 40)

Figure 30

MSEESLVLSTIEGPIAILTLNRPQALNALSPALIDDLIRHLEACDADDTIRVIIITGAGR
AFAAGADIKAMANATPIDMLTSGMIARWARIAAVRKPVIAAVNGYALGGGCELAMMCDII
IASENAQFGQPEINLGII PGAGGTQRLTRALGPYRAMELIITGATISAQEALAHGLVCRV
CPPESELLDEARRIAQTIATKSPLAVQLAKEAVRMAAETTVREGLAIELRNFYLLFASADQ
KEGMQAFIEKRPNFSGR (SEQ ID NO:41)

Figure 31

GGCGTAATCCGACCGGCAGGTTAGGGTCTTCTACTGGGGTCAAGGCGCGTCTCCTTTTGG
TGGCGCGAGCAACCGGGCTTTTCTGGCTTCAATGTACCATAGAGCGGTTACTTCGTGCA
ACGGGCGTGGTACAATCGAGAGCAACCTTTCGCAAAAGCTATCCAATCCTGCACACGTGC
ATCTGTTACAGGGTATTATTGTCGGCAAACGACAGTCCTGTCGTTTATGTACAAGGAGAT
CAACGTATGAGTGAAGAGTCTCTGGTTCTCAGCACAAATTGAAGGCCCCATCGCCATCCTC
ACCCTCAATCGCCCCCAGGCCCTCAATGCGCTCAGTCCGGCCTTGATTGATGACCTCATT
CGCCATTTAGAAGCCTGCGATGCCGATGACACAATCCGCGTGATCATTATCACCGGCGCC
GGACGGGCATTGCTGCCGGCGCTGATATCAAAGCGATGGCCAAATGCCACGCCTATTGAT
ATGCTCACCAGTGGCATGATTGCGCGCTGGGCACGCATCGCCGCGGTGCGCAAACCGGTG
ATTGCTGCCGTGAATGGGTATGCGCTCGGTGGTGGTTGTGAATTGGCAATGATGTGCGAC
ATCATCATCGCCAGTGAAACGCGCAGTTCGGACAACCGGAAATCAATCTGGGCATCATT
CCCGGTGCTGGTGGCACCCACGGCTGACCCGCGCCCTTGGCCCGTATCGCGCAATGGAA
TTGATCCTGACCGGCGCGACCATCAGTGCTCAGGAAGCTCTCGCCACGGCCTGGTGTGC
CGGGTCTGCCCGCCTGAAAGCCTGCTCGATGAAGCCCGTCGGATCGCGCAAACCATTGCC
ACCAAATCACCACTGGCTGTACAGTTGGCGAAAAGAGGCAGTCCGTATGGCCGCCGAAACC
ACTGTGCGCGAGGGGTGGCTATCGAGCTGCGTAACTTCTATCTGCTGTTTGCCAGTGCT
GACCAAAAAGAGGGGATGCAGGCATTTATCGAGAAACGCGCTCCCAACTTCAGTGGTTCGT
TGATCACGCGCAGAACATGGCAGCAGGGGCAATACCTGCACGTA CTGCCTCCTGCCGCCA
TACTACCAGATGATCGAGCAGTAAAGGGTAAATACTCTATCAATCTGGCCAGATAAGCGG
TTGGGTAACAACGCAATGCTCCAAGGAGACGATCATGGACATACACGAGCGATTGCGAT
CTCTCGAACGCGAAAATGCT (SEQ ID NO:42)

```
SEQ ID NO: 40      1 -----atgagtga-----agagt-----
SEQ ID NO: 43      1 -----atgacgta-----cgaaa-----
SEQ ID NO: 44      1 atggccgccctgcgtgt-----cctgctgtcctgcgccgcggcc
SEQ ID NO: 45      1 atggccgccctgcgtgtcctgtcctgcccagagc-----

SEQ ID NO: 40      14 -----ct-----ctg-----gttctc-agcacaattgaa
SEQ ID NO: 43      14 -----cc-----atc-----ctggtcgagcgc---gat
SEQ ID NO: 44      41 cgctgaggccc-----ccg-----gttcgc-tgtccgcctgg
SEQ ID NO: 45      33 -----ctgcaactcgtgtgtgtcccgattcgc-tgccagaattc

SEQ ID NO: 40      37 ggcccatcgcc-----atcctcacc-----
SEQ ID NO: 43      34 cagcgagttggc-----attatcacg-----
SEQ ID NO: 44      73 cgtcccttcgctcgggtgctaactttgagtacatcatcgcaaaaaag
SEQ ID NO: 45      73 cggccttcgctcgggtgctaactttcagtacatcatcacg-----

SEQ ID NO: 40      58 -----c-----
SEQ ID NO: 43      55 -----c-----
SEQ ID NO: 44      123 agggagaataacaccgtgggttgatccaac-----
SEQ ID NO: 45      115 -----gaaaagaaggaaaagaata

SEQ ID NO: 40      59' -----tcaatcgccccaggccctcaatgcgctc
SEQ ID NO: 43      56 -----tgaaccgtccccaggcactgaacgcgctc
SEQ ID NO: 44      155 -----tgaaccgccccaggccctcaatgcactt
SEQ ID NO: 45      134 gcagcgtggggtgatccagtgaaccgtcccaaagcactcaatgcactt

SEQ ID NO: 40      88 agtccggccttgattgatgacctcattc--gccatttagaagcctgcgat
SEQ ID NO: 43      85 a--acagccagg--tgatgaacgaggtc--acca--gcgctgcaaccgaa
SEQ ID NO: 44      184 tgcgatggcctgattgacgagctcaaccaggccctgaaga--tcttcgag
SEQ ID NO: 45      184 tgcaatggactgattgaggagctcaacc--aagcactggagacctttgag

SEQ ID NO: 40      136 ---gccgatgacaca---atccgcgtgatcattatcacggcgccggagc
SEQ ID NO: 43      127 ctggacgatgaccggacattggggcgatcatcatcacgggttcggccaa
SEQ ID NO: 44      232 ---gaggaccggcc---gttggggcattgtcctcacggcggggataa
SEQ ID NO: 45      232 ---gaagatcccgt---gtggcgccattgtgctcactggtggggagaa

SEQ ID NO: 40      180 ggcatttgctgcggcgctgatataaagcgatggccaa-----tgcc
SEQ ID NO: 43      177 agcgtttgcgcgggagccgacatcaaagaaatggccga-----cctg
SEQ ID NO: 44      276 ggcctttgcagctggagctgatataaggaaatgcagaacctgagtttc
SEQ ID NO: 45      276 ggcctttgcagccggagctgacatcaaggaaatgcagaa-----ccgg

SEQ ID NO: 40      223 acgcctattgatatgctcaccagtggcatgattgcgcgc---tgggcacg
SEQ ID NO: 43      220 acgttcgocgacgcgttcaccgcccacttcttcgccacc---tggggcaa
SEQ ID NO: 44      326 aggactgtt-----actccagcaagtcttgaagcac---tggggcca
SEQ ID NO: 45      319 acatttcagga-ctgttactca--ggcaagttcctgagccactgggacca

SEQ ID NO: 40      270 catcgccgcggtgcgcaaacgggtgattgctgccgtgaatgggtatgcgc
SEQ ID NO: 43      267 gctggccgcgctgcgcaccccagcatcgccgcggtggcgggatacgcgc
SEQ ID NO: 44      366 cctcaccagggtcaagaagcagtcacgcgtgctgtcaatggctatccgt
SEQ ID NO: 45      366 tatcaccggatcaagaaacgggtcatcgcgctgtcaatggctatgctc

SEQ ID NO: 40      320 tcggtggtggtgtgaattggcaatgatgtgcgacatcatcatcgccagt
SEQ ID NO: 43      317 tcggcggtgctgcgagctggcgatgatgtgcgacgtgctgatcccgcc
SEQ ID NO: 44      416 ttggcggggctgtgagcttgccatgatgtgtgatatacatctatgccgt
SEQ ID NO: 45      416 ttggtggggctgtgaacttgccatgatgtgcgatatcatctatgctggt
```

Figure 32A

SEQ ID NO: 40	370	gaaaacgcgcagttcggacaaccggaatcaatctgggcattcattcccg
SEQ ID NO: 43	367	gacaccgcgaagtctcgacagcccgagataaagctgggcgtgctgccagg
SEQ ID NO: 44	466	gagaaaggccagtttgcacagccggagatcttaataggaaccatcccagg
SEQ ID NO: 45	466	gagaaaggccagtttggacagccagaaatcctcctggggaccatcccagg
SEQ ID NO: 40	420	tgctggtggcacccaacggctgacccgcgccttggcccgatcgcgcgaa
SEQ ID NO: 43	417	catgggcggctcccagcggctgacccgggctatcggcaaggctaaggcga
SEQ ID NO: 44	516	tcagggcgccacccagagactcaccctgctgttgggaagtgcgtggagc
SEQ ID NO: 45	516	tcagggggcactcagagactcacccgagcagtcggcaaatcactagcaa
SEQ ID NO: 40	470	tggaattgatcctgacccgcgcgaccatcagtgtcaggaagctctcgcc
SEQ ID NO: 43	467	tggacctcatcctgacccggcgccacatggacgcccgcgaggc-cgagcg
SEQ ID NO: 44	566	tggagatggtcctcaccggtgacgcgatctcagcccaggagcg-caaagca
SEQ ID NO: 45	566	tggagatggtcctcactggtgaccgaatttcagcacaggatgc-caagca
SEQ ID NO: 40	520	ca-c-ggcctggtgtgcccgggtctgcccgcctgaaagcctgctcgatgaa
SEQ ID NO: 43	516	cagc-ggtctggtttcacgggtggtgcccgcgcgacttgctgaccgaa
SEQ ID NO: 44	615	ag-caggctctgtcagcaagatttgcctgttgagacactggtggaagaa
SEQ ID NO: 45	615	ag-caggctctgttaagcaagatttttcccgctgaaacactggttgaagag
SEQ ID NO: 40	568	gcccgctggatcgcgcaaacatttgccaccaaatcaccactggctgtaca
SEQ ID NO: 43	565	gccagggccactgccacgaccatttcgcagatgtcggcctcggcggcccg
SEQ ID NO: 44	664	gccatccagtgtgcagaaaaaattgccagcaattctaaaattgtagtagc
SEQ ID NO: 45	664	gccatccaatgtgcagaaaagatcgccaacaattccaagatcatagtagc
SEQ ID NO: 40	618	gttggcgaaagaggcagtcctgtatggccgcgaaaccactgtgcgcgagg
SEQ ID NO: 43	615	gatggccaaggaggccgtcaacogggtttcgaatccagtttgtccgagg
SEQ ID NO: 44	714	gatggccaaagaatcagtgaatgcagcttttgaaatgacattaacagaag
SEQ ID NO: 45	714	catggcgaaagaatctgtgaatgcagcctttgaaatgacgttaacagaag
SEQ ID NO: 40	668	ggttggctatcgagctgcgtaacttctatctgctgtttgccagtgtgac
SEQ ID NO: 43	665	ggctgctctacgaacgcggccttttccattcggcctttcgcgaccgaagac
SEQ ID NO: 44	764	gaagtaagttggagaagaactctttattcaacctttgccactgatgac
SEQ ID NO: 45	764	gaaataagctggagaagaagctcttctattccacctttgccactgatgac
SEQ ID NO: 40	718	caaaaagaggggatgcaggcatttatcgagaaacgcgctcccaacttcag
SEQ ID NO: 43	715	caatccgaaggatggcagcgttcacgcgagaaacgcgctccccagttcac
SEQ ID NO: 44	814	cggaaagaagggatgaccgcgtttgtggaaaagagaaaggccaacttcaa
SEQ ID NO: 45	814	cggagagaagggatgtctgcctttgtggagaaaagggaaggccaacttcaa
SEQ ID NO: 40	768	tggtcgttga
SEQ ID NO: 43	765	ccaccgatga
SEQ ID NO: 44	864	agaccagtga
SEQ ID NO: 45	864	agaccactga

Figure 32B

Figure 33

```
SEQ ID NO:41      1 -mseeslv-----lstiegp-----
SEQ ID NO:46      1 -mtyetil-----ver-dqr-----
SEQ ID NO:47      1 -maalrvl-----lscargplrppvrcpawrpfasganfeyiaekrg
SEQ ID NO:48      1 maalrallpracnsllspvrcpefrrfasganfqiitekkgknss----

SEQ ID NO:41      15 ----iailtlnrpqalnalspaliddlrhleacdaddtirviiitgagr
SEQ ID NO:46      14 ----vgiitlnrpqalnalsqvmnevtfaateldddpdigaiiitgsak
SEQ ID NO:47      43 knntvgliqlnrpkalnalcldglidelnqalkifeedpavgaiivltggdk
SEQ ID NO:48      47 ----vgliqlnrpkalnalcnglieelnqaletfeedpavgaiivltggek

SEQ ID NO:41      61 afaagadikamanatpidmtsgmiarwariaavrkpviaavngyalggg
SEQ ID NO:46      60 afaagadikemadltfadaftadffatwgklaavrtptiaavagyalggg
SEQ ID NO:47      93 afaagadikemqnlstfqcyskflkhwdhltqvkpviaavngyafggg
SEQ ID NO:48      93 afaagadikemqnrftqdcysgkflshwdhitrikkpviaavngyalggg

SEQ ID NO:41      111 celammcdiiiasenaqfgqpeinlgiipgaggtqrltralgyprameli
SEQ ID NO:46      110 celammcdvliaadtakfgqpeiklgvlpmggsqrltraigkakamdli
SEQ ID NO:47      143 celammcdiiyagekaqfaqpeillgtipgaggtqrltravgkslamemv
SEQ ID NO:48      143 celammcdiiyagekaqfgqpeillgtipgaggtqrltravgkslamemv

SEQ ID NO:41      161 ltgatisaqaalahglvcrvcppeslldearriaqtiatsplavqlake
SEQ ID NO:46      160 ltgrtmdaaeaersglvsrvvpaddlltearatattisqmsasaaarmake
SEQ ID NO:47      193 ltgdrisaqdaqaglvsklcpvetlveeaiqcaekiasnkskivvamake
SEQ ID NO:48      193 ltgdrisaqdaqaglvskifpvetlveeaiqcaekiannskiivvamake

SEQ ID NO:41      211 avrmaaettvreglaielrnfyllfasadqkegmqafiekrapnfsgr
SEQ ID NO:46      210 avnrafesslsegllyerrlfhsafatedqsegmaafiekrapqfthr
SEQ ID NO:47      243 svnaafemtlttegnkleklfystfatddrkegmtafvekrkanfkdk
SEQ ID NO:48      243 svnaafemtlttegnkleklfystfatddrregmsafvekrkanfkdh
```

Figure 34





Figure 35A



Cloning of PCR assembly in pET11a vector




Figure 35B




Figure 36A





Figure 36B

Cloning of PCR assembly 2 in pET11a vector



Cloning of E2 in pTHrEI




Figure 37A




Figure 37B
Cloning of PCR assembly 2 in pET11a vector




Figure 38A






Figure 38B

Cloning of E1 gene separately in pPROLar.A vector



Cloning of E2 in pTH

pE11TH (operon 5)



ATGATCGACACTGCGCCCTTGCCCCACCACGGGCGCCCGCTCTAATCCGATTCGGGAT
CGAGTTGATTGGGAAGCTCAGCGCGCTGCTGCGCTGGCAGATCCCGGTGCCTTTTCATGGC
GCGATTGCCCGGACAGTTATCCACTGGTACGACCCACAACACCATTGCTGGATTTCGCTTC
AACGAGTCTAGTCAGCGTTGGGAAGGGCTGGATGCCGCTACCGGTGCCCTGTAACGGTA
GACTATCCCGCCGATTATCAGCCCTGGCAACAGGCGTTTGATGATAGTGAAGCGCCGTTT
TACCGCTGGTTTAGTGGTGGGTTGACAAATGCCTGCTTTAATGAAGTAGACGGCATGTC
ATGATGGGCTATGGCGACGAGGTGGCTACTACTTTGAAGGTGACCGCTGGGATAACTCG
CTCAACAATGGTCGTGGTGGTCCGCTTGTCCAGGAGACAATCACGCGCGGGCGCCTGTTG
GTGGAGGTGGTGAAGGCTGCGCAGGTGTTGCGTGATCTGGGCTGAAGAAGGGTGATCCGG
ATTGCTCTGAATATGCCGAATATTATGCCGAGATTATTATACGGAAGCGGCAAAACGA
CTGGGTATTCTGTACACCGCGGCTTCGGTGGCTTCGCGACAAGACTCTTCCGACCGT
ATTCACAATGCCGGTGCACGAGTGGTGATTACCTCTGATGGTGCGTACCGCAACGCGCAG
GTGTGCCCTACAAAGAAGCGGTATACCGATCAGGCGCTCGATAAGTATATTCCGGTTGAG
ACGGCGCAGGCGATTGTTGCGCAGACCCTGGCCACCTTGCCCTGACTGAGTCGCAGCGC
CAGACGATCATCACCAGTGGAGGCGCACTGGCCGGTGAGATTACGGTTGAGCGCTCG
GACGTGATGCGTGGGGTTGGTTCTGCCCTCGCAAAGCTCCGCGATCTTGATGCAAGCGTG
CAGGCAAGGTGCGTACAGTACTGGCGCAGGCGCTGGTCGAGTCGCGCGCGGGTTGAA
GCTGTGGTGGTGTGCGTCATACCGGTCAGGAGATTTTGTGGAACGAGGGCGAGATCGC
TGGAGTCACGACTTGCTGGATGCTGCGCTGGCGAAGATTCTGGCCAATGCGCGTGCTGCC
GGCTTTGATGTGCACAGTGAGAATGATCTGCTCAATCTCCCGATGACCAGCTTATCCGT
GCCGCTACGCCAGTATTCCTGTGAACCGGTTGATGCTGAATATCCGATGTTTATCATT
TACACATCGGGTAGCACCGGTAAGCCCAAGGGTGTGATCCACGTTACGGCGGTTATGTC
GCCGGTGTGGTGACACCTTGCGGGTCAGTTTTGACGCCGAGCCGGGTGATACGATATAT
GTGATCGCCGATCCGGGTGGATCACCGGTCAGAGCTATATGCTCACAGCCACAATGGCC
GGTCGGCTGACCGGGTGATTGCCGAGGGATCACCCTCTTCCCTCAGCCGGGCGTTAT
GCCAGCATCATCGAGCGCTATGGGGTGACAGATCTTAAAGGCGGTGTGACCTTCCTCAAG
ACAGTGATGTCCAATCCGCAGAATGTTGAAGATGTGCGACTCTATGATATGCACTCGCTG
CGGGTTGCAACCTTCTGCGCCGAGCCGGTCAGTCCGCGGTGACGAGTTTGGTATGCAG
ATCATGACCCCGAGTATATCAATTCGTACTGGGCGACCGAGCAGGTTGGAATTGCTCTGG
ACGCATTTCTACGGTAATCAGGACTTCCGCTTCGTCGCGATGCCATACCTATCCCTTG
CCCTGGGTGATGGGTGATGCTGGGTGGCCGAACTGATGAGAGCGGGACGACGCGCTAT
CGGGTCGCTGATTTGATGAGAAGGGCGAGATTGTGATTACCGCCCCGTATCCCTACCTG
ACCCGCACACTCTGGGGTGATGTGCCCGGTTTCGAGGCGTACCTGCGCGGTGAGATTCCG
CTGCGGGCCTGGAAGGGTGATGCCGAGCGTTTCGTCAAGACCTACTGGCGACGTGGGCCA
AACGGTGAATGGGGCTATATCCAGGGTGATTTTGCCATCAAGTACCCGATGGTAGCTTC
ACGCTCCACGGACGCCCTGACGATGTGATCAATGTGTCGGGCCACOGTATGGGCACCGAG
GAGATTGAGGGTGCCATTTTGGCTGACCGCCAGATCACGCCGACTCGCCCGTCGGTAAT
TGTATTGTGGTCGGTGCGCCGACCGTGAGAAGGGTCTGACCCCGGTTGCCCTTCAATCAA
CCTGCGCTGGCCGTCTGACCGGCGCCGACCGGCGCCGTCTCGATGAGCTGGTGCGT
ACCGAGAAGGGGCGGTGAGTGTCCAGAGGATTACATCGAGGTGAGTGCCTTTCCCGAA
ACCCGACGCGGGAAGTATATGCGGCGCTTTTTCGCAATATGATGCTCGATGAACCACTG
GGTGATACGACGAGTTGCGCAATCCTGAAGTGCTCGAAGAGATTGCAGCCAAGATCGCT
GAGTGGAAACCGGTGACGCTATGGCCGAAGAGCAGCAGATCATCGAACGCTATCGCTAC
TTCCGGATCGAGTATCACCCACCAACGGCCAGTGCGGGTAAACTCGCGGTAGTGACGGTG
ACAAATCCGCCGGTGAACGCACTGAATGAGCGTGCGCTCGATGAGTTGAACACAATTGTT
GACCACCTGGCCCGTCTGAGGATGTTGCCGCAATTGTCTTACCGGACAGGGCGCCAGG
AGTTTTGTCGCCGCGCTGATATTGCGCAGTTGCTCGAAGAGATTATACGTTGAAGAG
GCAATGGCCCTGCCGAATAACGCCCATCTTGCTTTCCGCAAGATTGAGCGTATGAATAAG

Figure 39A

CCGTGTATCGCGCGATCAACGGTGTGGCGCTCGGTGGTGGTCTGGAATTCGCCATGGCC
TGCCATTACCGGGTTGCCGATGTCTATGCCGAATTCGGTCAGCCAGAGATTAATCTGCGC
TTGCTACCTGGTTATGGTGGCACGCAGCGCTTGCCGCGCCTGTTGTACAAGCGCAACAAC
GGCACCGGTCTGCTCCGAGCGCTGGAGATGATTCTGGGTGGGCGTAGCGTACCGGCTGAT
GAGGCGCTGAAGCTGGGTCTGATCGATGCCATTGCTACCGGCGATCAGGACTCACTGTCTG
CTGGCATGCGCGTTAGCCCGTGCCGAATCGGCGCCGATGGTCAGTTGATCGAGTCGGCT
GCGGTGACCCAGGCTTTCCGCCATCGCCACGAGCAGCTTGACGAGTGGCGCAAACCAGAC
CCGCGCTTTGCCGATGACGAATGCGCTCGATTATCGCCCATCCACGTATCGAGCGGATT
ATCCGGCAGGCCATACCGTTGGGCGCGATGCGGCAGTGCATCGGGCACTGGATGCAATC
CGCTATGGCATTATCCACGGCTTCGAGGCCGGTCTGGAGCACGAGGCCAAGCTCTTTGCC
GAGGCAGTGGTTGACCCGAACGGTGGCAAGCGTGGTATTCGCGAGTTCCTCGACCGCCAG
AGTGGCGCGTTGCCAACCCGCCGACCATTTGATTACACCTGAACAGGAGCAACTCTTGCGC
GATCAGAAAGAACTGTTGCCGGTTGGTTCACCCCTCTTCCCGGTGTTGACCGGATTCCG
AAGTGGCAGTACGCGCAGGCGGTTATTCGTGATCCGGACACCGGTGCGGCGGCTCACGGC
GATCCCATCGTGGCTGAAAAGCAGATTATTGTGCCGGTGGAAACGCCCCCGGCCAATCAG
GCGCTGATCTATGTTCTGGCCTCGGAGGTGAACCTCAACGATATCTGGGCGATTACCGGT
ATTCGGGTGTACGGTTTGATGAGCACGACCGCGACTGGCAGCTTACCGGTTCAAGTGGC
ATCGGCCTGATCGTTGCGCTGGGTGAAGAGGCGCGACGCGAAGGCCGGCTGAAGGTGGGT
GATCTGGTGGCGATCTACTCGGGCAGTCGGATCTGCTCTACCGCTGATGGGCCTTGAT
CCGATGGCCGCCGATTTCGTCTATCCAGGGGAACGACACGCCAGATGGATCGCATCAGCAA
TTTATGCTGGCCCAGGCCCCGAGTGTCTGCCCATCCCAACCGATATGTCTATCGAGGCA
GCCGGCAGCTACATCCTCAATCTCGGTACGATCTATCGCGCCCTCTTTACGACGTTGCAA
ATCAAGGCCGGACGCAACCATCTTTATCGAGGGTGCGGCGACCGGTACCGGTCTGGACGCA
GCGCGCTCGGCGGCCCGGAATGGTCTGCGCGTAATTGGAATGGTCAGTTCGTCTCACGT
GCGTCTACGCTGCTGGCTGCGGGTGCCACGGTGCGATTAAACCGTAAAGACCGGAGGTT
GCCGATTGTTTACGCGCGTGCCCGAAGATCCATCAGCCTGGGCAGCCTGGGAAGCCGCC
GGTCAGCCGTTGCTGGCGATGTTCCGGGCGCAGAACGACGGGCGACTGGCCGATTATGTG
GTCTCGCACGCGGGCGAGACGGCCTTCCGCGCAGTTTCCAGCTTCTCGGCGAGCCACGC
GATGGTCACATTCCGACGCTCACATTCTACGGTGCCACCACTGGCTACCACTTCACTTTC
CTGGGTAAGCCAGGGTCAGCTTCGCCGACCGAGATGCTGCGGCGGGCCAATCTCCGCGCC
GGTGAGGCGGTGTTGATCTACTACGGGGTTGGGAGCGATGACCTGGTAGATACCGGCGGT
CTGGAGGCTATCGAGGCGGGCGGCAAAATGGGAGCGCGGATCGTCTGTTACCGTCAGC
GATGCGCAACGCGAGTTTGTCTCTCGTTGGGCTTCGGGGCTGCCCTACGTGGTGTCTGTC
AGCCTGGCGGAACCTCAAACGGCGCTTCGGCGATGAGTTTGAGTGGCCGCGCACGATGCCG
CCGTTGCCGAACGCCCGCCAGGACCCGCGAGGGTCTGAAAGAGGCTGTCCGCGCGCTTCAAC
GATCTGGTCTTCAAGCCGCTAGGAAGCGCGGTGCGTGTCTTTCGCGAGTGCCGACAAT
CCGCGTGGCTACCCGATCTGATCATCGAGCGGGCTGCCACGATGCACTGGCGGTGAGC
GCGATGCTGATCAAGCCCTTACCGGACGGATTGTCTACTTCGAGGACATTGGTGGGCGG
CGTTACTCCTTCTTCGACCGCAAACTCTGGGTGCGCCAGCGCCGATCTACATGCCGACG
GCACAGATCTTTGTACGCACCTCTCAAATGCGTATGAAATTCTGCGTCTGAATGATGAG
ATCAGCGCCGGTCTGCTGACGATTACCGAGCCGGCAGTGGTGCCGTGGGATGAACTACCC
GAAGCACATCAGGCGATGTGGGAAAATCGCCACACGGCGGCCACTTATGTGGTGAATCAT
GCCTTACCACGTCTCGGCCTAAAGAACAGGGACGAGCTGTACGAGGCGTGGACGGCCGGC
GAGCGGTAG (SEQ ID NO:129)

Figure 39B

```

SEQ ID NO:39      1 -----midtaplappraprenpirdrvdwe
SEQ ID NO:130     1 mglpeervrsgsgsrgqeeagaggrarswap--ppevarsahvpalsqrry
SEQ ID NO:131     1 -----mslelkekeselpfdeqiind
                               PL PP RS P

SEQ ID NO:39      26 aqraaaladpgafhgaiartvihwydpqhhcwifnessqrwegldaatg
SEQ ID NO:130     49 elhrrsveeprefwgdiake-fywktpcpgpflryn-----
SEQ ID NO:131     22 kwrs-----kytpidayfkfhrqtvenlesf--wesv----
                               R P F G IA T I WY P H R NES WE

SEQ ID NO:39      76 apvtvdypadygpwqqaiddseap-fyrwfsggltnacfnvdrhvm-mg
SEQ ID NO:130     84 -----fdvtkgkifiewmkgattnicynvldrnvhkek
SEQ ID NO:131     52 -akelew---fkpwdkvldasnp-fykwfvggrlnlsylavdrhvk-tw
                               PW FD S P FY WF GG TN C N VDRHV

SEQ ID NO:39      124 ygdevayyefegdrwdnslnngrggpvvqetitrllvevvkaaqlr-d
SEQ ID NO:130     117 lgdkvafywegne-----pgetqtityhqlivqvcqfsnvlr-k
SEQ ID NO:131     96 rknklaiewegepvdn-----gyptdrkrklyydyrevnrwaymlqn
                               GD VA Y EG D G P IT LLVEV A VLR

SEQ ID NO:39      173 lglkkgdrialnmpnimpqiyyte-aakrlgilytpvfggfcdktlsdri
SEQ ID NO:130     155 qgikqgdrvalympmipelvaml-acarigalhsivfagfsaeslceri
SEQ ID NO:131     141 fgvkkgdkitlylp-mvpelpitmlaawrigaitsvvfagfsadalaeri
                               G KKGDRIAL MP I P T AA R G L VF GFS L RI

SEQ ID NO:39      222 hnagarvitsdgaayrnaqvpykeaytdqal----dkyipvetaqaiva
SEQ ID NO:130     204 ldsscslittdafyrgeklvnikel-adealqkckqkgfpvrc--civv
SEQ ID NO:131     190 ndsqsrivitadgfwrrgrvvrakev-----
                               R VIT DG YR VV KE D AL K PV IV

SEQ ID NO:39      268 qtlatpltesqrqtiiteveaalageitversdvmrgvgsalaklrddl
SEQ ID NO:130     251 khlgrael-----gmqdsts-----
SEQ ID NO:131     216 -----vdaal-----
                               L L V AAL G G

SEQ ID NO:39      318 asvqakvrtvlaqalvespprveavvvvrhtg-qeilwnegrdrwshdl1
SEQ ID NO:130     266 -----qspikrscpdv-----qiswnqgidlwshelm
SEQ ID NO:131     221 -----ekatgvesvivlprlgldvpmtegrdywnklm
                               ESPP VE V VV G I WNEGRD W H L

SEQ ID NO:39      367 daalakilanaraagfdvhsendlilnpddqliralysipcep--vdae
SEQ ID NO:130     294 qea-----gde-----cepewcdae
SEQ ID NO:131     255 q-----gipn-----ayiepep--vese
                               A P D A I CEP VDAE

SEQ ID NO:39      415 ypmfiitysgstgkpkgvihvhggyvagvvhtlrvsfdaepgdtyviad
SEQ ID NO:130     309 dplfilytsgstgkpkgvvhtvggymlyvattfkyvdfhaedvfwtad
SEQ ID NO:131     272 hpsfilytsgttgkpkgivhdtggwavhvayatmkwvfdirdddifwtad
                               P FI YTSSTGKPKGV H GGY V T FD D AD

SEQ ID NO:39      465 pgwitgqsymltatmagrltgviaegsplfpsagryasierygvqifka
SEQ ID NO:130     359 igwitghsyvtygplangatsvlfegiptypdvnlrwsivdkykvtkfyt
SEQ ID NO:131     322 igwvtghsyvvlgpllmgateviyegapdpqpdrwsierygvtfityt
                               GWITG SY A T VI EG P P R SIERYGV IF

```

Figure 40A

SEQ ID NO:39 515 gvtflktvmsnpqnvdrlydmhslrvatfcaepvspavqqfgmqimtp
SEQ ID NO:130 409 aptairllmkfgd--epvtkhsraqlvgitvgepinpeawlyhrvvga
SEQ ID NO:131 372 aptairmfmyge--ewprkhdsltrihsvgepinpeawwayrvign
T M E VR D SLRV EP P

SEQ ID NO:39 565 q---yi---nsywatehggivwthfygnqdfplrdahtyplpwmgdvw
SEQ ID NO:130 457 qrcpiv---dtfwqtetggghmltpipgat--pmkpqsatfp---ffgva
SEQ ID NO:131 420 e---kvafgstwwmtetggivishapgliylvmpkpgtngpplpqfevdv-
Q W TE GGIV TH G P P T PLP DV

SEQ ID NO:39 609 vaetdesgttryrvadfdkgeivitapypyltrtlwgdvpqfeaylrge
SEQ ID NO:130 498 pailnesg---eelegeaegylvfkqpwpgimrtvy-----
SEQ ID NO:131 466 ---vdengnp---appgvkgyivikkpwpqmlhgiw-----
A DESG A KG VI P P RT W

SEQ ID NO:39 659 iplrawkgdaerfvktywrrqpngegyiqgdfaikypdgafthgrpdd
SEQ ID NO:130 531 -----gnherfettyfkkfpg---yyvtgdgcqrdqgyywtgridd
SEQ ID NO:131 496 -----gdperyktywsrfpg---mfyagdyaikdkdgyiwlgrade
GD ERF KTYW R P Y GD AIK DG GR DD

SEQ ID NO:39 709 vinvsghrmgteeeiegailrdrqitpdsppvncivvgaphrekgltpvaf
SEQ ID NO:130 571 mlnvsghllstaevesalve-----heavaeaavvghphvpkgeclycf
SEQ ID NO:131 536 vikvaghrlgtyelesali-----shpavaesaavvgvpdaikgevpiaf
VINVSGHR GT E E A V VVG PH KG P AF

SEQ ID NO:39 759 iqpapgrhltagadrrrldelvrtekgavsvpedyle--vsafpetrsgkym
SEQ ID NO:130 615 vtlcdghtfspklteelkkqirekigpiatp-dyiqnapglpktrsgkim
SEQ ID NO:131 580 vvlkqgvapsdelrkelrehvrrtigpiaepaqiff-vtklpktrsgkim
G R L E VR G P DYI V P TRSGK M

SEQ ID NO:39 808 rrlrlnmml--deplgdtttlrnpveleeiaakiaewkrrqrmaeeqqie
SEQ ID NO:130 664 rrvlrkiaqndhdldgmstvadpsvi-----
SEQ ID NO:131 629 rrlkavat-gaplgdvt-----
RR LR D PLGD TT P V

SEQ ID NO:39 857 ryryfrieypptasagklavvtvtnppvnalneralidelntivdhlarr
SEQ ID NO:130 690 -----
SEQ ID NO:131 647 -----

SEQ ID NO:39 907 qdvaavftgqgarsfvagadirqlleeihtveeamalpnnahlafrkie
SEQ ID NO:130 690 -----shl-----
SEQ ID NO:131 647 -----ledetsveeak-----
LE VEEA HL

SEQ ID NO:39 957 rmnkpciaaingvalggglefamachyrvadvyaeqgpeinlrllpgyg
SEQ ID NO:130 693 -----
SEQ ID NO:131 658 -----

SEQ ID NO:39 1007 gtqrlprllykrnngtgllralemlggrsvpadealkglidaiatgdq
SEQ ID NO:130 693 -----
SEQ ID NO:131 658 -----raye-----
RA E

SEQ ID NO:39 1057 dsllsacalaraaigadgqliesaaavtqafrrhrheqldewrkpdprfadd
SEQ ID NO:130 693 -----fshr-----
SEQ ID NO:131 662 -----
F HR

Figure 40B

SEQ ID NO:39 1107 elrsiahprieriirqahtvgrdaavhraldairygiihgfeaglehea
SEQ ID NO:130 697 -----
SEQ ID NO:131 662 -----

SEQ ID NO:39 1157 klfaeavdpnggkrgirefldrqsapltrrrplitpeqeqlldqkell
SEQ ID NO:130 697 -----
SEQ ID NO:131 662 -----

SEQ ID NO:39 1207 pvgsppffpgvdripkwqyaqavirdpdtgaaahgdpivaekqiivverp
SEQ ID NO:130 697 -----
SEQ ID NO:131 662 -----

SEQ ID NO:39 1257 ranqaliyvasevnfndiwaitgipvsrfdehdrdwhvtgaggigiliva
SEQ ID NO:130 697 -----
SEQ ID NO:131 662 -----

SEQ ID NO:39 1307 lgeearregrlkvgdlvaiysgqsdlisplmgldpmaadvfiqgndtpdg
SEQ ID NO:130 697 -----
SEQ ID NO:131 662 -----

SEQ ID NO:39 1357 shqqfmlaqapqclpiptdmsieaagsyilnltiyralfttlqikagrt
SEQ ID NO:130 697 -----cl-----tiq-----
SEQ ID NO:131 662 -----eika-----
CL T QIKA

SEQ ID NO:39 1407 ifiegaatgtgldaarsaarngrlvigmvssssrastllaagahgainrk
SEQ ID NO:130 702 -----
SEQ ID NO:131 666 -----

SEQ ID NO:39 1457 dpevadcftrvpedpsawaaweaaagqpllamfraqndgrladyvvshage
SEQ ID NO:130 702 -----
SEQ ID NO:131 666 -----

SEQ ID NO:39 1507 tafprsfqllgeprdgthptltfygatsgyhftflgkpgsasptemlrre
SEQ ID NO:130 702 -----
SEQ ID NO:131 666 -----

SEQ ID NO:39 1557 nlrageavliyygvgsddldvtggleaieaargmgarivvvtvsdaqref
SEQ ID NO:130 702 -----
SEQ ID NO:131 666 -----

SEQ ID NO:39 1607 vslgfgaalrgvvslaelkrrfgdefewprtmpplnarqdpqglkeav
SEQ ID NO:130 702 -----
SEQ ID NO:131 666 -----emart-----
E RT

SEQ ID NO:39 1657 rrfndlvfkplgsavgvflrsadnprgypdliieraahdalavsamlikp
SEQ ID NO:130 702 -----
SEQ ID NO:131 671 -----

Figure 40C


```
SEQ ID NO:39 1707 ftgrivvyfedigrrysffapqiwwrqrriymptaqifgthlsnayeilr
SEQ ID NO:130 702 -----
SEQ ID NO:131 671 -----

SEQ ID NO:39 1757 lndeisagiltitepavvpwdelpeahqamwenrhtaatyvvnhalprlg
SEQ ID NO:130 702 -----
SEQ ID NO:131 671 -----

SEQ ID NO:39 1807 lknrdelyeawtager
SEQ ID NO:130 702 -----
SEQ ID NO:131 671 -----
```

Figure 40D

```
SEQ ID NO:39      1 midtaplappraprenpirdrvdweaqraaaladpgafhgaiartvihwy
SEQ ID NO:132     1 -----
SEQ ID NO:133     1 -----

SEQ ID NO:39      51 dpqhhcwirfnessqrwegldaatgapvtvdypadyqpwwqafddseapf
SEQ ID NO:132     1 -----
SEQ ID NO:133     1 -----md-----
                                   D

SEQ ID NO:39      101 yrwfsggltnacfnvdrhvmmggygdevayyfeqdrwdnslnngrggpvv
SEQ ID NO:132     1 -----melnn-----
SEQ ID NO:133     3 -----fnnv-----
                                   FN V                               LNN

SEQ ID NO:39      151 qetitrllvevvkaaqlrdlgkkgdrialnmpnimpqiyyteaakr
SEQ ID NO:132     6 -----
SEQ ID NO:133     7 -----llnkddgial-----
                                   L K D IAL

SEQ ID NO:39      201 lgilytpvfqgfsdktlsdrihnagarvvitsdgayrnaqvvpvpykeaytd
SEQ ID NO:132     6 -----
SEQ ID NO:133     17 -----

SEQ ID NO:39      251 qaldkyipvetaqaivaqtlatlpitesqrqtiiteveaalageitvers
SEQ ID NO:132     6 -----vileke-----
SEQ ID NO:133     17 -----
                                   I E E

SEQ ID NO:39      301 dvmrgvgsalaklrldasvqakvrtvlaqalvespprveavvvvrhtgq
SEQ ID NO:132     12 -----
SEQ ID NO:133     17 -----

SEQ ID NO:39      351 eilwnegrdrwshdlldaalakilanaraagfdvhsendlnlpddqlir
SEQ ID NO:132     12 -----
SEQ ID NO:133     17 -----iinn-----
                                   I N

SEQ ID NO:39      401 alyasipcepvdaeypmfiytsgstgkpgkviyhvggyvagvvhtrvs
SEQ ID NO:132     12 -----
SEQ ID NO:133     21 -----

SEQ ID NO:39      451 fdaepgdtiyviadpgwitgqsymltatmagrltgviaegsplfpsagry
SEQ ID NO:132     12 -----
SEQ ID NO:133     21 -----

SEQ ID NO:39      501 asierygvqifkagvtflktvmsnpqnvdrlydmhslrvatfcaepv
SEQ ID NO:132     12 -----
SEQ ID NO:133     21 -----
```

Figure 41A

```
SEQ ID NO:39 551 spavqqfmgqintpqyinsywatehggivwthfygnqdfplrpdahtyp1
SEQ ID NO:132 12 -----
SEQ ID NO:133 21 -----rpka-----
                                RP A

SEQ ID NO:39 601 pwvmgdvwvaetdesgttryrvadfdekgeivitapypyltrtlwgdvpg
SEQ ID NO:132 12 -----
SEQ ID NO:133 25 -----

SEQ ID NO:39 651 feaylrgeiplrawkgdaerfvktywrrgpngegyiqgdfaikypdgsf
SEQ ID NO:132 12 -----
SEQ ID NO:133 25 -----

SEQ ID NO:39 701 tlhgrpddvinvaghrmgteelegailrdrqitpdpvgncivvgaphre
SEQ ID NO:132 12 -----
SEQ ID NO:133 25 -----

SEQ ID NO:39 751 kgltpvafiqpapgrhltgadrrridelvrtekavsvpedyievsafpe
SEQ ID NO:132 12 -----
SEQ ID NO:133 25 -----

SEQ ID NO:39 801 trsgkymrrflrnmmldeplgdtttlrnpveleiaakiaewkrrqrmae
SEQ ID NO:132 12 -----
SEQ ID NO:133 25 -----

SEQ ID NO:39 851 eqqieryryfrieypptasagklavvtvtnpp-vnalneraldelnti
SEQ ID NO:132 12 -----gkvavvtinrpkalnlnsdtkemdyv
SEQ ID NO:133 25 -----lnalnyetlkeldsv
                                GK AVVT P NALN L EL

SEQ ID NO:39 900 vdhlarrqdvaavftggarsfvagadirqlleeihtve-eamalpnna
SEQ ID NO:132 40 igeiendsevlaviltgagexsfvagadisem-kemntiegrkfgilgnk
SEQ ID NO:133 40 ldivendkeikvliitgsgektfvagadiaemsn--mtpl-eakkfslyg
                                D V A TG G SFVAGADI E T E EA N

SEQ ID NO:39 949 hlafrkiermnkpciaaingvalggglefamachyrvadvyaeffgqpein
SEQ ID NO:132 89 --vfrllellekpviaavngfalgggceiamsdriassnarfgqpevg
SEQ ID NO:133 87 qkvfrkiemlskpviaavngfalgggcelsmacdriasknakfgqpevg
                                FRKIE KP IAA NG ALGGG E AMAC R A A FGQPE

SEQ ID NO:39 999 lrllpgygggtqrlprllykrnngtgllralemilggrsvpadealkigli
SEQ ID NO:132 137 lgitpgfggtqrlsrly-----gmgmakqliftagnikadealriglv
SEQ ID NO:133 137 lgiipgfggtqrlprli-----gtakakeliftgdmnsdeaykigli
                                L PG GGTQRLPRL G A E I G ADEALK GLI

SEQ ID NO:39 1049 daiatgdqdsllacalaraaigadgqliesaaavtqafrrhrheqldewrk
SEQ ID NO:132 180 n-----
SEQ ID NO:133 180 skvv-----

SEQ ID NO:39 1099 pdprfaddelrsiihprieriirqahtvgrdaavhraldairygiihgf
SEQ ID NO:132 181 -----
SEQ ID NO:133 184 -----elsdli-----
                                EL I
```

Figure 41B

```
SEQ ID NO:39 1149 eagleheaklf aeavdpnggkrgirefldrqsapltrrplitpeqeql
SEQ ID NO:132 181 -----kvveps-----el
SEQ ID NO:133 190 -----eeakklak-----
                        EAK A VV P L

SEQ ID NO:39 1199 lrdqkellpvgsppfpgvdripkwqyaqavirdpdtgaaahgdpivaekq
SEQ ID NO:132 189 mntakei-----kmmsksq
SEQ ID NO:133 198 -----
                        KE Q

SEQ ID NO:39 1249 iivpverprangaliyvlasevnfndiwaitgipvsrfdedhrdwhvtgs
SEQ ID NO:132 196 -----ank-----ivsnapva
SEQ ID NO:133 205 i-----
                        I AN PV

SEQ ID NO:39 1299 ggiglivalgeearregrlkvgdvhaiysggsdlisplmgldpmaadfvi
SEQ ID NO:132 207 -----vklskqainrgm-----
SEQ ID NO:133 206 -----aislakeainkg-----
                        V L EA G

SEQ ID NO:39 1349 qgndtpdgshqqfmlaqapqclpiptdmsieaagsyilnltiyralftt
SEQ ID NO:132 219 -----qc-didtalafesea-----fgcfst
SEQ ID NO:133 218 -----metdld-----
                        QC I TD E F T

SEQ ID NO:39 1399 lqikagrtifiegaatgtgldaarsaarnglrvigmvssssrastllaag
SEQ ID NO:132 240 edgkdantafie-----
SEQ ID NO:133 224 -----tgntieaekfsl-----
                        K T FIE TG A

SEQ ID NO:39 1449 ahgainrkdpevadcftrvpedpsawaaweagqpllamfraqndgrlad
SEQ ID NO:132 252 -----
SEQ ID NO:133 236 -----cft-----
                        CFT

SEQ ID NO:39 1499 yvshagetafprsfqllegeprdgthptltfygatsgyhftflgkpgsas
SEQ ID NO:132 252 -----
SEQ ID NO:133 239 -----

SEQ ID NO:39 1549 ptemlrranlrageavliyygvgsddlvdtgglaieaearqmgarivvvt
SEQ ID NO:132 252 -----
SEQ ID NO:133 239 -----

SEQ ID NO:39 1599 vsdaqrefvislgfgaalrgvvsiaelkrrfgdefewprtmpplpnarqd
SEQ ID NO:132 252 -----krk-----
SEQ ID NO:133 239 -tddqke-----gmiafse-kr-
                        D Q E G E KR

SEQ ID NO:39 1649 pqglkeavrrfndlvfkplgsavgvflrsadnprgypdlieraahdala
SEQ ID NO:132 255 -----ie-----
SEQ ID NO:133 254 -----
                        IE

SEQ ID NO:39 1699 vsamlikpftgrivyfediggrrysffapqiwwrqrriymptaqifgthl
SEQ ID NO:132 257 -----
SEQ ID NO:133 254 -----apk-----fgk-----
                        AP FG
```

Figure 41C

```
SEQ ID NO:39 1749 snayeilrlndeisaglltitepavvpwdelpeahqamwenrhtaatyvv
SEQ ID NO:132 257 -----
SEQ ID NO:133 260 -----

SEQ ID NO:39 1799 nhalpriglknrdelyeawtager
SEQ ID NO:132 257 -----gfknr-----
SEQ ID NO:133 260 -----
G KNR
```

Figure 41D

```
SEQ ID NO:39      1 midtaplappprsrnpirdrvdweaqradaadpgafhgaiartvihwy
SEQ ID NO:134     1 -----
SEQ ID NO:135     1 -----

SEQ ID NO:39      51 dpqhchcwfirfnessqrwegldaagapvtvdypadyqpwwqafddseapf
SEQ ID NO:134     1 -----maasaap-----
SEQ ID NO:135     1 -----
                        AA  AP

SEQ ID NO:39      101 yrwfsggltfnacfnvdrhvmmggygdevayyefegdrwdnslnnrggppvv
SEQ ID NO:134     8 -----
SEQ ID NO:135     1 -----

SEQ ID NO:39      151 getitrrrllvevkaaqvlrdlglkkgdrialnmpnimpqiyyteaakr
SEQ ID NO:134     8 -----
SEQ ID NO:135     1 -----

SEQ ID NO:39      201 lgilytpvfggfsdktlsdrihnagarvvitsdgayrnaqvpykeaytd
SEQ ID NO:134     8 -----awtg-----
SEQ ID NO:135     1 -----
                        A  T

SEQ ID NO:39      251 qaldkyipvetaqaivaqtlatpltesqrqtiiteveaalageitvers
SEQ ID NO:134     12 q-----taeak-----
SEQ ID NO:135     1 -----mtigtlettaakd-----
                        Q          QTL T  L          T  E

SEQ ID NO:39      301 dvmrgvgsalaklrdldasvqakvrtvlaqalvespprveavvvrrhtgq
SEQ ID NO:134     18 d-----
SEQ ID NO:135     14 -----
                        D

SEQ ID NO:39      351 eilwnegrdrwshdlldaalakilanaraagfdvhsendlilnpddqlir
SEQ ID NO:134     19 -----
SEQ ID NO:135     14 -----

SEQ ID NO:39      401 alyasipcepvdaeypmfiiytsgtgkpgkviyhvggyvaggvvtlrsv
SEQ ID NO:134     19 -----
SEQ ID NO:135     14 -----

SEQ ID NO:39      451 fdaepgdtiyviadpgwitgqsymltatmagrltgviaegsplfpsagry
SEQ ID NO:134     19 -----
SEQ ID NO:135     14 -----

SEQ ID NO:39      501 asierygvqifkagvtflktvmsnpqnvdrlydmhslrvatfcaepv
SEQ ID NO:134     19 -----lyei-----
SEQ ID NO:135     14 -----lyei-----
                        LY
```

Figure 42A

```
SEQ ID NO:39      551 spavqqfgmqimtpqyinsyatehggivwthfygnqdfplrpdahypl
SEQ ID NO:134     23 -----
SEQ ID NO:135     18 -----

SEQ ID NO:39      601 pwvmgdvwvaetdesgttryrvadfdkgeivitapypyltrtlwgdvpg
SEQ ID NO:134     23 -----
SEQ ID NO:135     18 -----

SEQ ID NO:39      651 feaylrgeiplrawkgdaerfvktywrrgpngegyiqgdfaikypdgsf
SEQ ID NO:134     23 -----geip-----
SEQ ID NO:135     18 -----geip-----
                        GEIP

SEQ ID NO:39      701 tlhgrpddvinvsghrmgteiegalldrqrqitdpvpgncivvgaphre
SEQ ID NO:134     27 -----
SEQ ID NO:135     22 -----

SEQ ID NO:39      751 kgltpvafiqpapgrhltgadrrrldelvrtekavsvpedyievsafpe
SEQ ID NO:134     27 -----
SEQ ID NO:135     22 -----pafhv-----pk
                        P H P

SEQ ID NO:39      801 trsgkymrrflrnmmldeplgdtttlrrnpeveeiaakiaewkrqrmae
SEQ ID NO:134     27 -----plg-----hvpakmyawairr-----
SEQ ID NO:135     29 t-----myawsirk-----
                        T PLG AK W R

SEQ ID NO:39      851 eqqieryryfrieyphtasagklavvtvtnppvnalneraldeltiv
SEQ ID NO:134     43 -----erh-----
SEQ ID NO:135     38 -----
                        ER

SEQ ID NO:39      901 dhlarrgdvaaivftggarsfvagadirqlleeihtveeamalpnnahl
SEQ ID NO:134     46 -----
SEQ ID NO:135     38 -----

SEQ ID NO:39      951 afrkiermnkpciaaingvalggglefamachyrvadvyae fgqpeinlr
SEQ ID NO:134     46 -----gpe-----
SEQ ID NO:135     38 -----erhgkp-----
                        ER KP G PE

SEQ ID NO:39      1001 llpgygggtqrilprllykrnngtgllralemilggrsvpadealkglida
SEQ ID NO:134     50 -----
SEQ ID NO:135     44 -----

SEQ ID NO:39      1051 iatgdqdsislacalaraaigadgqliesaaavtqafrrheqldewrkpd
SEQ ID NO:134     50 -----
SEQ ID NO:135     44 -----tqamq-----
                        TQA

SEQ ID NO:39      1101 prfaddelrsiihprieriirqahtvgrdaavhraldairygiihgfea
SEQ ID NO:134     50 -----qsh-----
SEQ ID NO:135     49 -----
                        Q H
```

Figure 42B

```
SEQ ID NO:39 1151 gleheaklfaeavvdpnggkrgirefldrqsapltrrrplitpegeqllr
SEQ ID NO:134 53 -----
SEQ ID NO:135 49 -----

SEQ ID NO:39 1201 dqkellpvgsppffgvdrpikwqyaqavirdpdtgaahgdpivaekqii
SEQ ID NO:134 53 -qlvlpv-----wei-----gd-----
SEQ ID NO:135 49 -----vevptweige-----
Q E LPV V P W GD

SEQ ID NO:39 1251 vpverpranqaliyvasevnfndiwaitgipvsrfdehdrdwhvtgsgg
SEQ ID NO:134 65 -----devlvvmaagvnyngvwaglgpispfdvhkgeyhiagsda
SEQ ID NO:135 60 -----devlvvmaagvnyngvwaalgpispdghkqpfhiaagsda
L YV A VN N WA G P S FD H H GS

SEQ ID NO:39 1301 iglivalgeearregrlkvgdilaiysggsdlisp-lmgldpm-aadf-
SEQ ID NO:134 107 sgiwkvkgakvk---rwkvgdevivhcnqddgddeecnggdp-fsptqr
SEQ ID NO:135 102 sgiwkvkgakvk---rwklgdevivhcnqddgddeecnggdpfssqr-
G G R KVG D V I Q D G DPM

SEQ ID NO:39 1348 iqgndtpdgshqqfmlaqapqclpiptdmsieaagsyilnlgtiyralf-
SEQ ID NO:134 153 iwgyetgdgsfaqfcrvqsrqlmarpkhltweeaacytltlatayrmlfg
SEQ ID NO:135 148 iwgyetpdgsfaqfcrvqsrqlprpkhltweeaacytltlatayrmlfg
I G TPDGS QF Q Q LP P E A Y L L T YR LF

SEQ ID NO:39 1397 -ttlqikagrtifiegaatgtgldaarsaarnlrvigmvssssraatl1
SEQ ID NO:134 203 haphtrvpqgnvliwgasgglgvfgvqlcaasganaiavisdeskrdyvm
SEQ ID NO:135 198 hkpheikpgqnvliwgasgglgvfatqlaavaganaigvssedkrefvl
K G I GA G G A AA G IG VSS S L

SEQ ID NO:39 1446 aagahgainrkdpevadcftrvpdpesawaaweaagp1lamfraqndgr
SEQ ID NO:134 253 slgakgvnrkd---fdc---w-----
SEQ ID NO:135 248 smgakavlnrge---fncwgqlpk-----
GA G INRKD DC P

SEQ ID NO:39 1496 ladyvvshagetafprsfqllgeprdgthiptltfygatsgyhftflgkpg
SEQ ID NO:134 269 -----gqlptv-----
SEQ ID NO:135 269 -----vngpef-----
G PT G F

SEQ ID NO:39 1546 sasptemlrranlrageavliyygvgsddldvtgglaieaarqmgariv
SEQ ID NO:134 275 -----
SEQ ID NO:135 275 -----

SEQ ID NO:39 1596 vvtvsdaqrefvlslgfgaalrgvvs1aelkrrfgedefewprtmppipna
SEQ ID NO:134 275 -----ns
SEQ ID NO:135 275 -----ndymke-----srkfgkai-wqit-----
D E R FG W T N

SEQ ID NO:39 1646 rqpdpqglkeavrrfndlvfkplgsavgvflrsadnprgypdliieraahd
SEQ ID NO:134 277 peyntwlkea-rkfgkaiwditgkndv-----divfehpggea
SEQ ID NO:135 293 -----gnkdv-----dmvfehpggea
GLKEA R F G V D E

SEQ ID NO:39 1696 alavsamlikpftgrivyfediggrrrysffapqiwvrqrrymptaqifg
SEQ ID NO:134 314 tfpvstlvakr-ggmivfcagttgfnitfdaryvwmrkriq-----g
SEQ ID NO:135 308 tfpvsvflvkr-ggmivicagttgfnltmdarflwmrkriq-----g
VS L K G IV G F A W RQ RI G
```

Figure 42C


```
SEQ ID NO:39 1746 thlsnayeilrlndeisaglltitepavvpwdelpeahqamwenrhta  
SEQ ID NO:134 356 shfahlkqasaanqfvmdrrvdpcmsevfwpdkipahtkmwknghppgn  
SEQ ID NO:135 350 shfanlmqasaanqlvidrrvdpclsevfwpdqipaahkmlanghlpn  
                H N      N      V PWD P AH MW N H  
  
SEQ ID NO:39 1796 yvvnhalprlgknrdelyeawtager  
SEQ ID NO:134 406 mavlnstragirtvedvieagplkam  
SEQ ID NO:135 400 mavlvcaqrpgirtfeevqelsgap--  
                V      R GL      E EA A
```

Figure 42D

Figure 43




Figure 44









Figure 45





























ATGGCGACGGGGGAGTCCATGAGCGGAACAGGACGACTGGCAGGAAAGATTGCGTTAATT
ACCGGTGGCGCCGGCAATATCGGCAGTGAATTGACACGTCGCTTTCTCGCAGAGGGAGCG
ACGGTCATTATTAGTGGACGGAATCGGGCGAAGTTGACCGCACTGGCCGAACGGATGCAG
GCAGAGGCAGGAGTGCCGGCAAAGCGCATCGATCTCGAAGTCATGGATGGGAGTGATCCG
GTCGCGGTACGTGCCGGTATCGAAGCGATTGTGGCCCGTCACGGCCAGATCGACATTCTG
GTCAACAATGCAGGAAGTGCCGGTGCCAGCGTCGTCTGGCCGAGATTCCACTACTGAA
GCTGAATTAGGCCCTGGCGCCGAAGAGACGCTTCATGCCAGCATCGCCAATTTACTTGGT
ATGGGATGGCATCTGATGCGTATTGCGGCACCTCATATGCCGGTAGGAAGTGCCGTCATC
AATGTCTCGACCATCTTTTACGGGCTGAGTACTACGGGCGGATTCCGTATGTCACCCCT
AAAGCTGCTCTTAATGCTCTATCTCAACTTGCTGCGCGTGAGTTAGGTGCACGTGGCATC
CGCGTTAATACGATCTTTCCCGGCCGATTGAAAGTGATCGCATCCGTACAGTGTTCCAG
CGTATGGATCAGCTCAAGGGGCGCCCGAAGGCGACACAGCGCACCATTTTTTGAACACC
ATGCGATTGTGTCTGTGCCAACGACCAGGGCGCGCTTGAACGTGGTTCCCTCCGTCGGT
GATGTGGCAGACGCCGCTGTCTTTCTGGCCAGTGCCGAATCCGCCGCTCTCTCCGGTGAG
ACGATTGAGGTTACGCACGGAATGGAGTTGCCGGCCTGCAGTGAGACCAGCCTGCTGGCC
CGTACTGATCTGCGCACGATTGATGCCAGTGCCGCGCACGACGCTCATCTGCGCCGGCGAC
CAGATTGAAGAGGTGATGGCGCTCACCGGTATGTTGCGTACCTGTGGGAGTGAAGTGATC
ATCGGCTTCCGTTCCGCTGCGCGCTGGCCCGAGTTCGAGCAGGCAGTCAATGAGAGTCGG
CGGCTGGCCGGCGCAGACTTTACGCTCCCATTTGCTTGCCACTCGATCCACGCGATCCG
GCAACAATTGACGCTGTCTTCGATTGGGCCGGCGAGAATACCGGCGGGATTTCATGCAGCG
GTGATTCTGCCTGCTACCAGTCACGAACCGGCACCGTGCCTGATTGAGGTTGATGATGAG
CGGGTGCTGAATTTCTGGCCGATGAAATCACCGGGACAATTGTGATTGCCAGTCGCCCTG
GCCCGTTACTGGCAGTCGCAACGGCTTACCCCGGCGCACGTGCGCGTGGGCCGCGTGT
ATTTTTCTCTCGAACGGTGCCGATCAAAATGGGAATGTTTACGGACGCAATTCAAAGTGCC
GCTATCGTCAAGTCATTCGTGTGTGGCGTCACGAGGCTGAACTTGACTATCAGCGTGCC
AGCGCCCGCGGTGATCATGTGTGCGCGGTATGGGCCAATCAGATTGTGCGCTTCGCT
AACCGCAGCCTTGAAGGGTTAGAATTTGCCTGTGCCTGGACAGCTCAATTGCTCCATAGT
CAACGCCATATCAATGAGATTACCTCAACATCCCTGCCAACATTAGCGCCACCACCGGC
GCACGCAGTGATCGGTGCGATGGGCGGAAAGCCTGATCGGGTTGCATTTGGGGAAAGTT
GCCTTGATTACCGGTGGCAGCGCCGGTATTGGTGGGCAGATCGGGCGCCTCTGGCTTTG
AGTGGCGCGCGCGTGATGCTGGCAGCCCGTGATCGGCATAAGCTCGAACAGATGCAGGCG
ATGATCCAATCTGAGCTGGCTGAGGTGGGGTATACCGATGTCGAAGATCGCGTCCACATT
GCACCGGGTGCAGTGTGAGTAGCGAAGCGCAGCTTGCGGATCTTGTTGAACGTACCCTG
TCAGCTTTTGGCACCGTCGATTATCTGATCAACAACGCCGGGATCGCCGGGTGTCGAAGAG
ATGGTTATCGATATGCCAGTTGAGGGATGGCGCCATACCCTCTTCGCCAATCTGATCAGC
AACTACTCGTTGATGCGCAAATGGCGCCGTTGATGAAAAAACAGGGTAGCGGTTACATC
CTTAACGTCTCATCATACTTTGGCGGTGAAAAAGATGCGGCCATTCCCTACCCCAACCGT
GCCGATTACGCCGTCTCGAAGGCTGGTCAGCGGGCAATGGCCGAAGTCTTTGCGCGCTTC
CTTGGCCCCGAGATACAGATCAATGCCATTGCGCCGGGTCCGGTCGAAGGTGATCGCTTG
CGCGGTACCGGTGAACGTCCCGGCCTCTTTGCCCGTCGGGCGCGGCTGATTTTGAGAAC
AAGCGGCTGAATGAGCTTCACGCTGCTCTTATCGCGGCTGCGCGCACCGATGAGCGATCT
ATGCACGAACTGGTTGAACTGCTCTTACCCAATGATGTGGCCGCACTAGAGCAGAATCCC
GCAGCACCTACCGGTTGCGTGAACGGCAGCGTTCGCGAGCGAAGGCATCCGGCG
GCATCATCAAGCAGTGCGCTGCTGAACCGTTCAATTGCCGCTAAATTGCTGGCTCGTTTG
CATAATGGTGGCTATGTGTTGCCTGCCGACATCTTTGCAAACCTGCCAAACCCGCCGAT
CCCTTCTTACCCGAGCCAGATTGATCGCGAGGCTCGCAAGGTTGCTGACGGCATCATG
GGGATGCTCTACCTGCAACGGATGCCGACTGAGTTTGATGTGCAATGGCCACCGTCTAT
TACCTTGCCGACCGCAATGTCAGTGGTGAGACATTCACCCATCAGGTGGTTTGCCTTAC

Figure 49A

GAACGCACCCCTACCGGTGGCGAACTCTTCGGCTTGCCCTCACCGGAACGGCTGGCGGAG
CTGGTCGGAAGCACGGTCTATCTGATAGGTGAACATCTGACTGAACACCTTAACCTGCTT
GCCCCGTGCGTACCTCGAACGTTACGGGGCACGTCAGGTAGTGATGATTGTTGAGACAGAA
ACCGGGGCAGAGACAATGCGTCGCTTGCTCCACGATCACGTCGAGGCTGGTCGGCTGATG
ACTATTGTGGCCGGTGATCAGATCGAAGCCGCTATCGACCAGGCTATCACTCGCTACGGT
CCCCCAGGGCCGGTCGTCTGTACCCCTTCCGGCCACTGCCGACGGTACCACTGGTCGGG
CGTAAAGACAGTGACTGGAGCACAGTGTTGAGTGAGGCTGAATTTGCCGAGTTGTGCGAA
CACCAGCTCACCACCATTTCCGGGTAGCGCGCAAGATTGCCCTGAGTGATGGTGCCAGT
CTCGCGCTGGTCACTCCCGAAACTACGGCTACCTCAACTACCGAGCAATTTGCTCTGGCT
AACTTCATCAAAACGACCCTTCACGCTTTTACGGCTACGATTGGTGTCGAGAGCGAAAGA
ACTGCTCAGCGCATTCTGATCAATCAAGTCGATCTGACCCGGCGTGCGCGTGCCGAAGAG
CCGCGTGATCCGCACGAGCGTCAACAAGAACTGGAACGTTTTATCGAGGCAGTCTTGCTG
GTCAGTGCACCACTCCCGCTGAAGCCGATACCCGTTACGCCGGGCGGATTCATCGCGGA
CGGGCGATTACCGTGTAA (SEQ ID NO:140)

Figure 49B

Figure 50

MATGESMSGTGRLAGKIALITGGAGNIGSELTRRFLAEGATVIIISGRNRAKLTALAERMO
AEAGVPAKRIDLEVMDGSDPVAVRAGIEAIVARHGQIDILVNNAGSAGAQRRLAEIPLTE
AELGPGAETLHASIANLLGMGWHLMRIAPHMPVGSVINVSTIFSRAEYYGRI PYVTP
KAALNALSQLAARELGARGIRVNTIFPGPIESDRITVFQRMQDLKGRPEGDTAHHFLNT
MRLCRANDQGALERRRFPSVGDVADAAVFLASAESAALSGETIEVTHGMELPACSETSLA
RTDLRTIDASGRTTLICAGDQIEEVMALTMGLRTCGSEVIIGFRSAAALAQFEQAVNESR
RLAGADFTPPIALPLDPRDPATIDAVFDWAGENTGGIHAAVILPATSHEPAPCVIEVDDE
RVLNFLADEITGTIVIASRLARYWQSQRITPGARARGPRVIFLSNGADQNGNVYGRIQSA
AIGQLIRVWRHEAELDYQRASAAGDHVLPVWVWQIVRFANRSLEGLEFACAWTAQLLHS
QRHINEITLNI PANISATTGARSASVGWAESLIGLHLGKVALITGGSAGIGGQIGRLLAL
SGARVMLAARDRHKLEQMAMIQSELAIEVGYTDVEDRVHIAPGCDVSSEAQLADLVERTL
SAFGTVDYLINNAGIAGVEEMVIDMPVEGWRHTLFANLISNYSLMRKLAPLMKKQSGSYI
LNVSSYFGGEKDAAIPYPNRADYAVSKAGQRAMAEVFARFLGPEIQINAIAPGPVEGDRL
RGTGERPGLFARRARLILENKRLNELHAALIAAARTDERSMHVELLLPNDVAALEQNP
AAPALRELARRFRSEGDFAASSSSALLNRSIAAKLLARLHNGGYVLPADIFANLPNPPD
PFFTRAQIDREARKVRDGINMGLYLQRMPTFEDVAMATVYYLADRNVSGETFHPSGGLRY
ERTPTGGELFGLPSPERLAELVGSTVYLI GEHLTEHLNLLARAYLERYGARQVVMIVETE
TGAETMRLLHDHVEAGRLMTIVAGDQIEAIDQAITRYGRPGPVVCTPFRPLPTVPLVG
RKDSDWSTVLSEAEFAELCEHQLTHHFRVARKIALSDGASLALVTPETTATSTTEQFALA
NFIKTTLHAFTATIGVESERTAQRILINQVDLTRRARAEPRDPHERQQELERFIEAVLL
VTAPLPPEADTRYAGRIHRGRAITV (SEQ ID NO:141)

Figure 51

TCTTTCTGGCCAGTGCCGAATCCGCCGCTCTCTCCGGTGAGACGATTGAGGTTACGCACG
GAATGGAGTTGCCGGCCTGCAGTGAGACCAGCCTGCTGGCCCGTACTGATCTGCGCACGA
TTGATGCCAGTGGCCGCACGACGCTCATCTGCGCCGGCGACCAGATTGAAGAGGTGATGG
CGCTCACCGGTATGTTGCGTACCTGTGGGAGTGAAGTGATCATCGGCTTCCGTTCCGGCTG
CGGCGCTGGCCAGTTCGAGCAGGCAGTCAATGAGAGTCGGCGGCTGGCCGGCGCAGACT
TTACGCCTCCCATTGCCTTGCCACTCGATCCACGCG (SEQ ID NO:142)

```
SEQ ID NO:141      1 matgesmagtgrlagkialitggagnigseltrrflaegatviisgrnra
SEQ ID NO:143      1 -----mfankvvlvtggssgigaatveafvkegasvafvgrnqa
SEQ ID NO:144      1 -----mrlegkvclitgaasgigkattllfaqegatviagdiske
SEQ ID NO:145      1 -----
SEQ ID NO:146      1 -----mekf-----
SEQ ID NO:147      1 -----mrllhkrtlvttggsdgiglaiaaeafsegadvliivrdaa

SEQ ID NO:141      51 ktalaermqa--e-agvpakridlevmdgsdpvavragieaivarhqql
SEQ ID NO:143      40 klkevesrcqq--hganilaikadv----skdeeakiivqqtvdkgfkl
SEQ ID NO:144      41 nldslvk--ea--e--glp-----gkv
SEQ ID NO:145      1 -----
SEQ ID NO:146      5 -----
SEQ ID NO:147      41 kleaarqklaalqg-aga----vetssadlatslgvatvveqvketqrpl

SEQ ID NO:141      98 dilvnnagsagaqrrlaeiplteaelpggaeetlhasianllgmghlrmr
SEQ ID NO:143      83 dvlvnnagil---rfasv--leptliqtfdetmntnlrpvv---lits
SEQ ID NO:144      57 d-----
SEQ ID NO:145      1 -----
SEQ ID NO:146      5 -----
SEQ ID NO:147      86 dipinnagvadl-----vpfesv----seaqfghsfalnvaaffitq

SEQ ID NO:141      148 laaphm-pvgsavinvtifgr-aeyygrip--yvtpkaalnalsqlaar
SEQ ID NO:143      123 laiphliatkgsivnvssilstivripqims--yavskaamdhtfklaal
SEQ ID NO:144      58 -----p--yv-----lnv-----
SEQ ID NO:145      1 -----
SEQ ID NO:146      5 ---php-p-----
SEQ ID NO:147      125 gllphf-gagasiinissyfar-kmpkrpssvyslskgalnsltrslaf

SEQ ID NO:141      194 elgargirvntifpgpiesdrirtvfqrmqdkgrpegdtahhflntmrl
SEQ ID NO:143      171 elapsqgvrsvnsvngppv-----
SEQ ID NO:144      64 -----tdr-----
SEQ ID NO:145      1 -----mnpmdrqtgegqepqh-----
SEQ ID NO:146      9 -----
SEQ ID NO:147      173 elgprgirvnaiapgtvdt-----

SEQ ID NO:141      244 crandqgalerrfsvvgdvadaavflasaesaalsgetievthgmelpac
SEQ ID NO:143      188 -----ltdia-----
SEQ ID NO:144      67 -----
SEQ ID NO:145      16 -----
SEQ ID NO:146      9 -----fpr-----
SEQ ID NO:147      192 -----amrr-----

SEQ ID NO:141      294 setsllartdlrtidasgrttlicagdqievmaltgmrlrtcgseviigf
SEQ ID NO:143      193 -----
SEQ ID NO:144      67 -----dqikev-----
SEQ ID NO:145      16 -----
SEQ ID NO:146      12 -----qtqem-----
SEQ ID NO:147      196 -----ktvd-----

SEQ ID NO:141      344 rsaaalaqfeqavnesrrlagadftppialpldprdpavidavfdwagen
SEQ ID NO:143      193 -----agsgfsdpdl-----ed
SEQ ID NO:144      73 -----
SEQ ID NO:145      16 -----qdrqpgieskmp-----
SEQ ID NO:146      17 -----pgttdrm-----
SEQ ID NO:147      200 -----
```

Figure 52A

```
SEQ ID NO:141 394 tggihaaivilpatshpapcvievddervlnfladeitgtiviasrlary
SEQ ID NO:143 205 tg-----ahtp-----
SEQ ID NO:144 73 -----
SEQ ID NO:145 29 -----lp-----
SEQ ID NO:146 24 -----qplp-----
SEQ ID NO:147 200 -----

SEQ ID NO:141 444 wqsqrlltpgarargprviflsgadqngnvvgriqsaaigqlirvwrhea
SEQ ID NO:143 211 -----
SEQ ID NO:144 73 -----
SEQ ID NO:145 31 -----lsededyrgs--gklk-----
SEQ ID NO:146 28 -----dhg-----
SEQ ID NO:147 200 -----

SEQ ID NO:141 494 eldygrasaagdhvlpvwanqivrfaansleglefacawtaqlhhsqrh
SEQ ID NO:143 211 -----
SEQ ID NO:144 73 -----
SEQ ID NO:145 45 -----
SEQ ID NO:146 31 ensyqgsgrlkd-----
SEQ ID NO:147 200 -----

SEQ ID NO:141 544 ineitlnipanisattgarsasvsgaesliglhlqkvalitggsagigggq
SEQ ID NO:143 211 -----lgkaa-----
SEQ ID NO:144 73 -----
SEQ ID NO:145 45 -----gkvaiitggdsgigra
SEQ ID NO:146 43 -----kraiitggdsgigra
SEQ ID NO:147 200 -----nlpa-----

SEQ ID NO:141 594 igrllalsgarvmlaardrhk-leqmqaniqselaevgytdvedrvhiap
SEQ ID NO:143 216 -----qse-----
SEQ ID NO:144 73 -----
SEQ ID NO:145 61 aaiafakegadisilyldehsdaeetrkrieke-----nvrcllip
SEQ ID NO:146 58 vaiayaregadvlisylsehd----damatkalve---eagrkvavlaa
SEQ ID NO:147 204 -----

SEQ ID NO:141 643 gcdvsseaqladlvertlsafgtvdylinnagiagveemvidmpvegwrh
SEQ ID NO:143 219 -----eiadmi-----
SEQ ID NO:144 73 -----vekvvqkygridvlnnagitrdallvrmkeedwda
SEQ ID NO:145 102 g-dvgdenhceqavqqtvdhfgkldilvnnaaeqhpqdsilnisteqlek
SEQ ID NO:146 99 g-diqssdhcrrivetavrelggidilvnnaahqatfkniedisdeewel
SEQ ID NO:147 204 -----eakaelkayvers-----

SEQ ID NO:141 693 tlfanlisnyslmrklaplmmkkgsgyilnvssyfggekdaiipypnrad
SEQ ID NO:143 225 -----
SEQ ID NO:144 109 vinvnlkgvfnvtqmvvpymikqrngsivnvssvvg-----iygnpgqtn
SEQ ID NO:145 151 tfrtnifsmfhtkkaiphl--qegcaiinttsitayegdtal----id
SEQ ID NO:146 148 tfrvnmhamfylvtaavphmkk-gsa-iintasi-----nadvpnpilla
SEQ ID NO:147 217 -----

SEQ ID NO:141 743 yavskagqramaevfarfl-gpe-iqinaiapgpvegdrirgtgerpglf
SEQ ID NO:143 225 -----
SEQ ID NO:144 154 yaaskagvigmtktwakelagrnrirvnavapgfi-----
SEQ ID NO:145 194 ysstkgaivsftrsmaksl-adkgirvnavapgpi-----
SEQ ID NO:146 191 yattkgaihnsaglaqml-aergirvnavapgpi-----
SEQ ID NO:147 217 yplgrigr-----
```

Figure 52B

```
SEQ ID NO:141 791 arrarlilenkrlnelhaaliaaartdersmhelvellipndvaaleqnp
SEQ ID NO:143 225 -----
SEQ ID NO:144 189 -----
SEQ ID NO:145 228 -----wtp
SEQ ID NO:146 225 -----wtlipstmpedtva-dfgk
SEQ ID NO:147 225 -----pddlagm-----

SEQ ID NO:141 841 aaptalrelarrfrsegdpaassssallnrsiaakllarlhnggyvlpad
SEQ ID NO:143 225 -----
SEQ ID NO:144 189 -----
SEQ ID NO:145 231 lipatfpe-----
SEQ ID NO:146 244 qvp-----mkrpgqpvelasa-----yvmlad
SEQ ID NO:147 232 -----

SEQ ID NO:141 891 ifanlpnppdpfftraqidrearkvrdgimgmlylqxmptefdvamatvy
SEQ ID NO:143 225 -----vy
SEQ ID NO:144 189 -----
SEQ ID NO:145 239 -----ekvkq-----
SEQ ID NO:146 266 pmssy-----
SEQ ID NO:147 232 -----av

SEQ ID NO:141 941 yladrnvsgetfhpsgglryertptggelfglpsperlaelvgstvyli
SEQ ID NO:143 227 lasdk-----aksvtgscyi--
SEQ ID NO:144 189 -----tpmteklpekareta--
SEQ ID NO:145 244 -----hgldtp-----
SEQ ID NO:146 271 -----vsgatiavtgg-----
SEQ ID NO:147 234 yla----sdeaawtsggi-----

SEQ ID NO:141 991 ehltelnllaraylerygarqvmivetetgaetmrrllhdhveagrlm
SEQ ID NO:143 242 -----
SEQ ID NO:144 204 -----lsriplgrfgkpe-----evaqvi
SEQ ID NO:145 250 -----
SEQ ID NO:146 282 -----
SEQ ID NO:147 248 -----

SEQ ID NO:141 1041 tivagdqieaaidqaitrygrpgpvvctpfrplptvplvgrkdsdstvl
SEQ ID NO:143 242 -----
SEQ ID NO:144 223 lflasdessyvtgqvi---gidggglvi-----
SEQ ID NO:145 250 -----mgrpgqp-----
SEQ ID NO:146 282 -----kpfl-----
SEQ ID NO:147 248 -----favdggyt-----

SEQ ID NO:141 1091 seaefaelcehqthhfrvarkialsdgaslalvtpettatstteqfala
SEQ ID NO:143 242 -----mdnglalq-----
SEQ ID NO:144 247 -----
SEQ ID NO:145 258 -----eha-----gayvillasdes-----
SEQ ID NO:146 286 -----
SEQ ID NO:147 256 -----

SEQ ID NO:141 1141 nfikttlhaftatigvesertaqrilingvdltrraraeprdpheqqe
SEQ ID NO:143 250 -----
SEQ ID NO:144 247 -----
SEQ ID NO:145 272 -----symtggtihvn-----
SEQ ID NO:146 286 -----
SEQ ID NO:147 256 -----
```

Figure 52C

SEQ ID NO:141	1191	lerfieavllvtaplpeadtryagrihrgraitv
SEQ ID NO:143	250	-----
SEQ ID NO:144	247	-----
SEQ ID NO:145	283	-----ggrfist
SEQ ID NO:146	286	-----
SEQ ID NO:147	256	-----ag-----

Figure 52D

```
SEQ ID NO:140 1 atggcgacggggagtcocatgagcggaacaggacgactggcaggaaagat
SEQ ID NO:148 1 -----atga-----gacttctgcacaagcg
SEQ ID NO:149 1 -----atg-----ttcgcaataaaagt
SEQ ID NO:150 1 -----atgaggcttgaagggaag--
SEQ ID NO:151 1 -----atggaaa--
SEQ ID NO:152 1 -----

SEQ ID NO:140 51 tgcgt-taattacoggtggcgccggcaatatcggcagtgaattgacacgt
SEQ ID NO:148 21 cacgc-tggtgacggcggtc-----
SEQ ID NO:149 18 ggtac-tagtaacaggtggtagctccggtatcggc-----
SEQ ID NO:150 20 tgtgtctgatcacagg---ggctgcaagcgggatagggaag-gccacca
SEQ ID NO:151 8 -----aatttcgca-----ccct
SEQ ID NO:152 1 -----

SEQ ID NO:140 100 cgctt--tctcgagagggagcgacggtcattattagtggacggaatcgg
SEQ ID NO:148 42 -----ggacggtatcgg
SEQ ID NO:149 52 -----gcagctactgt-----
SEQ ID NO:150 65 cgcttcttttcgcacagggaag-----ga
SEQ ID NO:151 22 ccctt--tc-----
SEQ ID NO:152 1 -----

SEQ ID NO:140 148 gcgaagttgaccgactggccgaacggatgcaggcagaggcaggagtgc
SEQ ID NO:148 54 cc-----tggcaatcgcdgaggcggttcctgagcagg-----
SEQ ID NO:149 63 -----ggaagcattc-----
SEQ ID NO:150 88 gctacggtgatcg--ctggc-----gat-----
SEQ ID NO:151 29 -----
SEQ ID NO:152 1 -----gtgaaccaatgg----acaga--caaacagaaggacaag----

SEQ ID NO:140 198 ggcaaagcgcacatcgatctcgaagtcattggtgggagtgatccggtcgcgg
SEQ ID NO:148 86 -----gcgc-----cgatgtcct-----
SEQ ID NO:149 73 -----gttaaggaagg-----
SEQ ID NO:150 109 -----atctcga-----
SEQ ID NO:151 29 -----
SEQ ID NO:152 35 -----aaccgcagc-----atcagg-----

SEQ ID NO:140 248 tacgtgccggtatcgaagcgattgtggcccgtcacggccagatcgacatt
SEQ ID NO:148 99 -----gatcgtcgccgtgacgcc-----
SEQ ID NO:149 84 -----cgcttctgtagccttcgtg-----
SEQ ID NO:150 116 -----aagaaaatctcgactct
SEQ ID NO:151 29 -----cccgcca-----
SEQ ID NO:152 50 -----acagacagccgggcatt

SEQ ID NO:140 298 ctggtcaacaatgcaggaagtgcgggtgccagcgtcgtctggccgagat
SEQ ID NO:148 118 -----gcc-----
SEQ ID NO:149 103 -----ggaagaaaccaagccaag-----
SEQ ID NO:150 133 cttgtgaaagaggcagaagg-----
SEQ ID NO:151 36 -----aaccaggaatgcc-----
SEQ ID NO:152 67 g-agtcaaaaatgaa-----tccgctgcc-----

SEQ ID NO:140 348 tccactcactgaagctgaattaggccctggcgccgaagagacgcttcattg
SEQ ID NO:148 121 -----aagct-----cgaagccgcgc-----g
SEQ ID NO:149 121 -----cttaag--gaagtag-----agagccgc-----tg
SEQ ID NO:150 153 -----
SEQ ID NO:151 51 -----
SEQ ID NO:152 90 -----
```

Figure 53A

```
SEQ ID NO:140 398 ccagcatcgccaatttacttggtatgggatggcatctgatgcgtattgcg
SEQ ID NO:148 138 ccagaagc-----tggcg
SEQ ID NO:149 144 ccagcagc-----
SEQ ID NO:150 153 -----actt-----
SEQ ID NO:151 51 -----cg
SEQ ID NO:152 90 -----gctgtcagaggacgaggattatc

SEQ ID NO:140 448 gcacctcatatgccggtaggaagtgcggtcatcaatgtctcgaccatctt
SEQ ID NO:148 151 gc-----tcttgcca---
SEQ ID NO:149 152 -----atggagccaacatc--
SEQ ID NO:150 157 -----ccgg--ggaag-----
SEQ ID NO:151 53 gcac-----
SEQ ID NO:152 113 g-----aggaa-----

SEQ ID NO:140 498 ttcacgggctgagtactacgggcggttcggtatgtcaccctaaagctg
SEQ ID NO:148 162 -----ggc-----
SEQ ID NO:149 166 -----ctggctatcaaag-----cagatgtctcc---aaag---
SEQ ID NO:150 166 -----
SEQ ID NO:151 57 -----tac--cgatcggatgc-----agccg
SEQ ID NO:152 119 -----gctg-----aaaactg

SEQ ID NO:140 548 ctcttaatgctctatctcaacttgctgcgcgtgagttaggtgcacgtggc
SEQ ID NO:148 165 -----cggcgc-----ggtggagacgtc
SEQ ID NO:149 194 -----acgagga
SEQ ID NO:150 166 -----
SEQ ID NO:151 76 c-----tgccgat-----cacgggg-
SEQ ID NO:152 130 aaaggaa-----aagttg-----

SEQ ID NO:140 598 atccgcgttaatacgaatcttcccgcccgattgaaagtatcgcatccg
SEQ ID NO:148 183 gtccgc-----cgatcttgcc-----
SEQ ID NO:149 201 agc-----gaaaatcatcgta-----
SEQ ID NO:150 166 -----gttgatccctacgtt-----ttgaacgtgaccg-----
SEQ ID NO:151 92 -----aaaac-----tcct
SEQ ID NO:152 143 -----cgatcattactgg-----

SEQ ID NO:140 648 tacagtgttcacgcgtatggatcagctcaagggcgcccgaaaggcgaca
SEQ ID NO:148 199 -----
SEQ ID NO:149 217 -----
SEQ ID NO:150 194 -acag-----ggatcagataaag-----gaag-----
SEQ ID NO:151 101 accaggggttcc-----ggacgcctgaag-----
SEQ ID NO:152 156 -----aggcgaca

SEQ ID NO:140 698 cagcgcaccattttttgaacaccatgcgattgtgtcgtgccaacgaccag
SEQ ID NO:148 199 -----accag
SEQ ID NO:149 217 -----caacaa-----
SEQ ID NO:150 215 -----ttgtggaaaa-----agtcgttcaaa-----ag
SEQ ID NO:151 124 -----gacaag
SEQ ID NO:152 164 -----

SEQ ID NO:140 748 ggcgcgcttgaacgtcggttccctccgctcggtgatgtggcagacgccgc
SEQ ID NO:148 204 -----cct-----
SEQ ID NO:149 223 -----ac
SEQ ID NO:150 238 tacg-----gtcgaatc-----gatgt-----
SEQ ID NO:151 130 agagc-----catcatcacggcgccggga-----cagcggcatc
SEQ ID NO:152 164 -----
```

Figure 53B


```
SEQ ID NO:140 798 tgtctttctggccagtgccgaatccgccgtctctccggtgagacgattg
SEQ ID NO:148 207 -----cggtgtcgcaaccgtcg-tcgagcaggtgaaa-----
SEQ ID NO:149 225 tgtc-----gacaagttc-----gggaagcttg
SEQ ID NO:150 255 -----tctggtga-----
SEQ ID NO:151 163 gg-----cagggccgtggcga-----tcgcc-----
SEQ ID NO:152 164 -----

SEQ ID NO:140 848 aggttacgcacggaatggagttgccggcctgcagtgagaccagcctgctg
SEQ ID NO:148 238 -----gagaccggcc-----
SEQ ID NO:149 248 atgt-----
SEQ ID NO:150 263 -----
SEQ ID NO:151 184 ---tatgcgcgcgaggag-----c
SEQ ID NO:152 164 -----gcggaat-----agggagagc-----

SEQ ID NO:140 898 gcccgctactgatctgcgcacgattgatgccagtgccgcacgacgctcat
SEQ ID NO:148 248 -----ggccgctcgacattcct
SEQ ID NO:149 252 -----gcttggt-----acaacgc-----
SEQ ID NO:150 263 -----acaacgc-----
SEQ ID NO:151 201 ggacgtccttatcagc-----tat
SEQ ID NO:152 180 -----

SEQ ID NO:140 948 ctgcgcgcgcgaccagattgaagaggtgatggcgctcaccggtatgttgc
SEQ ID NO:148 265 at-----caacaatg-----ccggt-----
SEQ ID NO:149 267 -----
SEQ ID NO:150 270 -----
SEQ ID NO:151 220 ctgag-----cgagcatgacgacgcgatggccaccaaggct-----
SEQ ID NO:152 180 -----

SEQ ID NO:140 998 gtacctgtgggagtgaaagtgatcatcggttccggttcggctgcggcgctg
SEQ ID NO:148 280 -----gtcgcgcgacctc
SEQ ID NO:149 267 -----tgggatt-----ctacggttcg-----
SEQ ID NO:150 270 -----gggaat-----
SEQ ID NO:151 256 -----ctggtggag-gaag-----
SEQ ID NO:152 180 -----

SEQ ID NO:140 1048 gccagtttcgagcaggcagtcgaatgagagtcggcggtggccggcgcgaga
SEQ ID NO:148 292 gtgccggttcga-----gagcgtcagcg-----aggcgca--
SEQ ID NO:149 284 -----cgagtggt-----tctggagccga
SEQ ID NO:150 276 -----
SEQ ID NO:151 269 ---caggtcgc-aaggccgt-----gcttgccgcggcgga
SEQ ID NO:152 180 -----agcag-----

SEQ ID NO:140 1098 ctttacgcctcccattgccttgccactcgatccacgcgatccggcaacaa
SEQ ID NO:148 321 -----gtccagcactcc
SEQ ID NO:149 302 cttta-----ataca-----aactt
SEQ ID NO:150 276 -----aaciaa
SEQ ID NO:151 300 c-----atccagtcg-tccg---acca
SEQ ID NO:152 185 -----ctattgcctt-----

SEQ ID NO:140 1148 ttgacgctg--tcttcgattggccggcgagaataccggcgggattcatg
SEQ ID NO:148 334 ttcgcgctc-----aatgtggcgg-----cggcg-----
SEQ ID NO:149 317 ttga-----
SEQ ID NO:150 281 gggatgc-----gcttcttg
SEQ ID NO:151 318 ttgccgcaggatcgtcgaaacggccgttcgggaactcggcgcat-----
SEQ ID NO:152 195 -----
```

Figure 53C

```
SEQ ID NO:140 1196 cagcgggtgattctgcctgctaccagtcacgaaccggcaccgtgctgtgatt
SEQ ID NO:148 358 -----ttcttctt-----cacc-----
SEQ ID NO:149 321 -----tgaaact-----
SEQ ID NO:150 296 -----
SEQ ID NO:151 363 -----
SEQ ID NO:152 195 -----tgcta-----

SEQ ID NO:140 1246 gaggttgatgatgagcgggtgctgaattttctggccgatgaaatcaccgg
SEQ ID NO:148 370 -----caggggctgctgccgcattt-----
SEQ ID NO:149 328 -----atgaac-----acgaatttac--g
SEQ ID NO:150 296 -----tgag-----gatgaaa-----
SEQ ID NO:151 363 -----gatgaaa-----c
SEQ ID NO:152 200 -----aagagggggctga-----

SEQ ID NO:140 1296 gacaattgtgattgccagtcgcctggcccggttactggcagtcgcaacggc
SEQ ID NO:148 390 -----
SEQ ID NO:149 345 tccagttgtcctcatcactagcctg-----
SEQ ID NO:150 307 -----
SEQ ID NO:151 364 gaca-----
SEQ ID NO:152 213 -----

SEQ ID NO:140 1346 ttacccccggcgcaactgctgctggcgctgcatTTTTCTCTCGAAC
SEQ ID NO:148 390 -----cggcgc-----c
SEQ ID NO:149 370 -----
SEQ ID NO:150 307 -----
SEQ ID NO:151 368 -----TTCTCGTCAAC
SEQ ID NO:152 213 -----TATCTCCATTCTAT---ac

SEQ ID NO:140 1396 ggtgccgatcaaaatgggaatgtttacggacgcattcaaatgcccgtat
SEQ ID NO:148 397 ggtgc-----at
SEQ ID NO:149 370 -----gctat
SEQ ID NO:150 307 -----gaagaagactgggatg-----
SEQ ID NO:151 379 aatgc-----
SEQ ID NO:152 229 ttagacgagca-----ttcggacgca-----

SEQ ID NO:140 1446 cggtcagctcattcgtgtgtggcgtcacgaggctgaactgactatcagc
SEQ ID NO:148 404 cgatca-----
SEQ ID NO:149 375 ccctcatttgatt-----gctacaaaaggag-----
SEQ ID NO:150 323 cggt-----aataaac
SEQ ID NO:151 384 -----
SEQ ID NO:152 250 -----gagg-----aac

SEQ ID NO:140 1496 gtgccagcgccgcggtgatcatgtgctgccgcggtatgggccaatcag
SEQ ID NO:148 410 -----
SEQ ID NO:149 402 -----
SEQ ID NO:150 334 gtg-----aatc--
SEQ ID NO:151 384 -----agcccatcag
SEQ ID NO:152 258 acgcaaacg-----gatc-----gaaaaggag

SEQ ID NO:140 1546 attgtgcgcttcgctaaccgcagccttgaagggttagaatttgctgtgc
SEQ ID NO:148 410 -----
SEQ ID NO:149 402 -----
SEQ ID NO:150 341 -----tgaagggt-----
SEQ ID NO:151 394 -----gcgaccttcaag-----
SEQ ID NO:152 280 aatgtccgctgc-----ctgcttatcc
```

Figure 53D

```
SEQ ID NO:140 1596 ctggacagctcaattgctccatagtcacgccatatcaatgagattaccc
SEQ ID NO:148 410 -----
SEQ ID NO:149 402 -----catagttaacg---tatccagtata-----
SEQ ID NO:150 349 -----gttttcaacg-----
SEQ ID NO:151 406 -----
SEQ ID NO:152 302 cggga-----

SEQ ID NO:140 1646 tcaacatccctgccaacattagcgccaccacggcgccagtcagtcgc
SEQ ID NO:148 410 tcaacatctcttctctattt-----cgcccgca-----
SEQ ID NO:149 424 -----ctgtctacaatag-----
SEQ ID NO:150 359 -----
SEQ ID NO:151 406 --aacatc---gaagacatcagcgac-----
SEQ ID NO:152 307 -----

SEQ ID NO:140 1696 gtcggatggcggaagcctgatcggttgcatctggggaagtgcctt
SEQ ID NO:148 437 -----
SEQ ID NO:149 437 -----
SEQ ID NO:150 359 -----
SEQ ID NO:151 427 -----gagga-----
SEQ ID NO:152 307 ---gatg-----ttgggga-----

SEQ ID NO:140 1746 gattaccggtggcagcgccggtattggtgggcagatcgggcgccctctgg
SEQ ID NO:148 437 -----
SEQ ID NO:149 437 -----
SEQ ID NO:150 359 -----
SEQ ID NO:151 432 -----gtggg-----
SEQ ID NO:152 318 -----

SEQ ID NO:140 1796 ctttgagtggcgcgcgctgatgctggcagcccgatcggcataagctc
SEQ ID NO:148 437 -----
SEQ ID NO:149 437 -----taa-----
SEQ ID NO:150 359 -----
SEQ ID NO:151 437 -----agctgacattccg-----c
SEQ ID NO:152 318 -----

SEQ ID NO:140 1846 gaacagatgcaggcgatgatccaatctgagctggctgaggtgggtatac
SEQ ID NO:148 437 -----agatgatcc-----
SEQ ID NO:149 440 -----gaatac-----
SEQ ID NO:150 359 -----tgactcagatgg-----
SEQ ID NO:151 451 gtcaacatgcacgccatgttc-----tac-----
SEQ ID NO:152 318 -----cga-gaaccattgtgaacaagctg-----

SEQ ID NO:140 1896 cgatgtcgaagatcgctccacattgcaccgggctgcgatgtgagtagcg
SEQ ID NO:148 446 -----cg-----
SEQ ID NO:149 446 c-----
SEQ ID NO:150 371 -----
SEQ ID NO:151 475 c--tgaccaag-----gcagcgg-----
SEQ ID NO:152 341 -----tgca-----

SEQ ID NO:140 1946 aagcgcagcttgcgatcttgttgaacgtaccctgtcagcttttggcacc
SEQ ID NO:148 448 aagcg-----gccatc-----cagc
SEQ ID NO:149 447 -----
SEQ ID NO:150 371 -----
SEQ ID NO:151 491 -----tgccgcacatgaagaa-----gggcagc
SEQ ID NO:152 345 ----gcaaacagtggacc-----atthtggtaaa
```

Figure 53E

```
SEQ ID NO:140 1996 gtcgattatctga-tcaacaacgcccgggatcgccggtgtcgaagagatgg
SEQ ID NO:148 463 gtctactccctgt-ccaagggcgc-----
SEQ ID NO:149 447 -----
SEQ ID NO:150 371 -----
SEQ ID NO:151 514 g-----cga-tcatcaacaccg-----
SEQ ID NO:152 370 ctcgat-atcttagtgaacaacgccg-----

SEQ ID NO:140 2045 ttatcgatatgccagttgagggatggcgccataccctcttcgccaatctg
SEQ ID NO:148 486 -----gttga-----
SEQ ID NO:149 447 -----agggattatgtcatacagt-----
SEQ ID NO:150 371 -----
SEQ ID NO:151 530 -----cttcca-----tcaatgccgacgttcccaatccg
SEQ ID NO:152 395 -----ctg

SEQ ID NO:140 2095 atcagcaactactcgttgatgcgcaaaactggcgccgttgatgaaaaaca
SEQ ID NO:148 491 -----actcgttga-----
SEQ ID NO:149 466 -----
SEQ ID NO:150 371 -----tggtgccctacatgatcaaaaca
SEQ ID NO:151 559 atc-----ctactcgccatgcg-----accacca
SEQ ID NO:152 398 aacagcatc-----ccca

SEQ ID NO:140 2145 gggtagcgggttacatccttaacgtctcatcatactttggcggtgaaaaag
SEQ ID NO:148 500 -----
SEQ ID NO:149 466 -----
SEQ ID NO:150 393 gaggaacggttcgatcgtgaacgtctcctctgtcgttgg-----aat
SEQ ID NO:151 584 agggcgcg-----atc-----cacaattt-----
SEQ ID NO:152 411 ggacag-----cattctcaatafttcaaca-----

SEQ ID NO:140 2195 atgcggccattccctaccccaaccgtgccgattacgccgtctcgaaggct
SEQ ID NO:148 500 -----ccagatcgct
SEQ ID NO:149 466 -----gtgtcaaaggct
SEQ ID NO:150 435 atacgggaat-----cctggtcagacgaattacgcccgtcgaaggcg
SEQ ID NO:151 603 -----cagcgccg-----gtctcg-----
SEQ ID NO:152 436 -----

SEQ ID NO:140 2245 ggtcagcgggcaatggccgaagtctttgcgcgttccttggcccg---ga
SEQ ID NO:148 510 ggccttcgag-----ctcggcccgcgcgg
SEQ ID NO:149 478 g-----
SEQ ID NO:150 478 ggagtcataggaatgacc-aagacgt-----
SEQ ID NO:151 617 ---cgcagatgctggccgaa-----cgcg---g-
SEQ ID NO:152 436 gaacagctggaa-----aaaacctttcgc-----

SEQ ID NO:140 2292 gatacagatcaatgccattgcgcgggtccggtcgaaggatcgcttgc
SEQ ID NO:148 534 catccgcgtcaacgccatcgccccggcacggtcga-----
SEQ ID NO:149 479 -----
SEQ ID NO:150 503 -----gggcgaaggaaactcgct---
SEQ ID NO:151 639 gataagagtgaatgtcgtggccccgggcccgcgc-----
SEQ ID NO:152 460 -acaaatattttttccat-----

SEQ ID NO:140 2342 gcggtaccggtgaacgtcccggcctctttgcccgtcgggcgcggctgatt
SEQ ID NO:148 570 -----
SEQ ID NO:149 479 -----
SEQ ID NO:150 520 -----
SEQ ID NO:151 673 -----tggaacgcgcgtg---
SEQ ID NO:152 477 -----
```

Figure 53F

```
SEQ ID NO:140 2392 ttggagaacaagcggctgaatgagcttcacgctgctcttatcgcggtgc
SEQ ID NO:148 570 -----
SEQ ID NO:149 479 -----
SEQ ID NO:150 520 -----ggaagaaacatcagggagaac-----gctgt
SEQ ID NO:151 685 -----atccctccaccatgc-----
SEQ ID NO:152 477 -----gtttca-----

SEQ ID NO:140 2442 gcgcaccgatgagcgatctatgcacgaactggtgaactgctcttaccca
SEQ ID NO:148 570 -----
SEQ ID NO:149 479 -----ctatg---gatcacttcacaaaat-----
SEQ ID NO:150 546 g-gcacc-----cgga
SEQ ID NO:151 701 -----ccgagga-----
SEQ ID NO:152 483 -----tatg-acgaa-----

SEQ ID NO:140 2492 atgatgtggccgcactagagcagaatcccgacgacctaaccggttgctg
SEQ ID NO:148 570 -----cacc-----
SEQ ID NO:149 500 -----tggcagcgttgagctg-----gctccttctggcgtgcga
SEQ ID NO:150 556 ttcata-----agaaaccccatgac-----
SEQ ID NO:151 708 -----taccg-----
SEQ ID NO:152 492 -----gaaagctttgcct-----

SEQ ID NO:140 2542 gaactggcacgacgttttcgcagcgaaggcgatccggcgcatcatcaag
SEQ ID NO:148 574 -----gccatgcggcg-----caag
SEQ ID NO:149 535 g-----
SEQ ID NO:150 576 -----cgaaaaacttccag-----aaaaag
SEQ ID NO:151 713 -----tcgccgatttcg-----
SEQ ID NO:152 505 cacctg-----caag

SEQ ID NO:140 2592 cagtgcgctgctgaaccgttcaattgccgctaattgctggctcgtttgc
SEQ ID NO:148 589 -----accgt-----
SEQ ID NO:149 536 -----tgaac---tcagt-----
SEQ ID NO:150 596 c-----ccgtgaaacggcc-----
SEQ ID NO:151 725 -----gc-----
SEQ ID NO:152 515 aggggtg-----tgccatta-----

SEQ ID NO:140 2642 ataatgggtggtatgtgttcctgccgacatctttgcaaacctgccaaac
SEQ ID NO:148 594 -----cgac-----aacctgcc-----
SEQ ID NO:149 546 -----caaccctg-----
SEQ ID NO:150 610 -----ctttccaga-----
SEQ ID NO:151 727 aaacaggtgcctatg-----acgacat-----
SEQ ID NO:152 530 ttaat-----

SEQ ID NO:140 2692 ccgcccgatccctcttccaccgagccagattgatcgcgaggctcgcaa
SEQ ID NO:148 606 -----
SEQ ID NO:149 554 -----gaccagttct-----
SEQ ID NO:150 619 -----atacc-----gctgggaa
SEQ ID NO:151 742 -----aa-----
SEQ ID NO:152 542 -----cgattaccgctt-----

SEQ ID NO:140 2742 ggttcgtgacggcatcatggggatgctctacctgcaacggatgccgactg
SEQ ID NO:148 606 -----ggccga-----
SEQ ID NO:149 564 -----tac-----
SEQ ID NO:150 632 ggtttgggaagccagaagagg-----
SEQ ID NO:151 744 g-----
SEQ ID NO:152 554 -----atgaaggggat-----acgg-----
```

Figure 53G

```
SEQ ID NO:140 2792 agtttgatgtcgcaatggccaccgtctattaccttgccgaccgcaatgtc
SEQ ID NO:148 612 -----ggcca-----aggccgaactgaaggcc
SEQ ID NO:149 567 ----tgatatcgc-----
SEQ ID NO:150 653 -----tggcgca-----
SEQ ID NO:151 745 -----cgaccg-----
SEQ ID NO:152 569 -----cgттаattgattattccagcacaaaq--

SEQ ID NO:140 2842 agtgggtgagaca-ttccacccatcaggtggtttgcgttacgaacgcaccc
SEQ ID NO:148 634 tatg-----tcgaacgcagc-
SEQ ID NO:149 576 -----
SEQ ID NO:150 660 ---ggttatactcttcctcgcatcggacgagtcgagttacg-----
SEQ ID NO:151 751 -----
SEQ ID NO:152 595 ---ggtgcga-----ttgtttcctttacg-----

SEQ ID NO:140 2891 ctaccggtggcgaactcttcggcttgccctcacccggaacggctggcgga
SEQ ID NO:148 649 -----tatccgctgggcccgcacatcgg-cggtccggacgac
SEQ ID NO:149 576 -----ag
SEQ ID NO:150 698 -----tcaccggacagg-----
SEQ ID NO:151 751 -----ggccagccc-----gtggaa
SEQ ID NO:152 616 cgttccatggcgaagtc---gcttgc-----

SEQ ID NO:140 2941 ctggtcggaagcacggtctatctgataggtgaacatctgactgaacacct
SEQ ID NO:148 682 ctgcgcgcatggcggtttatct-----
SEQ ID NO:149 578 ctggt-----tctggct-----
SEQ ID NO:150 710 -----tgatag-----
SEQ ID NO:151 766 ctcg-----cctcggcctatgtcat-----
SEQ ID NO:152 639 -----agataaa-----

SEQ ID NO:140 2991 taacctgcttgcccgtgcgtacctcgaacgttacggggcacgtcaggtag
SEQ ID NO:148 705 -----
SEQ ID NO:149 590 -----
SEQ ID NO:150 716 -----
SEQ ID NO:151 786 -----
SEQ ID NO:152 646 -----ggca-----

SEQ ID NO:140 3041 tgatgattgttgagacagaaaccggggcagagacaatgcgtcgcttgctc
SEQ ID NO:148 705 -----
SEQ ID NO:149 590 -----tttctc
SEQ ID NO:150 716 -----
SEQ ID NO:151 786 -----
SEQ ID NO:152 650 -----tcagagtgaatgcg-----

SEQ ID NO:140 3091 cacgatcacgtcgaggctggtcggtgatgactattgtggccggtgatca
SEQ ID NO:148 705 -----
SEQ ID NO:149 596 c-----tgatct
SEQ ID NO:150 716 -----
SEQ ID NO:151 786 -----gctgg-----
SEQ ID NO:152 664 -----gtggcgcccgggt-----

SEQ ID NO:140 3141 gatcgaagccgctatcgaccaggctatcactcgctacggtcgcccagggc
SEQ ID NO:148 705 -----agccagcgacgaggc-----
SEQ ID NO:149 603 gcttgaag-----
SEQ ID NO:150 716 -----
SEQ ID NO:151 791 ---cggatccgatgtcga-----gctac-----
SEQ ID NO:152 676 -----ccgatttgacaccgct-----
```

Figure 53H

```
SEQ ID NO:140 3191 cggtcgtctgtacccccctccggccactgccgacggtaccactggtcggg
SEQ ID NO:148 720 -----
SEQ ID NO:149 611 -----
SEQ ID NO:150 716 -----
SEQ ID NO:151 811 -----
SEQ ID NO:152 693 -----tattccgg-----cgacattccctgagg-----

SEQ ID NO:140 3241 cgtaaagacagtgactggagcacagtgttgagtgaggctgaatttgccga
SEQ ID NO:148 720 -----ggcctgga-----cga
SEQ ID NO:149 611 -----atacaggg-----
SEQ ID NO:150 716 -----gaat-----
SEQ ID NO:151 811 -----gtgtcaggcgca-----
SEQ ID NO:152 716 -----aaaaagtga-aacagcac-----ggcttgataaccca

SEQ ID NO:140 3291 gttgtgcgaacaccagctcaccacatttccgggtagcgcgcaagattg
SEQ ID NO:148 731 gcggtgggatac-----tttg
SEQ ID NO:149 619 -----gctcatacaccgt-----
SEQ ID NO:150 720 -----
SEQ ID NO:151 823 -----acgattg
SEQ ID NO:152 748 ---atgggaagaccgggacagcc-----ggttgagc-----

SEQ ID NO:140 3341 ccctgagtgatgggtgc-cagtctcgcgctggctcactcccgaaactacggc
SEQ ID NO:148 746 ccgtg---gatggg-----
SEQ ID NO:149 632 ---tggggaaagctgcgcagtct-----
SEQ ID NO:150 720 -----agatgg-----
SEQ ID NO:151 830 ccgtga-----
SEQ ID NO:152 776 -----atgcaggcgc-ctatgtctgctggcgctctgacgaa-----

SEQ ID NO:140 3390 tacctcaactaccgagcaatttgctctggctaacttcatcaaaacgaccc
SEQ ID NO:148 757 -----
SEQ ID NO:149 652 -----gaggagattgct-----
SEQ ID NO:150 726 -----
SEQ ID NO:151 836 -----
SEQ ID NO:152 811 -----tcttcta-----

SEQ ID NO:140 3440 ttcacgcttttacggctacgattgggtgcgagagcgaaagaactgctcag
SEQ ID NO:148 757 -----ggcta-----
SEQ ID NO:149 664 -----gatatgatt-----
SEQ ID NO:150 726 -----
SEQ ID NO:151 836 -----
SEQ ID NO:152 819 -----tatga-----cag

SEQ ID NO:140 3490 cgcattctgatcaatcaagtcgatctgacccggcggtgcgctgccgaaga
SEQ ID NO:148 762 -----
SEQ ID NO:149 673 -----gtgtatctg-----gctagtataaagc
SEQ ID NO:150 726 -----gg
SEQ ID NO:151 836 -----
SEQ ID NO:152 827 ggca---gaccattcatgt-----gaatg

SEQ ID NO:140 3540 gccgcgtgatccgcacgagcgtcaacaagaactggaacgttttatcgagg
SEQ ID NO:148 762 -----
SEQ ID NO:149 696 taagagtgtt-----acggggtcctgttat-----
SEQ ID NO:150 728 gcctcgtgat-----
SEQ ID NO:151 836 -----
SEQ ID NO:152 848 gcggc-----cgttttat-----
```

Figure 53I

```
SEQ ID NO:140 3590 cagtcttgctgggtcactgcaccactcccgctgaagccgatacccgttac
SEQ ID NO:148 762 -----
SEQ ID NO:149 721 ----atcatggacaatg---gactcgcgc-----
SEQ ID NO:150 738 -----ctga-----
SEQ ID NO:151 836 -----ccggcggcaagcc-----
SEQ ID NO:152 861 -----

SEQ ID NO:140 3640 gccggggcggattcatcgcggacgggcgattaccgtgtaa
SEQ ID NO:148 762 -----cacggccggatga-----
SEQ ID NO:149 743 -----tgca-----gtaa
SEQ ID NO:150 742 -----
SEQ ID NO:151 849 -----tttcctttga-
SEQ ID NO:152 861 -----ttcaac-----gtaa
```

Figure 53J

Figure 54




Figure 55




Figure S6

```
1  MVGKKVVHHL MMSAKDAHYT GNLVNGARIV NQWGDVGTEL
41  MVYVDGDISL FLGYKDIEFT APVYVGDFME YHGWIEKVG
81  QSYTCKFEAW KVATMVDITN PQDTRATAACE PPVLCGRATG
121 SLFIAKKDQR GPQESSFKER KHPGE (SEQ ID NO:160)
```

Figure 57

```
1  MVGKKVVHHL MMSAKDAHYT GNLVNGARIV NQWGDVGTEL
41  MVYVDGDISL FLGYKDIEFT APVYVGDFME YHGWIEKVG
81  QSYTCKFEAW KVAKMVDITN PQDTRATACE PPVLCGTATG
121 SLFIAKDNQR GPQESSFKDA KHPQ (SEQ ID NO:161)
```

Figure 58

```
1  ATGGTAGGTA AAAAGGTTGT ACATCATTTA ATGATGAGCG
41  CAAAAGATGC TCACTATACT GGAAACTTAG TAAACGGCGC
81  TAGAATTGTG AATCAGTGGG GCGACGTTGG TACAGAATTA
121 ATGGTTTATG TTGATGGTGA CATAAGCTTA TTCTTGGGCT
161 ACAAAGATAT CGAATTCACA GTCCTGTAT ATGTTGGTGA
201 CTTTATGGAA TACCACGGCT GGATTGAAAA AGTTGGTAAC
241 CAGTCCTATA CATGTAAATT TGAAGCATGG AAAGTTGCAA
281 CAATGGTTGA TATCACAAAT CCTCAGGATA CACGCGCAAC
321 AGCTTGTGAG CCTCCGGTAT TGTGCGGAAG AGCAACGGGT
361 AGTTTGTTC TCGCAAAAAA AGATCAGAGA GGCCCTCAGG
401 AATCCTCTTT TAAAGAGAGA AAGCACCCCG GTGAATGA
(SEQ ID NO:162)
```

Figure 59

```
1  ATGGTAGGTA AAAAGGTTGT ACATCATTTA ATGATGAGCG
41  CAAAAGATGC TCACTATACT GGAAACTTAG TAAACGGCGC
81  TAGAATTGTG AATCAGTGGG GCGACGTAGG TACAGAATTA
121 ATGGTTTATG TTGATGGTGA CATCAGCTTA TTCTTGGGCT
161 ACAAAGATAT CGAATTCACA GTCCTGTAT ATGTTGGTGA
201 TTTTATGGAA TACCACGGCT GGATTGAAAA AGTTGGCAAC
241 CAGTCCTATA CATGTAAATT TGAAGCATGG AAAGTAGCAA
281 AGATGGTTGA TATCACAAAT CCACAGGATA CACGTGCAAC
321 AGCTTGTGAA CCTCCGGTAC TTTGTGGTAC TGCAACAGGC
361 AGCCTTTTCA TCGCAAAGGA TAATCAGAGA GGTCTCAGG
401 AATCTTCCTT CAAGGATGCA AAGCACCTC AATAA
(SEQ ID NO:163)
```

3-HYDROXYPROPIONIC ACID AND OTHER ORGANIC COMPOUNDS

CROSS REFERENCE TO RELATED APPLICATIONS

This is a continuation of U.S. application Ser. No. 13/467,165 filed May 9, 2012, now U.S. Pat. No. 8,501,455, which is a divisional of U.S. application Ser. No. 13/294,820 filed Nov. 11, 2011, now U.S. Pat. No. 8,198,066, which is a divisional of U.S. application Ser. No. 12/127,700 filed May 27, 2008, now U.S. Pat. No. 8,076,120, which is a divisional of U.S. application Ser. No. 11/539,856 filed Oct. 9, 2006, now U.S. Pat. No. 7,638,316, which is a divisional of U.S. application Ser. No. 10/432,443 filed Oct. 20, 2003 now U.S. Pat. No. 7,186,541, which is the National Stage of International Application No. PCT/US01/43607, filed Nov. 20, 2001, which in turn claims the benefit of U.S. Provisional Application Nos. 60/252,123 filed Nov. 20, 2000, 60/285,478 filed Apr. 20, 2001, 60/306,727 filed Jul. 20, 2001, and 60/317,845 filed Sep. 7, 2001, all herein incorporated by reference.

FIELD OF THE INVENTION

The invention relates to enzymes and methods that can be used to produce organic acids and related products.

BACKGROUND

Organic chemicals such as organic acids, esters, and polyols can be used to synthesize plastic materials and other products. To meet the increasing demand for organic chemicals, more efficient and cost effective production methods are being developed which utilize raw materials based on carbohydrates rather than hydrocarbons. For example, certain bacteria have been used to produce large quantities of lactic acid used in the production of polylactic acid.

3-hydroxypropionic acid (3-HP) is an organic acid. Although several chemical synthesis routes have been described to produce 3-HP, only one biocatalytic route has been heretofore previously disclosed (WO 01/16346 to Suthers, et al.). 3-HP has utility for specialty synthesis and can be converted to commercially important intermediates by known art in the chemical industry, e.g., acrylic acid by dehydration, malonic acid by oxidation, esters by esterification reactions with alcohols, and reduction to 1,3-propanediol.

SUMMARY

The invention relates to methods and materials involved in producing 3-hydroxypropionic acid and other organic compounds (e.g., 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, esters of 3-HP, and malonic acid and its esters). Specifically, the invention provides nucleic acid molecules, polypeptides, host cells, and methods that can be used to produce 3-HP and other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, esters of 3-HP, and malonic acid and its esters. 3-HP has potential to be both biologically and commercially important. For example, the nutritional industry can use 3-HP as a food, feed additive or preservative, while the derivatives mentioned above can be produced from 3-HP. The nucleic acid molecules described herein can be used to engineer host cells with the ability to produce 3-HP as well as other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, and esters of 3-HP. The polypep-

tides described herein can be used in cell-free systems to make 3-HP as well as other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, and esters of 3-HP. The host cells described herein can be used in culture systems to produce large quantities of 3-HP as well as other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, and esters of 3-HP.

One aspect of the invention provides cells that have lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity, and methods of making products such as those described herein by culturing at least one of the cells that have lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity. In some embodiments, the cell can also contain an exogenous nucleic acid molecule that encodes one or more of the following polypeptides: a polypeptide having E1 activator activity; an E2 α polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; an E2 β polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; and a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity. Additionally, the cell can have CoA transferase activity, CoA synthetase activity, poly hydroxyacid synthase activity, 3-hydroxypropionyl-CoA hydrolase activity, 3-hydroxyisobutryl-CoA hydrolase activity, and/or lipase activity. Moreover, the cell can contain at least one exogenous nucleic acid molecule that expresses one or more polypeptides that have CoA transferase activity, 3-hydroxypropionyl-CoA hydrolase activity, 3-hydroxyisobutryl-CoA hydrolase activity, CoA synthetase activity, poly hydroxyacid synthase activity, and/or lipase activity.

In another embodiment of the invention, the cell that has lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity produces a product, for example, 3-HP, polymerized 3-HP, and/or an ester of 3-HP, such as methyl hydroxypropionate, ethyl hydroxypropionate, propyl hydroxypropionate, and/or butyl hydroxypropionate. Accordingly, the invention also provides methods of producing one or more of these products. These methods involve culturing the cell that has lactyl-CoA dehydratase activity and 3-hydroxypropionyl-CoA dehydratase activity under conditions that allow the product to be produced. These cells also can have CoA synthetase activity and/or poly hydroxyacid synthase activity.

Another aspect of the invention provides cells that have CoA synthetase activity, lactyl-CoA dehydratase activity, and poly hydroxyacid synthase activity. In some embodiments, these cells also can contain an exogenous nucleic acid molecule that encodes one or more of the following polypeptides: a polypeptide having E1 activator activity; an E2 α polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; an E2 β polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; a polypeptide having CoA synthetase activity; and a polypeptide having poly hydroxyacid synthase activity.

In another embodiment of the invention, the cell that has CoA synthetase activity, lactyl-CoA dehydratase activity, and poly hydroxyacid synthase activity can produce a product, for example, polymerized acrylate.

Another aspect of the invention provides a cell comprising CoA transferase activity, lactyl-CoA dehydratase activity, and lipase activity. In some embodiments, the cell also can contain an exogenous nucleic acid molecule that encodes one or more of the following polypeptides: a polypeptide having CoA transferase activity; a polypeptide having E1 activator activity; an E2 α polypeptide that is a subunit of an enzyme having lactyl-CoA dehydratase activity; an E2 β polypeptide

that is a subunit of an enzyme having lactyl-CoA dehydratase activity; and a polypeptide having lipase activity. This cell can be used, among other things, to produce products such as esters of acrylate (e.g., methyl acrylate, ethyl acrylate, propyl acrylate, and butyl acrylate).

In some embodiments, 1,3 propanediol can be created from either 3-HP-CoA or 3-HP via the use of polypeptides having enzymatic activity. These polypeptides can be used either in vitro or in vivo. When converting 3-HP-CoA to 1,3 propanediol, polypeptides having oxidoreductase activity or reductase activity (e.g., enzymes from the 1.1.1.-class of enzymes) can be used. Alternatively, when creating 1,3 propanediol from 3-HP, a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme from the 1.1.1.32 class) can be used.

In some embodiments of the invention, products are produced in vitro (outside of a cell). In other embodiments of the invention, products are produced using a combination of in vitro and in vivo (within a cell) methods. In yet other embodiments of the invention, products are produced in vivo. For methods involving in vivo steps, the cells can be isolated cultured cells or whole organisms such as transgenic plants, non-human mammals, or single-celled organisms such as yeast and bacteria (e.g., *Lactobacillus*, *Lactococcus*, *Bacillus*, and *Escherichia* cells). Hereinafter such cells are referred to as production cells. Products produced by these production cells can be organic products such as 3-HP and/or the nucleic acid molecules and polypeptides described herein.

Another aspect of the invention provides polypeptides having an amino acid sequence that (1) is set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161, (2) is at least 10 contiguous amino acid residues of a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161, (3) has at least 65 percent sequence identity with at least 10 contiguous amino acid residues of a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161, (4) is a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 having conservative amino acid substitutions, or (5) has at least 65 percent sequence identity with a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. Accordingly, the invention also provides nucleic acid sequences that encode any of the polypeptides described herein as well as specific binding agents that bind to any of the polypeptides described herein. Likewise, the invention provides transformed cells that contain any of the nucleic acid sequences that encode any of the polypeptides described herein. These cells can be used to produce nucleic acid molecules, polypeptides, and organic compounds. The polypeptides can be used to catalyze the formation of organic compounds or can be used as antigens to create specific binding agents.

In yet another embodiment, the invention provides isolated nucleic acid molecules that contain at least one of the following nucleic acid sequences: (1) a nucleic acid sequence as set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163; (2) a nucleic acid sequence having at least 10 consecutive nucleotides from a sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163; (3) a nucleic acid sequences that hybridize under hybridization conditions (e.g., moderately or highly stringent hybridization conditions) to a sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163; (4) a nucleic acid sequence having 65 percent sequence identity with at least 10 consecutive nucleotides from a sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38,

40, 42, 129, 140, 142, 162, or 163; and (5) a nucleic acid sequence having at least 65 percent sequence identity with a sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. Accordingly, the invention also provides a production cell that contains at least one exogenous nucleic acid having any the nucleic acid sequences provided above. The production cell can be used to express polypeptides that have an enzymatic activity such as CoA transferase activity, lactyl-CoA dehydratase activity, CoA synthase activity, dehydratase activity, dehydrogenase activity, malonyl CoA reductase activity, β -alanine ammonia lyase activity, and/or 3-hydroxypropionyl-CoA dehydratase activity. Accordingly, the invention also provides methods of producing polypeptides encoded by the nucleic acid sequences described above.

The invention also provides several methods such as methods for making 3-HP from lactate, phosphoenolpyruvate (PEP), or pyruvate. In some embodiments, methods for making 3-HP from lactate, PEP, or pyruvate involve culturing a cell containing at least one exogenous nucleic acid under conditions that allow the cell to produce 3-HP. These methods can be practiced using the various types of production cells described herein. In some embodiments, the production cells can have one or more of the following activities: CoA transferase activity, 3-hydroxypropionyl-CoA hydrolase activity, 3-hydroxyisobutryl-CoA hydrolase activity, dehydratase activity, and/or malonyl CoA reductase activity.

In other embodiments, the methods involve making 3-HP wherein lactate is contacted with a first polypeptide having CoA transferase activity or CoA synthetase activity such that lactyl-CoA is formed, then contacting lactyl-CoA with a second polypeptide having lactyl-CoA dehydratase activity to form acrylyl-CoA, then contacting acrylyl-CoA with a third polypeptide having 3-hydroxypropionyl-CoA dehydratase activity to form 3-hydroxypropionic acid-CoA, and then contacting 3-hydroxypropionic acid-CoA with the first polypeptide to form 3-HP or with a fourth polypeptide having 3-hydroxypropionyl-CoA hydrolase activity or 3-hydroxyisobutryl-CoA hydrolase activity to form 3-HP.

Another aspect of the invention provides methods for making polymerized 3-HP. These methods involve making 3-hydroxypropionic acid-CoA as described above, and then contacting the 3-hydroxypropionic acid-CoA with a polypeptide having poly hydroxyacid synthase activity to form polymerized 3-HP.

In yet another embodiment of the invention, methods for making an ester of 3-HP are provided. These methods involve making 3-HP as described above, and then additionally contacting 3-HP with a fifth polypeptide having lipase activity to form an ester.

The invention also provides methods for making polymerized acrylate. These methods involve culturing a cell that has both CoA synthetase activity, lactyl-CoA dehydratase activity, and poly hydroxyacid synthase activity such that polymerized acrylate is made. Accordingly, the invention also provides methods of making polymerized acrylate wherein lactate is contacted with a first polypeptide having CoA synthetase activity to form lactyl-CoA, then contacting lactyl-CoA with a second polypeptide having lactyl-CoA dehydratase activity to form acrylyl-CoA, and then contacting acrylyl-CoA with a third polypeptide having poly hydroxyacid synthase activity to form polymerized acrylate.

The invention also provides methods of making an ester of acrylate. These methods involve culturing a cell that has CoA transferase activity, lipase activity, and lactyl-CoA dehydratase activity under conditions that allow the cell to produce an ester.

5

In another embodiment, the invention provides methods for making an ester of acrylate, wherein acrylyl-CoA is formed as described above, and then acrylyl-CoA is contacted with a polypeptide having CoA transferase activity to form acrylate, and acrylate is contacted with a polypeptide having lipase activity to form the ester.

The invention also provides methods for making 3-HP. These methods involve culturing a cell containing at least one exogenous nucleic acid that encodes at least one polypeptide such that 3-HP is produced from acetyl-CoA or malonyl-CoA.

Alternative embodiments provide methods of making 3-HP, wherein acetyl-CoA is contacted with a first polypeptide having acetyl-CoA carboxylase activity to form malonyl-CoA, and malonyl-CoA is contacted with a second polypeptide having malonyl-CoA reductase activity to form 3-HP.

In other embodiments, malonyl-CoA can be contacted with a polypeptide having malonyl-CoA reductase activity so that 3-HP can be made.

In another embodiment, the invention provides a method for making 3-HP that uses a β -alanine intermediate. This method can be performed by contacting β -alanine CoA with a first polypeptide having β -alanyl-CoA ammonia lyase activity (such as a polypeptide having the amino acid sequence set forth in SEQ ID NO: 160 or 161) to form acrylyl-CoA, contacting acrylyl-CoA with a second polypeptide having 3-HP-CoA dehydratase activity to form 3-HP-CoA, and contacting 3-HP-CoA with a third polypeptide having glutamate dehydrogenase activity to make 3-HP.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a diagram of a pathway for making 3-HP.

FIG. 2 is a diagram of a pathway for making polymerized 3-HP.

FIG. 3 is a diagram of a pathway for making esters of 3-HP.

FIG. 4 is a diagram of a pathway for making polymerized acrylic acid.

FIG. 5 is a diagram of a pathway for making esters of acrylate.

FIG. 6 is a listing of a nucleic acid sequence that encodes a polypeptide having CoA transferase activity (SEQ ID NO:1).

FIG. 7 is a listing of an amino acid sequence of a polypeptide having CoA transferase activity (SEQ ID NO:2).

FIGS. 8A-D show an alignment of the nucleic acid sequences set forth in SEQ ID NOs:1, 3, 4, and 5.

FIGS. 9A-B show an alignment of the amino acid sequences set forth in SEQ ID NOs:2, 6, 7, and 8.

FIG. 10 is a listing of a nucleic acid sequence that encodes a polypeptide having E1 activator activity (SEQ ID NO:9).

FIG. 11 is a listing of an amino acid sequence of a polypeptide having E1 activator activity (SEQ ID NO:10).

6

FIGS. 12A-B show an alignment of the nucleic acid sequences set forth in SEQ ID NOs:9, 11, 12, and 13.

FIG. 13 is an alignment of the amino acid sequences set forth in SEQ ID NOs:10, 14, 15, and 16.

FIG. 14 is a listing of a nucleic acid sequence that encodes an E2 α subunit of an enzyme having lactyl-CoA dehydratase activity (SEQ ID NO:17).

FIG. 15 is a listing of an amino acid sequence of an E2 α subunit of an enzyme having lactyl-CoA dehydratase activity (SEQ ID NO:18).

FIGS. 16A-C show an alignment of the nucleic acid sequences set forth in SEQ ID NOs:17, 19, 20, and 21.

FIG. 17 is an alignment of the amino acid sequences set forth in SEQ ID NOs:18, 22, 23, and 24.

FIG. 18 is a listing of a nucleic acid sequence that encodes an E2 β subunit of an enzyme having lactyl-CoA dehydratase activity (SEQ ID NO:25). The "G" at position 443 can be an "A"; and the "A" at position 571 can be a "G".

FIG. 19 is a listing of an amino acid sequence of an E2 β subunit of an enzyme having lactyl-CoA dehydratase activity (SEQ ID NO:26).

FIGS. 20A-C show an alignment of the nucleic acid sequences set forth in SEQ ID NOs:25, 27, 28, and 29.

FIG. 21 is an alignment of the amino acid sequences set forth in SEQ ID NOs:26, 30, 31, and 32.

FIGS. 22A-B show a listing of a nucleic acid sequence of genomic DNA from *Megasphaera elsdenii* (SEQ ID NO:33).

FIG. 23 is a listing of a nucleic acid sequence that encodes a polypeptide from *Megasphaera elsdenii* (SEQ ID NO:34).

FIG. 24 is a listing of an amino acid sequence of a polypeptide from *Megasphaera elsdenii* (SEQ ID NO:35).

FIG. 25 is a listing of a nucleic acid sequence that encodes a polypeptide having enzymatic activity (SEQ ID NO:36).

FIG. 26 is a listing of an amino acid sequence of a polypeptide having enzymatic activity (SEQ ID NO:37).

FIGS. 27A-B show a listing of a nucleic acid sequence that contains non-coding as well as coding sequence of a polypeptide having CoA synthase, dehydratase, and dehydrogenase activity (SEQ ID NO:38). The start site for the coding sequence is at position 480, a ribosome binding site is at position 466-473, and the stop codon is at position 5946.

FIG. 28 is a listing of an amino acid sequence from a polypeptide having CoA synthase, dehydratase, and dehydrogenase activity (SEQ ID NO:39).

FIG. 29 is a listing of a nucleic acid sequence that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (SEQ ID NO:40).

FIG. 30 is a listing of an amino acid sequence of a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (SEQ ID NO:41).

FIG. 31 is a listing of a nucleic acid sequence that contains non-coding as well as coding sequence of a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (SEQ ID NO:42).

FIGS. 32A-B show an alignment of the nucleic acid sequences set forth in SEQ ID NOs:40, 43, 44, and 45.

FIG. 33 is an alignment of the amino acid sequences set forth in SEQ ID NOs:41, 46, 47, and 48.

FIG. 34 is a diagram of the construction of a synthetic operon (pTDH) that encodes for polypeptides having CoA transferase activity, lactyl-CoA dehydratase activity (E1, E2 α , and E2 β), and 3-hydroxypropionyl-CoA dehydratase activity (3-HP-CoA dehydratase).

FIGS. 35A and B is a diagram of the construction of a synthetic operon (pHTD) that encodes for polypeptides having CoA transferase activity, lactyl-CoA dehydratase activity

(E1, E2 α , and E2 β), and 3-hydroxypropionyl-CoA dehydratase activity (3-HP-CoA dehydratase).

FIGS. 36A and B is a diagram of the construction of a synthetic operon (pEIITHrEI) that encodes for polypeptides having CoA transferase activity, lactyl-CoA dehydratase activity (E1, E2 α , and E2 β), and 3-hydroxypropionyl-CoA dehydratase activity (3-HP-CoA dehydratase).

FIGS. 37A and B is a diagram of the construction of a synthetic operon (pEIITHrEI) that encodes for polypeptides having CoA transferase activity, lactyl-CoA dehydratase activity (E1, E2 α , and E2 β), and 3-hydroxypropionyl-CoA dehydratase activity (3-HP-CoA dehydratase).

FIGS. 38A and B is a diagram of the construction of two plasmids, pEIITH and pPROEI. The pEIITH plasmid encodes polypeptides having CoA transferase activity, lactyl-CoA dehydratase activity (E2 α and E2 β), and 3-hydroxypropionyl-CoA dehydratase activity (3-HP-CoA dehydratase), and the pPROEI plasmid encodes a polypeptide having E1 activator activity.

FIGS. 39A-B show a listing of a nucleic acid sequence that encodes a polypeptide having CoA synthase, dehydratase, and dehydrogenase activity (SEQ ID NO:129).

FIGS. 40A-D show an alignment of the amino acid sequences set forth in SEQ ID NOs:39, 130, and 131. The uppercase amino acid residues represent positions where that amino acid residue is present in two or more sequences.

FIGS. 41A-D show an alignment of the amino acid sequences set forth in SEQ ID NOs:39, 132, and 133. The uppercase amino acid residues represent positions where that amino acid residue is present in two or more sequences.

FIGS. 42A-D show an alignment of the amino acid sequences set forth in SEQ ID NOs:39, 134, and 135. The uppercase amino acid residues represent positions where that amino acid residue is present in two or more sequences.

FIG. 43 is a diagram of several pathways for making organic compounds using the multifunctional OS17 enzyme.

FIG. 44 is a diagram of a pathway for making 3-HP via acetyl-CoA and malonyl-CoA.

FIG. 45 is a diagram of pMSD8, pET30a/acc1, pFN476, and PET286 constructs.

FIGS. 46A-F show a total ion chromatogram and five mass spectrums of Coenzyme A thioesters. (A) is total ion chromatogram illustrating the separation of Coenzyme A and four CoA-organic thioesters: 1=Coenzyme A, 2=lactyl-CoA, 3=acetyl-CoA, 4=acrylyl-CoA, 5=propionyl-CoA. (B) is a mass spectrum of Coenzyme A. (C) is a mass spectrum of lactyl-CoA. (D) is a mass spectrum of acetyl-CoA. (E) is a mass spectrum of acrylyl-CoA. (F) is a mass spectrum of propionyl-CoA.

FIGS. 47A-B show ion chromatograms and mass spectrums. (A) is a total ion chromatogram of a mixture of lactyl-CoA and 3-HP-CoA. The insert is the mass spectrum recorded under peak 1. (B) is a total ion chromatogram of lactyl-CoA. The insert is the mass spectrum recorded under peak 2. In each panel, peak 1 is 3-HP-CoA, and peak 2 is lactyl-CoA. The peak labeled with an asterisk was confirmed not to be a CoA ester.

FIGS. 48A-B show ion chromatograms and mass spectrums. (A) is a total ion chromatogram of CoA esters derived from a broth produced by *E. coli* transfected with pEIITHrEI. The insert is the mass spectrum recorded under peak 1. (B) is a total ion chromatogram of CoA esters derived from a broth produced by control *E. coli* not transfected with pEIITHrEI. The insert is the mass spectrum recorded under peak 2. In each panel, peak 1 is 3-HP-CoA, and peak 2 is lactyl-CoA. The peaks labeled with an asterisk were confirmed not to be a CoA ester.

FIGS. 49A-B show a listing of a nucleic acid sequence that encodes a polypeptide having malonyl-CoA reductase activity (SEQ ID NO: 140).

FIG. 50 is a listing of an amino acid sequence of a polypeptide having malonyl-CoA reductase activity (SEQ ID NO:141).

FIG. 51 is a listing of a nucleic acid sequence that encodes a portion of a polypeptide having malonyl-CoA reductase activity (SEQ ID NO:142).

FIGS. 52A-D shows an alignment of the amino acid sequences set forth in SEQ ID NOs: 141, 143, 144, 145, 146, and 147.

FIGS. 53A-J show an alignment of the nucleic acid sequences set forth in SEQ ID NOs: 140, 148, 149, 150, 151, and 152.

FIG. 54 is a diagram of a pathway for making 3-HP via a β -alanine intermediate.

FIG. 55 is a diagram of a pathway for making 3-HP via a β -alanine intermediate.

FIG. 56 is a listing of an amino acid sequence of a polypeptide having β -alanyl-CoA ammonia lyase activity (SEQ ID NO:160).

FIG. 57 is a listing of an amino acid sequence of a polypeptide having β -alanyl-CoA ammonia lyase activity (SEQ ID NO:161).

FIG. 58 is a listing of a nucleic acid sequence that encodes a polypeptide having β -alanyl-CoA ammonia lyase activity (SEQ ID NO:162).

FIG. 59 is a listing of a nucleic acid sequence that can encode a polypeptide having β -alanyl-CoA ammonia lyase activity (SEQ ID NO:163).

DETAILED DESCRIPTION

I. Terms

Nucleic acid: The term “nucleic acid” as used herein encompasses both RNA and DNA including, without limitation, cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. The nucleic acid can be double-stranded or single-stranded. Where single-stranded, the nucleic acid can be the sense strand or the antisense strand. In addition, nucleic acid can be circular or linear.

Isolated: The term “isolated” as used herein with reference to nucleic acid refers to a naturally-occurring nucleic acid that is not immediately contiguous with both of the sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally-occurring genome of the organism from which it is derived. For example, an isolated nucleic acid can be, without limitation, a recombinant DNA molecule of any length, provided one of the nucleic acid sequences normally found immediately flanking that recombinant DNA molecule in a naturally-occurring genome is removed or absent. Thus, an isolated nucleic acid includes, without limitation, a recombinant DNA that exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences as well as recombinant DNA that is incorporated into a vector, an autonomously replicating plasmid, a virus (e.g., a retrovirus, adenovirus, or herpes virus), or into the genomic DNA of a prokaryote or eukaryote. In addition, an isolated nucleic acid can include a recombinant DNA molecule that is part of a hybrid or fusion nucleic acid sequence.

The term “isolated” as used herein with reference to nucleic acid also includes any non-naturally-occurring nucleic acid since non-naturally-occurring nucleic acid

sequences are not found in nature and do not have immediately contiguous sequences in a naturally-occurring genome. For example, non-naturally-occurring nucleic acid such as an engineered nucleic acid is considered to be isolated nucleic acid. Engineered nucleic acid can be made using common molecular cloning or chemical nucleic acid synthesis techniques. Isolated non-naturally-occurring nucleic acid can be independent of other sequences, or incorporated into a vector, an autonomously replicating plasmid, a virus (e.g., a retrovirus, adenovirus, or herpes virus), or the genomic DNA of a prokaryote or eukaryote. In addition, a non-naturally-occurring nucleic acid can include a nucleic acid molecule that is part of a hybrid or fusion nucleic acid sequence.

It will be apparent to those of skill in the art that a nucleic acid existing among hundreds to millions of other nucleic acid molecules within, for example, cDNA or genomic libraries, or gel slices containing a genomic DNA restriction digest is not to be considered an isolated nucleic acid.

Exogenous: The term "exogenous" as used herein with reference to nucleic acid and a particular cell refers to any nucleic acid that does not originate from that particular cell as found in nature. Thus, non-naturally-occurring nucleic acid is considered to be exogenous to a cell once introduced into the cell. Nucleic acid that is naturally-occurring also can be exogenous to a particular cell. For example, an entire chromosome isolated from a cell of person X is an exogenous nucleic acid with respect to a cell of person Y once that chromosome is introduced into Y's cell.

Hybridization: The term "hybridization" as used herein refers to a method of testing for complementarity in the nucleotide sequence of two nucleic acid molecules, based on the ability of complementary single-stranded DNA and/or RNA to form a duplex molecule. Nucleic acid hybridization techniques can be used to obtain an isolated nucleic acid within the scope of the invention. Briefly, any nucleic acid having some homology to a sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163 can be used as a probe to identify a similar nucleic acid by hybridization under conditions of moderate to high stringency. Once identified, the nucleic acid then can be purified, sequenced, and analyzed to determine whether it is within the scope of the invention as described herein.

Hybridization can be done by Southern or Northern analysis to identify a DNA or RNA sequence, respectively, that hybridizes to a probe. The probe can be labeled with a biotin, digoxigenin, an enzyme, or a radioisotope such as ^{32}P . The DNA or RNA to be analyzed can be electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook et al., (1989) *Molecular Cloning*, second edition, Cold Spring Harbor Laboratory, Plainview, N.Y. Typically, a probe is at least about 20 nucleotides in length. For example, a probe corresponding to a 20 nucleotide sequence set forth in SEQ ID NO: 1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, or 142 can be used to identify an identical or similar nucleic acid. In addition, probes longer or shorter than 20 nucleotides can be used.

The invention also provides isolated nucleic acid sequences that are at least about 12 bases in length (e.g., at least about 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 100, 250, 500, 750, 1000, 1500, 2000, 3000, 4000, or 5000 bases in length) and hybridize, under hybridization conditions, to the sense or antisense strand of a nucleic acid having the sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36,

38, 40, 42, 129, 140, 142, 162, or 163. The hybridization conditions can be moderately or highly stringent hybridization conditions.

For the purpose of this invention, moderately stringent hybridization conditions mean the hybridization is performed at about 42° C. in a hybridization solution containing 25 mM KPO_4 (pH 7.4), 5×SSC, 5× Denhart's solution, 50 $\mu\text{g/mL}$ denatured, sonicated salmon sperm DNA, 50% formamide, 10% Dextran sulfate, and 1-15 ng/mL probe (about 5×10^7 cpm/ μg), while the washes are performed at about 50° C. with a wash solution containing 2×SSC and 0.1% sodium dodecyl sulfate.

Highly stringent hybridization conditions mean the hybridization is performed at about 42° C. in a hybridization solution containing 25 mM KPO_4 (pH 7.4), 5×SSC, 5× Denhart's solution, 50 $\mu\text{g/mL}$ denatured, sonicated salmon sperm DNA, 50% formamide, 10% Dextran sulfate, and 1-15 ng/mL probe (about 5×10^7 cpm/ μg), while the washes are performed at about 65° C. with a wash solution containing 0.2×SSC and 0.1% sodium dodecyl sulfate.

Purified: The term "purified" as used herein does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified polypeptide or nucleic acid preparation can be one in which the subject polypeptide or nucleic acid, respectively, is at a higher concentration than the polypeptide or nucleic acid would be in its natural environment within an organism. For example, a polypeptide preparation can be considered purified if the polypeptide content in the preparation represents at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 98%, or 99% of the total protein content of the preparation.

Transformed: A "transformed" cell is a cell into which a nucleic acid molecule has been introduced by, for example, molecular biology techniques. As used herein, the term "transformation" encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell including, without limitation, transfection with a viral vector, conjugation, transformation with a plasmid vector, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Recombinant: A "recombinant" nucleic acid is one having (1) a sequence that is not naturally occurring in the organism in which it is expressed or (2) a sequence made by an artificial combination of two otherwise-separated, shorter sequences. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. "Recombinant" is also used to describe nucleic acid molecules that have been artificially manipulated, but contain the same regulatory sequences and coding regions that are found in the organism from which the nucleic acid was isolated.

Specific binding agent: A "specific binding agent" is an agent that is capable of specifically binding to any of the polypeptide described herein, and can include polyclonal antibodies, monoclonal antibodies (including humanized monoclonal antibodies), and fragments of monoclonal antibodies such as Fab, F(ab')_2 , and Fv fragments as well as any other agent capable of specifically binding to an epitope of such polypeptides.

Antibodies to the polypeptides provided herein (or fragments thereof) can be used to purify or identify such polypeptides. The amino acid and nucleic acid sequences provided herein allow for the production of specific antibody-based binding agents that recognize the polypeptides described herein.

Monoclonal or polyclonal antibodies can be produced to the polypeptides, portions of the polypeptides, or variants thereof. Optimally, antibodies raised against one or more epitopes on a polypeptide antigen will specifically detect that polypeptide. That is, antibodies raised against one particular polypeptide would recognize and bind that particular polypeptide, and would not substantially recognize or bind to other polypeptides. The determination that an antibody specifically binds to a particular polypeptide is made by any one of a number of standard immunoassay methods; for instance, Western blotting (See, e.g., Sambrook et al. (ed.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

To determine that a given antibody preparation (such as a preparation produced in a mouse against a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2) specifically detects the appropriate polypeptide (e.g., a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2) by Western blotting, total cellular protein can be extracted from cells and separated by SDS-polyacrylamide gel electrophoresis. The separated total cellular protein can then be transferred to a membrane (e.g., nitrocellulose), and the antibody preparation incubated with the membrane. After washing the membrane to remove non-specifically bound antibodies, the presence of specifically bound antibodies can be detected using an appropriate secondary antibody (e.g., an anti-mouse antibody) conjugated to an enzyme such as alkaline phosphatase since application of 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a densely blue-colored compound by immuno-localized alkaline phosphatase.

Substantially pure polypeptides suitable for use as an immunogen can be obtained from transfected cells, transformed cells, or wild-type cells. Polypeptide concentrations in the final preparation can be adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter. In addition, polypeptides ranging in size from full-length polypeptides to polypeptides having as few as nine amino acid residues can be utilized as immunogens. Such polypeptides can be produced in cell culture, can be chemically synthesized using standard methods, or can be obtained by cleaving large polypeptides into smaller polypeptides that can be purified. Polypeptides having as few as nine amino acid residues in length can be immunogenic when presented to an immune system in the context of a Major Histocompatibility Complex (MHC) molecule such as an MHC class I or MHC class II molecule. Accordingly, polypeptides having at least 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, or more consecutive amino acid residues of any amino acid sequence disclosed herein can be used as immunogens for producing antibodies.

Monoclonal antibodies to any of the polypeptides disclosed herein can be prepared from murine hybridomas according to the classic method of Kohler & Milstein (*Nature* 256:495 (1975)) or a derivative method thereof.

Polyclonal antiserum containing antibodies to the heterogeneous epitopes of any polypeptide disclosed herein can be prepared by immunizing suitable animals with the polypeptide (or fragment thereof), which can be unmodified or modified to enhance immunogenicity. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (*J. Clin. Endocrinol. Metab.* 33:988-991 (1971)).

Antibody fragments can be used in place of whole antibodies and can be readily expressed in prokaryotic host cells.

Methods of making and using immunologically effective portions of monoclonal antibodies, also referred to as "antibody fragments," are well known and include those described in Better & Horowitz (*Methods Enzymol.* 178:476-496 (1989)), Glockshuber et al. (*Biochemistry* 29:1362-1367 (1990)), U.S. Pat. No. 5,648,237 ("Expression of Functional Antibody Fragments"), U.S. Pat. No. 4,946,778 ("Single Polypeptide Chain Binding Molecules"), U.S. Pat. No. 5,455,030 ("Immunotherapy Using Single Chain Polypeptide Binding Molecules"), and references cited therein.

Operably linked: A first nucleic acid sequence is "operably linked" with a second nucleic acid sequence whenever the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two polypeptide-coding regions, in the same reading frame.

Probes and primers: Nucleic acid probes and primers can be prepared readily based on the amino acid sequences and nucleic acid sequences provided herein. A "probe" includes an isolated nucleic acid containing a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed in, for example, Sambrook et al. (ed.), *Molecular Cloning: A Laboratory Manual* 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, and Ausubel et al. (ed.) *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (with periodic updates), 1987.

"Primers" are typically nucleic acid molecules having ten or more nucleotides (e.g., nucleic acid molecules having between about 10 nucleotides and about 100 nucleotides). A primer can be annealed to a complementary target nucleic acid strand by nucleic acid hybridization to form a hybrid between the primer and the target nucleic acid strand, and then extended along the target nucleic acid strand by, for example, a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, for example, by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, for example, in references such as Sambrook et al. (ed.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; Ausubel et al. (ed.), *Current Protocols in Molecular Biology*, Greene Publishing and Wiley-Interscience, New York (with periodic updates), 1987; and Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press: San Diego, 1990. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, .COPYRGT. 1991, Whitehead Institute for Biomedical Research, Cambridge, Mass.). One of skill in the art will appreciate that the specificity of a particular probe or primer increases with the length, but that a probe or primer can range in size from a full-length sequence to sequences as short as five consecutive nucleotides. Thus, for example, a primer of 20 consecutive nucleotides can anneal to a target with a higher specificity than a corresponding primer of only 15 nucleotides. Thus, in order to obtain greater specificity, probes and primers can be selected that comprise, for example, 10, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750,

13

800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5450, or more consecutive nucleotides.

Percent sequence Identity: The “percent sequence identity” between a particular nucleic acid or amino acid sequence and a sequence referenced by a particular sequence identification number is determined as follows. First, a nucleic acid or amino acid sequence is compared to the sequence set forth in a particular sequence identification number using the BLAST 2 Sequences (BL2seq) program from the stand-alone version of BLASTZ containing BLASTN version 2.0.14 and BLASTP version 2.0.14. This stand-alone version of BLASTZ can be obtained from Fish & Richardson’s web site (www.fr.com) or the United States government’s National Center for Biotechnology Information web site (www.ncbi.nlm.nih.gov). Instructions explaining how to use the BL2seq program can be found in the readme file accompanying BLASTZ. BL2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. To compare two nucleic acid sequences, the options are set as follows: `-i` is set to a file containing the first nucleic acid sequence to be compared (e.g., `C:\seq1.txt`); `-j` is set to a file containing the second nucleic acid sequence to be compared (e.g., `C:\seq2.txt`); `-p` is set to `blastn`; `-o` is set to any desired file name (e.g., `C:\output.txt`); `-q` is set to `-1`; `-r` is set to `2`; and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two sequences: `C:\BL2seq -i c:\seq1.txt -j c:\seq2.txt -p blastn -o c:\output.txt -q -1 -r 2`. To compare two amino acid sequences, the options of BL2seq are set as follows: `-i` is set to a file containing the first amino acid sequence to be compared (e.g., `C:\seq1.txt`); `-j` is set to a file containing the second amino acid sequence to be compared (e.g., `C:\seq2.txt`); `-p` is set to `blastp`; `-o` is set to any desired file name (e.g., `C:\output.txt`); and all other options are left at their default setting. For example, the following command can be used to generate an output file containing a comparison between two amino acid sequences: `C:\BL2seq -i c:\seq1.txt -j c:\seq2.txt -p blastp -o c:\output.txt`. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.

Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence (e.g., SEQ ID NO:1), or by an articulated length (e.g., 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, a nucleic acid sequence that has 1166 matches when aligned with the sequence set forth in SEQ ID NO:1 is 75.0 percent identical to the sequence set forth in SEQ ID NO:1 (i.e., $1166 \div 1554 \times 100 = 75.0$). It is noted that the percent sequence identity value is rounded to the nearest

14

tenth. For example, 75.11, 75.12, 75.13, and 75.14 is rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 is rounded up to 75.2. It is also noted that the length value will always be an integer. In another example, a target sequence containing a 20-nucleotide region that aligns with 20 consecutive nucleotides from an identified sequence as follows contains a region that shares 75 percent sequence identity to that identified sequence (i.e., $15 \div 20 \times 100 = 75$).

	1	20
Target Sequence:	AGGTCGTGTACTGTCACTCA	
Identified Sequence:	ACGTGGTGAACCTGCCAGTGA	

Conservative substitution: The term “conservative substitution” as used herein refers to any of the amino acid substitutions set forth in Table 1. Typically, conservative substitutions have little to no impact on the activity of a polypeptide. A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes that polypeptide using, for example, standard procedures such as site-directed mutagenesis or PCR.

TABLE 1

Original Residue	Conservative Substitution(s)
Ala	ser
Arg	lys
Asn	gln; his
Asp	glu
Cys	ser
Gln	asn
Glu	asp
Gly	pro
His	asn; gln
Ile	leu; val
Leu	ile; val
Lys	arg; gln; glu
Met	leu; ile
Phe	met; leu; tyr
Ser	thr
Thr	ser
Trp	tyr
Tyr	trp; phe
Val	ile; leu

II. Metabolic Pathways

The invention provides methods and materials related to producing 3-HP as well as other organic compounds (e.g., 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, and esters of 3-HP). Specifically, the invention provides isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP as well as other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, polymerized 3-HP, and esters of 3-HP.

Accordingly, the invention provides several metabolic pathways that can be used to produce organic compounds from PEP (FIGS. 1-5, 43-44, 54, and 55). As depicted in FIG. 1, lactate can be converted into lactyl-CoA by a polypeptide having CoA transferase activity (EC 2.8.3.1); the resulting lactyl-CoA can be converted into acrylyl-CoA by a polypeptide (or multiple polypeptide complex such as an activated E2 α and E2 β complex) having lactyl-CoA dehydratase activity (EC 4.2.1.54); the resulting acrylyl-CoA can be converted

into 3-hydroxypropionyl-CoA (3-HP-CoA) by a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (EC 4.2.1.-); and the resulting 3-HP-CoA can be converted into 3-HP by a polypeptide having CoA transferase activity, a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity (EC 3.1.2.-), or a polypeptide having 3-hydroxyisobutryl-CoA hydrolase activity (EC 3.1.2.4).

Polypeptides having CoA transferase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Megasphaera elsdenii*, *Clostridium propionicum*, *Clostridium kluyveri*, and *Escherichia coli*. For example, nucleic acid that encodes a polypeptide having CoA transferase activity can be obtained from *Megasphaera elsdenii* as described in Example 1 and can have a sequence as set forth in SEQ ID NO: 1. In addition, polypeptides having CoA transferase activity as well as nucleic acid encoding such polypeptides can be obtained as described herein. For example, the variations to SEQ ID NO: 1 provided herein can be used to encode a polypeptide having CoA transferase activity.

Polypeptides (or the polypeptides of a multiple polypeptide complex such as an activated E2 α and E2 β complex) having lactyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Megasphaera elsdenii* and *Clostridium propionicum*. For example, nucleic acid encoding an E1 activator, an E2 α subunit, and an E2 β subunit that can form a multiple polypeptide complex having lactyl-CoA dehydratase activity can be obtained from *Megasphaera elsdenii* as described in Example 2. The nucleic acid encoding the E1 activator can contain a sequence as set forth in SEQ ID NO: 9; the nucleic acid encoding the E2 α subunit can contain a sequence as set forth in SEQ ID NO: 17; and the nucleic acid encoding the E2 β subunit can contain a sequence as set forth in SEQ ID NO: 25. In addition, polypeptides (or the polypeptides of a multiple polypeptide complex) having lactyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides can be obtained as described herein. For example, the variations to SEQ ID NO: 9, 17, and 25 provided herein can be used to encode the polypeptides of a multiple polypeptide complex having CoA transferase activity.

Polypeptides having 3-hydroxypropionyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Chloroflexus aurantiacus*, *Candida rugosa*, *Rhodospirillum rubrum*, and *Rhodobacter capsulatus*. For example, nucleic acid that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity can be obtained from *Chloroflexus aurantiacus* as described in Example 3 and can have a sequence as set forth in SEQ ID NO: 40. In addition, polypeptides having 3-hydroxypropionyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides can be obtained as described herein. For example, the variations to SEQ ID NO: 40 provided herein can be used to encode a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity.

Polypeptides having 3-hydroxypropionyl-CoA hydrolase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Candida rugosa*. Polypeptides having 3-hydroxyisobutryl-CoA hydrolase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Pseudomonas fluorescens*, *rattus*, and *homo sapiens*. For example, nucleic acid that encodes a polypeptide having 3-hydroxyisobutryl-CoA

hydrolase activity can be obtained from *homo sapiens* and can have a sequence as set forth in GenBank® accession number U66669.

The term "polypeptide having enzymatic activity" as used herein refers to any polypeptide that catalyzes a chemical reaction of other substances without itself being destroyed or altered upon completion of the reaction. Typically, a polypeptide having enzymatic activity catalyzes the formation of one or more products from one or more substrates. Such polypeptides can have any type of enzymatic activity including, without limitation, the enzymatic activity or enzymatic activities associated with enzymes such as dehydratases/hydratases, 3-hydroxypropionyl-CoA dehydratases/hydratases, CoA transferases, lactyl-CoA dehydratases, 3-hydroxypropionyl-CoA hydrolases, 3-hydroxyisobutryl-CoA hydrolases, polyhydroxyacid synthases, CoA synthetases, malonyl-CoA reductases, β -alanine ammonia lyases, and lipases.

As depicted in FIG. 2, lactate can be converted into lactyl-CoA by a polypeptide having CoA synthetase activity (EC 6.2.1.-); the resulting lactyl-CoA can be converted into acrylyl-CoA by a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; the resulting acrylyl-CoA can be converted into 3-HP-CoA by a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity; and the resulting 3-HP-CoA can be converted into polymerized 3-HP by a polypeptide having polyhydroxyacid synthase activity (EC 2.3.1.-). Polypeptides having CoA synthetase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Escherichia coli*, *Rhodobacter sphaeroides*, *Saccharomyces cerevisiae*, and *Salmonella enterica*. For example, nucleic acid that encodes a polypeptide having CoA synthetase activity can be obtained from *Escherichia coli* and can have a sequence as set forth in GenBank® accession number U00006. Polypeptides (or multiple polypeptide complexes) having lactyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides can be obtained as provided herein. Polypeptides having 3-hydroxypropionyl-CoA dehydratase activity as well as nucleic acid encoding such polypeptides also can be obtained as provided herein. Polypeptides having polyhydroxyacid synthase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Rhodobacter sphaeroides*, *Comamonas acidovorans*, *Ralstonia eutropha*, and *Pseudomonas oleovorans*. For example, nucleic acid that encodes a polypeptide having polyhydroxyacid synthase activity can be obtained from *Rhodobacter sphaeroides* and can have a sequence as set forth in GenBank® accession number X97200.

As depicted in FIG. 3, lactate can be converted into lactyl-CoA by a polypeptide having CoA transferase activity; the resulting lactyl-CoA can be converted into acrylyl-CoA by a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; the resulting acrylyl-CoA can be converted into 3-HP-CoA by a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity; the resulting 3-HP-CoA can be converted into 3-HP by a polypeptide having CoA transferase activity, a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity, or a polypeptide having 3-hydroxyisobutryl-CoA hydrolase activity; and the resulting 3-HP can be converted into an ester of 3-HP by a polypeptide having lipase activity (EC 3.1.1.-). Polypeptides having lipase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Candida rugosa*, *Candida tropicalis*, and *Candida albicans*. For example, nucleic acid that encodes a polypep-

17

tide having lipase activity can be obtained from *Candida rugosa* and can have a sequence as set forth in GenBank® accession number A81171.

As depicted in FIG. 4, lactate can be converted into lactyl-CoA by a polypeptide having CoA synthetase activity; the resulting lactyl-CoA can be converted into acrylyl-CoA by a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; and the resulting acrylyl-CoA can be converted into polymerized acrylate by a polypeptide having poly hydroxyacid synthase activity.

As depicted in FIG. 5, lactate can be converted into lactyl-CoA by a polypeptide having CoA transferase activity; the resulting lactyl-CoA can be converted into acrylyl-CoA by a polypeptide (or multiple polypeptide complex) having lactyl-CoA dehydratase activity; the resulting acrylyl-CoA can be converted into acrylate by a polypeptide having CoA transferase activity; and the resulting acrylate can be converted into an ester of acrylate by a polypeptide having lipase activity.

As depicted in FIG. 44, acetyl-CoA can be converted into malonyl-CoA by a polypeptide having acetyl-CoA carboxylase activity, and the resulting malonyl-CoA can be converted into 3-HP by a polypeptide having malonyl-CoA reductase activity. Polypeptides having acetyl-CoA carboxylase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Escherichia coli* and *Chloroflexus aurantiacus*. For example, nucleic acid that encodes a polypeptide having acetyl-CoA carboxylase activity can be obtained from *Escherichia coli* and can have a sequence as set forth in GenBank® accession number M96394 or U18997. Polypeptides having malonyl-CoA reductase activity as well as nucleic acid encoding such polypeptides can be obtained from various species including, without limitation, *Chloroflexus aurantiacus*, *Sulfolobus metallicus*, and *Acidianus brierleyi*. For example, nucleic acid that encodes a polypeptide having malonyl-CoA reductase activity can be obtained as described herein and can have a sequence similar to the sequence set forth in SEQ ID NO: 140. In addition, polypeptides having malonyl-CoA reductase activity as well as nucleic acid encoding such polypeptides can be obtained as described herein. For example, the variations to SEQ ID NO: 140 provided herein can be used to encode a polypeptide having malonyl-CoA reductase activity.

Polypeptides having malonyl-CoA reductase activity can use NADPH as a co-factor. For example, the polypeptide having the amino acid sequence set forth in SEQ ID NO: 141 is a polypeptide having malonyl-CoA reductase activity that uses NADPH as a co-factor when converting malonyl-CoA into 3-HP. Likewise, polypeptides having malonyl-CoA reductase activity can use NADH as a co-factor. Such polypeptides can be obtained by converting a polypeptide that has malonyl-CoA reductase activity and uses NADPH as a cofactor into a polypeptide that has malonyl-CoA reductase activity and uses NADH as a cofactor. Any method can be used to convert a polypeptide that uses NADPH as a cofactor into a polypeptide that uses NADH as a cofactor such as those described by others (Eppink et al., *J. Mol. Biol.*, 292(1):87-96 (1999), Hall and Tomsett, *Microbiology*, 146(Pt 6):1399-406 (2000), and Dohr et al., *Proc. Natl. Acad. Sci.*, 98(1):81-86 (2001)). For example, mutagenesis can be used to convert the polypeptide encoded by the nucleic acid sequence set forth in SEQ ID NO: 140 into a polypeptide that, when converting malonyl-CoA into 3-HP, uses NADH as a co-factor instead of NADPH.

As depicted in FIG. 43, propionate can be converted into propionyl-CoA by a polypeptide having CoA synthetase

18

activity such as the polypeptide having the sequence set forth in SEQ ID NO: 39; the resulting propionyl-CoA can be converted into acrylyl-CoA by a polypeptide having dehydrogenase activity such as the polypeptide having the sequence set forth in SEQ ID NO: 39; and the resulting acrylyl-CoA can be converted into (1) acrylate by a polypeptide having CoA transferase activity or CoA hydrolase activity, (2) 3-HP-CoA by a polypeptide having 3-HP dehydratase activity (also referred to as acrylyl-CoA hydratase or simply hydratase) such as the polypeptide having the sequence set forth in SEQ ID NO:39, or (3) polymerized acrylate by a polypeptide having poly hydroxyacid synthase activity. The resulting acrylate can be converted into an ester of acrylate by a polypeptide having lipase activity. The resulting 3-HP-CoA can be converted into (1) 3-HP by a polypeptide having CoA transferase activity, a polypeptide having 3-hydroxypropionyl-CoA hydrolase activity (EC 3.1.2.-), or a polypeptide having 3-hydroxyisobutyryl-CoA hydrolase activity (EC 3.1.2.4), or (2) polymerized 3-HP by a polypeptide having poly hydroxyacid synthase activity (EC 2.3.1.-).

As depicted in FIG. 54, PEP can be converted into β -alanine. β -alanine can be converted into β -alanyl-CoA through the use of a polypeptide having CoA transferase activity. β -alanyl-CoA can then be converted into acrylyl-CoA through the use of a polypeptide having β -alanyl-CoA ammonia lyase activity. Acrylyl-CoA can then be converted into 3-HP-CoA through the use of a polypeptide having 3-HP-CoA dehydratase activity, and a polypeptide having glutamate dehydrogenase activity can be used to convert 3-HP-CoA into 3-HP.

As depicted in FIG. 55, 3-HP can be made from β -alanine by first contacting β -alanine with a polypeptide having 4,4-aminobutyrate aminotransferase activity to create malonate semialdehyde. The malonate semialdehyde can be converted into 3-HP with a polypeptide having 3-HP dehydrogenase activity or a polypeptide having 3-hydroxyisobutyrate dehydrogenase activity.

III. Nucleic Acid Molecules and Polypeptides

The invention provides isolated nucleic acid that contains the entire nucleic acid sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. In addition, the invention provides isolated nucleic acid that contains a portion of the nucleic acid sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. For example, the invention provides isolated nucleic acid that contains a 15 nucleotide sequence identical to any 15 nucleotide sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163 including, without limitation, the sequence starting at nucleotide number 1 and ending at nucleotide number 15, the sequence starting at nucleotide number 2 and ending at nucleotide number 16, the sequence starting at nucleotide number 3 and ending at nucleotide number 17, and so forth. It will be appreciated that the invention also provides isolated nucleic acid that contains a nucleotide sequence that is greater than 15 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more nucleotides) in length and identical to any portion of the sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. For example, the invention provides isolated nucleic acid that contains a 25 nucleotide sequence identical to any 25 nucleotide sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163 including, without limitation, the sequence starting at nucleotide number 1 and ending at nucleotide number 25, the sequence starting at

nucleotide number 2 and ending at nucleotide number 26, the sequence starting at nucleotide number 3 and ending at nucleotide number 27, and so forth. Additional examples include, without limitation, isolated nucleic acids that contain a nucleotide sequence that is 50 or more nucleotides (e.g., 100, 150, 200, 250, 300, or more nucleotides) in length and identical to any portion of the sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. Such isolated nucleic acids can include, without limitation, those isolated nucleic acids containing a nucleic acid sequence represented in a single line of sequence depicted in FIG. 6, 10, 14, 18, 22, 23, 25, 27, 29, 31, 39, 49, or 51 since each line of sequence depicted in these figures, with the possible exception of the last line, provides a nucleotide sequence containing at least 50 bases.

In addition, the invention provides isolated nucleic acid that contains a variation of the nucleic acid sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. For example, the invention provides isolated nucleic acid containing a nucleic acid sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163 that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e.g., single deletion together with multiple insertions). Such isolated nucleic acid molecules can share at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, or 99 percent sequence identity with a sequence set forth in SEQ ID NO: 1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163.

The invention provides multiple examples of isolated nucleic acid that contains a variation of a nucleic acid sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. For example, FIGS. 8A-D provide the sequence set forth in SEQ ID NO: 1 aligned with three other nucleic acid sequences. Examples of variations of the sequence set forth in SEQ ID NO:1 include, without limitation, any variation of the sequence set forth in SEQ ID NO:1 provided in FIGS. 8A-D. Such variations are provided in FIGS. 8A-D in that a comparison of the nucleotide (or lack thereof) at a particular position of the sequence set forth in SEQ ID NO:1 with the nucleotide (or lack thereof) at the same aligned position of any of the other three nucleic acid sequences depicted in FIGS. 8A-D (i.e., SEQ ID NOs:3, 4, and 5) provides a list of specific changes for the sequence set forth in SEQ ID NO:1. For example, the "a" at position 49 of SEQ ID NO:1 can be substituted with an "c" as indicated in FIGS. 8A-D. As also indicated in FIGS. 8A-D, the "a" at position 590 of SEQ ID NO:1 can be substituted with a "atgg"; an "aac" can be inserted before the "g" at position 393 of SEQ ID NO:1; or the "gaa" at position 736 of SEQ ID NO:1 can be deleted. It will be appreciated that the sequence set forth in SEQ ID NO:1 can contain any number of variations as well as any combination of types of variations. For example, the sequence set forth in SEQ ID NO:1 can contain one variation provided in FIGS. 8A-D or more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, or more) of the variations provided in FIGS. 8A-D. It is noted that the nucleic acid sequences provided by FIGS. 8A-D can encode polypeptides having CoA transferase activity. The invention also provides isolated nucleic acid that contains a variant of a portion of the sequence set forth in SEQ ID NO:1 as depicted in FIGS. 8A-D and described herein.

Likewise, FIGS. 12A-B provide variations of SEQ ID NO:9 and portions thereof. FIGS. 16A-C provide variations of SEQ ID NO:17 and portions thereof; FIGS. 20A-C provide variations of SEQ ID NO:25 and portions thereof; FIGS.

32A-B provide variations of SEQ ID NO:40 and portions thereof and FIGS. 53A-J provides variations of SEQ ID NO:140.

The invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes the entire amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. In addition, the invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes a portion of the amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes a 15 amino acid sequence identical to any 15 amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 including, without limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 15, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 16, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 17, and so forth. It will be appreciated that the invention also provides isolated nucleic acid that contains a nucleic acid sequence that encodes an amino acid sequence that is greater than 15 amino acid residues (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acid residues) in length and identical to any portion of the sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes a 25 amino acid sequence identical to any 25 amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 including, without limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 25, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 26, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 27, and so forth. Additional examples include, without limitation, isolated nucleic acids that contain a nucleic acid sequence that encodes an amino acid sequence that is 50 or more amino acid residues (e.g., 100, 150, 200, 250, 300, or more amino acid residues) in length and identical to any portion of the sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. Such isolated nucleic acids can include, without limitation, those isolated nucleic acids containing a nucleic acid sequence that encodes an amino acid sequence represented in a single line of sequence depicted in FIG. 7, 11, 15, 19, 24, 26, 28, 30, or 50 since each line of sequence depicted in these figures, with the possible exception of the last line, provides an amino acid sequence containing at least 50 residues.

In addition, the invention provides isolated nucleic acid that contains a nucleic acid sequence that encodes an amino acid sequence having a variation of the amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides isolated nucleic acid containing a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e.g., single deletion together with multiple insertions). Such isolated nucleic acid molecules can contain a nucleic acid sequence encoding an amino acid sequence that shares at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, or 99 percent sequence identity with a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161.

The invention provides multiple examples of isolated nucleic acid containing a nucleic acid sequence encoding an amino acid sequence having a variation of an amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, FIGS. 9A-B provide the amino acid sequence set forth in SEQ ID NO:2 aligned with three other amino acid sequences. Examples of variations of the sequence set forth in SEQ ID NO:2 include, without limitation, any variation of the sequence set forth in SEQ ID NO:2 provided in FIGS. 9A-B. Such variations are provided in FIGS. 9A-B in that a comparison of the amino acid residue (or lack thereof) at a particular position of the sequence set forth in SEQ ID NO:2 with the amino acid residue (or lack thereof) at the same aligned position of any of the other three amino acid sequences of FIGS. 9A-B (i.e., SEQ ID NOs:6, 7, and 8) provides a list of specific changes for the sequence set forth in SEQ ID NO:2. For example, the "k" at position 17 of SEQ ID NO:2 can be substituted with a "p" or "h" as indicated in FIGS. 9A-B. As also indicated in FIGS. 9A-B, the "v" at position 125 of SEQ ID NO:2 can be substituted with an "i" or "f". It will be appreciated that the sequence set forth in SEQ ID NO:2 can contain any number of variations as well as any combination of types of variations. For example, the sequence set forth in SEQ ID NO:2 can contain one variation provided in FIGS. 9A-B or more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, or more) of the variations provided in FIGS. 9A-B. It is noted that the amino acid sequences provided in FIGS. 9A-B can be polypeptides having CoA transferase activity.

The invention also provides isolated nucleic acid containing a nucleic acid sequence encoding an amino acid sequence that contains a variant of a portion of the sequence set forth in SEQ ID NO:2 as depicted in FIGS. 9A-B and described herein.

Likewise, FIG. 13 provides variations of SEQ ID NO:10 and portions thereof; FIG. 17 provides variations of SEQ ID NO:18 and portions thereof; FIG. 21 provides variations of SEQ ID NO:26 and portions thereof; FIG. 33 provides variations of SEQ ID NO:41 and portions thereof; FIGS. 40, 41, and 42 provide variations of SEQ ID NO:39; and FIGS. 52A-D provide variations of SEQ ID NO:141 and portions thereof.

It is noted that codon preferences and codon usage tables for a particular species can be used to engineer isolated nucleic acid molecules that take advantage of the codon usage preferences of that particular species. For example, the isolated nucleic acid provided herein can be designed to have codons that are preferentially used by a particular organism of interest.

The invention also provides isolated nucleic acid that is at least about 12 bases in length (e.g., at least about 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 100, 250, 500, 750, 1000, 1500, 2000, 3000, 4000, or 5000 bases in length) and hybridizes, under hybridization conditions, to the sense or antisense strand of a nucleic acid having the sequence set forth in SEQ ID NO:1, 9, 17, 25, 33, 34, 36, 38, 40, 42, 129, 140, 142, 162, or 163. The hybridization conditions can be moderately or highly stringent hybridization conditions.

The invention provides polypeptides that contain the entire amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. In addition, the invention provides polypeptides that contain a portion of the amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides polypeptides that contain a 15 amino acid sequence identical to any 15 amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 including, without

limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 15, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 16, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 17, and so forth. It will be appreciated that the invention also provides polypeptides that contain an amino acid sequence that is greater than 15 amino acid residues (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acid residues) in length and identical to any portion of the sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides polypeptides that contain a 25 amino acid sequence identical to any 25 amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 including, without limitation, the sequence starting at amino acid residue number 1 and ending at amino acid residue number 25, the sequence starting at amino acid residue number 2 and ending at amino acid residue number 26, the sequence starting at amino acid residue number 3 and ending at amino acid residue number 27, and so forth. Additional examples include, without limitation, polypeptides that contain an amino acid sequence that is 50 or more amino acid residues (e.g., 100, 150, 200, 250, 300, or more amino acid residues) in length and identical to any portion of the sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. Such polypeptides can include, without limitation, those polypeptides containing a amino acid sequence represented in a single line of sequence depicted in FIG. 7, 11, 15, 19, 24, 26, 28, 30, or 50 since each line of sequence depicted in these figures, with the possible exception of the last line, provides an amino acid sequence containing at least 50 residues.

In addition, the invention provides polypeptides that an amino acid sequence having a variation of the amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, the invention provides polypeptides containing an amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 that contains a single insertion, a single deletion, a single substitution, multiple insertions, multiple deletions, multiple substitutions, or any combination thereof (e.g., single deletion together with multiple insertions). Such polypeptides can contain an amino acid sequence that shares at least 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, or 99 percent sequence identity with a sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161.

The invention provides multiple examples of polypeptides containing an amino acid sequence having a variation of an amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161. For example, FIGS. 9A-B provide the amino acid sequence set forth in SEQ ID NO:2 aligned with three other amino acid sequences. Examples of variations of the sequence set forth in SEQ ID NO:2 include, without limitation, any variation of the sequence set forth in SEQ ID NO:2 provided in FIGS. 9A-B. Such variations are provided in FIGS. 9A-B in that a comparison of the amino acid residue (or lack thereof) at a particular position of the sequence set forth in SEQ ID NO:2 with the amino acid residue (or lack thereof) at the same aligned position of any of the other three amino acid sequences of FIGS. 9A-B (i.e., SEQ ID NOs:6, 7, and 8) provides a list of specific changes for the sequence set forth in SEQ ID NO:2. For example, the "k" at position 17 of SEQ ID NO:2 can be substituted with a "p" or "h" as indicated in FIGS. 9A-B. As also indicated in FIGS. 9A-B, the "v" at position 125 of SEQ ID NO:2 can be substituted with an "i" or "f". It will be appreciated that the sequence set forth in SEQ ID NO:2 can contain any number of

variations as well as any combination of types of variations. For example, the sequence set forth in SEQ ID NO:2 can contain one variation provided in FIGS. 9A-B or more than one (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, or more) of the variations provided in FIGS. 9A-B. It is noted that the amino acid sequences provided in FIGS. 9A-B can be polypeptides having CoA transferase activity.

The invention also provides polypeptides containing an amino acid sequence that contains a variant of a portion of the sequence set forth in SEQ ID NO:2 as depicted in FIGS. 9A-B and described herein.

Likewise, FIG. 13 provides variations of SEQ ID NO:10 and portions thereof; FIG. 17 provides variations of SEQ ID NO:18 and portions thereof; FIG. 21 provides variations of SEQ ID NO:26 and portions thereof; FIG. 33 provides variations of SEQ ID NO:41 and portions thereof; FIGS. 40, 41, and 42 provide variations of SEQ ID NO:39; and FIGS. 52A-D provide variations of SEQ ID NO:141 and portions thereof.

Polypeptides having a variant amino acid sequence can retain enzymatic activity. Such polypeptides can be produced by manipulating the nucleotide sequence encoding a polypeptide using standard procedures such as site-directed mutagenesis or PCR. One type of modification includes the substitution of one or more amino acid residues for amino acid residues having a similar biochemical property. For example, a polypeptide can have an amino acid sequence set forth in SEQ ID NO:2, 10, 18, 26, 35, 37, 39, 41, 141, 160, or 161 with one or more conservative substitutions.

More substantial changes can be obtained by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining: (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation; (b) the charge or hydrophobicity of the polypeptide at the target site; or (c) the bulk of the side chain. The substitutions that in general are expected to produce the greatest changes in polypeptide function are those in which: (a) a hydrophilic residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, valine or alanine; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysine, arginine, or histidine, is substituted for (or by) an electronegative residue, e.g., glutamic acid or aspartic acid; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine. The effects of these amino acid substitutions (or other deletions or additions) can be assessed for polypeptides having enzymatic activity by analyzing the ability of the polypeptide to catalyze the conversion of the same substrate as the related native polypeptide to the same product as the related native polypeptide. Accordingly, polypeptides having 5, 10, 20, 30, 40, 50 or less conservative substitutions are provided by the invention.

Polypeptides and nucleic acid encoding polypeptide can be produced by standard DNA mutagenesis techniques, for example, M13 primer mutagenesis. Details of these techniques are provided in Sambrook et al. (ed.), *Molecular Cloning: A Laboratory Manual* 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring, Harbor, N.Y., 1989, Ch. 15. Nucleic acid molecules can contain changes of a coding region to fit the codon usage bias of the particular organism into which the molecule is to be introduced.

Alternatively, the coding region can be altered by taking advantage of the degeneracy of the genetic code to alter the coding sequence in such a way that, while the nucleic acid

sequence is substantially altered, it nevertheless encodes a polypeptide having an amino acid sequence identical or substantially similar to the native amino acid sequence. For example, the ninth amino acid residue of the sequence set forth in SEQ ID NO: 2 is alanine, which is encoded in the open reading frame by the nucleotide codon triplet GCT. Because of the degeneracy of the genetic code, three other nucleotide codon triplets—GCA, GCC, and GCG—also code for alanine. Thus, the nucleic acid sequence of the open reading frame can be changed at this position to any of these three codons without affecting the amino acid sequence of the encoded polypeptide or the characteristics of the polypeptide. Based upon the degeneracy of the genetic code, nucleic acid variants can be derived from a nucleic acid sequence disclosed herein using a standard DNA mutagenesis techniques as described herein, or by synthesis of nucleic acid sequences. Thus, this invention also encompasses nucleic acid molecules that encode the same polypeptide but vary in nucleic acid sequence by virtue of the degeneracy of the genetic code.

IV. Methods of Making 3-HP and Other Organic Acids

Each step provided in the pathways depicted in FIGS. 1-5, 43-44, 54, and 55 can be performed within a cell (in vivo) or outside a cell (in vitro, e.g., in a container or column). Additionally, the organic acid products can be generated through a combination of in vivo synthesis and in vitro synthesis. Moreover, the in vitro synthesis step, or steps, can be via chemical reaction or enzymatic reaction.

For example, a microorganism provided herein can be used to perform the steps provided in FIG. 1, or an extract containing polypeptides having the indicated enzymatic activities can be used to perform the steps provided in FIG. 1. In addition, chemical treatments can be used to perform the conversions provided in FIGS. 1-5, 43-44, 54, and 55. For example, acrylyl-CoA can be converted into acrylate by hydrolysis. Other chemical treatments include, without limitation, trans esterification to convert acrylate into an acrylate ester.

Carbon sources suitable as starting points for bioconversion include carbohydrates and synthetic intermediates. Examples of carbohydrates which cells are capable of metabolizing to pyruvate include sugars such as dextrose, triglycerides, and fatty acids.

Additionally, intermediate chemical products can be starting points. For example, acetic acid and carbon dioxide can be introduced into a fermentation broth. Acetyl-CoA, malonyl-CoA, and 3-HP can be sequentially produced using a polypeptide having CoA synthase activity, a polypeptide having acetyl-CoA carboxylase activity, and a polypeptide having malonyl-CoA reductase activity. Other useful intermediate chemical starting points can include propionic acid, acrylic acid, lactic acid, pyruvic acid, and β -alanine.

A. Expression of Polypeptides

The polypeptides described herein can be produced individually in a host cell or in combination in a host cell. Moreover, the polypeptides having a particular enzymatic activity can be a polypeptide that is either naturally-occurring or non-naturally-occurring. A naturally-occurring polypeptide is any polypeptide having an amino acid sequence as found in nature, including wild-type and polymorphic polypeptides. Such naturally-occurring polypeptides can be obtained from any species including, without limitation, animal (e.g., mammalian), plant, fungal, and bacterial species. A non-naturally-occurring polypeptide is any polypeptide having an amino acid sequence that is not found in nature. Thus, a non-natu-

rally-occurring polypeptide can be a mutated version of a naturally-occurring polypeptide, or an engineered polypeptide. For example, a non-naturally-occurring polypeptide having 3-hydroxypropionyl-CoA dehydratase activity can be a mutated version of a naturally-occurring polypeptide having 3-hydroxypropionyl-CoA dehydratase activity that retains at least some 3-hydroxypropionyl-CoA dehydratase activity. A polypeptide can be mutated by, for example, sequence additions, deletions, substitutions, or combinations thereof.

The invention provides genetically modified cells that can be used to perform one or more steps of the steps in the metabolic pathways described herein or the genetically modified cells can be used to produce the disclosed polypeptides for subsequent use in vitro. For example, an individual microorganism can contain exogenous nucleic acid such that each of the polypeptides necessary to perform the steps depicted in FIG. 1, 2, 3, 4, 5, 43, 44, 54, or 55 are expressed. It is important to note that such cells can contain any number of exogenous nucleic acid molecules. For example, a particular cell can contain six exogenous nucleic acid molecules with each one encoding one of the six polypeptides necessary to convert lactate into 3-HP as depicted in FIG. 1, or a particular cell can endogenously produce polypeptides necessary to convert lactate into acrylyl-CoA while containing exogenous nucleic acid that encodes polypeptides necessary to convert acrylyl-CoA into 3-HP.

In addition, a single exogenous nucleic acid molecule can encode one or more than one polypeptide. For example, a single exogenous nucleic acid molecule can contain sequences that encode three different polypeptides. Further, the cells described herein can contain a single copy, or multiple copies (e.g., about 5, 10, 20, 35, 50, 75, 100 or 150 copies), of a particular exogenous nucleic acid molecule. For example, a particular cell can contain about 50 copies of the constructs depicted in FIG. 34, 35, 36, 37, 38, or 45. Again, the cells described herein can contain more than one particular exogenous nucleic acid molecule. For example, a particular cell can contain about 50 copies of exogenous nucleic acid molecule X as well as about 75 copies of exogenous nucleic acid molecule Y.

In another embodiment, a cell within the scope of the invention can contain an exogenous nucleic acid molecule that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity. Such cells can have any level of 3-hydroxypropionyl-CoA dehydratase activity. For example, a cell containing an exogenous nucleic acid molecule that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity can have 3-hydroxypropionyl-CoA dehydratase activity with a specific activity greater than about 1 mg 3-HP-CoA formed per gram dry cell weight per hour (e.g., greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 500, or more mg 3-HP-CoA formed per gram dry cell weight per hour). Alternatively, a cell can have 3-hydroxypropionyl-CoA dehydratase activity such that a cell extract from 1×10^6 cells has a specific activity greater than about 1 μ g 3-HP-CoA formed per mg total protein per 10 minutes (e.g., greater than about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 500, or more μ g 3-HP-CoA formed per mg total protein per 10 minutes).

A nucleic acid molecule encoding a polypeptide having enzymatic activity can be identified and obtained using any method such as those described herein. For example, nucleic acid molecules that encode a polypeptide having enzymatic activity can be identified and obtained using common molecular cloning or chemical nucleic acid synthesis proce-

dures and techniques, including PCR. In addition, standard nucleic acid sequencing techniques and software programs that translate nucleic acid sequences into amino acid sequences based on the genetic code can be used to determine whether or not a particular nucleic acid has any sequence homology with known enzymatic polypeptides. Sequence alignment software such as MEGALIGN® (DNASTAR, Madison, Wis., 1997) can be used to compare various sequences. In addition, nucleic acid molecules encoding known enzymatic polypeptides can be mutated using common molecular cloning techniques (e.g., site-directed mutagenesis). Possible mutations include, without limitation, deletions, insertions, and base substitutions, as well as combinations of deletions, insertions, and base substitutions. Further, nucleic acid and amino acid databases (e.g., GenBank®) can be used to identify a nucleic acid sequence that encodes a polypeptide having enzymatic activity. Briefly, any amino acid sequence having some homology to a polypeptide having enzymatic activity, or any nucleic acid sequence having some homology to a sequence encoding a polypeptide having enzymatic activity can be used as a query to search GenBank®. The identified polypeptides then can be analyzed to determine whether or not they exhibit enzymatic activity.

In addition, nucleic acid hybridization techniques can be used to identify and obtain a nucleic acid molecule that encodes a polypeptide having enzymatic activity. Briefly, any nucleic acid molecule that encodes a known enzymatic polypeptide, or fragment thereof, can be used as a probe to identify a similar nucleic acid molecules by hybridization under conditions of moderate to high stringency. Such similar nucleic acid molecules then can be isolated, sequenced, and analyzed to determine whether the encoded polypeptide has enzymatic activity.

Expression cloning techniques also can be used to identify and obtain a nucleic acid molecule that encodes a polypeptide having enzymatic activity. For example, a substrate known to interact with a particular enzymatic polypeptide can be used to screen a phage display library containing that enzymatic polypeptide. Phage display libraries can be generated as described elsewhere (Burritt et al., *Anal. Biochem.* 238:1-13 (1990)), or can be obtained from commercial suppliers such as Novagen (Madison, Wis.).

Further, polypeptide sequencing techniques can be used to identify and obtain a nucleic acid molecule that encodes a polypeptide having enzymatic activity. For example, a purified polypeptide can be separated by gel electrophoresis, and its amino acid sequence determined by, for example, amino acid microsequencing techniques. Once determined, the amino acid sequence can be used to design degenerate oligonucleotide primers. Degenerate oligonucleotide primers can be used to obtain the nucleic acid encoding the polypeptide by PCR. Once obtained, the nucleic acid can be sequenced, cloned into an appropriate expression vector, and introduced into a microorganism.

Any method can be used to introduce an exogenous nucleic acid molecule into a cell. In fact, many methods for introducing nucleic acid into microorganisms such as bacteria and yeast are well known to those skilled in the art. For example, heat shock, lipofection, electroporation, conjugation, fusion of protoplasts, and biolistic delivery are common methods for introducing nucleic acid into bacteria and yeast cells. See, e.g., Ito et al., *J. Bacteriol.* 153:163-168 (1983); Durrrens et al., *Curr. Genet.* 18:7-12 (1990); and Becker and Guarente, *Methods in Enzymology* 194:182-187 (1991).

An exogenous nucleic acid molecule contained within a particular cell of the invention can be maintained within that cell in any form. For example, exogenous nucleic acid mol-

ecules can be integrated into the genome of the cell or maintained in an episomal state. In other words, a cell of the invention can be a stable or transient transformant. Again, a microorganism described herein can contain a single copy, or multiple copies (e.g., about 5, 10, 20, 35, 50, 75, 100 or 150 copies), of a particular exogenous nucleic acid molecule as described herein.

Methods for expressing an amino acid sequence from an exogenous nucleic acid molecule are well known to those skilled in the art. Such methods include, without limitation, constructing a nucleic acid such that a regulatory element promotes the expression of a nucleic acid sequence that encodes a polypeptide. Typically, regulatory elements are DNA sequences that regulate the expression of other DNA sequences at the level of transcription. Thus, regulatory elements include, without limitation, promoters, enhancers, and the like. Any type of promoter can be used to express an amino acid sequence from an exogenous nucleic acid molecule. Examples of promoters include, without limitation, constitutive promoters, tissue-specific promoters, and promoters responsive or unresponsive to a particular stimulus (e.g., light, oxygen, chemical concentration, and the like). Moreover, methods for expressing a polypeptide from an exogenous nucleic acid molecule in cells such as bacterial cells and yeast cells are well known to those skilled in the art. For example, nucleic acid constructs that are capable of expressing exogenous polypeptides within *E. coli* are well known. See, e.g., Sambrook et al., *Molecular cloning: a laboratory manual*, Cold Spring Harbour Laboratory Press, New York, USA, second edition (1989).

B. Production of Organic Acids and Related Products Via Host Cells

The nucleic acid and amino acid sequences provided herein can be used with cells to produce 3-HP and/or other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of 3-HP, and polymerized 3-HP. Such cells can be from any species including those listed within the taxonomy web pages at the National Institute of Health sponsored by the United States government (www.ncbi.nlm.nih.gov). The cells can be eukaryotic or prokaryotic. For example, genetically modified cells of the invention can be mammalian cells (e.g., human, murine, and bovine cells), plant cells (e.g., corn, wheat, rice, and soybean cells), fungal cells (e.g., *Aspergillus* and *Rhizopus* cells), yeast cells, or bacterial cells (e.g., *Lactobacillus*, *Lactococcus*, *Bacillus*, *Escherichia*, and *Clostridium* cells). A cell of the invention also can be a microorganism. The term "microorganism" as used herein refers to any microscopic organism including, without limitation, bacteria, algae, fungi, and protozoa. Thus, *E. coli*, *S. cerevisiae*, *Kluveromyces fragilis*, *Candida blankii*, *Candida rugosa*, and *Pichia pastoris* are considered microorganisms and can be used as described herein.

Typically, a cell of the invention is genetically modified such that a particular organic compound is produced. In one embodiment, the invention provides cells that make 3-HP from PEP. Examples biosynthetic pathways that can be used by cells to make 3-HP are shown in FIGS. 1-5, 43-44, 54, and 55.

Generally, cells that are genetically modified to synthesize a particular organic compound contain one or more exogenous nucleic acid molecules that encode polypeptides having specific enzymatic activities. For example, a microorganism can contain exogenous nucleic acid that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity. In this case, acrylyl-CoA can be converted into 3-hydroxypropionic acid-CoA which can lead to the production of

3-HP. It is noted that a cell can be given an exogenous nucleic acid molecule that encodes a polypeptide having an enzymatic activity that catalyzes the production of a compound not normally produced by that cell. Alternatively, a cell can be given an exogenous nucleic acid molecule that encodes a polypeptide having an enzymatic activity that catalyzes the production of a compound that is normally produced by that cell. In this case, the genetically modified cell can produce more of the compound, or can produce the compound more efficiently, than a similar cell not having the genetic modification.

In one embodiment, the invention provides a cell containing an exogenous nucleic acid molecule that encodes a polypeptide having enzymatic activity that leads to the formation of 3-HP. It is noted that the produced 3-HP can be secreted from the cell, eliminating the need to disrupt cell membranes to retrieve the organic compound. Typically, the cell of the invention produces 3-HP with the concentration being at least about 100 mg per L (e.g., at least about 1 g/L, 5 g/L, 10 g/L, 25 g/L, 50 g/L, 75 g/L, 80 g/L, 90 g/L, 100 g/L, or 120 g/L). When determining the yield of an organic compound such as 3-HP for a particular cell, any method can be used. See, e.g., *Applied Environmental Microbiology* 59(12): 4261-4265 (1993). Typically, a cell within the scope of the invention such as a microorganism catabolizes a hexose carbon source such as glucose. A cell, however, can catabolize a variety of carbon sources such as pentose sugars (e.g., ribose, arabinose, xylose, and lyxose), fatty acids, acetate, or glycerols. In other words, a cell within the scope of the invention can utilize a variety of carbon sources.

As described herein, a cell within the scope of the invention can contain an exogenous nucleic acid molecule that encodes a polypeptide having enzymatic activity that leads to the formation of 3-HP or other organic compounds such as 1,3-propanediol, acrylic acid, poly-acrylate, acrylate-esters, 3-HP-esters, and poly-3-HP. Methods of identifying cells that contain exogenous nucleic acid are well known to those skilled in the art. Such methods include, without limitation, PCR and nucleic acid hybridization techniques such as Northern and Southern analysis (see hybridization described herein). In some cases, immunohisto-chemistry and biochemical techniques can be used to determine if a cell contains a particular nucleic acid by detecting the expression of the polypeptide encoded by that particular nucleic acid molecule. For example, an antibody having specificity for a polypeptide can be used to determine whether or not a particular cell contains nucleic acid encoding that polypeptide. Further, biochemical techniques can be used to determine if a cell contains a particular nucleic acid molecule encoding a polypeptide having enzymatic activity by detecting an organic product produced as a result of the expression of the polypeptide having enzymatic activity. For example, detection of 3-HP after introduction of exogenous nucleic acid that encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity into a cell that does not normally express such a polypeptide can indicate that that cell not only contains the introduced exogenous nucleic acid molecule but also expresses the encoded polypeptide from that introduced exogenous nucleic acid molecule. Methods for detecting specific enzymatic activities or the presence of particular organic products are well known to those skilled in the art. For example, the presence of an organic compound such as 3-HP can be determined as described elsewhere. See, Sullivan and Clarke, *J. Assoc. Offic. Agr. Chemists*, 38:514-518 (1955).

C. Cells with Reduced Polypeptide Activity

The invention also provides genetically modified cells having reduced polypeptide activity. The term "reduced" as used

herein with respect to a cell and a particular polypeptide's activity refers to a lower level of activity than that measured in a comparable cell of the same species. For example, a particular microorganism lacking enzymatic activity X is considered to have reduced enzymatic activity X if a comparable microorganism has at least some enzymatic activity X. It is noted that a cell can have the activity of any type of polypeptide reduced including, without limitation, enzymes, transcription factors, transporters, receptors, signal molecules, and the like. For example, a cell can contain an exogenous nucleic acid molecule that disrupts a regulatory and/or coding sequence of a polypeptide having pyruvate decarboxylase activity or alcohol dehydrogenase activity. Disrupting pyruvate decarboxylase and/or alcohol dehydrogenase expression can lead to the accumulation of lactate as well as products produced from lactate such as 3-HP, 1,3-propanediol, acrylic acid, poly-acrylate, acrylate-esters, 3-HP-esters, and poly-3-HP. It is also noted that reduced polypeptide activities can be the result of lower polypeptide concentration, lower specific activity of a polypeptide, or combinations thereof. Many different methods can be used to make a cell having reduced polypeptide activity. For example, a cell can be engineered to have a disrupted regulatory sequence or polypeptide-encoding sequence using common mutagenesis or knock-out technology. See, e.g., *Methods in Yeast Genetics* (1997 edition), Adams, Gottschling, Kaiser, and Stens, Cold Spring Harbor Press (1998). Alternatively, antisense technology can be used to reduce the activity of a particular polypeptide. For example, a cell can be engineered to contain a cDNA that encodes an antisense molecule that prevents a polypeptide from being translated. The term "antisense molecule" as used herein encompasses any nucleic acid molecule or nucleic acid analog (e.g., peptide nucleic acids) that contains a sequence that corresponds to the coding strand of an endogenous polypeptide. An antisense molecule also can have flanking sequences (e.g., regulatory sequences). Thus, antisense molecules can be ribozymes or antisense oligonucleotides. A ribozyme can have any general structure including, without limitation, hairpin, hammerhead, or axhead structures, provided the molecule cleaves RNA. Further, gene silencing can be used to reduce the activity of a particular polypeptide.

A cell having reduced activity of a polypeptide can be identified using any method. For example, enzyme activity assays such as those described herein can be used to identify cells having a reduced enzyme activity.

A polypeptide having (1) the amino acid sequence set forth in SEQ ID NO:39 (the OS17 polypeptide) or (2) an amino acid sequence sharing at least about 60 percent sequence identity with the amino acid sequence set forth in SEQ ID NO:39 can have three functional domains: a domain having CoA-synthetase activity, a domain having 3-HP-CoA dehydratase activity, and a domain having CoA-reductase activity. Such polypeptides can be selectively modified by mutating and/or deleting domains such that one or two of the enzymatic activities are reduced. Reducing the dehydratase activity of the OS17 polypeptide can cause acrylyl-CoA to be created from propionyl-CoA. The acrylyl-CoA then can be contacted with a polypeptide having CoA hydrolase activity to produce acrylate from propionate (FIG. 43). Similarly, acrylyl-CoA can be created from 3-HP by using, for example, an OS17 polypeptide having reduced reductase activity.

D. Production of Organic Acids and Related Products Via In Vitro Techniques

In addition, purified polypeptides having enzymatic activity can be used alone or in combination with cells to produce 3-HP or other organic compounds such as 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of

3-HP, and polymerized 3-HP. For example, a preparation containing a substantially pure polypeptide having 3-hydroxypropionyl-CoA dehydratase activity can be used to catalyze the formation of 3-HP-CoA, a precursor to 3-HP. Further, cell-free extracts containing a polypeptide having enzymatic activity can be used alone or in combination with purified polypeptides and/or cells to produce 3-HP. For example, a cell-free extract containing a polypeptide having CoA transferase activity can be used to form lactyl-CoA, while a microorganism containing polypeptides have the enzymatic activities necessary to catalyze the reactions needed to form 3-HP from lactyl-CoA can be used to produce 3-HP. Any method can be used to produce a cell-free extract. For example, osmotic shock, sonication, and/or a repeated freeze-thaw cycle followed by filtration and/or centrifugation can be used to produce a cell-free extract from intact cells.

It is noted that a cell, purified polypeptide, and/or cell-free extract can be used to produce 3-HP that is, in turn, treated chemically to produce another compound. For example, a microorganism can be used to produce 3-HP, while a chemical process is used to modify 3-HP into a derivative such as polymerized 3-HP or an ester of 3-HP. Likewise, a chemical process can be used to produce a particular compound that is, in turn, converted into 3-HP or other organic compound (e.g., 1,3-propanediol, acrylic acid, polymerized acrylate, esters of acrylate, esters of 3-HP, and polymerized 3-HP) using a cell, substantially pure polypeptide, and/or cell-free extract described herein. For example, a chemical process can be used to produce acrylyl-CoA, while a microorganism can be used to convert acrylyl-CoA into 3-HP.

E. Fermentation of Cells to Produce Organic Acids

Typically, 3-HP is produced by providing a production cell, such as a microorganism, and culturing the microorganism with culture medium such that 3-HP is produced. In general, the culture media and/or culture conditions can be such that the microorganisms grow to an adequate density and produce 3-HP efficiently. For large-scale production processes, any method can be used such as those described elsewhere (*Manual of Industrial Microbiology and Biotechnology*, 2nd Edition, Editors: A. L. Demain and J. E. Davies, ASM Press; and *Principles of Fermentation Technology*, P. F. Stanbury and A. Whitaker, Pergamon). Briefly, a large tank (e.g., a 100 gallon, 200 gallon, 500 gallon, or more tank) containing appropriate culture medium with, for example, a glucose carbon source is inoculated with a particular microorganism. After inoculation, the microorganisms are incubated to allow biomass to be produced. Once a desired biomass is reached, the broth containing the microorganisms can be transferred to a second tank. This second tank can be any size. For example, the second tank can be larger, smaller, or the same size as the first tank. Typically, the second tank is larger than the first such that additional culture medium can be added to the broth from the first tank. In addition, the culture medium within this second tank can be the same as, or different from, that used in the first tank. For example, the first tank can contain medium with xylose, while the second tank contains medium with glucose.

Once transferred, the microorganisms can be incubated to allow for the production of 3-HP. Once produced, any method can be used to isolate the 3-HP. For example, common separation techniques can be used to remove the biomass from the broth, and common isolation procedures (e.g., extraction, distillation, and ion-exchange procedures) can be used to obtain the 3-HP from the microorganism-free broth. In addition, 3-HP can be isolated while it is being produced, or it can be isolated from the broth after the product production phase has been terminated.

F. Products Created from the Disclosed Biosynthetic Routes

The organic compounds produced from any of the steps provided in FIGS. 1-5, 43-44, 54, and 55 can be chemically converted into other organic compounds. For example, 3-HP can be hydrogenated to form 1,3 propanediol, a valuable polyester monomer. Hydrogenating an organic acid such as 3-HP can be performed using any method such as those used to hydrogenate succinic acid and/or lactic acid. For example, 3-HP can be hydrogenated using a metal catalyst. In another example, 3-HP can be dehydrated to form acrylic acid. Any method can be used to perform a dehydration reaction. For example, 3-HP can be heated in the presence of a catalyst (e.g., a metal or mineral acid catalyst) to form acrylic acid. Propanediol also can be created using polypeptides having oxidoreductase activity (e.g., enzymes is the 1.1.1.-class of enzymes) in vitro or in vivo.

V. Overview of Methodology Used to Create Biosynthetic Pathways that Make 3-HP from PEP

The invention provides methods of making 3-HP and related products from PEP via the use of biosynthetic pathways. Illustrative examples include methods involving the production of 3-HP via a lactate intermediate, a malonyl-CoA intermediate, and a β -alanine intermediate.

A. Biosynthetic Pathway for Making 3-HP Through a Lactic Acid Intermediate

A biosynthetic pathway that allows for the production of 3-HP from PEP was constructed (FIG. 1). This pathway involved using several polypeptides that were cloned and expressed as described herein. *M. elsdenii* cells (ATCC 17753) were used as a source of genomic DNA. Primers were used to identify and clone a nucleic acid sequence encoding a polypeptide having CoA transferase activity (SEQ ID NO: 1). The polypeptide was subsequently tested for enzymatic activity and found to have CoA transferase activity.

Similarly, PCR primers were used to identify nucleic acid sequences from *M. elsdenii* genomic DNA that encoded an E1 activator, E2 α , and E2 β polypeptides (SEQ ID NOs: 9, 17, and 25, respectively). These polypeptides were subsequently shown to have lactyl-CoA dehydratase activity.

Chloroflexus aurantiacus cells (ATCC 29365) were used as a source of genomic DNA. Initial cloning lead to the identification of nucleic acid sequences: OS17 (SEQ ID NO: 129) and OS19 (SEQ ID NO: 40). Subsequence assays revealed that OS17 encodes a polypeptide having CoA synthase activity, dehydratase activity, and dehydrogenase activity (propionyl-CoA synthetase). Subsequence assays also revealed that OS19 encodes a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity (also referred to as acrylyl-CoA hydratase activity).

Several operons were constructed for use in *E. coli*. These operons allow for the production of 3-HP in bacterial cells. Additional experiments allowed for the expression of these polypeptide is yeast, which can be used to produce 3-HP.

B. Biosynthetic Pathway for Making 3-HP Through a Malonyl-CoA Intermediate

Another pathway leading to the production of 3-HP from PEP was constructed. This pathway used a polypeptide having acetyl CoA carboxylase activity that was isolated from *E. coli* (Example 9), and a polypeptide having malonyl-CoA reductase activity that was isolated from *Chloroflexus aurantiacus* (Example 10). The combination of these two polypeptides allows for the production of 3-HP from acetyl-CoA (FIG. 44).

Nucleic acid encoding a polypeptide having malonyl-CoA reductase activity (SEQ ID NO: 140) was cloned, sequenced, and expressed. The polypeptide having malonyl-CoA reductase activity was then used to make 3-HP.

C. Biosynthetic Pathways for Making 3-HP Through a β -Alanine Intermediate

In general, prokaryotes and eukaryotes metabolize glucose via the Embden-Meyerhof-Parnas pathway to PEP, a central metabolite in carbon metabolism. The PEP generated from glucose is either carboxylated to oxaloacetate or is converted to pyruvate. Carboxylation of PEP to oxaloacetate can be catalyzed by a polypeptide having PEP carboxylase activity, a polypeptide having PEP carboxykinase activity, or a polypeptide having PEP transcarboxylase activity. Pyruvate that is generated from PEP by a polypeptide having pyruvate kinase activity can also be converted to oxaloacetate by a polypeptide having pyruvate carboxylase activity.

Oxaloacetate generated either from PEP or pyruvate can act as a precursor for production of aspartic acid. This conversion can be carried out by a polypeptide having aspartate aminotransferase activity, which transfers an amino group from glutamate to oxaloacetate. Glutamate consumed in this reaction can be regenerated by the action of a polypeptide having glutamate dehydrogenase activity or by the action of a polypeptide having 4,4-aminobutyrate aminotransferase activity. The decarboxylation of aspartate to β -alanine is catalyzed by a polypeptide having aspartate decarboxylase activity. β -alanine produced through this biochemistry can be converted to 3-HP via two possible pathways. These pathways are provided in FIGS. 54 and 55.

The steps involved in the production of β -alanine can be the same for both pathways. These steps can be accomplished by endogenous polypeptides in the host cells which convert PEP to β -alanine, or these steps can be accomplished with recombinant DNA technology using known polypeptides such as polypeptides having PEP-carboxykinase activity (4.1.1.32), aspartate aminotransferase activity (2.6.1.1), and aspartate alpha-decarboxylase activity (4.1.1.11).

As depicted in FIG. 54, a polypeptide having CoA transferase activity (e.g., a polypeptide having a sequence set forth in SEQ ID NO:2) can be used to convert β -alanine to β -alanyl-CoA. β -alanyl-CoA can be converted to acrylyl-CoA via a polypeptide having β -alanyl-CoA ammonia lyase activity (e.g., a polypeptide having a sequence set forth in SEQ ID NO:160). Acrylyl-CoA can be converted to 3-HP-CoA using a polypeptide having 3-HP-CoA dehydratase activity (e.g., a polypeptide having a sequence set forth in SEQ ID NO:40). 3-HP-CoA can be converted into 3-HP via a polypeptide having CoA transferase activity (e.g., a polypeptide having a sequence set forth in SEQ ID NO:2).

As depicted in FIG. 55, a polypeptide having 4,4-aminobutyrate aminotransferase activity (2.6.1.19) can be used to convert β -alanine into malonate semialdehyde. The malonate semialdehyde can be converted into 3-HP using either a polypeptide having 3-hydroxypropionate dehydrogenase activity (1.1.1.59) or a polypeptide having 3-hydroxyisobutyrate dehydrogenase activity.

EXAMPLES

Example 1

Cloning Nucleic Acid Molecules that Encode a Polypeptide Having CoA Transferase Activity

Genomic DNA was isolated from *Megasphaera elsdenii* cells (ATCC 17753) grown in 1053 Reinforced *Clostridium*

media under anaerobic conditions at 37° C. in roll tubes for 12-14 hours. Once grown, the cells were pelleted, washed with 5 mL of a 10 mM Tris solution, and repelleted. The pellet was resuspended in 1 mL of Gentra Cell Suspension Solution to which 14.2 mg of lysozyme and 4 µL of 20 mg/mL proteinase K solution was added. The cell suspension was incubated at 37° C. for 30 minutes. The genomic DNA was then isolated using a Gentra Genomic DNA Isolation Kit following the provided protocol. The precipitated genomic DNA was spooled and air-dried for 10 minutes. The genomic DNA was suspended in 500 µL of a 10 mM Tris solution and stored at 4° C.

Two degenerate forward (CoAF1 and CoAF2) and three degenerate reverse (CoAR1, CoAR2, and CoAR3) PCR primers were designed based on conserved acetoacetyl CoA transferase and propionate CoA transferase sequences (CoAF1 5'-GAAWSCGGYSCNATYGGYGG-3', SEQ ID NO: 49; CoAF2 5'-TTYTGYG-GYRSBTTYACBGCWGG-3', SEQ ID NO: 50; CoAR1 5'-CCWGCVGTRAAV-SYRC-CRCARAA-3', SEQ ID NO: 51; CoAR2 5'-AARACDSM-RCGTTTCVGTGA-TRTA-3', SEQ ID NO: 52; and CoAR3 5'-TCRAYRCCSGGWGCRAYTTC-3', SEQ ID NO: 53). The primers were used in all logical combinations in PCR using Taq polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.) and 1 ng of genomic DNA per µL reaction mix. PCR was conducted using a touchdown PCR program with 4 cycles at an annealing temperature of 59° C., 4 cycles at 57° C., 4 cycles at 55° C., and 18 cycles at 52° C. Each cycle used an initial 30-second denaturing step at 94° C. and a 3 minute extension at 72° C. The program had an initial denaturing step for 2 minutes at 94° C. and a final extension step of 4 minutes at 72° C. Time allowed for annealing was 45 seconds. The amounts of PCR primer used in the reactions were increased 2-8 fold above typical PCR amounts depending on the amount of degeneracy in the 3' end of the primer. In addition, separate PCR reactions containing each individual primer were made to identify PCR products resulting from single degenerate primers. Each PCR product (25 µL) was separated by electrophoresis using a 1% TAE (Tris-acetate-EDTA) agarose gel.

The CoAF1-CoAR2, CoAF1-CoAR3, CoAF2-CoAR2, and CoAF2-CoAR3 combinations produced a band of 423, 474, 177, and 228 bp, respectively. These bands matched the sizes based on other CoA transferase sequences. No band was visible from the individual primer control reactions. The CoAF1-CoAR3 fragment (474 bp) was isolated and purified using a Qiagen Gel Extraction Kit (Qiagen Inc., Valencia, Calif.). Four µL of the purified band was ligated into pCRII vector and transformed into TOP 10 *E. coli* cells by heat-shock using a TOPO cloning procedure (Invitrogen, Carlsbad, Calif.). Transformations were plated on LB media containing 100 µg/mL of ampicillin (Amp) and 50 µg/mL of 5-Bromo-4-Chloro-3-Indolyl-B-D-Galactopyranoside (X-gal). Single, white colonies were plated onto fresh media and screened in a PCR reaction using the CoAF1 and CoAR3 primers to confirm the presence of the insert.

Plasmid DNA obtained using a QiaPrep Spin Miniprep Kit (Qiagen, Inc) was quantified and used for DNA sequencing with M13R and M13F primers. Sequence analysis revealed that the CoAF1-CoAR3 fragment shared sequence similarity with acetoacetyl CoA transferase sequences.

Genome walking was performed to obtain the complete coding sequence. The following primers for genome walking in both upstream and downstream directions were designed using the portion of the 474 bp CoAF1-CoAR3 fragment sequence that was internal to the degenerate primers (COAGSP1F 5'-GAATGTTTACTCTGCGG-CACCT-

TCAC-3', SEQ ID NO:54; COAGSP2F 5'-GACCAGAT-CACTTTCAACG-GTCCTATG-3', SEQ ID NO:55; COAGSP1R 5'-GCATAGGAACCGTTGAAA-GT-GATCTGG-3', SEQ ID NO:56; and COAGSP2R 5'-GTTAG-TACCGAACTG-CTGACGTTGATG-3', SEQ ID NO:57). The COAGSP1F and COAGSP2F primers face downstream, while the COAGSP1R and COAGSP2R primers face upstream. In addition, the COAGSP2F and COAGSP2R primers are nested inside the COAGSP1F and COAGSP1R primers. Genome walking was performed using the Universal Genome Walking kit (Clontech Laboratories, Inc., Palo Alto, Calif.) with the exception that additional libraries were generated with enzymes Nru I, Sea I, and Hinc II. First round PCR was conducted in a Perkin Elmer 2400 Thermocycler with 7 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 36 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. Second round PCR used 5 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 20 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. The first and second round product (20 µL) was separated by electrophoresis on a 1% TAE agarose gel. Amplification products were obtained with the Stu I library for the reverse direction. The second round product of 1.5 Kb from this library was gel purified, cloned, and sequenced. Sequence analysis revealed that the sequence derived from genome walking overlapped with the CoAF1-CoAR3 fragment and shared sequence similarity with other sequences such as acetoacetyl CoA transferase sequences (FIGS. 8-9).

Nucleic acid encoding the CoA transferase (propionyl-CoA transferase or pct) from *Megasphaera elsdenii* was PCR amplified from chromosomal DNA using following PCR program: 25 cycles of 95° C. for 30 seconds to denature, 50° C. for 30 seconds to anneal, and 72° C. for 3 minutes for extension (plus 2 seconds per cycle). The primers used were designated PCT-1.114 (5'-ATGAGAAAAGTAGAAATCAT-TAC-3'; SEQ ID NO:58) and PCT-2.2045 (5'-GGCGGAAGTTGACGATAATG-3'; SEQ ID NO:59). The resulting PCR product (about 2 kb as judged by agarose gel electrophoresis) was purified using a Qiagen PCR purification kit (Qiagen Inc., Valencia, Calif.). The purified product was ligated to pETBlue-1 using the Perfectly Blunt cloning Kit (Novagen, Madison, Wis.). The ligation reaction was transformed into NovaBlue chemically competent cells (Novagen, Madison, Wis.) that were spread on LB agar plates supplemented with 50 µg/mL carbenicillin, 40 µg/mL IPTG, and 40 µg/mL X-Gal. White colonies were isolated and screened for the presence of inserts by restriction mapping. Isolates with the correct restriction pattern were sequenced from each end using the primers pETBlueUP and pETBlue-DOWN (Novagen) to confirm the sequence at the ligation points.

The plasmid was transformed into Tuner (DE3) pLacI chemically competent cells (Novagen, Madison, Wis.), and expression from the construct tested. Briefly, a culture was grown overnight to saturation and diluted 1:20 the following morning in fresh LB medium with the appropriate antibiotics. The culture was grown at 37° C. with aeration to an OD₆₀₀ of about 0.6. The culture was induced with IPTG at a final concentration of 100 µM. The culture was incubated for an additional two hours at 37° C. with aeration. Aliquots were taken pre-induction and 2 hours post-induction for SDS-PAGE analysis. A band of the expected molecular weight (55,653 Daltons predicted from the sequence) was observed after IPTG treatment. This band was not observed in cells containing a plasmid lacking the nucleic acid encoding the transferase.

Cell free extracts were prepared to assess enzymatic activity. Briefly, the cells were harvested by centrifugation and disrupted by sonication. The sonicated cell suspension was centrifuged to remove cell debris, and the supernatant was used in the assays.

Transferase activity was measured in the following assay. The assay mixture used contained 100 mM potassium phosphate buffer (pH 7.0), 200 mM sodium acetate, 1 mM dithio-bisnitrobenzoate (DTNB), 500 μ M oxaloacetate, 25 μ M CoA-ester substrate, and 3 μ g/mL citrate synthase. If present, the CoA transferase transfers the CoA from the CoA ester to acetate to form acetyl-CoA. The added citrate synthase condenses oxaloacetate and acetyl-CoA to form citrate and free CoASH. The free CoASH complexes with DTNB, and the formation of this complex can be measured by a change in the optical density at 412 nm. The activity of the CoA transferase was measured using the following substrates: lactyl-CoA, propionyl-CoA, acrylyl-CoA, and 3-hydroxypropionyl-CoA. The units/mg of protein was calculated using the following formula:

$$(\Delta E/\text{min} \times V_f \times \text{dilution factor}) / (V_s \times 14.2) = \text{units/mL}$$

where $\Delta E/\text{min}$ is the change in absorbance per minute at 412 nm, V_f is the final volume of the reaction, and V_s is the volume of sample added. The total protein concentration of the cell free extract was about 1 mg/mL so the units/mL equals units/mg.

Cell free extracts from cells containing nucleic acid encoding the CoA transferase exhibited CoA transferase activity (Table 2). The observed CoA transferase activity was detected for the lactyl-CoA, propionyl-CoA, acrylyl-CoA, and 3-hydroxypropionyl-CoA substrates (Table 2). The highest CoA transferase activity was detected for lactyl-CoA and propionyl-CoA.

TABLE 2

Substrate	Units/mg
Lactyl-CoA	211
Propionyl-CoA	144
Acrylyl-CoA	118
3-Hydroxypropionyl-CoA	110

The following assay was performed to test whether the CoA transferase activity can use the same CoA substrate donors as recipients. Specifically, CoA transferase activity was assessed using a Matrix-assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) Voyager RP workstation (PerSeptive Biosystems). The following five reactions were analyzed:

- 1) acetate+lactyl-CoA $\rightarrow$ lactate+acetyl-CoA
- 2) acetate+propionyl-CoA $\rightarrow$ propionate+acetyl-CoA
- 3) lactate+acetyl-CoA $\rightarrow$ acetate+lactyl-CoA
- 4) lactate+acrylyl-CoA $\rightarrow$ acrylate+lactyl-CoA
- 5) 3-hydroxypropionate+lactyl-CoA $\rightarrow$ lactate+3-hydroxypropionyl-CoA

MALDI-TOF MS was used to measure simultaneously the appearance of the product CoA ester and the disappearance of the donor CoA ester. The assay buffer contained 50 mM potassium phosphate (pH 7.0), 1 mM CoA ester, and 100 mM respective acid salt. Protein from a cell free extract prepared as described above was added to a final concentration of 0.005 mg/mL. A control reaction was prepared from a cell free

extract prepared from cells lacking the construct containing the CoA transferase-encoding nucleic acid. For each reaction, the cell free extract was added last to start the reaction. Reactions were allowed to proceed at room temperature and were stopped by adding 1 volume 10% trifluoroacetic acid (TFA). The reaction mixtures were purified prior to MALDI-TOF MS analysis using Sep Pak Vac C₁₈ 50 mg columns (Waters, Inc.). The columns were conditioned with 1 mL methanol and equilibrated with two washes of 1 mL 0.1% TFA. Each sample was applied to the column, and the flow through was discarded. The column was washed twice with 1 mL 0.1% TFA. The sample was eluted in 200 μ L 40% acetonitrile, 0.1% TFA. The acetonitrile was removed by centrifugation in vacuo. Samples were prepared for MALDI-TOF MS analysis by mixing 1:1 with 110 mM sinapinic acid in 0.1% TFA, 67% acetonitrile. The samples were allowed to air dry.

In reaction #1, the control sample exhibited a main peak at a molecular weight corresponding to lactyl-CoA (MW 841). There was a minor peak at the molecular weight corresponding to acetyl-CoA (MW 811). This minor peak was determined to be the left-over acetyl-CoA from the synthesis of lactyl-CoA. The reaction #1 sample containing the cell extract from cells transfected with the CoA transferase-encoding plasmid exhibited complete conversion of lactyl-CoA to acetyl-CoA. No peak was observed for lactyl-CoA. This result indicates that the CoA transferase activity can transfer CoA from lactyl-CoA to acetate to form acetyl-CoA.

In reaction #2, the control sample exhibited a dominant peak at a molecular weight corresponding to propionyl-CoA (MW 825). The reaction #2 sample containing the cell extract from cells transfected with the CoA transferase-encoding plasmid exhibited a dominant peak at a molecular weight corresponding to acetyl-CoA (MW 811). No peak was observed for propionyl-CoA. This result indicates that the CoA transferase activity can transfer CoA from propionyl-CoA to acetate to form acetyl-CoA.

In reaction #3, the control sample exhibited a dominant peak at a molecular weight corresponding to acetyl-CoA (MW 811). The reaction #3 sample containing the cell extract from cells transfected with the CoA transferase-encoding plasmid exhibited a peak corresponding to lactyl-CoA (MW 841). The peak corresponding to acetyl-CoA did not disappear. In fact, the ratio of the size of the two peaks was about 1:1. The observed appearance of the peak corresponding to lactyl-CoA demonstrates that the CoA transferase activity catalyzes reaction #3.

In reaction #4, the control sample exhibited a dominant peak at a molecular weight corresponding to acrylyl-CoA (MW 823). The reaction #4 sample containing the cell extract from cells transfected with the CoA transferase-encoding plasmid exhibited a dominant peak corresponding to lactyl-CoA (MW 841). This result demonstrates that the CoA transferase activity catalyzes reaction #4.

In reaction #5, deuterated lactyl-CoA was used to detect the transfer of CoA from lactate to 3-hydroxypropionate since lactic acid and 3-HP have the same molecular weight as do their respective CoA esters. Using deuterated lactyl-CoA allowed for the differentiation between lactyl-CoA and 3-hydroxypropionate using MALDI-TOF MS. The control sample exhibited a diffuse group of peaks at molecular weights ranging from MW 841 to 845 due to the varying amounts of hydrogen atoms that were replaced with deuterium atoms. In addition, a significant peak was observed at a molecular weight corresponding to acetyl-CoA (MW 811). This peak was determined to be the left-over acetyl-CoA from the synthesis of lactyl-CoA. The reaction #5 sample containing the cell extract from cells transfected with the CoA trans-

37

ferase-encoding plasmid exhibited a dominant peak at a molecular weight corresponding to 3-hydroxypropionyl-CoA (MW 841) as opposed to a group of peaks ranging from MW 841 to 845. This result demonstrates that the CoA transferase catalyzes reaction #5.

Example 2

Cloning Nucleic Acid Molecules that Encode a Multiple Polypeptide Complex Having Lactyl-CoA Dehydratase Activity

The following methods were used to clone an E1 activator polypeptide. Briefly, four degenerate forward and five degenerate reverse PCR primers were designed based on conserved sequences of E1 activator protein homologs (E1F1 5'-GCWACBGY-TAYGGYCG-3', SEQ ID NO:60; E1F2 5'-GTYRTYGAYRTYGGYGGYCAGGA-3', SEQ ID NO:61; E1F3 5'-ATGAACGAYAARTGYGCWGCWGG-3', SEQ ID NO:62; E1F4 5'-TGYGCWGCWGGYACBGY-CGYTT-3', SEQ ID NO:63; E1R1 5'-TCCT-GRCCRC-CRAYRTCAYRAC-3', SEQ ID NO:64; E1R2 5'-CCWGCWGCRCAY-TTRTCGTTTCAT-3', SEQ ID NO:65; E1R3 5'-AARCGRCCVGTGCCWGCWG-CRCA-3', SEQ ID NO:66; E1R4 5'-GCTTCGSWTTTCRACRATGSW-3', SEQ ID NO:67; and E1R5 5'-GSWRATRATTGCGWTCWGCRAA-3', SEQ ID NO:68).

The primers were used in all logical combinations in PCR using Taq polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.) and 1 ng of genomic DNA per μ L reaction mix. PCR was conducted using a touchdown PCR program with 4 cycles at an annealing temperature of 60° C., 4 cycles at 58° C., 4 cycles at 56° C., and 18 cycles at 54° C. Each cycle used an initial 30-second denaturing step at 94° C. and a 3 minute extension step at 72° C. The program had an initial denaturing step for 2 minutes at 94° C. and a final extension step of 4 minutes at 72° C. Time allowed for annealing was 45 seconds. The amounts of PCR primer used in the reactions were increased 2-10 fold above typical PCR amounts depending on the amount of degeneracy in the 3' end of the primer. In addition, separate PCR reactions containing each individual primer were made to identify PCR product resulting from single degenerate primers. Each PCR product (25 μ L) was separated by electrophoresis using a 1% TAE (Tris-acetate-EDTA) agarose gel.

The E1F2-E1R4, E1F2-E1R5, E1F3-E1R4, E1F3-E1R5, and E1F4-E1R4R2 combinations produced a band of 195, 207, 144, 156, and 144 bp, respectively. These bands matched the expected size based on E1 activator sequences from other species. No band was visible with individual primer control reactions. The E1F2-E1R5 fragment (207 bp) was isolated and purified using Qiagen Gel Extraction procedure (Qiagen Inc., Valencia, Calif.). The purified band (4 μ L) was ligated into a pCRII vector that then was transformed into TOP10 *E. coli* cells by heat-shock using a TOPO cloning procedure (Invitrogen, Carlsbad, Calif.). Transformations were plated on LB media containing 100 μ g/mL of ampicillin (Amp) and 50 μ g/mL of 5-Bromo-4-Chloro-3-Indolyl-B-D-Galactopyranoside (X-gal). Single, white colonies were plated onto fresh media and screened in a PCR reaction using the E1F2 and E1R5 primers to confirm the presence of the insert. Plasmid DNA was obtained from multiple colonies using a QiaPrep Spin Miniprep Kit (Qiagen, Inc). Once obtained, the plasmid DNA was quantified and used for DNA sequencing with M13R and M13F primers. Sequence analysis revealed a nucleic acid sequence encoding a polypeptide and revealed

38

that the E1F2-E1R5 fragment shared sequence similarity with E1 activator sequences (FIGS. 12-13).

Genome walking was performed to obtain the complete coding sequence of E2 α and β subunits. Briefly, four primers for performing genome walking in both upstream and downstream directions were designed using the portion of the 207 bp E1F2-E1R5 fragment sequence that was internal to the E1F2 and E1R5 degenerate primers (E1GSP1F 5'-ACGT-CATGTCGAAGGTACTGGAAATCC-3', SEQ ID NO:69; E1GSP2F 5'-GGGACTGGTACTTCAAATCGAAGCATC-3', SEQ ID NO:70; E1GSP1R 5'-TGACGGCAGCGGGATGCTTCGATTGA-3', SEQ ID NO:71; and E1GSP2R 5'-TCAGACATGGGGATTCCAGTACCTTC-3', SEQ ID NO:72). The E1GSP1F and E1GSP2F primers face downstream, while the E1GSP1R and E1GSP2R primers face upstream. In addition, the E1GSP2F and E1GSP2R primers are nested inside the E1GSP1F and E1GSP1R primers.

Genome walking was performed using the Universal Genome Walking Kit (ClonTech Laboratories, Inc., Palo Alto, Calif.) with the exception that additional libraries were generated with enzymes Nru I, Sea I, and Hinc II. First round PCR was performed in a Perkin Elmer 2400 Thermocycler with 7 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 36 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. Second round PCR used 5 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 20 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. The first and second round product (20 μ L) was separated by electrophoresis using 1% TAE agarose gel. Amplification products were obtained with the Stu I library for both forward and reverse directions. The second round product of about 1.5 kb for forward direction and 3 kb fragment for reverse direction from the Stu I library were gel purified, cloned, and sequenced. Sequence analysis revealed that the sequence derived from genome walking overlapped with the E1F2-E1R5 fragment.

To obtain additional sequence, a second genome walk was performed using a first round primer (E1GSPF5 5'-CCGTGTTACTTGGGAAGGTATCGCTGTCTG-3', SEQ ID NO:73) and a second round primer (E1GSPF6 5'-GCCAATGAAGGAGGAAA-CCACTAATGAGTC-3', SEQ ID NO:74). The genome walk was performed using the NruI, ScaI, and HincII libraries. In addition, ClonTech's Advantage-Genomic Polymerase was used for the PCR. First round PCR was performed in a Perkin Elmer 2400 Thermocycler with an initial denaturing step at 94° C. for 2 minutes, 7 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 36 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. Second round PCR used 5 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 20 cycles of 2 seconds at 94° C. and 3 minutes at 65° C. with a final extension at 65° C. for 4 minutes. The first and second round product (20 μ L) was separated by electrophoresis on a 1% agarose gel. An about 1.5 kb amplification product was obtained from second round PCR of the HincII library. This band was gel purified, cloned, and sequenced. Sequence analysis revealed that it overlapped with the previously obtained genome walk fragment. In addition, sequence analysis revealed a nucleic acid sequence encoding an E2 α subunit that shares sequence similarities with other sequences (FIGS. 16-17). Further, sequence analysis revealed a nucleic acid sequence encoding an E2 β subunit that shares sequence similarities with other sequences (FIGS. 20-21).

Additional PCR and sequence analysis revealed the order of polypeptide encoding sequences within the region containing the lactyl-CoA dehydratase-encoding sequences. Specifi-

cally, the E1GSP1F and COAGSP1R primer pair and the COAGSP1F and E1GSP1R primer pair were used to amplify fragments that encode both the CoA transferase and E1 activator polypeptides. Briefly, *M. elsdenii* genome DNA (1 ng) was used as a template. The PCR was conducted in Perkin Elmer 2400 Thermocycler using Long Template Polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.). The PCR program used was as follows: 94° C. for 2 minutes; 29 cycles of 94° C. for 30 seconds, 61° C. for 45 seconds, and 72° C. for 6 minutes; and a final extension of 72° C. for 10 minutes. Both PCR products (20 µL) were separated on a 1% agarose gel. An amplification product (about 1.5 kb) was obtained using the COAGSP1F and E1GSP1R primer pair. This product was gel purified, cloned, and sequenced (FIGS. 22A-B).

The organization of the *M. elsdenii* operon containing the lactyl-CoA dehydratase-encoding sequences was determined to containing the following polypeptide-encoding sequences in the following order: CoA transferase (FIG. 6), ORFX (FIG. 23), E1 activator protein of lactyl-CoA dehydratase (FIG. 10), E2α subunit of lactyl-CoA dehydratase (FIG. 14), E2 β subunit of lactyl-CoA dehydratase (FIG. 18), and truncated CoA dehydrogenase (FIG. 25).

The lactyl-CoA dehydratase (lactyl-CoA dehydratase or led) from *M. elsdenii* was PCR amplified from chromosomal DNA using the following program: 94° C. for 2 minutes; 7 cycles of 94° C. for 30 seconds, 47° C. for 45 seconds, and 72° C. for 3 minutes; 25 cycles of 94° C. for 30 seconds, 54° C. for 45 seconds, and 72° C. for 3 minutes; and 72° C. for 7 minutes. One primer pair was used (OSNBE1F 5'-GGGAAT-TCCATATG-AAAACGTGTGTACTCTC-3', SEQ ID NO:75 and OSNBE1R 5'-CGACGGAT-CCTTAGAG-GATTTCCGAGAAAGC-3', SEQ ID NO:76). The amplified product (about 3.2 kb) was separated on 1% agarose gel, cut from the gel, and purified with a Qiagen Gel Extraction kit (Qiagen, Valencia, Calif.). The purified product was digested with Nde I and BamHI restriction enzymes and ligated into pET11a vector (Novagen) digested with the same enzymes. The ligation reaction was transformed into NovaBlue chemically competent cells (Novagen) that then were spread on LB agar plates supplemented with 50 µg/mL carbenicillin. Isolated individual colonies were screened for the presence of inserts by restriction mapping. Isolates with the correct restriction pattern were sequenced from each end using Novagen primers (T7 promoter primer #69348-3 and T7 terminator primer #69337-3) to confirm the sequence at the ligation points.

A plasmid having the correct insert was transformed into Tuner (DE3) pLacI chemically competent cells (Novagen, Madison, Wis.). Expression from this construct was tested as follows. A culture was grown overnight to saturation and diluted 1:20 the following morning in fresh LB medium with the appropriate antibiotics. The culture was grown at 37° C. with aeration to an OD₆₀₀ of about 0.6. The culture was induced with IPTG at a final concentration of 100 µM. The culture was incubated for an additional two hours at 37° C. with aeration. Aliquots were taken pre-induction and 2 hours post-induction for SDS-PAGE analysis. Bands of the expected molecular weight (27,024 Daltons for the E1 subunit, 48,088 Daltons for the E2 α subunit, and 42,517 Daltons for the E2 β subunit-all predicted from the sequence) were observed. These bands were not observed in cells containing a plasmid lacking the nucleic acid encoding the three components of the lactyl-CoA dehydratase.

Cell free extracts were prepared by growing cells in a sealed serum bottle overnight at 37° C. Following overnight growth, the cultures were induced with 1 mM IPTG (added

using anaerobic technique) and incubated an additional 2 hours at 37° C. The cells were harvested by centrifugation and disrupted by sonication under strict anaerobic conditions. The sonicated cell suspension was centrifuged to remove cell debris, and the supernatant was used in the assays. The buffer used for cell resuspension/sonication was 50 mM Tris-HCl (pH 7.5), 200 µM ATP, 7 mM Mg(SO₄), 4 mM DTT, 1 mM dithionite, and 100 µM NADH.

Dehydratase activity was detected with MALDI-TOF MS. The assay was conducted in the same buffer as above with 1 mM lactyl-CoA or 1 mM acrylyl-CoA added and about 5 mg/mL cell free extract. Prior to MALDI-TOF MS analysis, samples were purified using Sep Pak Vac C₁₈ columns (Waters, Inc.) as described in Example 1. The following two reactions were analyzed:



In reaction #1, the control sample exhibited a peak at a molecular weight corresponding to acrylyl-CoA (MW 823). The reaction #1 sample containing the cell extract from cells transfected with the dehydratase-encoding plasmid exhibited a major peak at a molecular weight corresponding to lactyl-CoA (MW 841). This result indicates that the dehydratase activity can convert acrylyl-CoA into lactyl-CoA.

To detect dehydratase activity on lactyl-CoA, reaction #2 was carried out in 80% D₂O. The control sample exhibited a peak at a molecular weight corresponding to lactyl-CoA (MW 841). The reaction #2 sample containing the cell extract from cells transfected with the dehydratase-encoding plasmid revealed a lactyl-CoA peak shifted to a deuterated form. This result indicates that the dehydratase enzyme is active on lactyl-CoA. In addition, the results from both reactions indicate that the dehydratase enzyme can catalyze the lactyl-CoA $\longleftrightarrow$ acrylyl-CoA reaction in both directions.

Example 3

Cloning Nucleic Acid Molecules that Encode a Polypeptide Having 3-hydroxypropionyl CoA Dehydratase Activity

Genomic DNA was isolated from *Chloroflexus aurantiacus* cells (ATCC 29365). Briefly, *C. aurantiacus* cells in 920 Chloroflexus medium were grown in 50 mL cultures (Falcon 2070 polypropylene tubes) using an Innova 4230 Incubator, Shaker (New Brunswick Scientific; Edison, N.J.) at 50° C. with interior lights. Once grown, the cells were pelleted, washed with 5 mL of a 10 mM Tris solution, and re-pelleted. Genomic DNA was isolated from the pelleted cells using a Gentra Genomic "Puregene" DNA isolation kit (Gentra Systems; Minneapolis, Minn.). Briefly, the pelleted cells were resuspended in 1 mL Gentra Cell Suspension Solution to which 14.2 mg of lysozyme and 4 µL of 20 mg/mL proteinase K solution was added. The cell suspension was incubated at 37° C. for 30 minutes. The precipitated genomic DNA was recovered by centrifugation at 3500×g for 25 minutes and air-dried for 10 minutes. The genomic DNA was suspended in 300 µL of a 10 mM Tris solution and stored at 4° C.

The genomic DNA was used as a template in PCR amplification reactions with primers designed based on conserved domains of crotonase homologs and a *Chloroflexus aurantiacus* codon usage table. Briefly, two degenerate forward (CRF1 and CRF2) and three degenerate reverse (CRR1, CRR2, and CRR3) PCR primers were designed (CRF1 5'-AAYCGBCCVAARGCNCTSAAYGC-3', SEQ ID

NO:77; CRF2: 5'-TTYGTBGCNGGYGCNGAYAT-3', SEQ ID NO:78; CRR1 5'-ATRTCNG-CRCCNGCVACRAA-3', SEQ ID NO:79; CRR2 5'-CCRCCRCCSAGNG-CRWARC-CRTT-3', SEQ ID NO:80; and CRR3 5'-SSWNG-CRATVCGRAITRCAC-3', SEQ ID NO:81).

These primers were used in all logical combinations in PCR using Taq polymerase (Roche Molecular Biochemicals; Indianapolis, Ind.) and 1 ng of the genomic DNA per μ L reaction mix. The PCR was conducted using a touchdown PCR program with 4 cycles at an annealing temperature of 61° C., 4 cycles at 59° C., 4 cycles at 57° C., 4 cycles at 55° C., and 16 cycles at 52° C. Each cycle used an initial 30-second denaturing step at 94° C. and a 3-minute extension step at 72° C. The program also had an initial denaturing step for 2 minutes at 94° C. and a final extension step of 4 minutes at 72° C. The time allowed for annealing was 45 seconds. The amounts of PCR primer used in the reaction were increased 4-12 fold above typical PCR amounts depending on the amount of degeneracy in the 3' end of the primer. In addition, separate PCR reactions containing each individual primer were performed to identify amplification products resulting from single degenerate primers. Each PCR product (25 μ L) was separated by gel electrophoresis using a 1% TAE (Tris-acetate-EDTA) agarose gel.

The CRF1-CRR1 and CRF2-CRR2 combinations produced a unique band of about 120 and about 150 bp, respectively. These bands matched the expected size based on crotonase genes from other species. No 120 bp or 150 bp band was observed from individual primer control reactions. Both fragments (i.e., the 120 bp and 150 bp bands) were isolated and purified using the Qiagen Gel Extraction kit (Qiagen Inc., Valencia, Calif.). Each purified fragment (4 μ L) was ligated into pCRII vector that then was transformed into TOP10 *E. coli* cells by a heat-shock method using a TOPO cloning procedure (Invitrogen, Carlsbad, Calif.). Transformations were plated on LB media containing 100 μ g/mL of ampicillin (Amp) and 50 μ g/mL of 5-Bromo-4-Chloro-3-Indolyl-B-D-Galactopyranoside (X-gal). Single, white colonies were plated onto fresh media and screened in a PCR reaction using the CRF1 and CRR1 primers and the CRF2 and CRR2 primers to confirm the presence of the desired insert. Plasmid DNA was obtained from multiple colonies with the desired insert using a QiaPrep Spin Miniprep Kit (Qiagen, Inc.). Once obtained, the DNA was quantified and used for DNA sequencing with M13R and M13F primers. Sequence analysis revealed the presence of two different clones from the PCR product of about 150 bp. Each shared sequence similarity with crotonase and hydratase sequences. The two clones were designated OS17 (157 bp PCR product) and OS19 (151 bp PCR product).

Genome walking was performed to obtain the complete coding sequence of OS17. Briefly, primers for conducting genome walking in both upstream and downstream directions were designed using the portion of the 157 bp CRF2-CRR2 fragment sequence that was internal to the CRF2 and CRR2 degenerate primers (OS17F1 5'-CGCTG-ATATCGCCAGT-GCTCGAAG-3', SEQ ID NO:82; OS17F2 5'-CCCATCTTG-CTTCCGCAAGATTGAGC-3', SEQ ID NO:83; OS17F3 5'-CAATGGCCCTGCCGA-ATAACGCCCATCT-3', SEQ ID NO:84; OS17R1 5'-CTTCGAGCAACTGGCGAA-TAT-CAGCG-3', SEQ ID NO:85; OS17R2 5'-GCTCAATCT-GCGAAAGCAAG-ATGGG-3', SEQ ID NO:86; and OS17R3 5'-AGATGGGCGTATCGGCAGGGCC-ATTG-3', SEQ ID NO:87). The OS17F1, OS17F3, and OS17F2 primers face downstream, while the OS17R2, OS17R3, and OS17R1 primers face upstream.

Genome walking was conducted using the Universal Genome Walking kit (ClonTech Laboratories, Inc., Palo Alto, Calif.) with the exception that additional libraries were generated with enzymes Nru I, Fsp I, and Hinc II. The first round PCR was conducted in a Perkin Elmer 2400 Thermocycler with 7 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 36 cycles of 2 seconds at 94° C. and 3 minutes at 66° C. with a final extension at 66° C. for 4 minutes. Second round PCR used 5 cycles of 2 seconds at 94° C. and 3 minutes at 72° C., and 20 cycles of 2 seconds at 94° C. and 3 minutes at 66° C. with a final extension at 66° C. for 4 minutes. The first and second round amplification product (5 μ L) was separated by gel electrophoresis on a 1% TAE agarose gel. After the second round PCR, an amplification product of about 0.4 kb was obtained with the Fsp I library using the OS17R1 primer in the reverse direction, and an amplification product of about 0.6 kb was obtained with the Hinc II library using the OS17F2 primer in the forward direction. These PCR products were cloned and sequenced.

Sequence analysis revealed that the sequences derived from genome walking overlapped with the CRF2-CRR2 fragment and shared sequence similarity with crotonase and hydratase sequences.

A second genome walking was performed to obtain additional sequences. Six primers were designed for this second genome walk (OS17F4 5'-AAGCTGGG-TCTGATCGAT-GCCATTGCTACC-3', SEQ ID NO:88; OS17F5 5'-CTC-GATTATCG-CCCATCCACGTATCGAG-3', SEQ ID NO:89; OS17F6 5'-TGGATGCAATCCG-CTATGGCAT-TATCCACG-3', SEQ ID NO:90; OS17R4 5'-TCATTCAAGT-GCG-TTCACCGGCGGATTGTG-3', SEQ ID NO:91; OS17R5 5'-TCGATCCGGAAGT-AGCGATAGCGTTC-GATG-3', SEQ ID NO:92; and OS17R6 5'-CTTGGCTG-CAT-CTCTTCGAGCACTTCAGG-3', SEQ ID NO:93). The OS17F4, OS17F5, and OS17F6 primers faced downstream, while the OS17R4, OS17R5, and OS17R6 primers faced upstream.

The second genome walk was performed using the same methods described for the first genome walk. After the second round of walking, an amplification product of about 2.3 kb was obtained with a Hinc II library using the OS17R5 primer in the reverse direction, and an amplification product of about 0.6 kb was obtained with a Pvu II library using the OS17F5 primer in the forward direction. The PCR products were cloned and sequenced. Sequence analysis revealed that the sequences derived from the second genome walking overlapped with the sequence obtained during the first genome walking. In addition, the sequence analysis revealed a sequence with 3572 bp.

A BLAST search revealed that the polypeptide encoded by this sequence shares sequence similarity with polypeptides having three different activities. Specifically, the beginning of the OS17 encoded-polypeptide shares sequence similarity with CoA-synthetases, the middle region of the OS17 encoded-polypeptide shares sequence similarity with enoyl-CoA hydratases, and the end region of the OS17 encoded-polypeptide shares sequence similarity with CoA-reductases.

A third genome walk was performed using four primers (OS17UP-6 5'-CATCAGAGGTAATCACCACCTCGTGCA-3', SEQ ID NO:94; OS17UP-7 5'-AAGTAGTAGGCCAC-CTCGTCGCCATA-3', SEQ ID NO:95; OS17DN-1 5'-GC-CAATCAGGCGCTGATCTATGTCT-3', SEQ ID NO:96; and OS17DN-2 5'-CTGATCTATGTTCTGCGCTCG-GAGGT-3', SEQ ID NO:97). The OS17UP-6 and OS17UP-7 primers face upstream, while the OS17DN-1 and OS17DN-2 primers face downstream. The third genome walk yielded an amplification product of about 1.2 kb with a Nru I library

using the OS17UP-7 primer in the reverse direction. In addition, amplification products of about 4 kb and about 1.1 kb were obtained with a Hinc II and Fsp I library, respectively, using the OS17DN-2 primer in the forward direction. Sequence analysis revealed a nucleic acid sequence encoding a polypeptide (FIGS. 27-28). The complete OS17 gene had 5466 nucleotides and encoded a 1822 amino acid polypeptide. The calculated molecular weight of the OS17 polypeptide from the sequence was 201,346 (pI=5.71).

A BLAST search analysis revealed that the product of the OS17 nucleic acid has three different activities based on sequence similarity to (1) CoA-synthetases at the beginning of the OS17 sequence, (2) 3-HP dehydratases in the middle of the OS17 sequence, and (3) CoA-reductases at the end of the OS17 sequence. Thus, the OS17 clone appeared to encode a single enzyme capable of catalyzing three distinct reactions leading to the direct conversion of 3-hydroxypropionate to propionyl CoA: 3-HP→3-HP-CoA→acrylyl-CoA→propionyl-CoA.

The OS17 gene from *C. aurantiacus* was PCR amplified from chromosomal DNA using the following conditions: 94° C. for 3 minutes; 25 cycles of 94° C. for 30 seconds to denature, 54° C. for 30 seconds to anneal, and 68° C. for 6 minutes for extension; followed by 68° C. for 10 minutes for final extension. Two primers were used (OS17F 5'-GGGAAT-TCCATATGATCGACACTGCG-3', SEQ ID NO:136; and OS17R 5'-CGAAGGATCCAACGATAATCGGCTCAG-CAC-3', SEQ ID NO:137). The resulting PCR product (~5.6 Kb) was purified using Qiagen PCR purification kit (Qiagen Inc., Valencia, Calif.). The purified product was digested with NdeI and BamHI restriction enzymes, heated at 80° C. for 20 minutes to inactivate the enzymes, purified using Qiagen PCR purification kit, and ligated into a pET11a vector (Novagen, Madison, Wis.) previously digested with NdeI and BamHI enzymes. The ligation reaction was transformed into NovaBlue chemically competent cells (Novagen, Madison, Wis.) that were spread on LB agar plates supplemented with 50 µg/mL carbenicillin. Individual transformants were screened by PCR amplification of the OS17 DNA with the OS17F and OS17R primers and conditions as described above directly from colonies cells. Clones that yielded the 5.6 Kb product were used for plasmid purification with Qiagen QiaPrep Spin Miniprep Kit (Qiagen, Inc.). Resulting plasmids were transformed into *E. coli* BL21(DE3) cells, and OS17 polypeptide expression induced. The apparent molecular weight of the OS17 polypeptide according to SDS gel electrophoresis was about 190,000 Da.

To assay OS17 polypeptide function, a 100 mL culture of BL21-DE3/pET11a-OS17 cells was started using 1 mL of overnight grown culture as an inoculum. The culture was grown to an OD of 0.5-0.6 and was induced with 100 µM IPTG. After two and a half hours of induction, the cells were harvested by spinning at 8000 rpm in the floor centrifuge. The cells were washed with 10 mM Tris-HCl (pH 7.8) and passed twice through a French Press at a gauge pressure of 1000 psi. The cell debris was removed by centrifugation at 15,000 rpm. The activity of the OS17 polypeptide was measured spectrophotometrically, and the products formed during this enzymatic transformation were detected by LC/MS. The assay mix was as follows (*J. Bacteriol.*, 181:1088-1098 (1999)):

Reagent	Volume	Final Conc.
Tris-HCl (1000 mM, 7.8 pH)	10 µL	50 mM
MgCl ₂ (100 mM)	10 µL	5 mM

-continued

Reagent	Volume	Final Conc.
ATP (30 mM)	20 µL	3 mM
KCl (100 mM)	20 µL	10 mM
CoASH (5 mM)	20 µL	0.5 mM
NAD(P)H	20 µL	0.5 mM
3-hydroxypropionate	2 µL	1 mM
Protein extract (7 mg/mL)	20 (40) µL	140 µg
DI water	78 (58) µL	
Total	200 µL	

The initial rate of reaction was measured by monitoring the disappearance of NAD(P)H at 340 nm. The activity of the OS17 polypeptide was measured using 3-HP as the substrate. The units/mL of total protein was calculated using the formula set forth in Example 1. The activity of the expressed OS17 polypeptide was calculated to be 0.061 U/mL of total protein. The reaction products were purified using a Sep Pak Vac column (Waters). The column was conditioned with 1 mL methanol and washed two times with 0.5 mL 0.1% TFA. The sample was then applied to the column, and the column was washed two more times with 0.5 mL 0.1% TFA. The sample was eluted with 200 µL of 40% acetonitrile, 0.1% TFA. The acetonitrile was removed from the sample by vacuum centrifugation. The reaction products were analyzed by LC/MS.

Analyses of thioesters namely propionyl CoA, acrylyl CoA, and 3 HP CoA from the above reaction were carried out using a Waters/Micromass ZQ LC/MS instrument which had a Waters 2690 liquid chromatograph with a Waters 996 Photo-Diode Array (PDA) placed in series between the chromatograph and the single quadrupole mass spectrometer. LC separations were made using a 4.6×150 mm YMC ods-AQ (3 µm particles, 120 Å pores) reversed-phase chromatography column at room temperature. CoA esters were eluted in Buffer A (25 mM ammonium acetate, 0.5% acetic acid) with a linear gradient of buffer B (acetonitrile, 0.5% acetic acid). A flow rate of 0.25 mL/minute was used, and photodiode array UV absorbance was monitored from 200 to 400 nm. All parameters of the electrospray MS system were optimized and selected based on generation of protonated molecular ions ([M+H]⁺) of the analytes of interest and production of characteristic fragment ions. The following instrumental parameters were used for ESI-MS detection of CoA and organic acid-CoA thioesters in the positive ion mode; Extractor: 1 V; RF lens: 0 V; Source temperature: 100° C.; Desolvation temperature: 300° C.; Desolvation gas: 500 L/hour; Cone gas: 40 L/hour; Low mass resolution: 13.0; High mass resolution: 14.5; Ion energy: 0.5; Multiplier: 650. Uncertainties for mass charge ratios (m/z) and molecular masses are ±0.01%.

The enzyme assay mix from strains expressing the OS17 polypeptide exhibited peaks for propionyl CoA, acrylyl CoA, and 3-HP CoA with the propionyl CoA peak being the dominant peak. These peaks were missing in the enzyme assay mix obtained from the control strain, which carried vector pET11a without an insert. These results indicate that the OS17 polypeptide has CoA synthetase activity, CoA hydratase activity, and dehydrogenase activity.

Genome walking also was performed to obtain the complete coding sequence of OS19. Briefly, primers for conducting genome walking in both upstream and downstream directions were designed using the portion of the 151 bp CRF2-CRR2 fragment sequence that was internal to the CRF2 and CRR2 degenerate primers (OS19F1 5'-GGCTGATATCAAAGCGATGGCCAATGC-3', SEQ ID NO:98; OS19F2

5'-CCAC-GCCTATGATATGCTCACCAGTG-3', SEQ ID NO:99; OS19F3 5'-GCAAACCGG-TGATTGCTGCCGT-GAATGG-3', SEQ ID NO:100; OS19R1 5'-GCATTGGC-CAT-CGCTTTGATATCAGCC-3', SEQ ID NO:101; OS19R2 5'-CACTGGTGAGCATATC-AATAGGCGTGG-3', SEQ ID NO:102; and OS19R3 5'-CCATTCACGGCAG-CAA-TCACCGGTTTGC-3', SEQ ID NO:103). The OS19F1, OS19F2, and OS19F3 primers face downstream, while the OS19R1, OS19R2, and OS19R3 primers face upstream.

An amplification product of about 0.25 kb was obtained with the Fsp I library using the OS19R1 primer, while an amplification product of about 0.65 kb was obtained with the Pvu II library using the OS19R1 primer. In addition, an amplification product of about 0.4 kb was obtained with the Pvu II library using the OS19F3 primer. The PCR products were cloned and sequenced. Sequence analysis revealed that the sequences derived from genome walking overlapped with the CRF2-CRR2 fragment and shared sequence similarity with crotonase and hydratase sequences. The obtained sequences accounted for most of the coding sequence including the start codon.

A second genome walk was performed to obtain additional sequence using two primers (OS19F7 5'-TCATCATCGC-CAGTGAAAACGCGCAGTTCG-3', SEQ ID NO:104 and OS19F8 5'-GGATCGCGCAAACCATGCGCCAAATCAC-3', SEQ ID NO:105). The OS19F7 and OS19F8 primers face downstream.

An amplification product (about 0.7 kb) obtained from the Pvu II library was cloned and sequenced. Sequence analysis revealed that the sequence derived from the second genome walk overlapped with the sequence obtained from the first genome walk and contained the stop codon. The full-length OS19 clone was found to share sequence similarity with other sequences such as crotonase and enoyl-CoA hydratase sequences (FIGS. 32-33).




The OS19 clone was found to encode a polypeptide having 3-hydroxypropionyl-CoA dehydratase activity also referred to as acrylyl-CoA hydratase activity. The nucleic acid encoding the OS19 dehydratase from *C. aurantiacus* was PCR amplified from chromosomal DNA using the following conditions: 94° C. for 3 minutes; 25 cycles of 94° C. for 30 seconds to denature, 56° C. for 30 seconds to anneal, and 68° C. for 1 minute for extension; and 68° C. for 5 minutes for final extension. Two primers were used (OSACH3 5'-ATGAGTGAAAGAGTCTCTGGTTCTCAGC-3', SEQ ID NO:106 and OSACH2 5'-AGATCGCAATCGCTCGTGTATGTC-3', SEQ ID NO:107).

The resulting PCR product (about 1.2 kb) was separated by agarose gel electrophoresis and purified using Qiagen PCR purification kit (Qiagen Inc.; Valencia, Calif.). The purified product was ligated into pETBlue-1 using the Perfectly Blunt cloning Kit (Novagen; Madison, Wis.). The ligation reaction was transformed into NovaBlue chemically competent cells (Novagen, Madison, Wis.) that then were spread on LB agar plates supplemented with 50 µg/mL carbenicillin, 40 µg/mL IPTG, and 40 µg/mL X-Gal. White colonies were isolated and screened for the presence of inserts by restriction mapping. Isolates with the correct restriction pattern were sequenced from each end using the primer pETBlueUP and pETBlue-DOWN (Novagen) to confirm the sequence at the ligation points.

The plasmid containing the OS19 dehydratase-encoding sequence was transformed into Tuner (DE3) pLacI chemically competent cells (Novagen, Madison, Wis.), and expression from the construct tested. Briefly, a culture was grown overnight to saturation and diluted 1:20 the following morn-

ing in fresh LB medium with the appropriate antibiotics. The culture was grown at 37° C. and 250 rpm to an OD₆₀₀ of about 0.6. At this point, the culture was induced with IPTG at a final concentration of 1 mM. The culture was incubated for an additional two hours at 37° C. and 250 rpm. Aliquots were taken pre-induction and 2 hours post-induction for SDS-PAGE analysis. A band of the expected molecular weight (27,336 Daltons predicted from the sequence) was observed. This band was not observed in cells containing a plasmid lacking the nucleic acid encoding the hydratase.

Cell free extracts were prepared by growing cells as described above. The cells were harvested by centrifugation and disrupted by sonication. The sonicated cell suspension was centrifuged to remove cell debris, and the supernatant was used in the assays. The ability of the 3-hydroxypropionyl-CoA dehydratase to perform the following three reactions was measured using MALDI-TOF MS:



The assay mixture contained 50 mM Tris-HCl (pH 7.5), 1 mM CoA ester, and about 11 g cell free extract. Reactions were allowed to proceed at room temperature and were stopped by adding 1 volume 10% trifluoroacetic acid (TFA). The reaction mixtures were purified prior to MALDI-TOF MS analysis using Sep Pak Vac C₁₈ 50 mg columns (Waters, Inc.). The columns were conditioned with 1 mL methanol and then equilibrated with two washes of 1 mL 0.1% TFA. The sample was applied to the column, and the flow through was discarded. The column was washed twice with 1 mL 0.1% TFA. The sample was eluted in 200 µL 40% acetonitrile, 0.1% TFA. The acetonitrile was removed by centrifugation in vacuo. Samples were prepared for MALDI-TOF MS analysis by mixing 1:1 with 110 mM sinapinic acid in 0.1% TFA, 67% acetonitrile. The samples were allowed to air dry.

The conversion of acrylyl-CoA into 3-hydroxypropionyl-CoA catalyzed by the 3-hydroxypropionyl-CoA dehydratase was detected using the MALDI-TOF MS technique. In reaction #1, the control sample exhibited a dominant peak at a molecular weight corresponding to acrylyl-CoA (MW 823). The reaction #1 sample containing the cell extract from cells transfected with the 3-hydroxypropionyl-CoA dehydratase-encoding plasmid exhibited a dominant peak corresponding to 3-hydroxypropionyl-CoA (MW 841). This result demonstrates that the 3-hydroxypropionyl-CoA dehydratase activity catalyzes reaction #1.

To detect the conversion of 3-hydroxypropionyl-CoA into acrylyl-CoA, reaction #2 was carried out in 80% D₂O. The reaction #2 sample containing the cell extract from cells transfected with the 3-hydroxypropionyl-CoA dehydratase-encoding plasmid revealed incorporation of deuterium in the 3-hydroxypropionyl-CoA molecule. This result indicates that the 3-hydroxypropionyl-CoA dehydratase enzyme catalyzes reaction #2. In addition, the results from both #1 and #2 reactions indicate that the 3-hydroxypropionyl-CoA dehydratase enzyme can catalyze the 3-hydroxypropionyl-CoA $\leftrightarrow$ acrylyl-CoA reaction in both directions. It is noted that for both the #1 and #2 reactions, a peak was observed at MW 811, due to leftover acetyl-CoA from the synthesis of 3-hydroxypropionyl-CoA from 3-hydroxypropionate and acetyl-CoA.

The assays assessing conversion of crotonyl-CoA into 3-hydroxybutyryl-CoA also were carried out in 80% D₂O. In reaction #3, the control sample exhibited a dominant peak at

a molecular weight corresponding to crotonyl-CoA (MW 837). This result indicated that the crotonyl-CoA was not converted into other products. The reaction #3 sample containing the cell extract from cells transfected with the 3-hydroxypropionyl-CoA dehydratase-encoding plasmid exhibited a diffuse group of peaks corresponding to deuterated 3-hydroxybutyryl-CoA (MW 855 to MW 857). This result demonstrates that the 3-hydroxypropionyl-CoA dehydratase activity catalyzes reaction #3.

A series of control reactions were performed to confirm the specificity of the 3-hydroxypropionyl-CoA dehydratase. Lactyl-CoA (1 mM) was added to the reaction mixture containing 100 mM Tris (pH 7.0) both in the presence and the absence of the 3-hydroxypropionyl-CoA dehydratase. In both cases, the dominant peak observed had a molecular weight corresponding to lactyl-CoA (MW 841). This result indicates that lactyl-CoA is not affected by the presence of 3-hydroxypropionyl-CoA dehydratase activity even in the presence of D₂O meaning that the 3-hydroxypropionyl-CoA dehydratase enzyme does not attach a hydroxyl group at the alpha carbon position. The presence of 3-hydroxypropionyl-CoA in an 80% D₂O reaction mixture resulted in a shift upon addition of the 3-hydroxypropionyl-CoA dehydratase activity. In the absence of 3-hydroxypropionyl-CoA dehydratase activity, a peak corresponding to 3-hydroxypropionyl-CoA was observed in addition to a peak of MW 811. The MW 811 peak was due to leftover acetyl-CoA from the synthesis of 3-hydroxypropionyl-CoA. In the presence of 3-hydroxypropionyl-CoA dehydratase activity, a peak corresponding to deuterated 3-hydroxypropionyl-CoA was observed (MW 842) due to exchange of a hydroxyl group during the conversion of 3-hydroxypropionyl-CoA to acrylyl-CoA and vis-versa. These control reactions demonstrate that the 3-hydroxypropionyl-CoA dehydratase enzyme is active on 3-hydroxypropionyl-CoA and not active on lactyl-CoA. In addition, these results demonstrate that the product of the acrylyl-CoA reaction is 3-hydroxypropionyl-CoA not lactyl-CoA.

Example 4

Construction of Operon #1

The following operon was constructed and can be used to produce 3-HP in *E. coli* (FIG. 34). Briefly, the operon was cloned into a pET-11a expression vector under the control of a T7 promoter (Novagen, Madison, Wis.). The pET-11a expression vector is a 5677 bp plasmid that uses the ATG sequence of an NdeI restriction site as a start codon for inserted downstream sequences.

Nucleic acid molecules encoding a CoA transferase and a lactyl-CoA dehydratase were amplified from *Megasphaera elsdenii* genomic DNA by PCR. Two primers were used to amplify the CoA transferase-encoding sequence (OSNBpctF 5'-GGGAATTCC-ATATGAGAAAAGTAGAAATCATTA-CAGCTG-3', SEQ ID NO:108 and OSCTE-2 5'-GAGAG-TATACACAGTTTTCACCTCCTTTACAGCAGAGAT-3', SEQ ID NO:109), and two primers were used to amplify the lactyl-CoA dehydratase-encoding sequence (OSCTE-15'-ATCTCTGCTGTAAAGGAGGTGAAAAC-TGTGTACT-CTC-3', SEQ ID NO:110 and OSEBH-2 5'-ACGTTGATCTCCTTGTACATT-AGAGGATTTT-CGAGAAAGC-3', SEQ ID NO:111). A nucleic acid molecule encoding a 3-hydroxypropionyl-CoA dehydratase was amplified from *Chloroflexus aurantiacus* genomic DNA of by PCR using two primers (OSEBH-1 5'-GCTTTCTCGG-AAATCCTCTAATGTACAAGGAGATCAACGT-3', SEQ

ID NO:112 and OSHBR 5'-CGACGGATCCTCAACGAC-CACTGAAGITGG-3', SEQ ID NO:113).

PCR was conducted in a Perkin Elmer 2400 Thermocycler using 100 ng of genomic DNA and a mix of rTth polymerase (Applied Biosystems; Foster City, Calif.) and Pfu Turbo polymerase (Stratagene; La Jolla, Calif.) in 8:1 ratio. The polymerase mix ensured higher fidelity of the PCR reaction. The following PCR conditions were used: initial denaturation step of 94° C. for 2 minutes; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2 minutes; and a final extension at 68° C. for 5 minutes. The obtained PCR products were gel purified using a Qiagen Gel Extraction Kit (Qiagen, Inc.; Valencia, Calif.).

The CoA transferase, lactyl-CoA dehydratase (E1, E2 α subunit, and E2 β subunit), and 3-hydroxypropionyl-CoA dehydratase PCR products were assembled using PCR. The OSCTE-1 and OSCTE-2 primers as well as the OSEBH-1 and OSEBH-2 primers were complementary to each other. Thus, the complementary DNA ends could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSNBpctF and OSHBR) were added to the assembly PCR mixture, which contained 100 ng of each PCR product (i.e., the PCR products from the CoA-transferase, lactyl-CoA dehydratase, and 3-hydroxypropionyl-CoA dehydratase reactions) as well as the rTth polymerase/Pfu Turbo polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 25 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, and 68° C. for 6 minutes; and a final extension at 68° C. for 7 minutes. The assembled PCR product was gel purified and digested with restriction enzymes (NdeI and BamHI). The sites for these restriction enzymes were introduced into the assembled PCR product using the OSNBpctF (NdeI) and OSHBR (BamHI) primers. The digested PCR product was heated at 80° C. for 30 minutes to inactive the restriction enzymes and used directly for ligation into pET-11a vector.

The pET-11a vector was digested with NdeI and BamHI restriction enzymes, gel purified using a Qiagen Gel Extraction kit, treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.) and used in a ligation reaction with the assembled PCR product. The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The resulting ligation reaction was transformed into NovaBlue chemically competent cells (Novagen; Madison, Wis.) using a heat-shock method. Once heat shocked, the cells were plated on LB plates supplemented with 50 μ g/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.) and analyzed by digestion with NdeI and BamHI restriction enzymes.

Example 5

Construction of Operon #2

The following operon was constructed and can be used to produce 3-HP in *E. coli* (FIGS. 35A and B). Nucleic acid molecules encoding a CoA transferase and a lactyl-CoA dehydratase were amplified from *Megasphaera elsdenii* genomic DNA by PCR. Two primers were used to amplify the CoA transferase-encoding sequence (OSNBpctF and OSCTE-2), and two primers were used to amplify the lactyl-CoA dehydratase-encoding sequence (OSCTE-1 and OSNBpctR 5'-CGACGGATCCTTAGAGGATTT-CCGAGAAAGC-3', SEQ ID NO:114). A nucleic acid mol-

ecule encoding a 3-hydroxypropionyl-CoA dehydratase was amplified from *Chloroflexus aurantiacus* genomic DNA of by PCR using two primers (OSXNhF 5'-GGTGTCT-AGAGACAGTCCTGTCGTTTATGTAGAAGGAG-3', SEQ ID NO:115 and OSXNhR 5'-GGGAATTCCATATGCGTAACTTCCTCCTGCTATCAACGACCACTGAA-GTTGG-3', SEQ ID NO:116).

PCR was conducted in a Perkin Elmer 2400 Thermocycler using 100 ng of genomic DNA and a mix of rTth polymerase (Applied Biosystems; Foster City, Calif.) and Pfu Turbo polymerase (Stratagene; La Jolla, Calif.) in 8:1 ratio. The polymerase mix ensured higher fidelity of the PCR reaction. The following PCR conditions were used: initial denaturation step of 94° C. for 2 minutes; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2 minutes; and a final extension at 68° C. for 5 minutes. The obtained PCR products were gel purified using a Qiagen Gel Extraction Kit (Qiagen, Inc.; Valencia, Calif.).

The CoA transferase and lactyl-CoA dehydratase (E1, E2 α subunit, and E2 β subunit) PCR products were assembled using PCR. The OSCTE-1 and OSCTE-2 primers were complementary to each other. Thus, the 22 nucleotides at the end of the CoA transferase sequence and the 22 nucleotides at the beginning of the lactyl-CoA dehydratase could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSNBpctF and OSNBelR) were added to the assembly PCR mixture, which contained 100 ng of the CoA transferase PCR product, 100 ng of lactyl-CoA dehydratase PCR product, and the rTth polymerase/Pfu Turbo polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 5 minutes; and a final extension at 68° C. for 6 minutes.

The assembled PCR product was gel purified and digested with restriction enzymes (NdeI and BamHI). The sites for these restriction enzymes were introduced into the assembled PCR product using the OSNBpctF (NdeI) and OSNBelR (BamHI) primers. The digested PCR product was heated at 80° C. for 30 minutes to inactivate the restriction enzymes and used directly for ligation into a pET-11a vector.

The pET-11a vector was digested with NdeI and BamHI restriction enzymes, gel purified using a Qiagen Gel Extraction kit, treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.) and used in a ligation reaction with the assembled PCR product. The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The resulting ligation reaction was transformed into NovaBlue chemically competent cells (Novagen; Madison, Wis.) using a heat-shock method. Once heat shocked, the cells were plated on LB plates supplemented with 50 μ g/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.) and analyzed by digestion with NdeI and BamHI restriction enzymes. The digest revealed that the DNA fragment containing CoA transferase-encoding and lactyl-CoA dehydratase-encoding sequences was cloned into the pET-11a vector.

The plasmid carrying the CoA transferase-encoding and lactyl-CoA dehydratase-encoding sequences (pTD) was digested with XbaI and NdeI restriction enzymes, gel purified, and used for cloning the 3-hydroxypropionyl-CoA dehydratase-encoding product upstream of the CoA transferase-encoding sequence. Since this XbaI and NdeI digest eliminated a ribosome-binding site (RBS) from the pET-11a vector, a new homologous RBS was cloned into the plasmid

together with the 3-hydroxypropionyl-CoA dehydratase-encoding product. Briefly, the 3-hydroxypropionyl-CoA dehydratase-encoding PCR product was digested with XbaI and NdeI restriction enzymes, heated at 65° C. for 30 minutes to inactivate the restriction enzymes, and ligated into pTD. The ligation mixture was transformed into chemically competent NovaBlue cells (Novagen) that then were plated on LB plates supplemented with 50 μ g/mL carbenicillin.

Individual colonies were selected, and the plasmid DNA obtained using a Qiagen Spin Miniprep Kit. The obtained plasmids were digested with XbaI and NdeI restriction enzymes and analyzed by gel electrophoresis. pTD plasmids containing the inserted 3-hydroxypropionyl-CoA dehydratase-encoding PCR product were named pHTD. While expression of the lactyl-CoA hydratase, CoA transferase, and 3-hydroxypropionyl-CoA dehydratase sequences from pHTD was directed by a single T7 promoter, each coding sequence had an individual RBS upstream of their start codon.

To ensure the correct assembly and cloning of the lactyl-CoA hydratase, CoA transferase, and 3-hydroxypropionyl-CoA dehydratase sequences into one operon, both ends of the operon and all junctions between the coding sequences were sequenced. This DNA analysis revealed that the operon was assembled correctly.

The pHTD plasmid was transformed into BL21(DE3) cells to study the expression of the encoded sequences.

Example 6

Construction of Operons #3 and #4

Operon #3 (FIGS. 36A and B) and operon #4 (FIGS. 37A and B) each position the E1 activator at the end of the operon. Operon #3 contains a RBS between the 3-hydroxypropionyl-CoA dehydratase-encoding sequence and the E1 activator-encoding sequence. In operon #4, however, the stop codon of the 3-hydroxypropionyl-CoA dehydratase-encoding sequence is fused with the start codon of the E1 activator-encoding sequence as follows: TAGTG. The absence of the RBS in operon #4 can decrease the level of E1 activator expression.

To construct operon #3, nucleic acid molecules encoding a CoA transferase and a lactyl-CoA dehydratase were amplified from *Megasphaera elsdenii* genomic DNA by PCR. Two primers were used to amplify the CoA transferase-encoding sequence (OSNBpctF and OSHTR 5'-ACGTTGATCTCCTTCTACATTATTTTTTCAGT-CCCATG-3', SEQ ID NO:117), two primers were used to amplify the E2 α and β subunits of the lactyl-CoA dehydratase-encoding sequence (OSEIIXNF 5'-GGTGTCTAGAGTCAAAGGAGAGAA-CAAAATCATGAGTG-3', SEQ ID NO:118 and OSEIIXNR5'-GGGAATTCCATATGCGTAACTTCCTCCTGCTATTAGAGGA-TTCCGAGAAAGC-3', SEQ ID NO:119), and two primers were used to amplify the E1 activator of the lactyl-CoA dehydratase-encoding sequence (OSHRIF 5'-TCAGTG-GTCGTTGATCACGCTATAAAGAAAGGTGAAAACGTGTGTACTACTCTC-3', SEQ ID NO:120 and OSEIBR 5'-CGACGGATCCCTTTCCTTG-GAGCTCATGCTTTC-3', SEQ ID NO:121). A nucleic acid molecule encoding a 3-hydroxypropionyl-CoA dehydratase was amplified from *Chloroflexus aurantiacus* genomic DNA of by PCR using two primers (OSTHF 5'-CATGGGACTGAAAAATAATGTAGAAGGAGAT-CAACGT-3', SEQ ID NO:122 and OSEIRHR 5'-GAGAGTATACACAGTTTTCA-CCTTTCTTATAGCGTGATCAACGACCACTGA-3', SEQ ID NO:123).

PCR was conducted in a Perkin Elmer 2400 Thermocycler using 100 ng of genomic DNA and a mix of rTth polymerase (Applied Biosystems; Foster City, Calif.) and Pfu Turbo polymerase (Stratagene; La Jolla, Calif.) in 8:1 ratio. The polymerase mix ensured higher fidelity of the PCR reaction. The following PCR conditions were used: initial denaturation step of 94° C. for 2 minutes; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2 minutes; and a final extension at 68° C. for 5 minutes. The obtained PCR products were gel purified using a Qiagen Gel Extraction Kit (Qiagen, Inc.; Valencia, Calif.).

The 3-hydroxypropionyl-CoA dehydratase and E1 activator PCR products were assembled using PCR. The OSHrE1F and OSEIrHR primers were complementary to each other. Thus, the primers could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSTHF and OSE1BR) were added to the assembly PCR mixture, which contained 100 ng of the 3-hydroxypropionyl-CoA dehydratase PCR product, 100 ng of E1 activator PCR product, and the rTth polymerase/Pfu Turbo polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 1.5 minutes; and a final extension at 68° C. for 5 minutes.

The assembled PCR product was gel purified and used in a second assembly PCR with gel purified the CoA transferase PCR product. The OSTHF and OSHTR primers were complementary to each other. Thus, the complementary DNA ends could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSNBpctF and OSE1BR) were added to the second assembly PCR mixture, which contained 100 ng of the purified 3-hydroxypropionyl-CoA dehydratase/E1 PCR assembly, 100 ng of the purified CoA transferase PCR product, and the polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 3 minutes; and a final extension at 68° C. for 5 minutes.

The assembled PCR product was gel purified and digested with NdeI and BamHI restriction enzymes. The sites for these restriction enzymes were introduced into the assembled PCR products with the OSNBpctF (NdeI) and OSE1BR (BamHI) primers. The digested PCR product was heated at 80° C. for 30 minutes to inactivate the restriction enzymes and used directly for ligation into a pET11a vector.

The pET-11a vector was digested with NdeI and BamHI restriction enzymes, gel purified using a Qiagen Gel Extraction kit, treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.) and used in a ligation reaction with the assembled PCR product. The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The resulting ligation reaction was transformed into NovaBlue chemically competent cells (Novagen; Madison, Wis.) using a heat-shock method. Once heat shocked, the cells were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc.; Valencia, Calif.). The resulting plasmids carrying the CoA transferase, 3-hydroxypropionyl-CoA dehydratase, and E1 activator sequences (pTHrEI) were digested with XbaI and NdeI, purified using gel electrophoresis and a Qiagen Gel Extraction kit, and used as a vector for cloning of the E2 α subunit/E2 β subunit PCR product.

The E2 α subunit/E2 β subunit PCR product was digested with the same enzymes and ligated into the pTHrEI vector. The ligation reaction was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The ligation mixture was transformed into chemically competent NovaBlue cells (Novagen) that then were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.) and digested with XbaI and NdeI restriction enzymes for gel electrophoresis analysis. The resulting plasmids carrying the constructed operon #3 (pEIIThrEI) were transformed into BL21(DE3) cells to study the expression of the cloned sequences. Electrospray mass spectrometry assay confirmed that extracts from these cells have CoA transferase activity and 3-hydroxypropionyl-CoA dehydratase activity. Similar assays are used to confirm that extracts from these cells also have lactyl-CoA dehydratase activity.

To construct operon #4, nucleic acid molecules encoding a CoA transferase and a lactyl-CoA dehydratase were amplified from *Megasphaera elsdenii* genomic DNA by PCR. Two primers were used to amplify the CoA transferase-encoding sequence (OSNBpctF and OSHTR), two primers were used to amplify the E2 α and β subunits of the lactyl-CoA dehydratase-encoding sequence (OSEIIXNF and OSEIIXNR), and two primers were used to amplify the E1 activator of the lactyl-CoA dehydratase-encoding sequence (OSHEIF 5'-CCAACTTCAGTGGTCGTTAGTGAAAACACTGTGTAT-
ACTCTC-3', SEQ ID NO:124 and OSE1BR). A nucleic acid molecule encoding a 3-hydroxypropionyl-CoA dehydratase was amplified from *Chloroflexus aurantiacus* genomic DNA of by PCR using two primers (OSTHF and OSEIHR 5'-GAGAGTATACACAGTTTTCACATAACGAC-
CACTGAAGTTGG-3', SEQ ID NO:125).

PCR was conducted in a Perkin Elmer 2400 Thermocycler using 100 ng of genomic DNA and a mix of rTth polymerase (Applied Biosystems; Foster City, Calif.) and Pfu Turbo polymerase (Stratagene; La Jolla, Calif.) in 8:1 ratio. The polymerase mix ensured higher fidelity of the PCR reaction. The following PCR conditions were used: initial denaturation step of 94° C. for 2 minutes; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2 minutes; and a final extension at 68° C. for 5 minutes. The obtained PCR products were gel purified using a Qiagen Gel Extraction Kit (Qiagen, Inc.; Valencia, Calif.).

The 3-hydroxypropionyl-CoA dehydratase and E1 activator PCR products were assembled using PCR. The OSHEIF and OSEIHR primers were complementary to each other. Thus, the primers could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSTHF and OSE1BR) were added to the assembly PCR mixture, which contained 100 ng of the 3-hydroxypropionyl-CoA dehydratase PCR product, 100 ng of E1 activator PCR product, and the rTth polymerase/Pfu Turbo polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 1.5 minutes; and a final extension at 68° C. for 5 minutes.

The assembled PCR product was gel purified and used in a second assembly PCR with gel purified the CoA transferase PCR product. The OSTHF and OSHTR primers were complementary to each other. Thus, the complementary DNA ends could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSNBpctF and OSE1BR) were added to the second assembly PCR mixture, which

contained 100 ng of the purified 3-hydroxypropionyl-CoA dehydratase/E1 PCR assembly, 100 ng of the purified CoA transferase PCR product, and the polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 3 minutes; and a final extension at 68° C. for 5 minutes.

The assembled PCR product was gel purified and digested with NdeI and BamHI restriction enzymes. The sites for these restriction enzymes were introduced into the assembled PCR products with the OSNBpctF (NdeI) and OSEIBR (BamHI) primers. The digested PCR product was heated at 80° C. for 30 minutes to inactivate the restriction enzymes and used directly for ligation into a pET11a vector.

The pET-11a vector was digested with NdeI and BamHI restriction enzymes, gel purified using a Qiagen Gel Extraction kit, treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.) and used in a ligation reaction with the assembled PCR product. The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The resulting ligation reaction was transformed into NovaBlue chemically competent cells (Novagen; Madison, Wis.) using a heat-shock method. Once shocked, the cells were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.). The resulting plasmids carrying the CoA transferase, 3-hydroxypropionyl-CoA dehydratase, and E1 activator sequences (pTHE1) were digested with XbaI and NdeI, purified using gel electrophoresis and a Qiagen Gel Extraction kit, and used as a vector for cloning of the E2 α subunit/E2 β subunit PCR product.

The E2 α subunit/E2 β subunit PCR product was digested with the same enzymes and ligated into the pTHE1 vector. The ligation reaction was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals, Indianapolis, Ind.). The ligation mixture was transformed into chemically competent NovaBlue cells (Novagen) that then were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.) and digested with XbaI and NdeI restriction enzymes for gel electrophoresis analysis. The resulting plasmids carrying the constructed operon #4 (pEITHE1) were transformed into BL21(DE3) cells to study the expression of the cloned sequences. Electrospray mass spectrometry assays confirmed that extracts from these cells have CoA transferase activity and 3-hydroxypropionyl-CoA dehydratase activity. Similar assays are used to confirm that extracts from these cells also have lactyl-CoA dehydratase activity.

E. coli plasmid pEITHrEI carrying a synthetic 3-HP operon was digested with NruI, XbaI and BamHI restriction enzymes, XbaI-BamHI DNA fragment was gel purified with Quagen Gel Extraction Kit (Qiagen, Inc., Valencia Calif.) and used for further cloning into Bacillus vector pWH1520 (MöBiTec BmBH, Gottingen, Germany). Vector pWH1520 was digested with SpeI and BamHI restriction enzymes and gel purified with Qiagen Gel Extraction Kit. The XbaI-BamHI fragment carrying 3-HP operon was ligated into WH1520 vector at 16° C. overnight using T4 ligase. The ligation mixture was transformed into chemically competent TOP 10 cells and plated on LB plates supplemented with 50 µg/ml carbenicillin. One clone named *B. megaterium* (pBPO26) was used for assays of CoA-transferase and CoA-hydratase activities.

The assays were performed as described above for *E. Coli*. The enzymatic activity was 5 U/mg and 13 U/mg respectively.

Example 7

Construction of a Two Plasmid System

The following constructs were constructed and can be used to produce 3-HP in *E. coli* (FIGS. 38A and B). Nucleic acid molecules encoding a CoA transferase and a lactyl-CoA dehydratase were amplified from *Megasphaera elsdenii* genomic DNA by PCR. Two primers were used to amplify the CoA transferase-encoding sequence (OSNBpctF and OSHTR), two primers were used to amplify the E2 α and β subunits of the lactyl-CoA dehydratase-encoding sequence (OSEIXNF and OSEIXNR), and two primers were used to amplify the E1 activator of the lactyl-CoA dehydratase-encoding sequence (E1PROF 5'-GTTCGACAGAAATCCCAT-CAATCGCAGCAATCCCAAC-3', SEQ ID NO:126 and E1PROR 5'-TAACATGGTACCGACAGAAGCGGAC-CAGCA-AACGA-3', SEQ ID NO:127). A nucleic acid molecule encoding a 3-hydroxypropionyl-CoA dehydratase was amplified from *Chloroflexus aurantiacus* genomic DNA of by PCR using two primers (OSTHF and OSHBR 5'-CGACG-GATCCTCAACGACCA-CTGAAGTTGG-3', SEQ ID NO:128).

PCR was conducted in a Perkin Elmer 2400 Thermocycler using 100 ng of genomic DNA and a mix of rTth polymerase (Applied Biosystems; Foster City, Calif.) and Pfu Turbo polymerase (Stratagene; La Jolla, Calif.) in 8:1 ratio. The polymerase mix ensured higher fidelity of the PCR reaction. The following PCR conditions were used: initial denaturation step of 94° C. for 2 minutes; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2 minutes; and a final extension at 68° C. for 5 minutes. The obtained PCR products were gel purified using a Qiagen Gel Extraction Kit (Qiagen, Inc.; Valencia, Calif.).

The CoA transferase PCR product and the 3-hydroxypropionyl-CoA dehydratase PCR product were assembled using PCR. The OSTHF and OSHTR primers were complementary to each other. Thus, the complementary DNA ends could anneal to each other during the PCR reaction extending the DNA in both direction. To ensure the efficiency of the assembly, two end primers (OSNBpctF and OSHBR) were added to the assembly PCR mixture, which contained 100 ng of the purified CoA transferase PCR product, 100 ng of the purified 3-hydroxypropionyl-CoA dehydratase PCR product, and the polymerase mix described above. The following PCR conditions were used to assemble the products: 94° C. for 1 minute; 20 cycles of 94° C. for 30 seconds, 54° C. for 30 seconds, and 68° C. for 2.5 minutes; and a final extension at 68° C. for 5 minutes.

The assembled PCR product was gel purified and digested with NdeI and BamHI restriction enzymes. The sites for these restriction enzymes were introduced into the assembled PCR products with the OSNBpctF (NdeI) and OSHBR (BamHI) primers. The digested PCR product was heated at 80° C. for 30 minutes to inactivate the restriction enzymes and used directly for ligation into a pET11a vector.

The pET-11a vector was digested with NdeI and BamHI restriction enzymes, gel purified using a Qiagen Gel Extraction kit, treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.) and used in a ligation reaction with the assembled PCR product. The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The

resulting ligation reaction was transformed into NovaBlue chemically competent cells (Novagen; Madison, Wis.) using a heat-shock method. Once shocked, the cells were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc.; Valencia, Calif.) and digested with NdeI and BamHI restriction enzymes for gel electrophoresis analysis. The resulting plasmids carrying the CoA transferase and 3-hydroxypropionyl-CoA dehydratase (pTH) were digested with XbaI and NdeI, purified using gel electrophoresis and a Qiagen Gel Extraction kit, and used as a vector for cloning of the E2 α subunit/E2 β subunit PCR product.

The E2 α subunit/E2 β subunit PCR product digested with the same enzymes was ligated into the pTH vector. The ligation reaction was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The ligation mixture was transformed into chemically competent NovaBlue cells (Novagen) that then were plated on LB plates supplemented with 50 µg/mL carbenicillin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc.; Valencia, Calif.) and digested with XbaI and NdeI restriction enzymes for gel electrophoresis analysis. The resulting plasmids carrying the E2 α and β subunits of the lactyl-CoA dehydratase, the CoA transferase, and the 3-hydroxypropionyl-CoA dehydratase (pEIITH) were transformed into BL21(DE3) cells to study the expression of the cloned sequences.

The gel purified E1 activator PCR product was digested with EcoR and KpnI restriction enzymes, heated at 65° C. for 30 minutes, and ligated into a vector (pPROLar.A) that was digested with EcoR and KpnI restriction enzymes, gel purified using Qiagen Gel Extraction kit, and treated with shrimp alkaline phosphatase (Roche Molecular Biochemicals; Indianapolis, Ind.). The ligation was performed at 16° C. overnight using T4 ligase (Roche Molecular Biochemicals; Indianapolis, Ind.). The resulting ligation reaction was transformed into DH10B electro-competent cells (Gibco Life Technologies; Gaithersburg, Md.) using electroporation. Once electroporated, the cells were plated on LB plates supplemented with 25 µg/mL kanamycin. The plasmid DNA was purified from individual colonies using a QiaPrep Spin Miniprep Kit (Qiagen Inc., Valencia, Calif.) and digested with EcoR and KpnI restriction enzymes for gel electrophoresis analysis. The resulting plasmids carrying the E1 activator (pPROEI) are transformed into BL21(DE3) cells to study the expression of the cloned sequence.

The pPROEI and pEIITH plasmids are compatible plasmids that can be used in the same bacterial host cell. In addition, the expression from the pPROEI and pEIITH plasmids can be induced at different levels using IPTG and arabinose, allowing for the fine-tuning of the expression of the cloned sequences.

Example 8

Production of 3-HP

3-HP was produced using recombinant *E. coli* in a small-scale batch fermentation reaction. The construction of strain ALS848 (also designated as TA3476 (*J. Bacteriol.*, 143: 1081-1085 (1980))) that carried inducible T7 RNA polymerase was performed using λDE3 lysogenization kit (Novagen, Madison, Wis.) according to the manufacturer's instructions. The constructed strain was designated ALS484 (DE3). Strain ALS484(DE3) was transformed with pEIITHrEI plasmid using standard electroporation techniques.

The transformants were selected on LB/carbenicillin (50 µg/mL) plates. A single colony was used to inoculate 4 mL culture in a 15 mL culture tube. Strain ALS484(DE3) strain carrying vector pET11a was used as a control. The cells were grown at 37° C. and 250 rpm in an Innova 4230 Incubator Shaker (New Brunswick Scientific, Edison, N.J.) for eight to nine hours. This culture (3 mL) was used to start an anaerobic fermentation. Two 100 mL anaerobic cultures of ALS(DE3)/pET11a and ALS(DE3)pEIITHrEI were grown in serum bottles using LB media supplemented with 0.4% glucose, 50 µg/mL carbenicillin, and 100 mM MOPS. The cultures were grown overnight at 37° C. without shaking. The overnight grown cultures were sub-cultured in serum bottles using fresh LB media supplemented with 0.4% glucose, 50 µg/mL carbenicillin, and 100 mM MOPS. The starting OD (600) of these cultures was adjusted to 0.3. These serum bottles were incubated at 37° C. without shaking. After one hour of incubation, the cultures were induced with 100 µM IPTG. A 3 mL sample was taken from each of the serum bottles at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours. The samples were transferred into two properly labeled 2 mL microcentrifuge tubes, each containing 1.5 mL sample. The samples were spun down in a microcentrifuge centrifuge at 14000 g for 3 minutes. The supernatant was passed through a 0.45µ syringe filter, and the resulting filtrate was stored at -20° C. until further analysis. The formation of fermentation products, mainly lactate and 3-hydroxypropionate, was measured by detecting derivatized CoA esters of lactate and 3-HP using LC/MS.

The following methods were performed to convert lactate and 3-HP into their respective CoA esters. Briefly, the filtrates were mixed with CoA-reaction buffer (200 mM potassium phosphate buffer, 2 mM acetyl-CoA, and 0.1 mg/mL purified transferase) in 1:1 ratio. The reaction was allowed to proceed for 20 minutes at room temperature. The reaction was stopped by adding 1 volume of 10% TFA. The sample was purified using Sep Pak Vac columns (Waters). The column was conditioned with methanol and washed two times with 0.1% TFA. The sample was then applied to the column, and the column was washed two more times with 0.1% TFA. The sample was eluted with 40% acetonitrile, 0.1% TFA. The acetonitrile was removed from the sample by vacuum centrifugation. The samples were then analyzed by LC/MS.

Analysis of the standard CoA/CoA thioester mixtures and the CoA thioester mixtures derived from fermentation broths were carried out using a Waters/Micromass ZQ LC/MS instrument which had a Waters 2690 liquid chromatograph with a Waters 996 Photo-Diode Array (PDA) absorbance monitor placed in series between the chromatograph and the single quadrupole mass spectrometer. LC separations were made using a 4.6×150 mm YMC ODS-AQ (3 µm particles, 120 Å pores) reversed-phase chromatography column at room temperature. Two gradient elution systems were developed using different mobile phases for the separation of the CoA esters. These two systems are summarized in Table 3. Elution system 1 was developed to provide the most rapid and efficient separation of the five-component CoA/CoA thioester mixture (CoA, acetyl-CoA, lactyl-CoA, acrylyl-CoA, and propionyl-CoA), while elution system 2 was developed to provide baseline separation of the structurally isomeric esters lactyl-CoA and 3HP-CoA in addition to separation of the remaining esters listed above. In all cases, the flow rate was 0.250 mL/minute, and photodiode array UV absorbance was monitored from 200 nm to 400 nm. All parameters of the electrospray MS system were optimized and selected based on generation of protonated molecular ions ([M+H]⁺) of the analytes of interest and production of

57

characteristic fragment ions. The following instrumental parameters were used for ESI-MS detection of CoA and organic acid-CoA thioesters in the positive ion mode: Capillary: 4.0 V; Cone: 56 V; Extractor: 1 V; RF lens: 0 V; Source temperature: 100° C.; Desolvation temperature: 300° C.; Desolvation gas: 500 L/hour, Cone gas: 40 L/hour; Low mass resolution: 13.0; High mass resolution: 14.5; Ion energy: 0.5; Multiplier: 650. Uncertainties for reported mass/charge ratios (m/z) and molecular masses are $\pm 0.01\%$. Table 3 provides a summary of gradient elution systems for the separation of organic acid-Coenzyme A thioesters.

TABLE 3

System	Buffer A	Buffer B	Gradient	
			Time	Percent B
1	25 mM ammonium acetate 0.5% acetic acid	ACN 0.5% acetic acid	0	10
			40	40
			42	100
			47	100
			50	10
2	25 mM ammonium acetate 10 mM TEA 0.5% acetic acid	ACN 0.5% acetic acid	0	10
			10	10
			45	60
			50	100
			53	100
			54	10

The following methods were used to separate the derivatized 3-hydroxypropionyl-CoA, which was formed from 3-HP, from 2-hydroxypropionyl-CoA (i.e., lactyl-CoA), which was formed from lactate. Because these structural isomers have identical masses and mass spectral fragmentation behavior, the separation and identification of these analytes in a mixture depends on their chromatographic separation. While elution system 1 provided excellent separation of the CoA thioesters tested (FIGS. 46A-F), it was unable to resolve 3-HP-CoA and lactyl-CoA. An alternative LC elution system was developed using ammonium acetate and triethylamine (system 2; Table 3).

The ability of system 2 to separate 3-HP-CoA and lactyl-CoA was tested on a mixture of these two compounds. Comparing the results from a mixture of 3-HP-CoA and lactyl-CoA (FIG. 47A) to the results from lactyl-CoA only (FIG. 47B) revealed that system 2 can separate 3-HP-CoA and lactyl-CoA. The mass spectrum recorded under peak 1 (FIG. 47A insert) was used to identify peak 1 as being a hydroxypropionyl-CoA thioester when compared to FIG. 46C. In addition, comparison of FIGS. 47A and 47B as well as the mass spectra results corresponding to each peak revealed that peak 1 corresponds to 3-HP-CoA and peak 2 corresponds to lactyl-CoA.

System 2 was used to confirm that *E. coli* transfected with pEIIThrEI produced 3-HP in that 3-HP-CoA was detected. Specifically, an ion chromatogram for m/z=840 in the analysis of a CoA transferase-treated fermentation broth aliquot collected from a culture of *E. coli* containing pEIIThrEI revealed the presence of 3-HP-CoA (FIG. 48A). The CoA transferase-treated fermentation broth aliquot collected from a culture of *E. coli* lacking pEIIThrEI did not exhibit the peak corresponding to 3-HP-CoA (FIG. 48B). Thus, these results indicate that the pEIIThrEI plasmid directs the expression of polypeptides having propionyl-CoA transferase activity, lactyl-CoA dehydratase activity, and acrylyl-CoA hydratase activity. These results also indicate that expression of these polypeptides leads to the formation of 3-HP.

58

Example 9

Cloning Nucleic Acid Molecules that Encode a Polypeptide Having Acetyl CoA Carboxylase Activity

Polypeptides having acetyl-CoA carboxylase activity catalyze the first committed step of the fatty acid synthesis by carboxylation of acetyl-CoA to malonyl-CoA. Polypeptides having acetyl-CoA carboxylase activity are also responsible for providing malonyl-CoA for the biosynthesis of very-long-chain fatty acids required for proper cell function. Polypeptides having acetyl-CoA carboxylase activity can be biotin dependent enzymes in which the cofactor biotin is post-translationally attached to a specific lysine residue. The reaction catalyzed by such polypeptides consists of two discrete half reactions. In the first half reaction, biotin is carboxylated by biocarbonate in an ATP-dependent reaction to form carboxy-biotin. In the second half reaction, the carboxyl group is transferred to acetyl-CoA to form malonyl-CoA.

Prokaryotic and eukaryotic polypeptides having acetyl-CoA carboxylase activity exist. The prokaryotic polypeptide is a multi-subunit enzyme (four subunits), where each of the subunits is encoded by a different nucleic acid sequence. For example, in *E. coli*, the following genes encode for the four subunits of acetyl-CoA carboxylase:

accA: Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (GenBank® accession number M96394)

accB: Biotin carboxyl carrier protein (GenBank® accession number U18997)

accC: Biotin carboxylase (GenBank® accession number U18997)

accD: Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta (GenBank® accession number M68934)

The eukaryotic polypeptide is a high molecular weight multi-functional enzyme encoded by a single gene. For example, in *Saccharomyces cerevisiae*, the acetyl-CoA carboxylase can have the sequence set forth in GenBank® accession number M92156.

The prokaryotic type acetyl-CoA carboxylase from *E. coli* was overexpressed using T7 promoter vector pFN476 as described elsewhere (Davis et al. *J. Biol. Chem.*, 275:28593-28598 (2000)). The eukaryotic type acetyl-CoA carboxylase gene was amplified from *Saccharomyces cerevisiae* genomic DNA. Two primers were designed to amplify the acc1 gene from in *S. cerevisiae* (acc1F 5'-atagGCGGCCGACAGGAATGCTGTATGAGCGAAGAAAGCTTATT C-3', SEQ ID NO: 138 where the bold is homologous sequence, the italics is a Not I site, the underline is a RBS, and the lowercase is extra; and acc1R 5'-atgctcgcatCTCGAGTAG-CTAAATTAAATACATCAATAGTA-3', SEQ ID NO: 139 where the bold is homologous sequence, the italics is a Xho I site, and the lowercase is extra). The following PCR mix is used to amplify acc1 gene 10xpfu buffer (10 μ L), dNTP (10 mM; 2 μ L), cDNA (2 μ L), acc1F (100 μ M; 1 μ L), acc1R (100 μ M; 1 μ L), pfu enzyme (2.5 units/ μ L; 2 μ L), and DI water (82 μ L). The following protocol was used to amplify the acc1 gene. After performing PCR, the PCR product was separated on a gel, and the band corresponding to acc1 nucleic acid (about 6.7 Kb) was gel isolated using Qiagen gel isolation kit. The PCR fragment is digested with Not I and Xho I (New England BioLab) restriction enzymes. The digested PCR fragment is then ligated to pET30a which was restricted with Not I and Xho I and dephosphorylated with SAP enzyme. The *E. coli* strain DH10B was transformed with 1 μ L of the ligation mix, and the cells were recovered in 1 mL of SOC media. The transformed cells were selected on LB/kanamycin (50 μ g/ μ L)

plates. Eight single colonies are selected, and PCR was used to screen for the correct insert. The plasmid having correct insert was isolated using Qiagen Spin Mini prep kit.

To obtain a polypeptide having acetyl-CoA carboxylase activity, the plasmid pMSD8 or pET30a/acc1 overexpressing *E. coli* or *S. cerevisiae* acetyl-CoA carboxylase was transformed into Tuner pLacI chemically competent cells (Novagen, Madison, Wis.). The transformed cells were selected on LB/chloramphenicol (25 µg/mL) plus carbencillin (50 µg/mL) or kanamycin (50 µg/mL).

A crude extract of this strain can be prepared in the following manner. An overnight culture of Tuner pLacI with pMSD8 is subcultured into 200 mL (in one liter baffle culture flask) of fresh M9 media supplemented with 0.4% glucose, 1 µg/mL thiamine, 0.1% casamino acids, and 50 µg/mL carbencillin or 50 µg/mL kanamycin and 25 µg/mL chloramphenicol. The culture is grown at 37° C. in a shaker with 250 rpm agitation until it reaches an optical density at 600 nm of about 0.6. IPTG is then added to a final concentration of 100 µM. The culture is then incubated for an additional 3 hours with shaking speed of 250 rpm at 37° C. Cells are harvested by centrifugation at 8000×g and are washed one time with 0.85% NaCl. The cell pellet was resuspended in a minimal volume of 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂, 100 mM KCl, 2 mM DTT, and 5% glycerol. The cells are lysed by passing them two times through a French Pressure cell at 1000 psig pressure. The cell debris was removed by centrifugation for 20 minutes at 30,000×g.

The enzyme can be assayed using a method from Davis et al. (*J. Biol. Chem.*, 275:28593-28598 (2000)).

Example 10

Cloning a Nucleic Acid Molecule that Encodes a Polypeptide Having Malonyl-CoA Reductase Activity from *Chloroflexus aurantiacus*

A polypeptide having malonyl-CoA reductase activity was partially purified from *Chloroflexus aurantiacus* and used to obtain amino acid micro-sequencing results. The amino acid sequencing results were used to identify and clone the nucleic acid that encodes a polypeptide having malonyl-CoA reductase activity.

Biomass required for protein purification was grown in B. Braun BIostat B fermenters (B. Braun Biotech International GmbH, Melsungen, Germany). A glass vessel fitted with a water jacket for heating was used to grow the required biomass. The glass vessel was connected to its own control unit. The liquid working volume was 4 µL, and the fermenter was operated at 55° C. with 75 rpm of agitation. Carbon dioxide was occasionally bubbled through the headspace of the fermenter to maintain anaerobic conditions. The pH of the cultures was monitored using a standard pH probe and was maintained between 8.0 and 8.3. The inoculum for the fermenters was grown in two 250 mL bottles in an Innova 4230 Incubator, Shaker (New Brunswick Scientific, Edison, N.J.) at 55° C. with interior lights. The fermenters were illuminated by three 65 W plant light reflector lamps (General Electric, Cleveland, Ohio). Each lamp was placed approximately 50 cm away from the glass vessel. The media used for the inoculum and the fermenter culture was as follows per liter: 0.07 g EDTA, 1 mL micronutrient solution, 1 mL FeCl₃ solution, 0.06 g CaSO₄·2H₂O, 0.1 g MgSO₄·7H₂O, 0.008 g NaCl, 0.075 g KCl, 0.103 g KNO₃, 0.68 g NaNO₃, 0.111 g Na₂HPO₄, 0.2 g NH₄Cl, 1 g yeast extract, 2.5 g casamino acid, 0.5 g Glycyl-Glycine, and 900 mL DI water. The micronutrient solution contained the following per liter: 0.5 mL

H₂SO₄ (conc.), 2.28 g MnSO₄·7H₂O, 0.5 g ZnSO₄·7H₂O, 0.5 g H₃BO₃, 0.025 g CuSO₄·2H₂O, 0.025 g Na₂MoO₄·2H₂O, and 0.045 g CoCl₂·6H₂O. The FeCl₃ solution contained 0.2905 g FeCl₃ per liter. After adjusting the pH of the media to 8.2 to 8.4, 0.75 g/L Na₂S·9H₂O was added, the pH was readjusted to 8.2 to 8.4, and the media was filter-sterilized through a 0.22µ filter.

The fermenter was inoculated with 500 mL of grown culture. The fermentation was stopped, and the biomass was harvested after the cell density was about 0.5 to 0.6 units at 600 nm.

The cells were harvested by centrifugation at 5000×g (Beckman JLA 8.1000 rotor) at 4° C., washed with 1 volume of ice cold 0.85% NaCl, and centrifuged again. The cell pellet was resuspended in 30 mL of ice cold 100 mM Tris-HCl (pH 7.8) buffer that was supplemented with 2 mM DTT, 5 mM MgCl₂, 0.4 mM PEFABLOC (Roche Molecular Biochemicals, Indianapolis, Ind.), 1% streptomycin sulfate, and 2 tablets of Complete EDTA-free protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, Ind.). The cell suspension was lysed by passing the suspension, three times, through a 50 mL French Pressure Cell operated at 1600 psi (gauge reading). Cell debris was removed by centrifugation at 30,000×g (Beckman JA 25.50 rotor). The crude extract was filtered prior to chromatography using a 0.2 µm HT Tuffryn membrane syringe filter (Pall Corp., Ann Arbor, Mich.). The protein concentration of the crude extract was 29 mg/mL, which was determined using the BioRad Protein Assay according to the manufacturer's microassay protocol. Bovine gamma globulin was used for the standard curve determination. This assay was based on the Bradford dye-binding procedure (Bradford, *Anal. Biochem.*, 72:248 (1976)).

Before starting the protein purification, the following assay was used to determine the activity of malonyl-CoA reductase in the crude extract. A 50 µL aliquot of the cell extract (29 mg/mL) was added to 10 µL 1M Tris-HCl (final concentration in assay 100 mM), 10 µL 10 mM malonyl CoA (final concentration in assay 1 mM), 5.5 µL 5.5 mM NADPH (final concentration in assay 0.3 mM), and 24.5 µL DI water in a 96 well UV transparent plate (Corning, N.Y.). The enzyme activity was measured at 45° C. using SpectraMAX Plus 96 well plate reader (Molecular devices Sunnyvale, Calif.). The activity of malonyl-CoA reductase was monitored by measuring the disappearance of NADPH at 340 nm wavelength. The crude extract exhibited malonyl-CoA reductase activity.

The 5 mL (total 145 mg) protein cell extract was diluted with 20 mL buffer A (20 mM ethanolamine (pH 9.0), 5 mM MgCl₂, 2 mM DTT). The chromatographic protein purification was conducted using a BioLogic protein purification system (BioRad Hercules, Calif.). The 25 mL of cell suspension was loaded onto a UNO Q-6 ion-exchange column that had been equilibrated with buffer A at a rate of 1 mL/minute. After sample loading, the column was washed with 2.5 times column volume of buffer A at a rate of 2 mL/minute. The proteins were eluted with a linear gradient of NaCl in buffer A from 0-0.33 M in 25 Column volume. During the entire chromatographic separation, three mL fractions were collected. The collection tubes contained 50 µL of Tris-HCl (pH 6.5) so that the pH of the eluted sample dropped to about pH 7. Major chromatographic peaks were detected in the region that corresponded to fractions 18 to 21 and 23 to 30. A 200 µL sample was taken from these fractions and concentrated in a microcentrifuge at 4° C. using a Microcon YM-10 columns (Millipore Corp., Bedford, Mass.) as per manufacture's instructions. To each of the concentrated fraction, buffer A-Tris (100 mM Tris-HCl (pH 7.8), 5 mM MgCl₂, 2 mM DTT) was added to bring the total volume to 100 µL. Each of

these fractions was tested for the malonyl-CoA reductase activity using the spectrophotometric assay described above. The majority of specific malonyl CoA activity was found in fractions 18 to 21. These fractions were pooled together, and the pooled sample was desalted using PD-10 column (Amersham Pharmacia Piscataway, N.J.) as per manufacture's instructions.

The 10.5 mL of desalted protein extract was diluted with buffer A-Tris to a volume of 25 mL. This desalted diluted sample was applied to a 1 mL HiTrap Blue column (Amersham Pharmacia Piscataway, N.J.) which was equilibrated with buffer A-Tris. The sample was loaded at a rate of 0.1 mL/minute. Unbound proteins were washed with 2.5 CV buffer A-Tris. The protein was eluted with 100 mM Tris (pH 7.8), 5 mM MgCl₂, 2 mM DTT, 2 mM NADPH, and 1 M NaCl. During this separation process, one mL fractions were collected. A 200 μ L sample was drawn from fractions 49 to 54 and concentrated. Buffer A-Tris was added to each of the concentrated fractions to bring the total volume to 100 μ L. Fractions were assayed for enzyme activity as described above. The highest specific activity was observed in fraction 51. The entire fraction 51 was concentrated as described above, and the concentrated sample was separated on an SDS-PAGE gel.

Electrophoresis was carried out using a Bio-Rad Protean II minigel system and pre-cast SDS-PAGE gels (4-15%), or a Protean II XI system and 16 cm $\times$ 20 cm $\times$ 1 mm SDS-PAGE gels (10%) cast as per the manufacturer's protocol. The gels were run according to the manufacturer's instructions with a running buffer of 25 mM Tris-HCl (pH 8.3), 192 mM glycine, and 0.1% SDS.

A gel thickness of 1 mm was used to run samples from fraction 51. Protein from fraction 51 was loaded onto 10% SDS-PAGE (3 lanes, each containing 75.1 g of total protein). The gels were stained briefly with Coomassie blue (Bio-Rad, Hercules, Calif.) and then destained to a clear background with a 10% acetic acid and 20% methanol solution. The staining revealed a band of about 130 to 140 KDa.

The protein band of about 130-140 KDa was excised with no excess unstained gel present. An equal area gel without protein was excised as a negative control. The gel slices were placed in uncolored microcentrifuge tubes, prewashed with 50% acetonitrile in HPLC-grade water, washed twice with 50% acetonitrile, and shipped on dry ice to Harvard Microchemistry Sequencing Facility, Cambridge, Mass.

After in-situ enzymatic digestion of the polypeptide sample with trypsin, the resulting polypeptides were separated by micro-capillary reverse-phase HPLC. The HPLC was directly coupled to the nano-electrospray ionization source of a Finnigan LCQ quadrupole ion trap mass spectrometer (μ LC/MS/MS). Individual sequence spectra (MS/MS) were acquired on-line at high sensitivity for the multiple polypeptides separated during the chromatographic run. The MS/MS spectra of the polypeptides were correlated with known sequences using the algorithm Sequest developed at the University of Washington (Eng et al., *J. Am. Soc. Mass Spectrom.*, 5:976 (1994)) and programs developed at Harvard (Chittum et al., *Biochemistry*, 37:10866 (1998)). The results were reviewed for consensus with known proteins and for manual confirmation of fidelity.

A similar purification procedure was used to obtain another sample (protein 1 sample) that was subjected to the same analysis that was used to evaluate the fraction 51 sample.

The polypeptide sequence results indicated that the polypeptides obtained from both the fraction 51 sample and the protein 1 sample had similarity to the six (764, 799, 859, 923, 1090, 1024) contigs sequenced from the *C. aurantiacus*

genome and presented on the Joint Genome Institute's web site (<http://www.jgi.doe.gov/>). The 764 contig was the most prominent of the six with about 40 peptide sequences showing similarity. BLASTX analysis of each of these contigs on the GenBank web site (<http://www.ncbi.nlm.nih.gov/BLAST/>) indicated that the DNA sequence of the 764 contig (4201 bases) encoded for polypeptides that had a dehydrogenase/reductase type activity. Close inspection of the 764 contig, however, revealed that this contig did not have an appropriate ORF that would encode for a 130-140 KDa polypeptide.

BASLTX analysis also was conducted using the other five contigs. The results of this analysis were as follows. The 799 contig (3173 bases) appeared to encode polypeptides having phosphate and dehydrogenase type activities. The 859 contig (5865 bases) appeared to encode polypeptides having synthetase type activities. The 923 contig (5660 bases) appeared to encode polypeptides having elongation factor and synthetase type activities. The 1090 contig (15201 bases) appeared to encode polypeptides having dehydrogenase/reductase and cytochrome and sigma factor activities. The 1024 contig (12276 bases) appeared to encode polypeptides having dehydrogenase and decarboxylase and synthetase type activities. Thus, the 859 and 923 contigs were eliminated from any further analysis.

The results from the BLASTX analysis also revealed that the dehydrogenase found in the 1024 contig was most likely an inositol monophosphate dehydrogenase. Thus, the 1024 contig was eliminated as a possible candidate that might encode for a polypeptide having malonyl-CoA reductase activity. The 799 contig also was eliminated since this contig is part of the OS17 polypeptide described above.

This narrowed down the search to 2 contigs, the 764 and 1090 contigs. Since the contigs were identified using the same protein sample and the dehydrogenase activities found in these contigs gave very similar BLASTX results, it was hypothesized that they are part of the same polypeptide. Additional evidence supporting this hypothesis was obtained from the discovery that the 764 and 1090 contigs are adjacent to each other in the *C. aurantiacus* genome as revealed by an analysis of scaffold data provided by the Joint Genome Institute. Sequence similarity and assembly analysis, however, revealed no overlapping sequence between these two contigs, possibly due to the presence of gaps in the genome sequencing.

The polypeptide sequences that belonged to the 764 and 1090 contigs were mapped. Based on this analysis, an appropriate coding frame and potential start and stop codons were identified. The following PCR primers were designed to PCR amplify a fragment that encoded for a polypeptide having malonyl-CoA reductase activity: PRO140F 5'-ATGGC-GACGGGCGAGTCCATGAG-3', SEQ ID NO:153; PRO140R 5'-GGACACGAAGAAGAGGGGCGACAC-3', SEQ ID NO:154; and PRO140UP 5'-GAACTGTCTGGAG-TAAGGCTGTC-3', SEQ ID NO:155. The PRO140F primer was designed based on the sequence of the 1090 contig and corresponds to the start of the potential start codon. The twelfth base was change from G to C to avoid primer-dimer formation. This change does not change the amino acid that was encoded by the codon. The PRO140R primer was designed based on sequence of the 764 contig and corresponds to a region located about 1 kB downstream from the potential stop codon. The PRO140UPF primer was designed based on sequence of the 1090 contig and corresponds to a region located about 300 bases upstream of potential start codon.

63

Genomic *C. aurantiacus* DNA was obtained. Briefly, *C. aurantiacus* was grown in 50 mL cultures for 3 to 4 days. Cells were pelleted and washed with 5 mL of a 10 mM Tris solution. The genomic DNA was then isolated using the gram positive bacteria protocol provided with Gentra Genomic “Puregene” DNA isolation kit (Gentra Systems, Minneapolis, Minn.). The cell pellet was resuspended in 1 mL Gentra Cell Suspension Solution to which 14.2 mg of lysozyme and 4 μ L of 20 mg/mL proteinase K solution was added. The cell suspension was incubated at 37° C. for 30 minutes. The precipitated genomic DNA was recovered by centrifugation at 3500 g for 25 minutes and air-dried for 10 minutes. The genomic DNA was suspended in an appropriate amount of a 10 mM Tris solution and stored at 4° C.

Two PCR reactions were set-up using *C. aurantiacus* genomic DNA as template as follows:

PCR Reaction #1	PCR program		
3.3 X rTH polymerase Buffer	30 μ L	94° C. 2 minutes	
Mg(OAC) (25 mM)	4 μ L	29 cycles of:	
dNTP Mix (10 mM)	3 μ L	94° C. 30 seconds	
PRO140F (100 μ M)	2 μ L	63° C. 45 seconds	
PRO140R (100 μ M)	2 μ L	68° C. 4.5 minutes	
Genomic DNA (100 ng/mL)	1 μ L	68° C. 7 minutes	
rTH polymerase (2 U/ μ L)	2 μ L	4° C. Until further use	
pfu polymerase (2.5 U/ μ L)	0.25 μ L		
DI water	55.75 μ L		
Total	100 μ L		

PCR Reaction #2	PCR program		
3.3 X rTH polymerase Buffer	30 μ L	94° C. 2 minutes	
Mg(OAC) (25 mM)	4 μ L	29 cycles of:	
dNTP Mix (10 mM)	3 μ L	94° C. 30 seconds	
PRO140UPF (100 μ M)	2 μ L	60° C. 45 seconds	
PRO140R (100 μ M)	2 μ L	68° C. 4.5 minutes	
Genomic DNA (100 ng/mL)	1 μ L	68° C. 7 minutes	
rTH polymerase (2 U/ μ L)	2 μ L	4° C. Until further use	
pfu polymerase 2.5 U/ μ L)	0.25 μ L		
DI water	55.75 μ L		
Total	100 μ L		

The products from both PCR reactions were separated on a 0.8% TAE gel. Both PCR reactions produced a product of 4.7 to 5 Kb in size. This approximately matched the expected size of a nucleic acid molecule that could encode a polypeptide having malonyl-CoA reductase activity.

Both PCR products were sequenced using sequencing primers (1090Fseq 5'-GATTCCGTATGTCACCCCTA-3', SEQ ID NO:156; and 764Rseq 5'-CAGGCGACTGGCAAT-CACAA-3', SEQ ID NO:157). The sequence analysis revealed a gap between the 764 and 1090 contigs. The nucleic acid sequence between the sequences from the 764 and 1090 contigs was greater than 300 base pairs in length (FIG. 51). In addition, the sequence analysis revealed an ORF of 3678 bases that showed similarities to dehydrogenase/reductase type enzymes (FIGS. 52A-D). The amino acid sequence encoded by this ORF is 1225 amino acids in length (FIG. 50). Also, BLASTP analysis of the amino acid sequence encoded by this ORF revealed two short chain dehydrogenase domains (adh type). These results are consistent with a polypeptide having malonyl-CoA reductase activity since such an enzyme involves two reduction steps for the conversion of malonyl

64

CoA to 3-HP. Further, the computed MW of the polypeptide was determined to be about 134 KDa.

PCR was conducted using the PRO140F/PRO140R primer pair, *C. aurantiacus* genomic DNA, and the protocol described above as PCR reaction #1. After the PCR was completed, 0.25 U of Taq polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.) was added to the PCR mix, which was then incubated at 72° C. for 10 minutes. The PCR product was column purified using Qiagen PCR purification kit (Qiagen Inc., Valencia, Calif.). The purified PCR product was then TOPO cloned into expression vector pCRT7/CT as per manufacture's instructions (Invitrogen, Carlsbad, Calif.). TOP10 F' chemical competent cells were transformed with the TOPO ligation mix as per manufacture's instructions (Invitrogen, Carlsbad, Calif.). The cells were recovered for half an hour, and the transformants were selected on LB/ampicillin (100 μ g/mL) plates. Twenty single colonies were selected, and the plasmid DNA was isolated using Qiagen spin Mini prep kit (Qiagen Inc., Valencia, Calif.).

Each of these twenty clones were tested for correct orientation and right insert size by PCR. Briefly, plasmid DNA was used as a template, and the following two primers were used in the PCR amplification: PCRT7 5'-GAGACCACAACG-GTTTCCCTCTA-3', SEQ ID NO:158; and PRO140R 5'-GGACACGAAGAACAGGGCGACAC-3', SEQ ID NO:159. The following PCR reaction mix and program was used:

PCR Reaction	PCR program		
3.3 X rTH polymerase Buffer	7.5 μ L	94° C. 2 minutes	
Mg(OAC) (25 mM)	1 μ L	25 cycles of:	
dNTP Mix (10 mM)	0.5 μ L	94° C. 30 seconds	
PCRT7 (100 μ M)	0.125 μ L	55° C. 45 seconds	
PRO140R (100 μ M)	0.125 μ L	68° C. 4 minutes	
Plasmid DNA	0.5 μ L	68° C. 7 minutes	
rTH polymerase (2 U/ μ L)	0.5 μ L	4° C. Until further use	
DI water	14.75 μ L		
Total	25 μ L		

Out of twenty clone tested, only one clone exhibited the correct insert (Clone #P-10). Chemical competent cells of BL21(DE3)pLysS (Invitrogen, Carlsbad, Calif.) were transformed with 2 μ L of the P-10 plasmid DNA as per the manufacture's instructions. The cells were recovered at 37° C. for 30 minutes and were plated on LB ampicillin (100 μ g/mL) and chloramphenicol (25 μ g/mL).

A 20 mL culture of BL21(DE3)pLysS/P-10 and a 20 mL control culture of BL21(DE3)pLysS was incubated overnight. Using the overnight cultures as an inoculum, two 100 mL BL21(DE3)pLysS/P-10 clone cultures and two control strain cultures (BL21(DE3)pLysS) were started. All the cultures were induced with IPTG when they reached an OD of about 0.5 at 600 nm. The control strain culture was induced with 10 μ M IPTG or 100 μ M IPTG, while one of the BL21 (DE3)pLysS/P-10 clone cultures was induced with 10 μ M IPTG and the other with 100 μ M IPTG. The cultures were grown for 2.5 hours after induction. Aliquots were taken from each of the culture flasks before and after 2.5 hours of induction and separated using 4-15% SDS-PAGE to analyze polypeptide expression. In the induced BL21 (DE3)pLysS/P-10 samples, a band corresponding to a polypeptide having a molecular weight of about 135 KDa was observed. This band was absent in the control strain samples and in samples taken before IPTG induction.

65

To assess malonyl-CoA reductase activity, BL21(DE3) pLysS/P-10 and BL21(DE3)pLysS cells were cultured and then harvested by centrifugation at 8,000×g (Rotor JA 16.250, Beckman Coulter, Fullerton, Calif.). Once harvested, the cells were washed once with an equal volume of a 0.85% NaCl solution. The cell pellets were resuspended into 100 mM Tris-HCl buffer that was supplemented with 5 mM Mg₂Cl and 2 mM DTT. The cells were disrupted by passing twice through a French Press Cell at 1,000 psi pressure (Gauge value). The cell debris was removed by centrifugation at 30,000×g (Rotor JA 25.50, Beckman Coulter, Fullerton, Calif.). The cell extract was maintained at 4° C. or on ice until further use.

Activity of malonyl-CoA reductase was measured at 37° C. for both the control cells and the IPTG-induced cells. The activity of malonyl-CoA reductase was monitored by observing the disappearance of added NADPH as described above. No activity was found in the cell extract of the control strain, while the cell extract from the IPTG-induced BL21(DE3) pLysS/P-10 cells displayed malonyl-CoA reductase activity with a specific activity calculated to be about 0.0942 μmole/minute/mg of total protein.

Malonyl-CoA reductase activity also was measured by analyzing 3-HP formation from malonyl CoA using the following reaction conducted at 37° C.:

	Volume	Final conc.
Tris HCl (1M)	10 μL	100 mM
Malonyl CoA (10 mM)	40 μL	4 mM
NADPH (10 mM)	30 μL	3 mM
Cell extract	20 μL	
Total	100 μL	

The reaction was carried out at 37° C. for 30 minutes. In the control reaction, a cell extract from BL21(DE3)pLysS was added to a final concentration of 322 mg total protein. In the experimental reaction mix, a cell extract from BL21(DE3) pLysS/P-10 was added to a final concentration of 226 mg of total protein. The reaction mixtures were frozen at -20° C. until further analysis.

Chromatographic separation of the components in the reaction mixtures was performed using a HPX-87H (7.8×300 mm) organic acid HPLC column (BioRad Laboratories, Hercules, Calif.). The column was maintained at 60° C. Mobile phase composition was HPLC grade water pH to 2.5 using trifluoroacetic acid (TFA) and was delivered at a flow rate of 0.6 mL/minute.

Detection of 3-HP in the reaction samples was accomplished using a Waters/Micromass ZQ LC/MS instrument consisting of a Waters 2690 liquid chromatograph (Waters Corp., Milford, Mass.) with a Waters 996 Photo-diode Array (PDA) absorbance monitor placed in series between the chromatograph and the single quadrupole mass spectrometer. The ionization source was an Atmospheric Pressure Chemical Ionization (APCI) ionization source. All parameters of the APCI-MS system were optimized and selected based on the generation of the protonated molecular ion ([M+H])⁺ of 3-HP. The following parameters were used to detect 3-HP in the positive ion mode: Corona: 10 μA; Cone: 20V; Extractor: 2V; RF lens: 0.2V; Source temperature: 100° C.; APCI Probe temperature: 300° C.; Desolvation gas: 500 L/hour, Cone gas: 50 L/hour; Low mass resolution: 15; High mass resolution: 15; Ion energy: 1.0; Multiplier: 650. Data was collected in Selected Ion Reporting (SIR) mode set at m/z=90.9.

66

Both the control reaction sample and the experimental reaction sample were probed for presence of 3-HP using the HPLC-mass spectroscopy technique. In the control samples, no 3-HP peak was observed, while the experimental sample exhibited a peak that matched the retention and the mass of 3-HP.

Example 11

Constructing Recombinant Cells that Produce 3-HP

A pathway to make 3-hydroxypropionate directly from glucose via acetyl CoA is presented in FIG. 44. Most organisms such as *E. coli*, *Bacillus*, and yeast produce acetyl CoA from glucose via glycolysis and the action of pyruvate dehydrogenase. In order to divert the acetyl CoA generated from glucose, it is desirable to overexpress two genes, one encoding for acetyl CoA carboxylase and the other encoding malonyl-CoA reductase. As an example, these genes are expressed in *E. coli* through a T7 promoter using vectors pET30a and pFN476. The vector pET30a has a pBR ori and kanamycin resistance, while pFN476 has pSC101 ori and uses carbamycin resistance for selection. Because these two vectors have compatible ori and different markers they can be maintained in *E. coli* at the same time. Hence, the constructs used to engineer *E. coli* for direct production of 3-hydroxypropionate from glucose are pMSD8 (pFN476/accABCD) (Davis et al., *J. Biol. Chem.*, 275:28593-28598, 2000) and pET30a/malonyl-CoA reductase or pET30a/acc1 and pFN476/malonyl-CoA reductase. The constructs are depicted in FIG. 45.

To test the production of 3-hydroxypropionate from glucose, *E. coli* strain Tuner pLacI carrying plasmid pMSD8 (pFN476/accABCD) and pET30a/malonyl-CoA reductase or pET30a/acc1 and pFN476/malonyl-CoA reductase are grown in a B. Braun BIOSTAT B fermenter. A glass vessel fitted with a water jacket for heating is used to conduct this experiment. The fermenter working volume is 1.5 L and is operated at 37° C. The fermenter is continuously supplied with oxygen by bubbling sterile air through it at a rate of 1 vvm. The agitation is cascaded to the dissolve oxygen concentration which is maintained at 40% DO. The pH of the liquid media is maintained at 7 using 2 N NaOH. The *E. coli* strain is grown in M9 media supplemented with 1% glucose, 1 μg/mL thiamine, 0.1% casamino acids, 10 μg/mL biotin, 50 μg/mL carbencillin, 50 μg/mL kanamycin, and 25 μg/mL chloramphenicol. The expression of the genes is induced when the cell density reached 0.5 OD (600 nm) by adding 100 μM IPTG. After induction, samples of 2 mL volume are taken at 1, 2, 3, 4, and 8 hours. In addition, at 3 hours after induction, a 200 mL sample is taken to make a cell extract. The 2 mL samples are spun, and the supernatant is used to analyze products using LC/MS technique. The supernatant is stored at -20° C. until further analysis.

The extract is prepared by spinning the 200 mL of cell suspension at 8000 g and washing the cell pellet with 50 mL of 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂, 100 mM KCl, 2 mM DTT, and 5% glycerol. The cell suspension is spun again at 8000 g, and the pellet is resuspended into 5 mL of 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂, 100 mM KCl, 2 mM DTT, and 5% glycerol. The cells are disrupted by passing twice through a French Press at 1000 pisp. The cell debris is removed by centrifugation for 20 minutes at 30,000 g. All the operations are conducted at 4° C. To demonstrated in vitro formation of 3-hydroxypropionate using this recombinant cell extract, the following reaction of 200 μL is conducted at 37° C. The reaction mix is as follows: Tris HCl (pH 8.0; 100 mM), ATP (1 mM), MgCl₂ (5 mM), KCl (100 mM), DTT (5

67

mM), NaHCO₃ (40 mM), NADPH (0.5 mM), acetyl CoA (0.5 mM), and cell extract (0.2 mg). The reaction is stopped after 15 minutes by adding 1 volume of 10% trifluoroacetic acid (TFA). The products of this reaction are detected using an LC/MS technique.

The detection and analysis for the presence of 3-hydroxypropionate in the supernatant and the in vitro reaction mixture is carried out using a Waters/Micromass ZQ LC/MS instrument. This instrument consists of a Waters 2690 liquid chromatograph with a Waters 2410 refractive index detector placed in series between the chromatograph and the single quadrupole mass spectrometer. LC separations are made using a Bio-Rad Aminex 87-H ion-exchange column at 45° C. Sugars, alcohol, and organic acid products are eluted with 0.015% TFA buffer. For elution, the buffer is passed at a flow rate of 0.6 mL/minute. For detection and quantification of 3-hydroxypropionate, a sample obtained from TCI, America (Portland, Oreg.) is used as a standard.

Example 12

Cloning of Propionyl-CoA Transferase, Lactyl-CoA Dehydratase (LDH), and a Hydratase (OS19) for Expression in *Saccharomyces cerevisiae*

The pESC Yeast Epitope Tagging Vector System (Stratagene, La Jolla, Calif.) was used in cloning the genes involved in 3-hydroxypropionic acid production via lactic acid. The pESC vectors each contain GAL1 and GAL10 promoters in opposing directions, allowing the expression of two genes from each vector. The GAL1 and GAL10 promoters are repressed by glucose and induced by galactose. Each of the four available pESC vectors has a different yeast-selectable marker (HIS3, TRP1, LEU2, URA3) so multiple plasmids can be maintained in a single strain. Each cloning region has a polylinker site for gene insertion, a transcription terminator, and an epitope coding sequence for C-terminal or N-terminal epitope tagging of expressed proteins. The pESC vectors also have a ColE1 origin of replication and an ampicillin resistance gene to allow replication and selection in *E. coli*. The following vector/promoter/nucleic acid combinations were constructed:

Vector	Promoter	Polypeptide	Source of nucleic acid
pESC-Trp	GAL1	OS19 hydratase	<i>Chloroflexus aurantiacus</i>
	GAL10	E1	<i>Megasphaera elsdenii</i>
pESC-Leu	GAL1	E2α	<i>Megasphaera elsdenii</i>
	GAL10	E2β	<i>Megasphaera elsdenii</i>
pESC-His	GAL1	D-LDH	<i>Escherichia coli</i>
	GAL10	PCT	<i>Megasphaera elsdenii</i>

The primers used were as follows:

OS19APAF: (SEQ ID NO: 164)
 5' - ATAGGGCCCGAGAGATCAAACCATGGGTGAAGAGTCT -
 CTGGTTC - 3'
 OS19SALR: (SEQ ID NO: 165)
 5' - CCTCTGCTACAGTCGACACAACGACCACTGAAGTTG -
 GGAG - 3'

68

-continued

OS19KPNR: (SEQ ID NO: 166)
 5' - AGTCTGCTATCGGTACCTCAACGACCACTGAAGTTG -
 GGAG - 3'
 EINOTF: (SEQ ID NO: 167)
 5' - ATAGCGGCCGCATAATGGTACTCTCGGAATCGACG -
 TTGG - 3'
 EICLAR: (SEQ ID NO: 168)
 5' - CCCCATCGATACATATTTCTTGATTTTATCATAAGCA -
 ATC - 3'
 EIIαAPAF: (SEQ ID NO: 169)
 5' - CCAGGGCCCATATGGGTGAAGAAAAACAGTAGA -
 TATTG - 3'
 EIIαSALR: (SEQ ID NO: 170)
 5' - GGTAGACTTGTCGACGTAGTGGTTTCCTCCTTCATT -
 GG - 3'
 EIIβNOTF: (SEQ ID NO: 171)
 5' - ATAGCGGCCGCATAATGGGTGAGATCGACGAACCTTA -
 TCAG - 3'
 EIIβSPER: (SEQ ID NO: 172)
 5' - AGGTTCAACTAGTTCGTAGAGGATTTCCGAGAAAGC -
 CTG - 3'
 LDHAPAF: (SEQ ID NO: 173)
 5' - CTAGGGCCCATATGGAACCTGCGGTTTATAG -
 CAC - 3'
 LDHXHOR: (SEQ ID NO: 174)
 5' - ACTTCTCGAGTTAAACCAAGTTCGTTCGGGCA -
 GGT - 3'
 PCTSPEF: (SEQ ID NO: 175)
 5' - GGGACTAGTATAATGGGAAAAGTAGAAATCAT -
 TACAG - 3'
 PCTPACR: (SEQ ID NO: 176)
 5' - CGGCTTAATTAACAGCAGAGATTTATTTTTCAT -
 GTCC - 3'

All restriction enzymes were obtained from New England Biolabs, Beverly, Mass. All plasmid DNA preparations were done using QIAprep Spin Miniprep Kits, and all gel purifications were done using QIAquick Gel Extraction Kits (Qiagen, Valencia, Calif.).

A. Construction of the pESC-Trp/OS19 Hydratase Vector

Two constructs in pESC-Trp were made for the OS19 nucleic acid from *C. aurantiacus*. One of these constructs utilized the Apa I and Sal I restriction sites of the GAL1 multiple cloning site and was designed to include the c-myc epitope. The second construct utilized the Apa I and Kpn I sites and thus did not include the c-myc epitope sequence.

Six µg of pESC-Trp vector DNA was digested with the restriction enzyme Apa I and the digest was purified using a QIAquick PCR Purification Column. Three µg of the Apa I-digested vector DNA was then digested with the restriction enzyme Kpn I, and 3 µg was digested with Sal I. The double-

digested vector DNAs were separated on a 1% TAE-agarose gel, purified, dephosphorylated with shrimp alkaline phosphatase (Roche Biochemical Products, Indianapolis, Ind.), and purified with a QIAquick PCR Purification Column. The nucleic acid encoding the *Chloroflexus aurantiacus* polypeptide having hydratase activity (OS19) was amplified from genomic DNA using the PCR primer pair OS19APAF and OS19SALR and the primer pair OS19APAF and OS19 KPNR. OS19APAF was designed to introduce an Apa I restriction site and a translation initiation site (ACCATGG) at the beginning of the amplified fragment. The OS19 KPNR primer was designed to introduce a Kpn I restriction site at the end of the amplified fragment and to contain the translational stop codon for the hydratase gene. OS19SALR introduces a Sal I site at the end of the amplified fragment and has an altered stop codon so that translation continues in-frame through the vector c-myc epitope. The PCR mix contained the following: IX Expand PCR buffer, 100 ng *C. aurantiacus* genomic DNA, 0.2 µM of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase (Roche) in a final volume of 100 µL. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30 seconds, 57° C. for 1 minute, and 72° C. for 2.25 minutes; 24 cycles of 94° C. for 30 seconds, 62° C. for 1 minute, and 72° C. for 2.25 minutes; and a final extension for 7 minutes at 72° C. The amplification product was then separated by gel electrophoresis using a 1% TAE-agarose gel. A 0.8 Kb fragment was excised from the gel and purified for each primer pair. The purified fragments were digested with Kpn I or Sal I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Apa I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

50-60 ng of the digested PCR product containing the nucleic acid encoding the *C. aurantiacus* polypeptide having hydratase activity (OS19) and 50 ng of the prepared pESC-Trp vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One µL of the ligation reaction was used to electroporate 40 µL of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LB plates containing 100 µg/mL of carbenicillin (LBC). Individual colonies were screened using colony PCR with the appropriate PCR primers. Individual colonies were suspended in about 25 µL of 10 mM Tris, and 2 µL of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 µL of the heated cells was used in a 25 µL PCR reaction. The PCR mix contained the following: 1×Taq buffer, 0.2 µM each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the nucleic acid from genomic DNA.

Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR. A construct with a confirmed sequence was transformed into *S. cerevisiae* strain YPH500 using a Frozen-EZ Yeast Transformation II™ Kit (Zymo Research, Orange, Calif.). Transformation reactions were plated on SC-Trp media (see Stratagene pESC Vector Instruction Manual for media recipes). Individual yeast colonies were screened for the presence of the OS19 nucleic acid by

colony PCR. Colonies were suspended in 20 µL of Y-Lysis Buffer (Zymo Research) containing 5 units of zymolase and heated at 37° C. for 10 minutes. Three µL of this suspension was then used in a 25 µL PCR reaction using the PCR reaction mixture and program described for the colony screen of the *E. coli* transformants. The pESC-Trp vector was also transformed into YPH500 for use as a hydratase assay control and transformants were screened by PCR using GAL1 and GAL10 primers.

B. Construction of the pESC-Trp/OS19/E1 Hydratase Vector
Plasmid DNA of a pESC-Trp/OS19 construct (Apa I-Sal I sites) with confirmed sequence and positive assay results was used for insertion of the nucleic acid for the *M. elsdenii* E1 activator polypeptide downstream of the GAL10 promoter. Three µg of plasmid DNA was digested with the restriction enzyme Cla I, and the digest was purified using a QIAquick PCR Purification Column. The vector DNA was then digested with the restriction enzyme Not I, and the digest was inactivated by heating to 65° C. for 20 minutes. The double-digested vector DNA was dephosphorylated with shrimp alkaline phosphatase (Roche), separated on a 1% TAE-agarose gel, and gel purified.

The nucleic acid encoding the *M. elsdenii* E1 activator polypeptide was amplified from genomic DNA using the PCR primer pair EINOTF and EICLAR. EINOTF was designed to introduce a Not I restriction site and a translation initiation site at the beginning of the amplified fragment. The EICLAR primer was designed to introduce a Cla I restriction site at the end of the amplified fragment and to contain an altered translational stop codon to allow in-frame translation of the FLAG epitope. The PCR mix contained the following: 1×Expand PCR buffer, 100 ng *M. elsdenii* genomic DNA, 0.2 µM of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase in a final volume of 100 µL. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30 seconds, 55° C. for 45 seconds, and 72° C. for 3 minutes; 24 cycles of 94° C. for 30 seconds, 62° C. for 45 seconds, and 72° C. for 3 minutes; and a final extension for 7 minutes at 72° C. The amplification product was then separated by gel electrophoresis using a 1% TAE-agarose gel, and a 0.8 Kb fragment was excised and purified. The purified fragment was digested with Cla I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Not I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

60 ng of the digested PCR product containing the nucleic acid for the *M. elsdenii* E1 activator polypeptide and 70 ng of the prepared pESC-Trp/OS19 hydratase vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One µL of the ligation reaction was used to electroporate 40 µL of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LBC media. Individual colonies were screened using colony PCR with the EINOTF and EICLAR primers. Individual colonies were suspended in about 25 µL of 10 mM Tris, and 2 µL of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 µL of the heated cells was used in a 25 µL PCR reaction. The PCR mix contained the following: 1×Taq buffer, 0.2 µM each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the gene from genomic DNA. Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR.

C. Construction of the pESC-Leu/EII α /EII β Vector

Three μ g of DNA of the vector pESC-Leu was digested with the restriction enzyme Apa I, and the digest was purified using a QIAquick PCR Purification Column. The vector DNA was then digested with the restriction enzyme Sal I, and the digest was inactivated by heating to 65° C. for 20 minutes. The double-digested vector DNA was dephosphorylated with shrimp alkaline phosphatase (Roche), separated on a 1% TAE-agarose gel, and gel purified.

The nucleic acid encoding the *M. elsdenii* E2 α polypeptide was amplified from genomic DNA using the PCR primer pair EII α APAF and EII α SALR. EII α APAF was designed to introduce an Apa I restriction site and a translation initiation site at the beginning of the amplified fragment. The EII α SALR primer was designed to introduce a Sal I restriction site at the end of the amplified fragment and to contain an altered translational stop codon to allow in-frame translation of the c-myc epitope. The PCR mix contained the following: 1 $\times$ Expand PCR buffer, 100 ng *M. elsdenii* genomic DNA, 0.2 μ M of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase in a final volume of 100 μ L. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30 seconds, 55° C. for 1 minute, and 72° C. for 3 minutes; 24 cycles of 94° C. for 30 seconds, 62° C. for 1 minute, and 72° C. for 3 minutes; and a final extension for 7 minutes at 72° C. The amplification product was then separated by gel electrophoresis using a 1% TAE-agarose gel, and a 1.3 Kb fragment was excised and purified. The purified fragment was digested with Apa I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Sal I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

80 ng of the digested PCR product containing the nucleic acid encoding the *M. elsdenii* E2 α polypeptide and 80 ng of the prepared pESC-Leu vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One μ L of the ligation reaction was used to electroporate 40 μ L of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LBC media. Individual colonies were screened using colony PCR with the EII α APAF and EII α SALR primers. Individual colonies were suspended in about 25 μ L of 10 mM Tris, and 2 μ L of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 μ L of the heated cells used in a 25 μ L PCR reaction. The PCR mix contained the following: 1 $\times$ Taq buffer, 0.2 μ M each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the gene from genomic DNA. Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR.

Plasmid DNA of a pESC-Leu/EII α vector with confirmed sequence was used for insertion of the nucleic acid encoding the *M. elsdenii* E2 β polypeptide. Three μ g of plasmid DNA was digested with the restriction enzyme Spe I, and the digest was purified using a QIAquick PCR Purification Column. The vector DNA was then digested with the restriction enzyme Not I and gel purified from a 1% TAE-agarose gel. The double-digested vector DNA was then dephosphorylated with shrimp alkaline phosphatase (Roche) and purified with a QIAquick PCR Purification Column.

The nucleic acid encoding the *M. elsdenii* E2 β polypeptide was amplified from genomic DNA using the PCR primer pair EII β NOTF and EII β SPER. The EII β NOTF primer was designed to introduce a Not I restriction site and a translation

initiation site at the beginning of the amplified fragment. The EII β SPER primer was designed to introduce an Spe I restriction site at the end of the amplified fragment and to contain an altered translational stop codon to allow for in-frame translation of the FLAG epitope. The PCR mix contained the following: 1 $\times$ Expand PCR buffer, 100 ng *M. elsdenii* genomic DNA, 0.2 μ M of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase in a final volume of 100 μ L. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30 seconds, 55° C. for 45 seconds, and 72° C. for 3 minutes; 24 cycles of 94° C. for 30 seconds, 62° C. for 45 seconds, and 72° C. for 3 minutes; and a final extension for 7 minutes at 72° C. The amplification product was separated by gel electrophoresis using a 1% TAE-agarose gel, and a 1.1 Kb fragment was excised and purified. The purified fragment was digested with Spe I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Not I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

38 ng of the digested PCR product containing the nucleic acid encoding the *M. elsdenii* E2 β polypeptide and 50 ng of the prepared pESC-Leu/EII α vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One μ L of the ligation reaction was used to electroporate 40 μ L of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LBC plates. Individual colonies were screened using colony PCR with the EII β NOTF and EII β SPER primers. Individual colonies were suspended in about 25 μ L of 10 mM Tris, and 2 μ L of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 μ L of the heated cells was used in a 25 μ L PCR reaction. The PCR mix contained the following: 1 $\times$ Taq buffer, 0.2 μ M each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the gene from genomic DNA.

Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR. A pESC-Leu/EII α /EII β construct with a confirmed sequence was co-transformed along with the pESC-Trp/OS19/E1 vector into *S. cerevisiae* strain YPH500 using a Frozen-EZ Yeast Transformation II™ Kit (Zymo Research, Orange, Calif.). Transformation reactions were plated on SC-Trp-Leu media. Individual yeast colonies were screened for the presence of the OS19, E1, E2 α , and E2 β nucleic acid by colony PCR. Colonies were suspended in 20 μ L of Y-Lysis Buffer (Zymo Research) containing 5 units of zymolase and heated at 37° C. for 10 minutes. Three μ L of this suspension was then used in a 25 μ L PCR reaction using the PCR reaction mixtures and programs described for the colony screens of the *E. coli* transformants. The pESC-Trp/OS19 and pESC-Leu vectors were also co-transformed into YPH500 for use as a lactyl-CoA dehydratase assay control. These transformants were colony screened using the GAL1 and GAL10 primers (Instruction manual, pESC Yeast Epitope Tagging Vectors, Stratagene).

D. Construction of the pESC-his/D-LDH/PCT Vector

Three μ g of DNA of the vector pESC-His was digested with the restriction enzyme Xho I, and the digest was purified using a QIAquick PCR Purification Column. The vector DNA was then digested with the restriction enzyme Apa I and gel purified from a 1% TAE-agarose gel. The double-digested vector DNA was dephosphorylated with shrimp alkaline phosphatase (Roche) and purified using a QIAquick PCR Purification Column.

The *E. coli* D-LDH gene was amplified from genomic DNA of strain DH10B using the PCR primer pair LDHAPAF and LDHXHR. LDHAPAF was designed to introduce an Apa I restriction site and a translation initiation site at the beginning of the amplified fragment. The LDHXHR primer was designed to introduce an Xho I restriction site at the end of the amplified fragment and to contain the translational stop codon for the D-LDH gene. The PCR mix contained the following: 1× Expand PCR buffer, 100 ng *E. coli* genomic DNA, 0.2 μM of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase in a final volume of 100 μL. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30 seconds, 59° C. for 45 seconds, and 72° C. for 2 minutes; 24 cycles of 94° C. for 30 seconds, 64° C. for 45 seconds, and 72° C. for 2 minutes; and a final extension for 7 minutes at 72° C. The amplification product was separated by gel electrophoresis using a 1% TAE-agarose gel, and a 1.0 Kb fragment was excised and purified. The purified fragment was digested with Apa I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Xho I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

80 ng of the digested PCR product containing the *E. coli* D-LDH gene and 80 ng of the prepared pESC-His vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One μL of the ligation reaction was used to electroporate 40 μL of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LBC media. Individual colonies were screened using colony PCR with the LDHAPAF and LDHXHR primers. Individual colonies were suspended in about 25 μL of 10 mM Tris, and 2 μL of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 μL of the heated cells used in a 25 μL PCR reaction. The PCR mix contained the following: 1×Taq buffer, 0.2 μM each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the gene from genomic DNA. Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR.

Plasmid DNA of a pESC-His/D-LDH construct with a confirmed sequence was used for insertion of the nucleic acid encoding the *M. elsdenii* PCT polypeptide. Three μg of plasmid DNA was digested with the restriction enzyme Pac I, and the digest was purified using a QIAquick PCR Purification Column. The vector DNA was then digested with the restriction enzyme Spe I and gel purified from a 1% TAE-agarose gel. The double-digested vector DNA was dephosphorylated with shrimp alkaline phosphatase (Roche) and purified with a QIAquick PCR Purification Column.

The nucleic acid encoding the *M. elsdenii* PCT polypeptide was amplified from genomic DNA using the PCR primer pair PCTSPEF and PCTPACR. PCTSPEF was designed to introduce an Spe I restriction site and a translation initiation site at the beginning of the amplified fragment. The PCTPACR primer was designed to introduce a Pac I restriction site at the end of the amplified fragment and to contain the translational stop codon for the PCT gene. The PCR mix contained the following: 1× Expand PCR buffer, 100 ng *M. elsdenii* genomic DNA, 0.2 μM of each primer, 0.2 mM each dNTP, and 5.25 units of Expand DNA Polymerase in a final volume of 100 μL. The PCR reaction was performed in an MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 1 minute; 8 cycles of 94° C. for 30

seconds, 56° C. for 45 seconds, and 72° C. for 2.5 minutes; 24 cycles of 94° C. for 30 seconds, 64° C. for 45 seconds, and 72° C. for 2.5 minutes; and a final extension for 7 minutes at 72° C. The amplification product was separated by gel electrophoresis using a 1% TAE-agarose gel, and a 1.55 Kb fragment was excised and purified. The purified fragment was digested with Pac I restriction enzyme, purified with a QIAquick PCR Purification Column, digested with Spe I restriction enzyme, purified again with a QIAquick PCR Purification Column, and quantified on a minigel.

95 ng of the digested PCR product containing the nucleic acid encoding the *M. elsdenii* PCT polypeptide and 75 ng of the prepared pESC-His/D-LDH vector were ligated using T4 DNA ligase at 16° C. for 16 hours. One μL of the ligation reaction was used to electroporate 40 μL of *E. coli* Electromax™ DH10B™ cells. The electroporated cells were plated onto LBC plates. Individual colonies were screened using colony PCR with the PCTSPEF and PCTPACR primers. Individual colonies were suspended in about 25 μL of 10 mM Tris, and 2 μL of the suspension was plated on LBC media. The remnant suspension was heated for 10 minutes at 95° C. to break open the bacterial cells, and 2 μL of the heated cells used in a 25 μL PCR reaction. The PCR mix contained the following: 1×Taq buffer, 0.2 μM each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR program used was the same as described above for amplification of the gene from genomic DNA.

Plasmid DNA was isolated from cultures of colonies having the desired insert and was sequenced to confirm the lack of nucleotide errors from PCR. A construct with a confirmed sequence was transformed into *S. cerevisiae* strain YPH500 using a Frozen-EZ Yeast Transformation II™ Kit (Zymo Research, Orange, Calif.). Transformation reactions were plated on SC-His media. Individual yeast colonies were screened for the presence of the D-LDH and PCT genes by colony PCR. Colonies were suspended in 20 μL of Y-Lysis Buffer (Zymo Research) containing 5 units of zymolase and heated at 37° C. for 10 minutes. Three μL of this suspension was then used in a 25 μL PCR reaction using the PCR reaction mixture and program described for the colony screen of the *E. coli* transformants. The pESC-His vector was also transformed into YPH500 for use as an assay control, and transformants were screened by PCR using GAL1 and GAL10 primers.

Example 13

Expression of Enzymes in *S. cerevisiae*

A. Hydratase Activity in Transformed Yeast

Individual colonies carrying the pESC-Trp/OS19 construct or the pESC-Trp vector (negative control) were used to inoculate 5 mL cultures of SC-Trp media containing 2% glucose. These cultures were grown for 16 hours at 30° C. and used to inoculate 35 mL of the same media. The subcultures were grown for 7 hours at 30° C., and their OD_{600s} were determined. A volume of cells giving an OD×volume equal to 40 was pelleted, washed with SC-Trp media with no carbon source, and repelleted. The cells were suspended in 5 mL of SC-Trp media containing 2% galactose and used to inoculate a total volume of 100 mL of this media. Cultures were grown for 17.5 hours at 30° C. and 250 rpm. Cells were then pelleted, rinsed in 0.85% NaCl, and repelleted. Cell pellets (70 mg) were suspended in 140 μL of 50 mM TrisHCl, pH 7.5, and an equal volume (pellet plus buffer) of pre-rinsed glass beads (Sigma, 150-212 microns) was added. This mixture was vor-

texted for 30 seconds and placed on ice for 1 minute, and the vortexing/cooling cycle was repeated 8 additional times. The cells were then centrifuged for 6 minutes at 5,000 g, and the supernatant was removed to a fresh tube. The beads/pellet were washed twice with 250 μ L of buffer, centrifuged, and the supernatants joined with the first supernatant.

An *E. coli* strain carrying the pETBlue-1/OS19 construct, described previously, was used as a positive control for hydratase assays. A culture of this strain was grown to saturation overnight and diluted 1:20 the following morning in fresh LBC media. The culture was grown at 37° C. and 250 rpm to an OD₆₀₀ of 0.6, at which point it was induced with IPTG at a final concentration of 1 mM. The culture was incubated for an additional two hours at 37° C. and 250 rpm. Cells were pelleted, washed with 0.85% NaCl, and repelleted. Cells were disrupted using BugBuster™ Protein Extraction Reagent and Benzonase® (Novagen) as per manufacturer's instructions with a 20 minute incubation at room temperature. After centrifugation at 16,000 g and 4° C., the supernatant was transferred to a new tube and used in the activity assay.

Total protein content of cell extracts from *S. cerevisiae* described above were quantified using a microplate Bio-Rad Protein Assay (Bio-Rad, Hercules, Calif.). The OS19 constructs (both Apa I-Sal I and Apa I-Kpn I sites) in YPH500, the pESC-Trp negative control in YPH500, and the pETBlue-1/OS19 construct in *E. coli* were tested for their ability to convert acrylyl-CoA to 3-hydroxypropionyl-CoA. The assay was conducted as previously described for the pETBlue-1/OS19 constructs in the *E. coli* Tuner strain. When cell extract of the negative control strain was added to the reaction mixture containing acrylyl-CoA, one dominant peak of MW 823 was exhibited. This peak corresponds to acrylyl-CoA and indicates that acrylyl-CoA was not converted to any other product. When cell extract of the strain carrying a pESC-Trp/OS19 construct (either Apa I-Sal I or Apa I-Kpn I sites) was added to the reaction mix, the dominant peak shifted to MW 841, which corresponds to 3-hydroxypropionyl-CoA. The reaction mix from the *E. coli* control also showed the MW 841 peak. A time course study was conducted for the pESC-Trp/OS19 (Apa I-Sal I) construct, which measured the appearance of the MW 841 and MW 823 peaks after 0, 1, 3, 7, 15, 30, and 60 minutes of reaction time. An increase in the 3-hydroxypropionyl-CoA peak was seen over time with the cell extracts from both this construct and the *E. coli* control, whereas cell extract from the YPH500 strain with vector only showed a dominant acrylyl-CoA peak.

B. Propionyl CoA-Transferase Activity in Transformed Yeast

Individual colonies of *S. cerevisiae* strain YPH500 carrying the pESC-His/D-LDH or pESC-His/D-LDH/PCT construct or the pESC-His vector with no insert (negative control) were used to inoculate 5 mL cultures of SC-His media containing 2% glucose. These cultures were grown for 16 hours at 30° C. and 250 rpm and were then used to inoculate 35 mL of the same media. The subcultures were grown for 7 hours at 30° C., and their OD₆₀₀s were determined. For each strain, a volume of cells giving an OD×volume equal to 40 was pelleted, washed with SC-His media with no carbon source, and repelleted. The cells were suspended in 5 mL of SC-His media containing 2% galactose and used to inoculate a total volume of 100 mL of this media. Cultures were grown for 16.75 hours at 30° C. and 250 rpm. Cells were then pelleted, rinsed in 0.85% NaCl, and repelleted. Cell pellets (70 mg) were suspended in 140 μ L of 100 mM potassium phosphate buffer, pH 7.5, and an equal volume (pellet plus buffer) of

pre-rinsed glass beads (Sigma, 150-212 microns) was added. This mixture was vortexed for 30 seconds and placed on ice for 1 minute, and the vortexing/cooling cycle was repeated 8 additional times. The cells were then centrifuged for 6 minutes at 5,000 g, and the supernatant was removed to a fresh tube. The beads/pellet were washed twice with 250 μ L of buffer and centrifuged, and the supernatants joined with the first supernatant.

An *E. coli* strain carrying the pETBlue-1/PCT construct, described previously, was used as a positive control for propionyl CoA transferase assays. A culture of this strain was grown to saturation overnight and diluted 1:20 the following morning in fresh LB media containing 100 μ g/mL of carbenicillin. The culture was grown at 37° C. and 250 rpm to an OD₆₀₀ of 0.6, at which point it was induced with IPTG at a final concentration of 1 mM. The culture was incubated for an additional two hours at 37° C. and 250 rpm. Cells were pelleted, washed with 0.85% NaCl, and repelleted. Cells were disrupted using BugBuster™ Protein Extraction Reagent and Benzonase® (Novagen) as per manufacturer's instructions with a 20 minute incubation at room temperature. After centrifugation at 16,000 g and 4° C., the supernatant was transferred to a new tube and used in the activity assay.

Total protein content of cell extracts was quantified using a microplate Bio-Rad Protein Assay (Bio-Rad, Hercules, Calif.). The D-LDH and D-LDH/PCT constructs in *S. cerevisiae* strain YPH500, the pESC-His negative control in YPH500, and the pETBlue-1/PCT construct in *E. coli* were tested for their ability to catalyze the conversion of propionyl-CoA and acetate to acetyl-CoA and propionate. The assay mixture used was that previously described for the pETBlue-1/PCT constructs in the *E. coli* Tuner strain.

When 1 μ g of total cell extract protein of the negative control strain or the YPH500/pESC-His/D-LDH strain was added to the reaction mixture, no increase in absorbance (0.00 to 0.00) was seen over 11 minutes. Increases in absorbance from 0.00 to 0.04 and from 0.00 to 0.06 were seen, respectively, with 1 μ g of cell extract protein from the YPH500/pESC-His/D-LDH/PCT strain and the *E. coli*/PCT strain. With 2 mg of total cell extract protein, the negative control strain and the YPH500/pESC-His/D-LDH strain showed an increase in absorbance from 0.00 to 0.01 over 11 minutes, whereas increases from 0.00 to 0.10 and 0.00 to 0.08 were seen, respectively, with the YPH500/pESC-His/D-LDH/PCT strain and the *E. coli*/PCT strain.

C. Lactyl-CoA Dehydratase Activity in Transformed Yeast

Individual colonies of *S. cerevisiae* strain YPH500 carrying the pESC-His/D-LDH or pESC-His/D-LDH/PCT construct or the pESC-His vector with no insert (negative control) were used to inoculate 5 mL cultures of SC-His media containing 4% glucose. These cultures were grown for 23 hours at 30° C. and used to inoculate 35 mL of SC-His media containing 2% raffinose. The subcultures were grown for 8 hours at 30° C., and their OD₆₀₀s were determined. For each strain, a volume of cells giving an OD×volume equal to 40 was pelleted, resuspended in 10 mL of SC-His media containing 2% galactose, and used to inoculate a total volume of 100 mL of this media. Cultures were grown for 17 hours at 30° C. and 250 rpm. Cells were then pelleted, rinsed in 0.85% NaCl, and repelleted. Cell pellets (190 mg) were suspended in 380 μ L of 100 mM potassium phosphate buffer, pH 7.5, and an equal volume (pellet plus buffer) of pre-rinsed glass beads (Sigma, 150-212 microns) was added. This mixture was vortexed for 30 seconds and placed on ice for 1 minute, and the

vortexing/cooling cycle was repeated 7 additional times. The cells were then centrifuged for 6 minutes at 5,000 g and the supernatant was removed to a fresh tube. The beads/pellet were washed twice with 300 μ L of buffer and centrifuged, and the supernatants joined with the first supernatant.

An anaerobically-grown culture of *E. coli* strain DH10B was used as a positive control for D-LDH assays. A culture of this strain was grown to saturation overnight and diluted 1:20 the following morning in fresh LB media. The culture was grown anaerobically at 37° C. for 7.5 hours. Cells were pelleted, washed with 0.85% NaCl, and repelleted. Cells were disrupted using BugBuster™ Protein Extraction Reagent and Benzonase® (Novagen) as per manufacturer's instructions with a 20-minute incubation at room temperature. After centrifugation at 16,000 g and 4° C., the supernatant was transferred to a new tube and used in the activity assay.

Total protein content of cell extracts was quantified using a microplate Bio-Rad Protein Assay (Bio-Rad, Hercules, Calif.). The D-LDH and D-LDH/PCT constructs in YPH500, the pESC-His negative control in YPH500, and the anaerobically-grown *E. coli* strain were tested for their ability to catalyze the conversion of pyruvate to lactate by assaying the concurrent oxidation of NADH to NAD. The assay mixture contained 100 mM potassium phosphate buffer, pH 7.5, 0.2 mM NADH, and 0.5-1.0 μ g of cell extract. The reaction was started by the addition of sodium pyruvate to a final concentration of 5 mM, and the decrease in absorbance at 340 nm was measured over 10 minutes. When 0.5 μ g of total cell extract protein of the negative control strain was added to the reaction mixture, a decrease in absorbance from -0.01 to -0.02 was seen over 200 seconds. A decrease in absorbance from -0.21 to -0.47 and -0.20 to -0.47 over 200 seconds was seen, respectively, for cell extract from the YPH500/pESC-His/D-LDH or YPH500/pESC-His/D-LDH/PCT strains. 0.5 μ L (7.85 μ g) of cell extract from the anaerobically-grown *E. coli* strain showed a decrease in absorbance very similar to that for 1 μ g of cell extract of the YPH500/pESC-His/D-LDH/PCT strain. When 4 μ g of cell extract was used, the YPH500/pESC-His/D-LDH/PCT strain showed a decrease in absorbance from -0.18 to -0.60 over 10 minutes, whereas the negative control strain showed no decrease in absorbance (-0.08 to -0.08).

D. Demonstration of 3-HP Production in *S. cerevisiae*

The pESC-Trp/OS19/E1, pESC-Leu/EIIa/EIIB, and pESC-His/D-LDH/PCT constructs were transformed into a single strain of *S. cerevisiae* YPH500 using a Frozen-EZ Yeast Transformation II™ Kit (Zymo Research, Orange, Calif.). A negative control strain was also developed by transformation of the pESC-Trp, pESC-Leu, and pESC-His vectors into a single YPH500 strain. Transformation reactions were plated on SC-Trp-Leu-His media. Individual yeast colonies were screened by colony PCR for the presence or absence of nucleic acid corresponding to each construct.

The strain carrying all six genes and the negative control strain were grown in 5 mL of SC-Trp-Leu-His media containing 2% glucose. These cultures were grown for 31 hours at 30° C., and 2 mL was used to inoculate 50 mL of the same media. The subcultures were grown for 19 hours at 30° C., and their OD600s were determined. For each strain, a volume of cells giving an OD $\times$ volume equal to 100 was pelleted, washed with SC-Trp-Leu-His media with no carbon source, and repelleted. The cells were suspended in 10 mL of SC-Trp-Leu-His media containing 2% galactose and 2% raffinose and used to inoculate a total volume of 250 mL of this media. The

cultures were grown in bottles at 30° C. with no shaking, and samples were taken at 0, 4.5, 20, 28.5, 45, and 70 hours. Samples were spun down to remove cells and the supernatant was filtered using 0.45 micron Acrodisc Syringe Filters (Pall Gelman Laboratory, Ann Arbor, Mich.).

100 microliters of the filtered broth was used to derive CoA esters of any lactate or 3-HP in the broth using 6 micrograms of purified propionyl-CoA transferase, 50 mM potassium phosphate buffer (pH 7.0), and 1 mM acetyl-CoA. The reaction was allowed to proceed at room temperature for 15 minutes and was stopped by adding 1 volume 10% trifluoroacetic acid. The reaction mixtures were purified using Sep Pak C18 columns as previously described and analyzed by LC/MS.

Example 14

Constructing a Biosynthetic Pathway that Produces Organic Acids from β -alanine

One possible pathway to 3-HP from β -alanine involves the use of a polypeptide having CoA transferase activity (e.g., an enzyme from a class of enzymes that transfers a CoA group from one metabolite to the other). As shown in FIG. 54, β -alanine can be converted to β -alanyl-CoA using a polypeptide having CoA transferase activity and CoA donors such as acetyl-CoA or propionyl-CoA. Alternatively, β -alanyl-CoA can be generated by the action of a polypeptide having CoA synthetase activity. The β -alanyl-CoA can be deaminated to form acrylyl-CoA by a polypeptide having β -alanyl-CoA ammonia lyase activity. The hydration of acrylyl-CoA at the β position to yield 3-HP-CoA can be carried out by a polypeptide having 3-HP-CoA dehydratase activity. The 3-HP-CoA can act as a CoA donor for β -alanine, a reaction that can be catalyzed by a polypeptide having CoA transferase activity, thus yielding 3-HP as a product. Alternatively, 3-HP-CoA can be hydrolyzed to yield 3-HP by a polypeptide having specific CoA hydrolase activity.

Methods for isolating, sequencing, expressing, and testing the activity of a polypeptide having CoA transferase activity are described herein.

A. Isolation of a Polypeptide Having 3-Alanyl-CoA Ammonia Lyase Activity

Polypeptides having β -alanyl-CoA ammonia lyase activity can catalyze the conversion of β -alanyl-CoA into acrylyl-CoA. The activity of such polypeptides has been described by Vagelos et al. (*J. Biol. Chem.*, 234:490-497 (1959)) in *Clostridium propionicum*. This polypeptide can be used as part of the acrylate pathway in *Clostridium propionicum* to produce propionic acid.

C. propionicum was grown at 37° C. in an anoxic medium containing 0.2% yeast extract, 0.2% trypticase peptone, 0.05% cysteine, 0.5% β -alanine, 0.4% VRB-salts, 5 mM potassium phosphate, pH 7.0. The cells were harvested after 12 hours and washed twice with 50 mM potassium phosphate (Kpi), pH 7.0. About 2 g of wet packed cells were re-suspended in 40 mL of Kpi, pH 7.0, 1 mM MgCl₂, 1 mM EDTA, and 1 mM DTT (Buffer A), and homogenized by sonication at about 85-100 W power using a 3 mm tip (Branson sonifier 250). Cell debris was removed by centrifugation at 100,000 g for 45 minutes in a Centrifuge T-1080 Ultra centrifuge, and the cell free extract (~110 U/mg activity) was subjected to anion exchange chromatography on Source-15Q-material. The Source-15Q column was loaded with 32 mL of cell free extract. The column was developed by a linear gradient of 0 M to 0.5 M NaCl within column volumes. The polypeptide eluted between 70-110 mM NaCl.

The solution was adjusted to a final concentration of 1 M $(\text{NH}_4)_2\text{SO}_4$ and applied onto a Resource-Phe column equilibrated with 1 M $(\text{NH}_4)_2\text{SO}_4$ in buffer A. The polypeptide did not bind to this column.

The final preparation was obtained after concentration in an Amicon chamber (filter cut-off 30 kDa). The functional polypeptide is composed of four polypeptide sub-units, each having a molecular mass of 16 kDa. The polypeptide had a final specific activity of 1033 U/mg in the standard assay (see below).

The polypeptide sample after every purification step was separated on a 15% SDS-PAGE gel. The gel was stained with 0.1% Coomassie R 250, and the destaining was achieved by using 7.1% acetic acid/5% ethanol solution.

The polypeptide was desalted by RP-HPLC and subjected to N-terminal sequencing by gas phase Edman degradation. The results of this analysis yielded a 35 amino acid N-terminal sequence of the polypeptide. The sequence was as follows:

(SEQ ID NO: 177)
MV - GKQVHHLMSAKDAHYTGNLVNGARIVNQWGD.

B. Amplification of a Gene Fragment

The 35 amino acid sequence of the polypeptide having β -alanine-CoA ammonia lyase activity was used to design primers with which to amplify the corresponding DNA from genome of *C. propionicum*. Genomic DNA from *C. propionicum* was isolated using the Gentra Genomic DNA isolation Kit (Gentra Systems, Minneapolis) following the genomic DNA protocol for gram-positive bacteria. A codon usage table for *Clostridium propionicum* was used to back translate the seven amino acids on either end of the amino acid sequence to obtain 20-nucleotide degenerate primers:

ACLF: (SEQ ID NO: 178)
5' -ATGGTGGGYAARAARGTWGT-3'
ACLR: (SEQ ID NO: 179)
5' -TCRCCCCAYTGRTTWACRAT-3'

The primers were used in a 50 μL PCR reaction containing 1 $\times$ Taq PCR buffer, 0.6 μM each primer, 0.2 mM each dNTP, 2 units of Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, Ind.), 2.5% (v/v) DMSO, and 100 ng of genomic DNA. PCR was conducted using a touchdown PCR program with 4 cycles at an annealing temperature of 58° C., 4 cycles at 56° C., 4 cycles at 54° C., and 24 cycles at 52° C. Each cycle used an initial 30 second denaturing step at 94° C. and a 1.25 minute extension at 72° C., and the program had an initial denaturation step at 94° C. for 2 minutes and final extension at 72° C. for 5 minutes. The amounts of PCR primer used in the reaction were increased three-fold above typical PCR amounts due to the amount of degeneracy in the 3' end of the primer. In addition, separate PCR reactions containing each individual primer were made to identify PCR product resulting from single degenerate primers. Twenty μL of each PCR product was separated on a 2.0% TAE (Tris-acetate-EDTA)-agarose gel.

A band of about 100 bp was produced by the reaction containing both the forward and reverse primers, but was not present in the individual forward and reverse primer control reactions. This fragment was excised and purified using a QIAquick Gel Extraction Kit (Qiagen, Valencia, Calif.). Four microliters of the purified band was ligated into pCRII-TOPO

vector and transformed by a heat-shock method into TOP10 *E. coli* cells using a TOPO cloning procedure (Invitrogen, Carlsbad, Calif.). Transformations were plated on LB media containing 50 $\mu\text{g/mL}$ of kanamycin and 50 $\mu\text{g/mL}$ of 5-Bromo-4-Chloro-3-Indolyl-B-D-Galactopyranoside (X-gal). Individual, white colonies were resuspended in 25 μL of 10 mM Tris and heated for 10 minutes at 95° C. to break open the bacterial cells. Two microliters of the heated cells were used in a 25 μL PCR reaction using M13R and M13F universal primers homologous to the pCRII-TOPO vector. The PCR mix contained the following: 1 $\times$ Taq PCR buffer, 0.2 μM each primer, 0.2 mM each dNTP, and 1 unit of Taq DNA polymerase per reaction. The PCR reaction was performed in a MJ Research PTC100 under the following conditions: an initial denaturation at 94° C. for 2 minutes; 30 cycles of 94° C. for 30 seconds, 52° C. for 1 minute, and 72° C. for 1.25 minutes; and a final extension for 7 minutes at 72° C. Plasmid DNA was obtained (QIAprep Spin Miniprep Kit, Qiagen) from cultures of colonies showing the desired insert and was used for DNA sequencing with M13R universal primer. The following nucleic acid sequence was internal to the degenerate primers and corresponds to a portion of the 35 amino acid residue sequence:

(SEQ ID NO: 180)
5' -ACATCATTTAATGATGA-
GCGCAAAAGATGCTCACTATACTGGAACTTAGTAAACGGCGCTAGA-3'.

C. Genome Walking to Obtain the Complete Coding Sequence

Primers for conducting genome walking in both upstream and downstream directions were designed using the portion of the nucleic acid sequence that was internal to the degenerate primers. The primer sequences were as follows:

ACLGSP1F: (SEQ ID NO: 181)
5' -GTACATCATTTAATGATGAGCGCAAAAGATG-3'
ACLGSP2F: (SEQ ID NO: 182)
5' -GATGCTCACTATACTGGAACTTAGTAAAC-3'
ACLGSP1R: (SEQ ID NO: 183)
5' -ATTCTAGCGCGGTTTACTAAGTTTCAG-3'
ACLGSP2R: (SEQ ID NO: 184)
5' -CCAGTATAGTGAGCATCTTTTGCGCTCATC-3'

GSP1F and GSP2F are primers facing downstream, GSP1R and GSP2R are primers facing upstream, and GSP2F and GSP2R are primers nested inside GSP1F and GSP1R, respectively. Genome walking libraries were constructed according to the manual for CLONTECH's Universal Genome Walking Kit (CLONTECH Laboratories, Palo Alto, Calif.), with the exception that the restriction enzymes Ssp I and Hinc II were used in addition to Dra I, EcoR V, and Pvu II. PCR was conducted in a Perkin Elmer 9700 Thermocycler using the following reaction mix: 1 $\times$ XL Buffer II, 0.2 mM each dNTP, 1.25 mM $\text{Mg}(\text{OAc})_2$, 0.2 μM each primer, 2 units of rTth DNA polymerase XL (Applied Biosystems, Foster City, Calif.), and 1 μL of library per 50 μL reaction. First round PCR used an initial denaturation at 94° C. for 5 seconds; 7 cycles consisting of 2 sec at 94° C. and 3 min at 70° C.; 32 cycles consisting of 2 sec at 94° C. and 3 min at 64° C.; and a final extension at 64° C. for 4 min. Second round PCR used

81

an initial denaturation at 94° C. for 15 seconds; 5 cycles consisting of 5 sec at 94° C. and 3 min at 70° C.; 26 cycles consisting of 5 sec at 94° C. and 3 min at 64° C.; and a final extension at 66° C. for 7 min. Twenty μ L of each first and second round product was run on a 1.0% TAE-agarose gel. In the second round PCR for the forward reactions, a 1.4 Kb band was obtained for Dra I, a 1.5 Kb band for Hinc II, a 4.0 Kb band for Pvu II, and 2.0 and 2.6 Kb bands were obtained for Ssp I. In the second round PCR for the reverse reactions, a 1.5 Kb band was obtained for Dra I, a 0.8 Kb band for EcoR V, a 2.0 Kb band for Hinc II, a 2.9 Kb band for Pvu II, and a 1.5 Kb band was obtained for Ssp I. Several of these fragments were gel purified, cloned, and sequenced.

The coding sequence of the polypeptide having 3-alanyl-CoA ammonia lyase activity is set forth in SEQ ID NO:162. This coding sequence encodes the amino acid sequence set forth in SEQ ID NO:160. The coding sequence was cloned and expressed in bacterial cells. A polypeptide with the expected size was isolated and tested for enzymatic activity.

The isolation of a nucleic acid molecule encoding a polypeptide having 3-HP-CoA dehydratase activity (e.g., the seventh enzymatic activity in FIG. 54, which can be accomplished with a polypeptide having the amino acid sequence set forth in SEQ ID NO:41) is described herein. This polypeptide in combination with a polypeptide having CoA transferase activity (e.g., a polypeptide having the amino acid sequence set forth in SEQ ID NO:2) and a polypeptide having β -alanyl-CoA ammonia lyase activity (e.g., a polypeptide having the amino acid sequence set forth in SEQ ID NO: 160) provides one method of making 3-HP from β -alanine.

Example 15

Constructing a Biosynthetic Pathway that Produces Organic Acids from β -alanine

In another pathway, β -alanine generated from aspartate can be deaminated by a polypeptide having 4,4-aminobutyrate aminotransferase activity (FIG. 55). This reaction also can regenerate glutamate that is consumed in the formation of aspartate. The deamination of β -alanine can yield malonate semialdehyde, which can be further reduced to 3-HP by a polypeptide having 3-hydroxypropionate dehydrogenase activity or a polypeptide having 3-hydroxyisobutyrate dehydrogenase activity. Such polypeptides can be obtained as follows.

A. Cloning gabT (4-Aminobutyrate Aminotransferase) from *C. acetobutylicum*

The following PCR primers were designed based on a published sequence for a gabT gene from *Clostridium acetobutylicum* (GenBank#AE007654):

Cac aba nco sen: (SEQ ID NO: 185)
5' -GAGCCATGGAAGAAATAATGCTAAAG-3'
Cac aba bam anti: (SEQ ID NO: 186)
5' -AGAGGATGGCTTTTAAATCGCTATTC-3'

The primers introduced a NcoI site at the 5' end and a BamH I site at the 3' end. A PCR reaction was set up using chromosomal DNA from *C. acetobutylicum* as the template.

82

H ₂ O	80.75 μ L	PCR Program
Taq Plus Long 10x Buffer	10 μ L	94° C. 5 minutes
dNTP mix (10 mM)	3 μ L	25 cycles of:
Cac aba nco sen (20 mM)	2 μ L	94° C. 30 seconds
Cac aba bam anti (20 mM)	2 μ L	50° C. 30 seconds
<i>C. acetobutylicum</i> DNA (~100 ng)	1 μ L	72° C. 80 seconds +
Taq Plus Long (5 U/mL)	1 μ L	2 seconds/cycle
Pfu (2.5 U/mL)	0.25 μ L	1 cycle of: 68° C. 7 minutes
		4° C. until use

Upon agarose gel analysis a single band was observed of ~1.3 Kb in size. This fragment was purified using QIAquick PCR purification kit (Qiagen, Valencia, Calif.) and cloned into pCRII TOPO using the TOPO Zero Blunt PCR cloning kit (Invitrogen, Carlsbad, Calif.). 1 μ L of the pCRII TOPO ligation mix was used to transform chemically competent TOP10 *E. coli* cells. The cells were for 1 hour in SOC media, and the transformants were selected on LB/kanamycin (50 μ g/mL) plates. Single colonies of the transformant grown overnight in LB/kanamycin media, and the plasmid DNA was extracted using a Mini prep kit (Qiagen, Valencia, Calif.). The super-coiled plasmid DNA was separated on a 1% agarose gel digested, and the colonies with insert were selected. The insert was sequenced to confirm the sequence and its quality.

The plasmid having the correct insert was digested with restriction enzyme Nco I and BamH I. The digested insert was gel isolated and ligated to pET28b expression vector that was also restricted with Nco I and BamH I enzymes. 1 μ L of ligation mix was used to transform chemically competent TOP10 *E. coli* cells. The cells were recovered for 1 hour in SOC media, and the transformants were selected on LB/kanamycin (50 μ g/mL) plates. The super-coiled plasmid DNA was separated on a 1% agarose gel digested, and the colonies with insert were selected. The plasmid with the insert was isolated using a Mini prep kit (Qiagen, Valencia, Calif.), and 1 μ L of this plasmid DNA was used to transform electrocompetent BL21(DE3) (Novagen, Madison, Wis.). These cells were used to check the expression of a polypeptide having 4-aminobutyrate aminotransferase activity.

B. Cloning mmsB (3-Hydroxyisobutyrate Dehydrogenase) from *P. aeruginosa*

The following PCR primers were designed based on a published sequence for a mmsB gene from *Pseudomona aeruginosa* (GenBank#M84911):

Ppu hid nde sen: (SEQ ID NO: 187)
5' -ATACATATGACCGACCGACATCGCATT-3'
Ppu hid sal anti: (SEQ ID NO: 188)
5' -ATAGTCGACGGTCAGTCCTTGCCGCG-3'

The primers introduced a Nde I site at the 5' end and a BamH I site at the 3' end.

H ₂ O	80.75 μ L	PCR Program
Taq Plus Long 10x Buffer	10 μ L	94° C. 5 minutes
dNTP mix (10mM)	3 μ L	25 cycles of:
		94° C. 30 seconds
		55° C. 30 seconds
		72° C. 90 seconds + 2
		seconds/cycle
Ppu hid nde sen (20 μ M)	2 μ L	68° C. 7 minutes
Ppu hid sal anti (20 μ M)	2 μ L	4° C. until use

-continued

<i>C. acetobutylicum</i> DNA (~100 ng)	1 µL
Taq Plus Long (Stratagene, La Jolla, CA)	1 µL
Pfu (Stratagene, La Jolla, CA)	0.25 µL

A PCR reaction was set up using chromosomal DNA from *P. aeruginosa* as the template. Chromosomal DNA was obtained from ATCC (Manassas, Va.) *P. aeruginosa* 17933D.

Upon agarose gel analysis, a single band was observed of ~1.6 Kb in size. This fragment was purified using QIAquick PCR purification kit (Qiagen, Valencia, Calif.) and cloned into pCRII TOPO using the TOPO Zero Blunt PCR cloning kit (Invitrogen, Carlsbad, Calif.). 1 µL of the pCRII TOPO ligation mix was used to transform chemically competent TOP10 *E. coli* cells. The cells were recovered for 1 hour in SOC media, and the transformants were selected on LB/kanamycin (50 µg/mL) plates. Single colonies of the transformant grown overnight in LB/kanamycin media, and the plasmid DNA was extracted using a Mini prep kit (Qiagen, Valencia, Calif.). The super-coiled plasmid DNA was separated on a 1% agarose gel and digested, and the colonies with insert were selected. The insert was sequenced to confirm the sequence and its quality.

The plasmid having the correct insert was digested with restriction enzyme Nde I and BamHI. The digested insert was gel isolated and ligated to pET30a expression vector that was also restricted with Nde I and BamH I enzymes. 1 µL of ligation mix was used to transform chemically competent TOP 10 *E. coli* cells. The cells were recovered for 1 hour in SOC media, and the transformants were selected on LB/kanamycin (50 µg/mL) plates. The super-coiled plasmid DNA was separated on a 1% agarose gel and digested, and the colonies with insert were selected. The plasmid with the insert was isolated using a Mini prep kit (Qiagen, Valencia, Calif.), and 1 µL of this plasmid DNA was used to transform electrocompetent BL21(DE3) (Novagen, Madison, Wis.). These cells were used to check the expression of a polypeptide having 3-hydroxyisobutyrate dehydrogenase activity.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 194

<210> SEQ ID NO 1

<211> LENGTH: 1554

<212> TYPE: DNA

<213> ORGANISM: *Megasphaera elsdenii*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) .. (1551)

<400> SEQUENCE: 1

```

atg aga aaa gta gaa atc att aca gct gaa caa gca gct cag ctc gta      48
Met Arg Lys Val Glu Ile Ile Thr Ala Glu Gln Ala Ala Gln Leu Val
1          5          10          15

aaa gac aac gac acg att acg tct atc ggc ttt gtc agc agc gcc cat      96
Lys Asp Asn Asp Thr Ile Thr Ser Ile Gly Phe Val Ser Ser Ala His
          20          25          30

ccg gaa gca ctg acc aaa gct ttg gaa aaa cgg ttc ctg gac acg aac      144
Pro Glu Ala Leu Thr Lys Ala Leu Glu Lys Arg Phe Leu Asp Thr Asn
          35          40          45

acc ccg cag aac ttg acc tac atc tat gca ggc tct cag ggc aaa cgc      192
Thr Pro Gln Asn Leu Thr Tyr Ile Tyr Ala Gly Ser Gln Gly Lys Arg
          50          55          60

gat ggc cgt gcc gct gaa cat ctg gca cac aca ggc ctt ttg aaa cgc      240
Asp Gly Arg Ala Ala Glu His Leu Ala His Thr Gly Leu Leu Lys Arg
          65          70          75          80

gcc atc atc ggt cac tgg cag act gta ccg gct atc ggt aaa ctg gct      288
Ala Ile Ile Gly His Trp Gln Thr Val Pro Ala Ile Gly Lys Leu Ala
          85          90          95

gtc gaa aac aag att gaa gct tac aac ttc tcg cag ggc acg ttg gtc      336
Val Glu Asn Lys Ile Glu Ala Tyr Asn Phe Ser Gln Gly Thr Leu Val
          100          105          110

cac tgg ttc cgc gcc ttg gca ggt cat aag ctc ggc gtc ttc acc gac      384
His Trp Phe Arg Ala Leu Ala Gly His Lys Leu Gly Val Phe Thr Asp
          115          120          125

atc ggt ctg gaa act ttc ctc gat ccc cgt cag ctc ggc ggc aag ctc      432
Ile Gly Leu Glu Thr Phe Leu Asp Pro Arg Gln Leu Gly Gly Lys Leu

```


-continued

130	135	140	
aat gac gta acc aaa gaa gac ctc gtc aaa ctg atc gaa gtc gat ggt Asn Asp Val Thr Lys Glu Asp Leu Val Lys Leu Ile Glu Val Asp Gly 145 150 155 160			480
cat gaa cag ctt ttc tac ccg acc ttc ccg gtc aac gta gct ttc ctc His Glu Gln Leu Phe Tyr Pro Thr Phe Pro Val Asn Val Ala Phe Leu 165 170 175			528
cgc ggt acg tat gct gat gaa tcc gcc aat atc acc atg gac gaa gaa Arg Gly Thr Tyr Ala Asp Glu Ser Gly Asn Ile Thr Met Asp Glu Glu 180 185 190			576
atc ggg cct ttc gaa agc act tcc gta gcc cag gcc gtt cac aac tgt Ile Gly Pro Phe Glu Ser Thr Ser Val Ala Gln Ala Val His Asn Cys 195 200 205			624
ggc ggt aaa gtc gtc gtc cag gtc aaa gac gtc gtc gct cac gcc agc Gly Gly Lys Val Val Val Gln Val Lys Asp Val Val Ala His Gly Ser 210 215 220			672
ctc gac ccg cgc atg gtc aag atc cct gcc atc tat gtc gac tac gtc Leu Asp Pro Arg Met Val Lys Ile Pro Gly Ile Tyr Val Asp Tyr Val 225 230 235 240			720
gtc gta gca gct ccg gaa gac cat cag cag acg tat gac tgc gaa tac Val Val Ala Ala Pro Glu Asp His Gln Gln Thr Tyr Asp Cys Glu Tyr 245 250 255			768
gat ccg tcc ctc agc ggt gaa cat cgt gct cct gaa gcc gct acc gat Asp Pro Ser Leu Ser Gly Glu His Arg Ala Pro Glu Gly Ala Thr Asp 260 265 270			816
gca gct ctc ccc atg agc gct aag aaa atc atc gcc cgc cgc gcc gct Ala Ala Leu Pro Met Ser Ala Lys Lys Ile Ile Gly Arg Arg Gly Ala 275 280 285			864
ttg gaa ttg act gaa aac gct gtc gtc aac ctc gcc gtc ggt gct ccg Leu Glu Leu Thr Glu Asn Ala Val Val Asn Leu Gly Val Gly Ala Pro 290 295 300			912
gaa tac gtt gct tct gtt gcc ggt gaa gaa ggt atc gcc gat acc att Glu Tyr Val Ala Ser Val Ala Gly Glu Glu Gly Ile Ala Asp Thr Ile 305 310 315 320			960
acc ctg acc gtc gaa ggt gcc gcc atc ggt gcc gta ccg cag gcc ggt Thr Leu Thr Val Glu Gly Gly Ala Ile Gly Gly Val Pro Gln Gly Gly 325 330 335			1008
gcc cgc ttc ggt tcg tcc cgc aat gcc gat gcc atc atc gac cac acc Ala Arg Phe Gly Ser Ser Arg Asn Ala Asp Ala Ile Ile Asp His Thr 340 345 350			1056
tat cag ttc gac ttc tac gat gcc gcc ggt ctg gac atc gct tac ctc Tyr Gln Phe Asp Phe Tyr Asp Gly Gly Gly Leu Asp Ile Ala Tyr Leu 355 360 365			1104
ggc ctg gcc cag tgc gat gcc tcg gcc aac atc aac gtc agc aag ttc Gly Leu Ala Gln Cys Asp Gly Ser Gly Asn Ile Asn Val Ser Lys Phe 370 375 380			1152
ggt act aac gtt gcc gcc tgc gcc ggt ttc ccc aac att tcc cag cag Gly Thr Asn Val Ala Gly Cys Gly Gly Phe Pro Asn Ile Ser Gln Gln 385 390 395 400			1200
aca ccg aat gtt tac ttc tgc gcc acc ttc acg gct gcc gcc ttg aaa Thr Pro Asn Val Tyr Phe Cys Gly Thr Phe Thr Ala Gly Gly Leu Lys 405 410 415			1248
atc gct gtc gaa gac gcc aaa gtc aag atc ctc cag gaa gcc aaa gcc Ile Ala Val Glu Asp Gly Lys Val Lys Ile Leu Gln Glu Gly Lys Ala 420 425 430			1296
aag aag ttc atc aaa gct gtc gac cag atc act ttc aac ggt tcc tat Lys Lys Phe Ile Lys Ala Val Asp Gln Ile Thr Phe Asn Gly Ser Tyr 435 440 445			1344
gca gcc cgc aac gcc aaa cac gtt ctc tac atc aca gaa cgc tgc gta Ala Ala Arg Asn Gly Lys His Val Leu Tyr Ile Thr Glu Arg Cys Val			1392

-continued

450	455	460	
ttt gaa ctg acc aaa gaa ggc ttg aaa ctc atc gaa gtc gca ccg ggc			1440
Phe Glu Leu Thr Lys Glu Gly Leu Lys Leu Ile Glu Val Ala Pro Gly			
465	470	475	480
atc gat att gaa aaa gat atc ctc gct cac atg gac ttc aag ccg atc			1488
Ile Asp Ile Glu Lys Asp Ile Leu Ala His Met Asp Phe Lys Pro Ile			
	485	490	495
att gat aat ccg aaa ctc atg gat gcc cgc ctc ttc cag gac ggt ccc			1536
Ile Asp Asn Pro Lys Leu Met Asp Ala Arg Leu Phe Gln Asp Gly Pro			
	500	505	510
atg gga ctg aaa aaa taa			1554
Met Gly Leu Lys Lys			
	515		

<210> SEQ ID NO 2
 <211> LENGTH: 517
 <212> TYPE: PRT
 <213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 2

```

Met Arg Lys Val Glu Ile Ile Thr Ala Glu Gln Ala Ala Gln Leu Val
1      5      10      15

Lys Asp Asn Asp Thr Ile Thr Ser Ile Gly Phe Val Ser Ser Ala His
20      25      30

Pro Glu Ala Leu Thr Lys Ala Leu Glu Lys Arg Phe Leu Asp Thr Asn
35      40      45

Thr Pro Gln Asn Leu Thr Tyr Ile Tyr Ala Gly Ser Gln Gly Lys Arg
50      55      60

Asp Gly Arg Ala Ala Glu His Leu Ala His Thr Gly Leu Leu Lys Arg
65      70      75      80

Ala Ile Ile Gly His Trp Gln Thr Val Pro Ala Ile Gly Lys Leu Ala
85      90      95

Val Glu Asn Lys Ile Glu Ala Tyr Asn Phe Ser Gln Gly Thr Leu Val
100     105     110

His Trp Phe Arg Ala Leu Ala Gly His Lys Leu Gly Val Phe Thr Asp
115     120     125

Ile Gly Leu Glu Thr Phe Leu Asp Pro Arg Gln Leu Gly Gly Lys Leu
130     135     140

Asn Asp Val Thr Lys Glu Asp Leu Val Lys Leu Ile Glu Val Asp Gly
145     150     155     160

His Glu Gln Leu Phe Tyr Pro Thr Phe Pro Val Asn Val Ala Phe Leu
165     170     175

Arg Gly Thr Tyr Ala Asp Glu Ser Gly Asn Ile Thr Met Asp Glu Glu
180     185     190

Ile Gly Pro Phe Glu Ser Thr Ser Val Ala Gln Ala Val His Asn Cys
195     200     205

Gly Gly Lys Val Val Val Gln Val Lys Asp Val Val Ala His Gly Ser
210     215     220

Leu Asp Pro Arg Met Val Lys Ile Pro Gly Ile Tyr Val Asp Tyr Val
225     230     235     240

Val Val Ala Ala Pro Glu Asp His Gln Gln Thr Tyr Asp Cys Glu Tyr
245     250     255

Asp Pro Ser Leu Ser Gly Glu His Arg Ala Pro Glu Gly Ala Thr Asp
260     265     270

Ala Ala Leu Pro Met Ser Ala Lys Lys Ile Ile Gly Arg Arg Gly Ala
275     280     285

```

-continued

Leu Glu Leu Thr Glu Asn Ala Val Val Asn Leu Gly Val Gly Ala Pro
 290 295 300
 Glu Tyr Val Ala Ser Val Ala Gly Glu Glu Gly Ile Ala Asp Thr Ile
 305 310 315 320
 Thr Leu Thr Val Glu Gly Gly Ala Ile Gly Gly Val Pro Gln Gly Gly
 325 330 335
 Ala Arg Phe Gly Ser Ser Arg Asn Ala Asp Ala Ile Ile Asp His Thr
 340 345 350
 Tyr Gln Phe Asp Phe Tyr Asp Gly Gly Gly Leu Asp Ile Ala Tyr Leu
 355 360 365
 Gly Leu Ala Gln Cys Asp Gly Ser Gly Asn Ile Asn Val Ser Lys Phe
 370 375 380
 Gly Thr Asn Val Ala Gly Cys Gly Gly Phe Pro Asn Ile Ser Gln Gln
 385 390 395 400
 Thr Pro Asn Val Tyr Phe Cys Gly Thr Phe Thr Ala Gly Gly Leu Lys
 405 410 415
 Ile Ala Val Glu Asp Gly Lys Val Lys Ile Leu Gln Glu Gly Lys Ala
 420 425 430
 Lys Lys Phe Ile Lys Ala Val Asp Gln Ile Thr Phe Asn Gly Ser Tyr
 435 440 445
 Ala Ala Arg Asn Gly Lys His Val Leu Tyr Ile Thr Glu Arg Cys Val
 450 455 460
 Phe Glu Leu Thr Lys Glu Gly Leu Lys Leu Ile Glu Val Ala Pro Gly
 465 470 475 480
 Ile Asp Ile Glu Lys Asp Ile Leu Ala His Met Asp Phe Lys Pro Ile
 485 490 495
 Ile Asp Asn Pro Lys Leu Met Asp Ala Arg Leu Phe Gln Asp Gly Pro
 500 505 510
 Met Gly Leu Lys Lys
 515

<210> SEQ ID NO 3
 <211> LENGTH: 1560
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 3

gtgccggtcc tgtcggcaca ggaagcgggtg aattatattc ccgacgaagc aacactttgt	60
gtgttaggcg ctggcggcgg tattctggaa gccaccacgt taattactgc tcttgtgat	120
aaatataaac agactcaaac accacgtaat ttatcgatta ttagtccaac agggcttggc	180
gatecgcgccg accgtggtat tagtcctctg gcgcaagaag gtctggtgaa atgggcatta	240
tgtggtcact ggggacaatc gccgcgtatt tctgaactcg cagaacaaaa taaaattatt	300
gcttataact acccacaagg tgtacttaca caaaccttac gcgccgccgc agcccaccag	360
cctggtatta ttagtgatat tggcatcggg acatttgtcg atccacgcca gcaaggcggc	420
aaactgaatg aagtcactaa agaagacctg attaaactgg tcgagtttga taacaaagaa	480
tatctctatt acaaagcgat tgcgccagat attgccttca ttgcgctac cacctgcgac	540
agtgaaggct acgccacttt tgaagatgag gtgatgtatc tcgacgcatt gggtattgcc	600
caggcgggtgc acaataacgg cgggtattgtg atgatgcagg tgcagaaaat ggtaagaaa	660
gccacgctgc atcctaaatc tgtccgtatt ccgggttata tggtggatat tgtggtggtc	720
gatccggatc aaaccaact gtatggcggg gcaccgggta accgctttat ttctggtgac	780
ttcacccctg atgacagtac caaacttagc ctgcccctaa accaacgtaa attagttgcg	840

-continued

cggcgcgc	tattcgaaat	gcgtaaaggc	gcggtgggga	atgtcggcgt	cggtattgct	900
gacggcattg	gcctgggtcgc	ccgagaagaa	ggttgtgctg	atgactttat	tctgacggta	960
gaaacaggtc	cgattggcgg	aattacttca	caggggatcg	cctttggcgc	gaacgtgaat	1020
accogtgcca	ttctggatat	gacgtcccag	tttgattttt	atcacgggtg	cggtctggat	1080
gtttgttatt	tgagttttgc	tgaagtcgac	cagcacggta	acgtcggcgt	gcataaattc	1140
aatggtaaaa	tcatgggcac	cggtggattt	attgatatca	gtgccacttc	gaagaaaatc	1200
attttctgcg	gcacattaac	tgccggcagt	ttaaaaacag	aaattaccga	cgccaaatta	1260
aatatcgtcc	aggaaggacg	ggtgaagaaa	tttattcggg	aactaccgga	aattactttc	1320
agcggaaaaa	tcgtctcga	gcgagggctg	gatgttcggt	atatcactga	gcgcgcagta	1380
ttcacgctga	aagaagacgg	cctgcattta	atcgaaatcg	cccctggcgt	cgatttacia	1440
aaagatattc	tcgacaaaat	ggatttcacc	ccagtgtatt	cgccagaact	caaactgatg	1500
gacgaaagat	tatttatcga	tgccggcgatg	ggttttgtcc	tgctgaagc	ggctcattaa	1560

<210> SEQ ID NO 4

<211> LENGTH: 1566

<212> TYPE: DNA

<213> ORGANISM: *Caenorhabditis elegans*

<400> SEQUENCE: 4

atgccgattc	tctcaaaaat	atgggcggct	ccagcagctg	gaatcttgag	aaaaactccg	60
agaaatgctc	atcaaatgag	gctaattctca	atgacatcct	cgatgaaagc	aaaagtcttt	120
aactctgccg	aagaagccgt	gaaggatatt	ccagataatg	caaagctttt	agttggcggc	180
ttcggactat	gcggaatccc	agaaaatctc	atccaagcta	tcacaaaaac	tggtcaaaaa	240
ggtcttacct	gtgtatcaaa	caatgcggga	gttgataatt	ggggacttgg	cttgctcctt	300
caaaactcgac	aaatcaagaa	aatgatctca	tcgtacgtcg	gtgaaaacgg	agaatttgct	360
cgacaatatc	ttagcggaga	gctcagttg	gaattcacac	cacaaggaac	actcgcgcaa	420
cgaattcgtg	cagctgggtg	cggtgttccc	gcattctaca	caccaacagg	atacggtaac	480
cagattcaag	aaggagggtg	tccgattaag	tacagtaaaa	ctgaaaaagg	aaagattgaa	540
gttgcaagta	aagcgaaaga	aacacgacaa	ttcaatggaa	ttaattatgt	aatggaagag	600
gctatttggg	gagattttgc	attgatcaag	gcgtggagag	cagatactct	tggaaatatt	660
caattcagac	atgctgctgg	aaatttcaat	aatccaatgt	gcaaagcctc	taaatgcacc	720
atcgtcgaag	tagaggaaat	cgtcgaaccg	ggagtaattg	ctccaaacga	tgtgcacatt	780
ccatcaatct	attgtcatcg	tctagttttg	ggaaagaact	acaaaaaac	aatcgaaacg	840
ccaatgttcg	cacacgaagg	accaataaaa	ccatctacat	cggctgctgg	aaaatcgaga	900
gaaatcattg	cagcagctgc	agccttggag	ttcacagatg	gaatgtacgc	caatttgggt	960
atcgggattc	cgactttggc	gccaaattat	ataccaaatg	gatttactgt	tcatttgcaa	1020
agtgagaatg	gtattattgg	agtgggacca	tatccaagaa	aaggaaacaga	agacgccgat	1080
ctcattaatg	ctggaaaaga	gccaaattact	cttctcaaag	gagcttcaat	tgttggttct	1140
gatgaatcat	tcgcaatgat	tcgtgggtct	catatggata	ttactgtgct	cggtgcactt	1200
cagtgtctc	agtttgagga	tttagcgaat	tggatgattc	cgggaaaatt	ggtgaaagga	1260
atgggcgggt	caatggatct	tgtctctgct	cccggagccc	gtgtgatcgt	tgtaatggag	1320
catgtatcga	agaacggaga	gccaaaaatt	ctagagcact	gcgaacttcc	tctgaccggc	1380
aaaggagtaa	tttcccgaat	cattactgat	atggcagttt	tcgacgtgga	cacaaagaac	1440

-continued

```

ggattgacat tgatcgaagt caggaaggat cttactgtag atgatatcaa gaaactcacc 1500
gcttgcaaat tcgaaatttc cgaaaatctg aagccaatgg gacaggctcc tcttaatcaa 1560
ggataa 1566

```

```

<210> SEQ ID NO 5
<211> LENGTH: 672
<212> TYPE: DNA
<213> ORGANISM: Haemophilus influenzae

```

```

<400> SEQUENCE: 5

```

```

atgaatgcaa aagaattaat cgctcgccga attgcatgg aattacatga tggagatatt 60
gttaatctcg gtattggttt accaacacag gttgttaatt atttacctga taatgtcaat 120
attacacttc aatcagaaaa tggctttctt ggtttaactg catttgacct agaaaaatgct 180
aattcaaact tagtaaatgc tgggtggtcag ccttgtggaa ttaaaaaagg cggctctact 240
tttgatagtg ctttttcttt cgctttaatt cgtggcggtc atgttgatgc ctgtgtgcta 300
ggtggtactt aagttgatca agaagcaaat ctgctaact ggatggtgcc tggcaaaatg 360
gtaccaggaa tgggcggagc aatggactta gtgactggtg caaaaaaagt gattattggc 420
atggaacatt gtgccaagtc aggttctctc aaaattctaa agaaatgtac attaccgctc 480
acagcaagta aaaaagtgtc catggtggtt accgaattgg cagtatttaa cttcattgaa 540
ggcagattag ttctaaaaga acatgctcct catgtggatt tagaacaat taaagccaaa 600
acagaagccg atttcattgt tgccgatgat ttcaaagaaa tgcaaatcag ccagaaagga 660
cttgaattat ga 672

```

```

<210> SEQ ID NO 6
<211> LENGTH: 519
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 6

```

```

Met Pro Val Leu Ser Ala Gln Glu Ala Val Asn Tyr Ile Pro Asp Glu
1          5          10          15
Ala Thr Leu Cys Val Leu Gly Ala Gly Gly Gly Ile Leu Glu Ala Thr
20          25          30
Thr Leu Ile Thr Ala Leu Ala Asp Lys Tyr Lys Gln Thr Gln Thr Pro
35          40          45
Arg Asn Leu Ser Ile Ile Ser Pro Thr Gly Leu Gly Asp Arg Ala Asp
50          55          60
Arg Gly Ile Ser Pro Leu Ala Gln Glu Gly Leu Val Lys Trp Ala Leu
65          70          75          80
Cys Gly His Trp Gly Gln Ser Pro Arg Ile Ser Glu Leu Ala Glu Gln
85          90          95
Asn Lys Ile Ile Ala Tyr Asn Tyr Pro Gln Gly Val Leu Thr Gln Thr
100         105         110
Leu Arg Ala Ala Ala Ala His Gln Pro Gly Ile Ile Ser Asp Ile Gly
115         120         125
Ile Gly Thr Phe Val Asp Pro Arg Gln Gln Gly Gly Lys Leu Asn Glu
130         135         140
Val Thr Lys Glu Asp Leu Ile Lys Leu Val Glu Phe Asp Asn Lys Glu
145         150         155         160
Tyr Leu Tyr Tyr Lys Ala Ile Ala Pro Asp Ile Ala Phe Ile Arg Ala
165         170         175

```

-continued

Thr Thr Cys Asp Ser Glu Gly Tyr Ala Thr Phe Glu Asp Glu Val Met
 180 185 190
 Tyr Leu Asp Ala Leu Val Ile Ala Gln Ala Val His Asn Asn Gly Gly
 195 200 205
 Ile Val Met Met Gln Val Gln Lys Met Val Lys Lys Ala Thr Leu His
 210 215 220
 Pro Lys Ser Val Arg Ile Pro Gly Tyr Leu Val Asp Ile Val Val Val
 225 230 235 240
 Asp Pro Asp Gln Thr Gln Leu Tyr Gly Gly Ala Pro Val Asn Arg Phe
 245 250 255
 Ile Ser Gly Asp Phe Thr Leu Asp Asp Ser Thr Lys Leu Ser Leu Pro
 260 265 270
 Leu Asn Gln Arg Lys Leu Val Ala Arg Arg Ala Leu Phe Glu Met Arg
 275 280 285
 Lys Gly Ala Val Gly Asn Val Gly Val Gly Ile Ala Asp Gly Ile Gly
 290 295 300
 Leu Val Ala Arg Glu Glu Gly Cys Ala Asp Asp Phe Ile Leu Thr Val
 305 310 315 320
 Glu Thr Gly Pro Ile Gly Gly Ile Thr Ser Gln Gly Ile Ala Phe Gly
 325 330 335
 Ala Asn Val Asn Thr Arg Ala Ile Leu Asp Met Thr Ser Gln Phe Asp
 340 345 350
 Phe Tyr His Gly Gly Gly Leu Asp Val Cys Tyr Leu Ser Phe Ala Glu
 355 360 365
 Val Asp Gln His Gly Asn Val Gly Val His Lys Phe Asn Gly Lys Ile
 370 375 380
 Met Gly Thr Gly Gly Phe Ile Asp Ile Ser Ala Thr Ser Lys Lys Ile
 385 390 395 400
 Ile Phe Cys Gly Thr Leu Thr Ala Gly Ser Leu Lys Thr Glu Ile Thr
 405 410 415
 Asp Gly Lys Leu Asn Ile Val Gln Glu Gly Arg Val Lys Lys Phe Ile
 420 425 430
 Arg Glu Leu Pro Glu Ile Thr Phe Ser Gly Lys Ile Ala Leu Glu Arg
 435 440 445
 Gly Leu Asp Val Arg Tyr Ile Thr Glu Arg Ala Val Phe Thr Leu Lys
 450 455 460
 Glu Asp Gly Leu His Leu Ile Glu Ile Ala Pro Gly Val Asp Leu Gln
 465 470 475 480
 Lys Asp Ile Leu Asp Lys Met Asp Phe Thr Pro Val Ile Ser Pro Glu
 485 490 495
 Leu Lys Leu Met Asp Glu Arg Leu Phe Ile Asp Ala Ala Met Gly Phe
 500 505 510
 Val Leu Pro Glu Ala Ala His
 515

<210> SEQ ID NO 7

<211> LENGTH: 521

<212> TYPE: PRT

<213> ORGANISM: Caenorhabditis elegans

<400> SEQUENCE: 7

Met Pro Ile Leu Ser Lys Ile Trp Ala Ala Pro Ala Ala Gly Ile Leu
 1 5 10 15
 Arg Lys Thr Pro Arg Asn Ala His Gln Met Arg Leu Ile Ser Met Thr
 20 25 30

-continued

Ser	Ser	Met	Lys	Ala	Lys	Val	Phe	Asn	Ser	Ala	Glu	Glu	Ala	Val	Lys
		35					40					45			
Asp	Ile	Pro	Asp	Asn	Ala	Lys	Leu	Leu	Val	Gly	Gly	Phe	Gly	Leu	Cys
	50					55					60				
Gly	Ile	Pro	Glu	Asn	Leu	Ile	Gln	Ala	Ile	Thr	Lys	Thr	Gly	Gln	Lys
65					70					75					80
Gly	Leu	Thr	Cys	Val	Ser	Asn	Asn	Ala	Gly	Val	Asp	Asn	Trp	Gly	Leu
				85					90					95	
Gly	Leu	Leu	Leu	Gln	Thr	Arg	Gln	Ile	Lys	Lys	Met	Ile	Ser	Ser	Tyr
			100					105					110		
Val	Gly	Glu	Asn	Gly	Glu	Phe	Ala	Arg	Gln	Tyr	Leu	Ser	Gly	Glu	Leu
		115					120					125			
Glu	Leu	Glu	Phe	Thr	Pro	Gln	Gly	Thr	Leu	Ala	Glu	Arg	Ile	Arg	Ala
	130					135					140				
Ala	Gly	Ala	Gly	Val	Pro	Ala	Phe	Tyr	Thr	Pro	Thr	Gly	Tyr	Gly	Thr
145					150					155					160
Gln	Ile	Gln	Glu	Gly	Gly	Ala	Pro	Ile	Lys	Tyr	Ser	Lys	Thr	Glu	Lys
			165						170					175	
Gly	Lys	Ile	Glu	Val	Ala	Ser	Lys	Ala	Lys	Glu	Thr	Arg	Gln	Phe	Asn
		180						185					190		
Gly	Ile	Asn	Tyr	Val	Met	Glu	Glu	Ala	Ile	Trp	Gly	Asp	Phe	Ala	Leu
	195					200					205				
Ile	Lys	Ala	Trp	Arg	Ala	Asp	Thr	Leu	Gly	Asn	Ile	Gln	Phe	Arg	His
	210					215					220				
Ala	Ala	Gly	Asn	Phe	Asn	Asn	Pro	Met	Cys	Lys	Ala	Ser	Lys	Cys	Thr
225					230					235					240
Ile	Val	Glu	Val	Glu	Glu	Ile	Val	Glu	Pro	Gly	Val	Ile	Ala	Pro	Asn
			245					250						255	
Asp	Val	His	Ile	Pro	Ser	Ile	Tyr	Cys	His	Arg	Leu	Val	Leu	Gly	Lys
		260						265					270		
Asn	Tyr	Lys	Lys	Pro	Ile	Glu	Arg	Pro	Met	Phe	Ala	His	Glu	Gly	Pro
	275						280					285			
Ile	Lys	Pro	Ser	Thr	Ser	Ala	Ala	Gly	Lys	Ser	Arg	Glu	Ile	Ile	Ala
	290					295					300				
Ala	Arg	Ala	Ala	Leu	Glu	Phe	Thr	Asp	Gly	Met	Tyr	Ala	Asn	Leu	Gly
305					310				315						320
Ile	Gly	Ile	Pro	Thr	Leu	Ala	Pro	Asn	Tyr	Ile	Pro	Asn	Gly	Phe	Thr
			325					330						335	
Val	His	Leu	Gln	Ser	Glu	Asn	Gly	Ile	Ile	Gly	Val	Gly	Pro	Tyr	Pro
		340					345						350		
Arg	Lys	Gly	Thr	Glu	Asp	Ala	Asp	Leu	Ile	Asn	Ala	Gly	Lys	Glu	Pro
		355				360						365			
Ile	Thr	Leu	Leu	Lys	Gly	Ala	Ser	Ile	Val	Gly	Ser	Asp	Glu	Ser	Phe
	370					375					380				
Ala	Met	Ile	Arg	Gly	Ser	His	Met	Asp	Ile	Thr	Val	Leu	Gly	Ala	Leu
385					390				395						400
Gln	Cys	Ser	Gln	Phe	Gly	Asp	Leu	Ala	Asn	Trp	Met	Ile	Pro	Gly	Lys
			405					410						415	
Leu	Val	Lys	Gly	Met	Gly	Gly	Ala	Met	Asp	Leu	Val	Ser	Ala	Pro	Gly
		420					425					430			
Ala	Arg	Val	Ile	Val	Val	Met	Glu	His	Val	Ser	Lys	Asn	Gly	Glu	Pro
		435				440						445			
Lys	Ile	Leu	Glu	His	Cys	Glu	Leu	Pro	Leu	Thr	Gly	Lys	Gly	Val	Ile
	450					455					460				

-continued

Ser Arg Ile Ile Thr Asp Met Ala Val Phe Asp Val Asp Thr Lys Asn
465 470 475 480

Gly Leu Thr Leu Ile Glu Val Arg Lys Asp Leu Thr Val Asp Asp Ile
485 490 495

Lys Lys Leu Thr Ala Cys Lys Phe Glu Ile Ser Glu Asn Leu Lys Pro
500 505 510

Met Gly Gln Ala Pro Leu Asn Gln Gly
515 520

<210> SEQ ID NO 8
<211> LENGTH: 223
<212> TYPE: PRT
<213> ORGANISM: Haemophilus influenzae

<400> SEQUENCE: 8

Met Asn Ala Lys Glu Leu Ile Ala Arg Arg Ile Ala Met Glu Leu His
1 5 10 15

Asp Gly Asp Ile Val Asn Leu Gly Ile Gly Leu Pro Thr Gln Val Val
20 25 30

Asn Tyr Leu Pro Asp Asn Val Asn Ile Thr Leu Gln Ser Glu Asn Gly
35 40 45

Phe Leu Gly Leu Thr Ala Phe Asp Pro Glu Asn Ala Asn Ser Asn Leu
50 55 60

Val Asn Ala Gly Gly Gln Pro Cys Gly Ile Lys Lys Gly Gly Ser Thr
65 70 75 80

Phe Asp Ser Ala Phe Ser Phe Ala Leu Ile Arg Gly Gly His Val Asp
85 90 95

Ala Cys Val Leu Gly Gly Leu Glu Val Asp Gln Glu Ala Asn Leu Ala
100 105 110

Asn Trp Met Val Pro Gly Lys Met Val Pro Gly Met Gly Gly Ala Met
115 120 125

Asp Leu Val Thr Gly Ala Lys Lys Val Ile Ile Gly Met Glu His Cys
130 135 140

Ala Lys Ser Gly Ser Ser Lys Ile Leu Lys Lys Cys Thr Leu Pro Leu
145 150 155 160

Thr Ala Ser Lys Lys Val Ala Met Val Val Thr Glu Leu Ala Val Phe
165 170 175

Asn Phe Ile Glu Gly Arg Leu Val Leu Lys Glu His Ala Pro His Val
180 185 190

Asp Leu Glu Thr Ile Lys Ala Lys Thr Glu Ala Asp Phe Ile Val Ala
195 200 205

Asp Asp Phe Lys Glu Met Gln Ile Ser Gln Lys Gly Leu Glu Leu
210 215 220

<210> SEQ ID NO 9
<211> LENGTH: 786
<212> TYPE: DNA
<213> ORGANISM: Megaspheera elsdennii
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(783)

<400> SEQUENCE: 9

gtg aaa act gtg tat act ctc gga atc gac gtt ggt tct tct tct tcc 48
Val Lys Thr Val Tyr Thr Leu Gly Ile Asp Val Gly Ser Ser Ser Ser
1 5 10 15

aag gca gtc atc ctg gaa gat ggc aag aag atc gtc gcc cat gcc gtc 96
Lys Ala Val Ile Leu Glu Asp Gly Lys Lys Ile Val Ala His Ala Val

-continued

20	25	30	
ggt gaa atc ggc acc ggt tgc acc ggt ccg gaa cgc gtc ctg gac gaa			144
Val Glu Ile Gly Thr Gly Ser Thr Gly Pro Glu Arg Val Leu Asp Glu			
35	40	45	
gtc ttc aaa gat acc aac tta aaa att gaa gac atg gcg aac atc atc			192
Val Phe Lys Asp Thr Asn Leu Lys Ile Glu Asp Met Ala Asn Ile Ile			
50	55	60	
gcc aca ggc tat ggc cgt ttc aat gtc gac tgc gcc aaa ggc gaa gtc			240
Ala Thr Gly Tyr Gly Arg Phe Asn Val Asp Cys Ala Lys Gly Glu Val			
65	70	75	80
agc gaa atc acg tgc cat gcc aaa ggg gcc ctc ttt gaa tgc ccc ggt			288
Ser Glu Ile Thr Cys His Ala Lys Gly Ala Leu Phe Glu Cys Pro Gly			
85	90	95	
acg acg acc atc ctc gat atc ggc ggt cag gac gtc aag tcc atc aaa			336
Thr Thr Thr Ile Leu Asp Ile Gly Gly Gln Asp Val Lys Ser Ile Lys			
100	105	110	
ttg aat ggc cag ggc ctg gtc atg cag ttt gcc atg aac gac aaa tgc			384
Leu Asn Gly Gln Gly Leu Val Met Gln Phe Ala Met Asn Asp Lys Cys			
115	120	125	
gcc gct ggt acg ggc cgt ttc ctc gac gtc atg tgc aag gta ctg gaa			432
Ala Ala Gly Thr Gly Arg Phe Leu Asp Val Met Ser Lys Val Leu Glu			
130	135	140	
atc ccc atg tct gaa atg ggg gac tgg tac ttc aaa tgc aag cat ccc			480
Ile Pro Met Ser Glu Met Gly Asp Trp Tyr Phe Lys Ser Lys His Pro			
145	150	155	160
gct gcc gtc agc agt acc tgc acg gtt ttt gct gaa tgc gaa gtc att			528
Ala Ala Val Ser Ser Thr Cys Thr Val Phe Ala Glu Ser Glu Val Ile			
165	170	175	
tcc ctt ctt tcc aag aat gtc ccg aaa gaa gat atc gta gcc ggt gtc			576
Ser Leu Leu Ser Lys Asn Val Pro Lys Glu Asp Ile Val Ala Gly Val			
180	185	190	
cat cag tcc atc gcc gcc aaa gcc tgc gct ctc gtg cgc cgc gtc ggt			624
His Gln Ser Ile Ala Ala Lys Ala Cys Ala Leu Val Arg Arg Val Gly			
195	200	205	
gtc ggt gaa gac ctg acc atg acc ggc ggt ggc tcc cgc gat ccc ggc			672
Val Gly Glu Asp Leu Thr Met Thr Gly Gly Gly Ser Arg Asp Pro Gly			
210	215	220	
gtc gtc gat gcc gta tgc aaa gaa tta ggt att cct gtc aga gtc gct			720
Val Val Asp Ala Val Ser Lys Glu Leu Gly Ile Pro Val Arg Val Ala			
225	230	235	240
ctg cat ccc caa gcg gtg ggt gct ctc gga gct gct ttg att gct tat			768
Leu His Pro Gln Ala Val Gly Ala Leu Gly Ala Ala Leu Ile Ala Tyr			
245	250	255	
gat aaa atc aag aaa taa			786
Asp Lys Ile Lys Lys			
260			
<210> SEQ ID NO 10			
<211> LENGTH: 261			
<212> TYPE: PRT			
<213> ORGANISM: Megasphaera elsdenii			
<400> SEQUENCE: 10			
Val Lys Thr Val Tyr Thr Leu Gly Ile Asp Val Gly Ser Ser Ser Ser			
1	5	10	15
Lys Ala Val Ile Leu Glu Asp Gly Lys Lys Ile Val Ala His Ala Val			
20	25	30	
Val Glu Ile Gly Thr Gly Ser Thr Gly Pro Glu Arg Val Leu Asp Glu			
35	40	45	
Val Phe Lys Asp Thr Asn Leu Lys Ile Glu Asp Met Ala Asn Ile Ile			

-continued

50	55	60
Ala Thr Gly Tyr Gly Arg Phe Asn Val Asp Cys Ala Lys Gly Glu Val 65 70 75 80		
Ser Glu Ile Thr Cys His Ala Lys Gly Ala Leu Phe Glu Cys Pro Gly 85 90 95		
Thr Thr Thr Ile Leu Asp Ile Gly Gly Gln Asp Val Lys Ser Ile Lys 100 105 110		
Leu Asn Gly Gln Gly Leu Val Met Gln Phe Ala Met Asn Asp Lys Cys 115 120 125		
Ala Ala Gly Thr Gly Arg Phe Leu Asp Val Met Ser Lys Val Leu Glu 130 135 140		
Ile Pro Met Ser Glu Met Gly Asp Trp Tyr Phe Lys Ser Lys His Pro 145 150 155 160		
Ala Ala Val Ser Ser Thr Cys Thr Val Phe Ala Glu Ser Glu Val Ile 165 170 175		
Ser Leu Leu Ser Lys Asn Val Pro Lys Glu Asp Ile Val Ala Gly Val 180 185 190		
His Gln Ser Ile Ala Ala Lys Ala Cys Ala Leu Val Arg Arg Val Gly 195 200 205		
Val Gly Glu Asp Leu Thr Met Thr Gly Gly Gly Ser Arg Asp Pro Gly 210 215 220		
Val Val Asp Ala Val Ser Lys Glu Leu Gly Ile Pro Val Arg Val Ala 225 230 235 240		
Leu His Pro Gln Ala Val Gly Ala Leu Gly Ala Ala Leu Ile Ala Tyr 245 250 255		
Asp Lys Ile Lys Lys 260		

<210> SEQ ID NO 11

<211> LENGTH: 783

<212> TYPE: DNA

<213> ORGANISM: Acidaminococcus fermentans

<400> SEQUENCE: 11

atgagtatct ataccttggg aatcgatgtt ggatctactg catccaagtg cattatcctg	60
aaagatggaa aagaaatcgt ggcgaaatcc ctggtagccg tggggaccgg aacttcgggt	120
cccgacgggt ctatttcgga agtcctggaa aatgcccaca tgaaaaaaga agacatggcc	180
tttaccctgg ctaccggcta cggacgcaat tcgctggaag gcattgccga caagcagatg	240
agcgaaactga gctgccatgc catgggcgcc agctttatct ggcccaacgt ccataccgtc	300
atcgatatcg gcgggcagga tgtgaaggtc atccatgtgg aaaacggggac catgaccaat	360
ttccagatga atgataaatg cgctgccggg actggccggt tcctggatgt tatggccaat	420
atcctggaag tgaaggttcc cgacctggct gagctgggag ccaaatccac caaacgggtg	480
gctatcagct ccacctgtac tgtgtttgca gaaagtgaag tcatcagcca gctgtccaaa	540
ggaaccgaca agatcgacat cattgccggg atccatcgtt ctgtagccag ccgggtcatt	600
ggctcttgcca atcgggtggg gattgtgaaa gacgtgggtc tgaccggcgg tgtagcccag	660
aactatggcg tgagaggagc cctggaagaa ggccttggcg tggaaatcaa gacgtctccc	720
ctggctcagt acaacgggtgc cctgggtgcc gctctgtatg cgtataaaaa agcagccaaa	780
taa	783

<210> SEQ ID NO 12

<211> LENGTH: 774

-continued

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 12

```

gtggcagtg catattcgat tggcattgat tccggctcaa cgcgcccaa agggatctta    60
ctggcagacg gcgtgattac gcgcggttct ctcgttccaa ccccttttcg cccggcaaca    120
gcaattactg aagcctggga aactctgcgc gaagggttag agacaacgcc gtttctgacg    180
ctcaccggct acgggcggca actggtggat tttgccgata aacaggtaac ggaatctctc    240
tgtcacgggc tgggcgcacg gtttcttgcg ccagcaacgc gcgcggtaat cgacatcggt    300
ggtcaggaca gcaaagtgat tcagcttgat gatgacggta acctgtgcga ttctctgatg    360
aatgacaaat gcgcggcgcg caccgggcgt ttcttgagg tgatctcgcg cacgcttggc    420
accagcgctc agcaactcga cagcattacc gaaaatgtca cgcgcacgc catcacgagt    480
atgtgcacag tgtttgctga atcagaacgc atcagcctgc gctcagcggg cgtcgcgcca    540
gaagcgattc tcgcaggagt gattaacgcg atggcgcgga ggagtgcgaa ttctattgct    600
cgtctctcct gtgaagcgcc gattctgttt actggtggcg ttagtcattg ccagaagttt    660
gcccggtatg tggaaatctc cctgcgaatg ccggtaaata cccatcctga tgcgcaattt    720
gctggcgcaa ttggcgcggc ggtaattggt caacgagtga ggacacgccg atga        774

```

<210> SEQ ID NO 13

<211> LENGTH: 732

<212> TYPE: DNA

<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 13

```

atgatattag ggatagatgt tggatctaca acaacgaaga tggttctaata ggaagatagc    60
aagataatatt ggtataagat agaggatatt ggagttgtta ttgaggaaga tattttatta    120
aaaaatggta aggagattga acaaaaatat ccaatagata aaatcgttgc aactggatat    180
ggaaggcata aggttagttt tgcagataag atagttccag aagttattgc attgggaaaa    240
ggagctaact atttctttaa cgaggcagat ggagttatag acattggagg gcaagataca    300
aaggtcttaa agattgataa aaacggaaaa gttgttgatt ttatcctatc agataaatgt    360
gccgctggaa ctggaaaatt cttagaaaag gcattagata ttttaaaaat tgataaaaat    420
gagataaata aatacaaatc agataaatc gctaaaatat cttcaatgtg tgetgtcttt    480
gctgaaagtg agataataag cttactatca aaaaaagttc caaaggaagg cattttaatg    540
ggcgtctatg agagtataat aaatagggtt atcccaatga ccaataggct taaaattcaa    600
aacatagtggt ttagtggagg agttgctaaa aataagggtt tggttgagat gtttgagaaa    660
aaattgaata aaaaactact aattccaaaa gaaccacaga ttgtttgctg tgttgagagct    720
atattgggtt aa                                732

```

<210> SEQ ID NO 14

<211> LENGTH: 260

<212> TYPE: PRT

<213> ORGANISM: Acidaminococcus fermentans

<400> SEQUENCE: 14

```

Met Ser Ile Tyr Thr Leu Gly Ile Asp Val Gly Ser Thr Ala Ser Lys
1           5           10          15
Cys Ile Ile Leu Lys Asp Gly Lys Glu Ile Val Ala Lys Ser Leu Val
                20                25                30
Ala Val Gly Thr Gly Thr Ser Gly Pro Ala Arg Ser Ile Ser Glu Val

```

-continued

35	40	45
Leu Glu Asn Ala His Met Lys Lys Glu Asp Met Ala Phe Thr Leu Ala		
50	55	60
Thr Gly Tyr Gly Arg Asn Ser Leu Glu Gly Ile Ala Asp Lys Gln Met		
65	70	75
Ser Glu Leu Ser Cys His Ala Met Gly Ala Ser Phe Ile Trp Pro Asn		
	85	90
Val His Thr Val Ile Asp Ile Gly Gly Gln Asp Val Lys Val Ile His		
	100	105
Val Glu Asn Gly Thr Met Thr Asn Phe Gln Met Asn Asp Lys Cys Ala		
	115	120
Ala Gly Thr Gly Arg Phe Leu Asp Val Met Ala Asn Ile Leu Glu Val		
	130	135
Lys Val Ser Asp Leu Ala Glu Leu Gly Ala Lys Ser Thr Lys Arg Val		
	145	150
Ala Ile Ser Ser Thr Cys Thr Val Phe Ala Glu Ser Glu Val Ile Ser		
	165	170
Gln Leu Ser Lys Gly Thr Asp Lys Ile Asp Ile Ile Ala Gly Ile His		
	180	185
Arg Ser Val Ala Ser Arg Val Ile Gly Leu Ala Asn Arg Val Gly Ile		
	195	200
Val Lys Asp Val Val Met Thr Gly Gly Val Ala Gln Asn Tyr Gly Val		
	210	215
Arg Gly Ala Leu Glu Glu Gly Leu Gly Val Glu Ile Lys Thr Ser Pro		
	225	230
Leu Ala Gln Tyr Asn Gly Ala Leu Gly Ala Ala Leu Tyr Ala Tyr Lys		
	245	250
Lys Ala Ala Lys		
	260	

<210> SEQ ID NO 15

<211> LENGTH: 257

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 15

Met Ala Val Ala Tyr Ser Ile Gly Ile Asp Ser Gly Ser Thr Ala Thr		
1	5	10
Lys Gly Ile Leu Leu Ala Asp Gly Val Ile Thr Arg Arg Phe Leu Val		
	20	25
Pro Thr Pro Phe Arg Pro Ala Thr Ala Ile Thr Glu Ala Trp Glu Thr		
	35	40
Leu Arg Glu Gly Leu Glu Thr Thr Pro Phe Leu Thr Leu Thr Gly Tyr		
	50	55
Gly Arg Gln Leu Val Asp Phe Ala Asp Lys Gln Val Thr Glu Ile Ser		
	65	70
Cys His Gly Leu Gly Ala Arg Phe Leu Ala Pro Ala Thr Arg Ala Val		
	85	90
Ile Asp Ile Gly Gly Gln Asp Ser Lys Val Ile Gln Leu Asp Asp Asp		
	100	105
Gly Asn Leu Cys Asp Phe Leu Met Asn Asp Lys Cys Ala Ala Gly Thr		
	115	120
Gly Arg Phe Leu Glu Val Ile Ser Arg Thr Leu Gly Thr Ser Val Glu		
	130	135
Gln Leu Asp Ser Ile Thr Glu Asn Val Thr Pro His Ala Ile Thr Ser		

-continued

145	150	155	160
Met Cys Thr Val Phe Ala Glu Ser Glu Ala Ile Ser Leu Arg Ser Ala	165	170	175
Gly Val Ala Pro Glu Ala Ile Leu Ala Gly Val Ile Asn Ala Met Ala	180	185	190
Arg Arg Ser Ala Asn Phe Ile Ala Arg Leu Ser Cys Glu Ala Pro Ile	195	200	205
Leu Phe Thr Gly Gly Val Ser His Cys Gln Lys Phe Ala Arg Met Leu	210	215	220
Glu Ser His Leu Arg Met Pro Val Asn Thr His Pro Asp Ala Gln Phe	225	230	235
Ala Gly Ala Ile Gly Ala Ala Val Ile Gly Gln Arg Val Arg Thr Arg	245	250	255

Arg

<210> SEQ ID NO 16
 <211> LENGTH: 243
 <212> TYPE: PRT
 <213> ORGANISM: Methanocaldococcus jannaschii

 <400> SEQUENCE: 16

Met Ile Leu Gly Ile Asp Val Gly Ser Thr Thr Thr Lys Met Val Leu	1	5	10	15
Met Glu Asp Ser Lys Ile Ile Trp Tyr Lys Ile Glu Asp Ile Gly Val	20	25	30	
Val Ile Glu Glu Asp Ile Leu Leu Lys Met Val Lys Glu Ile Glu Gln	35	40	45	
Lys Tyr Pro Ile Asp Lys Ile Val Ala Thr Gly Tyr Gly Arg His Lys	50	55	60	
Val Ser Phe Ala Asp Lys Ile Val Pro Glu Val Ile Ala Leu Gly Lys	65	70	75	80
Gly Ala Asn Tyr Phe Phe Asn Glu Ala Asp Gly Val Ile Asp Ile Gly	85	90	95	
Gly Gln Asp Thr Lys Val Leu Lys Ile Asp Lys Asn Gly Lys Val Val	100	105	110	
Asp Phe Ile Leu Ser Asp Lys Cys Ala Ala Gly Thr Gly Lys Phe Leu	115	120	125	
Glu Lys Ala Leu Asp Ile Leu Lys Ile Asp Lys Asn Glu Ile Asn Lys	130	135	140	
Tyr Lys Ser Asp Asn Ile Ala Lys Ile Ser Ser Met Cys Ala Val Phe	145	150	155	160
Ala Glu Ser Glu Ile Ile Ser Leu Leu Ser Lys Lys Val Pro Lys Glu	165	170	175	
Gly Ile Leu Met Gly Val Tyr Glu Ser Ile Ile Asn Arg Val Ile Pro	180	185	190	
Met Thr Asn Arg Leu Lys Ile Gln Asn Ile Val Phe Ser Gly Gly Val	195	200	205	
Ala Lys Asn Lys Val Leu Val Glu Met Phe Glu Lys Lys Leu Asn Lys	210	215	220	
Lys Leu Leu Ile Pro Lys Glu Pro Gln Ile Val Cys Cys Val Gly Ala	225	230	235	240

Ile Leu Val

<210> SEQ ID NO 17
 <211> LENGTH: 1287

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Megasphaera elsdenii
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1284)

<400> SEQUENCE: 17

atg agt gaa gaa aaa aca gta gat att gaa agc atg agc tcc aag gaa      48
Met Ser Glu Glu Lys Thr Val Asp Ile Glu Ser Met Ser Ser Lys Glu
1          5          10          15

gcc ctt ggt tac ttc ttg ccg aaa gtc gat gaa gac gca cgt aaa gcg      96
Ala Leu Gly Tyr Phe Leu Pro Lys Val Asp Glu Asp Ala Arg Lys Ala
          20          25          30

aaa aaa gaa ggc cgc ctc gtt tgc tgg tcc gct tct gtc gct cct ccg     144
Lys Lys Glu Gly Arg Leu Val Cys Trp Ser Ala Ser Val Ala Pro Pro
          35          40          45

gaa ttc tgc acg gct atg gac atc gcc atc gtc tat ccg gaa act cac     192
Glu Phe Cys Thr Ala Met Asp Ile Ala Ile Val Tyr Pro Glu Thr His
          50          55          60

gca gct ggt atc ggt gcc cgt cac ggt gct ccg gcc atg ctc gaa gtt     240
Ala Ala Gly Ile Gly Ala Arg His Gly Ala Pro Ala Met Leu Glu Val
        65          70          75          80

gct gaa aac aaa ggt tac aac cag gac atc tgt tcc tac tgc cgc gtc     288
Ala Glu Asn Lys Gly Tyr Asn Gln Asp Ile Cys Ser Tyr Cys Arg Val
          85          90          95

aac atg ggc tac atg gaa ctc ctc aaa cag cag gct ctg aca ggc gaa     336
Asn Met Gly Tyr Met Glu Leu Leu Lys Gln Gln Ala Leu Thr Gly Glu
          100          105          110

acg ccg gaa gtc ctc aaa aac tcc ccg gct tct ccg att ccc ctt ccg     384
Thr Pro Glu Val Leu Lys Asn Ser Pro Ala Ser Pro Ile Pro Leu Pro
          115          120          125

gat gtt gtc ctc act tgc aac aac atc tgc aat acc ttg ctc aaa tgg     432
Asp Val Val Leu Thr Cys Asn Asn Ile Cys Asn Thr Leu Leu Lys Trp
          130          135          140

tat gaa aac ttg gct aaa gaa ttg aac gta cct ctc atc aac atc gac     480
Tyr Glu Asn Leu Ala Lys Glu Leu Asn Val Pro Leu Ile Asn Ile Asp
          145          150          155          160

gta ccg ttc aac cat gaa ttc cct gtt acg aaa cac gct aaa cag tac     528
Val Pro Phe Asn His Glu Phe Pro Val Thr Lys His Ala Lys Gln Tyr
          165          170          175

atc gtc ggc gaa ttc aaa cat gct atc aaa cag ctc gaa gac ctt tgc     576
Ile Val Gly Glu Phe Lys His Ala Ile Lys Gln Leu Glu Asp Leu Cys
          180          185          190

ggc cgt ccc ttc gac tat gac aaa ttc ttc gaa gta cag aaa cag aca     624
Gly Arg Pro Phe Asp Tyr Asp Lys Phe Phe Glu Val Gln Lys Gln Thr
          195          200          205

cag cgc tcc atc gct gcc tgg aac aaa atc gct acg tac ttc cag tac     672
Gln Arg Ser Ile Ala Ala Trp Asn Lys Ile Ala Thr Tyr Phe Gln Tyr
          210          215          220

aaa ccg tcg ccg ctc aac ggc ttc gac ctc ttc aac tac atg ggc ctc     720
Lys Pro Ser Pro Leu Asn Gly Phe Asp Leu Phe Asn Tyr Met Gly Leu
          225          230          235          240

gcc gtt gct gcc cgc tcc ttg aac tac tcg gaa atc acg ttc aac aaa     768
Ala Val Ala Ala Arg Ser Leu Asn Tyr Ser Glu Ile Thr Phe Asn Lys
          245          250          255

ttc ctc aaa gaa ttg gac gaa aaa gta gct aat aag aaa tgg gct ttc     816
Phe Leu Lys Glu Leu Asp Glu Lys Val Ala Asn Lys Lys Trp Ala Phe
          260          265          270

ggg gaa aac gaa aaa tcc cgt gtt act tgg gaa ggt atc gct gtc tgg     864
Gly Glu Asn Glu Lys Ser Arg Val Thr Trp Glu Gly Ile Ala Val Trp
          275          280          285

```

-continued

atc gct ctc ggc cac acc ttc aaa gaa ctc aaa ggt cag ggc gct ctc	912
Ile Ala Leu Gly His Thr Phe Lys Glu Leu Lys Gly Gln Gly Ala Leu	
290 295 300	
atg act ggt tcc gct tat cct ggc atg tgg gac gtt tcc tac gaa ccg	960
Met Thr Gly Ser Ala Tyr Pro Gly Met Trp Asp Val Ser Tyr Glu Pro	
305 310 315 320	
ggc gac ctc gaa tcc atg gca gaa gct tat tcc cgt aca tac atc aac	1008
Gly Asp Leu Glu Ser Met Ala Glu Tyr Ser Arg Thr Tyr Ile Asn	
325 330 335	
tgc tgc ctc gaa cag cgc ggt gct gtt ctt gaa aaa gtt gtc cgc gat	1056
Cys Cys Leu Glu Gln Arg Gly Ala Val Leu Glu Lys Val Val Arg Asp	
340 345 350	
ggc aaa tgc gac ggc ttg atc atg cac cag aac cgt tcc tgc aag aac	1104
Gly Lys Cys Asp Gly Leu Ile Met His Gln Asn Arg Ser Cys Lys Asn	
355 360 365	
atg agc ctc ctc aac aac gaa ggc ggc cag cgc atc cag aag aac ctc	1152
Met Ser Leu Leu Asn Asn Glu Gly Gly Gln Arg Ile Gln Lys Asn Leu	
370 375 380	
ggc gta ccg tac gtc atc ttc gac ggc gac cag acc gat gct cgt aac	1200
Gly Val Pro Tyr Val Ile Phe Asp Gly Asp Gln Thr Asp Ala Arg Asn	
385 390 395 400	
ttc tcg gaa gca cag ttc gat acc cgc gta gaa gct ttg gca gaa atg	1248
Phe Ser Glu Ala Gln Phe Asp Thr Arg Val Glu Ala Leu Ala Glu Met	
405 410 415	
atg gca gac aaa aaa gcc aat gaa gga gga aac cac taa	1287
Met Ala Asp Lys Lys Ala Asn Glu Gly Gly Asn His	
420 425	

<210> SEQ ID NO 18

<211> LENGTH: 428

<212> TYPE: PRT

<213> ORGANISM: Megaspheera elsdeni

<400> SEQUENCE: 18

Met Ser Glu Glu Lys Thr Val Asp Ile Glu Ser Met Ser Ser Lys Glu	
1 5 10 15	
Ala Leu Gly Tyr Phe Leu Pro Lys Val Asp Glu Asp Ala Arg Lys Ala	
20 25 30	
Lys Lys Glu Gly Arg Leu Val Cys Trp Ser Ala Ser Val Ala Pro Pro	
35 40 45	
Glu Phe Cys Thr Ala Met Asp Ile Ala Ile Val Tyr Pro Glu Thr His	
50 55 60	
Ala Ala Gly Ile Gly Ala Arg His Gly Ala Pro Ala Met Leu Glu Val	
65 70 75 80	
Ala Glu Asn Lys Gly Tyr Asn Gln Asp Ile Cys Ser Tyr Cys Arg Val	
85 90 95	
Asn Met Gly Tyr Met Glu Leu Leu Lys Gln Gln Ala Leu Thr Gly Glu	
100 105 110	
Thr Pro Glu Val Leu Lys Asn Ser Pro Ala Ser Pro Ile Pro Leu Pro	
115 120 125	
Asp Val Val Leu Thr Cys Asn Asn Ile Cys Asn Thr Leu Leu Lys Trp	
130 135 140	
Tyr Glu Asn Leu Ala Lys Glu Leu Asn Val Pro Leu Ile Asn Ile Asp	
145 150 155 160	
Val Pro Phe Asn His Glu Phe Pro Val Thr Lys His Ala Lys Gln Tyr	
165 170 175	
Ile Val Gly Glu Phe Lys His Ala Ile Lys Gln Leu Glu Asp Leu Cys	
180 185 190	

-continued

Gly	Arg	Pro	Phe	Asp	Tyr	Asp	Lys	Phe	Phe	Glu	Val	Gln	Lys	Gln	Thr
	195						200					205			
Gln	Arg	Ser	Ile	Ala	Ala	Trp	Asn	Lys	Ile	Ala	Thr	Tyr	Phe	Gln	Tyr
	210					215					220				
Lys	Pro	Ser	Pro	Leu	Asn	Gly	Phe	Asp	Leu	Phe	Asn	Tyr	Met	Gly	Leu
	225				230					235					240
Ala	Val	Ala	Ala	Arg	Ser	Leu	Asn	Tyr	Ser	Glu	Ile	Thr	Phe	Asn	Lys
				245					250					255	
Phe	Leu	Lys	Glu	Leu	Asp	Glu	Lys	Val	Ala	Asn	Lys	Lys	Trp	Ala	Phe
			260					265					270		
Gly	Glu	Asn	Glu	Lys	Ser	Arg	Val	Thr	Trp	Glu	Gly	Ile	Ala	Val	Trp
	275						280					285			
Ile	Ala	Leu	Gly	His	Thr	Phe	Lys	Glu	Leu	Lys	Gly	Gln	Gly	Ala	Leu
	290					295					300				
Met	Thr	Gly	Ser	Ala	Tyr	Pro	Gly	Met	Trp	Asp	Val	Ser	Tyr	Glu	Pro
	305				310					315					320
Gly	Asp	Leu	Glu	Ser	Met	Ala	Glu	Ala	Tyr	Ser	Arg	Thr	Tyr	Ile	Asn
				325					330					335	
Cys	Cys	Leu	Glu	Gln	Arg	Gly	Ala	Val	Leu	Glu	Lys	Val	Val	Arg	Asp
			340					345					350		
Gly	Lys	Cys	Asp	Gly	Leu	Ile	Met	His	Gln	Asn	Arg	Ser	Cys	Lys	Asn
	355						360					365			
Met	Ser	Leu	Leu	Asn	Asn	Glu	Gly	Gly	Gln	Arg	Ile	Gln	Lys	Asn	Leu
	370					375					380				
Gly	Val	Pro	Tyr	Val	Ile	Phe	Asp	Gly	Asp	Gln	Thr	Asp	Ala	Arg	Asn
	385				390					395					400
Phe	Ser	Glu	Ala	Gln	Phe	Asp	Thr	Arg	Val	Glu	Ala	Leu	Ala	Glu	Met
				405					410					415	
Met	Ala	Asp	Lys	Lys	Ala	Asn	Glu	Gly	Gly	Asn	His				
		420					425								

<210> SEQ ID NO 19

<211> LENGTH: 1434

<212> TYPE: DNA

<213> ORGANISM: Acidaminococcus fermentans

<400> SEQUENCE: 19

atgccaaaga cagtaagccc tggcggttcag gcattgagag atgtagttga aaaggtttac	60
agagaactgc gggaaccgaa agaaagagga gaaaaagtag gctggctctc ttccaagtgc	120
ccctgcgaac tggctgaatc ttttcggctg catgttgggt atccggaaaa ccaggctgct	180
ggtatcgctg ccaacgctga cggcgaagtg atgtgccagg ctgcagaaga tatcggttat	240
gacaacgata tctgcggcta tgcccgattt tccctggctt atgctgcccg gttccggggg	300
gcccaacaaaa tggacaaaga tggcaactat gtcatcaacc cccacagcgg caaacagatg	360
aaagatgcc aatggcaaaaa ggtattcgac gcagatggca aaccgtaat cgatcccaag	420
accctgaaac cctttgccac caccgacaac atctatgaaa tcgctgctct gccggaagg	480
gaagaaaaga ccgcgcgcca gaatgccctg cacaatatc gtcagatgac catgcccatt	540
ccggacttcg tgctgtgctg caacaacatc tgcaactgca tgaccaaatg gtatgaagac	600
attgcccgtc ggcacaacat tcctttgatc atgatcgacg ttccttacia cgaattcgac	660
catgtcaacg aagccaacgt gaaatacatc cgggtcccagc tggatacggc catccgtcaa	720
atggaagaaa tcaccggcaa gaagttcgat gaagacaaat tcgaacagtg ctgccagaac	780
gcccaaccga ctgccaaagc atggctgaag gtttgcgact acctgcagta caaacgggct	840

-continued

```

ccgttcaacg ggttcgacct gttcaaccat atggctgacg tggttaccgc ccgtggccgt 900
gtggaagctg ctgaagcttt cgaactgctg gccaaggaac tggaaacagca tgtgaaggaa 960
ggcaccacca ccgctccctt caaagaacag catcgtatca tgttcgaagg gatccctgc 1020
tggccgaaac tgccgaacct gttcaaacgg ctgaaagcca acggcctgaa catcacccgc 1080
gttgtatatg ctctgctttt cgggttcgtg tacaacaacc tggacgaatt ggtcaaagcc 1140
tactgcaaag ccccgaactc cgtcagcatc gaacagggtg ttgcctggcg tgaaggcctg 1200
atccgcgaca acaaggttga cggcgtagtg gttcactaca accggctcctg caaaccttgg 1260
agcggctaca tgctgaaat gcagcgtcgt ttcaccaaag acatgggtat cccactgct 1320
ggattcgacg gtgaccaggc tgaccggaga aacttcaacg cggtcagta tgagaccctg 1380
gttcagggct tggtcgaagc catggaagca aatgatgaaa agaaggggaa ataa 1434

```

```

<210> SEQ ID NO 20
<211> LENGTH: 1122
<212> TYPE: DNA
<213> ORGANISM: Methanocaldococcus jannaschii

```

```

<400> SEQUENCE: 20

```

```

atgatgaaat taaaggcaat tgaaaagttg atgcaaaaat tcgccagtag aaaagaacag 60
ctatataagc aaaaagaaga aggtagaaaa gtttttgtaa tgttctgtgc ctatgttcca 120
atagaaataa ttttagcagc aaatgcaatc ccagttgggt tgtgtggagg taaaaatgac 180
acaatcccaa tagcagagga ggatttgcca agaaacctat gccattaat aaaatcatcc 240
tatggtttta agaaggcaaa aacctgcctt tactttgaag catctgatat agttattgga 300
gaaactacct gtgaaggaaa gaagaagatg tttgagttga tggagagatt ggtgccaatg 360
catataatgc acctcccaca catgaaagat gaagattctt tgaaaatctg gattaaagaa 420
gttgaaaagc taaaagaatt ggttgagaaa gagactggaa ataaaataac agaggaaaag 480
ttaaaagaga cagttgataa agtaataaaa gttagggagt tgttttataa actctatgaa 540
ttgaggaaga ataaaccagc tccaattaag ggttttagatg ttttaaaatt attccagttt 600
gcctatttat tggatattga tgacacaata gggatttttag aggatttaat tgaggagtta 660
gaggagagag ttaaaaaagg agaaggttat gaaggaaa gaattttaat aactggctgt 720
ccaatggttg ctggaacaaa taagattggt gaaattattg aggaagttgg aggagtagtt 780
gttggtgaag aaagctgcac tggacaaga ttctttgaaa actttgttga gggctatagc 840
gtagaggaca ttgcaaaaag atactttaaa atcccatgtg cttgtagatt taaaaacgat 900
gagagagttg aaaatataaa gagattggtt aaagagttgg acgtcgatgg agttgtttat 960
tacactttgc agtattgcca tacatttaac atagaggag ctaaggtaga ggaggcatta 1020
aaagaggagg gcattccaat tataagaatt gaaactgact attctgaaag tgatagagag 1080
cagttaaaaa caaggttggg ggcatttatt gagatgattt aa 1122

```

```

<210> SEQ ID NO 21
<211> LENGTH: 1152
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 21

```

```

atgtcacttg tcaccgatct acccgccatt ttcgatcagt tctctgaagc tcgccagaca 60
ggctttctca ccgtcatgga tctcaaggag cgcggcattc cgctggttgg cacttactgc 120
acctttatgc cgcaagagat cccgatggca gccggtgcgg ttgtggtttc gctctgttcc 180

```

-continued

```

acctctgatg aaaccattga agaagcggag aaagatctgc cgcgcaacct ctgcccgctg 240
attaaaaagca gctacggcctt cggcaaaacc gataaatgcc cctacttcta cttttcggat 300
ctgggtggctg gtgaaaccac ctgcgacggc aaaaagaaaa tgtatgaata catggcggag 360
tttaagcctg ttcattgtgat gcaattgccc aacagcgcta aggacgatgc ctgcgctgcg 420
ttatggaag ccgagatgct gcgcttgcaa aaaacggtag aagaacgttt tgggcacgag 480
attagcgaag atgctctgcg cgatgccatt gcgctgaaaa accgcgaacg tcgcgcactg 540
gctaattttt atcatcttgg gcagttaaat cctccggcgc ttagcggcag cgacattctg 600
aaagtgggtt acggcgcaac cttccgggtc gataaagagg cgttgatcaa tgaactggat 660
gcaatgacgg cccgcgttcg tcagcagtgg gaagaaggcc agcgactgga cccgcgtccg 720
cgcattttaa tcaccggctg cccgattggc ggcgcagcag aaaaagtggt gcgcgcgatt 780
gaagagaatg gcggctgggt tgctcggtat gaaaactgca ccggggcgaa agcgaccgag 840
caatgcgtgg cagaaacggg cgatgtctac gacgcgtgg cgataaata tctggcgatt 900
ggctgctcct gtgtttcgcc gaacgatcag cgctgaaaa tgctcagcca gatggtggag 960
gaatatcagg tcgatggcgt agttgatgtg attttcagg cgtgccatac ctacgcggtg 1020
gaatcgctgg cgattaaacg tcattgtgcg cagcagcaca acattcetta tctcgctatt 1080
gaaacagact actccacctc ggatgtcggg cagctcagta cccgtgtcgc ggcctttatt 1140
gagatgctgt aa 1152

```

<210> SEQ ID NO 22

<211> LENGTH: 477

<212> TYPE: PRT

<213> ORGANISM: Acidaminococcus fermentans

<400> SEQUENCE: 22

```

Met Pro Lys Thr Val Ser Pro Gly Val Gln Ala Leu Arg Asp Val Val
1           5           10          15
Glu Lys Val Tyr Arg Glu Leu Arg Glu Pro Lys Glu Arg Gly Glu Lys
20          25          30
Val Gly Trp Ser Ser Ser Lys Phe Pro Cys Glu Leu Ala Glu Ser Phe
35          40          45
Arg Leu His Val Gly Tyr Pro Glu Asn Gln Ala Ala Gly Ile Ala Ala
50          55          60
Asn Arg Asp Gly Glu Val Met Cys Gln Ala Ala Glu Asp Ile Gly Tyr
65          70          75          80
Asp Asn Asp Ile Cys Gly Tyr Ala Arg Ile Ser Leu Ala Tyr Ala Ala
85          90          95
Gly Phe Arg Gly Ala Asn Lys Met Asp Lys Asp Gly Asn Tyr Val Ile
100         105         110
Asn Pro His Ser Gly Lys Gln Met Lys Asp Ala Asn Gly Lys Lys Val
115         120         125
Phe Asp Ala Asp Gly Lys Pro Val Ile Asp Pro Lys Thr Leu Lys Pro
130         135         140
Phe Ala Thr Thr Asp Asn Ile Tyr Glu Ile Ala Ala Leu Pro Glu Gly
145         150         155         160
Glu Glu Lys Thr Arg Arg Gln Asn Ala Leu His Lys Tyr Arg Gln Met
165         170         175
Thr Met Pro Met Pro Asp Phe Val Leu Cys Cys Asn Asn Ile Cys Asn
180         185         190
Cys Met Thr Lys Trp Tyr Glu Asp Ile Ala Arg Arg His Asn Ile Pro

```

-continued

195	200	205
Leu Ile Met Ile Asp Val Pro Tyr Asn Glu Phe Asp His Val Asn Glu 210 215 220		
Ala Asn Val Lys Tyr Ile Arg Ser Gln Leu Asp Thr Ala Ile Arg Gln 225 230 235 240		
Met Glu Glu Ile Thr Gly Lys Lys Phe Asp Glu Asp Lys Phe Glu Gln 245 250 255		
Cys Cys Gln Asn Ala Asn Arg Thr Ala Lys Ala Trp Leu Lys Val Cys 260 265 270		
Asp Tyr Leu Gln Tyr Lys Pro Ala Pro Phe Asn Gly Phe Asp Leu Phe 275 280 285		
Asn His Met Ala Asp Val Val Thr Ala Arg Gly Arg Val Glu Ala Ala 290 295 300		
Glu Ala Phe Glu Leu Leu Ala Lys Glu Leu Glu Gln His Val Lys Glu 305 310 315 320		
Gly Thr Thr Thr Ala Pro Phe Lys Glu Gln His Arg Ile Met Phe Glu 325 330 335		
Gly Ile Pro Cys Trp Pro Lys Leu Pro Asn Leu Phe Lys Pro Leu Lys 340 345 350		
Ala Asn Gly Leu Asn Ile Thr Gly Val Val Tyr Ala Pro Ala Phe Gly 355 360 365		
Phe Val Tyr Asn Asn Leu Asp Glu Leu Val Lys Ala Tyr Cys Lys Ala 370 375 380		
Pro Asn Ser Val Ser Ile Glu Gln Gly Val Ala Trp Arg Glu Gly Leu 385 390 395 400		
Ile Arg Asp Asn Lys Val Asp Gly Val Leu Val His Tyr Asn Arg Ser 405 410 415		
Cys Lys Pro Trp Ser Gly Tyr Met Pro Glu Met Gln Arg Arg Phe Thr 420 425 430		
Lys Asp Met Gly Ile Pro Thr Ala Gly Phe Asp Gly Asp Gln Ala Asp 435 440 445		
Pro Arg Asn Phe Asn Ala Ala Gln Tyr Glu Thr Arg Val Gln Gly Leu 450 455 460		
Val Glu Ala Met Glu Ala Asn Asp Glu Lys Lys Gly Lys 465 470 475		

<210> SEQ ID NO 23

<211> LENGTH: 373

<212> TYPE: PRT

<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 23

Met Met Lys Leu Lys Ala Ile Glu Lys Leu Met Gln Lys Phe Ala Ser 1 5 10 15
Arg Lys Glu Gln Leu Tyr Lys Gln Lys Glu Glu Gly Arg Lys Val Phe 20 25 30
Gly Met Phe Cys Ala Tyr Val Pro Ile Glu Ile Ile Leu Ala Ala Asn 35 40 45
Ala Ile Pro Val Gly Leu Cys Gly Gly Lys Asn Asp Thr Ile Pro Ile 50 55 60
Ala Glu Glu Asp Leu Pro Arg Asn Leu Cys Pro Leu Ile Lys Ser Ser 65 70 75 80
Tyr Gly Phe Lys Lys Ala Lys Thr Cys Pro Tyr Phe Glu Ala Ser Asp 85 90 95
Ile Val Ile Gly Glu Thr Thr Cys Glu Gly Lys Lys Lys Met Phe Glu

-continued

100					105					110					
Leu	Met	Glu	Arg	Leu	Val	Pro	Met	His	Ile	Met	His	Leu	Pro	His	Met
	115						120					125			
Lys	Asp	Glu	Asp	Ser	Leu	Lys	Ile	Trp	Ile	Lys	Glu	Val	Glu	Lys	Leu
	130					135					140				
Lys	Glu	Leu	Val	Glu	Lys	Glu	Thr	Gly	Asn	Lys	Ile	Thr	Glu	Glu	Lys
	145					150					155				160
Leu	Lys	Glu	Thr	Val	Asp	Lys	Val	Asn	Lys	Val	Arg	Glu	Leu	Phe	Tyr
				165					170					175	
Lys	Leu	Tyr	Glu	Leu	Arg	Lys	Asn	Lys	Pro	Ala	Pro	Ile	Lys	Gly	Leu
		180						185					190		
Asp	Val	Leu	Lys	Leu	Phe	Gln	Phe	Ala	Tyr	Leu	Leu	Asp	Ile	Asp	Asp
		195					200					205			
Thr	Ile	Gly	Ile	Leu	Glu	Asp	Leu	Ile	Glu	Glu	Leu	Glu	Glu	Arg	Val
	210					215					220				
Lys	Lys	Gly	Glu	Gly	Tyr	Glu	Gly	Lys	Arg	Ile	Leu	Ile	Thr	Gly	Cys
	225					230					235				240
Pro	Met	Val	Ala	Gly	Asn	Asn	Lys	Ile	Val	Glu	Ile	Ile	Glu	Glu	Val
				245					250					255	
Gly	Gly	Val	Val	Val	Gly	Glu	Glu	Ser	Cys	Thr	Gly	Thr	Arg	Phe	Phe
			260						265				270		
Glu	Asn	Phe	Val	Glu	Gly	Tyr	Ser	Val	Glu	Asp	Ile	Ala	Lys	Arg	Tyr
		275					280					285			
Phe	Lys	Ile	Pro	Cys	Ala	Cys	Arg	Phe	Lys	Asn	Asp	Glu	Arg	Val	Glu
	290					295					300				
Asn	Ile	Lys	Arg	Leu	Val	Lys	Glu	Leu	Asp	Val	Asp	Gly	Val	Val	Tyr
	305					310					315				320
Tyr	Thr	Leu	Gln	Tyr	Cys	His	Thr	Phe	Asn	Ile	Glu	Gly	Ala	Lys	Val
			325						330					335	
Glu	Glu	Ala	Leu	Lys	Glu	Glu	Gly	Ile	Pro	Ile	Ile	Arg	Ile	Glu	Thr
			340					345					350		
Asp	Tyr	Ser	Glu	Ser	Asp	Arg	Glu	Gln	Leu	Lys	Thr	Arg	Leu	Glu	Ala
		355					360					365			
Phe	Ile	Glu	Met	Ile											
	370														

<210> SEQ ID NO 24

<211> LENGTH: 383

<212> TYPE: PRT

<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 24

Met	Ser	Leu	Val	Thr	Asp	Leu	Pro	Ala	Ile	Phe	Asp	Gln	Phe	Ser	Glu
1				5					10					15	
Ala	Arg	Gln	Thr	Gly	Phe	Leu	Thr	Val	Met	Asp	Leu	Lys	Glu	Arg	Gly
			20					25					30		
Ile	Pro	Leu	Val	Gly	Thr	Tyr	Cys	Thr	Phe	Met	Pro	Gln	Glu	Ile	Pro
		35					40					45			
Met	Ala	Ala	Gly	Ala	Val	Val	Val	Ser	Leu	Cys	Ser	Thr	Ser	Asp	Glu
	50					55				60					
Thr	Ile	Glu	Glu	Ala	Glu	Lys	Asp	Leu	Pro	Arg	Asn	Leu	Cys	Pro	Leu
	65				70				75					80	
Ile	Lys	Ser	Ser	Tyr	Gly	Phe	Gly	Lys	Thr	Asp	Lys	Cys	Pro	Tyr	Phe
			85					90						95	
Tyr	Phe	Ser	Asp	Leu	Val	Val	Gly	Glu	Thr	Thr	Cys	Asp	Gly	Lys	Lys

-continued

100					105					110					
Lys	Met	Tyr	Glu	Tyr	Met	Ala	Glu	Phe	Lys	Pro	Val	His	Val	Met	Gln
115					120					125					
Leu	Pro	Asn	Ser	Val	Lys	Asp	Ala	Ser	Arg	Ala	Leu	Trp	Lys	Ala	
130					135					140					
Glu	Met	Leu	Arg	Leu	Gln	Lys	Thr	Val	Glu	Glu	Arg	Phe	Gly	His	Glu
145					150					155					
Ile	Ser	Glu	Asp	Ala	Leu	Arg	Asp	Ala	Ile	Ala	Leu	Lys	Asn	Arg	Glu
165					170					175					
Arg	Arg	Ala	Leu	Ala	Asn	Phe	Tyr	His	Leu	Gly	Gln	Leu	Asn	Pro	Pro
180					185					190					
Ala	Leu	Ser	Gly	Ser	Asp	Ile	Leu	Lys	Val	Val	Tyr	Gly	Ala	Thr	Phe
195					200					205					
Arg	Phe	Asp	Lys	Glu	Ala	Leu	Ile	Asn	Glu	Leu	Asp	Ala	Met	Thr	Ala
210					215					220					
Arg	Val	Arg	Gln	Gln	Trp	Glu	Glu	Gly	Gln	Arg	Leu	Asp	Pro	Arg	Pro
225					230					235					
Arg	Ile	Leu	Ile	Thr	Gly	Cys	Pro	Ile	Gly	Gly	Ala	Ala	Glu	Lys	Val
245					250					255					
Val	Arg	Ala	Ile	Glu	Glu	Asn	Gly	Gly	Trp	Val	Val	Gly	Tyr	Glu	Asn
260					265					270					
Cys	Thr	Gly	Ala	Lys	Ala	Thr	Glu	Gln	Cys	Val	Ala	Glu	Thr	Gly	Asp
275					280					285					
Val	Tyr	Asp	Ala	Leu	Ala	Asp	Lys	Tyr	Leu	Ala	Ile	Gly	Cys	Ser	Cys
290					295					300					
Val	Ser	Pro	Asn	Asp	Gln	Arg	Leu	Lys	Met	Leu	Ser	Gln	Met	Val	Glu
305					310					315					
Glu	Tyr	Gln	Val	Asp	Gly	Val	Val	Asp	Val	Ile	Leu	Gln	Ala	Cys	His
325					330					335					
Thr	Tyr	Ala	Val	Glu	Ser	Leu	Ala	Ile	Lys	Arg	His	Val	Arg	Gln	Gln
340					345					350					
His	Asn	Ile	Pro	Tyr	Ile	Ala	Ile	Glu	Thr	Asp	Tyr	Ser	Thr	Ser	Asp
355					360					365					
Val	Gly	Gln	Leu	Ser	Thr	Arg	Val	Ala	Ala	Phe	Ile	Glu	Met	Leu	
370					375					380					

<210> SEQ ID NO 25

<211> LENGTH: 1119

<212> TYPE: DNA

<213> ORGANISM: Megasphaera elsdenii

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1116)

<400> SEQUENCE: 25

atg agt cag atc gac gaa ctt atc agc aaa tta cag gaa gta tcc aac	48
Met Ser Gln Ile Asp Glu Leu Ile Ser Lys Leu Gln Glu Val Ser Asn	
1 5 10 15	
cat ccc cag aag acg gtt ttg aat tat aaa aaa cag ggt aaa ggc ctc	96
His Pro Gln Lys Thr Val Leu Asn Tyr Lys Lys Gln Gly Lys Gly Leu	
20 25 30	
gta ggc atg atg ccc tac tac gct ccg gaa gaa atc gta tat gct gca	144
Val Gly Met Met Pro Tyr Tyr Ala Pro Glu Glu Ile Val Tyr Ala Ala	
35 40 45	
ggc tac ctc ccg gta ggc atg ttc ggt tcc cag aac ccg cag atc tcc	192
Gly Tyr Leu Pro Val Gly Met Phe Gly Ser Gln Asn Pro Gln Ile Ser	
50 55 60	

-continued

gca gct cgt acg tac ctt cct ccg ttc gct tgc tcc ttg atg cag gct Ala Ala Arg Thr Tyr Leu Pro Pro Phe Ala Cys Ser Leu Met Gln Ala 65 70 75 80	240
gac atg gaa ctc cag ctc aac ggc acc tat gac tgc ctc gac gct gtt Asp Met Glu Leu Gln Leu Asn Gly Thr Tyr Asp Cys Leu Asp Ala Val 85 90 95	288
atc ttc tcc gtt cct tgc gac act ctc cgc tgc atg agc cag aaa tgg Ile Phe Ser Val Pro Cys Asp Thr Leu Arg Cys Met Ser Gln Lys Trp 100 105 110	336
cac ggc aaa gct ccg gtc atc gtc ttc aca cag ccg cag aac cgt aag His Gly Lys Ala Pro Val Ile Val Phe Thr Gln Pro Gln Asn Arg Lys 115 120 125	384
atc cgc ccg gct gtc gat ttc ctc aaa gct gaa tac gaa cat gtc cgt Ile Arg Pro Ala Val Asp Phe Leu Lys Ala Glu Tyr Glu His Val Arg 130 135 140	432
acg gaa ttg gga cgt atc ctc aac gta aaa atc tcc gac ctg gct atc Thr Glu Leu Gly Arg Ile Leu Asn Val Lys Ile Ser Asp Leu Ala Ile 145 150 155 160	480
cag gaa gct atc aaa gta tat aac gaa aac cgt cag gtt atg cgt gaa Gln Glu Ala Ile Lys Val Tyr Asn Glu Asn Arg Gln Val Met Arg Glu 165 170 175	528
ttc tgc gac gta gct gct cag tac ccg cag atc ttc act ccg ata aaa Phe Cys Asp Val Ala Ala Gln Tyr Pro Gln Ile Phe Thr Pro Ile Lys 180 185 190	576
cgt cat gac gtc atc aaa gcc cgc tgg ttc atg gac aaa gct gaa cac Arg His Asp Val Ile Lys Ala Arg Trp Phe Met Asp Lys Ala Glu His 195 200 205	624
acc gct ttg gtc cgc gaa ctc atc gac gct gtc aag aaa gaa ccg gta Thr Ala Leu Val Arg Glu Leu Ile Asp Ala Val Lys Lys Glu Pro Val 210 215 220	672
cag ccg tgg aat ggc aaa aaa gtc atc ctc tcc ggt atc atg gca gaa Gln Pro Trp Asn Gly Lys Lys Val Ile Leu Ser Gly Ile Met Ala Glu 225 230 235 240	720
ccg gat gaa ttc ctc gat atc ttc agc gaa ttc aac atc gct gtc gtc Pro Asp Glu Phe Leu Asp Ile Phe Ser Glu Phe Asn Ile Ala Val Val 245 250 255	768
gct gac gac ctc gct cag gaa tcc cgc cag ttc cgt aca gac gta ccg Ala Asp Asp Leu Ala Gln Glu Ser Arg Gln Phe Arg Thr Asp Val Pro 260 265 270	816
tcc ggc atc gat ccc ctc gaa cag ctc gct cag cag tgg cag gac ttc Ser Gly Ile Asp Pro Leu Glu Gln Leu Ala Gln Gln Trp Gln Asp Phe 275 280 285	864
gat ggc tgc ccg ctc gct ttg aac gaa gac aaa ccg cgt ggc cag atg Asp Gly Cys Pro Leu Ala Leu Asn Glu Asp Lys Pro Arg Gly Gln Met 290 295 300	912
ctc atc gac atg act aag aaa tac aat gct gac gcc gtc gtc atc tgc Leu Ile Asp Met Thr Lys Lys Tyr Asn Ala Asp Ala Val Val Ile Cys 305 310 315 320	960
atg atg cgt ttc tgc gat cct gaa gaa ttc gac tat ccg att tac aaa Met Met Arg Phe Cys Asp Pro Glu Glu Phe Asp Tyr Pro Ile Tyr Lys 325 330 335	1008
ccg gaa ttt gaa gct gct ggc gtt cgt tac acg gtc ctc gac ctc gac Pro Glu Phe Glu Ala Ala Gly Val Arg Tyr Thr Val Leu Asp Leu Asp 340 345 350	1056
atc gaa tct ccg tcc ctc gaa cag ctc cgc acc cgt atc cag gct ttc Ile Glu Ser Pro Ser Leu Glu Gln Leu Arg Thr Arg Ile Gln Ala Phe 355 360 365	1104
tcg gaa atc ctc taa Ser Glu Ile Leu 370	1119

-continued

```

<210> SEQ ID NO 26
<211> LENGTH: 372
<212> TYPE: PRT
<213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 26

Met Ser Gln Ile Asp Glu Leu Ile Ser Lys Leu Gln Glu Val Ser Asn
1          5          10          15
His Pro Gln Lys Thr Val Leu Asn Tyr Lys Lys Gln Gly Lys Gly Leu
          20          25          30
Val Gly Met Met Pro Tyr Tyr Ala Pro Glu Glu Ile Val Tyr Ala Ala
          35          40          45
Gly Tyr Leu Pro Val Gly Met Phe Gly Ser Gln Asn Pro Gln Ile Ser
          50          55          60
Ala Ala Arg Thr Tyr Leu Pro Pro Phe Ala Cys Ser Leu Met Gln Ala
          65          70          75          80
Asp Met Glu Leu Gln Leu Asn Gly Thr Tyr Asp Cys Leu Asp Ala Val
          85          90          95
Ile Phe Ser Val Pro Cys Asp Thr Leu Arg Cys Met Ser Gln Lys Trp
          100          105          110
His Gly Lys Ala Pro Val Ile Val Phe Thr Gln Pro Gln Asn Arg Lys
          115          120          125
Ile Arg Pro Ala Val Asp Phe Leu Lys Ala Glu Tyr Glu His Val Arg
          130          135          140
Thr Glu Leu Gly Arg Ile Leu Asn Val Lys Ile Ser Asp Leu Ala Ile
          145          150          155          160
Gln Glu Ala Ile Lys Val Tyr Asn Glu Asn Arg Gln Val Met Arg Glu
          165          170          175
Phe Cys Asp Val Ala Ala Gln Tyr Pro Gln Ile Phe Thr Pro Ile Lys
          180          185          190
Arg His Asp Val Ile Lys Ala Arg Trp Phe Met Asp Lys Ala Glu His
          195          200          205
Thr Ala Leu Val Arg Glu Leu Ile Asp Ala Val Lys Lys Glu Pro Val
          210          215          220
Gln Pro Trp Asn Gly Lys Lys Val Ile Leu Ser Gly Ile Met Ala Glu
          225          230          235          240
Pro Asp Glu Phe Leu Asp Ile Phe Ser Glu Phe Asn Ile Ala Val Val
          245          250          255
Ala Asp Asp Leu Ala Gln Glu Ser Arg Gln Phe Arg Thr Asp Val Pro
          260          265          270
Ser Gly Ile Asp Pro Leu Glu Gln Leu Ala Gln Gln Trp Gln Asp Phe
          275          280          285
Asp Gly Cys Pro Leu Ala Leu Asn Glu Asp Lys Pro Arg Gly Gln Met
          290          295          300
Leu Ile Asp Met Thr Lys Lys Tyr Asn Ala Asp Ala Val Val Ile Cys
          305          310          315          320
Met Met Arg Phe Cys Asp Pro Glu Glu Phe Asp Tyr Pro Ile Tyr Lys
          325          330          335
Pro Glu Phe Glu Ala Ala Gly Val Arg Tyr Thr Val Leu Asp Leu Asp
          340          345          350
Ile Glu Ser Pro Ser Leu Glu Gln Leu Arg Thr Arg Ile Gln Ala Phe
          355          360          365
Ser Glu Ile Leu
          370

```

-continued

<210> SEQ ID NO 27
<211> LENGTH: 1140
<212> TYPE: DNA
<213> ORGANISM: Acidaminococcus fermentans

<400> SEQUENCE: 27

```
atggctatca gtgcacttat tgaagagttc caaaaagtat ctgccagccc gaagaccatg    60
ctggccaaat ataaagccca gggcaaaaaa gccatcggtt gcctgccgta ctatgttccg    120
gaagaactgg tctatgctgc aggcattggtt cccatgggtg tatggggctg caatggcaaa    180
caggaagtcc gttccaagga atactgtgct tccttctact gcaccattgc ccagcagtct    240
ctggaaatgc tgctggacgg gaccctggat gggttggacg ggatcatcac tccggtactg    300
tgtgatcccc tgcgtcccat gagccagaac ttcaaagtgg ccatgaaaga caagatgccg    360
gttattttcc tggctcatcc ccaggtccgt cagaatgccg ccggcaagca gttcacctat    420
gatgcctaca gcgaagtgaagg gcccatctg gaagaaatct gcggccatga aatcaccaat    480
gatgccatcc tggatgccat caaagtgtac aacaagagcc gtgctgcccg ccgccaattc    540
tgcaaaactg ccaacgaaca tcctgatctg atcccggctt ccgtacgggc caccgtactg    600
cgtgccgctt acttcatgct gaaggatgaa tacaccgaaa agctggaaga actgaacaag    660
gaactggcag ctgctcctgc cggcaagttc gacggccaca aagtggttgt ttccggcatc    720
atctacaaca cggccggcat cctgaaagcc atggatgaca acaaaactgg cattgtctgt    780
gatgactgcg cttatgaaag ccgcagcttt gccgtggatg ctccggaaga tctggacaac    840
ggactgcatg ctctggctgt acagttctcc aaacagaaga acgatgttct gctgtacgat    900
cctgaatttg ccaagaatac ccgttctgaa cacgttgga atctggtaaa agaaagcggc    960
gcagaaggac tgatcgtgtt catgatgcag ttctgcgac cgaagaaat ggaatatcct   1020
gatctgaaga aggtcttgga tgcccaccac attcctcatg tgaagattgg tgtggaccag   1080
atgacccggg acttttggtc gggccagacc gctctggaag ctttcgcaga aagcctgtaa   1140
```

<210> SEQ ID NO 28
<211> LENGTH: 1122
<212> TYPE: DNA
<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 28

```
atgatgaaat taaaggcaat tgaaaagttg atgcaaaaat tcgccagtag aaaagaacag    60
ctatataagc aaaaagaaga aggtagaaaa gtttttgtaa tgttctgtgc ctatgttcca   120
atagaaataa ttttagcagc aaatgcaatc ccagttggtt tgtgtggagg taaaaatgac   180
acaatcccaa tagcagagga ggatttgcca agaaacctat gccattaat aaaatcatcc   240
tatggtttta agaaggcaaa aacctgccct tactttgaag catctgatat agttattgga   300
gaaactacct gtgaaggaaa gaagaagatg tttgagttga tggagagatt ggtgccaatg   360
catataatgc acctccca catgaaagat gaagattcct tgaaaatctg gattaaagaa   420
gttgaaaagc taaaagaatt ggttgagaaa gagactggaa ataaaataac agaggaaaag   480
ttaaagaga cagttgataa agtaataaaa gttagggagt tgttttataa actctatgaa   540
ttgaggaaga ataaaccagc tccaattaag ggttttagatg ttttaaaatt attccagttt   600
gcctatttat tggatattga tgacacaata gggatttttag aggatttaat tgaggagtta   660
gaggagagag ttaaaaaagg agaaggttat gaaggaaa gaattttaat aactggctgt   720
ccaatggttg ctggaaaaca taagattgtt gaaattattg aggaagttgg aggagtagtt   780
```


-continued

```

gttggtgaag aaagctgcac tggacaaga ttctttgaaa actttgttga gggctatagc 840
gtagaggaca ttgcaaaaag atactttaaa atcccatgtg cttgtagatt taaaaacgat 900
gagagagttg aaaatataaa gagattgggt aaagagttgg acgtcgatgg agttgtttat 960
tacactttgc agtattgccac tacatttaac atagaggagg ctaaggtaga ggaggcatta 1020
aaagaggagg gcattccaat tataagaatt gaaactgact attctgaaag tgatagagag 1080
cagttaaaaa caaggttga ggcatattt gagatgattt aa 1122

```

```

<210> SEQ ID NO 29
<211> LENGTH: 1152
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 29

```

```

atgtcacttg tcaccgatct acccgccatt ttcgatcagt tctctgaagc tcgccagaca 60
ggctttctca ccgtcatgga tctcaaggag cgcggcattc cgctgggttg cacttactgc 120
acctttatgc cgcaagagat cccgatggca gccgggtgcgg ttgtgggttc gctctgttcc 180
acctctgatg aaaccattga agaagcggag aaagatctgc cgcgcaacct ctgcccgctg 240
attaaaaagca gctacggcct cggcaaaacc gataaatgcc cctacttcta cttttcggat 300
ctggtgggtcg gtgaaaccac ctgcgacggc aaaaagaaaa tgtatgaata catggcggag 360
tttaagcctg ttcattgtgat gcaattgccc aacagcgtta aggacgatgc ctgcgctgcg 420
ttatggaag ccgagatgct gcgcttgcaa aaaacggtag aagaacgttt tgggcacgag 480
attagcgaag atgctctgcg cgatgccatt gcgctgaaaa accgcgaacg tcgcgcactg 540
gctaattttt atcatcttgg gcagttaaat cctccggcgc ttagcggcag cgacattctg 600
aaagtgggtt acggcgcaac cttccggttc gataaagagg cgttgatcaa tgaactggat 660
gcaatgaccg cccgcgttcg tcagcagtgg gaagaaggcc agcgaactga cccgcgtccg 720
cgcattttaa tcaccggctg cccgattggc ggccgcagcag aaaaagtggg gcgcgcgatt 780
gaagagaatg gcggctgggt tgctcggttat gaaaactgca ccggggcgaa agcgaccgag 840
caatgcgtgg cagaaacggg cgatgtctac gacgcgtgg cgataaata tctggcgatt 900
ggctgctcct gtgtttgcc gaacgatcag cgctgaaaa tgctcagcca gatggtggag 960
gaatatcagg tcgatggcgt agttgatgtg attttgcagg cgtgccatac ctacgcggtg 1020
gaatcgctgg cgattaacg tcatgtgcgc cagcagcaca acattcctta tatcgctatt 1080
gaaacagact actccacctc ggatgtcggg cagctcagta cccgtgtcgc ggcctttatt 1140
gagatgctgt aa 1152

```

```

<210> SEQ ID NO 30
<211> LENGTH: 379
<212> TYPE: PRT
<213> ORGANISM: Acidaminococcus fermentans

```

```

<400> SEQUENCE: 30

```

```

Met Ala Ile Ser Ala Leu Ile Glu Glu Phe Gln Lys Val Ser Ala Ser
1           5           10          15
Pro Lys Thr Met Leu Ala Lys Tyr Lys Ala Gln Gly Lys Lys Ala Ile
20          25          30
Gly Cys Leu Pro Tyr Tyr Val Pro Glu Glu Leu Val Tyr Ala Ala Gly
35          40          45
Met Val Pro Met Gly Val Trp Gly Cys Asn Gly Lys Gln Glu Val Arg
50          55          60

```

-continued

Ser	Lys	Glu	Tyr	Cys	Ala	Ser	Phe	Tyr	Cys	Thr	Ile	Ala	Gln	Gln	Ser	65	70	75	80
Leu	Glu	Met	Leu	Leu	Asp	Gly	Thr	Leu	Asp	Gly	Leu	Asp	Gly	Ile	Ile	85	90	95	
Thr	Pro	Val	Leu	Cys	Asp	Thr	Leu	Arg	Pro	Met	Ser	Gln	Asn	Phe	Lys	100	105	110	
Val	Ala	Met	Lys	Asp	Lys	Met	Pro	Val	Ile	Phe	Leu	Ala	His	Pro	Gln	115	120	125	
Val	Arg	Gln	Asn	Ala	Ala	Gly	Lys	Gln	Phe	Thr	Tyr	Asp	Ala	Tyr	Ser	130	135	140	
Glu	Val	Lys	Gly	His	Leu	Glu	Glu	Ile	Cys	Gly	His	Glu	Ile	Thr	Asn	145	150	155	160
Asp	Ala	Ile	Leu	Asp	Ala	Ile	Lys	Val	Tyr	Asn	Lys	Ser	Arg	Ala	Ala	165	170	175	
Arg	Arg	Glu	Phe	Cys	Lys	Leu	Ala	Asn	Glu	His	Pro	Asp	Leu	Ile	Pro	180	185	190	
Ala	Ser	Val	Arg	Ala	Thr	Val	Leu	Arg	Ala	Ala	Tyr	Phe	Met	Leu	Lys	195	200	205	
Asp	Glu	Tyr	Thr	Glu	Lys	Leu	Glu	Glu	Leu	Asn	Lys	Glu	Leu	Ala	Ala	210	215	220	
Ala	Pro	Ala	Gly	Lys	Phe	Asp	Gly	His	Lys	Val	Val	Val	Ser	Gly	Ile	225	230	235	240
Ile	Tyr	Asn	Thr	Pro	Gly	Ile	Leu	Lys	Ala	Met	Asp	Asp	Asn	Lys	Leu	245	250	255	
Ala	Ile	Ala	Ala	Asp	Asp	Cys	Ala	Tyr	Glu	Ser	Arg	Ser	Phe	Ala	Val	260	265	270	
Asp	Ala	Pro	Glu	Asp	Leu	Asp	Asn	Gly	Leu	His	Ala	Leu	Ala	Val	Gln	275	280	285	
Phe	Ser	Lys	Gln	Lys	Asn	Asp	Val	Leu	Leu	Tyr	Asp	Pro	Glu	Phe	Ala	290	295	300	
Lys	Asn	Thr	Arg	Ser	Glu	His	Val	Gly	Asn	Leu	Val	Lys	Glu	Ser	Gly	305	310	315	320
Ala	Glu	Gly	Leu	Ile	Val	Phe	Met	Met	Gln	Phe	Cys	Asp	Pro	Glu	Glu	325	330	335	
Met	Glu	Tyr	Pro	Asp	Leu	Lys	Lys	Ala	Leu	Asp	Ala	His	His	Ile	Pro	340	345	350	
His	Val	Lys	Ile	Gly	Val	Asp	Gln	Met	Thr	Arg	Asp	Phe	Gly	Gln	Ala	355	360	365	
Gln	Thr	Ala	Leu	Glu	Ala	Phe	Ala	Glu	Ser	Leu						370	375		

<210> SEQ ID NO 31

<211> LENGTH: 373

<212> TYPE: PRT

<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 31

Met	Met	Lys	Leu	Lys	Ala	Ile	Glu	Lys	Leu	Met	Gln	Lys	Phe	Ala	Ser	1	5	10	15
Arg	Lys	Glu	Gln	Leu	Tyr	Lys	Gln	Lys	Glu	Glu	Gly	Arg	Lys	Val	Phe	20	25	30	
Gly	Met	Phe	Cys	Ala	Tyr	Val	Pro	Ile	Glu	Ile	Ile	Leu	Ala	Ala	Asn	35	40	45	
Ala	Ile	Pro	Val	Gly	Leu	Cys	Gly	Gly	Lys	Asn	Asp	Thr	Ile	Pro	Ile	50	55	60	

-continued

Ala	Glu	Glu	Asp	Leu	Pro	Arg	Asn	Leu	Cys	Pro	Leu	Ile	Lys	Ser	Ser	65	70	75	80
Tyr	Gly	Phe	Lys	Lys	Ala	Lys	Thr	Cys	Pro	Tyr	Phe	Glu	Ala	Ser	Asp	85	90	95	
Ile	Val	Ile	Gly	Glu	Thr	Thr	Cys	Glu	Gly	Lys	Lys	Lys	Met	Phe	Glu	100	105	110	
Leu	Met	Glu	Arg	Leu	Val	Pro	Met	His	Ile	Met	His	Leu	Pro	His	Met	115	120	125	
Lys	Asp	Glu	Asp	Ser	Leu	Lys	Ile	Trp	Ile	Lys	Glu	Val	Glu	Lys	Leu	130	135	140	
Lys	Glu	Leu	Val	Glu	Lys	Glu	Thr	Gly	Asn	Lys	Ile	Thr	Glu	Glu	Lys	145	150	155	160
Leu	Lys	Glu	Thr	Val	Asp	Lys	Val	Asn	Lys	Val	Arg	Glu	Leu	Phe	Tyr	165	170	175	
Lys	Leu	Tyr	Glu	Leu	Arg	Lys	Asn	Lys	Pro	Ala	Pro	Ile	Lys	Gly	Leu	180	185	190	
Asp	Val	Leu	Lys	Leu	Phe	Gln	Phe	Ala	Tyr	Leu	Leu	Asp	Ile	Asp	Asp	195	200	205	
Thr	Ile	Gly	Ile	Leu	Glu	Asp	Leu	Ile	Glu	Glu	Leu	Glu	Glu	Arg	Val	210	215	220	
Lys	Lys	Gly	Glu	Gly	Tyr	Glu	Gly	Lys	Arg	Ile	Leu	Ile	Thr	Gly	Cys	225	230	235	240
Pro	Met	Val	Ala	Gly	Asn	Asn	Lys	Ile	Val	Glu	Ile	Ile	Glu	Glu	Val	245	250	255	
Gly	Gly	Val	Val	Val	Gly	Glu	Glu	Ser	Cys	Thr	Gly	Thr	Arg	Phe	Phe	260	265	270	
Glu	Asn	Phe	Val	Glu	Gly	Tyr	Ser	Val	Glu	Asp	Ile	Ala	Lys	Arg	Tyr	275	280	285	
Phe	Lys	Ile	Pro	Cys	Ala	Cys	Arg	Phe	Lys	Asn	Asp	Glu	Arg	Val	Glu	290	295	300	
Asn	Ile	Lys	Arg	Leu	Val	Lys	Glu	Leu	Asp	Val	Asp	Gly	Val	Val	Tyr	305	310	315	320
Tyr	Thr	Leu	Gln	Tyr	Cys	His	Thr	Phe	Asn	Ile	Glu	Gly	Ala	Lys	Val	325	330	335	
Glu	Glu	Ala	Leu	Lys	Glu	Glu	Gly	Ile	Pro	Ile	Ile	Arg	Ile	Glu	Thr	340	345	350	
Asp	Tyr	Ser	Glu	Ser	Asp	Arg	Glu	Gln	Leu	Lys	Thr	Arg	Leu	Glu	Ala	355	360	365	
Phe	Ile	Glu	Met	Ile												370			

<210> SEQ ID NO 32

<211> LENGTH: 383

<212> TYPE: PRT

<213> ORGANISM: Methanocaldococcus jannaschii

<400> SEQUENCE: 32

Met	Ser	Leu	Val	Thr	Asp	Leu	Pro	Ala	Ile	Phe	Asp	Gln	Phe	Ser	Glu	1	5	10	15
Ala	Arg	Gln	Thr	Gly	Phe	Leu	Thr	Val	Met	Asp	Leu	Lys	Glu	Arg	Gly	20	25	30	
Ile	Pro	Leu	Val	Gly	Thr	Tyr	Cys	Thr	Phe	Met	Pro	Gln	Glu	Ile	Pro	35	40	45	
Met	Ala	Ala	Gly	Ala	Val	Val	Val	Ser	Leu	Cys	Ser	Thr	Ser	Asp	Glu	50	55	60	

-continued

Thr	Ile	Glu	Glu	Ala	Glu	Lys	Asp	Leu	Pro	Arg	Asn	Leu	Cys	Pro	Leu	
65					70					75					80	
Ile	Lys	Ser	Ser	Tyr	Gly	Phe	Gly	Lys	Thr	Asp	Lys	Cys	Pro	Tyr	Phe	
				85					90					95		
Tyr	Phe	Ser	Asp	Leu	Val	Val	Gly	Glu	Thr	Thr	Cys	Asp	Gly	Lys	Lys	
			100					105					110			
Lys	Met	Tyr	Glu	Tyr	Met	Ala	Glu	Phe	Lys	Pro	Val	His	Val	Met	Gln	
		115					120					125				
Leu	Pro	Asn	Ser	Val	Lys	Asp	Asp	Ala	Ser	Arg	Ala	Leu	Trp	Lys	Ala	
		130				135						140				
Glu	Met	Leu	Arg	Leu	Gln	Lys	Thr	Val	Glu	Glu	Arg	Phe	Gly	His	Glu	
145					150					155					160	
Ile	Ser	Glu	Asp	Ala	Leu	Arg	Asp	Ala	Ile	Ala	Leu	Lys	Asn	Arg	Glu	
				165					170					175		
Arg	Arg	Ala	Leu	Ala	Asn	Phe	Tyr	His	Leu	Gly	Gln	Leu	Asn	Pro	Pro	
			180					185					190			
Ala	Leu	Ser	Gly	Ser	Asp	Ile	Leu	Lys	Val	Val	Tyr	Gly	Ala	Thr	Phe	
		195					200					205				
Arg	Phe	Asp	Lys	Glu	Ala	Leu	Ile	Asn	Glu	Leu	Asp	Ala	Met	Thr	Ala	
	210					215					220					
Arg	Val	Arg	Gln	Gln	Trp	Glu	Glu	Gly	Gln	Arg	Leu	Asp	Pro	Arg	Pro	
225				230						235					240	
Arg	Ile	Leu	Ile	Thr	Gly	Cys	Pro	Ile	Gly	Gly	Ala	Ala	Glu	Lys	Val	
				245					250					255		
Val	Arg	Ala	Ile	Glu	Glu	Asn	Gly	Gly	Trp	Val	Val	Gly	Tyr	Glu	Asn	
			260				265						270			
Cys	Thr	Gly	Ala	Lys	Ala	Thr	Glu	Gln	Cys	Val	Ala	Glu	Thr	Gly	Asp	
		275					280					285				
Val	Tyr	Asp	Ala	Leu	Ala	Asp	Lys	Tyr	Leu	Ala	Ile	Gly	Cys	Ser	Cys	
	290					295					300					
Val	Ser	Pro	Asn	Asp	Gln	Arg	Leu	Lys	Met	Leu	Ser	Gln	Met	Val	Glu	
305					310					315					320	
Glu	Tyr	Gln	Val	Asp	Gly	Val	Val	Asp	Val	Ile	Leu	Gln	Ala	Cys	His	
				325					330					335		
Thr	Tyr	Ala	Val	Glu	Ser	Leu	Ala	Ile	Lys	Arg	His	Val	Arg	Gln	Gln	
			340					345					350			
His	Asn	Ile	Pro	Tyr	Ile	Ala	Ile	Glu	Thr	Asp	Tyr	Ser	Thr	Ser	Asp	
		355					360				365					
Val	Gly	Gln	Leu	Ser	Thr	Arg	Val	Ala	Ala	Phe	Ile	Glu	Met	Leu		
	370					375					380					

<210> SEQ ID NO 33

<211> LENGTH: 6295

<212> TYPE: DNA

<213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 33

cgacggcccg ggctggtatc attctagtca gtaattcacc tttggaaaat tttcacaag	60
gcagtacgac agaagcgtcg atacattcca tttagcagga ggaagttacg gtaatgagaa	120
aagtagaaat cattacagct gaacaagcag ctacagctcgt aaaagacaac gacacgatta	180
cgtctatcgg ctttgtcagc agcgcccatc cggaagcact gaccaaagct ttggaaaaac	240
ggttcctgga cacgaacacc ccgcagaact tgacctacat ctatgcaggc tctcagggca	300
aacgcgatgg ccgtgccgct gaacatctgg cacacacagg ccttttgaaa cgcgccatca	360

-continued

tccgtcactg	gcagactgta	ccggctatcg	gtaactggc	tgtcgaaaac	aagattgaag	420
cttacaactt	ctcgcagggc	acgttggtcc	actggttccg	cgccttggca	ggtcataagc	480
tccggtcttt	caccgacatc	ggtctggaaa	ctttcctcga	tccccgtcag	ctcggcggca	540
agctcaatga	cgtaacccaa	gaagacctcg	tcaaactgat	cgaagtcgat	ggcatgaac	600
agcttttcta	cccgaccttc	ccggtaacg	tagctttect	ccgcggtacg	tatgctgatg	660
aatccggcaa	tatcaccatg	gacgaagaaa	tccggccttt	cgaagcact	tccgtagccc	720
aggccgttca	caactgtggc	ggtaaagtcg	tgtccaggt	caaagacgtc	gtcgtcacg	780
gcagcctcga	cccgcgcatg	gtcaagatcc	ctggcatcta	tgtcgactac	gtcgtcgtag	840
cagctccgga	agaccatcag	cagacgtatg	actgcgaata	cgtccgtcc	ctcagcggtg	900
aacatcgtgc	tcttgaaggc	gctaccgatg	cagctctccc	catgagcgtc	aagaaaatca	960
tccgcccgcg	cggcgctttg	gaattgactg	aaaacgctgt	cgtcaacctc	ggcgtcggtg	1020
ctccggaata	cgttgcttct	gttgccgggtg	aagaaggtat	cgccgatacc	attaccctga	1080
ccgtcgaagg	tggcgccatc	ggtggcgtac	cgcagggcgg	tgcccgcttc	ggttcgtccc	1140
gcaatgccga	tgccatcctc	gaccacacct	atcagttcga	cttctacgat	ggcggcggtc	1200
tggacatcgc	ttacctcgcc	ctggcccagt	gcgatggctc	gggcaacatc	aacgtcagca	1260
agttcggtag	taacgttgcc	ggctgcggcg	gtttcccaa	catttcccag	cagacaccga	1320
atgtttactt	ctgcggcacc	ttcacggctg	gcggttgaa	aatcgctgtc	gaagacggca	1380
aagtcaagat	cctccaggaa	ggcaaagcca	agaagttcat	caaagctgtc	gaccagatca	1440
ctttcaacgg	ttcctatgca	gcccgcacg	gcaaacacgt	tctctacatc	acagaacgct	1500
gcgtatttga	actgacccaa	gaaggcttga	aactcatcga	agtcgcaccg	ggcatcgata	1560
ttgaaaaaga	tatcctcgct	cacatggact	tcaagccgat	cattgataat	ccgaaactca	1620
tggatgcccc	cctcttcag	gacggtecca	tgggactgaa	aaaataaatc	tctgctgtaa	1680
aggagacttt	actatgaaac	caatgagact	acatcacgta	ggcattgtcc	tgcgcacctt	1740
agaaaaagcc	catgaattca	tgcagaataa	tggacttgaa	atcgactatg	ccggctatgt	1800
cgatgcttac	caggctgac	tcatcttcac	taagtttgg	gaatttgcca	gcccgaattga	1860
aatgattatc	ccgcactccg	gtgtgcttac	ccaattcaat	ggtggccgcg	gcggcattgc	1920
ccacatcgcc	ttcgaagtgg	acgatgtcga	agctgtccgc	caggaaatgg	aagcagattg	1980
tccgggatgc	atgttagaaa	agaaagctgt	ccagggtacg	gacgacatta	tcttcaactt	2040
ccgcgcgccg	acaaccaacc	agggatccct	cgttgaatat	gttcagacga	cagcacctat	2100
caccggccgc	ggcgaaaate	ctttcgttaa	gaatctcggc	ccggaaaaag	ggaagctcaa	2160
cgaacatgg	catcccatgc	gcctgcacca	tatcggcatc	gtcttgccga	ccttggaata	2220
ggcccatgaa	ttcatcaaga	ccaatggtct	ggaagtggat	tattccgggt	tcttcgacgc	2280
ctaccatgcg	gatctcattt	tactaaaaa	aggtgaaaac	agtacgccta	tcaattcat	2340
tattccccgt	gaaggggtcc	tcaaagattt	caatcatggc	aggggaggta	tgcctcatat	2400
cgcctttgaa	gtggatgatg	tcgaaaaggt	acgtcagatt	atggaaaagc	agaagcctgg	2460
ttgatgctc	gaaaagaaag	ccgtccgggg	aacggacgat	atcatcgtca	acttccgccg	2520
tcccagcagc	gacgcgggca	tcctcgtcga	atatgtccag	accgtagctc	ccatcaatcg	2580
cagcaatccc	aaccctttta	atgattgatt	ttttataaag	aaaggtgaaa	actgtgtata	2640
ctctcggaat	cgaagtgtgt	tcttcttctt	ccaaggcagt	catcctggaa	gatggcaaga	2700
agatcgctcg	ccatgcgcgc	gttgaaatcg	gcaccgggtc	gaccgggtccg	gaacgcgtcc	2760

-continued

tggacgaagt	cttcaaagat	accaacttaa	aaattgaaga	catggcgaaac	atcatcgcca	2820
caggctatgg	ccgtttcaat	gtcgactgcg	ccaaaggcga	agtcagcgaa	atcacgtgcc	2880
atgcaaaagg	ggccctcttt	gaatgccccc	gtacgacgac	catcctcgat	atcggcggtc	2940
aggacgtcaa	gtccatcaaa	ttgaatggcc	agggcctggg	catgcagttt	gccatgaacg	3000
acaaatggcg	cgctggtacg	ggccggtttc	tcgacgtcat	gtcgaaggta	ctggaaatcc	3060
ccatgtctga	aatgggggac	tggtaactta	aatcgaagca	tcccgtgcc	gtcagcagta	3120
cctgcacggg	ttttgctgaa	tcggaagtca	ttccctctct	ttccaagaat	gtcccgaag	3180
aagatatcgt	agccggtgtc	catcagtcga	tcgcccga	agcctgcgct	ctcgtgcgcc	3240
gcgtcgggtg	cggtgaagac	ctgacctga	ccggcggtgg	ctcccgcgat	cccggcgctg	3300
tcgatgccgt	atcgaaagaa	ttaggtattc	ctgtcagagt	cgctctgcat	ccccaagcgg	3360
tgggtgctct	cggagctgct	ttgattgctt	atgataaaat	caagaaataa	gtcaaaggag	3420
agaacaaaat	catgagtga	gaaaaaacag	tagatattga	aagcatgagc	tccaaggaag	3480
cccttggtta	cttcttgccg	aaagtcgatg	aagacgcacg	taaagcgaaa	aaagaaggcc	3540
gcctcgtttg	ctggtcgctc	tctgtcgtc	ctccggaatt	ctgcacggct	atggacatcg	3600
ccatcgtcta	tccggaact	cacgcagctg	gtatcgggtg	ccgtcacggg	gctccggcca	3660
tgctcgaagt	tgctgaaaa	aaaggttaca	accaggacat	ctgttcctac	tgccgcgtca	3720
acatgggcta	catggaactc	ctcaaacagc	aggtctctgac	aggcgaaacg	ccggaagtcc	3780
tcaaaaaact	cccggcttct	ccgattcccc	ttccggatgt	tgtcctcact	tgcaacaaca	3840
tctgcaatac	cttgctcaaa	tggatgaaa	acttggctaa	agaattgaac	gtacctctca	3900
tcaacatcga	cgtaccgttc	aaccatgaat	tcctgtttac	gaaacacgct	aaacagtaca	3960
tcgtcggcga	attcaaacat	gctatcaaac	agtcgaaga	cctttgcggc	cgctcccttcg	4020
actatgacaa	attcttcgaa	gtacagaaac	agacacagcg	ctccatcgct	gcttggaaaca	4080
aaatcgctac	gtacttccag	tacaaaccgt	cgccgctcaa	cggtctcgac	ctcttcaact	4140
acatgggcct	cgccgttgct	gcccgtctct	tgaactactc	ggaaatcacg	ttcaacaaat	4200
tcctcaaaga	attggacgaa	aaagtagcta	ataagaaatg	ggctttcggg	gaaaacgaaa	4260
aatcccggtg	tacttgggaa	ggatcgtctg	tctggatcgc	tctcgccac	acettcaaag	4320
aactcaaagg	tcaggcgctc	ctcatgactg	gttccgctta	tcctggcatg	tgggacgttt	4380
cctacgaacc	gggcgacctc	gaatccatgg	cagaagctta	ttcccgta	tacatcaact	4440
gctgcctcga	acagcggcgt	gctgttcttg	aaaaagtgtg	ccgcgatggc	aaatgcgacg	4500
gcttgatcat	gcaccagaac	cgttcctgca	agaacatgag	cctcctcaac	aacgaaggcg	4560
gccagcgcat	ccagaagaac	ctcggcgtac	cgtacgtcat	cttcgacggc	gaccagaccg	4620
atgctcgtaa	cttctcggaa	gcacagttcg	atcccccggt	agaagctttg	gcagaaatga	4680
tggcagacaa	aaaagccaat	gaaggaggaa	accactaatg	agtcagatcg	acgaacttat	4740
cagcaaaatta	cagggaagtat	ccaaccatcc	ccagaagacg	gttttgtaatt	ataaaaaaca	4800
gggtaaaggc	ctcgtaggca	tgatgcccta	ctacgctccg	gaagaaatcg	tatatgctgc	4860
aggctacctc	ccggtaggca	tgttcgggtc	ccagaaccgg	cagatctccg	cagctcgtac	4920
gtaccttctc	ccgttcgctt	gctccttgat	gcaggctgac	atggaactcc	agctcaacgg	4980
cacctatgac	tgcttcgacg	ctgttatctt	ctccgttctc	tgcgacactc	tccgctgcat	5040
gagccagaaa	tggcagcgca	aagctccggg	catcgtcttc	acacagccgc	agaaccgtaa	5100
gatccgcccc	gctgtcgatt	tcctcaaacg	tgaatacgaa	catgtccgta	cggaaattggg	5160

-continued

acgtatcctc aacgtaaaaa tctccgacct ggctatccag gaagctatca aagtatataa	5220
cgaaaaccgt cagggttatgc gtgaattctg cgacgtagct gctcagtagc cgcagatctt	5280
cactccgata aaacgtcatg acgtcatcaa agcccgtctg ttcattggaca aagctgaaca	5340
caccgctttg gtccgcgaac tcatcgacgc tgtcaagaaa gaaccggtac agccgtggaa	5400
tggcaaaaaa gtcatectct ccggtatcat ggcagaaccg gatgaattcc tcgatatctt	5460
cagcgaattc aacatcgctg tcgtcgctga cgacctcgtc caggaatccc gccagtccg	5520
tacagacgta ccgtccggca tcgatccctt cgaacagctc gctcagcagt ggcaggactt	5580
cgatggctgc ccgctcgctt tgaacgaaga caaacccgtg ggcagatgc tcatcgacat	5640
gactaagaaa tacaatgctg acgccgtcgt catctgcatg atcggtttct gcgatcctga	5700
agaattcgac tatccgattt acaaacccga atttgaagct gctggcgctt gttacacggt	5760
ctcgcacctc gacatcgaat ctccgtccct cgaacagctc cgcacccgta tccaggtttt	5820
ctcggaatc ctctaagaat cgcctgaatc atcaaacatc tgggcgggac tccgaaaggt	5880
gcttgctaca tgatacattg cctgttttca ggcagacaga tttgcagctt gcggccccc	5940
ttgtacgggc tgcaagctgt caatgatgct ttaagacgg ctctgccgtt tttaaataaa	6000
aacataaaac catatataat ctattaggag gaaactcaat catggaattc aaactttctg	6060
aattacagca agatattcga aatctcgcaa aagatttcgc agaaaaaaa ttagctccca	6120
ctgtcaaaga gcgtgacgaa aaagaagttt tcgatcgtgc tacccttgac gaagtgggta	6180
ctctcgacct tctcggtatt ccctgggaag aagaaaacgg cggcgtaggc gctgacttcc	6240
tcagcctcgc agttgcttgc gaagaagtag ctaaagttac cagcccgggc cgtcgc	6295

<210> SEQ ID NO 34

<211> LENGTH: 915

<212> TYPE: DNA

<213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 34

atgaaaccaa tgagactaca tcacgtaggc attgtcctgc cgaccttaga aaaagcccat	60
gaattcatgc agaataatgg acttgaaatc gactatgccg gctatgtcga tgcttaccag	120
gctgatctca ttttcaactaa gtttggtgaa tttgccagcc cgattgaaat gattatcccg	180
cactccgggtg tgcttaccga attcaatggt ggccgcggcg gcattgccc catcgcttc	240
gaagtggacg atgtcgaagc tgtccgccag gaaatggaag cagattgtcc gggatgcatt	300
ttagaaaaga aagctgtcca gggtagcgac gacattatcg tcaacttcgg ccgcccgaca	360
accaaccagg gtatcctcgt tgaatatgtt cagacgacag cacctatcac cggcccgggc	420
gaaaatcctt tcgttaagaa tctcggcccg gaaaaagga agctcaacga aacatggcat	480
cccattgcgc tgcaccatat cggcatcgtc ttgccgacct tggaaaaggc ccatgaattc	540
atcaagacca atgggtctgga agtggtattt tccggtttcg tcgacgccta ccatgaggat	600
ctcattttca ctaaaaaagg tgaaaacagt acgcctatcg aattcattat tccccgtgaa	660
ggggtcctca aagatttcaa tcatggcagg ggaggtatcg ctcatatcgc ctttgaagtg	720
gatgatgtcg aaaaggtacg tcagattatg gaaagccaga agcctggttg catgctcgaa	780
aagaaagccg tccggggaac ggacgatatc atcgtcaact tccgccgtcc cagcacggac	840
gccggcatcc tcgtcgaata tgtccagacc gtagctccca tcaatcgcag caatcccaac	900
ccttttaatg attga	915

<210> SEQ ID NO 35

-continued

```

<211> LENGTH: 304
<212> TYPE: PRT
<213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 35

Met Lys Pro Met Arg Leu His His Val Gly Ile Val Leu Pro Thr Leu
 1             5             10             15

Glu Lys Ala His Glu Phe Met Gln Asn Asn Gly Leu Glu Ile Asp Tyr
          20             25             30

Ala Gly Tyr Val Asp Ala Tyr Gln Ala Asp Leu Ile Phe Thr Lys Phe
          35             40             45

Gly Glu Phe Ala Ser Pro Ile Glu Met Ile Ile Pro His Ser Gly Val
 50             55             60

Leu Thr Gln Phe Asn Gly Gly Arg Gly Gly Ile Ala His Ile Ala Phe
65             70             75             80

Glu Val Asp Asp Val Glu Ala Val Arg Gln Glu Met Glu Ala Asp Cys
          85             90             95

Pro Gly Cys Met Leu Glu Lys Lys Ala Val Gln Gly Thr Asp Asp Ile
          100            105            110

Ile Val Asn Phe Arg Arg Pro Thr Thr Asn Gln Gly Ile Leu Val Glu
          115            120            125

Tyr Val Gln Thr Thr Ala Pro Ile Thr Gly Arg Gly Glu Asn Pro Phe
          130            135            140

Val Lys Asn Leu Gly Pro Glu Lys Gly Lys Leu Asn Glu Thr Trp His
          145            150            155            160

Pro Met Arg Leu His His Ile Gly Ile Val Leu Pro Thr Leu Glu Lys
          165            170            175

Ala His Glu Phe Ile Lys Thr Asn Gly Leu Glu Val Asp Tyr Ser Gly
          180            185            190

Phe Val Asp Ala Tyr His Ala Asp Leu Ile Phe Thr Lys Lys Gly Glu
          195            200            205

Asn Ser Thr Pro Ile Glu Phe Ile Ile Pro Arg Glu Gly Val Leu Lys
          210            215            220

Asp Phe Asn His Gly Arg Gly Gly Ile Ala His Ile Ala Phe Glu Val
          225            230            235            240

Asp Asp Val Glu Lys Val Arg Gln Ile Met Glu Ser Gln Lys Pro Gly
          245            250            255

Cys Met Leu Glu Lys Lys Ala Val Arg Gly Thr Asp Asp Ile Ile Val
          260            265            270

Asn Phe Arg Arg Pro Ser Thr Asp Ala Gly Ile Leu Val Glu Tyr Val
          275            280            285

Gln Thr Val Ala Pro Ile Asn Arg Ser Asn Pro Asn Pro Phe Asn Asp
          290            295            300

```

```

<210> SEQ ID NO 36
<211> LENGTH: 254
<212> TYPE: DNA
<213> ORGANISM: Megasphaera elsdenii

```

```

<400> SEQUENCE: 36

atggaattca aactttctga attacagcaa gatatcgcaa atctcgcaaa agatttcgca    60
gaaaaaaaaat tagctcccac tgtcaaagag cgtgacgaaa aagaagtttt cgatcgtgct    120
atccttgacg aagtgggtac tctcggcctt ctcgggtattc cctgggaaga agaaaacggc    180
ggcgtaggcg ctgacttctc cagcctcgca gttgcttgcg aagaagtagc taaagttacc    240
agcccgggcc gtcg                                     254

```


-continued

<210> SEQ ID NO 37
 <211> LENGTH: 84
 <212> TYPE: PRT
 <213> ORGANISM: Megasphaera elsdenii

<400> SEQUENCE: 37

```

Met Glu Phe Lys Leu Ser Glu Leu Gln Gln Asp Ile Ala Asn Leu Ala
 1             5             10             15

Lys Asp Phe Ala Glu Lys Lys Leu Ala Pro Thr Val Lys Glu Arg Asp
          20             25             30

Glu Lys Glu Val Phe Asp Arg Ala Ile Leu Asp Glu Val Gly Thr Leu
          35             40             45

Gly Leu Leu Gly Ile Pro Trp Glu Glu Glu Asn Gly Gly Val Gly Ala
 50             55             60

Asp Phe Leu Ser Leu Ala Val Ala Cys Glu Glu Val Ala Lys Val Thr
65             70             75             80

Ser Pro Gly Arg
  
```

<210> SEQ ID NO 38
 <211> LENGTH: 6141
 <212> TYPE: DNA
 <213> ORGANISM: Chloroflexus aurantiacus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (480)..(5945)

<400> SEQUENCE: 38

```

gtgagcacac acttgatagc tgatgccgtc aatgatcagt tgttcgtcta tagcaggctg      60
aaaggacatg ggtttggtca cagtctgagc agttgcaggc agtcaaacac gttcgtaact      120
acgctgtaga tgatataagc agtataccat cttgctacgc tctcgttgat cagggttgaat      180
gctttgagga aggtcaggcg aatagccatg cctcttgttt ccagaacatg gcatggggat      240
ggatcgacgg taccctgtcg gatgcatgct atgcgtggca ttcatatcat caaccagaat      300
ttgatcttga actacacagc aattctgcgc gttatgcaag tgtcttcggt cagatgggtga      360
acaattctca attggtgagg tcttgacgaa ttgcgttata cactgtaggc tatagtatgc      420
accccttggt atctatatca caaccggtct attagcattt gcgtcaagga ggatgggtcg      479
atg atc gac act gcg ccc ctt gcc cca cca cgg gcg ccc cgc tct aat      527
Met Ile Asp Thr Ala Pro Leu Ala Pro Pro Arg Ala Pro Arg Ser Asn
 1             5             10             15

ccg att cgg gat cga gtt gat tgg gaa gct cag cgc gct gct gcg ctg      575
Pro Ile Arg Asp Arg Val Asp Trp Glu Ala Gln Arg Ala Ala Ala Leu
          20             25             30

gca gat ccc ggt gcc ttt cat ggc gcg att gcc cgg aca gtt atc cac      623
Ala Asp Pro Gly Ala Phe His Gly Ala Ile Ala Arg Thr Val Ile His
          35             40             45

tgg tac gac cca caa cac cat tgc tgg att cgc ttc aac gag tct agt      671
Trp Tyr Asp Pro Gln His His Cys Trp Ile Arg Phe Asn Glu Ser Ser
          50             55             60

cag cgt tgg gaa ggg ctg gat gcc gct acc ggt gcc cct gta acg gta      719
Gln Arg Trp Glu Gly Leu Asp Ala Ala Thr Gly Ala Pro Val Thr Val
65             70             75             80

gac tat ccc gcc gat tat cag ccc tgg caa cag gcg ttt gat gat agt      767
Asp Tyr Pro Ala Asp Tyr Gln Pro Trp Gln Gln Ala Phe Asp Asp Ser
          85             90             95

gaa gcg ccg ttt tac cgc tgg ttt agt ggt ggg ttg aca aat gcc tgc      815
Glu Ala Pro Phe Tyr Arg Trp Phe Ser Gly Gly Leu Thr Asn Ala Cys
          100             105             110
  
```

-continued

ttt aat gaa gta gac cgg cat gtc atg atg ggc tat ggc gac gag gtg	863
Phe Asn Glu Val Asp Arg His Val Met Met Gly Tyr Gly Asp Glu Val	
115 120 125	
gcc tac tac ttt gaa ggt gac cgc tgg gat aac tcg ctc aac aat ggt	911
Ala Tyr Tyr Phe Glu Gly Asp Arg Trp Asp Asn Ser Leu Asn Asn Gly	
130 135 140	
cgt ggt ggt ccg gtt gtc cag gag aca atc acg cgg cgg cgc ctg ttg	959
Arg Gly Gly Pro Val Val Gln Glu Thr Ile Thr Arg Arg Arg Leu Leu	
145 150 155 160	
gtg gag gtg gtg aag gct gcg cag gtg ttg cgt gat ctg ggc ctg aag	1007
Val Glu Val Val Lys Ala Ala Gln Val Leu Arg Asp Leu Gly Leu Lys	
165 170 175	
aag ggt gat ccg att gct ctg aat atg ccg aat att atg ccg cag att	1055
Lys Gly Asp Arg Ile Ala Leu Asn Met Pro Asn Ile Met Pro Gln Ile	
180 185 190	
tat tat acg gaa gcg gca aaa cga ctg ggt att ctg tac acg ccg gtc	1103
Tyr Tyr Thr Glu Ala Ala Lys Arg Leu Gly Ile Leu Tyr Thr Pro Val	
195 200 205	
ttc ggt ggc ttc tcg gac aag act ctt tcc gac cgt att cac aat gcc	1151
Phe Gly Gly Phe Ser Asp Lys Thr Leu Ser Asp Arg Ile His Asn Ala	
210 215 220	
ggt gca cga gtg gtg att acc tct gat ggt gcg tac cgc aac gcg cag	1199
Gly Ala Arg Val Val Ile Thr Ser Asp Gly Ala Tyr Arg Asn Ala Gln	
225 230 235 240	
gtg gtg ccc tac aaa gaa gcg tat acc gat cag gcg ctc gat aag tat	1247
Val Val Pro Tyr Lys Glu Ala Tyr Thr Asp Gln Ala Leu Asp Lys Tyr	
245 250 255	
att ccg gtt gag acg gcg cag gcg att gtt gcg cag acc ctg gcc acc	1295
Ile Pro Val Glu Thr Ala Gln Ala Ile Val Ala Gln Thr Leu Ala Thr	
260 265 270	
ttg ccc ctg act gag tcg cag cgc cag acg atc atc acc gaa gtg gag	1343
Leu Pro Leu Thr Glu Ser Gln Arg Gln Thr Ile Ile Thr Glu Val Glu	
275 280 285	
gcc gca ctg gcc ggt gag att acg gtt gag cgc tcg gac gtg atg cgt	1391
Ala Ala Leu Ala Gly Glu Ile Thr Val Glu Arg Ser Asp Val Met Arg	
290 295 300	
ggg gtt ggt tct gcc ctc gca aag ctc cgc gat ctt gat gca agc gtg	1439
Gly Val Gly Ser Ala Leu Ala Lys Leu Arg Asp Leu Asp Ala Ser Val	
305 310 315 320	
cag gca aag gtg cgt aca gta ctg gcg cag gcg ctg gtc gag tcg ccg	1487
Gln Ala Lys Val Arg Thr Val Leu Ala Gln Ala Leu Val Glu Ser Pro	
325 330 335	
ccg cgg gtt gaa gct gtg gtg gtt gtg cgt cat acc ggt cag gag att	1535
Pro Arg Val Glu Ala Val Val Val Val Arg His Thr Gly Gln Glu Ile	
340 345 350	
ttg tgg aac gag ggg cga gat cgc tgg agt cac gac ttg ctg gat gct	1583
Leu Trp Asn Glu Gly Arg Asp Arg Trp Ser His Asp Leu Leu Asp Ala	
355 360 365	
gcg ctg gcg aag att ctg gcc aat gcg cgt gct gcc ggc ttt gat gtg	1631
Ala Leu Ala Lys Ile Leu Ala Asn Ala Arg Ala Ala Gly Phe Asp Val	
370 375 380	
cac agt gag aat gat ctg ctc aat ctc ccc gat gac cag ctt atc cgt	1679
His Ser Glu Asn Asp Leu Leu Asn Leu Pro Asp Asp Gln Leu Ile Arg	
385 390 395 400	
gcg ctc tac gcc agt att ccc tgt gaa ccg gtt gat gct gaa tat ccg	1727
Ala Leu Tyr Ala Ser Ile Pro Cys Glu Pro Val Asp Ala Glu Tyr Pro	
405 410 415	
atg ttt atc att tac aca tcg ggt agc acc ggt aag ccc aag ggt gtg	1775
Met Phe Ile Ile Tyr Thr Ser Gly Ser Thr Gly Lys Pro Lys Gly Val	
420 425 430	

-continued

atc cac gtt cac ggc ggt tat gtc gcc ggt gtg gtg cac acc ttg cgg Ile His Val His Gly Gly Tyr Val Ala Gly Val Val His Thr Leu Arg 435 440 445	1823
gtc agt ttt gac gcc gag ccg ggt gat acg ata tat gtg atc gcc gat Val Ser Phe Asp Ala Glu Pro Gly Asp Thr Ile Tyr Val Ile Ala Asp 450 455 460	1871
ccg ggc tgg atc acc ggt cag agc tat atg ctc aca gcc aca atg gcc Pro Gly Trp Ile Thr Gly Gln Ser Tyr Met Leu Thr Ala Thr Met Ala 465 470 475 480	1919
ggg cgg ctg acc ggg gtg att gcc gag gga tca cgg ctc ttc ccc tca Gly Arg Leu Thr Tyr Ala Ser Ile Ile Glu Arg Tyr Gly Val Gln Ile Phe 485 490 495	1967
gcc ggg cgt tat gcc agc atc atc gag cgc tat ggg gtg cag atc ttt Ala Gly Arg Tyr Ala Ser Ile Ile Glu Arg Tyr Gly Val Gln Ile Phe 500 505 510	2015
aag gcg ggt gtg acc ttc ctc aag aca gtg atg tcc aat ccg cag aat Lys Ala Gly Val Thr Phe Leu Lys Thr Val Met Ser Asn Pro Gln Asn 515 520 525	2063
gtt gaa gat gtg cga ctc tat gat atg cac tcg ctg cgg gtt gca acc Val Glu Asp Val Arg Leu Tyr Asp Met His Ser Leu Arg Val Ala Thr 530 535 540	2111
ttc tgc gcc gag ccg gtc agt ccg gcg gtg cag cag ttt ggt atg cag Phe Cys Ala Glu Pro Val Ser Pro Ala Val Gln Gln Phe Gly Met Gln 545 550 555 560	2159
atc atg acc ccg cag tat atc aat tcg tac tgg gcg acc gag cac ggt Ile Met Thr Pro Gln Tyr Ile Asn Ser Tyr Trp Ala Thr Glu His Gly 565 570 575	2207
gga att gtc tgg acg cat ttc tac ggt aat cag gac ttc ccg ctt cgt Gly Ile Val Trp Thr His Phe Tyr Gly Asn Gln Asp Phe Pro Leu Arg 580 585 590	2255
ccc gat gcc cat acc tat ccc ttg ccc tgg gtg atg ggt gat gtc tgg Pro Asp Ala His Thr Tyr Pro Leu Pro Trp Val Met Gly Asp Val Trp 595 600 605	2303
gtg gcc gaa act gat gag agc ggg acg acg cgc tat cgg gtc gct gat Val Ala Glu Thr Asp Glu Ser Gly Thr Thr Arg Tyr Arg Val Ala Asp 610 615 620	2351
ttc gat gag aag ggc gag att gtg att acc gcc ccg tat ccc tac ctg Phe Asp Glu Lys Gly Glu Ile Val Ile Thr Ala Pro Tyr Pro Tyr Leu 625 630 635 640	2399
acc cgc aca ctc tgg ggt gat gtg ccc ggt ttc gag gcg tac ctg cgc Thr Arg Thr Leu Trp Gly Asp Val Pro Gly Phe Glu Ala Tyr Leu Arg 645 650 655	2447
ggg gag att ccg ctg cgg gcc tgg aag ggt gat gcc gag cgt ttc gtc Gly Glu Ile Pro Leu Arg Ala Trp Lys Gly Asp Ala Glu Arg Phe Val 660 665 670	2495
aag acc tac tgg cga cgt ggg cca aac ggt gaa tgg ggc tat atc cag Lys Thr Tyr Trp Arg Arg Gly Pro Asn Gly Glu Trp Gly Tyr Ile Gln 675 680 685	2543
ggg gat ttt gcc atc aag tac ccc gat ggt agc ttc acg ctc cac gga Gly Asp Phe Ala Ile Lys Tyr Pro Asp Gly Ser Phe Thr Leu His Gly 690 695 700	2591
cgc cct gac gat gtg atc aat gtg tcg ggc cac cgt atg ggc acc gag Arg Pro Asp Asp Val Ile Asn Val Ser Gly His Arg Met Gly Thr Glu 705 710 715 720	2639
gag att gag ggt gcc att ttg cgt gac cgc cag atc acg ccc gac tcg Glu Ile Glu Gly Ala Ile Leu Arg Asp Arg Gln Ile Thr Pro Asp Ser 725 730 735	2687
ccc gtc ggt aat tgt att gtg gtc ggt gcg ccg cac cgt gag aag ggt Pro Val Gly Asn Cys Ile Val Val Gly Ala Pro His Arg Glu Lys Gly 740 745 750	2735

-continued

ctg acc ccg gtt gcc ttc att caa cct gcg cct ggc cgt cat ctg acc Leu Thr Pro Val Ala Phe Ile Gln Pro Ala Pro Gly Arg His Leu Thr 755 760 765	2783
ggc gcc gac cgg cgc cgt ctc gat gag ctg gtg cgt acc gag aag ggg Gly Ala Asp Arg Arg Arg Leu Asp Glu Leu Val Arg Thr Glu Lys Gly 770 775 780	2831
gcg gtc agt gtc cca gag gat tac atc gag gtc agt gcc ttt ccc gaa Ala Val Ser Val Pro Glu Asp Tyr Ile Glu Val Ser Ala Phe Pro Glu 785 790 795 800	2879
acc cgc agc ggg aag tat atg cgg cgc ttt ttg cgc aat atg atg ctc Thr Arg Ser Gly Lys Tyr Met Arg Arg Phe Leu Arg Asn Met Met Leu 805 810 815	2927
gat gaa cca ctg ggt gat acg acg acg ttg cgc aat cct gaa gtg ctc Asp Glu Pro Leu Gly Asp Thr Thr Thr Leu Arg Asn Pro Glu Val Leu 820 825 830	2975
gaa gag att gca gcc aag atc gct gag tgg aaa cgc cgt cag cgt atg Glu Glu Ile Ala Ala Lys Ile Ala Glu Trp Lys Arg Arg Gln Arg Met 835 840 845	3023
gcc gaa gag cag cag atc atc gaa cgc tat cgc tac ttc cgg atc gag Ala Glu Glu Gln Gln Ile Ile Glu Arg Tyr Arg Tyr Phe Arg Ile Glu 850 855 860	3071
tat cac cca cca acg gcc agt gcg ggt aaa ctc gcg gta gtg acg gtg Tyr His Pro Pro Thr Ala Ser Ala Gly Lys Leu Ala Val Val Thr Val 865 870 875 880	3119
aca aat ccg ccg gtg aac gca ctg aat gag cgt gcg ctc gat gag ttg Thr Asn Pro Pro Val Asn Ala Leu Asn Glu Arg Ala Leu Asp Glu Leu 885 890 895	3167
aac aca att gtt gac cac ctg gcc cgt cgt cag gat gtt gcc gca att Asn Thr Ile Val Asp His Leu Ala Arg Arg Gln Asp Val Ala Ala Ile 900 905 910	3215
gtc ttc acc gga cag ggc gcc agg agt ttt gtc gcc ggc gct gat att Val Phe Thr Gly Gln Gly Ala Arg Ser Phe Val Ala Gly Ala Asp Ile 915 920 925	3263
cgc cag ttg ctc gaa gag att cat acg gtt gaa gag gca atg gcc ctg Arg Gln Leu Leu Glu Glu Ile His Thr Val Glu Glu Ala Met Ala Leu 930 935 940	3311
ccg aat aac gcc cat ctt gct ttc cgc aag att gag cgt atg aat aag Pro Asn Asn Ala His Leu Ala Phe Arg Lys Ile Glu Arg Met Asn Lys 945 950 955 960	3359
ccg tgt atc gcg gcg atc aac ggt gtg gcg ctc ggt ggt ggt ctg gaa Pro Cys Ile Ala Ala Ile Asn Gly Val Ala Leu Gly Gly Gly Leu Glu 965 970 975	3407
ttc gcc atg gcc tgc cat tac cgg gtt gcc gat gtc tat gcc gaa ttc Phe Ala Met Ala Cys His Tyr Arg Val Ala Asp Val Tyr Ala Glu Phe 980 985 990	3455
ggt cag cca gag att aat ctg cgc ttg cta cct ggt tat ggt ggc acg Gly Gln Pro Glu Ile Asn Leu Arg Leu Leu Pro Gly Tyr Gly Gly Thr 995 1000 1005	3503
cag cgc ttg ccg cgc ctg ttg tac aag cgc aac aac ggc acc ggt Gln Arg Leu Pro Arg Leu Leu Tyr Lys Arg Asn Asn Gly Thr Gly 1010 1015 1020	3548
ctg ctc cga gcg ctg gag atg att ctg ggt ggg cgt agc gta ccg Leu Leu Arg Ala Leu Glu Met Ile Leu Gly Gly Arg Ser Val Pro 1025 1030 1035	3593
gct gat gag gcg ctg aag ctg ggt ctg atc gat gcc att gct acc Ala Asp Glu Ala Leu Lys Leu Gly Leu Ile Asp Ala Ile Ala Thr 1040 1045 1050	3638
ggc gat cag gac tca ctg tcg ctg gca tgc gcg tta gcc cgt gcc Gly Asp Gln Asp Ser Leu Ser Leu Ala Cys Ala Leu Ala Arg Ala 1055 1060 1065	3683

-continued

gca atc Ala Ile 1070	ggc gcc gat ggt cag Gly Ala Asp Gly Gln 1075	ttg atc gag tcg gct Leu Ile Glu Ser Ala 1080	gcg gtg acc Ala Val Thr	3728
cag gct Gln Ala 1085	ttc cgc cat cgc cac Phe Arg His Arg His 1090	gag cag ctt gac gag Glu Gln Leu Asp Glu 1095	tgg cgc aaa Trp Arg Lys	3773
cca gac Pro Asp 1100	ccg cgc ttt gcc gat Pro Arg Phe Ala Asp 1105	gac gaa ctg cgc tcg Asp Glu Leu Arg Ser 1110	att atc gcc Ile Ile Ala	3818
cat cca His Pro 1115	cgt atc gag cgg att Arg Ile Glu Arg Ile 1120	atc cgg cag gcc cat Ile Arg Gln Ala His 1125	acc gtt ggg Thr Val Gly	3863
cgc gat Arg Asp 1130	gcg gca gtg cat cgg Ala Ala Val His Arg 1135	gca ctg gat gca atc Ala Leu Asp Ala Ile 1140	cgc tat ggc Arg Tyr Gly	3908
att atc Ile Ile 1145	cac ggc ttc gag gcc His Gly Phe Glu Ala 1150	ggc ctg gag cac gag Gly Leu Glu His Glu 1155	gcg aag ctc Ala Lys Leu	3953
ttt gcc Phe Ala 1160	gag gca gtg gtt gac Glu Ala Val Val Asp 1165	ccg aac ggt ggc aag Pro Asn Gly Gly Lys 1170	cgt ggt att Arg Gly Ile	3998
cgc gag Arg Glu 1175	ttc ctc gac cgc cag Phe Leu Asp Arg Gln 1180	agt gcg ccg ttg cca Ser Ala Pro Leu Pro 1185	acc cgc cga Thr Arg Arg	4043
cca ttg Pro Leu 1190	att aca cct gaa cag Ile Thr Pro Glu Gln 1195	gag caa ctc ttg cgc Glu Gln Leu Leu Arg 1200	gat cag aaa Asp Gln Lys	4088
gaa ctg Glu Leu 1205	ttg ccg gtt ggt tca Leu Pro Val Gly Ser 1210	ccc ttc ttc ccc ggt Pro Phe Phe Pro Gly 1215	gtt gac cgg Val Asp Arg	4133
att ccg Ile Pro 1220	aag tgg cag tac gcg Lys Trp Gln Tyr Ala 1225	cag gcg gtt att cgt Gln Ala Val Ile Arg 1230	gat ccg gac Asp Pro Asp	4178
acc ggt Thr Gly 1235	gcg gcg gct cac ggc Ala Ala Ala His Gly 1240	gat ccc atc gtg gct Asp Pro Ile Val Ala 1245	gaa aag cag Glu Lys Gln	4223
att att Ile Ile 1250	gtg ccg gtg gaa cgc Val Pro Val Glu Arg 1255	ccc cgc gcc aat cag Pro Arg Ala Asn Gln 1260	gcg ctg atc Ala Leu Ile	4268
tat gtt Tyr Val 1265	ctg gcc tcg gag gtg Leu Ala Ser Glu Val 1270	aac ttc aac gat atc Asn Phe Asn Asp Ile 1275	tgg gcg att Trp Ala Ile	4313
acc ggt Thr Gly 1280	att ccg gtg tca cgg Ile Pro Val Ser Arg 1285	ttt gat gag cac gac Phe Asp Glu His Asp 1290	cgc gac tgg Arg Asp Trp	4358
cac gtt His Val 1295	acc ggt tca ggt ggc Thr Gly Ser Gly Glu 1300	atc ggc ctg atc gtt Ile Gly Leu Ile Val 1305	gcg ctg ggt Ala Leu Gly	4403
gaa gag Glu Glu 1310	gcg cga cgc gaa ggc Ala Arg Arg Glu Gly 1315	cgg ctg aag gtg ggt Arg Leu Lys Val Gly 1320	gat ctg gtg Asp Leu Val	4448
gcg atc Ala Ile 1325	tac tcc ggg cag tcg Tyr Ser Gly Gln Ser 1330	gat ctg ctc tca ccg Asp Leu Leu Ser Pro 1335	ctg atg ggc Leu Met Gly	4493
ctt gat Leu Asp 1340	ccg atg gcc gcc gat Pro Met Ala Ala Asp 1345	ttc gtc atc cag ggg Phe Val Ile Gln Gly 1350	aac gac acg Asn Asp Thr	4538
cca gat Pro Asp 1355	gga tcg cat cag caa Gly Ser His Gln Gln 1360	ttt atg ctg gcc cag Phe Met Leu Ala Gln 1365	gcc ccg cag Ala Pro Gln	4583

-continued

tgt ctg	ccc atc cca acc gat	atg tct atc gag gca	gcc ggc agc	4628
Cys Leu	Pro Ile Pro Thr Asp	Met Ser Ile Glu Ala	Ala Gly Ser	
1370	1375	1380		
tac atc	ctc aat ctc ggt acg	atc tat cgc gcc ctc	ttt acg acg	4673
Tyr Ile	Leu Asn Leu Gly Thr	Ile Tyr Arg Ala Leu	Phe Thr Thr	
1385	1390	1395		
ttg caa	atc aag gcc gga cgc	acc atc ttt atc gag	ggg ggc ggc	4718
Leu Gln	Ile Lys Ala Gly Arg	Thr Ile Phe Ile Glu	Gly Ala Ala	
1400	1405	1410		
acc ggt	acc ggt ctg gac gca	gcg cgc tcg gcg gcc	cgg aat ggt	4763
Thr Gly	Thr Gly Leu Asp Ala	Ala Arg Ser Ala Ala	Arg Asn Gly	
1415	1420	1425		
ctg cgc	gta att gga atg gtc	agt tcg tcg tca cgt	gcg tct acg	4808
Leu Arg	Val Ile Gly Met Val	Ser Ser Ser Ser Arg	Ala Ser Thr	
1430	1435	1440		
ctg ctg	gct gcg ggt gcc cac	ggg gcg att aac cgt	aaa gac ccg	4853
Leu Leu	Ala Ala Gly Ala His	Gly Ala Ile Asn Arg	Lys Asp Pro	
1445	1450	1455		
gag gtt	gcc gat tgt ttc acg	gcg gtg ccc gaa gat	cca tca gcc	4898
Glu Val	Ala Asp Cys Phe Thr	Arg Val Pro Glu Asp	Pro Ser Ala	
1460	1465	1470		
tgg gca	gcc tgg gaa gcc gcc	ggg cag ccg ttg ctg	gcg atg ttc	4943
Trp Ala	Ala Trp Glu Ala Ala	Gly Gln Pro Leu Leu	Ala Met Phe	
1475	1480	1485		
cgg gcg	cag aac gac ggg cga	ctg gcc gat tat gtg	gtc tcg cac	4988
Arg Ala	Gln Asn Asp Gly Arg	Leu Ala Asp Tyr Val	Val Ser His	
1490	1495	1500		
gcg ggc	gag acg gcc ttc ccg	gcg agt ttc cag ctt	ctc ggc gag	5033
Ala Gly	Glu Thr Ala Phe Pro	Arg Ser Phe Gln Leu	Leu Gly Glu	
1505	1510	1515		
cca cgc	gat ggt cac att ccg	acg ctc aca ttc tac	ggg gcc acc	5078
Pro Arg	Asp Gly His Ile Pro	Thr Leu Thr Phe Tyr	Gly Ala Thr	
1520	1525	1530		
agt ggc	tac cac ttc acc ttc	ctg ggt aag cca ggg	tca gct tcg	5123
Ser Gly	Tyr His Phe Thr Phe	Leu Gly Lys Pro Gly	Ser Ala Ser	
1535	1540	1545		
ccg acc	gag atg ctg cgg cgg	gcc aat ctc cgc gcc	ggg gag gcg	5168
Pro Thr	Glu Met Leu Arg Arg	Ala Asn Leu Arg Ala	Gly Glu Ala	
1550	1555	1560		
gtg ttg	atc tac tac ggg gtt	ggg agc gat gac ctg	gta gat acc	5213
Val Leu	Ile Tyr Tyr Gly Val	Gly Ser Asp Asp Leu	Val Asp Thr	
1565	1570	1575		
ggc ggt	ctg gag gct atc gag	gcg gcg ccg caa atg	gga gcg ccg	5258
Gly Gly	Leu Glu Ala Ile Glu	Ala Ala Arg Gln Met	Gly Ala Arg	
1580	1585	1590		
atc gtc	gtc gtt acc gtc agc	gat gcg caa cgc gag	ttt gtc ctc	5303
Ile Val	Val Val Thr Val Ser	Asp Ala Gln Arg Glu	Phe Val Leu	
1595	1600	1605		
tcg ttg	ggc ttc ggg gct gcc	cta cgt ggt gtc gtc	agc ctg gcg	5348
Ser Leu	Gly Phe Gly Ala Ala	Leu Arg Gly Val Val	Ser Leu Ala	
1610	1615	1620		
gaa ctc	aaa ccg cgc ttc ggc	gat gag ttt gag tgg	ccg cgc acg	5393
Glu Leu	Lys Arg Arg Phe Gly	Asp Glu Phe Glu Trp	Pro Arg Thr	
1625	1630	1635		
atg ccg	ccg ttg ccg aac gcc	gcg cag gac ccg cag	ggg ctg aaa	5438
Met Pro	Pro Leu Pro Asn Ala	Arg Gln Asp Pro Gln	Gly Leu Lys	
1640	1645	1650		
gag gct	gtc cgc cgc ttc aac	gat ctg gtc ttc aag	ccg cta gga	5483
Glu Ala	Val Arg Arg Phe Asn	Asp Leu Val Phe Lys	Pro Leu Gly	
1655	1660	1665		

-continued

agc gcg gtc ggt gtc ttc ttg cgg agt gcc gac aat ccg cgt ggc 5528
Ser Ala Val Gly Val Phe Leu Arg Ser Ala Asp Asn Pro Arg Gly
1670 1675 1680
tac ccc gat ctg atc atc gag cgg gct gcc cac gat gca ctg gcg 5573
Tyr Pro Asp Leu Ile Ile Glu Arg Ala Ala His Asp Ala Leu Ala
1685 1690 1695
gtg agc gcg atg ctg atc aag ccc ttc acc gga cgg att gtc tac 5618
Val Ser Ala Met Leu Ile Lys Pro Phe Thr Gly Arg Ile Val Tyr
1700 1705 1710
ttc gag gac att ggt ggg cgg cgt tac tcc ttc ttc gca ccg caa 5663
Phe Glu Asp Ile Gly Gly Arg Arg Tyr Ser Phe Phe Ala Pro Gln
1715 1720 1725
atc tgg gtg cgc cag cgc cgc atc tac atg ccg acg gca cag atc 5708
Ile Trp Val Arg Gln Arg Arg Ile Tyr Met Pro Thr Ala Gln Ile
1730 1735 1740
ttt ggt acg cac ctc tca aat gcg tat gaa att ctg cgt ctg aat 5753
Phe Gly Thr His Leu Ser Asn Ala Tyr Glu Ile Leu Arg Leu Asn
1745 1750 1755
gat gag atc agc gcc ggt ctg ctg acg att acc gag ccg gca gtg 5798
Asp Glu Ile Ser Ala Gly Leu Leu Thr Ile Thr Glu Pro Ala Val
1760 1765 1770
gtg ccg tgg gat gaa cta ccc gaa gca cat cag gcg atg tgg gaa 5843
Val Pro Trp Asp Glu Leu Pro Glu Ala His Gln Ala Met Trp Glu
1775 1780 1785
aat cgc cac acg gcg gcc act tat gtg gtg aat cat gcc tta cca 5888
Asn Arg His Thr Ala Ala Thr Tyr Val Val Asn His Ala Leu Pro
1790 1795 1800
cgt ctc ggc cta aag aac agg gac gag ctg tac gag gcg tgg acg 5933
Arg Leu Gly Leu Lys Asn Arg Asp Glu Leu Tyr Glu Ala Trp Thr
1805 1810 1815
gcc gcc gag cgg tagcgcggtat gggtattgaa caggtaacgg acggaagatc 5985
Ala Gly Glu Arg
1820
gaaccttccg tccgttatct tttggccgtc gaagcgtgct gagccgatta tcgttgccgt 6045
ggttgtcccg atgggcagac gcgctogaac cagatgatac caccgacggc tatcgtcacc 6105
aaaccggcga agaccaggta agcctctgaa ggacgc 6141

<210> SEQ ID NO 39

<211> LENGTH: 1822

<212> TYPE: PRT

<213> ORGANISM: Chloroflexus aurantiacus

<400> SEQUENCE: 39

Met Ile Asp Thr Ala Pro Leu Ala Pro Pro Arg Ala Pro Arg Ser Asn
1 5 10 15

Pro Ile Arg Asp Arg Val Asp Trp Glu Ala Gln Arg Ala Ala Leu
20 25 30

Ala Asp Pro Gly Ala Phe His Gly Ala Ile Ala Arg Thr Val Ile His
35 40 45

Trp Tyr Asp Pro Gln His His Cys Trp Ile Arg Phe Asn Glu Ser Ser
50 55 60

Gln Arg Trp Glu Gly Leu Asp Ala Ala Thr Gly Ala Pro Val Thr Val
65 70 75 80

Asp Tyr Pro Ala Asp Tyr Gln Pro Trp Gln Gln Ala Phe Asp Asp Ser
85 90 95

Glu Ala Pro Phe Tyr Arg Trp Phe Ser Gly Gly Leu Thr Asn Ala Cys
100 105 110

Phe 115	Asn	Glu	Val	Asp	Arg	His	Val	Met	Met	Gly	Tyr	Gly 125	Asp	Glu	Val
Ala 130	Tyr	Tyr	Phe	Glu	Gly 135	Asp	Arg	Trp	Asp	Asn	Ser 140	Leu	Asn	Asn	Gly
Arg 145	Gly	Gly	Pro	Val	Val 150	Gln	Glu	Thr	Ile	Thr 155	Arg	Arg	Arg	Leu	Leu 160
Val	Glu	Val	Val	Lys 165	Ala	Ala	Gln	Val	Leu 170	Arg	Asp	Leu	Gly	Leu 175	Lys
Lys	Gly	Asp	Arg	Ile	Ala	Leu	Asn	Met 185	Pro	Asn	Ile	Met 190	Pro	Gln	Ile
Tyr	Tyr	Thr 195	Glu	Ala	Ala	Lys	Arg 200	Leu	Gly	Ile	Leu	Tyr 205	Thr	Pro	Val
Phe 210	Gly	Gly	Phe	Ser	Asp	Lys 215	Thr	Leu	Ser	Asp	Arg 220	Ile	His	Asn	Ala
Gly 225	Ala	Arg	Val	Val	Ile 230	Thr	Ser	Asp	Gly	Ala 235	Tyr	Arg	Asn	Ala	Gln 240
Val	Val	Pro	Tyr	Lys 245	Glu	Ala	Tyr	Thr	Asp 250	Gln	Ala	Leu	Asp	Lys 255	Tyr
Ile	Pro	Val	Glu	Thr	Ala	Gln	Ala	Ile 265	Val	Ala	Gln	Thr	Leu 270	Ala	Thr
Leu	Pro	Leu 275	Thr	Glu	Ser	Gln	Arg 280	Gln	Thr	Ile	Ile	Thr 285	Glu	Val	Glu
Ala	Ala 290	Leu	Ala	Gly	Glu	Ile 295	Thr	Val	Glu	Arg	Ser 300	Asp	Val	Met	Arg
Gly 305	Val	Gly	Ser	Ala	Leu 310	Ala	Lys	Leu	Arg	Asp 315	Leu	Asp	Ala	Ser	Val 320
Gln	Ala	Lys	Val	Arg 325	Thr	Val	Leu	Ala	Gln 330	Ala	Leu	Val	Glu	Ser 335	Pro
Pro	Arg	Val	Glu 340	Ala	Val	Val	Val	Val 345	Arg	His	Thr	Gly	Gln 350	Glu	Ile
Leu	Trp	Asn 355	Glu	Gly	Arg	Asp	Arg 360	Trp	Ser	His	Asp	Leu 365	Leu	Asp	Ala
Ala	Leu 370	Ala	Lys	Ile	Leu	Ala	Asn 375	Ala	Arg	Ala	Ala 380	Gly	Phe	Asp	Val
His 385	Ser	Glu	Asn	Asp	Leu 390	Leu	Asn	Leu	Pro	Asp 395	Asp	Gln	Leu	Ile	Arg 400
Ala	Leu	Tyr	Ala	Ser 405	Ile	Pro	Cys	Glu	Pro	Val	Asp	Ala	Glu	Tyr 415	Pro
Met	Phe	Ile	Ile	Tyr 420	Thr	Ser	Gly	Ser 425	Thr	Gly	Lys	Pro	Lys 430	Gly	Val
Ile	His	Val	His	Gly 435	Gly	Tyr	Val 440	Ala	Gly	Val	Val	His 445	Thr	Leu	Arg
Val	Ser	Phe	Asp	Ala	Glu 455	Pro	Gly	Asp	Thr	Ile	Tyr	Val	Ile	Ala	Asp
Pro	Gly	Trp	Ile	Thr	Gly 470	Gln	Ser	Tyr	Met	Leu	Thr	Ala	Thr	Met	Ala 480
Gly	Arg	Leu	Thr	Gly 485	Val	Ile	Ala	Glu	Gly	Ser	Pro	Leu	Phe	Pro	Ser
Ala	Gly	Arg	Tyr	Ala	Ser 500	Ile	Ile	Glu	Arg	Tyr	Gly	Val	Gln 510	Ile	Phe
Lys	Ala	Gly	Val	Thr	Phe	Leu	Lys 520	Thr	Val	Met	Ser	Asn 525	Pro	Gln	Asn
Val	Glu	Asp	Val	Arg	Leu	Tyr	Asp 535	Met	His	Ser	Leu	Arg	Val	Ala	Thr

-continued

Phe 545	Cys	Ala	Glu	Pro	Val 550	Ser	Pro	Ala	Val	Gln 555	Gln	Phe	Gly	Met	Gln 560
Ile	Met	Thr	Pro	Gln 565	Tyr	Ile	Asn	Ser	Tyr 570	Trp	Ala	Thr	Glu	His 575	Gly
Gly	Ile	Val	Trp 580	Thr	His	Phe	Tyr	Gly 585	Asn	Gln	Asp	Phe	Pro	Leu	Arg
Pro	Asp	Ala 595	His	Thr	Tyr	Pro	Leu 600	Pro	Trp	Val	Met	Gly 605	Asp	Val	Trp
Val	Ala 610	Glu	Thr	Asp	Glu 615	Ser	Gly	Thr	Thr	Arg	Tyr 620	Arg	Val	Ala	Asp
Phe 625	Asp	Glu	Lys	Gly	Glu 630	Ile	Val	Ile	Thr	Ala 635	Pro	Tyr	Pro	Tyr	Leu
Thr	Arg	Thr	Leu 645	Trp	Gly	Asp	Val	Pro	Gly 650	Phe	Glu	Ala	Tyr	Leu	Arg
Gly	Glu	Ile	Pro 660	Leu	Arg	Ala	Trp	Lys 665	Gly	Asp	Ala	Glu	Arg	Phe	Val
Lys	Thr	Tyr 675	Trp	Arg	Arg	Gly	Pro 680	Asn	Gly	Glu	Trp	Gly 685	Tyr	Ile	Gln
Gly	Asp	Phe 690	Ala	Ile	Lys 695	Tyr	Pro	Asp	Gly	Ser	Phe 700	Thr	Leu	His	Gly
Arg	Pro	Asp 705	Asp	Val	Ile 710	Asn	Val	Ser	Gly	His 715	Arg	Met	Gly	Thr	Glu
Glu	Ile	Glu	Gly 725	Ala	Ile	Leu	Arg	Asp	Arg 730	Gln	Ile	Thr	Pro	Asp	Ser
Pro	Val	Gly	Asn 740	Cys	Ile	Val	Val	Gly 745	Ala	Pro	His	Arg	Glu	Lys	Gly
Leu	Thr	Pro 755	Val	Ala	Phe	Ile	Gln 760	Pro	Ala	Pro	Gly 765	Arg	His	Leu	Thr
Gly	Ala	Asp 770	Arg	Arg	Arg	Leu 775	Asp	Glu	Leu	Val	Arg 780	Thr	Glu	Lys	Gly
Ala	Val	Ser 785	Val	Pro	Glu 790	Asp	Tyr	Ile	Glu	Val 795	Ser	Ala	Phe	Pro	Glu
Thr	Arg	Ser	Gly 805	Lys	Tyr	Met	Arg	Arg	Phe 810	Leu	Arg	Asn	Met	Met	Leu
Asp	Glu	Pro	Leu 820	Gly	Asp	Thr	Thr	Thr	Leu	Arg	Asn	Pro	Glu	Val	Leu
Glu	Glu	Ile 835	Ala	Ala	Lys	Ile	Ala 840	Glu	Trp	Lys	Arg	Arg	Gln	Arg	Met
Ala	Glu	Glu 850	Gln	Gln	Ile	Ile	Glu 855	Arg	Tyr	Arg	Tyr 860	Phe	Arg	Ile	Glu
Tyr	His	Pro 865	Pro	Thr	Ala 870	Ser	Ala	Gly	Lys	Leu	Ala	Val	Val	Thr	Val
Thr	Asn	Pro	Pro 885	Val	Asn	Ala	Leu	Asn 890	Glu	Arg	Ala	Leu	Asp	Glu	Leu
Asn	Thr	Ile 900	Val	Asp	His	Leu	Ala 905	Arg	Arg	Gln	Asp	Val	Ala	Ala	Ile
Val	Phe	Thr 915	Gly	Gln	Gly	Ala	Arg 920	Ser	Phe	Val	Ala	Gly 925	Ala	Asp	Ile
Arg	Gln	Leu 930	Leu	Glu	Glu	Ile 935	His	Thr	Val	Glu	Glu	Ala	Met	Ala	Leu
Pro	Asn	Asn 945	Ala	His	Leu 950	Ala	Phe	Arg	Lys	Ile 955	Glu	Arg	Met	Asn	Lys
Pro	Cys	Ile	Ala	Ala	Ile	Asn	Gly	Val	Ala	Leu	Gly	Gly	Gly	Leu	Glu

-continued

965							970					975				
Phe	Ala	Met	Ala	Cys	His	Tyr	Arg	Val	Ala	Asp	Val	Tyr	Ala	Glu	Phe	
			980				985						990			
Gly	Gln	Pro	Glu	Ile	Asn	Leu	Arg	Leu	Leu	Pro	Gly	Tyr	Gly	Gly	Thr	
		995				1000						1005				
Gln	Arg	Leu	Pro	Arg	Leu	Leu	Tyr	Lys	Arg	Asn	Asn	Gly	Thr	Gly		
1010					1015					1020						
Leu	Leu	Arg	Ala	Leu	Glu	Met	Ile	Leu	Gly	Gly	Arg	Ser	Val	Pro		
1025					1030					1035						
Ala	Asp	Glu	Ala	Leu	Lys	Leu	Gly	Leu	Ile	Asp	Ala	Ile	Ala	Thr		
1040					1045					1050						
Gly	Asp	Gln	Asp	Ser	Leu	Ser	Leu	Ala	Cys	Ala	Leu	Ala	Arg	Ala		
1055					1060					1065						
Ala	Ile	Gly	Ala	Asp	Gly	Gln	Leu	Ile	Glu	Ser	Ala	Ala	Val	Thr		
1070					1075					1080						
Gln	Ala	Phe	Arg	His	Arg	His	Glu	Gln	Leu	Asp	Glu	Trp	Arg	Lys		
1085					1090					1095						
Pro	Asp	Pro	Arg	Phe	Ala	Asp	Asp	Glu	Leu	Arg	Ser	Ile	Ile	Ala		
1100					1105					1110						
His	Pro	Arg	Ile	Glu	Arg	Ile	Ile	Arg	Gln	Ala	His	Thr	Val	Gly		
1115					1120					1125						
Arg	Asp	Ala	Ala	Val	His	Arg	Ala	Leu	Asp	Ala	Ile	Arg	Tyr	Gly		
1130					1135					1140						
Ile	Ile	His	Gly	Phe	Glu	Ala	Gly	Leu	Glu	His	Glu	Ala	Lys	Leu		
1145					1150					1155						
Phe	Ala	Glu	Ala	Val	Val	Asp	Pro	Asn	Gly	Gly	Lys	Arg	Gly	Ile		
1160					1165					1170						
Arg	Glu	Phe	Leu	Asp	Arg	Gln	Ser	Ala	Pro	Leu	Pro	Thr	Arg	Arg		
1175					1180					1185						
Pro	Leu	Ile	Thr	Pro	Glu	Gln	Glu	Gln	Leu	Leu	Arg	Asp	Gln	Lys		
1190					1195					1200						
Glu	Leu	Leu	Pro	Val	Gly	Ser	Pro	Phe	Phe	Pro	Gly	Val	Asp	Arg		
1205					1210					1215						
Ile	Pro	Lys	Trp	Gln	Tyr	Ala	Gln	Ala	Val	Ile	Arg	Asp	Pro	Asp		
1220					1225					1230						
Thr	Gly	Ala	Ala	Ala	His	Gly	Asp	Pro	Ile	Val	Ala	Glu	Lys	Gln		
1235					1240					1245						
Ile	Ile	Val	Pro	Val	Glu	Arg	Pro	Arg	Ala	Asn	Gln	Ala	Leu	Ile		
1250					1255					1260						
Tyr	Val	Leu	Ala	Ser	Glu	Val	Asn	Phe	Asn	Asp	Ile	Trp	Ala	Ile		
1265					1270					1275						
Thr	Gly	Ile	Pro	Val	Ser	Arg	Phe	Asp	Glu	His	Asp	Arg	Asp	Trp		
1280					1285					1290						
His	Val	Thr	Gly	Ser	Gly	Gly	Ile	Gly	Leu	Ile	Val	Ala	Leu	Gly		
1295					1300					1305						
Glu	Glu	Ala	Arg	Arg	Glu	Gly	Arg	Leu	Lys	Val	Gly	Asp	Leu	Val		
1310					1315					1320						
Ala	Ile	Tyr	Ser	Gly	Gln	Ser	Asp	Leu	Leu	Ser	Pro	Leu	Met	Gly		
1325					1330					1335						
Leu	Asp	Pro	Met	Ala	Ala	Asp	Phe	Val	Ile	Gln	Gly	Asn	Asp	Thr		
1340					1345					1350						
Pro	Asp	Gly	Ser	His	Gln	Gln	Phe	Met	Leu	Ala	Gln	Ala	Pro	Gln		
1355					1360					1365						

-continued

Cys	Leu	Pro	Ile	Pro	Thr	Asp	Met	Ser	Ile	Glu	Ala	Ala	Gly	Ser
1370						1375					1380			
Tyr	Ile	Leu	Asn	Leu	Gly	Thr	Ile	Tyr	Arg	Ala	Leu	Phe	Thr	Thr
1385						1390					1395			
Leu	Gln	Ile	Lys	Ala	Gly	Arg	Thr	Ile	Phe	Ile	Glu	Gly	Ala	Ala
1400						1405					1410			
Thr	Gly	Thr	Gly	Leu	Asp	Ala	Ala	Arg	Ser	Ala	Ala	Arg	Asn	Gly
1415						1420					1425			
Leu	Arg	Val	Ile	Gly	Met	Val	Ser	Ser	Ser	Ser	Arg	Ala	Ser	Thr
1430						1435					1440			
Leu	Leu	Ala	Ala	Gly	Ala	His	Gly	Ala	Ile	Asn	Arg	Lys	Asp	Pro
1445						1450					1455			
Glu	Val	Ala	Asp	Cys	Phe	Thr	Arg	Val	Pro	Glu	Asp	Pro	Ser	Ala
1460						1465					1470			
Trp	Ala	Ala	Trp	Glu	Ala	Ala	Gly	Gln	Pro	Leu	Leu	Ala	Met	Phe
1475						1480					1485			
Arg	Ala	Gln	Asn	Asp	Gly	Arg	Leu	Ala	Asp	Tyr	Val	Val	Ser	His
1490						1495					1500			
Ala	Gly	Glu	Thr	Ala	Phe	Pro	Arg	Ser	Phe	Gln	Leu	Leu	Gly	Glu
1505						1510					1515			
Pro	Arg	Asp	Gly	His	Ile	Pro	Thr	Leu	Thr	Phe	Tyr	Gly	Ala	Thr
1520						1525					1530			
Ser	Gly	Tyr	His	Phe	Thr	Phe	Leu	Gly	Lys	Pro	Gly	Ser	Ala	Ser
1535						1540					1545			
Pro	Thr	Glu	Met	Leu	Arg	Arg	Ala	Asn	Leu	Arg	Ala	Gly	Glu	Ala
1550						1555					1560			
Val	Leu	Ile	Tyr	Tyr	Gly	Val	Gly	Ser	Asp	Asp	Leu	Val	Asp	Thr
1565						1570					1575			
Gly	Gly	Leu	Glu	Ala	Ile	Glu	Ala	Ala	Arg	Gln	Met	Gly	Ala	Arg
1580						1585					1590			
Ile	Val	Val	Val	Thr	Val	Ser	Asp	Ala	Gln	Arg	Glu	Phe	Val	Leu
1595						1600					1605			
Ser	Leu	Gly	Phe	Gly	Ala	Ala	Leu	Arg	Gly	Val	Val	Ser	Leu	Ala
1610						1615					1620			
Glu	Leu	Lys	Arg	Arg	Phe	Gly	Asp	Glu	Phe	Glu	Trp	Pro	Arg	Thr
1625						1630					1635			
Met	Pro	Pro	Leu	Pro	Asn	Ala	Arg	Gln	Asp	Pro	Gln	Gly	Leu	Lys
1640						1645					1650			
Glu	Ala	Val	Arg	Arg	Phe	Asn	Asp	Leu	Val	Phe	Lys	Pro	Leu	Gly
1655						1660					1665			
Ser	Ala	Val	Gly	Val	Phe	Leu	Arg	Ser	Ala	Asp	Asn	Pro	Arg	Gly
1670						1675					1680			
Tyr	Pro	Asp	Leu	Ile	Ile	Glu	Arg	Ala	Ala	His	Asp	Ala	Leu	Ala
1685						1690					1695			
Val	Ser	Ala	Met	Leu	Ile	Lys	Pro	Phe	Thr	Gly	Arg	Ile	Val	Tyr
1700						1705					1710			
Phe	Glu	Asp	Ile	Gly	Gly	Arg	Arg	Tyr	Ser	Phe	Phe	Ala	Pro	Gln
1715						1720					1725			
Ile	Trp	Val	Arg	Gln	Arg	Arg	Ile	Tyr	Met	Pro	Thr	Ala	Gln	Ile
1730						1735					1740			
Phe	Gly	Thr	His	Leu	Ser	Asn	Ala	Tyr	Glu	Ile	Leu	Arg	Leu	Asn
1745						1750					1755			
Asp	Glu	Ile	Ser	Ala	Gly	Leu	Leu	Thr	Ile	Thr	Glu	Pro	Ala	Val
1760						1765					1770			

-continued

Val Pro Trp Asp Glu Leu Pro Glu Ala His Gln Ala Met Trp Glu
 1775 1780 1785

Asn Arg His Thr Ala Ala Thr Tyr Val Val Asn His Ala Leu Pro
 1790 1795 1800

Arg Leu Gly Leu Lys Asn Arg Asp Glu Leu Tyr Glu Ala Trp Thr
 1805 1810 1815

Ala Gly Glu Arg
 1820

<210> SEQ ID NO 40
 <211> LENGTH: 777
 <212> TYPE: DNA
 <213> ORGANISM: Chloroflexus aurantiacus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(774)

<400> SEQUENCE: 40

atg agt gaa gag tct ctg gtt ctc agc aca att gaa ggc ccc atc gcc Met Ser Glu Glu Ser Leu Val Leu Ser Thr Ile Glu Gly Pro Ile Ala 1 5 10 15	48
atc ctc acc ctc aat cgc ccc cag gcc ctc aat gcg ctc agt ccg gcc Ile Leu Thr Leu Asn Arg Pro Gln Ala Leu Asn Ala Leu Ser Pro Ala 20 25 30	96
ttg att gat gac ctc att cgc cat tta gaa gcc tgc gat gcc gat gac Leu Ile Asp Asp Leu Ile Arg His Leu Glu Ala Cys Asp Ala Asp Asp 35 40 45	144
aca atc cgc gtg atc att atc acc ggc gcc gga cgg gca ttt gct gcc Thr Ile Arg Val Ile Ile Ile Thr Gly Ala Gly Arg Ala Phe Ala Ala 50 55 60	192
ggc gct gat atc aaa gcg atg gcc aat gcc acg cct att gat atg ctc Gly Ala Asp Ile Lys Ala Met Ala Asn Ala Thr Pro Ile Asp Met Leu 65 70 75 80	240
acc agt ggc atg att gcg cgc tgg gca cgc atc gcc gcg gtg cgc aaa Thr Ser Gly Met Ile Ala Arg Trp Ala Arg Ile Ala Ala Val Arg Lys 85 90 95	288
ccg gtg att gct gcc gtg aat ggg tat gcg ctc ggt ggt ggt tgt gaa Pro Val Ile Ala Ala Val Asn Gly Tyr Ala Leu Gly Gly Gly Cys Glu 100 105 110	336
ttg gca atg atg tgc gac atc atc atc gcc agt gaa aac gcg cag ttc Leu Ala Met Met Cys Asp Ile Ile Ile Ala Ser Glu Asn Ala Gln Phe 115 120 125	384
gga caa ccg gaa atc aat ctg ggc atc att ccc ggt gct ggt ggc acc Gly Gln Pro Glu Ile Asn Leu Gly Ile Ile Pro Gly Ala Gly Gly Thr 130 135 140	432
caa cgg ctg acc cgc gcc ctt ggc ccg tat cgc gca atg gaa ttg atc Gln Arg Leu Thr Arg Ala Leu Gly Pro Tyr Arg Ala Met Glu Leu Ile 145 150 155 160	480
ctg acc ggc gcg acc atc agt gct cag gaa gct ctc gcc cac ggc ctg Leu Thr Gly Ala Thr Ile Ser Ala Gln Glu Ala Leu Ala His Gly Leu 165 170 175	528
gtg tgc cgg gtc tgc ccg cct gaa agc ctg ctc gat gaa gcc cgt cgg Val Cys Arg Val Cys Pro Pro Glu Ser Leu Leu Asp Glu Ala Arg Arg 180 185 190	576
atc gcg caa acc att gcc acc aaa tca cca ctg gct gta cag ttg gcg Ile Ala Gln Thr Ile Ala Thr Lys Ser Pro Leu Ala Val Gln Leu Ala 195 200 205	624
aaa gag gca gtc cgt atg gcc gcc gaa acc act gtg cgc gag ggg ttg Lys Glu Ala Val Arg Met Ala Ala Glu Thr Thr Val Arg Glu Gly Leu 210 215 220	672

-continued

```

gct atc gag ctg cgt aac ttc tat ctg ctg ttt gcc agt gct gac caa      720
Ala Ile Glu Leu Arg Asn Phe Tyr Leu Leu Phe Ala Ser Ala Asp Gln
225                230                235                240

aaa gag ggg atg cag gca ttt atc gag aaa cgc gct ccc aac ttc agt      768
Lys Glu Gly Met Gln Ala Phe Ile Glu Lys Arg Ala Pro Asn Phe Ser
                245                250                255

ggt cgt tga      777
Gly Arg

```

```

<210> SEQ ID NO 41
<211> LENGTH: 258
<212> TYPE: PRT
<213> ORGANISM: Chloroflexus aurantiacus

```

```

<400> SEQUENCE: 41

```

```

Met Ser Glu Glu Ser Leu Val Leu Ser Thr Ile Glu Gly Pro Ile Ala
1          5          10          15

Ile Leu Thr Leu Asn Arg Pro Gln Ala Leu Asn Ala Leu Ser Pro Ala
20          25          30

Leu Ile Asp Asp Leu Ile Arg His Leu Glu Ala Cys Asp Ala Asp Asp
35          40          45

Thr Ile Arg Val Ile Ile Ile Thr Gly Ala Gly Arg Ala Phe Ala Ala
50          55          60

Gly Ala Asp Ile Lys Ala Met Ala Asn Ala Thr Pro Ile Asp Met Leu
65          70          75          80

Thr Ser Gly Met Ile Ala Arg Trp Ala Arg Ile Ala Ala Val Arg Lys
85          90          95

Pro Val Ile Ala Ala Val Asn Gly Tyr Ala Leu Gly Gly Gly Cys Glu
100         105         110

Leu Ala Met Met Cys Asp Ile Ile Ile Ala Ser Glu Asn Ala Gln Phe
115         120         125

Gly Gln Pro Glu Ile Asn Leu Gly Ile Ile Pro Gly Ala Gly Gly Thr
130         135         140

Gln Arg Leu Thr Arg Ala Leu Gly Pro Tyr Arg Ala Met Glu Leu Ile
145         150         155         160

Leu Thr Gly Ala Thr Ile Ser Ala Gln Glu Ala Leu Ala His Gly Leu
165         170         175

Val Cys Arg Val Cys Pro Pro Glu Ser Leu Leu Asp Glu Ala Arg Arg
180         185         190

Ile Ala Gln Thr Ile Ala Thr Lys Ser Pro Leu Ala Val Gln Leu Ala
195         200         205

Lys Glu Ala Val Arg Met Ala Ala Glu Thr Thr Val Arg Glu Gly Leu
210         215         220

Ala Ile Glu Leu Arg Asn Phe Tyr Leu Leu Phe Ala Ser Ala Asp Gln
225         230         235         240

Lys Glu Gly Met Gln Ala Phe Ile Glu Lys Arg Ala Pro Asn Phe Ser
245         250         255

Gly Arg

```

```

<210> SEQ ID NO 42
<211> LENGTH: 1220
<212> TYPE: DNA
<213> ORGANISM: Chloroflexus aurantiacus

```

```

<400> SEQUENCE: 42

```

```

ggcgtaatcc gaccggcagg ttagggcttt ctactggggg caaggcgcgt ctcccttttg      60
tggcgcgagc aacccggctt ttcctggctt caatgtacca tagagcggtt acttcgtgca    120

```

-continued

```

acgggctggg tacaatcgag agcaaccttt cgcaaaagct atccaatcct gcacacgtgc 180
atctgttaca ggggtattatt gtccgcaaac gacagtccctg tcgtttatgt acaaggagat 240
caacgtatga gtgaagagtc tctggttctc agcacaattg aaggcccat cgccatcctc 300
accctcaatc gccccaggc cctcaatgcg ctccagtcgg ccttgattga tgacctcatt 360
cgccatttag aagcctgcga tgccgatgac acaatccgcg tgatcattat caccggcgcc 420
ggacgggcat ttgctgccg cgctgatatc aaagcgatgg ccaatgccac gcctattgat 480
atgctacca gtggcatgat tgcgcgctgg gcacgcatcg ccgcggtgcg caaacgggtg 540
attgctgccg tgaatgggta tgcgctcggg ggtggttggtg aattggcaat gatgtgcgac 600
atcatcatcg ccagtgaaaa cgcgagttc ggacaaccgg aaatcaatct gggcatcatt 660
cccggctctg gtggcaccca acggctgacc cgcgcccttg gcccgatcg cgcaatggaa 720
ttgatcctga ccggcgcgac catcagtgcg caggaaagtc tcgccacgg cctggtgtgc 780
cgggtctgcc cgctgaaaag cctgctcgat gaagcccgtc ggatcgcgca aaccattgcc 840
accaaatac cactggctgt acagttggcg aaagaggcag tccgtatggc cgccgaaacc 900
actgtgcgcg aggggttgcc tatcgagctg cgtaacttct atctgctggt tgccagtgcg 960
gacaaaaag aggggatgca ggcatttacc gagaaacgcg ctcccaactt cagtggctgt 1020
tgatcacgcg cagaacatgg cagcaggggc aatactgca cgtactgct cctgccgcca 1080
tactaccaga tgatcgagca gtaaagggta aatactctat caatctggcc agataagcgg 1140
ttgggtaaca acgcaatgct ccaaaggaga cgatcatgga catacacgag cgattgcgat 1200
ctctcgaacg cgaaaatgct 1220

```

```

<210> SEQ ID NO 43
<211> LENGTH: 774
<212> TYPE: DNA
<213> ORGANISM: Mycobacterium tuberculosis

```

```

<400> SEQUENCE: 43

```

```

atgacgtacg aaaccatcct ggtcgagcgc gatcagcgag ttggcattat cacgctgaac 60
cgccccagg cactgaacgc gctcaacagc caggtgatga acgaggtcac cagcgctgca 120
accgaactgg acgatgacct ggacattggg gcgatcatca tcaccggttc ggccaaagcg 180
tttgccgccc gagccgacat caaagaaatg gccgacctga cgttcgccga cgcgttcacc 240
gccgacttct tcgccacctg gggcaagctg gccgccgtgc gcaccccgac gatcgccgcg 300
gtggcgggat acgcgctcgg cgggtggctgc gagctggcga tgatgtgcga cgtgctgac 360
gccgccgaca ccgcgaagtt cggacagccc gagataaagc tgggcgtgct gccaggcatg 420
ggcggctccc agcggctgac ccgggctatc ggcaaggcta aggcgatgga cctcatcctg 480
accgggcgca ccatggacgc cgccgaggcc gagcgacgcg gtcgtggttc acgggtgggtg 540
ccggccgacg acttgctgac cgaagccagg gccactgcca cgaccatttc gcagatgtcg 600
gcctcggcgg ccgggatggc caaggaggcc gtcaaccggg ctttcgaatc cagtttgtcc 660
gaggggctgc tctacgaacg ccggcttttc cattcggtt tcgcgaccga agaccaatcc 720
gaaggtatgg cagcgttcat cgagaaacgc gctccccagt tcaccaccg atga 774

```

```

<210> SEQ ID NO 44
<211> LENGTH: 873
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 44

```

-continued

```

atggcgcccc tgcgtgtcct gctgtcctgc gcccgcgccc cgctgaggcc cccggttcgc      60
tgccccgcct ggcgctccct cgcctcgggt gctaactttg agtacatcat cgcagaaaaa      120
agaggaaga ataacaccgt ggggttgatc caactgaacc gcccgaaggc cctcaatgca      180
ctttgcgatg gcctgattga cgagctcaac caggccctga agatcttcga ggaggaccgc      240
gccgttgggg gcattgtcct caccggcggg gataaggcct ttgcagctgg agctgatatc      300
aaggaaatgc agaacctgag tttccaggac tgttactcca gcaagttcct gaagcactgg      360
ggccacctca cccagggtcaa gaagccagtc atcgctgctg tcaatggcta tccggtttggc      420
gggggctgtg agcttgccat gatgtgtgat atcatctatg ccggtgagaa ggcccagttt      480
gcacagccgg agatcttaat aggaaccatc ccagggtcag gcggcaccca gagactcacc      540
cgtgctgttg ggaagtcgct ggagctggag atggtcctca ccggtgacgc gatctcagcc      600
caggacgcca agcaagcagg tcttgtcagc aagatttgct ctgttgagac actggtggaa      660
gaagccatcc agtgtgcaga aaaaattgcc agcaattcta aaattgtagt agcgtatggc      720
aaagaatcag tgaatgcagc ttttgaaatg acattaacag aaggaagtaa gttggagaag      780
aaactctttt attcaacctt tgccactgat gaccggaaag aagggatgac cgcgtttgtg      840
gaaaagagaa aggccaaact caaagaccag tga                                     873

```

```

<210> SEQ ID NO 45
<211> LENGTH: 873
<212> TYPE: DNA
<213> ORGANISM: Rattus norvegicus

<400> SEQUENCE: 45

```

```

atggcgcccc tgcgtgtcct gctgcccaga gcctgcaact cgctgttgct cccagttcgc      60
tgcccagaat tccggcgctt cgcctcgggt gctaactttc agtacatcat cccgaaaaag      120
aaaggaaga atagcagcgt ggggttgatc cagttgaacc gtcccaaagc actcaatgca      180
ctttgcaatg gactgattga ggagctcaac caagcactgg agacctttga ggaagatccc      240
gctgtggggc ccatttgtct cactgggtggg gagaaggcct ttgcagccgg agctgacatc      300
aaggaaatgc agaaccggac atttcaggac tgttactcag gcaagttcct gagccactgg      360
gaccatatca cccggatcaa gaaaccggtc atcgcggtcg tcaatggcta tgctcttggt      420
gggggctgtg aacttgccat gatgtgcat atcatctatg ctggtgagaa agcccagttt      480
ggacagccag aaatcctcct ggggaccatc ccagggtcag ggggcactca gagactcacc      540
cgagcagtcg gcaaatcact agcaatggag atggtcctca ctggtgaccg aatttcagca      600
caggatgcca agcaagcagg tcttgtaagc aagatttttc ccgttgaaac actggttgaa      660
gaggccatcc aatgtgcaga aaagatgcc aacaattcca agatcatagt agccatggcg      720
aaagaatctg tgaatgcagc ctttgaaatg acgttaacag aaggaaataa gctggagaag      780
aagctcttct attccacctt tgccactgat gaccggagag aagggatgct tgcctttgtg      840
gagaaaagga aggccaaact caaagaccac tga                                     873

```

```

<210> SEQ ID NO 46
<211> LENGTH: 257
<212> TYPE: PRT
<213> ORGANISM: Mycobacterium tuberculosis

<400> SEQUENCE: 46

```

```

Met Thr Tyr Glu Thr Ile Leu Val Glu Arg Asp Gln Arg Val Gly Ile
1           5           10           15

```

-continued

Ile	Thr	Leu	Asn	Arg	Pro	Gln	Ala	Leu	Asn	Ala	Leu	Asn	Ser	Gln	Val
			20					25					30		
Met	Asn	Glu	Val	Thr	Ser	Ala	Ala	Thr	Glu	Leu	Asp	Asp	Asp	Pro	Asp
	35						40					45			
Ile	Gly	Ala	Ile	Ile	Ile	Thr	Gly	Ser	Ala	Lys	Ala	Phe	Ala	Ala	Gly
	50					55					60				
Ala	Asp	Ile	Lys	Glu	Met	Ala	Asp	Leu	Thr	Phe	Ala	Asp	Ala	Phe	Thr
65					70					75					80
Ala	Asp	Phe	Phe	Ala	Thr	Trp	Gly	Lys	Leu	Ala	Ala	Val	Arg	Thr	Pro
				85					90					95	
Thr	Ile	Ala	Ala	Val	Ala	Gly	Tyr	Ala	Leu	Gly	Gly	Gly	Cys	Glu	Leu
		100						105					110		
Ala	Met	Met	Cys	Asp	Val	Leu	Ile	Ala	Ala	Asp	Thr	Ala	Lys	Phe	Gly
	115						120					125			
Gln	Pro	Glu	Ile	Lys	Leu	Gly	Val	Leu	Pro	Gly	Met	Gly	Gly	Ser	Gln
	130					135					140				
Arg	Leu	Thr	Arg	Ala	Ile	Gly	Lys	Ala	Lys	Ala	Met	Asp	Leu	Ile	Leu
145					150					155					160
Thr	Gly	Arg	Thr	Met	Asp	Ala	Ala	Glu	Ala	Glu	Arg	Ser	Gly	Leu	Val
				165					170					175	
Ser	Arg	Val	Val	Pro	Ala	Asp	Asp	Leu	Leu	Thr	Glu	Ala	Arg	Ala	Thr
		180						185					190		
Ala	Thr	Thr	Ile	Ser	Gln	Met	Ser	Ala	Ser	Ala	Ala	Arg	Met	Ala	Lys
	195					200						205			
Glu	Ala	Val	Asn	Arg	Ala	Phe	Glu	Ser	Ser	Leu	Ser	Glu	Gly	Leu	Leu
	210					215					220				
Tyr	Glu	Arg	Arg	Leu	Phe	His	Ser	Ala	Phe	Ala	Thr	Glu	Asp	Gln	Ser
225					230					235					240
Glu	Gly	Met	Ala	Ala	Phe	Ile	Glu	Lys	Arg	Ala	Pro	Gln	Phe	Thr	His
			245						250					255	

Arg

<210> SEQ ID NO 47

<211> LENGTH: 290

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

Met	Ala	Ala	Leu	Arg	Val	Leu	Leu	Ser	Cys	Ala	Arg	Gly	Pro	Leu	Arg
1				5					10					15	
Pro	Pro	Val	Arg	Cys	Pro	Ala	Trp	Arg	Pro	Phe	Ala	Ser	Gly	Ala	Asn
		20						25					30		
Phe	Glu	Tyr	Ile	Ile	Ala	Glu	Lys	Arg	Gly	Lys	Asn	Asn	Thr	Val	Gly
	35						40					45			
Leu	Ile	Gln	Leu	Asn	Arg	Pro	Lys	Ala	Leu	Asn	Ala	Leu	Cys	Asp	Gly
	50				55						60				
Leu	Ile	Asp	Glu	Leu	Asn	Gln	Ala	Leu	Lys	Ile	Phe	Glu	Glu	Asp	Pro
65					70					75					80
Ala	Val	Gly	Ala	Ile	Val	Leu	Thr	Gly	Gly	Asp	Lys	Ala	Phe	Ala	Ala
			85						90					95	
Gly	Ala	Asp	Ile	Lys	Glu	Met	Gln	Asn	Leu	Ser	Phe	Gln	Asp	Cys	Tyr
	100						105						110		
Ser	Ser	Lys	Phe	Leu	Lys	His	Trp	Asp	His	Leu	Thr	Gln	Val	Lys	Lys
	115					120						125			
Pro	Val	Ile	Ala	Ala	Val	Asn	Gly	Tyr	Ala	Phe	Gly	Gly	Gly	Cys	Glu

-continued

130	135	140
Leu Ala Met Met Cys Asp Ile Ile Tyr Ala Gly Glu Lys Ala Gln Phe 145 150 155 160		
Ala Gln Pro Glu Ile Leu Ile Gly Thr Ile Pro Gly Ala Gly Gly Thr 165 170 175		
Gln Arg Leu Thr Arg Ala Val Gly Lys Ser Leu Ala Met Glu Met Val 180 185 190		
Leu Thr Gly Asp Arg Ile Ser Ala Gln Asp Ala Lys Gln Ala Gly Leu 195 200 205		
Val Ser Lys Ile Cys Pro Val Glu Thr Leu Val Glu Glu Ala Ile Gln 210 215 220		
Cys Ala Glu Lys Ile Ala Ser Asn Ser Lys Ile Val Val Ala Met Ala 225 230 235 240		
Lys Glu Ser Val Asn Ala Ala Phe Glu Met Thr Leu Thr Glu Gly Ser 245 250 255		
Lys Leu Glu Lys Lys Leu Phe Tyr Ser Thr Phe Ala Thr Asp Asp Arg 260 265 270		
Lys Glu Gly Met Thr Ala Phe Val Glu Lys Arg Lys Ala Asn Phe Lys 275 280 285		
Asp Gln 290		
<210> SEQ ID NO 48		
<211> LENGTH: 290		
<212> TYPE: PRT		
<213> ORGANISM: Rattus norvegicus		
<400> SEQUENCE: 48		
Met Ala Ala Leu Arg Ala Leu Leu Pro Arg Ala Cys Asn Ser Leu Leu 1 5 10 15		
Ser Pro Val Arg Cys Pro Glu Phe Arg Arg Phe Ala Ser Gly Ala Asn 20 25 30		
Phe Gln Tyr Ile Ile Thr Glu Lys Lys Gly Lys Asn Ser Ser Val Gly 35 40 45		
Leu Ile Gln Leu Asn Arg Pro Lys Ala Leu Asn Ala Leu Cys Asn Gly 50 55 60		
Leu Ile Glu Glu Leu Asn Gln Ala Leu Glu Thr Phe Glu Glu Asp Pro 65 70 75 80		
Ala Val Gly Ala Ile Val Leu Thr Gly Gly Glu Lys Ala Phe Ala Ala 85 90 95		
Gly Ala Asp Ile Lys Glu Met Gln Asn Arg Thr Phe Gln Asp Cys Tyr 100 105 110		
Ser Gly Lys Phe Leu Ser His Trp Asp His Ile Thr Arg Ile Lys Lys 115 120 125		
Pro Val Ile Ala Ala Val Asn Gly Tyr Ala Leu Gly Gly Gly Cys Glu 130 135 140		
Leu Ala Met Met Cys Asp Ile Ile Tyr Ala Gly Glu Lys Ala Gln Phe 145 150 155 160		
Gly Gln Pro Glu Ile Leu Leu Gly Thr Ile Pro Gly Ala Gly Gly Thr 165 170 175		
Gln Arg Leu Thr Arg Ala Val Gly Lys Ser Leu Ala Met Glu Met Val 180 185 190		
Leu Thr Gly Asp Arg Ile Ser Ala Gln Asp Ala Lys Gln Ala Gly Leu 195 200 205		
Val Ser Lys Ile Phe Pro Val Glu Thr Leu Val Glu Glu Ala Ile Gln		

-continued

210	215	220	
Cys Ala Glu Lys Ile	Ala Asn Asn Ser Lys	Ile Ile Val Ala Met Ala	
225	230	235	240
Lys Glu Ser Val Asn	Ala Ala Phe Glu Met Thr	Leu Thr Glu Gly Asn	
	245	250	255
Lys Leu Glu Lys Lys	Leu Phe Tyr Ser Thr Phe	Ala Thr Asp Asp Arg	
	260	265	270
Arg Glu Gly Met Ser	Ala Phe Val Glu Lys Arg	Lys Ala Asn Phe Lys	
	275	280	285
Asp His			
290			
<210> SEQ ID NO 49			
<211> LENGTH: 20			
<212> TYPE: DNA			
<213> ORGANISM: Artificial Sequence			
<220> FEATURE:			
<223> OTHER INFORMATION: Primer			
<220> FEATURE:			
<221> NAME/KEY: misc_feature			
<222> LOCATION: (1)..(20)			
<223> OTHER INFORMATION: n is any nucleotide; w is a or t; y is t or c; s is g or c			
<400> SEQUENCE: 49			
gaawscggys cnatygggygg			20
<210> SEQ ID NO 50			
<211> LENGTH: 23			
<212> TYPE: DNA			
<213> ORGANISM: Artificial Sequence			
<220> FEATURE:			
<223> OTHER INFORMATION: Primer			
<400> SEQUENCE: 50			
ttytgyggyr sbttyacbgc wgg			23
<210> SEQ ID NO 51			
<211> LENGTH: 23			
<212> TYPE: DNA			
<213> ORGANISM: Artificial Sequence			
<220> FEATURE:			
<223> OTHER INFORMATION: Primer			
<400> SEQUENCE: 51			
ccwgcvgtra avsyrcrcra raa			23
<210> SEQ ID NO 52			
<211> LENGTH: 23			
<212> TYPE: DNA			
<213> ORGANISM: Artificial Sequence			
<220> FEATURE:			
<223> OTHER INFORMATION: Primer			
<400> SEQUENCE: 52			
aaracdsmrc gttcvgtrat rta			23
<210> SEQ ID NO 53			
<211> LENGTH: 20			
<212> TYPE: DNA			
<213> ORGANISM: Artificial Sequence			
<220> FEATURE:			
<223> OTHER INFORMATION: Primer			
<400> SEQUENCE: 53			

-continued

tcrayrccsg gwgcrayttc 20

<210> SEQ ID NO 54
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 54

gaatgtttac ttctgcgga ccttcac 27

<210> SEQ ID NO 55
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 55

gaccagatca ctttcaacgg ttcctatg 28

<210> SEQ ID NO 56
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 56

gcataggaac cggtgaaagt gatctgg 27

<210> SEQ ID NO 57
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 57

gttagtaccg aacttgctga cgttgatg 28

<210> SEQ ID NO 58
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 58

atgagaaaag tagaaatcat tac 23

<210> SEQ ID NO 59
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 59

ggcggaagtt gacgataatg 20

<210> SEQ ID NO 60
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 60

gcwacbggyt ayggycg

17

<210> SEQ ID NO 61

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 61

gtyrtygayr tygggyggyca gga

23

<210> SEQ ID NO 62

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 62

atgaacgaya artgygcwgc wgg

23

<210> SEQ ID NO 63

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 63

tgygcwgcwg gyacbggycg ytt

23

<210> SEQ ID NO 64

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 64

tcctgrccrc crayrtcray rac

23

<210> SEQ ID NO 65

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 65

ccwgcwgcrc ayttrtcggt cat

23

<210> SEQ ID NO 66

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 66

aarcgrccvg trccwgcwgc rca

23

<210> SEQ ID NO 67

-continued

<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 67

gcttcgswtt cracratgsw

20

<210> SEQ ID NO 68
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 68

gswrtract tgcwttcwg craa

24

<210> SEQ ID NO 69
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 69

acgtcatgtc gaaggtactg gaaatcc

27

<210> SEQ ID NO 70
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 70

gggactggta cttcaaatcg aagcatc

27

<210> SEQ ID NO 71
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 71

tgacggcagc gggatgcttc gatttga

27

<210> SEQ ID NO 72
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 72

tcagacatgg ggatttcag taccttc

27

<210> SEQ ID NO 73
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 73

-continued

ccgtgttact tgggaaggta tcgctgtctg 30

<210> SEQ ID NO 74
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 74

gccaatgaag gaggaaacca ctaatgagtc 30

<210> SEQ ID NO 75
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 75

gggaattcca tatgaaaact gtgtatactc tc 32

<210> SEQ ID NO 76
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 76

cgacggatcc ttagaggatt tccgagaaag c 31

<210> SEQ ID NO 77
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(23)
<223> OTHER INFORMATION: n is any nucleotide; y is t or c; b is g, c or
t; v is a, g, or c; s is g or c

<400> SEQUENCE: 77

aaycgbccva argcnctsaa ygc 23

<210> SEQ ID NO 78
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: n is any nucleotide; y is t or c; b is c, g, or
t

<400> SEQUENCE: 78

ttygtbgcng gygcngayat 20

<210> SEQ ID NO 79
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<220> FEATURE:

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(20)
<223> OTHER INFORMATION: n is any nucleotide; r is g or a; v is a, g, or
c.

```

```

<400> SEQUENCE: 79

```

```

atrtcngcgc cngcvacraa 20

```

```

<210> SEQ ID NO 80
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(23)
<223> OTHER INFORMATION: n is any nucleotide; r is g or a; s is g or c;
w is a or t.

```

```

<400> SEQUENCE: 80

```

```

ccrccrccsa gngcrwarcc rtt 23

```

```

<210> SEQ ID NO 81
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(21)
<223> OTHER INFORMATION: n is any nucleotide; r is g or a; s is g or c;
w is a or t; v is a, g or c.

```

```

<400> SEQUENCE: 81

```

```

sswngcratv cgratrtcra c 21

```

```

<210> SEQ ID NO 82
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

```

```

<400> SEQUENCE: 82

```

```

cgctgatatt cgccagttgc tcgaag 26

```

```

<210> SEQ ID NO 83
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

```

```

<400> SEQUENCE: 83

```

```

cccatcttgc tttccgcaag attgagc 27

```

```

<210> SEQ ID NO 84
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

```

```

<400> SEQUENCE: 84

```

```

caatggccct gccgaataac gcccatct 28

```

-continued

<210> SEQ ID NO 85
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 85

cttcgagcaa ctggcgaata tcagcg

26

<210> SEQ ID NO 86
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 86

gctcaatctt gcggaaagca agatggg

27

<210> SEQ ID NO 87
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 87

agatgggcgt tattcggcag ggccattg

28

<210> SEQ ID NO 88
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 88

aagctggggtc tgatcgatgc cattgctacc

30

<210> SEQ ID NO 89
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 89

ctcgattatc gcccatccac gtatcgag

28

<210> SEQ ID NO 90
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 90

tggtatgcaat ccgctatggc attatccacg

30

<210> SEQ ID NO 91
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 91

-continued

tcattcagtg cgttcaccgg cggatttgtc 30

<210> SEQ ID NO 92
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 92

tcgatccgga agtagcgata gcgttcgatg 30

<210> SEQ ID NO 93
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 93

cttggtgca atctcttcga gcacttcagg 30

<210> SEQ ID NO 94
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 94

catcagaggt aatcaccact cgtgca 26

<210> SEQ ID NO 95
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 95

aagtagtagg ccacctcgtc gccata 26

<210> SEQ ID NO 96
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 96

gccaatcagg cgctgatcta tgttct 26

<210> SEQ ID NO 97
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 97

ctgatctatg ttctggcctc ggaggt 26

<210> SEQ ID NO 98
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 98

ggctgatatc aaagcgatgg ccaatgc

27

<210> SEQ ID NO 99
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 99

ccacgcctat tgatatgctc accagtg

27

<210> SEQ ID NO 100
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 100

gcaaaccggt gattgctgcc gtgaatgg

28

<210> SEQ ID NO 101
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 101

gcattggcca tcgctttgat atcagcc

27

<210> SEQ ID NO 102
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 102

cactggtgag catatcaata ggcgtgg

27

<210> SEQ ID NO 103
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 103

ccattcacgg cagcaatcac cggtttgc

28

<210> SEQ ID NO 104
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 104

tcatcatcgc cagtgaaaac gcgcagttcg

30

-continued

<210> SEQ ID NO 105
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 105

ggatcgcgca aaccattgcc accaaatcac

30

<210> SEQ ID NO 106
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 106

atgagtgaag agtctctggt tctcagc

27

<210> SEQ ID NO 107
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 107

agatcgcaat cgctcgtgta tgtc

24

<210> SEQ ID NO 108
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 108

gggaattcca tatgagaaaa gtagaaatca ttacagctg

39

<210> SEQ ID NO 109
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 109

gagagtatac acagttttca cctcctttac agcagagat

39

<210> SEQ ID NO 110
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 110

atctctgctg taaaggaggt gaaaactgtg tataactctc

39

<210> SEQ ID NO 111
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 111

-continued

acgttgatct ccttgatcat tagaggattt ccgagaaagc 40

<210> SEQ ID NO 112
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 112

gctttctcgg aaatcctcta atgtacaagg agatcaacgt 40

<210> SEQ ID NO 113
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 113

cgacggatcc tcaacgacca ctgaagttgg 30

<210> SEQ ID NO 114
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 114

cgacggatcc ttagaggatt tccgagaaag c 31

<210> SEQ ID NO 115
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 115

ggtgtctaga gacagtcctg tcgtttatgt agaaggag 38

<210> SEQ ID NO 116
<211> LENGTH: 52
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 116

gggaattcca tatgcgtaac ttcctcctgc tatcaacgac cactgaagtt gg 52

<210> SEQ ID NO 117
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 117

acgttgatct ccttctacat tattttttca gtcccatg 38

<210> SEQ ID NO 118
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 118

ggtgtctaga gtcaaaggag agaacaaaat catgagtg 38

<210> SEQ ID NO 119
<211> LENGTH: 53
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 119

gggaattcca tatgcgtaac ttctctctgc tattagagga ttcccgagaa agc 53

<210> SEQ ID NO 120
<211> LENGTH: 52
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 120

tcagtggctg ttgatcacgc tataaagaaa ggtgaaaact gtgtatactc tc 52

<210> SEQ ID NO 121
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 121

cgacggatcc cttccttgga gctcatgctt tc 32

<210> SEQ ID NO 122
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 122

catgggactg aaaaaataat gtagaaggag atcaacgt 38

<210> SEQ ID NO 123
<211> LENGTH: 52
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 123

gagagtatac acagttttca cctttcttta tagcgtgac aacgaccact ga 52

<210> SEQ ID NO 124
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 124

ccaacttcag tggctgtag tgaaaactgt gtatactctc 40

-continued

```

<210> SEQ ID NO 125
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 125

gagagtatac acagttttca ctaacgacca ctgaagttgg          40

<210> SEQ ID NO 126
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 126

gtcgcagaat tcccatcaat cgcagcaatc ccaac              35

<210> SEQ ID NO 127
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 127

taacatggta ccgacagaag cggaccagca aacga              35

<210> SEQ ID NO 128
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 128

cgacggatcc tcaacgacca ctgaagttgg                    30

<210> SEQ ID NO 129
<211> LENGTH: 5469
<212> TYPE: DNA
<213> ORGANISM: Chloroflexus aurantiacus

<400> SEQUENCE: 129

atgatcgaca ctgcgcccct tgccccacca cgggcgcccc gctctaattcc gattcgggat    60
cgagttgatt gggaagctca gcgcgctgct gcgctggcag atcccggtgc ctttcatggc    120
gcgattgccc ggacagttat ccaactggtac gaccacacaac accattgctg gattcgcttc    180
aacgagtcta gtcagcgttg ggaagggctg gatgccgcta ccggtgcccc tgtaacggta    240
gactatcccc ccgattatca gccctggcaa caggcggttg atgatatga agcgccgttt    300
taccgctggt ttagtggtgg gttgacaaaat gcctgcttta atgaagtaga ccggcatgtc    360
atgatgggct atggcgacga ggtggcctac tactttgaag gtgaccgctg ggataactcg    420
ctcaacaatg gtcgtggtgg tccggttgtc caggagacaa tcacgcggcg gcgcctgttg    480
gtggaggtgg tgaagctgc gcaggtgttg cgtgatctgg gcctgaagaa gggtgatcgg    540
attgctctga atatgccgaa tattatgccg cagatttatt atacggaagc ggcaaaacga    600
ctgggtattc tgtacacgcc ggtcttcggt ggcttctcgg acaagactct ttccgaccgt    660
attcacaatg ccggtgcacg agtggtgatt acctctgatg gtgcgtaccg caacgcgcag    720
gtggtgccct acaaagaagc gtataccgat caggcgctcg ataagtatat tccggttgag    780

```

-continued

acggcgccagg	cgattgttgc	gcagaccctg	gccaccttgc	ccctgactga	gtcgcagcgc	840
cagacgatca	tcaccgaagt	ggaggccgca	ctggccggtg	agattacggt	tgagcgcctc	900
gacgtgatgc	gtgggggttg	ttctgccctc	gcaaagctcc	gcgatcttga	tgcaagcgtg	960
caggcaaagg	tcggtacagt	actggcgag	gcgctggctg	agtcgcccgc	gcgggttgaa	1020
gctgtggtgg	ttgtgcgtca	taccggctcag	gagattttgt	ggaacgaggg	gcgagatcgc	1080
tgagatcacg	acttgctgga	tgctgcgctg	gcgaagattc	tgccaatgc	gcgtgctgcc	1140
ggctttgatg	tcacacgtga	gaatgatctg	ctcaatctcc	ccgatgacca	gcttatccgt	1200
gcgctctacg	ccagtattcc	ctgtgaaccg	gttgatgctg	aatatccgat	gtttatcatt	1260
tacacatcgg	gtagcaccgg	taagcccaag	ggtgtgatcc	acgttcacgg	cggttatgtc	1320
gccgggtggtg	tcacacacct	gcgggtcagt	tttgacgccg	agccgggtga	tacgatatat	1380
gtgatcgccg	atccgggctg	gatcaccggt	cagagctata	tgctcacagc	cacaatggcc	1440
ggtcggtgga	ccggggtgat	tgccgaggga	tcaccgctct	tccctcagc	cgggcggtat	1500
gccagcatca	tcgagcgcta	tggggtgcag	atctttaagg	cggtgtgtac	cttctcaag	1560
acagtgatgt	ccaatccgca	gaatgttgaa	gatgtgcgac	tctatgat	gcactcgctg	1620
cggttgcaa	ccttctgcgc	cgagccggtc	agtcggcgcg	tgacgcagtt	tggtatgcag	1680
atcatgaccc	cgcagtatat	caattcgtac	tgggcgaccg	agcacggtgg	aattgtctgg	1740
acgcatttct	acggtaataca	ggacttcccg	cttcgtcccg	atgccatac	ctatcccttg	1800
cctgggtgga	tggtgtgatgt	ctgggtggcc	gaaactgatg	agagcgggac	gacgcgtat	1860
cggttcgctg	atttcgatga	gaagggcgag	attgtgatta	ccgccccgta	tccctacctg	1920
accgcacac	tctgggggtga	tgtgcccggg	ttcgaggcgt	acctgcgcgg	tgagattccg	1980
ctgcgggct	ggaaggggtga	tgccgagcgt	ttcgtcaaga	cctactggcg	acgtgggcca	2040
aacgggtgaat	ggggctatat	ccagggtgat	tttgccatca	agtaccccg	tggtagcttc	2100
acgctccacg	gacgcctcga	cgatgtgac	aatgtgtcgg	gccaccgtat	gggcaccgag	2160
gagattgagg	gtgccatttt	gcgtgaccgc	cagatcacgc	ccgactcgcc	cgctcgtaat	2220
tgtattgtgg	tcggtgcgcc	gcaccgtgag	aagggctctga	ccccggttgc	cttcattcaa	2280
cctgcgcctg	gccgtcatct	gaccggcgcc	gaccggcgcc	gtctcgatga	gctgggtcgt	2340
accgagaagg	gggggttcag	tgtcccagag	gattacatcg	aggtcagtgc	ctttcccgaa	2400
accgcagcg	ggaagtatat	gcggcgcttt	ttgcgcaata	tgatgctcga	tgaaccactg	2460
ggtgatacga	cgacgttgcg	caatcctgaa	gtgctcgaag	agattgcagc	caagatcgct	2520
gagtggaaac	gccgtcagcg	tatggccgaa	gagcagcaga	tcacggaacg	ctatcgctac	2580
ttccggatcg	agtatcaccc	accaacggcc	agtcggggta	aactcgcggt	agtgaacggtg	2640
acaaatccgc	cggtgaacgc	actgaatgag	cgtgcgctcg	atgagttgaa	cacaattgtt	2700
gaccacctgg	cccgtcgtca	ggatgttgcc	gcaattgtct	tcaccggaca	ggcgccagg	2760
agttttgtcg	ccggcgctga	tattcgccag	ttgctcgaag	agattcatac	ggttgaagag	2820
gcaatggccc	tgccgaataa	cgcccatctt	gctttccgca	agattgagcg	tatgaataag	2880
ccgtgtatcg	cggcgatcaa	cggtgtggcg	ctcggtggtg	gtctggaatt	cgccatggcc	2940
tgccattacc	gggttgccga	tgtctatgcc	gaattcggtc	agccagagat	taatctgcgc	3000
ttgctacctg	gttatgggtg	cacgcagcgc	ttgcgcgcc	tggtgtacaa	gcgcaacaac	3060
ggcaccggtc	tgctccgagc	gctggagatg	attctgggtg	ggcgtagcgt	accggctgat	3120
gaggcgctga	agctgggtct	gatcgatgcc	attgctaccg	gcgatcagga	ctcactgtcg	3180

-continued

ctggcatgcg	cgttagcccg	tgccgcaatc	ggcgccgatg	gtcagttgat	cgagtcggct	3240
gcggtgaccc	aggctttccg	ccatcgccac	gagcagcttg	acgagtggcg	caaaccagac	3300
ccgcgctttg	ccgatgacga	actgcgctcg	attatcgccc	atccacgtat	cgagcggatt	3360
atccggcagg	cccataccgt	tgggcgcatg	gcggcagtcg	atcgggcact	ggatgcaatc	3420
cgctatggca	ttatccacgg	cttcgaggcc	ggtctggagc	acgaggcgaa	gctctttgcc	3480
gaggcagtg	ttgacccgaa	cggtggcaag	cgtggtattc	gcgagttcct	cgaccgccag	3540
agtgcgccgt	tgccaaccgg	ccgaccattg	attacacctg	aacaggagca	actcttgccg	3600
gatcagaaa	aactgttgcc	ggttggttca	ccctctctcc	ccggtgttga	ccggattccg	3660
aagtggcagt	acgcgcaggc	ggttattcgt	gatccggaca	ccggtgcggc	ggctcacggc	3720
gatcccatcg	tggtgaaaa	gcagattatt	gtgccggtgg	aacgcccccg	cgccaatcag	3780
gcgctgatct	atgtttcggc	ctcggaggtg	aacttcaacg	atatctgggc	gattaccggt	3840
attccggtgt	cacggtttga	tgagcacgac	cgcgactggc	acgttaccgg	ttcaggtggc	3900
atcggcctga	tcgttgccgt	gggtgaagag	gcgcgacgcg	aaggccggct	gaaggtgggt	3960
gatctggtgg	cgatctactc	cgggcagtcg	gatctgctct	caccgctgat	gggccttgat	4020
ccgatggccg	ccgatttcgt	catccagggg	aacgacacgc	cagatggatc	gcacagcaa	4080
tttatgctgg	cccaggcccc	gcagtgtctg	cccatcccaa	ccgatatgtc	tatcgaggca	4140
gccggcagct	acatcctcaa	tctcggtacg	atctatcgcg	ccctctttac	gacgttgcaa	4200
atcaaggccg	gacgcaccat	ctttatcgag	ggtgcggcga	ccgttaccgg	tctggacgca	4260
gcgcgcctcg	cggccccgaa	tggtctgcgc	gtaattggaa	tggtcagttc	gtcgtcacgt	4320
gcgtctacgc	tgtctgctgc	gggtgcccac	ggtgcgatta	accgtaaaga	cccggagggt	4380
gccgattgtt	tcacgcgcgt	gccccgaagat	ccatcagcct	gggcagcctg	ggaagccgcc	4440
ggtcagccgt	tgtctggcat	gttcggggcg	cagaacgacg	ggcgactggc	cgattatgtg	4500
gtctcgacgc	cgggcgagac	ggccttcccg	cgcagtttcc	agcttctcgg	cgagccacgc	4560
gatggtcaca	ttccgacgct	cacattctac	ggtgccacca	gtggctacca	cttcaccttc	4620
ctgggtaagc	cagggtcagc	ttcgccgacc	gagatgctgc	ggcgggccaa	tctccgcgcc	4680
ggtgaggcgg	tgttgatcta	ctacgggggt	gggagcgatg	acctggtaga	taccggcggt	4740
ctggaggcta	tcgaggcgcc	gcggcaaatg	ggagcgcgga	tcgtcgtcgt	taccgtcagc	4800
gatgcgcaac	gcgagtttgt	cctctcgttg	ggcttcgggg	ctgccctacg	tggtgtcgtc	4860
agcctggcgg	aactcaaacg	gcgcttcggc	gatgagtttg	agtggccgcg	cacgatgccg	4920
ccgttgccga	acgcccgcga	ggacccgcag	ggtctgaaag	aggctgtccg	ccgcttcaac	4980
gatctggtct	tcaagccgct	aggaagcgcg	gtcgggtgtct	tcttgccgag	tgccgacaat	5040
ccgcgtggct	accccgatct	gatcatcgag	cgggctgccc	acgatgcact	ggcggtgagc	5100
gcgatgctga	tcaagccctt	caccggacgg	attgtctact	tcgaggacat	tggtgggcgg	5160
cgttactcct	tcttcgcacc	gcaaatctgg	gtgcgccagc	gccgcactca	catgccgacg	5220
gcacagatct	ttggtacgca	cctctcaaat	gcgtatgaaa	ttctgcgtct	gaatgatgag	5280
atcagcgccg	gtctgctgac	gattaccgag	ccggcagtg	tgccgtggga	tgaactaccc	5340
gaagcacatc	aggcgatgtg	ggaaaatcgc	cacacggcgg	ccacttatgt	ggtgaatcat	5400
gccttaccac	gtctcggcct	aaagaacagg	gacgagctgt	acgaggcgtg	gacggccggc	5460
gagcggtag						5469

-continued

```

<210> SEQ ID NO 130
<211> LENGTH: 701
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 130

Met Gly Leu Pro Glu Glu Arg Val Arg Ser Gly Ser Gly Ser Arg Gly
 1          5          10          15

Gln Glu Glu Ala Gly Ala Gly Gly Arg Ala Arg Ser Trp Ser Pro Pro
      20          25          30

Pro Glu Val Ser Arg Ser Ala His Val Pro Ser Leu Gln Arg Tyr Arg
      35          40          45

Glu Leu His Arg Arg Ser Val Glu Glu Pro Arg Glu Phe Trp Gly Asp
 50          55          60

Ile Ala Lys Glu Phe Tyr Trp Lys Thr Pro Cys Pro Gly Pro Phe Leu
 65          70          75          80

Arg Tyr Asn Phe Asp Val Thr Lys Gly Lys Ile Phe Ile Glu Trp Met
      85          90          95

Lys Gly Ala Thr Thr Asn Ile Cys Tyr Asn Val Leu Asp Arg Asn Val
      100          105          110

His Glu Lys Lys Leu Gly Asp Lys Val Ala Phe Tyr Trp Glu Gly Asn
      115          120          125

Glu Pro Gly Glu Thr Thr Gln Ile Thr Tyr His Gln Leu Leu Val Gln
      130          135          140

Val Cys Gln Phe Ser Asn Val Leu Arg Lys Gln Gly Ile Gln Lys Gly
      145          150          155          160

Asp Arg Val Ala Ile Tyr Met Pro Met Ile Pro Glu Leu Val Val Ala
      165          170          175

Met Leu Ala Cys Ala Arg Ile Gly Ala Leu His Ser Ile Val Phe Ala
      180          185          190

Gly Phe Ser Ser Glu Ser Leu Cys Glu Arg Ile Leu Asp Ser Ser Cys
      195          200          205

Ser Leu Leu Ile Thr Thr Asp Ala Phe Tyr Arg Gly Glu Lys Leu Val
      210          215          220

Asn Leu Lys Glu Leu Ala Asp Glu Ala Leu Gln Lys Cys Gln Glu Lys
      225          230          235          240

Gly Phe Pro Val Arg Cys Cys Ile Val Val Lys His Leu Gly Arg Ala
      245          250          255

Glu Leu Gly Met Gly Asp Ser Thr Ser Gln Ser Pro Pro Ile Lys Arg
      260          265          270

Ser Cys Pro Asp Val Gln Ile Ser Trp Asn Gln Gly Ile Asp Leu Trp
      275          280          285

Trp His Glu Leu Met Gln Glu Ala Gly Asp Glu Cys Glu Pro Glu Trp
      290          295          300

Cys Asp Ala Glu Asp Pro Leu Phe Ile Leu Tyr Thr Ser Gly Ser Thr
      305          310          315          320

Gly Lys Pro Lys Gly Val Val His Thr Val Gly Gly Tyr Met Leu Tyr
      325          330          335

Val Ala Thr Thr Phe Lys Tyr Val Phe Asp Phe His Ala Glu Asp Val
      340          345          350

Phe Trp Cys Thr Ala Asp Ile Gly Trp Ile Thr Gly His Ser Tyr Val
      355          360          365

Thr Tyr Gly Pro Leu Ala Asn Gly Ala Thr Ser Val Leu Phe Glu Gly
      370          375          380

Ile Pro Thr Tyr Pro Asp Val Asn Arg Leu Trp Ser Ile Val Asp Lys

```

-continued

385	390	395	400
Tyr Lys Val Thr	Lys Phe Tyr Thr	Ala Pro Thr Ala	Ile Arg Leu Leu
	405	410	415
Met Lys Phe Gly	Asp Glu Pro Val	Thr Lys His Ser	Arg Ala Ser Leu
	420	425	430
Gln Val Leu Gly	Thr Val Gly Glu	Pro Ile Asn Pro	Glu Ala Trp Leu
	435	440	445
Trp Tyr His Arg	Val Val Gly Ala	Gln Arg Cys Pro	Ile Val Asp Thr
	450	455	460
Phe Trp Gln Thr	Glu Thr Gly Gly	His Met Leu Thr	Pro Leu Pro Gly
	465	470	475
Ala Thr Pro Met	Lys Pro Gly Ser	Ala Thr Phe Pro	Phe Phe Gly Val
	485	490	495
Ala Pro Ala Ile	Leu Asn Glu Ser	Gly Glu Glu Leu	Glu Gly Glu Ala
	500	505	510
Glu Gly Tyr Leu	Val Phe Lys Gln	Pro Trp Pro Gly	Ile Met Arg Thr
	515	520	525
Val Tyr Gly Asn	His Glu Arg Phe	Glu Thr Thr Tyr	Phe Lys Lys Phe
	530	535	540
Pro Gly Tyr Tyr	Val Thr Gly Asp	Gly Cys Gln Arg	Asp Gln Asp Gly
	545	550	555
Tyr Tyr Trp Ile	Thr Gly Arg Ile	Asp Asp Met Leu	Asn Val Ser Gly
	565	570	575
His Leu Leu Ser	Thr Ala Glu Val	Glu Ser Ala Leu	Val Glu His Glu
	580	585	590
Ala Val Ala Glu	Ala Ala Val Val	Gly His Pro His	Pro Val Lys Gly
	595	600	605
Glu Cys Leu Tyr	Cys Phe Val Thr	Leu Cys Asp Gly	His Thr Phe Ser
	610	615	620
Pro Lys Leu Thr	Glu Glu Leu Lys	Lys Gln Ile Arg	Glu Lys Ile Gly
	625	630	635
Pro Ile Ala Thr	Pro Asp Tyr Ile	Gln Asn Ala Pro	Gly Leu Pro Lys
	645	650	655
Thr Arg Ser Gly	Lys Ile Met Arg	Arg Val Leu Arg	Lys Ile Ala Gln
	660	665	670
Asn Asp His Asp	Leu Gly Asp Met	Ser Thr Val Ala	Asp Pro Ser Val
	675	680	685
Ile Ser His Leu	Phe Ser His Arg	Cys Leu Thr Ile	Gln
	690	695	700

<210> SEQ ID NO 131

<211> LENGTH: 670

<212> TYPE: PRT

<213> ORGANISM: Pyrobaculum aerophilum

<400> SEQUENCE: 131

Met Ser Leu Glu	Leu Lys Glu Lys	Glu Ser Glu Leu	Pro Phe Asp Glu
1	5	10	15
Gln Ile Ile Asn	Asp Lys Trp Arg	Ser Lys Tyr Thr	Pro Ile Asp Ala
	20	25	30
Tyr Phe Lys Phe	His Arg Gln Thr	Val Glu Asn Leu	Glu Ser Phe Trp
	35	40	45
Glu Ser Val Ala	Lys Glu Leu Glu	Trp Phe Lys Pro	Trp Asp Lys Val
	50	55	60
Leu Asp Ala Ser	Asn Pro Pro Phe	Tyr Lys Trp Phe	Val Gly Gly Arg

-continued

65	70	75	80
Leu Asn Leu Ser Tyr 85	Leu Ala Val Asp Arg 90	His Val Lys Thr Trp Arg 95	
Lys Asn Lys Leu Ala Ile Glu Trp 100	Glu Gly Glu Pro Val Asp Glu Asn 105		
Gly Tyr Pro Thr Asp Arg Arg Lys Leu Thr Tyr Tyr Asp Leu Tyr Arg 115		120	125
Glu Val Asn Arg Val Ala Tyr Met Leu Lys Gln Asn Phe Gly Val Lys 130		135	140
Lys Gly Asp Lys Ile Thr Leu Tyr Leu Pro Met Val Pro Glu Leu Pro 145		150	155
Ile Thr Met Leu Ala Ala Trp Arg Ile Gly Ala Ile Thr Ser Val Val 165		170	175
Phe Ser Gly Phe Ser Ala Asp Ala Leu Ala Glu Arg Ile Asn Asp Ser 180		185	190
Gln Ser Arg Ile Val Ile Thr Ala Asp Gly Phe Trp Arg Arg Gly Arg 195		200	205
Val Val Arg Leu Lys Glu Val Val Asp Ala Ala Leu Glu Lys Ala Thr 210		215	220
Gly Val Glu Ser Val Ile Val Leu Pro Arg Leu Gly Leu Lys Asp Val 225		230	235
Pro Met Thr Glu Gly Arg Asp Tyr Trp Trp Asn Lys Leu Met Gln Gly 245		250	255
Ile Pro Pro Asn Ala Tyr Ile Glu Pro Glu Pro Val Glu Ser Glu His 260		265	270
Pro Ser Phe Ile Leu Tyr Thr Ser Gly Thr Thr Gly Lys Pro Lys Gly 275		280	285
Ile Val His Asp Thr Gly Gly Trp Ala Val His Val Tyr Ala Thr Met 290		295	300
Lys Trp Val Phe Asp Ile Arg Asp Asp Asp Ile Phe Trp Cys Thr Ala 305		310	315
Asp Ile Gly Trp Val Thr Gly His Ser Tyr Val Val Leu Gly Pro Leu 325		330	335
Leu Met Gly Ala Thr Glu Val Ile Tyr Glu Gly Ala Pro Asp Tyr Pro 340		345	350
Gln Pro Asp Arg Trp Trp Ser Ile Ile Glu Arg Tyr Gly Val Thr Ile 355		360	365
Phe Tyr Thr Ser Pro Thr Ala Ile Arg Met Phe Met Arg Tyr Gly Glu 370		375	380
Glu Trp Pro Arg Lys His Asp Leu Ser Thr Leu Arg Ile Ile His Ser 385		390	395
Val Gly Glu Pro Ile Asn Pro Glu Ala Trp Arg Trp Ala Tyr Arg Val 405		410	415
Leu Gly Asn Glu Lys Val Ala Phe Gly Ser Thr Trp Trp Met Thr Glu 420		425	430
Thr Gly Gly Ile Val Ile Ser His Ala Pro Gly Leu Tyr Leu Val Pro 435		440	445
Met Lys Pro Gly Thr Asn Gly Pro Pro Leu Pro Gly Phe Glu Val Asp 450		455	460
Val Val Asp Glu Asn Gly Asn Pro Ala Pro Pro Gly Val Lys Gly Tyr 465		470	475
Leu Val Ile Lys Lys Pro Trp Pro Gly Met Leu His Gly Ile Trp Gly 485		490	495

-continued

Asp	Pro	Glu	Arg	Tyr	Ile	Lys	Thr	Tyr	Trp	Ser	Arg	Phe	Pro	Gly	Met
			500					505					510		
Phe	Tyr	Ala	Gly	Asp	Tyr	Ala	Ile	Lys	Asp	Lys	Asp	Gly	Tyr	Ile	Trp
		515					520					525			
Val	Leu	Gly	Arg	Ala	Asp	Glu	Val	Ile	Lys	Val	Ala	Gly	His	Arg	Leu
	530					535					540				
Gly	Thr	Tyr	Glu	Leu	Glu	Ser	Ala	Leu	Ile	Ser	His	Pro	Ala	Val	Ala
545					550					555					560
Glu	Ser	Ala	Val	Val	Gly	Val	Pro	Asp	Ala	Ile	Lys	Gly	Glu	Val	Pro
			565					570						575	
Ile	Ala	Phe	Val	Val	Leu	Lys	Gln	Gly	Val	Ala	Pro	Ser	Asp	Glu	Leu
		580					585						590		
Arg	Lys	Glu	Leu	Arg	Glu	His	Val	Arg	Arg	Thr	Ile	Gly	Pro	Ile	Ala
		595				600						605			
Glu	Pro	Ala	Gln	Ile	Phe	Phe	Val	Thr	Lys	Leu	Pro	Lys	Thr	Arg	Ser
	610				615						620				
Gly	Lys	Ile	Met	Arg	Arg	Leu	Leu	Lys	Ala	Val	Ala	Thr	Gly	Ala	Pro
625				630					635						640
Leu	Gly	Asp	Val	Thr	Thr	Leu	Glu	Asp	Glu	Thr	Ser	Val	Glu	Glu	Ala
			645					650					655		
Lys	Arg	Ala	Tyr	Glu	Glu	Ile	Lys	Ala	Glu	Met	Ala	Arg	Thr		
		660					665					670			

<210> SEQ ID NO 132

<211> LENGTH: 261

<212> TYPE: PRT

<213> ORGANISM: Clostridium acetobutylicum

<400> SEQUENCE: 132

Met	Glu	Leu	Asn	Asn	Val	Ile	Leu	Glu	Lys	Glu	Gly	Lys	Val	Ala	Val
1			5					10					15		
Val	Thr	Ile	Asn	Arg	Pro	Lys	Ala	Leu	Asn	Ala	Leu	Asn	Ser	Asp	Thr
		20					25					30			
Leu	Lys	Glu	Met	Asp	Tyr	Val	Ile	Gly	Glu	Ile	Glu	Asn	Asp	Ser	Glu
	35					40					45				
Val	Leu	Ala	Val	Ile	Leu	Thr	Gly	Ala	Gly	Glu	Lys	Ser	Phe	Val	Ala
	50				55					60					
Gly	Ala	Asp	Ile	Ser	Glu	Met	Lys	Glu	Met	Asn	Thr	Ile	Glu	Gly	Arg
65				70				75						80	
Lys	Phe	Gly	Ile	Leu	Gly	Asn	Lys	Val	Phe	Arg	Arg	Leu	Glu	Leu	Leu
		85					90						95		
Glu	Lys	Pro	Val	Ile	Ala	Ala	Val	Asn	Gly	Phe	Ala	Leu	Gly	Gly	Gly
	100						105					110			
Cys	Glu	Ile	Ala	Met	Ser	Cys	Asp	Ile	Arg	Ile	Ala	Ser	Ser	Asn	Ala
	115					120					125				
Arg	Phe	Gly	Gln	Pro	Glu	Val	Gly	Leu	Gly	Ile	Thr	Pro	Gly	Phe	Gly
	130				135						140				
Gly	Thr	Gln	Arg	Leu	Ser	Arg	Leu	Val	Gly	Met	Gly	Met	Ala	Lys	Gln
145				150					155						160
Leu	Ile	Phe	Thr	Ala	Gln	Asn	Ile	Lys	Ala	Asp	Glu	Ala	Leu	Arg	Ile
		165					170							175	
Gly	Leu	Val	Asn	Lys	Val	Val	Glu	Pro	Ser	Glu	Leu	Met	Asn	Thr	Ala
	180						185						190		
Lys	Glu	Ile	Ala	Asn	Lys	Ile	Val	Ser	Asn	Ala	Pro	Val	Ala	Val	Lys
	195					200					205				

-continued

Leu Ser Lys Gln Ala Ile Asn Arg Gly Met Gln Cys Asp Ile Asp Thr
 210 215 220

Ala Leu Ala Phe Glu Ser Glu Ala Phe Gly Glu Cys Phe Ser Thr Glu
 225 230 235 240

Asp Gln Lys Asp Ala Met Thr Ala Phe Ile Glu Lys Arg Lys Ile Glu
 245 250 255

Gly Phe Lys Asn Arg
 260

<210> SEQ ID NO 133
 <211> LENGTH: 259
 <212> TYPE: PRT
 <213> ORGANISM: Thermoanaerobacterium thermosaccharolyticum

<400> SEQUENCE: 133

Met Asp Phe Asn Asn Val Leu Leu Asn Lys Asp Asp Gly Ile Ala Leu
 1 5 10 15

Ile Ile Ile Asn Arg Pro Lys Ala Leu Asn Ala Leu Asn Tyr Glu Thr
 20 25 30

Leu Lys Glu Leu Asp Ser Val Leu Asp Ile Val Glu Asn Asp Lys Glu
 35 40 45

Ile Lys Val Leu Ile Ile Thr Gly Ser Gly Glu Lys Thr Phe Val Ala
 50 55 60

Gly Ala Asp Ile Ala Glu Met Ser Asn Met Thr Pro Leu Glu Ala Lys
 65 70 75 80

Lys Phe Ser Leu Tyr Gly Gln Lys Val Phe Arg Lys Ile Glu Met Leu
 85 90 95

Ser Lys Pro Val Ile Ala Ala Val Asn Gly Phe Ala Leu Gly Gly Gly
 100 105 110

Cys Glu Leu Ser Met Ala Cys Asp Ile Arg Ile Ala Ser Lys Asn Ala
 115 120 125

Lys Phe Gly Gln Pro Glu Val Gly Leu Gly Ile Ile Pro Gly Phe Ser
 130 135 140

Gly Thr Gln Arg Leu Pro Arg Leu Ile Gly Thr Ser Lys Ala Lys Glu
 145 150 155 160

Leu Ile Phe Thr Gly Asp Met Ile Asn Ser Asp Glu Ala Tyr Lys Ile
 165 170 175

Gly Leu Ile Ser Lys Val Val Glu Leu Ser Asp Leu Ile Glu Glu Ala
 180 185 190

Lys Lys Leu Ala Lys Lys Met Met Ser Lys Ser Gln Ile Ala Ile Ser
 195 200 205

Leu Ala Lys Glu Ala Ile Asn Lys Gly Met Glu Thr Asp Leu Asp Thr
 210 215 220

Gly Asn Thr Ile Glu Ala Glu Lys Phe Ser Leu Cys Phe Thr Thr Asp
 225 230 235 240

Asp Gln Lys Glu Gly Met Ile Ala Phe Ser Glu Lys Arg Ala Pro Lys
 245 250 255

Phe Gly Lys

<210> SEQ ID NO 134
 <211> LENGTH: 432
 <212> TYPE: PRT
 <213> ORGANISM: Methylobacterium extorquens

<400> SEQUENCE: 134

Met Ala Ala Ser Ala Ala Pro Ala Trp Thr Gly Gln Thr Ala Glu Ala
 1 5 10 15

-continued

Lys Asp Leu Tyr Glu Leu Gly Glu Ile Pro Pro Leu Gly His Val Pro
 20 25 30
 Ala Lys Met Tyr Ala Trp Ala Ile Arg Arg Glu Arg His Gly Pro Pro
 35 40 45
 Glu Gln Ser His Gln Leu Glu Val Leu Pro Val Trp Glu Ile Gly Asp
 50 55 60
 Asp Glu Val Leu Val Tyr Val Met Ala Ala Gly Val Asn Tyr Asn Gly
 65 70 75 80
 Val Trp Ala Gly Leu Gly Glu Pro Ile Ser Pro Phe Asp Val His Lys
 85 90 95
 Gly Glu Tyr His Ile Ala Gly Ser Asp Ala Ser Gly Ile Val Trp Lys
 100 105 110
 Val Gly Ala Lys Val Lys Arg Trp Lys Val Gly Asp Glu Val Ile Val
 115 120 125
 His Cys Asn Gln Asp Asp Gly Asp Asp Glu Glu Cys Asn Gly Gly Asp
 130 135 140
 Pro Met Phe Ser Pro Thr Gln Arg Ile Trp Gly Tyr Glu Thr Gly Asp
 145 150 155 160
 Gly Ser Phe Ala Gln Phe Cys Arg Val Gln Ser Arg Gln Leu Met Ala
 165 170 175
 Arg Pro Lys His Leu Thr Trp Glu Glu Ala Ala Cys Tyr Thr Leu Thr
 180 185 190
 Leu Ala Thr Ala Tyr Arg Met Leu Phe Gly His Ala Pro His Thr Val
 195 200 205
 Arg Pro Gly Gln Asn Val Leu Ile Trp Gly Ala Ser Gly Gly Leu Gly
 210 215 220
 Val Phe Gly Val Gln Leu Cys Ala Ala Ser Gly Ala Asn Ala Ile Ala
 225 230 235 240
 Val Ile Ser Asp Glu Ser Lys Arg Asp Tyr Val Met Ser Leu Gly Ala
 245 250 255
 Lys Gly Val Ile Asn Arg Lys Asp Phe Asp Cys Trp Gly Gln Leu Pro
 260 265 270
 Thr Val Asn Ser Pro Glu Tyr Asn Thr Trp Leu Lys Glu Ala Arg Lys
 275 280 285
 Phe Gly Lys Ala Ile Trp Asp Ile Thr Gly Lys Gly Asn Asp Val Asp
 290 295 300
 Ile Val Phe Glu His Pro Gly Glu Ala Thr Phe Pro Val Ser Thr Leu
 305 310 315 320
 Val Ala Lys Arg Gly Gly Met Ile Val Phe Cys Ala Gly Thr Thr Gly
 325 330 335
 Phe Asn Ile Thr Phe Asp Ala Arg Tyr Val Trp Met Arg Gln Lys Arg
 340 345 350
 Ile Gln Gly Ser His Phe Ala His Leu Lys Gln Ala Ser Ala Ala Asn
 355 360 365
 Gln Phe Val Met Asp Arg Arg Val Asp Pro Cys Met Ser Glu Val Phe
 370 375 380
 Pro Trp Asp Lys Ile Pro Ala Ala His Thr Lys Met Trp Lys Asn Gln
 385 390 395 400
 His Pro Pro Gly Asn Met Ala Val Leu Val Asn Ser Thr Arg Ala Gly
 405 410 415
 Leu Arg Thr Val Glu Asp Val Ile Glu Ala Gly Pro Leu Lys Ala Met
 420 425 430

-continued

```

<210> SEQ ID NO 135
<211> LENGTH: 424
<212> TYPE: PRT
<213> ORGANISM: Caulobacter crescentus

<400> SEQUENCE: 135

Met Thr Ile Gln Thr Leu Glu Thr Thr Ala Leu Lys Asp Leu Tyr Glu
 1             5             10             15

Ile Gly Glu Ile Pro Pro Ala Phe His Val Pro Lys Thr Met Tyr Ala
 20             25             30

Trp Ser Ile Arg Lys Glu Arg His Gly Lys Pro Thr Gln Ala Met Gln
 35             40             45

Val Glu Val Val Pro Thr Trp Glu Ile Gly Glu Asp Glu Val Leu Val
 50             55             60

Leu Val Met Ala Ala Gly Val Asn Tyr Asn Gly Val Trp Ala Ala Leu
 65             70             75             80

Gly Glu Pro Ile Ser Pro Leu Asp Gly His Lys Gln Pro Phe His Ile
 85             90             95

Ala Gly Ser Asp Ala Ser Gly Ile Val Trp Lys Val Gly Ala Lys Val
100            105            110

Lys Arg Trp Lys Leu Gly Asp Glu Val Val Ile His Cys Asn Gln Asp
115            120            125

Asp Gly Asp Asp Glu Glu Cys Asn Gly Gly Asp Pro Met Phe Ser Ser
130            135            140

Ser Gln Arg Ile Trp Gly Tyr Glu Thr Pro Asp Gly Ser Phe Ala Gln
145            150            155            160

Phe Cys Arg Val Gln Ser Arg Gln Leu Leu Pro Arg Pro Lys His Leu
165            170            175

Thr Trp Glu Glu Ser Ala Cys Tyr Thr Leu Thr Leu Ala Thr Ala Tyr
180            185            190

Arg Met Leu Phe Gly His Lys Pro His Glu Leu Lys Pro Gly Gln Asn
195            200            205

Val Leu Val Trp Gly Ala Ser Gly Gly Leu Gly Val Phe Ala Thr Gln
210            215            220

Leu Ala Ala Val Ala Gly Ala Asn Ala Ile Gly Val Val Ser Ser Glu
225            230            235            240

Asp Lys Arg Glu Phe Val Leu Ser Met Gly Ala Lys Ala Val Leu Asn
245            250            255

Arg Gly Glu Phe Asn Cys Trp Gly Gln Leu Pro Lys Val Asn Gly Pro
260            265            270

Glu Phe Asn Asp Tyr Met Lys Glu Ser Arg Lys Phe Gly Lys Ala Ile
275            280            285

Trp Gln Ile Thr Gly Asn Lys Asp Val Asp Met Val Phe Glu His Pro
290            295            300

Gly Glu Gln Thr Phe Pro Val Ser Val Phe Leu Val Lys Arg Gly Gly
305            310            315            320

Met Val Val Ile Cys Ala Gly Thr Thr Gly Phe Asn Leu Thr Met Asp
325            330            335

Ala Arg Phe Leu Trp Met Arg Gln Lys Arg Val Gln Gly Ser His Phe
340            345            350

Ala Asn Leu Met Gln Ala Ser Ala Ala Asn Gln Leu Val Ile Asp Arg
355            360            365

Arg Val Asp Pro Cys Leu Ser Glu Val Phe Pro Trp Asp Gln Ile Pro
370            375            380

Ala Ala His Glu Lys Met Leu Ala Asn Gln His Leu Pro Gly Asn Met

```

-continued

385	390	395	400	
Ala Val Leu Val Cys Ala Gln Arg Pro Gly Leu Arg Thr Phe Glu Glu				
	405	410	415	
Val Gln Glu Leu Ser Gly Ala Pro				
	420			
 <210> SEQ ID NO 136				
<211> LENGTH: 26				
<212> TYPE: DNA				
<213> ORGANISM: Artificial Sequence				
<220> FEATURE:				
<223> OTHER INFORMATION: Primer				
 <400> SEQUENCE: 136				
gggaattcca tatgatcgac actgcg				26
 <210> SEQ ID NO 137				
<211> LENGTH: 30				
<212> TYPE: DNA				
<213> ORGANISM: Artificial Sequence				
<220> FEATURE:				
<223> OTHER INFORMATION: Primer				
 <400> SEQUENCE: 137				
cgaaggatcc aacgataatc ggctcagcac				30
 <210> SEQ ID NO 138				
<211> LENGTH: 44				
<212> TYPE: DNA				
<213> ORGANISM: Artificial Sequence				
<220> FEATURE:				
<223> OTHER INFORMATION: Primer				
 <400> SEQUENCE: 138				
ataggcggcc gcaggaatgc tgtatgagcg aagaaagctt attc				44
 <210> SEQ ID NO 139				
<211> LENGTH: 43				
<212> TYPE: DNA				
<213> ORGANISM: Artificial Sequence				
<220> FEATURE:				
<223> OTHER INFORMATION: Primer				
 <400> SEQUENCE: 139				
atgctcgcat ctcgagtagc taaattaaat tacatcaata gta				43
 <210> SEQ ID NO 140				
<211> LENGTH: 3678				
<212> TYPE: DNA				
<213> ORGANISM: Chloroflexus aurantiacus				
<220> FEATURE:				
<221> NAME/KEY: CDS				
<222> LOCATION: (1)..(3675)				
 <400> SEQUENCE: 140				
atg gcg acg ggg gag tcc atg agc gga aca gga cga ctg gca gga aag				48
Met Ala Thr Gly Glu Ser Met Ser Gly Thr Gly Arg Leu Ala Gly Lys				
1 5 10 15				
att gcg tta att acc ggt ggc gcc ggc aat atc ggc agt gaa ttg aca				96
Ile Ala Leu Ile Thr Gly Gly Ala Gly Asn Ile Gly Ser Glu Leu Thr				
20 25 30				
cgt cgc ttt ctc gca gag gga gcg acg gtc att att agt gga cgg aat				144
Arg Arg Phe Leu Ala Glu Gly Ala Thr Val Ile Ile Ser Gly Arg Asn				
35 40 45				
cgg gcg aag ttg acc gca ctg gcc gaa cgg atg cag gca gag gca gga				192

-continued

Arg	Ala	Lys	Leu	Thr	Ala	Leu	Ala	Glu	Arg	Met	Gln	Ala	Glu	Ala	Gly	
50						55					60					
gtg	ccg	gca	aag	cgc	atc	gat	ctc	gaa	gtc	atg	gat	ggg	agt	gat	ccg	240
Val	Pro	Ala	Lys	Arg	Ile	Asp	Leu	Glu	Val	Met	Asp	Gly	Ser	Asp	Pro	
65					70					75					80	
gtc	gcg	gta	cgt	gcc	ggg	atc	gaa	gcg	att	gtg	gcc	cgt	cac	ggc	cag	288
Val	Ala	Val	Arg	Ala	Gly	Ile	Glu	Ala	Ile	Val	Ala	Arg	His	Gly	Gln	
				85					90					95		
atc	gac	att	ctg	gtc	aac	aat	gca	gga	agt	gcc	ggg	gcc	cag	cgt	cgt	336
Ile	Asp	Ile	Leu	Val	Asn	Asn	Ala	Gly	Ser	Ala	Gly	Ala	Gln	Arg	Arg	
			100					105					110			
ctg	gcc	gag	att	cca	ctc	act	gaa	gct	gaa	tta	ggc	cct	ggc	gcc	gaa	384
Leu	Ala	Glu	Ile	Pro	Leu	Thr	Glu	Ala	Glu	Leu	Gly	Pro	Gly	Ala	Glu	
			115				120					125				
gag	acg	ctt	cat	gcc	agc	atc	gcc	aat	tta	ctt	ggg	atg	gga	tgg	cat	432
Glu	Thr	Leu	His	Ala	Ser	Ile	Ala	Asn	Leu	Leu	Gly	Met	Gly	Trp	His	
			130			135					140					
ctg	atg	cgt	att	gcg	gca	cct	cat	atg	ccg	gta	gga	agt	gcg	gtc	atc	480
Leu	Met	Arg	Ile	Ala	Ala	Pro	His	Met	Pro	Val	Gly	Ser	Ala	Val	Ile	
					150					155					160	
aat	gtc	tcg	acc	atc	ttt	tca	cgg	gct	gag	tac	tac	ggg	cgg	att	ccg	528
Asn	Val	Ser	Thr	Ile	Phe	Ser	Arg	Ala	Glu	Tyr	Tyr	Gly	Arg	Ile	Pro	
				165					170					175		
tat	gtc	acc	cct	aaa	gct	gct	ctt	aat	gct	cta	tct	caa	ctt	gct	gcg	576
Tyr	Val	Thr	Pro	Lys	Ala	Ala	Leu	Asn	Ala	Leu	Ser	Gln	Leu	Ala	Ala	
			180					185					190			
cgt	gag	tta	ggg	gca	cgt	ggc	atc	cgc	gtt	aat	acg	atc	ttt	ccc	ggc	624
Arg	Glu	Leu	Gly	Ala	Arg	Gly	Ile	Arg	Val	Asn	Thr	Ile	Phe	Pro	Gly	
			195				200					205				
ccg	att	gaa	agt	gat	cgc	atc	cgt	aca	gtg	ttc	cag	cgt	atg	gat	cag	672
Pro	Ile	Glu	Ser	Asp	Arg	Ile	Arg	Thr	Val	Phe	Gln	Arg	Met	Asp	Gln	
						215					220					
ctc	aag	ggg	cgg	ccc	gaa	ggc	gac	aca	gcg	cac	cat	ttt	ttg	aac	acc	720
Leu	Lys	Gly	Arg	Pro	Glu	Gly	Asp	Thr	Ala	His	His	Phe	Leu	Asn	Thr	
					230					235					240	
atg	cga	ttg	tgt	cgt	gcc	aac	gac	cag	ggc	gcg	ctt	gaa	cgt	cgg	ttc	768
Met	Arg	Leu	Cys	Arg	Ala	Asn	Asp	Gln	Gly	Ala	Leu	Glu	Arg	Arg	Phe	
				245					250					255		
ccc	tcc	gtc	ggg	gat	gtg	gca	gac	gcc	gct	gtc	ttt	ctg	gcc	agt	gcc	816
Pro	Ser	Val	Gly	Asp	Val	Ala	Asp	Ala	Ala	Val	Phe	Leu	Ala	Ser	Ala	
				260				265					270			
gaa	tcc	gcc	gct	ctc	tcc	ggg	gag	acg	att	gag	gtt	acg	cac	gga	atg	864
Glu	Ser	Ala	Ala	Leu	Ser	Gly	Glu	Thr	Ile	Glu	Val	Thr	His	Gly	Met	
				275				280				285				
gag	ttg	ccg	gcc	tgc	agt	gag	acc	agc	ctg	ctg	gcc	cgt	act	gat	ctg	912
Glu	Leu	Pro	Ala	Cys	Ser	Glu	Thr	Ser	Leu	Leu	Ala	Arg	Thr	Asp	Leu	
				290			295					300				
cgc	acg	att	gat	gcc	agt	ggc	cgc	acg	acg	ctc	atc	tgc	gcc	ggc	gac	960
Arg	Thr	Ile	Asp	Ala	Ser	Gly	Arg	Thr	Thr	Leu	Ile	Cys	Ala	Gly	Asp	
				305		310				315					320	
cag	att	gaa	gag	gtg	atg	gcg	ctc	acc	ggg	atg	ttg	cgt	acc	tgt	ggg	1008
Gln	Ile	Glu	Glu	Val	Met	Ala	Leu	Thr	Gly	Met	Leu	Arg	Thr	Cys	Gly	
				325					330					335		
agt	gaa	gtg	atc	atc	ggc	ttc	cgt	tcg	gct	gcg	gcg	ctg	gcc	cag	ttc	1056
Ser	Glu	Val	Ile	Ile	Gly	Phe	Arg	Ser	Ala	Ala	Ala	Leu	Ala	Gln	Phe	
				340				345					350			
gag	cag	gca	gtc	aat	gag	agt	cgg	cgg	ctg	gcc	ggc	gca	gac	ttt	acg	1104
Glu	Gln	Ala	Val	Asn	Glu	Ser	Arg	Arg	Leu	Ala	Gly	Ala	Asp	Phe	Thr	
				355			360					365				
cct	ccc	att	gcc	ttg	cca	ctc	gat	cca	cgc	gat	ccg	gca	aca	att	gac	1152

-continued

Pro 370	Pro 375	Ile 385	Ala 390	Leu 395	Pro 400	Leu 405	Asp 410	Pro 415	Arg 420	Asp 425	Pro 430	Ala 435	Thr 440	Ile 445	Asp 450	
gct	gtc	ttc	gat	tgg	gcc	ggc	gag	aat	acc	ggc	ggg	att	cat	gca	gcg	1200
Ala	Val	Phe	Asp	Trp	Ala	Gly	Glu	Asn	Thr	Gly	Gly	Ile	His	Ala	Ala	
385					390					395					400	
gtg	att	ctg	cct	gct	acc	agt	cac	gaa	ccg	gca	ccg	tgc	gtg	att	gag	1248
Val	Ile	Leu	Pro	Ala	Thr	Ser	His	Glu	Pro	Ala	Pro	Cys	Val	Ile	Glu	
				405					410					415		
gtt	gat	gat	gag	cgg	gtg	ctg	aat	ttt	ctg	gcc	gat	gaa	atc	acc	ggg	1296
Val	Asp	Asp	Glu	Arg	Val	Leu	Asn	Phe	Leu	Ala	Asp	Glu	Ile	Thr	Gly	
			420					425						430		
aca	att	gtg	att	gcc	agt	cgc	ctg	gcc	cgt	tac	tgg	cag	tcg	caa	cgg	1344
Thr	Ile	Val	Ile	Ala	Ser	Arg	Leu	Ala	Arg	Tyr	Trp	Gln	Ser	Gln	Arg	
		435					440							445		
ctt	acc	ccc	ggc	gca	cgt	gcg	cgt	ggg	ccg	cgt	gtc	att	ttt	ctc	tcg	1392
Leu	Thr	Pro	Gly	Ala	Arg	Ala	Arg	Gly	Pro	Arg	Val	Ile	Phe	Leu	Ser	
	450					455					460					
aac	ggt	gcc	gat	caa	aat	ggg	aat	gtt	tac	gga	cgc	att	caa	agt	gcc	1440
Asn	Gly	Ala	Asp	Gln	Asn	Gly	Asn	Val	Tyr	Gly	Arg	Ile	Gln	Ser	Ala	
465				470						475					480	
gct	atc	ggt	cag	ctc	att	cgt	gtg	tgg	cgt	cac	gag	gct	gaa	ctt	gac	1488
Ala	Ile	Gly	Gln	Leu	Ile	Arg	Val	Trp	Arg	His	Glu	Ala	Glu	Leu	Asp	
			485						490					495		
tat	cag	cgt	gcc	agc	gcc	gcc	ggt	gat	cat	gtg	ctg	ccg	ccg	gta	tgg	1536
Tyr	Gln	Arg	Ala	Ser	Ala	Ala	Gly	Asp	His	Val	Leu	Pro	Pro	Val	Trp	
			500					505						510		
gcc	aat	cag	att	gtg	cgc	ttc	gct	aac	cgc	agc	ctt	gaa	ggg	tta	gaa	1584
Ala	Asn	Gln	Ile	Val	Arg	Phe	Ala	Asn	Arg	Ser	Leu	Glu	Gly	Leu	Glu	
		515					520					525				
ttt	gcc	tgt	gcc	tgg	aca	gct	caa	ttg	ctc	cat	agt	caa	cgc	cat	atc	1632
Phe	Ala	Cys	Ala	Trp	Thr	Ala	Gln	Leu	Leu	His	Ser	Gln	Arg	His	Ile	
	530					535					540					
aat	gag	att	acc	ctc	aac	atc	cct	gcc	aac	att	agc	gcc	acc	acc	ggc	1680
Asn	Glu	Ile	Thr	Leu	Asn	Ile	Pro	Ala	Asn	Ile	Ser	Ala	Thr	Thr	Gly	
545					550					555					560	
gca	cgc	agt	gca	tcg	gtc	gga	tgg	gcg	gaa	agc	ctg	atc	ggg	ttg	cat	1728
Ala	Arg	Ser	Ala	Ser	Val	Gly	Trp	Ala	Glu	Ser	Leu	Ile	Gly	Leu	His	
			565						570					575		
ttg	ggg	aaa	gtt	gcc	ttg	att	acc	ggt	ggc	agc	gcc	ggt	att	ggt	ggg	1776
Leu	Gly	Lys	Val	Ala	Leu	Ile	Thr	Gly	Gly	Ser	Ala	Gly	Ile	Gly	Gly	
		580						585					590			
cag	atc	ggg	cgc	ctc	ctg	gct	ttg	agt	ggc	gcg	cgc	gtg	atg	ctg	gca	1824
Gln	Ile	Gly	Arg	Leu	Leu	Ala	Leu	Ser	Gly	Ala	Arg	Val	Met	Leu	Ala	
		595					600					605				
gcc	cgt	gat	cgg	cat	aag	ctc	gaa	cag	atg	cag	gcg	atg	atc	caa	tct	1872
Ala	Arg	Asp	Arg	His	Lys	Leu	Glu	Gln	Met	Gln	Ala	Met	Ile	Gln	Ser	
		610				615						620				
gag	ctg	gct	gag	gtg	ggg	tat	acc	gat	gtc	gaa	gat	cgc	gtc	cac	att	1920
Glu	Leu	Ala	Glu	Val	Gly	Tyr	Thr	Asp	Val	Glu	Asp	Arg	Val	His	Ile	
		625			630					635					640	
gca	ccg	ggc	tgc	gat	gtg	agt	agc	gaa	gcg	cag	ctt	gcg	gat	ctt	gtt	1968
Ala	Pro	Gly	Cys	Asp	Val	Ser	Ser	Glu	Ala	Gln	Leu	Ala	Asp	Leu	Val	
			645						650					655		
gaa	cgt	acc	ctg	tca	gct	ttt	ggc	acc	gtc	gat	tat	ctg	atc	aac	aac	2016
Glu	Arg	Thr	Leu	Ser	Ala	Phe	Gly	Thr	Val	Asp	Tyr	Leu	Ile	Asn	Asn	
			660					665					670			
gcc	ggg	atc	gcc	ggt	gtc	gaa	gag	atg	gtt	atc	gat	atg	cca	gtt	gag	2064
Ala	Gly	Ile	Ala	Gly	Val	Glu	Glu	Met	Val	Ile	Asp	Met	Pro	Val	Glu	
		675				680						685				
gga	tgg	cgc	cat	acc	ctc	ttc	gcc	aat	ctg	atc	agc	aac	tac	tcg	ttg	2112

-continued

Gly	Trp	Arg	His	Thr	Leu	Phe	Ala	Asn	Leu	Ile	Ser	Asn	Tyr	Ser	Leu	
	690					695					700					
atg	cgc	aaa	ctg	gcg	ccg	ttg	atg	aaa	aaa	cag	ggg	agc	ggg	tac	atc	2160
Met	Arg	Lys	Leu	Ala	Pro	Leu	Met	Lys	Lys	Gln	Gly	Ser	Gly	Tyr	Ile	
705					710					715					720	
ctt	aac	gtc	tca	tca	tac	ttt	ggc	ggg	gaa	aaa	gat	gcg	gcc	att	ccc	2208
Leu	Asn	Val	Ser	Ser	Tyr	Phe	Gly	Gly	Glu	Lys	Asp	Ala	Ala	Ile	Pro	
			725						730					735		
tac	ccc	aac	cgt	gcc	gat	tac	gcc	gtc	tcg	aag	gct	ggg	cag	cgg	gca	2256
Tyr	Pro	Asn	Arg	Ala	Asp	Tyr	Ala	Val	Ser	Lys	Ala	Gly	Gln	Arg	Ala	
			740					745					750			
atg	gcc	gaa	gtc	ttt	gcg	cgc	ttc	ctt	ggc	ccg	gag	ata	cag	atc	aat	2304
Met	Ala	Glu	Val	Phe	Ala	Arg	Phe	Leu	Gly	Pro	Glu	Ile	Gln	Ile	Asn	
	755				760							765				
gcc	att	gcg	ccg	ggg	ccg	gtc	gaa	ggg	gat	cgc	ttg	cgc	ggg	acc	ggg	2352
Ala	Ile	Ala	Pro	Gly	Pro	Val	Glu	Gly	Asp	Arg	Leu	Arg	Gly	Thr	Gly	
	770				775						780					
gaa	cgt	ccc	ggc	ctc	ttt	gcc	cgt	cgg	gcg	cgg	ctg	att	ttg	gag	aac	2400
Glu	Arg	Pro	Gly	Leu	Phe	Ala	Arg	Arg	Ala	Arg	Leu	Ile	Leu	Glu	Asn	
785					790				795						800	
aag	cgg	ctg	aat	gag	ctt	cac	gct	gct	ctt	atc	gcg	gct	gcg	cgc	acc	2448
Lys	Arg	Leu	Asn	Glu	Leu	His	Ala	Ala	Leu	Ile	Ala	Ala	Ala	Arg	Thr	
			805						810					815		
gat	gag	cga	tct	atg	cac	gaa	ctg	gtt	gaa	ctg	ctc	tta	ccc	aat	gat	2496
Asp	Glu	Arg	Ser	Met	His	Glu	Leu	Val	Glu	Leu	Leu	Leu	Pro	Asn	Asp	
			820					825					830			
gtg	gcc	gca	cta	gag	cag	aat	ccc	gca	gca	cct	acc	gcg	ttg	cgt	gaa	2544
Val	Ala	Ala	Leu	Glu	Gln	Asn	Pro	Ala	Ala	Pro	Thr	Ala	Leu	Arg	Glu	
	835					840						845				
ctg	gca	cga	cgt	ttt	cgc	agc	gaa	ggc	gat	ccg	gcg	gca	tca	tca	agc	2592
Leu	Ala	Arg	Arg	Phe	Arg	Ser	Glu	Gly	Asp	Pro	Ala	Ala	Ser	Ser	Ser	
	850				855							860				
agt	gcg	ctg	ctg	aac	cgt	tca	att	gcc	gct	aaa	ttg	ctg	gct	cgt	ttg	2640
Ser	Ala	Leu	Leu	Asn	Arg	Ser	Ile	Ala	Ala	Lys	Leu	Leu	Ala	Arg	Leu	
865					870					875					880	
cat	aat	ggg	ggc	tat	gtg	ttg	cct	gcc	gac	atc	ttt	gca	aac	ctg	cca	2688
His	Asn	Gly	Gly	Tyr	Val	Leu	Pro	Ala	Asp	Ile	Phe	Ala	Asn	Leu	Pro	
			885						890					895		
aac	ccg	ccc	gat	ccc	ttc	ttc	acc	cga	gcc	cag	att	gat	cgc	gag	gct	2736
Asn	Pro	Pro	Asp	Pro	Phe	Phe	Thr	Arg	Ala	Gln	Ile	Asp	Arg	Glu	Ala	
			900					905					910			
cgc	aag	gtt	cgt	gac	ggc	atc	atg	ggg	atg	ctc	tac	ctg	caa	cgg	atg	2784
Arg	Lys	Val	Arg	Asp	Gly	Ile	Met	Gly	Met	Leu	Tyr	Leu	Gln	Arg	Met	
	915					920						925				
ccg	act	gag	ttt	gat	gtc	gca	atg	gcc	acc	gtc	tat	tac	ctt	gcc	gac	2832
Pro	Thr	Glu	Phe	Asp	Val	Ala	Met	Ala	Thr	Val	Tyr	Tyr	Leu	Ala	Asp	
	930					935						940				
cgc	aat	gtc	agt	ggg	gag	aca	ttc	cac	cca	tca	ggg	ggg	ttg	cgt	tac	2880
Arg	Asn	Val	Ser	Gly	Glu	Thr	Phe	His	Pro	Ser	Gly	Gly	Leu	Arg	Tyr	
945					950					955					960	
gaa	cgc	acc	cct	acc	ggg	ggc	gaa	ctc	ttc	ggc	ttg	ccc	tca	cgg	gaa	2928
Glu	Arg	Thr	Pro	Thr	Gly	Gly	Glu	Leu	Phe	Gly	Leu	Pro	Ser	Pro	Glu	
			965						970					975		
cgg	ctg	gcg	gag	ctg	gtc	gga	agc	acg	gtc	tat	ctg	ata	ggg	gaa	cat	2976
Arg	Leu	Ala	Glu	Leu	Val	Gly	Ser	Thr	Val	Tyr	Leu	Ile	Gly	Glu	His	
			980					985					990			
ctg	act	gaa	cac	ctt	aac	ctg	ctt	gcc	cgt	gcg	tac	ctc	gaa	cgt	tac	3024
Leu	Thr	Glu	His	Leu	Asn	Leu	Leu	Ala	Arg	Ala	Tyr	Leu	Glu	Arg	Tyr	
		995				1000						1005				
ggg	gca	cgt	cag	gta	gtg	atg	att	gtt	gag	aca	gaa	acc	ggg	gca		3069

Gly 1010	Ala	Arg	Gln	Val	Val	Met 1015	Ile	Val	Glu	Thr	Glu 1020	Thr	Gly	Ala	
gag Glu	aca Thr	atg Met	cgt Arg	cgc Arg	ttg Leu	ctc Leu 1030	cac His	gat Asp	cac His	gtc Val	gag Glu 1035	gct Ala	ggc Gly	cgg Arg	3114
ctg Leu	atg Met	act Thr	att Ile	gtg Val	gcc Ala	ggc Gly 1045	gat Asp	cag Gln	atc Ile	gaa Glu	gcc Ala 1050	gct Ala	atc Ile	gac Asp	3159
cag Gln	gct Ala	atc Ile	act Thr	cgc Arg	tac Tyr	ggc Gly 1060	cgc Arg	cca Pro	ggg Gly	ccg Pro	gtc Val 1065	gtc Val	tgt Cys	acc Thr	3204
ccc Pro	ttc Phe	cgg Arg	cca Pro	ctg Leu	ccg Pro	acg Thr 1075	gta Val	cca Pro	ctg Leu	gtc Val	ggg Gly 1080	cgt Arg	aaa Lys	gac Asp	3249
agt Ser	gac Asp	tgg Trp	agc Ser	aca Thr	gtg Val	ttg Leu 1090	agt Ser	gag Glu	gct Ala	gaa Glu	ttt Phe 1095	gcc Ala	gag Glu	ttg Leu	3294
tgc Cys	gaa Glu	cac His	cag Gln	ctc Leu	acc Thr	cac His 1105	cat His	ttc Phe	cgg Arg	gta Val	gcg Ala 1110	cgc Arg	aag Lys	att Ile	3339
gcc Ala	ctg Leu	agt Ser	gat Asp	ggc Gly	gcc Ala	agt Ser 1120	ctc Leu	gcg Ala	ctg Leu	gtc Val	act Thr 1125	ccc Pro	gaa Glu	act Thr	3384
acg Thr	gct Ala	acc Thr	tca Ser	act Thr	acc Thr	gag Glu 1135	caa Gln	ttt Phe	gct Ala	ctg Leu	gct Ala 1140	aac Asn	ttc Phe	atc Ile	3429
aaa Lys	acg Thr	acc Thr	ctt Leu	cac His	gct Ala	ttt Phe 1150	acg Thr	gct Ala	acg Thr	att Ile	ggc Gly 1155	gtc Val	gag Glu	agc Ser	3474
gaa Glu	aga Arg	act Thr	gct Ala	cag Gln	cgc Arg	att Ile 1165	ctg Leu	atc Ile	aat Asn	caa Gln	gtc Val 1170	gat Asp	ctg Leu	acc Thr	3519
cgg Arg	cgt Arg	gcg Ala	cgt Arg	gcc Ala	gaa Glu	gag Glu 1180	ccg Pro	cgt Arg	gat Asp	ccg Pro	cac His 1185	gag Glu	cgt Arg	caa Gln	3564
caa Gln	gaa Glu	ctg Leu	gaa Glu	cgt Arg	ttt Phe	atc Ile 1195	gag Glu	gca Ala	gtc Val	ttg Leu	ctg Leu 1200	gtc Val	act Thr	gca Ala	3609
cca Pro	ctc Leu	ccg Pro	cct Pro	gaa Glu	gcc Ala	gat Asp 1210	acc Thr	cgt Arg	tac Tyr	gcc Ala	ggg Gly 1215	cgg Arg	att Ile	cat His	3654
cgc Arg	gga Gly	cgg Arg	gcg Ala	att Ile	acc Thr	gtg Val 1225	taa								3678

<400> SEQUENCE: 141

Met	Ala	Thr	Gly	Glu	Ser	Met	Ser	Gly	Thr	Gly	Arg	Leu	Ala	Gly	Lys
1				5					10					15	
Ile	Ala	Leu	Ile	Thr	Gly	Gly	Ala	Gly	Asn	Ile	Gly	Ser	Glu	Leu	Thr
			20					25					30		
Arg	Arg	Phe	Leu	Ala	Glu	Gly	Ala	Thr	Val	Ile	Ile	Ser	Gly	Arg	Asn
		35					40					45			
Arg	Ala	Lys	Leu	Thr	Ala	Leu	Ala	Glu	Arg	Met	Gln	Ala	Glu	Ala	Gly
	50					55					60				
Val	Pro	Ala	Lys	Arg	Ile	Asp	Leu	Glu	Val	Met	Asp	Gly	Ser	Asp	Pro

-continued

65	70	75	80
Val Ala Val Arg	Ala Gly Ile Glu	Ala Ile Val Ala Arg	His Gly Gln
	85	90	95
Ile Asp Ile Leu	Val Asn Asn Ala Gly Ser	Ala Gly Ala Gln Arg	Arg
	100	105	110
Leu Ala Glu Ile	Pro Leu Thr Glu Ala Glu	Leu Gly Pro Gly Ala Glu	
	115	120	125
Glu Thr Leu His	Ala Ser Ile Ala Asn Leu Leu	Gly Met Gly Trp His	
	130	135	140
Leu Met Arg Ile	Ala Ala Pro His Met Pro	Val Gly Ser Ala Val Ile	
	145	150	155
Asn Val Ser Thr	Ile Phe Ser Arg Ala Glu Tyr	Tyr Gly Arg Ile Pro	
	165	170	175
Tyr Val Thr Pro	Lys Ala Ala Leu Asn Ala Leu Ser	Gln Leu Ala Ala	
	180	185	190
Arg Glu Leu Gly	Ala Arg Gly Ile Arg Val Asn Thr	Ile Phe Pro Gly	
	195	200	205
Pro Ile Glu Ser	Asp Arg Ile Arg Thr Val Phe	Gln Arg Met Asp Gln	
	210	215	220
Leu Lys Gly Arg	Pro Glu Gly Asp Thr Ala His His	Phe Leu Asn Thr	
	225	230	235
Met Arg Leu Cys	Arg Ala Asn Asp Gln Gly Ala Leu Glu	Arg Arg Phe	
	245	250	255
Pro Ser Val Gly	Asp Val Ala Asp Ala Ala Val Phe	Leu Ala Ser Ala	
	260	265	270
Glu Ser Ala Ala	Leu Ser Gly Glu Thr Ile Glu Val Thr	His Gly Met	
	275	280	285
Glu Leu Pro Ala	Cys Ser Glu Thr Ser Leu Leu Ala Arg	Thr Asp Leu	
	290	295	300
Arg Thr Ile Asp	Ala Ser Gly Arg Thr Thr Leu Ile Cys	Ala Gly Asp	
	305	310	315
Gln Ile Glu Glu	Val Met Ala Leu Thr Gly Met Leu Arg	Thr Cys Gly	
	325	330	335
Ser Glu Val Ile	Ile Gly Phe Arg Ser Ala Ala Ala Leu Ala	Gln Phe	
	340	345	350
Glu Gln Ala Val	Asn Glu Ser Arg Arg Leu Ala Gly Ala Asp	Phe Thr	
	355	360	365
Pro Pro Ile Ala	Leu Pro Leu Asp Pro Arg Asp Pro Ala Thr	Ile Asp	
	370	375	380
Ala Val Phe Asp	Trp Ala Gly Glu Asn Thr Gly Gly Ile His	Ala Ala	
	385	390	395
Val Ile Leu Pro	Ala Thr Ser His Glu Pro Ala Pro Cys Val	Ile Glu	
	405	410	415
Val Asp Asp Glu	Arg Val Leu Asn Phe Leu Ala Asp Glu Ile Thr	Gly	
	420	425	430
Thr Ile Val Ile	Ala Ser Arg Leu Ala Arg Tyr Trp Gln Ser	Gln Arg	
	435	440	445
Leu Thr Pro Gly	Ala Arg Ala Arg Gly Pro Arg Val Ile Phe	Leu Ser	
	450	455	460
Asn Gly Ala Asp	Gln Asn Gly Asn Val Tyr Gly Arg Ile Gln Ser	Ala	
	465	470	475
Ala Ile Gly Gln	Leu Ile Arg Val Trp Arg His Glu Ala Glu	Leu Asp	
	485	490	495

-continued

Tyr	Gln	Arg	Ala	Ser	Ala	Ala	Gly	Asp	His	Val	Leu	Pro	Pro	Val	Trp
			500					505					510		
Ala	Asn	Gln	Ile	Val	Arg	Phe	Ala	Asn	Arg	Ser	Leu	Glu	Gly	Leu	Glu
		515					520					525			
Phe	Ala	Cys	Ala	Trp	Thr	Ala	Gln	Leu	Leu	His	Ser	Gln	Arg	His	Ile
	530					535					540				
Asn	Glu	Ile	Thr	Leu	Asn	Ile	Pro	Ala	Asn	Ile	Ser	Ala	Thr	Thr	Gly
545					550					555					560
Ala	Arg	Ser	Ala	Ser	Val	Gly	Trp	Ala	Glu	Ser	Leu	Ile	Gly	Leu	His
				565					570					575	
Leu	Gly	Lys	Val	Ala	Leu	Ile	Thr	Gly	Gly	Ser	Ala	Gly	Ile	Gly	Gly
			580					585					590		
Gln	Ile	Gly	Arg	Leu	Leu	Ala	Leu	Ser	Gly	Ala	Arg	Val	Met	Leu	Ala
		595					600					605			
Ala	Arg	Asp	Arg	His	Lys	Leu	Glu	Gln	Met	Gln	Ala	Met	Ile	Gln	Ser
	610					615					620				
Glu	Leu	Ala	Glu	Val	Gly	Tyr	Thr	Asp	Val	Glu	Asp	Arg	Val	His	Ile
625					630					635					640
Ala	Pro	Gly	Cys	Asp	Val	Ser	Ser	Glu	Ala	Gln	Leu	Ala	Asp	Leu	Val
				645					650					655	
Glu	Arg	Thr	Leu	Ser	Ala	Phe	Gly	Thr	Val	Asp	Tyr	Leu	Ile	Asn	Asn
			660					665					670		
Ala	Gly	Ile	Ala	Gly	Val	Glu	Glu	Met	Val	Ile	Asp	Met	Pro	Val	Glu
		675					680					685			
Gly	Trp	Arg	His	Thr	Leu	Phe	Ala	Asn	Leu	Ile	Ser	Asn	Tyr	Ser	Leu
	690					695					700				
Met	Arg	Lys	Leu	Ala	Pro	Leu	Met	Lys	Lys	Gln	Gly	Ser	Gly	Tyr	Ile
705					710					715					720
Leu	Asn	Val	Ser	Ser	Tyr	Phe	Gly	Gly	Glu	Lys	Asp	Ala	Ala	Ile	Pro
				725					730					735	
Tyr	Pro	Asn	Arg	Ala	Asp	Tyr	Ala	Val	Ser	Lys	Ala	Gly	Gln	Arg	Ala
			740					745					750		
Met	Ala	Glu	Val	Phe	Ala	Arg	Phe	Leu	Gly	Pro	Glu	Ile	Gln	Ile	Asn
		755					760					765			
Ala	Ile	Ala	Pro	Gly	Pro	Val	Glu	Gly	Asp	Arg	Leu	Arg	Gly	Thr	Gly
	770					775					780				
Glu	Arg	Pro	Gly	Leu	Phe	Ala	Arg	Arg	Ala	Arg	Leu	Ile	Leu	Glu	Asn
785					790					795					800
Lys	Arg	Leu	Asn	Glu	Leu	His	Ala	Ala	Leu	Ile	Ala	Ala	Ala	Arg	Thr
				805					810					815	
Asp	Glu	Arg	Ser	Met	His	Glu	Leu	Val	Glu	Leu	Leu	Leu	Pro	Asn	Asp
			820					825					830		
Val	Ala	Ala	Leu	Glu	Gln	Asn	Pro	Ala	Ala	Pro	Thr	Ala	Leu	Arg	Glu
		835					840					845			
Leu	Ala	Arg	Arg	Phe	Arg	Ser	Glu	Gly	Asp	Pro	Ala	Ala	Ser	Ser	Ser
	850					855					860				
Ser	Ala	Leu	Leu	Asn	Arg	Ser	Ile	Ala	Ala	Lys	Leu	Leu	Ala	Arg	Leu
865					870					875					880
His	Asn	Gly	Gly	Tyr	Val	Leu	Pro	Ala	Asp	Ile	Phe	Ala	Asn	Leu	Pro
				885					890					895	
Asn	Pro	Pro	Asp	Pro	Phe	Phe	Thr	Arg	Ala	Gln	Ile	Asp	Arg	Glu	Ala
			900					905					910		
Arg	Lys	Val	Arg	Asp	Gly	Ile	Met	Gly	Met	Leu	Tyr	Leu	Gln	Arg	Met
		915					920						925		

-continued

Pro Thr Glu Phe Asp Val Ala Met Ala Thr Val Tyr Tyr Leu Ala Asp
 930 935 940
 Arg Asn Val Ser Gly Glu Thr Phe His Pro Ser Gly Gly Leu Arg Tyr
 945 950 955 960
 Glu Arg Thr Pro Thr Gly Gly Glu Leu Phe Gly Leu Pro Ser Pro Glu
 965 970 975
 Arg Leu Ala Glu Leu Val Gly Ser Thr Val Tyr Leu Ile Gly Glu His
 980 985 990
 Leu Thr Glu His Leu Asn Leu Leu Ala Arg Ala Tyr Leu Glu Arg Tyr
 995 1000 1005
 Gly Ala Arg Gln Val Val Met Ile Val Glu Thr Glu Thr Gly Ala
 1010 1015 1020
 Glu Thr Met Arg Arg Leu Leu His Asp His Val Glu Ala Gly Arg
 1025 1030 1035
 Leu Met Thr Ile Val Ala Gly Asp Gln Ile Glu Ala Ala Ile Asp
 1040 1045 1050
 Gln Ala Ile Thr Arg Tyr Gly Arg Pro Gly Pro Val Val Cys Thr
 1055 1060 1065
 Pro Phe Arg Pro Leu Pro Thr Val Pro Leu Val Gly Arg Lys Asp
 1070 1075 1080
 Ser Asp Trp Ser Thr Val Leu Ser Glu Ala Glu Phe Ala Glu Leu
 1085 1090 1095
 Cys Glu His Gln Leu Thr His His Phe Arg Val Ala Arg Lys Ile
 1100 1105 1110
 Ala Leu Ser Asp Gly Ala Ser Leu Ala Leu Val Thr Pro Glu Thr
 1115 1120 1125
 Thr Ala Thr Ser Thr Thr Glu Gln Phe Ala Leu Ala Asn Phe Ile
 1130 1135 1140
 Lys Thr Thr Leu His Ala Phe Thr Ala Thr Ile Gly Val Glu Ser
 1145 1150 1155
 Glu Arg Thr Ala Gln Arg Ile Leu Ile Asn Gln Val Asp Leu Thr
 1160 1165 1170
 Arg Arg Ala Arg Ala Glu Glu Pro Arg Asp Pro His Glu Arg Gln
 1175 1180 1185
 Gln Glu Leu Glu Arg Phe Ile Glu Ala Val Leu Leu Val Thr Ala
 1190 1195 1200
 Pro Leu Pro Pro Glu Ala Asp Thr Arg Tyr Ala Gly Arg Ile His
 1205 1210 1215
 Arg Gly Arg Ala Ile Thr Val
 1220 1225

<210> SEQ ID NO 142

<211> LENGTH: 336

<212> TYPE: DNA

<213> ORGANISM: Chloroflexus aurantiacus

<400> SEQUENCE: 142

tctttctggc cagtgcgcgaa tccgcgcgtc tctccggtga gacgattgag gttacgcacg 60
 gaatggagtt gccggcctgc agtgagacca gcctgctggc cgtactgat ctgcgcacga 120
 ttgatgccag tggccgcacg acgctcatct gcgcgcgcga ccagattgaa gaggtgatgg 180
 cgctcaccgg tatgttgctg acctgtggga gtgaagtgat catcggttc cgttcggctg 240
 cggcgctggc ccagttcgag caggcagtca atgagagtcg gcggctggcc ggcgcagact 300
 ttacgcctcc cattgccttg ccaactcgatc cacgcg 336

-continued

```

<210> SEQ ID NO 143
<211> LENGTH: 249
<212> TYPE: PRT
<213> ORGANISM: Spodoptera littoralis

<400> SEQUENCE: 143

Met Phe Ala Asn Lys Val Val Leu Val Thr Gly Gly Ser Ser Gly Ile
 1             5             10            15

Gly Ala Ala Thr Val Glu Ala Phe Val Lys Glu Gly Ala Ser Val Ala
      20             25            30

Phe Val Gly Arg Asn Gln Ala Lys Leu Lys Glu Val Glu Ser Arg Cys
      35             40            45

Gln Gln His Gly Ala Asn Ile Leu Ala Ile Lys Ala Asp Val Ser Lys
      50             55            60

Asp Glu Glu Ala Lys Ile Ile Val Gln Gln Thr Val Asp Lys Phe Gly
 65             70             75            80

Lys Leu Asp Val Leu Val Asn Asn Ala Gly Ile Leu Arg Phe Ala Ser
      85             90            95

Val Leu Glu Pro Thr Leu Ile Gln Thr Phe Asp Glu Thr Met Asn Thr
      100            105           110

Asn Leu Arg Pro Val Val Leu Ile Thr Ser Leu Ala Ile Pro His Leu
      115            120           125

Ile Ala Thr Lys Gly Ser Ile Val Asn Val Ser Ser Ile Leu Ser Thr
      130            135           140

Ile Val Arg Ile Pro Gly Ile Met Ser Tyr Ser Val Ser Lys Ala Ala
 145            150            155           160

Met Asp His Phe Thr Lys Leu Ala Ala Leu Glu Leu Ala Pro Ser Gly
      165            170           175

Val Arg Val Asn Ser Val Asn Pro Gly Pro Val Leu Thr Asp Ile Ala
      180            185           190

Ala Gly Ser Gly Phe Ser Pro Asp Leu Leu Glu Asp Thr Gly Ala His
      195            200           205

Thr Pro Leu Gly Lys Ala Ala Gln Ser Glu Glu Ile Ala Asp Met Ile
      210            215           220

Val Tyr Leu Ala Ser Asp Lys Ala Lys Ser Val Thr Gly Ser Cys Tyr
 225            230            235           240

Ile Met Asp Asn Gly Leu Ala Leu Gln
      245

```

```

<210> SEQ ID NO 144
<211> LENGTH: 246
<212> TYPE: PRT
<213> ORGANISM: Thermotoga maritima

```

```

<400> SEQUENCE: 144

Met Arg Leu Glu Gly Lys Val Cys Leu Ile Thr Gly Ala Ala Ser Gly
 1             5             10            15

Ile Gly Lys Ala Thr Thr Leu Leu Phe Ala Gln Glu Gly Ala Thr Val
      20             25            30

Ile Ala Gly Asp Ile Ser Lys Glu Asn Leu Asp Ser Leu Val Lys Glu
      35             40            45

Ala Glu Gly Leu Pro Gly Lys Val Asp Pro Tyr Val Leu Asn Val Thr
      50             55            60

Asp Arg Asp Gln Ile Lys Glu Val Val Glu Lys Val Val Gln Lys Tyr
 65             70             75            80

```


-continued

Gly Arg Ile Asp Val Leu Val Asn Asn Ala Gly Ile Thr Arg Asp Ala
 85 90 95
 Leu Leu Val Arg Met Lys Glu Glu Asp Trp Asp Ala Val Ile Asn Val
 100 105 110
 Asn Leu Lys Gly Val Phe Asn Val Thr Gln Met Val Val Pro Tyr Met
 115 120 125
 Ile Lys Gln Arg Asn Gly Ser Ile Val Asn Val Ser Ser Val Val Gly
 130 135 140
 Ile Tyr Gly Asn Pro Gly Gln Thr Asn Tyr Ala Ala Ser Lys Ala Gly
 145 150 155 160
 Val Ile Gly Met Thr Lys Thr Trp Ala Lys Glu Leu Ala Gly Arg Asn
 165 170 175
 Ile Arg Val Asn Ala Val Ala Pro Gly Phe Ile Glu Thr Pro Met Thr
 180 185 190
 Glu Lys Leu Pro Glu Lys Ala Arg Glu Thr Ala Leu Ser Arg Ile Pro
 195 200 205
 Leu Gly Arg Phe Gly Lys Pro Glu Glu Val Ala Gln Val Ile Leu Phe
 210 215 220
 Leu Ala Ser Asp Glu Ser Ser Tyr Val Thr Gly Gln Val Ile Gly Ile
 225 230 235 240
 Asp Gly Gly Leu Val Ile
 245

<210> SEQ ID NO 145

<211> LENGTH: 289

<212> TYPE: PRT

<213> ORGANISM: Bacillus subtilis

<400> SEQUENCE: 145

Met Asn Pro Met Asp Arg Gln Thr Glu Gly Gln Glu Pro Gln His Gln
 1 5 10 15
 Asp Arg Gln Pro Gly Ile Glu Ser Lys Met Asn Pro Leu Pro Leu Ser
 20 25 30
 Glu Asp Glu Asp Tyr Arg Gly Ser Gly Lys Leu Lys Gly Lys Val Ala
 35 40 45
 Ile Ile Thr Gly Gly Asp Ser Gly Ile Gly Arg Ala Ala Ala Ile Ala
 50 55 60
 Phe Ala Lys Glu Gly Ala Asp Ile Ser Ile Leu Tyr Leu Asp Glu His
 65 70 75 80
 Ser Asp Ala Glu Glu Thr Arg Lys Arg Ile Glu Lys Glu Asn Val Arg
 85 90 95
 Cys Leu Leu Ile Pro Gly Asp Val Gly Asp Glu Asn His Cys Glu Gln
 100 105 110
 Ala Val Gln Gln Thr Val Asp His Phe Gly Lys Leu Asp Ile Leu Val
 115 120 125
 Asn Asn Ala Ala Glu Gln His Pro Gln Asp Ser Ile Leu Asn Ile Ser
 130 135 140
 Thr Glu Gln Leu Glu Lys Thr Phe Arg Thr Asn Ile Phe Ser Met Phe
 145 150 155 160
 His Met Thr Lys Lys Ala Leu Pro His Leu Gln Glu Gly Cys Ala Ile
 165 170 175
 Ile Asn Thr Thr Ser Ile Thr Ala Tyr Glu Gly Asp Thr Ala Leu Ile
 180 185 190
 Asp Tyr Ser Ser Thr Lys Gly Ala Ile Val Ser Phe Thr Arg Ser Met
 195 200 205

-continued

Ala Lys Ser Leu Ala Asp Lys Gly Ile Arg Val Asn Ala Val Ala Pro
 210 215 220

Gly Pro Ile Trp Thr Pro Leu Ile Pro Ala Thr Phe Pro Glu Glu Lys
 225 230 235 240

Val Lys Gln His Gly Leu Asp Thr Pro Met Gly Arg Pro Gly Gln Pro
 245 250 255

Val Glu His Ala Gly Ala Tyr Val Leu Leu Ala Ser Asp Glu Ser Ser
 260 265 270

Tyr Met Thr Gly Gln Thr Ile His Val Asn Gly Gly Arg Phe Ile Ser
 275 280 285

Thr

<210> SEQ ID NO 146

<211> LENGTH: 285

<212> TYPE: PRT

<213> ORGANISM: Sinorhizobium meliloti

<400> SEQUENCE: 146

Met Glu Lys Phe Pro His Pro Pro Phe Pro Arg Gln Thr Gln Glu Met
 1 5 10 15

Pro Gly Thr Thr Asp Arg Met Gln Pro Leu Pro Asp His Gly Glu Asn
 20 25 30

Ser Tyr Gln Gly Ser Gly Arg Leu Lys Asp Lys Arg Ala Ile Ile Thr
 35 40 45

Gly Gly Asp Ser Gly Ile Gly Arg Ala Val Ala Ile Ala Tyr Ala Arg
 50 55 60

Glu Gly Ala Asp Val Leu Ile Ser Tyr Leu Ser Glu His Asp Asp Ala
 65 70 75 80

Met Ala Thr Lys Ala Leu Val Glu Glu Ala Gly Arg Lys Ala Val Leu
 85 90 95

Ala Ala Gly Asp Ile Gln Ser Ser Asp His Cys Arg Arg Ile Val Glu
 100 105 110

Thr Ala Val Arg Glu Leu Gly Gly Ile Asp Ile Leu Val Asn Asn Ala
 115 120 125

Ala His Gln Ala Thr Phe Lys Asn Ile Glu Asp Ile Ser Asp Glu Glu
 130 135 140

Trp Glu Leu Thr Phe Arg Val Asn Met His Ala Met Phe Tyr Leu Thr
 145 150 155 160

Lys Ala Ala Val Pro His Met Lys Lys Gly Ser Ala Ile Ile Asn Thr
 165 170 175

Ala Ser Ile Asn Ala Asp Val Pro Asn Pro Ile Leu Leu Ala Tyr Ala
 180 185 190

Thr Thr Lys Gly Ala Ile His Asn Phe Ser Ala Gly Leu Ala Gln Met
 195 200 205

Leu Ala Glu Arg Gly Ile Arg Val Asn Val Val Ala Pro Gly Pro Ile
 210 215 220

Trp Thr Pro Leu Ile Pro Ser Thr Met Pro Glu Asp Thr Val Ala Asp
 225 230 235 240

Phe Gly Lys Gln Val Pro Met Lys Arg Pro Gly Gln Pro Val Glu Leu
 245 250 255

Ala Ser Ala Tyr Val Met Leu Ala Asp Pro Met Ser Ser Tyr Val Ser
 260 265 270

Gly Ala Thr Ile Ala Val Thr Gly Gly Lys Pro Phe Leu
 275 280 285

-continued

<210> SEQ ID NO 147
 <211> LENGTH: 257
 <212> TYPE: PRT
 <213> ORGANISM: Mesorhizobium loti

<400> SEQUENCE: 147

Met Arg Leu Leu His Lys Arg Thr Leu Val Thr Gly Gly Ser Asp Gly
 1 5 10 15
 Ile Gly Leu Ala Ile Ala Glu Ala Phe Leu Ser Glu Gly Ala Asp Val
 20 25 30
 Leu Ile Val Gly Arg Asp Ala Ala Lys Leu Glu Ala Ala Arg Gln Lys
 35 40 45
 Leu Ala Ala Leu Gly Gln Ala Gly Ala Val Glu Thr Ser Ser Ala Asp
 50 55 60
 Leu Ala Thr Ser Leu Gly Val Ala Thr Val Val Glu Gln Val Lys Glu
 65 70 75 80
 Thr Gly Arg Pro Leu Asp Ile Pro Ile Asn Asn Ala Gly Val Ala Asp
 85 90 95
 Leu Val Pro Phe Glu Ser Val Ser Glu Ala Gln Phe Gln His Ser Phe
 100 105 110
 Ala Leu Asn Val Ala Ala Ala Phe Phe Leu Thr Gln Gly Leu Leu Pro
 115 120 125
 His Phe Gly Ala Gly Ala Ser Ile Ile Asn Ile Ser Ser Tyr Phe Ala
 130 135 140
 Arg Lys Met Ile Pro Lys Arg Pro Ser Ser Val Tyr Ser Leu Ser Lys
 145 150 155 160
 Gly Ala Leu Asn Ser Leu Thr Arg Ser Leu Ala Phe Glu Leu Gly Pro
 165 170 175
 Arg Gly Ile Arg Val Asn Ala Ile Ala Pro Gly Thr Val Asp Thr Ala
 180 185 190
 Met Arg Arg Lys Thr Val Asp Asn Leu Pro Ala Glu Ala Lys Ala Glu
 195 200 205
 Leu Lys Ala Tyr Val Glu Arg Ser Tyr Pro Leu Gly Arg Ile Gly Arg
 210 215 220
 Pro Asp Asp Leu Ala Gly Met Ala Val Tyr Leu Ala Ser Asp Glu Ala
 225 230 235 240
 Ala Trp Thr Ser Gly Gly Ile Phe Ala Val Asp Gly Gly Tyr Thr Ala
 245 250 255
 Gly

<210> SEQ ID NO 148
 <211> LENGTH: 774
 <212> TYPE: DNA
 <213> ORGANISM: Mesorhizobium loti

<400> SEQUENCE: 148

atgagacttc tgcacaagcg cacgctgggtg accggcggtt cggacggtat cggcctggca 60
 atcgccgagg cgctcctgag cgagggcgcc gatgtcctga tcgtcggccg tgacgccgcc 120
 aagctcgaag ccgcgcgccca gaagctggcg gctcttgccc aggcggcgcc ggtggagacg 180
 tcgtccgccg atcttgccac cagcctcggt gtcgcaaccg tcgtcgagca ggtgaaagag 240
 accggccggc cgctcgacat tcctatcaac aatgccggtg tcgccgacct cgtgccgttc 300
 gagagcgta gcgagggcga gttccagcac tccttcgcgc tcaatgtggc ggcggcggttc 360
 ttctcacc ccagggtgct gccgcatttc ggccgggtg catcgatcat caacatctct 420
 tcctatttcg ccgcaagat gatccgaag cgcccatcca gcgtctactc cctgtccaag 480

-continued

```

ggcgcggttga actcggttgac cagatcgctg gccttcgagc tcggccccg cggeatccgc 540
gtcaacgccca tcgccccggg cacgggtgcac accgccatgc ggcgcaagac cgtcgacaaac 600
ctgccgggccc aggccaaagg cgaactgaag gcctatgtcg aacgcagcta tccgctgggc 660
cgatcgggcc gtccggacga cctcgccggc atggcggttt atctagccag cgacgaggcg 720
gcctggacga gcggtgggat ctttgccgtg gatggtggct acacggccgg atga 774

```

```

<210> SEQ ID NO 149
<211> LENGTH: 750
<212> TYPE: DNA
<213> ORGANISM: Spodoptera littoralis

```

```

<400> SEQUENCE: 149

```

```

atgttcgcaa ataaagtggg actagtaaca ggtggtagct ccggtatcgg cgcagctact 60
gtggaagcat tcgttaagga aggcgcttct gtagccttcg tgggaagaaa ccaagccaag 120
cttaaggaag tagagagccg ctgccagcag catggagcca acatcctggc tatcaaagca 180
gatgtctcca aagacgagga agcgaaaatc atcgtacaac aaactgtcga caagttcggg 240
aagcttgatg tgcttgtaa caacgctggg attctacggt tcgcgagtgt tctggagccg 300
actttaatac aaacttttga tgaaactatg aacacgaatt tacgtccagt tgtctcctc 360
actagcctgg ctatccctca tttgattgct acaaaaggga gcatagttaa cgtatccagt 420
atactgtcta caatagtaag aataccaggg attatgtcat acagtgtgtc aaaggctgct 480
atggatcaact tcacaaaatt ggcagcgttg gagctggtc cttctggcgt gcgagtgaac 540
tcagtcaacc ctggaccagt tcttactgat atcgcagctg gttctggctt ttctcctgat 600
ctgcttgaag atacaggggc tcatacaccg ttggggaaag ctgcgcagtc tgaggagatt 660
gctgatatga ttgtgtatct ggctagtgat aaagctaaga gtgttacggg gtctgttat 720
atcatggaca atggactcgc gctgcagtaa 750

```

```

<210> SEQ ID NO 150
<211> LENGTH: 741
<212> TYPE: DNA
<213> ORGANISM: Thermotoga maritima

```

```

<400> SEQUENCE: 150

```

```

atgaggcttg aagggaaagt gtgtctgac acaggggctg caagcgggat agggaaagcc 60
accacgcttc ttttcgcaca ggaaggagct acggtgatcg ctggcgatat ctcgaaagaa 120
aatctcgact ctcttgtaa agaggcagaa ggacttccgg ggaagggtga tcctacgtt 180
ttgaacgtga ccgacaggga tcagataaag gaagttgtgg aaaaagtcgt tcaaaagtac 240
ggtcgaatcg atgttctggt gaacaacgcg ggaataacaa gggatgcgct tcttgtgagg 300
atgaaagaag aagactggga tgcgtaata aacgtgaatc tgaagggtgt tttcaacgtg 360
actcagatgg tgggtgccct catgatcaaa cagaggaaac gttcgatcgt gaacgtctcc 420
tctgtcgttg gaatatccg gaatcctggt cagacgaatt acgcggcgtc gaaggcggga 480
gtcataggaa tgaccaagac gtgggcgaag gaactcgtg gaagaaacat cagggtgaac 540
gctgtggcac ccgattcat agaaaccccc atgaccgaaa aacttccaga aaaagcccgt 600
gaaacggccc tttccagaat accgctggga aggtttggga agccagaaga ggtggcgag 660
gttatactct tctcgcacg ggacgagtc agttacgtca ccggacaggt gataggaata 720
gatgggggcc tcgtgatctg a 741

```

-continued

<210> SEQ ID NO 151
<211> LENGTH: 858
<212> TYPE: DNA
<213> ORGANISM: *Sinorhizobium meliloti*

<400> SEQUENCE: 151

```
atggaaaaat ttccgcaccc tccctttccc cgccaaaccc aggaaatgcc cggcactacc    60
gatcggatgc agccgctgcc cgatcacggg gaaaactcct accagggttc cggacgcctg    120
aaggacaaga gagccatcat caccggcggg gacagcggca tcggcagggc cgtggcgatc    180
gcctatgcgc gcgagggagc ggacgtcctt atcagctatc tgagcgagca tgacgacgcg    240
atggccacca aggctctggt ggaggaagca ggtcgcaagg ccgtgcttgc cgccggcgcgac    300
atccagtcgt ccgaccattg ccgcaggatc gtcgaaacgg ccgttcggga actcggcggc    360
atcgacattc tcgtcaacaa tgcagcccat caggcgacct tcaagaacat cgaagacatc    420
agcgacgagg agtgggagct gacattccgc gtcaacatgc acgccatggt ctacctgacc    480
aaggcagcgg tgcgcacat gaagaagggc agcgcgatca tcaacaccgc ttccatcaat    540
gccgacgttc ccaatccgat cctactcgcc tatgcgacca ccaagggcgc gatccacaat    600
ttcagcgccg gtctcgcgca gatgtggcc gaacgcggga taagagtga tgctgtggcc    660
ccgggcccga tctggacgcc gctgatcccc tccaccatgc ccgaggatac cgtcgccgat    720
ttcggcaaac aggtgcctat gaagcgaccg ggccagcccg tggaaactgc ctcggcctat    780
gtcatgtgg cggatccgat gtcgagctac gtgtcaggcg caacgattgc cgtgaccggc    840
ggcaagcctt tcctttga                                858
```

<210> SEQ ID NO 152
<211> LENGTH: 870
<212> TYPE: DNA
<213> ORGANISM: *Bacillus subtilis*

<400> SEQUENCE: 152

```
gtgaacccaa tggacagaca aacagaagga caagaaccgc agcatcagga cagacagccg    60
ggcattgagt caaaaatgaa tccgctgccg ctgtcagagg acgaggatta tcgaggaagc    120
ggaaaactga aaggaaaagt tgcgatcatt actggaggcg acagcggaat agggagagca    180
gcagctattg cctttgctaa agagggggct gatatctcca ttctatactt agacgagcat    240
tcggacgcag aggaaacacg caaacggatc gaaaaggaga atgtccgctg cctgcttate    300
ccgggagatg ttggggacga gaaccattgt gaacaagctg tgcagcaaac agtggaccat    360
tttggtaaac tcgatatctt agtgaacaac gccgctgaac agcatcccca ggacagcatt    420
ctcaatattt caacagaaca gctggaaaaa acctttcgca caaatatttt ttccatgttt    480
catatgacga agaaagcttt gcctcacctg caagaggggg gtgccattat taatacgaca    540
tcgattaccg cttatgaagg ggatacggcg ttaattgatt attccagcac aaagggtgcg    600
attgtttcct ttacgcgttc catggcgaag tcgcttgacg ataaaggcat cagagtgaat    660
gcggtggcgc ccggtccgat ttggacaccg cttattccgg cgacattccc tgaggaaaaa    720
gtgaaacagc acggcttgga taccccaatg ggaagaccgg gacagccggg tgagcatgca    780
ggcgcctatg ttctgtctgc gtctgacgaa tcttcctata tgacagggca gaccattcat    840
gtgaatggcg gccgttttat ttcaacgtaa                                870
```

<210> SEQ ID NO 153
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 153

atggcgacgg gcgagtccat gag 23

<210> SEQ ID NO 154
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 154

ggacacgaag aacagggcga cac 23

<210> SEQ ID NO 155
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 155

gaactgtctg gagtaaggct gtc 23

<210> SEQ ID NO 156
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 156

gattccgtat gtcacccta 20

<210> SEQ ID NO 157
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 157

caggcgactg gcaatcacia 20

<210> SEQ ID NO 158
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 158

gagaccacia cggtttccct cta 23

<210> SEQ ID NO 159
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 159

ggacacgaag aacagggcga cac 23

-continued

```

<210> SEQ ID NO 160
<211> LENGTH: 145
<212> TYPE: PRT
<213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 160
Met Val Gly Lys Lys Val Val His His Leu Met Met Ser Ala Lys Asp
 1             5             10             15
Ala His Tyr Thr Gly Asn Leu Val Asn Gly Ala Arg Ile Val Asn Gln
      20             25             30
Trp Gly Asp Val Gly Thr Glu Leu Met Val Tyr Val Asp Gly Asp Ile
      35             40             45
Ser Leu Phe Leu Gly Tyr Lys Asp Ile Glu Phe Thr Ala Pro Val Tyr
      50             55             60
Val Gly Asp Phe Met Glu Tyr His Gly Trp Ile Glu Lys Val Gly Asn
      65             70             75             80
Gln Ser Tyr Thr Cys Lys Phe Glu Ala Trp Lys Val Ala Thr Met Val
      85             90             95
Asp Ile Thr Asn Pro Gln Asp Thr Arg Ala Thr Ala Cys Glu Pro Pro
      100            105            110
Val Leu Cys Gly Arg Ala Thr Gly Ser Leu Phe Ile Ala Lys Lys Asp
      115            120            125
Gln Arg Gly Pro Gln Glu Ser Ser Phe Lys Glu Arg Lys His Pro Gly
      130            135            140
Glu
145

```

```

<210> SEQ ID NO 161
<211> LENGTH: 144
<212> TYPE: PRT
<213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 161
Met Val Gly Lys Lys Val Val His His Leu Met Met Ser Ala Lys Asp
 1             5             10             15
Ala His Tyr Thr Gly Asn Leu Val Asn Gly Ala Arg Ile Val Asn Gln
      20             25             30
Trp Gly Asp Val Gly Thr Glu Leu Met Val Tyr Val Asp Gly Asp Ile
      35             40             45
Ser Leu Phe Leu Gly Tyr Lys Asp Ile Glu Phe Thr Ala Pro Val Tyr
      50             55             60
Val Gly Asp Phe Met Glu Tyr His Gly Trp Ile Glu Lys Val Gly Asn
      65             70             75             80
Gln Ser Tyr Thr Cys Lys Phe Glu Ala Trp Lys Val Ala Lys Met Val
      85             90             95
Asp Ile Thr Asn Pro Gln Asp Thr Arg Ala Thr Ala Cys Glu Pro Pro
      100            105            110
Val Leu Cys Gly Thr Ala Thr Gly Ser Leu Phe Ile Ala Lys Asp Asn
      115            120            125
Gln Arg Gly Pro Gln Glu Ser Ser Phe Lys Asp Ala Lys His Pro Gln
      130            135            140

```

```

<210> SEQ ID NO 162
<211> LENGTH: 438
<212> TYPE: DNA
<213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 162

```

-continued

atggtaggta aaaaggttgt acatcattta atgatgagcg caaaagatgc tcactatact	60
ggaaacttag taaacggcgc tagaattgtg aatcagtggtg gcgacgttgg tacagaatta	120
atggtttatg ttgatgggtga cataagctta ttcttgggct acaaagatat cgaattcaca	180
gctcctgtat atgttggtga ctttatggaa taccacggct ggattgaaaa agttggtaac	240
cagtcctata catgtaaatt tgaagcatgg aaagttgcaa caatgggtga taccacaaat	300
cctcaggata cagcgcaac agcttgtgag cctccgggtat tgtgcggaag agcaacgggt	360
agtttgttca tcgcaaaaaa agatcagaga ggccctcagg aatcctcttt taaagagaga	420
aagcaccccg gtgaatga	438

<210> SEQ ID NO 163
 <211> LENGTH: 435
 <212> TYPE: DNA
 <213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 163

atggtaggta aaaaggttgt acatcattta atgatgagcg caaaagatgc tcactatact	60
ggaaacttag taaacggcgc tagaattgtg aatcagtggtg gcgacgtagg tacagaatta	120
atggtttatg ttgatgggtga catcagctta ttcttgggct acaaagatat cgaattcaca	180
gctcctgtat atgttggtga ttttatggaa taccacggct ggattgaaaa agttggcaac	240
cagtcctata catgtaaatt tgaagcatgg aaagtagcaa agatgggtga taccacaaat	300
ccacaggata cagctgcaac agcttgtgaa cctccgggtac tttgtggtac tgcaacaggc	360
agccttttca tcgcaaaagga taatcagaga ggccctcagg aatcctcctt caaggatgca	420
aagcacccctc aataa	435

<210> SEQ ID NO 164
 <211> LENGTH: 44
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 164

atagggccca ggagatcaaa ccatgggtga agagtctctg gttc	44
--	----

<210> SEQ ID NO 165
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 165

cctctgctac agtcgacaca acgaccactg aagttgggag	40
---	----

<210> SEQ ID NO 166
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 166

agttctgtat cggtaacctca acgaccactg aagttgggag	40
--	----

<210> SEQ ID NO 167
 <211> LENGTH: 40
 <212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 167

atagcggccg cataatggat actctcgaa tcgacgttgg 40

<210> SEQ ID NO 168
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 168

ccccatcgat acatatttct tgattttatc ataagcaatc 40

<210> SEQ ID NO 169
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 169

ccagggccca taatgggtga agaaaaaca gtagatattg 40

<210> SEQ ID NO 170
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 170

ggtagacttg tcgacgtagt ggtttcctcc ttcattgg 38

<210> SEQ ID NO 171
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 171

atagcggccg cataatgggt cagatcgacg aacttatcag 40

<210> SEQ ID NO 172
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 172

aggttcaact agttcgtaga ggatttccga gaaagcctg 39

<210> SEQ ID NO 173
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 173

ctagggccca taatggaact cgccgtttat agcac 35

-continued

<210> SEQ ID NO 174
 <211> LENGTH: 34
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 174

acttctcgag ttaaaccagt tcgttcgggc aggt

34

<210> SEQ ID NO 175
 <211> LENGTH: 37
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 175

gggactagta taatgggaaa agtagaaatc attacag

37

<210> SEQ ID NO 176
 <211> LENGTH: 37
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 176

cggtttaatt aacagcagag atttatTTTT tcagtcc

37

<210> SEQ ID NO 177
 <211> LENGTH: 35
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium propionicum

<400> SEQUENCE: 177

Met Val Gly Lys Lys Val Val His His Leu Met Met Ser Ala Lys Asp
 1 5 10 15

Ala His Tyr Thr Gly Asn Leu Val Asn Gly Ala Arg Ile Val Asn Gln
 20 25 30

Trp Gly Asp
 35

<210> SEQ ID NO 178
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 178

atggtwggga araargtwgt

20

<210> SEQ ID NO 179
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 179

tcrccccayt grttwacrat

20

<210> SEQ ID NO 180
 <211> LENGTH: 64

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 180

acatcattta atgatgagcg caaaagatgc tcactatact ggaaacttag taaacggcgc 60

taga 64

<210> SEQ ID NO 181
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 181

gtacatcatt taatgatgag cgcaaaagat g 31

<210> SEQ ID NO 182
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 182

gatgctcact atactggaaa cttagtaaac 30

<210> SEQ ID NO 183
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 183

attctagcgc cgtttactaa gtttccag 28

<210> SEQ ID NO 184
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 184

ccagtatagt gagcatcttt tgcgctcatc 30

<210> SEQ ID NO 185
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 185

gagccatgga agaaataaat gctaaag 27

<210> SEQ ID NO 186
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 186

-continued

agaggatggc tttttaaatc gctattc 27

<210> SEQ ID NO 187
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 187

atacatatga ccgaccgaca tcgcatt 27

<210> SEQ ID NO 188
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Primer

<400> SEQUENCE: 188

atagtcgacg ggtcagtcct tgccgcg 27

<210> SEQ ID NO 189
 <211> LENGTH: 960
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 189

atgagtctga atttccttga ttttgaacag ccgattgcag agctggaagc gaaaatcgat 60
 tctctgactg cggttagccg tcaggatgag aaactggata ttaacatcga tgaagaagtg 120
 catcgtctgc gtgaaaaaag cgtagaactg acacgtaaaa tcttcgccga tctcggtgca 180
 tggcagattg cgcaactggc acgccatcca cagcgtcctt ataccctgga ttacgttcgc 240
 ctggcatttg atgaatttga cgaactggct ggcgaccgcg cgtatgcaga cgataaagct 300
 atcgtcggtg gtatcgcccc tctcgatggt cgcccggtga tgatcattgg tcatcaaaaa 360
 ggtcgtgaaa ccaaaagaaa aattcgccgt aactttggta tgccagcgcc agaaggttac 420
 cgaaagcac tgcgtctgat gcaaatggct gaacgcttta agatgcctat catcaccttt 480
 atcgacaccc cgggggctta tcctggcggt ggcgcagaag agcgtggtca gtctgaagcc 540
 attgcacgca acctgcgtga aatgtctcgc ctccggctac cggtagtttg tacggttatc 600
 ggtgaagggt gttctggcgg tgcgctggcg attggcgtgg gcgataaagt gaatatgctg 660
 caatacagca cctattccgt tatctgcgg gaagggttggt cgtccattct gtggaagagc 720
 gccgacaaag cgccgctggc ggctgaagcg atgggtatca ttgctccgcg tctgaaagaa 780
 ctgaaactga tcgactccat catcccgga ccaactgggtg gtgctcaccg taaccgggaa 840
 gcgatggcgg catcgttgaa agcgcaactg ctggcggatc tggccgatct cgacgtgtta 900
 agcactgaag atttaaaaaa tcgctggtat cagcgcctga tgagctacgg ttacgcgtaa 960

<210> SEQ ID NO 190
 <211> LENGTH: 471
 <212> TYPE: DNA
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 190

atggatattc gtaagattaa aaaactgac gagctggttg aagaatcagg catctccgaa 60
 ctggaaaatt ctgaaggcga agagtcagta cgcattagcc gtgcagctcc tgccgcaagt 120
 ttccctgtga tgcaacaagc ttacgctgca ccaatgatgc agcagccagc tcaatctaac 180

-continued

```
gcagccgctc cggcgaccgt tccttccatg gaagcgccag cagcagcgga aatcagtgg 240
cacatcgta cgtccccgat ggttggtact ttctaccgca cccaagccc ggacgcaaaa 300
gcgttcacg aagtgggtca gaaagtcaac gtgggcgata ccctgtgcat cgttgaagcc 360
atgaaaatga tgaaccagat cgaagcggac aaatccggtg ccgtgaaagc aattctggtc 420
gaaagtggac aaccggtaga atttgacgag ccgctggtcg tcatcgagta a 471
```

```
<210> SEQ ID NO 191
<211> LENGTH: 1350
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
```

```
<400> SEQUENCE: 191
```

```
atgctggata aaattgttat tgccaaccgc ggcgagattg cattgcgtat tcttcgtgcc 60
tgtaagaac tgggcatcaa gactgtcgct gtgcactcca gcgcggatcg cgatctaaaa 120
cacgtattac tggcagatga aacggtctgt attggccctg ctccgtcagt aaaaagttat 180
ctgaacatcc cggcaatcat cagcgccgct gaaatcacgc gcgcagtagc aatccatccg 240
ggttacggct tcctctccga gaacgccaac tttgccgagc aggttgaacg ctccggcttt 300
atcttcattg gcccgaaagc agaaaccatt cgctgatgg gcgacaaagt atccgcaatc 360
gcggcgatga aaaaagcggg cgtcccttgc gtaccgggtt ctgacggccc gctggcgac 420
gatatggata aaaaccgtgc cattgctaaa cgcattgggt atccggtgat tatcaaagcc 480
tcggcgcgcg gcggcggtcg cggtatgcgc gtagtgccgc gcgacgctga actggcacia 540
tccatctcca tgaccctgac ggaagcgaaa gctgctttca gcaacgatat ggtttacatg 600
gagaaaatac tggaaaatac tcgccacgac gagattcagg tactggctga cggtcagggc 660
aacgctatct atctggcgga acgtgactgc tccatgcaac gccgccacca gaaagtggtc 720
gaagaagcgc cagcaccggg cattaccccg gaactgcgtc gctacatcgg cgaacgttgc 780
gctaaagcgt gtgttgatat cggctatcgc ggtgcaggtg ctttcaggtt cctgttcgaa 840
aacggcgagt tctatttcat cgaaatgaac acccgattc aggtagaaca cccggttaca 900
gaaatgatca cggcggttga cctgatcaaa gaacagctgc gtatcgctgc cggtcacccg 960
ctgtcgatca agcaagaaga agttcacgtt cgcggccatg cggtggaatg tcgtatcaac 1020
gccgaagatc cgaacacctt cctgccagt cccggcacia tcacccgttt ccacgcacct 1080
ggcggttttg gcgtacgttg ggagtctcat atctacgcgg gctacaccgt accgccgtac 1140
tatgactcaa tgatcggtga gctgatttgc tacggtgaaa accgtgacgt ggcgattgcc 1200
cgcatgaaga atgcgctgca ggagctgac atcgacggtg tcaaaaccaa cgttgatctg 1260
cagatccgca tcatgaatga cgagaacttc cagcatggtg gcaactaat ccaactatctg 1320
gagaaaaaac tcggtcttca ggaaaaataa 1350
```

```
<210> SEQ ID NO 192
<211> LENGTH: 915
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
```

```
<400> SEQUENCE: 192
```

```
atgagctgga ttgaacgaat taaaagcaac attactccca cccgcaaggc gagcattcct 60
gaaggggtgt ggactaatgt tgatagctgc ggtcaggttt tataccgcgc tgagctggaa 120
cgtaatcttg aggtctgtcc gaagtgtgac catcacatgc gtatgacagc gcgtaatcgc 180
ctgcatagcc tgtagatga aggaagcctt gtggagctgg gtagcagcgt tgagccgaaa 240
```

-continued

gatgtgctga agtttcgtga ctccaagaag tataaagacc gtctggcatc tgcgcagaaa	300
gaaaccggcg aaaaagatgc gctgggtgtg atgaaaggca ctctgtatgg aatgccggtt	360
gtcgtgcggt cattcgagtt cgcctttatg ggcggttcaa tggggctctgt tgtgggtgca	420
cgtttcgtgc gtgccgttga gcaggcgtg gaagataact gcccgctgat ctgcttctcc	480
gcctctgggtg gcgcacgtat gcaggaagca ctgatgtcgc tgatgcagat ggcgaaaacc	540
tctgcggcac tggcaaaaat gcaggagcgc ggcttgccgt acatctccgt gctgaccgac	600
ccgacgatgg gcggtgtttc tgcaagtctc gccatgctgg gcgatctcaa catcgctgaa	660
ccgaaagcgt taatcgcttt gccggtccgc gtgttatcga acagaaccgt tcgcgaaaaa	720
ctgccgctg gattccagcg cagtgaattc ctgatcgaga aaggcgcgat cgacatgatc	780
gtccgtcgtc cggaaatgcg cctgaaactg gcgagcattc tggcgaagtt gatgaatctg	840
ccagcgcga atcctgaagc gccgcgtgaa ggcgtagtgg taccgccggt accggatcag	900
gaacctgagg cctga	915

<210> SEQ ID NO 193

<211> LENGTH: 6714

<212> TYPE: DNA

<213> ORGANISM: *Saccharomyces cerevisiae*

<400> SEQUENCE: 193

atgagcgaag aaagcttatt cgagtcttct ccacagaaga tggagtacga aattacaaac	60
tactcagaaa gacatacaga acttccaggt catttcattg gcctcaatac agtagataaa	120
ctagaggagt ccccgtaag ggactttgtt aagagtcacg gtggtcacac ggtcatatcc	180
aaagatctga tagcaataa tgggtattgcc gccgtgaaag aaattagatc cgtcagaaaa	240
tgggcatacg agacgttcgg cgatgacaga accgtccaat tcgtcgccat ggccacccca	300
gaagatctgg aggccaacgc agaatatatc cgtatggccg atcaatacat tgaagtgcc	360
gggtgtacta ataataacaa ctacgctaac gtagacttga tcgtagacat cgcgaaaga	420
gcagacgtag acgccgtatg ggctggctgg ggtcacgcct ccgagaatcc actattgcct	480
gaaaaattgt cccagtctaa gaggaagtc atctttattg ggctccagg taacgccatg	540
aggctcttag gtgataaaat ctctctacc attgtcgtc aaagtgtctaa agtcccatgt	600
attccatggt ctggtagccg tgttgacacc gttcacgtgg acgagaaaa cggctctggtc	660
tctgtcgacg atgacatcta tcaaaagggt tgttgtaact ctctgaaga tggtttaca	720
aaggccaagc gtattggttt tcctgtcatg attaaggcat ccgaagggtg tgggtgtaaa	780
gggtatcagac aagttgaacg tgaagaagat ttcacgtctt tataaccacca ggcagccaac	840
gaaattccag gctcccccatt tttcatcatg aagttggccg gtagagcgcg tcaacttgaa	900
gttcaactgc tagcagatca gtacggtaca aatatttctt tgttcggtag agactgttcc	960
gttcagagac gtcatacaaa aattatcgaa gaagcaccag ttacaattgc caaggctgaa	1020
acatttcacg agatggaaaa ggctgccgtc agactgggga aactagtcgg ttatgtctct	1080
gccggtaccg tggagtatct atattctcat gatgatggaa aattctactt tttagaattg	1140
aaccaagat tacaagtcga gcatccaaca acggaaatgg tctccggtgt taacttacct	1200
gcagctcaat tacaaatcgc tatgggtatc cctatgcata gaataagtga cattagaact	1260
ttatatggta tgaatcctca ttctgcctca gaaatcgatt tcgaattcaa aactcaagat	1320
gccaccaaga aacaaagaag acctattcca aagggtcatt gtaccgcttg tcgtatcaca	1380
tcagaagatc caaacgatgg attcaagcca tcgggtggta ctttgcata actaaacttc	1440

-continued

cgttcttct	ctaagtgttg	gggttacttc	tccgtgggta	acaatggtaa	tattcactcc	1500
ttttcggact	ctcagttcgg	ccatatTTTT	gcttttggtg	aaaatagaca	agcttccagg	1560
aaacacatgg	ttgttgccct	gaaggaattg	tccattaggg	gtgatttcag	aactactgtg	1620
gaatacttga	tcaaactttt	ggaaactgaa	gatttcgagg	ataacactat	taccaccggc	1680
tggttggacg	atttgattac	tcataaaatg	accgctgaaa	agcctgatcc	aactcttgcc	1740
gtcatttgcg	gtgccgttac	aaaggctttc	ttagcatctg	aagaagcccg	ccacaagtat	1800
atcgaatcct	tacaaaaggg	acaagttcta	tctaaagacc	tactgcaaac	tatgttccct	1860
gtagatttta	tccatgaggg	taaaagatac	aagttcacgc	tagctaaatc	cggtaatgac	1920
cgttacacat	tatttatcaa	tggttctaaa	tgtgatatac	tactgcgtca	actatctgat	1980
gggtgctttt	tgattgccat	aggcggtaaa	tcgcatacca	tctattggaa	agaagaagtt	2040
gctgctacaa	gattatccgt	tgactctatg	actactttgt	tggaaagtga	aaacgatcca	2100
accagttgc	gtactccatc	ccctggtaaa	ttggttaaat	tcttgggtga	aaatgggtga	2160
cacattatca	agggccaacc	atatgcagaa	attgaagtta	tgaatgca	aatgcctttg	2220
gtttctcaag	aaaatgggat	cgtccagtta	ttaaagcaac	ctggttctac	cattgttgca	2280
gggtgatata	tggctattat	gactcttgac	gatccatcca	aggtcaagca	cgtctacca	2340
ttgaaggta	tgtctccaga	ttttggttct	ccagttatcg	aaggaaccaa	acctgcctat	2400
aaattcaagt	cattagtgtc	tactttggaa	aacattttga	agggttatga	caaccaagtt	2460
attatgaacg	cttctctgca	acaattgata	gaggttttga	gaaatccaaa	actgccttac	2520
tcagaatgga	aactacacat	ctctgcttta	cattcaagat	tgcttgctaa	gctagatgaa	2580
caaatggaag	agttagtgtc	acgttctttg	agcgtgggtg	ctgttttccc	agctagacaa	2640
ttaagtaaat	tgattgatata	ggcctggaag	aatcctgaat	acaaccccca	caaattgctg	2700
ggcgcgctcg	tggaaaccatt	ggcggatatt	gctcataagt	actctaaccg	gttagaagcc	2760
catgaacatt	ctatatattgt	ccatttcttg	gaagaatatt	acgaagtga	aaagttattc	2820
aatgggtccaa	atgttcgtga	ggaaaatata	attctgaaat	tgctgatga	aaaccctaaa	2880
gatctagata	aagttgcgct	aactgttttg	tctcattcga	aagtttcagc	gaagaataac	2940
ctgatcctag	ctatcttgaa	acattatcaa	ccattgtgca	agttatcttc	taaagtttct	3000
gccattttct	ctactcctct	acaacataatt	gttgaaactag	aatctaaggc	taccgctaag	3060
gtcgtcttac	aagcaagaga	aattttgatt	caaggcgctt	taccttcggc	caaggaaaga	3120
actgaacaaa	ttgaacatat	cttaaaatcc	tctgttgatg	aggttgccta	tggtctatcc	3180
aatccaaagc	gctctgaacc	agatttgaat	atcttgaagg	acttgatcga	ttctaattac	3240
gttgtgttcg	atgttttact	tcaattccta	acccatcaag	accagttgtg	gactgtgca	3300
gctgctcaag	tctatatctg	tcgtgcttat	cgtgcttaca	ccataggaga	tattagagtt	3360
cacgaagggtg	tcacagttcc	aattgttgaa	tggaaattcc	aactaccttc	agctgcgttc	3420
tccacccttc	caactgttaa	atctaaaatg	ggatgaaca	gggctgtttc	tgtttcagat	3480
ttgtcatatg	ttgcaaacag	tcagtcactc	ccgttaagag	aaggtatttt	gatggctgtg	3540
gatcatttag	atgatgttga	tgaatttttg	tcacaaagtt	tggaaagttat	tcctcgtcac	3600
caatcttctt	ctaaccgacc	tgctcctgat	cgttctggta	gctccgcata	gttgagtaat	3660
gttgctaagt	tttgtgttgc	ttctacagaa	ggtttcgaat	ctgaagagga	aattttggta	3720
aggttgagag	aaattttgga	tttgaataag	caggaaattaa	tcaatgcttc	tatccgtcgt	3780
atcacattta	tgttcggttt	taaagatggg	tcttatccaa	agtattatac	ttttaacggc	3840

-continued

ccaaattata	acgaaaaatga	aacaattcgt	cacattgagc	cggctttggc	cttccaactg	3900	
gaattaggaa	gattgtccaa	cttcaacatt	aaaccaat	ttt	tcactgataa	tagaaacatc	3960
catgtctacg	aagctgttag	taagacttct	ccattggata	agagattctt	tacaagaggt	4020	
attattagaa	cgggtcatat	cgtgatgac	atttctattc	aagaatatct	gacttctgaa	4080	
gctaacagat	tgatgagtga	tatattggat	aatttagaag	tcaccgacac	ttcaaattct	4140	
gatttgaatc	atatcttcat	caacttcatt	cgggtgtttg	atatctctcc	agaagatgtc	4200	
gaagccgct	tcggtggttt	cttagaaaga	tttggttaaga	gattgttgag	attgcgtgtt	4260	
tcttctgccg	aaattagaat	catcatcaaa	gatcctcaaa	cagggtgccc	agtaccattg	4320	
cgtgccttga	tcaataacgt	ttctggttat	gttatcaaaa	cagaaatgta	caccgaagtc	4380	
aagaacgcaa	aaggtgaatg	ggtatttaag	tctttgggta	aacctggatc	catgcattta	4440	
agacctattg	ctactcctta	ccctgttaag	gaatgggtgc	aacaaaaacg	ttataaggca	4500	
cacttgatgg	gtaccacata	tgtctatgac	ttcccagaat	tattccgccca	agcatcgtca	4560	
tcccaaggaa	aaaatttctc	tgcagatgtt	aagttaacag	atgatttctt	tatttccaac	4620	
gagttgattg	aagatgaaaa	cggcgaatta	actgaggtgg	aaagagaacc	tggtgccaac	4680	
gctattggta	tgggtgcctt	taagattact	gtaaagactc	ctgaatatcc	aagaggccgt	4740	
caatttgttg	ttgttgctaa	cgatatcaca	ttcaagatcg	gttcctttgg	tccacaagaa	4800	
gacgaattct	tcaataaggt	tactgaatat	gctagaaagc	gtggtatccc	aagaatttac	4860	
ttggctgcaa	actcaggtgc	cagaattggt	atggctgaag	agattgttcc	actatttcaa	4920	
gttgcatgga	atgatgctgc	caatccggac	aagggcttcc	aatacttata	cttaacaagt	4980	
gaaggtatgg	aaactttaaa	gaaatttgac	aaagaaaatt	ctgttctcac	tgaacgtact	5040	
gttataaaacg	gtgaagaaa	atttgtcatc	aagacaatta	ttggttctga	agatgggtta	5100	
ggtgtcgaat	gtctactgtg	atctggttta	attgctggtg	caacgtcaag	ggcttaccac	5160	
gatattctca	ctatcacctt	agtcacttgt	agatccgtcg	gtatcgggtc	ttatttggtt	5220	
cgtttgggtc	aaagagctat	tcaggtcgaa	ggccagccaa	ttatttggtta	tcggtgctta	5280	
ttactgggtg	ctcctgaatc	aacaaatgct	ggtagagaag	tttatacttc	taacttacia	5340	
ttgggtggta	ctcaaatcat	gtataacaac	gggttttcac	atttgactgc	tgttgacgat	5400	
ttagctgggtg	tagagaagat	tgttgaatgg	atgtcttatg	ttccagccaa	gcgtaatatg	5460	
ccagttccta	tcttggaac	taaagacaca	tgggatagac	cagttgattt	cactccaact	5520	
aatgatgaaa	cttacgatgt	aagatggatg	attgaaggtc	gtgagactga	aagtggattt	5580	
gaatatgggtt	tgtttgataa	agggctcttc	tttgaaactt	tgtcaggatg	ggccaaaggt	5640	
gttgctggtg	gtagagcccc	tcttggtggt	attccactgg	gtgttattgg	tgttgaacaa	5700	
agaactgtcg	agaacttgat	tcctgctgat	ccagctaata	caaatagtgc	tgaacatta	5760	
attcaagaac	ctggccaagt	ttggcatcca	aactccgcct	tcaagactgc	tcaagctatc	5820	
aatgacttta	acaacgggtga	acaattgccca	atgatgattt	tggccaactg	gagaggtttc	5880	
tctggtggtc	aacgtgatat	gttcaacgaa	gtcttgaagt	atggttcggt	tattgttgac	5940	
gcattgggtg	attacaaaca	accaattatt	atctatatcc	cacctaccgg	tgaactaaga	6000	
ggtggttcat	gggtgttgtt	cgatccaact	atcaacgctg	accaaagga	aatgtatgcc	6060	
gacgtcaacg	ctagagctgg	tgttttgaa	ccacaaggta	tggttggtat	caagttccgt	6120	
agagaaaaat	tgctggacac	catgaacaga	ttggatgaca	agtacagaga	attgagatct	6180	
caattatcca	acaagagttt	ggctccagaa	gtacatcagc	aatatccaa	gcaattagct	6240	

-continued

```

gatcgtgaga gagaactatt gccaatctac ggacaaatca gtcttcaatt tgctgatttg 6300
cacgataggt cttcacgtat ggtggccaag ggtgttattt ctaaggaact ggaatggacc 6360
gaggcacgtc gtttcttctt ctggagattg agaagaagat tgaacgaaga atatttgatt 6420
aaaaggttga gccatcaggt aggcgaagca tcaagattag aaaagatcgc aagaattaga 6480
tcgtggtacc ctgcttcagt ggaccatgaa gatgataggc aagtcgcaac atggattgaa 6540
gaaaactaca aaactttgga cgataaacta aagggtttga aattagagtc attcgctcaa 6600
gacttagcta aaaagatcag aagcgaccat gacaatgcta ttgatggatt atctgaagtt 6660
atcaagatgt tatctaccga tgataaagaa aaattgttga agactttgaa ataa 6714

```

<210> SEQ ID NO 194

<211> LENGTH: 1647

<212> TYPE: DNA

<213> ORGANISM: Unknown

<220> FEATURE:

<223> OTHER INFORMATION: lipase

<400> SEQUENCE: 194

```

atggagctcg ctcttgcgct cagcctcatt gcctcgggtg ctgctgcccc caccgccacg 60
ctcgccaacg gcgacaccat caccggtctc aacgccatca tcaacgaggc gttcctcggc 120
attccctttg ccgagccgccc ggtgggcaac ctccgcttca aggaccccggt gccgtactcc 180
ggctcgctcg atggccagaa gttcacgagc tacggcccca gctgtatgca gcagaacccc 240
gagggcacct acgagagagaa cctccccaag gcagcgctcg acttggtgat gcagtccaag 300
gtgtttgagg cggtagagccc gagcagcgag gactgtctca ccatcaacgt ggtgcggccg 360
ccgggcacca aggcgggtgc caacctcccg gtgatgctct ggatctttgg cggcgggttt 420
gaggtgggtg gcaccagcac ctccctcccc gccagatga tcaccaagag cattgcatg 480
ggcaagccca tcatccacgt gagcgtcaac taccgctgt cgtcgtgggg gttcttggt 540
ggcgacgaga tcaaggccga gggcagtgcc aacgcgggtt tgaaggacca gcgcttggt 600
atgcagtggg tggcgacaaa cattgcggcg tttggcgcg acccgaccaa ggtgacgatc 660
tttggcgaga gcgcgggcag catgtcgttc atgtgccaca ttctctggaa cgacggcgac 720
aacacgtaca agggcaagcc gctcttccgc gcgggcatca tgcagagcgg ggcgatggtg 780
ccgagcgacg ccgtggacgg catctacggc aacgagattt ttgacctctt ggcgtcgaac 840
gcgggctgcg gcagcgccag cgacaagctc gcgtgcttgc gcggtgtgag cagcgacacg 900
ttggaggacg ccaccaacaa ccccctggg ttcttggtgt actctcgtt gcggttgagc 960
tacctcccc ggcccgacgg cgtgaacatc accgacgaca tgtacgcctt ggtgcgcgag 1020
ggcaagtatg ccaacatccc tgtgatcatc ggcgaccaga acgacgaggg caccttcttt 1080
ggcaccagca gcttgaacgt gaccacggat gccaggcccc gcgagtattt caagcagagc 1140
tttgtccacg ccagcgacgc ggagatcgac acgttgatga cggcgtaacc cggcgacatc 1200
acccagggca gcccgcttca cacgggtatt ctcaacgccc taccctcgca gttcaagaga 1260
atcagcgcgg tgctcgcgga ccttggtctt acgcttgctc gtcgctactt cctcaaccac 1320
tacaccggcg gcaccaagta cagcttcttc agcaagcagc tcagcggtt gccggtgctc 1380
ggaaacgttc actccaacga cattgtcttc caggactact tgttgggcag cggtcgtctc 1440
atctacaaca acggttcat tgcgtttgcc acggacttgg accccaacac cgccgggttg 1500
ttggtgaagt ggcccgagta caccagcagc agccagagcg gcaacaactt gatgatgatc 1560

```

-continued

aacgccttg gcttgtacac cggaaggac aacttcgca cgcgcgcta cgacgcgttg 1620

ttctccaacc cgcgagctt ctttgtg

1647

We claim:

1. A transformed cell that produces 3-hydroxypropionic acid (3-HP), comprising:

an exogenous nucleic acid molecule encoding a protein that reduces malonyl-CoA, wherein the protein comprises at least 10 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141.

2. The transformed cell of claim 1, wherein the protein comprises at least 15 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141, and wherein the protein reduces malonyl-CoA.

3. The transformed cell of claim 1, wherein the protein comprises at least 25 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141, and wherein the protein reduces malonyl-CoA.

4. The transformed cell of claim 1, wherein the protein comprises at least 50 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141, wherein the protein reduces malonyl-CoA.

5. The transformed cell of claim 3, wherein the at least 25 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141 comprise:

- (i) amino acids 600 to 624 of SEQ ID NO: 141,
- (ii) amino acids 700 to 724 of SEQ ID NO: 141,
- (iii) amino acids 570 to 594 of SEQ ID NO: 141,
- (iv) amino acids 620 to 645 of SEQ ID NO: 141,
- (v) amino acids 573 to 597 of SEQ ID NO: 141,
- (vi) amino acids 598 to 622 of SEQ ID NO: 141,
- (vii) amino acids 650 to 674 of SEQ ID NO: 141,
- (viii) amino acids 684 to 708 of SEQ ID NO: 141,
- (ix) amino acids 709 to 733 of SEQ ID NO: 141,
- (x) amino acids 725 to 749 of SEQ ID NO: 141, or
- (xi) amino acids 750 to 774 of SEQ ID NO: 141,

and wherein the protein reduces malonyl-CoA.

6. The transformed cell of claim 1, wherein the protein comprises at least 95% sequence identity with at least 50 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141.

7. The transformed cell of claim 1, wherein the protein comprises at least 95% sequence identity with at least 25 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141.

8. The transformed cell of claim 7, wherein the at least 25 contiguous amino acid residues of the protein sequence set forth in SEQ ID NO: 141 comprise:

- (i) amino acids 600 to 624 of SEQ ID NO: 141,
- (ii) amino acids 700 to 724 of SEQ ID NO: 141,
- (iii) amino acids 570 to 594 of SEQ ID NO: 141,
- (iv) amino acids 620 to 645 of SEQ ID NO: 141,
- (v) amino acids 573 to 597 of SEQ ID NO: 141,
- (vi) amino acids 598 to 622 of SEQ ID NO: 141,

- (vii) amino acids 650 to 674 of SEQ ID NO: 141,
- (viii) amino acids 684 to 708 of SEQ ID NO: 141,
- (ix) amino acids 709 to 733 of SEQ ID NO: 141,
- (x) amino acids 725 to 749 of SEQ ID NO: 141, or
- (xi) amino acids 750 to 774 of SEQ ID NO: 141,

and wherein the protein reduces malonyl-CoA.

9. The transformed cell of claim 1, wherein the protein can convert malonyl-CoA to 3-HP.

10. The transformed cell of claim 1, wherein the exogenous nucleic acid molecule comprises at least 50 contiguous nucleotides of SEQ ID NO: 140.

11. The transformed cell of claim 1, wherein the exogenous nucleic acid molecule comprises at least 100 contiguous nucleotides of SEQ ID NO: 140.

12. A transformed cell comprising an exogenous nucleic acid molecule that hybridizes to SEQ ID NO: 140 under highly stringent hybridization conditions and encodes a protein that reduces malonyl-CoA, wherein the highly stringent hybridization conditions comprise hybridization performed at about 42° C. in a hybridization solution containing 25 mM KPO₄ (pH 7.4), 5×SSC, 5× Denhart's solution, 50 µg/mL denatured, sonicated salmon sperm DNA, 50% formamide, 10% Dextran sulfate, and 1-15 ng/mL of the exogenous nucleic acid molecule, and wherein washes are performed at about 65° C. with a wash solution comprising 0.2×SSC and 0.1% sodium dodecyl sulfate.

13. The transformed cell of claim 1, wherein the exogenous nucleic acid molecule comprises at least 95% sequence identity with at least 50 contiguous nucleotides of SEQ ID NO: 140.

14. The transformed cell of claim 1, wherein the exogenous nucleic acid molecule is part of a vector.

15. The transformed cell of claim 1, wherein the cell is a yeast, *Lactobacillus*, *Lactococcus*, *Bacillus*, or *Escherichia* cell.

16. The transformed cell of claim 1, wherein the cell is an *E. coli* cell.

17. A method for making 3-HP, comprising culturing the cell of claim 1 under conditions wherein said cell produces 3-HP from malonyl-CoA.

18. The method of claim 17, further comprising dehydrating the 3-HP to form acrylic acid.

19. The method of claim 17, wherein the cell is a yeast, *Lactobacillus*, *Lactococcus*, *Bacillus*, or *Escherichia* cell.

20. The method of claim 19, wherein the cell is an *E. coli* cell.

21. The method of claim 17, wherein the method produces at least 1 g/L 3-HP from the cell.

22. The method of claim 17, further comprising isolating the 3-HP.

* * * * *